id,slug2,created_at,,,,,,
1,celyad-successfully-doses-first-colorectal-cancer-patient-with-cyad-01-following-preconditioning-chemotherapy,05-09-2018 00:00,,,,,,
2,dynavax-announces-publication-of-preclinical-study-of-tlr9-agonist-in-lung-cancer,05-09-2018 00:00,,,,,,
3,janssen-submits-esketamine-nasal-spray-new-drug-application-to-us-fda-for-treatment-resistant-depression,05-09-2018 00:00,,,,,,
4,fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-keytruda-pembrolizumab-for-the-treatment-of-merkel-cell-carcinoma-a-rare-form-of-skin-cancer,04-09-2018 00:00,,,,,,
5,redx-pharma-announces-way-forward-for-rxc004,04-09-2018 00:00,,,,,,
6,boehringer-ingelheim-biopharmaceuticals-china-supports-beigene-in-its-china-nda-submission-of-anti-pd-1-antibody-tislelizumab,04-09-2018 00:00,,,,,,
7,novellusdx-and-primetech-sign-agreement-with-japan-agency,04-09-2018 00:00,,,,,,
8,cablivi-caplacizumab-approved-in-europe-for-adults-with-acquired-thrombotic-thrombocytopenic-purpura-attp,03-09-2018 00:00,,,,,,
9,a-group-of-dutch-doctors-and-health-advocates-are-taking-action-against-the-italian-pharmaceutical-firm-leadiant-biosciences-who-have-increased-the-price-of-a-lifesaving-drug-by-500-times-its-original-price,03-09-2018 00:00,,,,,,
10,novartis-to-streamline-production-in-response-to-lower-us-prices-nzz-am-sonntag,03-09-2018 00:00,,,,,,
11,pfizer-terminates-domagrozumab-pf-06252616-clinical-studies-for-the-treatment-of-duchenne-muscular-dystrophy,31-08-2018 00:00,,,,,,
12,update-on-tulip-1-phase-iii-trial-for-anifrolumab-in-systemic-lupus-erythematosus,31-08-2018 00:00,,,,,,
13,newly-added-guidance-documents,31-08-2018 00:00,,,,,,
14,vertex-and-genomics-plc-establish-collaboration-to-use-human-genetics-and-data-science-to-advance-discovery-of-precision-medicines,31-08-2018 00:00,,,,,,
15,us-food-and-drug-administration-accepts-bristol-myers-squibbs-application-for-sprycel-dasatinib-in-pediatric-patients-with-newly-diagnosed-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia,30-08-2018 00:00,,,,,,
16,european-commission-approves-new-easy-to-use-once-weekly-bydureon-bcise-device-for-patients-with-type-2-diabetes,30-08-2018 00:00,,,,,,
17,positive-phase-iii-results-for-roches-hemlibra-for-haemophilia-a-without-factor-viii-inhibitors-published-in-new-england-journal-of-medicine,30-08-2018 00:00,,,,,,
18,"european-commission-approves-blincyto-blinatumomab-for-use-in-pediatric-patients-with-philadelphia-chromosome-negative-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukemia
-",30-08-2018 00:00,,,,,,
19,xenon-announces-positive-xen1101-pharmacodynamic-data-from-phase-1b-tms-study,29-08-2018 00:00,,,,,,
20,emergent-biosolutions-joins-effort-to-combat-national-public-health-threat-from-opioid-overdose-through-acquisition-of-adapt-pharma-and-its-flagship-product-narcan-naloxone-hcl-nasal-spray,29-08-2018 00:00,,,,,,
21,alcon-announces-voluntary-global-market-withdrawal-of-cypass-micro-stent-for-surgical-glaucoma,29-08-2018 00:00,,,,,,
22,feedback-encouraged-to-allow-use-of-life-extending-treatment-on-nhs-for-those-with-blood-cancer,29-08-2018 00:00,,,,,,
23,biogen-and-eisai-report-data-from-long-term-extension-phase-1b-study-of-investigational-alzheimers-disease-treatment-aducanumab,28-08-2018 00:00,,,,,,
24,affimed-announces-collaboration-with-genentech-to-develop-novel-nk-cell-engager-based-immunotherapeutics-for-multiple-cancer-targets,28-08-2018 00:00,,,,,,
25,tafamidis-phase-3-transthyretin-amyloid-cardiomyopathy-attr-act-study-results-presented-as-late-breaking-data-at-the-esc-congress-2018,28-08-2018 00:00,,,,,,
26,abbvie-announces-imbruvica-ibrutinib-plus-rituximab-approval-by-us-fda-as-first-chemotherapy-free-combination-treatment-in-adults-with-waldenstrms-macroglobulinemia-a-rare-type-of-blood-cancer,28-08-2018 00:00,,,,,,
27,novartis-receives-european-commission-approval-of-its-car-t-cell-therapy-kymriah-tisagenlecleucel,27-08-2018 00:00,,,,,,
28,abbott-india-lines-up-100-product-launches-over-the-next-5-years,27-08-2018 00:00,,,,,,
29,yescarta-receives-european-marketing-authorization-for-treatment-of-relapsed-or-refractory-dlbcl-and-pmbc,27-08-2018 00:00,,,,,,
30,european-commission-grants-marketing-authorization-for-lenvima-lenvatinib-as-first-line-treatment-in-adults-with-advanced-or-unresectable-hepatocellular-carcinoma,25-08-2018 00:00,,,,,,
31,solar-1-trial-of-novartis-investigational-alpha-specific-pi3k-inhibitor-byl719-alpelisib-meets-primary-endpoint-in-hrher2-advanced-breast-cancer-with-pik3ca-mutation,24-08-2018 00:00,,,,,,
32,astrazeneca-provides-update-on-aeristo-phase-iiib-trial-for-bevespi-aerosphere-in-chronic-obstructive-pulmonary-disease,24-08-2018 00:00,,,,,,
33,shire-announces-fda-approval-of-takhzyro-lanadelumab-flyo-a-first-of-its-kind-mab-preventive-treatment-for-hereditary-angioedema,24-08-2018 00:00,,,,,,
34,bluebird-bio-and-gritstone-oncology-announce-strategic-collaboration-to-develop-novel-cancer-cell-therapies,23-08-2018 00:00,,,,,,
35,exact-sciences-and-pfizer-enter-into-us-promotion-agreement-for-cologuard,23-08-2018 00:00,,,,,,
36,argenx-announces-that-abbvie-has-exercised-its-exclusive-option-to-license-argx-115-a-novel-immuno-oncology-antibody,23-08-2018 00:00,,,,,,
37,pfizer-and-astellas-amend-clinical-research-protocols-for-two-phase-3-trials-of-enzalutamide-in-patients-with-hormone-sensitive-prostate-cancer,23-08-2018 00:00,,,,,,
38,sierra-oncology-acquires-momelotinib-an-investigational-janus-kinase-jak-12-and-activin-receptor-type-1-acvr1-inhibitor-for-myelofibrosis-from-gilead-sciences,22-08-2018 00:00,,,,,,
39,congo-approves-more-experimental-ebola-treatments-as-cases-rise,22-08-2018 00:00,,,,,,
40,evotec-and-novo-nordisk-form-strategic-research-alliance-in-diabetes-and-obesity,22-08-2018 00:00,,,,,,
41,glaxo-seeks-bids-mid-september-for-4-billion-india-sale,22-08-2018 00:00,,,,,,
42,kyowa-hakko-kirin-announces-results-of-early-phase-2-trial-of-kw-6356-for-parkinsons-disease-at-iaprd,21-08-2018 00:00,,,,,,
43,bio-thera-solutions-announces-china-national-drug-administration-acceptance-of-biologics-license-application-for-proposed-biosimilar-to-humira-adalimumab,21-08-2018 00:00,,,,,,
44,harbour-biomed-announces-global-strategic-partnership-with-kelun-biotech-to-develop-and-commercialize-a167-an-anti-pd-l1-antibody-for-treatment-of-cancer,21-08-2018 00:00,,,,,,
45,china-national-drug-administration-grants-rapid-approval-of-roches-alecensa-alectinib-as-a-treatment-for-alk-positive-lung-cancer,21-08-2018 00:00,,,,,,
46,fda-approves-expanded-label-for-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-alimta-and-platinum-chemotherapy-for-first-line-treatment-of-patients-with-metastatic-nonsquamous-nsclc-with-no-egfr-or-alk-genomic-tumor-aberrations,21-08-2018 00:00,,,,,,
47,avista-healthcare-public-acquisition-corp-to-combine-with-organogenesis-inc,20-08-2018 00:00,,,,,,
48,"this-is-an-initial-public-offering-of-shares-of-common-stock-of-principia-biopharma-inc-all-of-the-shares-of-common-stock-are-being-sold-by-the-company
-
-prior-to-this-offering-there-has-been-no-public-market-for-our-common-stock-it-is-currently-estimated-that-the-initial-public-offering-price-will-be-between-and-per-share-we-intend-to-apply-to-list-our-common-stock-on-the-nasdaq-global-market-under-the-symbol-prnb
-
-we-are-an-emerging-growth-company-as-defined-under-the-federal-securities-laws-and-as-such-we-have-elected-to-comply-with-certain-reduced-public-company-reporting-requirements-for-this-prospectus-and-may-elect-to-do-so-in-future-filings-for-information-regarding-these-reduced-reporting-requirements-see-prospectus-summaryemerging-growth-company",20-08-2018 00:00,,,,,,
49,us-food-and-drug-administration-approves-opdivo-nivolumab-as-the-first-new-medication-in-nearly-20-years-for-certain-patients-with-previously-treated-small-cell-lung-cancer,17-08-2018 00:00,,,,,,
50,eisai-and-merck-co-kenilworth-nj-usa-announce-fda-approval-of-lenvima-lenvatinib-capsules-for-first-line-treatment-of-unresectable-hepatocellular-carcinoma-hcc,17-08-2018 00:00,,,,,,
51,novo-nordisk-acquires-ziylo-ltd-to-accelerate-its-development-of-glucose-responsive-insulins,17-08-2018 00:00,,,,,,
52,fda-approves-first-generic-version-of-epipen,17-08-2018 00:00,,,,,,
53,pfizer-bets-on-biotech-flu-vaccine-in-425-million-biontech-alliance,16-08-2018 00:00,,,,,,
54,depomed-inc-announces-corporate-name-change-to-assertio-therapeutics-inc,16-08-2018 00:00,,,,,,
55,mylan-quietly-made-an-acquisition-for-almost-half-a-billion-dollars-in-july-that-it-didnt-tell-investors-about-right-away,16-08-2018 00:00,,,,,,
56,inova-diagnostics-receives-fda-clearance-for-test-to-detect-antibodies-to-hmgcr,14-08-2018 00:00,,,,,,
57,medtronic-launches-patient-engagement-program-that-leverages-gamification-to-help-motivate-and-engage-patients-living-with-diabetes,14-08-2018 00:00,,,,,,
58,mustang-bio-and-st-jude-childrens-research-hospital-enter-into-exclusive-worldwide-license-agreement-for-a-ground-breaking-clinical-stage-lentiviral-gene-therapy-with-curative-potential-for-x-linked-severe-combined-immunodeficiency,14-08-2018 00:00,,,,,,
59,fda-approves-galafold-migalastat-for-the-treatment-of-certain-adult-patients-with-fabry-disease,13-08-2018 00:00,,,,,,
60,fda-approves-first-of-its-kind-targeted-rna-based-therapy-to-treat-a-rare-disease,13-08-2018 00:00,,,,,,
61,fda-grants-breakthrough-therapy-designation-for-xolair-omalizumab-for-food-allergies,13-08-2018 00:00,,,,,,
62,astellas-announces-acquisition-of-quethera--acquisition-furthers-astellas-commitment-to-innovation-in-ophthalmology-with-addition-of-novel-gene-therapy-program-for-glaucoma,13-08-2018 00:00,,,,,,
64,jhl-biotech-receives-positive-chmp-scientific-advice-for-global-phase-iii-clinical-trial-of-proposed-trastuzumab-biosimilar-to-treat-breast-cancer,10-08-2018 00:00,,,,,,
65,perrigo-announces-plan-to-separate-prescription-pharmaceuticals-business,09-08-2018 00:00,,,,,,
66,us-food-and-drug-administration-approves-arakoda-tafenoquine-tablets-for-oral-use-first-preventative-antimalarial-approved-in-almost-two-decades,09-08-2018 00:00,,,,,,
67,cimzia-maker-ucb-signs-myhealthteams-to-pump-up-spondyloarthritis-social-network,08-08-2018 00:00,,,,,,
68,fda-approves-treatment-for-two-rare-types-of-non-hodgkin-lymphoma,08-08-2018 00:00,,,,,,
69,fda-approves-first-generic-drug-under-new-pathway-aimed-at-enhancing-market-competition-for-sole-source-drugs,08-08-2018 00:00,,,,,,
70,ironwood-ends-gout-drug-deal-with-az,07-08-2018 00:00,,,,,,
71,biolinerx-announces-positive-results-of-lead-in-period-for-phase-3-genesis-trial-in-stem-cell-mobilization,07-08-2018 00:00,,,,,,
72,mallinckrodt-forms-collaborative-research-partnership-with-washington-university-in-st-louis,07-08-2018 00:00,,,,,,
74,bluebird-bio-and-regeneron-announce-collaboration-to-discover-develop-and-commercialize-new-cell-therapies-for-cancer,06-08-2018 00:00,,,,,,
75,the-us-food-and-drug-administration-fda-has-granted-orphan-drug-designation-to-pharmamars-lurbinectedin,03-08-2018 00:00,,,,,,
76,celltrion-huh-juma-to-enter-the-australian-market,03-08-2018 00:00,,,,,,
77,the-chmp-issues-positive-opinion-to-expand-invokana-and-vokanamet-labels-to-include-positive-data-on-cardiovascular-and-renal-outcomes,03-08-2018 00:00,,,,,,
78,elanco-animal-health-files-ipo-registration-statement,03-08-2018 00:00,,,,,,
79,novelion-therapeutics-announces-marketing-authorization-for-myalepta-metreleptin-in-the-european-union-to-treat-generalized-and-partial-lipodystrophy,02-08-2018 00:00,,,,,,
80,laekna-acquires-exclusive-worldwide-rights-to-two-clinical-stage-oncology-assets,02-08-2018 00:00,,,,,,
81,with-diabetes-competitive-as-ever-novo-launches-ozempic-dtc-campaign,02-08-2018 00:00,,,,,,
82,xeljanz-tofacitinib-citrate-receives-marketing-authorization-in-the-european-union-for-moderately-to-severely-active-ulcerative-colitis,01-08-2018 00:00,,,,,,
83,leo-pharma-to-expand-its-lead-in-medical-dermatology-with-acquisition-of-bayers-prescription-dermatology-unit,01-08-2018 00:00,,,,,,
84,fda-approves-lusutrombopag-for-thrombocytopenia-in-adults-with-chronic-liver-disease,31-07-2018 00:00,,,,,,
85,pfizer-receives-european-approval-for-oncology-biosimilar-trazimera-trastuzumab,31-07-2018 00:00,,,,,,
86,pernix-therapeutics-announces-successful-closing-of-transaction-regarding-worldwide-rights-to-contrave-for-weight-loss,30-07-2018 00:00,,,,,,
87,progenics-pharmaceuticals-announces-fda-approval-for-azedra-iobenguane-i-131-to-treat-unresectable-locally-advanced-or-metastatic-pheochromocytoma-or-paraganglioma,30-07-2018 00:00,,,,,,
88,novartis-marks-a-new-era-for-migraine-patients-with-the-eu-approval-of-aimovig-a-first-of-its-kind-treatment-specifically-designed-for-migraine-prevention,30-07-2018 00:00,,,,,,
89,biolinerx-announces-expansion-of-immuno-oncology-collaboration-in-pancreatic-cancer,30-07-2018 00:00,,,,,,
90,lilly-announces-extension-of-cancer-research-collaboration-with-dana-farber-cancer-institute,30-07-2018 00:00,,,,,,
91,sun-pharmaceutical-industries-inc-issues-voluntary-nationwide-recall-of-riomet-metformin-hydrochloride-oral-solution-manufactured-by-a-contract-manufacturer-due-to-microbial-contamination,30-07-2018 00:00,,,,,,
92,chembio-diagnostics-announces-collaboration-with-find-to-develop-hepatitis-c-virus-point-of-care-diagnostic-test,28-07-2018 00:00,,,,,,
93,imfinzi-receives-positive-eu-chmp-opinion-for-locally-advanced-unresectable-non-small-cell-lung-cancer,27-07-2018 00:00,,,,,,
94,mercks-keytruda-threatens-pfizer-merck-kgaas-bavencio-with-merkel-cell-priority-tag,27-07-2018 00:00,,,,,,
95,dr-reddys-laboratories-announces-the-launch-of-hervycta-trastuzumab-biosimilar-in-india,26-07-2018 00:00,,,,,,
96,"united-states
-securities-and-exchange-commission
-washington-dc-20549
-
-form-8-k
-
-current-report
-pursuant-to-section-13-or-15d-of-the
-securities-exchange-act-of-1934
-date-of-report-date-of-earliest-event-reported-july-26-2018
-
-draft8k726azimage1jpg
-
-array-biopharma-inc
-exact-name-of-registrant-as-specified-in-its-charter
-
-delaware
-001-16633
-84-1460811
-state-or-other-jurisdiction-of-incorporation
-commission-file-number
-irs-employer-identification-no
-
-
-
-
-3200-walnut-street-boulder-colorado-80301
-address-of-principal-executive-offices-including-zip-code
-
-303-381-6600
-registrants-telephone-number-including-area-code
-
-
-former-name-or-former-address-if-changed-since-last-report",26-07-2018 00:00,,,,,,
97,gsk-and-23andme-sign-agreement-to-leverage-genetic-insights-for-the-development-of-novel-medicines,25-07-2018 00:00,,,,,,
98,jj-told-to-pay-rs-20-lakh-to-each-recipient-of-faulty-hip-implant,05-09-2018 00:00,,,,,,
99,novartis-to-divest-the-sandoz-us-dermatology-business-and-generic-us-oral-solids-portfolio-to-aurobindo,06-09-2018 00:00,,,,,,
100,gilead-and-galapagos-announce-tortuga-phase-2-study-of-filgotinib-in-ankylosing-spondylitis-achieves-primary-endpoint,06-09-2018 00:00,,,,,,
101,active-biotech-regains-global-rights-to-development-and-commercialization-of-laquinimod,06-09-2018 00:00,,,,,,
102,shire-acquires-sanaplasma-ag-boosting-plasma-collection-network-for-immunology-franchise,06-09-2018 00:00,,,,,,
103,monoferrictm-iron-isomaltoside-1000-for-injection-receives-marketing-approval-from-health-canada,07-09-2018 00:00,,,,,,
104,tezepelumab-granted-breakthrough-therapy-designation-by-us-fda,07-09-2018 00:00,,,,,,
105,tezepelumab-granted-breakthrough-therapy-designation-by-us-fda,07-09-2018 00:00,,,,,,
107,exelixis-announces-new-recommendations-for-cabometyx-cabozantinib-tablets-in-updated-national-comprehensive-cancer-network-clinical-practice-guidelines,10-09-2018 00:00,,,,,,
108,european-commission-approves-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-and-platinum-chemotherapy-for-the-first-line-treatment-of-patients-with-metastatic-nonsquamous-nsclc-with-no-egfr-or-alk-genomic-tumor-aberrations,10-09-2018 00:00,,,,,,
109,european-commission-approves-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-and-platinum-chemotherapy-for-the-first-line-treatment-of-patients-with-metastatic-nonsquamous-nsclc-with-no-egfr-or-alk-genomic-tumor-aberrations,10-09-2018 00:00,,,,,,
110,gsk-announces-results-of-indirect-treatment-comparisons-of-nucala-to-benralizumab-and-reslizumab-for-severe-eosinophilic-asthma,11-09-2018 00:00,,,,,,
111,elevian-launches-to-join-numerous-companies-focused-on-longevity-and-aging,11-09-2018 00:00,,,,,,
112,medtronic-announces-one-month-dapt-clinical-study-in-the-us-and-japan-with-resolute-onyx-des-in-high-bleeding-risk-patients,11-09-2018 00:00,,,,,,
113,mercks-zerbaxa-ceftolozane-and-tazobactam-met-primary-endpoints-of-non-inferiority-compared-to-meropenem-in-pivotal-phase-3-study-of-adult-patients-with-hospital-acquired-bacterial-pneumonia-or-ventilator-associated-bacterial-pneumonia,11-09-2018 00:00,,,,,,
115,novartis-survey-shows-psoriasis-patients-want-treatment-effect-beyond-clear-skin,12-09-2018 00:00,,,,,,
116,fda-to-review-supplemental-biologics-license-application-for-praluent-alirocumab-injection-as-potential-treatment-to-reduce-major-adverse-cardiovascular-events,12-09-2018 00:00,,,,,,
117,shire-granted-eu-marketing-authorization-for-veyvondi-vonicog-alfa-recombinant-von-willebrand-factor-for-adults-with-von-willebrand-disease,12-09-2018 00:00,,,,,,
118,gilead-precision-biosciences-to-develop-therapies-against-hep-b,13-09-2018 00:00,,,,,,
119,boehringer-ingelheim-acquires-all-viratherapeutics-shares-to-develop-next-generation-viral-based-immuno-oncology-therapies,13-09-2018 00:00,,,,,,
120,otezla-apremilast-showed-meaningful-improvements-in-clinical-and-quality-of-life-measures-of-psoriasis-beyond-those-captured-by-assessing-skin-alone,13-09-2018 00:00,,,,,,
121,fda-to-review-eylea-aflibercept-injection-for-the-treatment-of-diabetic-retinopathy,13-09-2018 00:00,,,,,,
122,vistagen-therapeutics-acquires-worldwide-license-of-phase-3-ready-cns-drug-candidate-from-pherin-pharmaceuticals-for-as-needed-treatment-of-social-anxiety-disorder,14-09-2018 00:00,,,,,,
123,moleculins-brain-cancer-drug-candidate-begins-patient-dosing-at-clinical-trial-being-conducted-at-md-anderson,14-09-2018 00:00,,,,,,
125,teva-announces-us-approval-of-ajovy-fremanezumab-vfrm-injection-the-first-and-only-anti-cgrp-treatment-with-both-quarterly-and-monthly-dosing-for-the-preventive-treatment-of-migraine-in-adults,17-09-2018 00:00,,,,,,
126,institut-curie-announces-creation-of-honing-biosciences,17-09-2018 00:00,,,,,,
127,leo-pharma-and-morphosys-expand-strategic-alliance-to-develop-peptide-derived-therapeutics,18-09-2018 00:00,,,,,,
128,fasenra-shows-consistent-safety-and-sustained-efficacy-in-long-term-phase-iii-bora-trial-in-severe-eosinophilic-asthma,18-09-2018 00:00,,,,,,
129,atomwise-enters-into-an-evaluation-agreement-?swith-pfizer,18-09-2018 00:00,,,,,,
130,moberg-pharma-och-cipher-pharmaceuticals-ingr-exklusivt-licensavtal-fr-mob-015-i-kanada,18-09-2018 00:00,,,,,,
131,sun-pharma-announces-australian-tga-approval-of-ilumya-tildrakizumab-for-treatment-of-moderate-to-severe-plaque-psoriasis,19-09-2018 00:00,,,,,,
132,marketing-say-hello-to-sophia-novo-nordisks-new-online-chatbot-available-247-for-diabetes-questions,19-09-2018 00:00,,,,,,
133,cancer-genetics-and-novellusdx-sign-definitive-agreement-to-merge,19-09-2018 00:00,,,,,,
134,leo-science-tech-hub-partners-with-epicore-biosystems-to-explore-wearable-skin-sensors-to-improve-dermatologic-treatment-regimens,19-09-2018 00:00,,,,,,
135,molecular-templates-announces-agreement-with-takeda-for-the-joint-development-of-a-protein-based-oncology-therapy,20-09-2018 00:00,,,,,,
136,hironic-skin-acne-treatment-equipment-afit-us-fda-approval,20-09-2018 00:00,,,,,,
137,mylan-and-fujifilm-kyowa-kirin-biologics-receive-european-marketing-authorization-for-hulio-biosimilar-adalimumab,NULL,1,9,NULL,NULL,20-09-2018 00:00,20-09-2018 00:00
138,medtronic-to-acquire-mazor-robotics,21-09-2018 00:00,,,,,,
139,sandoz-receives-positive-chmp-opinion-for-proposed-biosimilar-pegfilgrastim,21-09-2018 00:00,,,,,,
140,sandoz-receives-positive-chmp-opinion-for-proposed-biosimilar-pegfilgrastim,21-09-2018 00:00,,,,,,
141,bayer-receives-positive-chmp-opinion-for-its-hemophilia-a-treatment-bay94-9027,24-09-2018 00:00,,,,,,
142,sun-pharma-announces-australian-tga-approval-of-ilumya-tildrakizumab-for-treatment-of-moderate-to-severe-plaque-psoriasis,24-09-2018 00:00,,,,,,
143,enesi-pharma-and-walter-reed-army-institute-of-research-wrair-sign-cooperative-rd-agreement-crada-for-needle-free-solid-dose-vaccine-for-shigella-infection,24-09-2018 00:00,,,,,,
144,gilead-subsidiary-to-launch-authorized-generics-of-epclusa-sofosbuvirvelpatasvir-and-harvoni-ledipasvirsofosbuvir-for-the-treatment-of-chronic-hepatitis-c,24-09-2018 00:00,,,,,,
145,mylan-extends-commitment-to-fight-hivaids-by-partnering-with-atomo-diagnostics-to-expand-access-to-hiv-self-testing-in-low-and-middle-income-countries,25-09-2018 00:00,,,,,,
146,blincyto-blinatumomab-approved-in-japan-for-the-treatment-of-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukemia,25-09-2018 00:00,,,,,,
147,immutep-enters-into-clinical-trial-collaboration-and-supply-agreement-with-merck-kgaa-darmstadt-germany-and-pfizer,25-09-2018 00:00,,,,,,
148,stemcell-technologies-signs-exclusive-license-to-commercialize-human-pluripotent-stem-cell-derived-kidney-organoid-culture-system,25-09-2018 00:00,,,,,,
149,tris-pharma-expands-adhd-portfolio-with-acquisition-of-nextwave-pharmaceuticals,26-09-2018 00:00,,,,,,
150,cspc-pharmaceutical-group-limited-and-verastem-oncology-sign-exclusive-license-agreement-for-the-development-and-commercialization-of-copiktra-duvelisib-in-china,26-09-2018 00:00,,,,,,
151,agilent-to-expand-portfolio-and-capabilities-in-cell-analysis-with-acquisition-of-acea-biosciences,26-09-2018 00:00,,,,,,
152,alexion-to-acquire-syntimmune,27-09-2018 00:00,,,,,,
153,lyra-therapeutics-announces-295-million-series-b-financing-to-advance-innovative-therapeutics-for-ear-nose-and-throat-diseases,27-09-2018 00:00,,,,,,
154,samsung-bioepis-biologics-license-application-for-sb5-adalimumab-biosimilar-candidate-accepted-for-review-by-the-us-food-and-drug-administration,27-09-2018 00:00,,,,,,
155,lillys-emgality-galcanezumab-gnlm-receives-us-fda-approval-for-the-preventive-treatment-of-migraine-in-adults,28-09-2018 00:00,,,,,,
157,geron-announces-discontinuation-of-imetelstat-collaboration-by-janssen,28-09-2018 00:00,,,,,,
158,dova-pharmaceuticals-and-salix-enter-into-exclusive-co-promotion-agreement-for-dopteletavatrombopag,28-09-2018 00:00,,,,,,
159,us-fda-approves-vizimpro-dacomitinib-for-the-first-line-treatment-of-patients-with-egfr-mutated-metastatic-non-small-cell-lung-cancer,28-09-2018 00:00,,,,,,
160,tusk-therapeutics-to-be-acquired-by-roche,01-10-2018 00:00,,,,,,
161,teva-announces-exclusive-first-to-file-launch-of-a-generic-version-of-cialis-in-the-united-states,01-10-2018 00:00,,,,,,
162,taro-terminates-agreement-with-novabiotics,01-10-2018 00:00,,,,,,
163,hologic-closes-125m-focal-therapeutics-buyout,03-10-2018 00:00,,,,,,
164,hitachi-chemical-advanced-therapeutics-solutions-signs-three-year-agreement-with-gsk-to-provide-clinical-manufacturing-for-t-cell-therapy,03-10-2018 00:00,,,,,,
165,insmed-gets-fda-approval-for-first-mycobacterium-avium-complex-mac-lung-disease-therapy,03-10-2018 00:00,,,,,,
166,dragonfly-therapeutics-announces-new-multi-target-collaboration-with-merck-to-use-dragonflys-proprietary-trinket-platform-to-develop-novel-drug-candidates-for-patients-with-solid-tumors,03-10-2018 00:00,,,,,,
167,alnylam-launches-onpattro-patisiran-the-first-ever-rnai-therapeutic-in-germany,03-10-2018 00:00,,,,,,
168,novartis-licenses-three-novel-anti-infective-programs-to-boston-pharmaceuticals,03-10-2018 00:00,,,,,,
169,health-canada-approves-tresiba-for-children-with-type-1-diabetes,04-10-2018 00:00,,,,,,
170,celyad-announces-exclusive-agreement-for-horizon-discoverys-shrna-platform-to-develop-next-generation-allogeneic-car-t-therapies,04-10-2018 00:00,,,,,,
171,lillys-investigational-dual-gip-and-glp-1-receptor-agonist-shows-significant-reduction-in-hba1c-and-body-weight-in-people-with-type-2-diabetes,04-10-2018 00:00,,,,,,
172,fda-approves-roches-hemlibra-for-haemophilia-a-without-factor-viii-inhibitors,05-10-2018 00:00,,,,,,
174,novartis-announces-fda-and-ema-filing-acceptance-of-siponimod-the-first-and-only-drug-shown-to-meaningfully-delay-disability-progression-in-typical-spms-patients,08-10-2018 00:00,,,,,,
175,abbvie-receives-health-canada-approval-of-orilissa-elagolix-for-the-treatment-of-moderate-to-severe-pain-associated-with-endometriosis,08-10-2018 00:00,,,,,,
176,fda-approves-expanded-use-of-gardasil-9-to-include-individuals-27-through-45-years-old,08-10-2018 00:00,,,,,,
177,libtayo-cemiplimab-rwlc-data-at-esmo-2018-congress-provide-new-insights-in-six-tumor-types-under-investigation,09-10-2018 00:00,,,,,,
178,celgene-announces-phase-3-style-study-of-otezla-apremilast-in-moderate-to-severe-scalp-psoriasis-met-primary-endpoint,09-10-2018 00:00,,,,,,
179,roche-to-present-new-positive-data-from-its-broad-cancer-immunotherapy-programme-and-across-a-wide-range-of-cancers-at-the-european-society-for-medical-oncology-esmo-2018-congress,09-10-2018 00:00,,,,,,
180,mvp-signs-exclusive-penthrox-deal-for-china-with-daiichi-sankyo,09-10-2018 00:00,,,,,,
181,ocrevus-ocrelizumab-data-show-early-initiation-of-treatment-reduces-disability-progression-over-five-years-in-relapsing-and-primary-progressive-multiple-sclerosis,10-10-2018 00:00,,,,,,
183,therachon-expands-rare-disease-pipeline-with-acquisition-of-glypharma-therapeutic-inc,10-10-2018 00:00,,,,,,
184,new-analysis-estimates-the-positive-impact-of-jardiance-on-life-expectancy-in-adults-with-type-2-diabetes-and-established-cardiovascular-disease,10-10-2018 00:00,,,,,,
185,celltrion-inc-krx068270-and-teva-pharmaceutical-industries-ltd-nyse-and-tase-teva-today-announced-the-us-food-and-drug-administration-fda-oncologic-drugs-advisory-committee-voted-unanimously-16-0,11-10-2018 00:00,,,,,,
186,ionis-enters-new-collaboration-with-partner-to-develop-ionis-fb-l-rx-for-complement-mediated-diseases,11-10-2018 00:00,,,,,,
187,mundipharma-strengthens-position-as-a-leader-in-biosimilars-with-acquisition-of-development-company-cinfa-biotech,12-10-2018 00:00,,,,,,
188,sandoz-announces-global-resolution-of-biosimilar-adalimumab-patent-disputes-securing-patient-access,12-10-2018 00:00,,,,,,
189,lilly-and-metastatic-breast-cancer-advocates-launch-thriver-movement-to-elevate-understanding-of-the-daily-impact-of-the-disease-encourage-public-to-do-more-for-mbc,12-10-2018 00:00,,,,,,
190,roche-launches-ngs-avenio-tumor-tissue-analysis-kits-for-oncology-research,15-10-2018 00:00,,,,,,
191,merck-co-samsung-bioepis-terminate-deal-to-develop-insulin-follow-on-biologic,15-10-2018 00:00,,,,,,
192,roches-kadcyla-reduced-the-risk-of-disease-recurring-in-people-with-her2-positive-early-breast-cancer-with-residual-disease-after-neoadjuvant-treatment,15-10-2018 00:00,,,,,,
193,sarepta-and-lysogene-announce-exclusive-license-agreement-for-lys-saf302-a-late-stage-gene-therapy-for-the-treatment-of-mps-iiia-and-grant-of-option-rights-to-an-additional-cns-gene-therapy-candidate,16-10-2018 00:00,,,,,,
194,amgen-launches-amgevita-biosimilar-adalimumab-in-markets-across-europe,16-10-2018 00:00,,,,,,
195,novartis-5-year-data-in-psoriatic-arthritis-and-ankylosing-spondylitis-reinforces-cosentyx-leadership-in-spondyloarthritis-novartis-5-year-data-in-psoriatic-arthritis-and-ankylosing-spondylitis-reinforces-cosentyx-leadership-in-spondyloarthritis,16-10-2018 00:00,,,,,,
196,applying-deep-learning-to-metastatic-breast-cancer-detection,16-10-2018 00:00,,,,,,
197,us-fda-grants-lynparza-orphan-drug-designation-for-pancreatic-cancer,16-10-2018 00:00,,,,,,
198,dupixent-dupilumab-showed-positive-topline-results-in-two-phase-3-trials-of-patients-with-chronic-rhinosinusitis-with-nasal-polyps,16-10-2018 00:00,,,,,,
199,ferring-and-evotec-form-strategic-research-alliance-in-reproductive-medicine-and-womens-health,17-10-2018 00:00,,,,,,
200,voyager-therapeutics-announces-preclinical-data-for-huntingtons-disease-and-amyotrophic-lateral-sclerosis-programs-at-the-congress-of-the-european-society-of-gene-and-cell-therapy,17-10-2018 00:00,,,,,,
201,imraldi-biogen-adalimumab-biosimilar-referencing-humira-is-launched-in-the-european-union,17-10-2018 00:00,,,,,,
202,novartis-announces-planned-acquisition-of-endocyte-to-expand-expertise-in-radiopharmaceuticals-and-build-on-commitment-to-transformational-therapeutic-platforms,18-10-2018 00:00,,,,,,
203,axsome-therapeutics-receives-fda-orphan-drug-designation-for-axs-12-for-the-treatment-of-narcolepsy,18-10-2018 00:00,,,,,,
204,allergan-announces-completion-of-two-positive-safety-studies-for-ubrogepant-an-oral-cgrp-receptor-antagonist-for-the-acute-treatment-of-migraine,18-10-2018 00:00,,,,,,
205,eiger-biopharmaceuticals-announces-patent-protection-for-lonafarnib-boosted-with-ritonavir-for-treatment-of-hepatitis-delta-virus-infection-in-europe-and-japan,18-10-2018 00:00,,,,,,
206,health-canada-has-approved-invokana-canagliflozin-for-reduction-of-major-adverse-cardiovascular-events-mace-the-first-sglt2-inhibitor-in-canada-to-receive-this-indication1,18-10-2018 00:00,,,,,,
207,mylan-adds-to-womens-healthcare-portfolio-with-launch-of-generic-depo-provera-injection,20-10-2018 00:00,,,,,,
208,abbotts-heartmate-3-heart-pump-now-fda-approved-for-advanced-heart-failure-patients-not-eligible-for-a-heart-transplant,22-10-2018 00:00,,,,,,
209,roches-tecentriq-plus-chemotherapy-carboplatin-and-abraxane-as-an-initial-treatment-helped-people-with-advanced-non-squamous-non-small-cell-lung-cancer-live-significantly-longer-compared-to-chemotherapy-alone,22-10-2018 00:00,,,,,,
210,solo-1-phase-iii-trial-demonstrates-lynparza-maintenance-therapy-cut-risk-of-disease-progression-or-death-by-70-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovarian-cancer,22-10-2018 00:00,,,,,,
211,ucb-and-biogen-announce-topline-results-from-a-phase-2b-study-of-dapirolizumab-pegol-in-systemic-lupus-erythematosus,23-10-2018 00:00,,,,,,
212,novartis-announces-lancet-publication-of-pioneering-study-in-migraine-prevention-showing-efficacy-of-aimovig-where-other-treatments-have-failed,23-10-2018 00:00,,,,,,
213,astrazeneca-strengthens-and-expands-oncology-development-and-commercialisation-collaboration-with-innate-pharma,23-10-2018 00:00,,,,,,
214,acr-2018-lilly-announces-positive-results-for-two-phase-3-studies-of-taltz-ixekizumab-in-ankylosing-spondylitis-radiographic-axial-spondyloarthritis,23-10-2018 00:00,,,,,,
215,alcon-to-develop-smart-suite-digital-health-platform-for-cataract-surgery,23-10-2018 00:00,,,,,,
216,fda-grants-orphan-drug-designation-to-omeros-oms721-for-treatment-of-hematopoietic-stem-cell-transplant-associated-thrombotic-microangiopathy,24-10-2018 00:00,,,,,,
217,enterome-signs-global-licensing-co-development-and-co-promotion-agreement-with-takeda-for-the-treatment-of-crohns-disease,24-10-2018 00:00,,,,,,
218,leo-pharma-and-zymeworks-enter-into-bispecific-antibody-licensing-and-research-collaboration,24-10-2018 00:00,,,,,,
219,orion-and-amgen-to-collaborate-on-the-commercialisation-of-amgevita-biosimilar-adalimumab-in-finland,25-10-2018 00:00,,,,,,
220,phase-iii-trial-of-darolutamide-in-patients-with-non-metastatic-castration-resistant-prostate-cancer-meets-primary-endpoint,25-10-2018 00:00,,,,,,
221,complete-results-from-first-study-in-ongoing-phase-3-program-for-tanezumab-demonstrated-significant-improvement-in-pain-and-function-in-osteoarthritis-patients,25-10-2018 00:00,,,,,,
222,oxford-biomedica-notes-that-axovant-doses-first-patient-in-clinical-study-of-axo-lenti-pd-a-novel-gene-therapy-for-patients-with-parkinsons-disease,25-10-2018 00:00,,,,,,
223,phase-iii-harmonize-global-trial-of-lokelma-confirms-efficacy-in-maintaining-normal-potassium-levels-in-asian-patients-with-hyperkalaemia,26-10-2018 00:00,,,,,,
224,seattle-genetics-announces-multiple-data-presentations-evaluating-adcetris-brentuximab-vedotin-in-patients-with-hodgkin-lymphoma-at-ishl-2018-october-26-2018-at-800-am-edt,26-10-2018 00:00,,,,,,
225,esperion-announces-positive-top-line-results-from-final-pivotal-phase-3-study-of-bempedoic-acid,29-10-2018 00:00,,,,,,
226,novartis-announces-clinical-collaboration-with-pfizer-to-advance-the-treatment-of-nash,29-10-2018 00:00,,,,,,
227,proqr-in-licenses-worldwide-rights-to-ophthalmology-drug-candidate-from-ionis-pharmaceuticals,30-10-2018 00:00,,,,,,
228,jazz-pharmaceuticals-announces-fda-approval-of-xyrem-sodium-oxybate-for-the-treatment-of-cataplexy-or-excessive-daytime-sleepiness-in-pediatric-narcolepsy-patients,30-10-2018 00:00,,,,,,
229,agreement-with-grnenthal-for-rights-to-nexium-in-europe-and-vimovo-worldwide-ex-us,30-10-2018 00:00,,,,,,
230,astellas-receives-european-approval-for-xtandi-enzalutamide-for-adult-men-with-high-risk-non-metastatic-castration-resistant-prostate-cancer,30-10-2018 00:00,,,,,,
231,us-food-and-drug-administration-approves-gileads-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide-for-treatment-of-hiv-1-infection,30-10-2018 00:00,,,,,,
232,mirati-therapeutics-announces-submission-of-ind-application-for-mrtx849-a-kras-g12c-inhibitor-to-treat-non-small-cell-lung-cancer-and-colorectal-cancer,31-10-2018 00:00,,,,,,
233,halozyme-licenses-new-enhanze-targets-for-25-million-upfront-payment-future-milestones-and-royalties,31-10-2018 00:00,,,,,,
234,us-fda-approves-invokana-canagliflozin-to-reduce-the-risk-of-heart-attack-stroke-or-cardiovascular-death-in-adults-with-type-2-diabetes-and-established-cardiovascular-disease,31-10-2018 00:00,,,,,,
235,biocardia-and-cellprothera-partner-for-clinical-trial-and-marketing-in-singapore-of-early-stem-cell-therapy-for-patients-following-myocardial-infarction,31-10-2018 00:00,,,,,,
236,indias-lupin-recalls-6-752-bottles-of-testosterone-topical-solution-from-us-pti-in-econmic-times,05-11-2018 00:00,,,,,,
237,us-fda-approves-udenyca-pegfilgrastim-cbqv,05-11-2018 00:00,,,,,,
238,initial-results-from-emprise-real-world-evidence-study-show-jardiance-was-associated-with-reduced-risk-for-hospitalization-for-heart-failure-compared-with-dpp-4-inhibitors-in-people-with-type-2-diabetes-with-and-without-cardiovascular-disease,05-11-2018 00:00,,,,,,
239,regenxbio-and-abeona-therapeutics-announce-worldwide-exclusive-licenses-for-the-treatment-of-four-rare-lysosomal-storage-disorders-using-nav-aav9-vector,06-11-2018 00:00,,,,,,
240,flx-bio-announces-clinical-trial-collaboration-agreement-with-merck-for-ongoing-phase-12-study-of-flx475,06-11-2018 00:00,,,,,,
241,odyssey-outcomes-investigators-highlight-at-aha-that-praluent-alirocumab-injection-was-associated-with-fewer-deaths-from-any-cause,12-11-2018 00:00,,,,,,
242,us-fda-accepts-regulatory-submission-for-lynparza-maintenance-therapy-in-newly-diagnosed-brca-mutated-advanced-ovarian-cancer-and-grants-priority-review,12-11-2018 00:00,,,,,,
244,fda-grants-priority-review-to-roches-tecentriq-in-combination-with-abraxane-for-the-initial-treatment-of-people-with-pd-l1-positive-metastatic-triple-negative-breast-cancer,13-11-2018 00:00,,,,,,
245,biotime-and-asterias-biotherapeutics-enter-into-definitive-merger-agreement-to-create-leading-cell-therapy-company,15-11-2018 00:00,,,,,,
246,merck-begins-rolling-submission-of-licensure-application-for-v920-rvsv-g-zebov-gp-to-us-food-and-drug-administration,14-11-2018 00:00,,,,,,
247,invo-bioscience-enters-exclusive-us-licensing-agreement-with-ferring-pharmaceuticals-to-commercialize-the-novel-invocell-system-for-use-in-the-treatment-of-infertility,14-11-2018 00:00,,,,,,
248,wugen-announces-exclusive-license-agreement-for-car-t-therapy-technologies-from-washington-university-in-st-louis,14-11-2018 00:00,,,,,,
249,mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-os-compared-to-chemotherapy-in-patients-with-advanced-esophageal-or-esophagogastric-junction-carcinoma-whose-tumors-express-pd-l1-cps-10,15-11-2018 00:00,,,,,,
250,grnenthal-acquires-averitas-pharma-and-establishes-commercial-footprint-in-the-us,15-11-2018 00:00,,,,,,
251,lilly-submits-new-drug-application-to-the-fda-for-lasmiditan-for-acute-treatment-of-migraine-receives-breakthrough-therapy-designation-for-emgality-galcanezumab-gnlm-for-prevention-of-episodic-cluster-headache,15-11-2018 00:00,,,,,,
252,bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-of-opdivo-nivolumab-plus-low-dose-yervoy-ipilimumab-as-first-line-treatment-for-patients-with-intermediate-and-poor-risk-advanced-renal-cell-carcinoma,16-11-2018 00:00,,,,,,
253,exelixis-partner-ipsen-receives-european-commission-approval-for-cabometyx-cabozantinib-tablets-for-the-treatment-of-hepatocellular-carcinoma-in-adults-previously-treated-with-sorafenib,16-11-2018 00:00,,,,,,
254,pfizer-to-raise-us-drug-prices-in-january-after-previously-backing-down,19-11-2018 00:00,,,,,,
255,china-national-medical-products-administration-nmpa-approves-gileads-vemlidy-tenofovir-alafenamide-for-chronic-hepatitis-b-virus-hbv-infectio,19-11-2018 00:00,,,,,,
256,astrazeneca-provides-update-on-the-phase-iii-mystic-trial-of-imfinzi-and-tremelimumab-in-stage-iv-non-small-cell-lung-cancer,19-11-2018 00:00,,,,,,
257,astrazeneca-provides-update-on-the-phase-iii-mystic-trial-of-imfinzi-and-tremelimumab-in-stage-iv-non-small-cell-lung-cancer,19-11-2018 00:00,,,,,,
258,immunocore-to-co-develop-imc-c103c-a-t-cell-redirecting-bi-specific-biologic-with-genentech,20-11-2018 00:00,,,,,,
259,geovax-and-leidos-enter-into-a-collaboration-agreement-on-immunotherapy-research-program,20-11-2018 00:00,,,,,,
260,sandoz-and-pear-therapeutics-announce-launch-of-reset-for-treatment-of-patients-with-substance-use-disorder,20-11-2018 00:00,,,,,,
261,alphabet-unit-halts-glucose-detecting-contact-lens-project,20-11-2018 00:00,,,,,,
262,boston-scientific-announces-recommended-offer-to-acquire-btg-plc,21-11-2018 00:00,,,,,,
263,orthoxel-orthopaedic-trauma-device-company-announce-ce-mark-clearance-following-fda-510k-for-new-apex-femoral-nailing-system,21-11-2018 00:00,,,,,,
264,mylan-initiates-voluntary-nationwide-recall-of-15-lots-of-valsartan-tablets-usp-amlodipine-and-valsartan-tablets-usp-and-valsartan-and-hydrochlorothiazide-tablets-usp-due-to-the-detection-of-trace-amounts-of-ndea-n-nitrosodiethylamine-impurity-fou,21-11-2018 00:00,,,,,,
265,leo-pharma-and-pellepharm-announce-760-million-collaboration-to-advance-innovative-therapies-for-rare-skin-diseases,21-11-2018 00:00,,,,,,
266,abbvie-receives-us-fda-accelerated-approval-for-venclexta-venetoclax-for-treatment-of-newly-diagnosed-acute-myeloid-leukemia-patients-ineligible-for-intensive-chemotherapy,22-11-2018 00:00,,,,,,
267,zenith-epigenetics-announces-clinical-trial-collaboration-with-pfizer,22-11-2018 00:00,,,,,,
268,evotec-and-immuneering-to-collaborate-on-artificial-intelligence-ai-driven-ligand-identification-for-rare-hereditary-metabolic-diseases,22-11-2018 00:00,,,,,,
269,medtronic-to-acquire-nutrino-health,22-11-2018 00:00,,,,,,
270,indivior-announces-health-canada-approval-of-sublocade-buprenorphine-extended-release-injection-for-patients-with-moderate-to-severe-opioid-use-disorder,26-11-2018 00:00,,,,,,
271,european-commission-approves-pelmeg-pegfilgrastim-as-a-biosimilar-treatment-to-reduce-the-duration-of-neutropenia-and-incidence-of-febrile-neutropenia-in-adults-treated-with-chemotherapy,26-11-2018 00:00,,,,,,
272,novartis-announces-landmark-eu-approval-for-one-time-gene-therapy-luxturna-to-restore-vision-in-people-with-rare-inherited-retinal-disease,26-11-2018 00:00,,,,,,
273,bristol-myers-squibb-announces-checkmate-451-study-did-not-meet-primary-endpoint-of-overall-survival-with-opdivo-plus-yervoy-vs-placebo-as-a-maintenance-therapy-in-patients-with-extensive-stage-small-cell-lung-cancer-after-completion-of-first-line,27-11-2018 00:00,,,,,,
274,regenxbio-and-rocket-pharmaceuticals-announce-new-license-agreement-for-the-treatment-of-danon-disease-using-nav-aav9-vector,27-11-2018 00:00,,,,,,
275,sandoz-receives-eighth-european-commission-approval-for-a-biosimilar-with-ziextenzo-pegfilgrastim,27-11-2018 00:00,,,,,,
276,fda-approves-the-actpen-for-genentechs-actemra-a-single-dose-prefilled-autoinjector-for-the-treatment-of-rheumatoid-arthritis-giant-cell-arteritis-and-two-forms-of-juvenile-arthritis,27-11-2018 00:00,,,,,,
277,fda-approves-vitrakvi-larotrectinib-the-first-ever-trk-inhibitor-for-patients-with-advanced-solid-tumors-harboring-an-ntrk-gene-fusion1-2,28-11-2018 00:00,,,,,,
278,oral-semaglutide-demonstrates-greater-reductions-in-both-hba1c-and-body-weight-compared-to-victoza-in-japanese-people-with-type-2-diabetes,28-11-2018 00:00,,,,,,
279,zymeworks-and-beigene-announce-license-and-collaboration-agreement-for-zymeworks-her2-targeted-therapeutic-candidates-zw25-and-zw49-in-asia-pacific-and-research-and-license-agreement-for-zymeworks-azymetric-and-efect-platforms-globally,28-11-2018 00:00,,,,,,
280,mesa-biotech-receives-fda-510k-clearance-and-clia-waiver-for-its-accula-rsv-molecular-point-of-care-test,28-11-2018 00:00,,,,,,
281,genentech-acquires-jecure-therapeutics,29-11-2018 00:00,,,,,,
282,european-commission-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro-doravirine-an-nnrti-both-for-the-treatment-of-hiv-1-in,29-11-2018 00:00,,,,,,
283,q-biomed-inc-announces-acquisition-of-cancer-pain-drug-metastron-from-ge-healthcare,29-11-2018 00:00,,,,,,
284,electrocore-receives-fda-clearance-for-gammacore-nvns-for-adjunctive-use-for-the-preventive-treatment-of-cluster-headache-in-adults,29-11-2018 00:00,,,,,,
285,xospata-gilteritinib-approved-by-us-fda-for-adult-patients-with-relapsedrefractory-acute-myeloid-leukemia-aml-with-a-flt3-mutation,30-11-2018 00:00,,,,,,
286,vertex-announces-european-commission-approval-for-kalydeco-ivacaftor-to-treat-patients-with-cystic-fibrosis-aged-12-to,30-11-2018 00:00,,,,,,
287,ntu-singapore-and-ttsh-invent-smart-medical-device-for-early-intervention-of-congestive-heart-failure,30-11-2018 00:00,,,,,,
288,shire-receives-european-approval-for-takhzyro-lanadelumab-subcutaneous-injection-for-the-preventive-treatment-of-hereditary-angioedema,03-12-2018 00:00,,,,,,
289,bluebird-bio-and-celgene-corporation-present-initial-data-from-ongoing-phase-1-clinical-study-of-next-generation-anti-bcma-car-t-cell-therapy-bb21217-in-patients-with-relapsedrefractory-multiple-myeloma-at-ash-annual-meeting,03-12-2018 00:00,,,,,,
290,pfizer-presents-positive-26-week-data-for-pf-05280586-a-potential-biosimilar-to-rituximab-at-the-american-society-of-hematology-annual-meeting,03-12-2018 00:00,,,,,,
291,gsk-reaches-agreement-to-acquire-tesaro-an-oncology-focused-biopharmaceutical-company,03-12-2018 00:00,,,,,,
292,argenx-enters-exclusive-global-collaboration-and-license-agreement-with-cilag-gmbh-international-an-affiliate-of-janssen-for-cusatuzumab-argx-110,04-12-2018 00:00,,,,,,
293,kite-announces-two-year-data-for-yescarta-axicabtagene-ciloleucel-in-patients-with-refractory-large-b-cell-lymphoma,04-12-2018 00:00,,,,,,
294,crown-laboratories-acquires-select-consumer-healthcare-brands-from-glaxosmithkline,04-12-2018 00:00,,,,,,
295,roches-kadcyla-cut-the-risk-of-disease-recurring-by-half-compared-to-herceptin-in-people-with-her2-positive-early-breast-cancer-with-residual-disease-after-neoadjuvant-treatment,06-12-2018 00:00,,,,,,
296,domain-therapeutics-signs-multi-target-research-license-and-collaboration-agreement-with-boehringer-ingelheim-on-g-protein-coupled-receptors-gpcrs-for-central-nervous-system-pathologies,05-12-2018 00:00,,,,,,
297,icagen-enters-into-collaboration-to-develop-and-commercialize-therapy-for-neurological-diseases-collaboration-includes-the-initial-program-utilizing-icagens-drug-discovery-platform,06-12-2018 00:00,,,,,,
298,subtle-medical-receives-fda-510k-clearance-and-ce-mark-approval-for-subtlepet,06-12-2018 00:00,,,,,,
299,novartis-investigational-byl719-alpelisib-plus-fulvestrant-consistently-improved-pfs-in-patients-with-pik3ca-mutated-hrher2-advanced-breast-cancer-in-new-solar-1-analyses,07-12-2018 00:00,,,,,,
300,biogen-exercises-option-with-ionis-to-develop-and-commercialize-investigational-treatment-biib067-for-a-subtype-of-familial-amyotrophic-lateral-sclerosis-als-based-on-positive-phase-1-data,07-12-2018 00:00,,,,,,
301,intellia-therapeutics-and-novartis-expand-cell-therapy-collaboration-to-pursue-crisprcas9-based-genome-editing-in-additional-stem-cell-population,07-12-2018 00:00,,,,,,
302,china-national-medical-products-administration-approves-descovy-emtricitabine-tenofovir-alafenamide-for-the-treatment-of-hiv-1-infection,05-12-2018 00:00,,,,,,
303,nnovate-biopharmaceuticals-enters-into-a-collaboration-with-massachusetts-general-hospital-and-announces-capital-update-for-the-celiac-disease-clinical-program-and-its-nash-development-strategy,05-12-2018 00:00,,,,,,
304,celltrion-healthcare-presents-positive-results-for-ct-p10-biosimilar-rituximab-in-advanced-follicular-lymphoma-at-the-american-society-of-hematology-meeting-2018,05-12-2018 00:00,,,,,,
305,neuropace-announces-final-results-from-the-largest-prospective-clinical-study-in-the-field-of-neuromodulation-with-9-year-follow-up-at-the-2018-american-epilepsy-society-annual-meeting,05-12-2018 00:00,,,,,,
306,fda-approves-genentechs-tecentriq-in-combination-with-avastin-and-chemotherapy-for-the-initial-treatment-of-people-with-a-specific-type-of-metastatic-lung-cancer,07-12-2018 00:00,,,,,,
307,daiichi-reports-results-of-fam-trastuzumab-deruxtecan-ds-8201-in-p-i-study-for-her2-low-expressing-metastatic-breast-cancer,10-12-2018 00:00,,,,,,
308,merck-licenses-cyclicas-in-silico-artificial-intelligence-ai-based-ligand-express-platform,10-12-2018 00:00,,,,,,
309,astrazeneca-reports-imfinzi-durvalumab-tremelimumab-results-in-p-iii-eagle-trial-for-advanced-head-and-neck-cancer,10-12-2018 00:00,,,,,,
310,bristol-myers-squibb-and-vedanta-biosciences-announce-a-new-clinical-collaboration-to-evaluate-opdivo-nivolumab-and-ve800-in-patients-with-advanced-or-metastatic-cancers,11-12-2018 00:00,,,,,,
311,novartis-data-demonstrates-consistent-efficacy-and-tolerability-of-kisqali-combination-therapy-in-hrher2-advanced-breast-cancer-in-patients-with-difficult-to-treat-visceral-disease,11-12-2018 00:00,,,,,,
312,shionogi-and-ube-industries-entered-into-strategic-research-collaboration-for-novel-anti-rs-virus-drug-candidates,11-12-2018 00:00,,,,,,
313,sandoz-inc-and-pear-therapeutics-obtain-fda-clearance-for-reset-o-to-treat-opioid-use-disorder,11-12-2018 00:00,,,,,,
314,astellas-launches-xospata-gilteritinib-in-the-us-for-the-treatment-of-adult-patients-with-relapsedrefractory-acute-myeloid-leukemia-aml-with-a-flt3-mutation,12-12-2018 00:00,,,,,,
315,circassia-to-exercise-option-for-full-us-commercial-rights-to-copd-treatment-tudorza-from-astrazeneca,12-12-2018 00:00,,,,,,
316,johnson-johnson-announces-research-study-with-apple-watch-to-help-improve-afib-outcomes-including-stroke-prevention,18-01-2019 00:00,,,,,,
317,biomed-x-and-boehringer-ingelheim-to-investigate-early-intervention-in-psychiatric-diseases,18-01-2019 00:00,,,,,,
318,ironwood-pharmaceuticals-announces-approval-of-linzess-linaclotide-in-china-for-the-treatment-of-adults-with-ibs-c,16-01-2019 00:00,,,,,,
319,national-institutes-of-health-launches-fitbit-project-as-first-digital-health-technology-initiative-in-landmark-all-of-us-research-program,17-01-2019 00:00,,,,,,
320,luye-pharma-reaches-strategic-partnership-with-astrazeneca-strengthens-commitment-to-cardiovascular-therapeutic-field-luye-pharma-grants-astrazeneca-exclusives-rights-to-promote-xuezhikang-capsules-in-mainland-china,17-01-2019 00:00,,,,,,
321,roche-launches-upath-enterprise-software-with-improved-speed-performance-and-usability-for-digital-pathology,17-01-2019 00:00,,,,,,
322,abbott-to-acquire-cephea-valve-technologies-inc,17-01-2019 00:00,,,,,,
323,bioharmony-therapeutics-and-boehringer-ingelheim-collaborate-to-advance-bacteriophage-lysin-therapeutics-for-the-treatment-of-multi-drug-resistant-bacterial-infections,16-01-2019 00:00,,,,,,
324,beigene-receives-us-fda-breakthrough-therapy-designation-for-zanubrutinib-in-mantle-cell-lymphoma,16-01-2019 00:00,,,,,,
325,biomunex-pharmaceuticals-signs-a-licensing-agreement-with-sanofi-for-the-development-of-bi-and-multi-specific-antibodies,16-01-2019 00:00,,,,,,
326,fda-approves-worlds-first-device-for-treatment-of-premature-babies-and-newborns-with-an-opening-in-their-hearts-a-common-congenital-defect,15-01-2019 00:00,,,,,,
327,bio-thera-solutions-ltd-partners-with-cipla-ltd-to-market-key-cancer-biosimilar,15-01-2019 00:00,,,,,,
328,array-biopharma-announces-153-months-median-overall-survival-from-the-safety-lead-in-of-the-phase-3-beacon-crc-trial-of-the-combination-braftovi-mektovi-and-erbitux-in-braf-mutant-metastatic-colorectal-cancer,15-01-2019 00:00,,,,,,
329,exelixis-announces-us-fda-approval-of-cabometyx-cabozantinib-tablets-for-previously-treated-hepatocellular-carcinoma,15-01-2019 00:00,,,,,,
330,european-commission-approves-opdivo-nivolumab-plus-low-dose-yervoy-ipilimumab-for-first-line-treatment-of-patients-with-intermediate-and-poor-risk-advanced-renal-cell-carcinoma,15-01-2019 00:00,,,,,,
331,ascletis-and-alphamab-announce-strategic-collaboration-and-licensing-agreement-for-anti-pd-l1-to-treat-hepatitis-b-and-other-viral-diseases,14-01-2019 00:00,,,,,,
332,tium-bio-licenses-out-lung-disease-drug-candidate-for-us74-million,14-01-2019 00:00,,,,,,
333,puma-biotechnology-and-knight-therapeutics-enter-into-exclusive-license-agreement-to-commercialize-nerlynx-neratinib-in-canada,14-01-2019 00:00,,,,,,
335,ema-grants-orphan-drug-designation-to-rafael-pharmaceuticals-devimistat-cpi-613-for-treatment-of-patients-with-relapsed-or-refractory-acute-myeloid-leukemia-aml,11-01-2019 00:00,,,,,,
336,glenmark-pharmaceuticals-enters-into-an-exclusive-licensing-agreement-with-yuhan-corporation-for-commercializing-investigational-seasonal-allergic-rhinitis-nasal-spray-ryaltris-in-south-korea,11-01-2019 00:00,,,,,,
337,sumitomo-dainippon-pharma-announces-positive-topline-results-from-a-phase-iii-clinical-study-jewel-study-of-lurasidone-an-atypical-antipsychotic-agent-in-the-treatment-of-patients-with-schizophrenia,11-01-2019 00:00,,,,,,
338,empaticas-pediatric-seizure-predicting-smartband-wins-fda-nod,10-01-2019 00:00,,,,,,
339,elevian-and-insilico-enter-a-research-collaboration-to-discover-drugs-that-target-aging,10-01-2019 00:00,,,,,,
340,new-england-journal-of-medicine-publishes-positive-results-of-the-pivotal-trial-of-cablivi-caplacizumab-for-rare-blood-clotting-disorder,10-01-2019 00:00,,,,,,
341,immunogen-announces-sale-of-residual-kadcyla-royalties,09-01-2019 00:00,,,,,,
342,janssen-submits-application-to-european-medicines-agency-seeking-approval-of-stelara-ustekinumab-for-treatment-of-adult-patients-with-moderately-to-severely-active-ulcerative-colitis,09-01-2019 00:00,,,,,,
343,exelixis-collaborator-daiichi-sankyo-receives-regulatory-approval-for-minnebro-esaxerenone-tablets-for-the-treatment-of-hypertension-in-japan,09-01-2019 00:00,,,,,,
344,evenity-subcutaneous-injection-105mg-syringe-receives-the-first-in-the-world-approval-in-japan-for-the-treatment-of-osteoporosis-at-high-risk-of-fracture,09-01-2019 00:00,,,,,,
345,samsung-bioepis-partners-with-3sbio-to-expand-biosimilar-business-into-china,08-01-2019 00:00,,,,,,
346,lilly-announces-agreement-to-acquire-loxo-oncology,08-01-2019 00:00,,,,,,
347,novartis-investigational-therapy-crizanlizumab-seg101-receives-fda-breakthrough-therapy-designation-for-the-prevention-of-vaso-occlusive-crises-in-sickle-cell-disease,08-01-2019 00:00,,,,,,
348,merck-exercises-option-for-ngm-bios-investigational-insulin-sensitizer-ngm313-for-the-treatment-of-nash-and-type-2-diabetes,04-01-2019 00:00,,,,,,
349,boehringer-ingelheim-and-vanderbilt-university-announce-partnership-to-develop-novel-therapies-for-psychiatric-disorders,04-01-2019 00:00,,,,,,
350,esperion-announces-agreement-with-daiichi-sankyo-europe-dse-to-commercialize-bempedoic-acid-in-europe,04-01-2019 00:00,,,,,,
351,mercks-keytruda-pembrolizumab-receives-five-new-approvals-in-japan-including-in-advanced-non-small-cell-lung-cancer-nsclc-as-adjuvant-therapy-for-melanoma-and-in-advanced-microsatellite-instability-high-msi-h-tumors,03-01-2019 00:00,,,,,,
352,bristol-myers-squibb-to-acquire-celgene-to-create-a-premier-innovative-biopharma-company,03-01-2019 00:00,,,,,,
353,progenics-and-curium-announce-european-collaboration-for-prostate-cancer-imaging-agent-pyl,03-01-2019 00:00,,,,,,
354,aprinoia-therapeutics-licenses-tau-pet-imaging-tracer-apn-1607-to-celgene,03-01-2019 00:00,,,,,,
355,bristol-myers-squibbs-sprycel-dasatinib-tablets-now-approved-in-combination-with-chemotherapy-in-certain-pediatric-patients-with-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia,03-01-2019 00:00,,,,,,
356,adsing-multimedia-teva-announces-fda-approval-of-first-and-only-digital-inhaler-with-built-in-sensors-?-proair?-digihaler?-albuterol-sulfate-117-mcg-inhalation-powder,31-12-2018 00:00,,,,,,
357,inventisbio-and-betta-pharma-to-co-develop-novel-drug-for-non-small-cell-lung-cancer,31-12-2018 00:00,,,,,,
358,fda-approves-elzonris-tagraxofusp-the-first-treatment-for-blastic-plasmacytoid-dendritic-cell-neoplasm-and-first-cd123-targeted-therapy,31-12-2018 00:00,,,,,,
359,fda-approves-vaxelis-sanofi-and-msd?s-pediatric-hexavalent-combination-vaccine,29-12-2018 00:00,,,,,,
360,horizon-pharma-plc-announces-fda-approval-to-expand-the-age-range-for-ravicti-glycerol-phenylbutyrate-oral-liquid-to-include-newborns,28-12-2018 00:00,,,,,,
361,innovent-lilly-co-developed-tyvyt-gets-chinas-nmpa-approval-for-chl,28-12-2018 00:00,,,,,,
362,jhl-biotech-announces-first-patient-randomized-in-the-phase-iii-study-of-jhl1101-to-treat-diffuse-large-b-cell-lymphoma,28-12-2018 00:00,,,,,,
363,merck-and-pfizer-provide-update-on-javelin-ovarian-100-trial-of-avelumab-in-previously-untreated-advanced-ovarian-cancer,28-12-2018 00:00,,,,,,
364,lupin-and-abbvie-announce-partnership-to-develop-and-commercialize-novel-oncology-drug-to-treat-hematological-cancers,27-12-2018 00:00,,,,,,
365,alexion-receives-early-fda-approval-for-ultomiri-ravulizumab-cwvz-in-adults-with-paroxysmal-nocturnal-hemoglobinuria-pnh,27-12-2018 00:00,,,,,,
366,zydus-receives-approvals-from-the-usfda-for-doxycycline-hyclate-delayed-release-tablets-and-febuxostat-tablets,27-12-2018 00:00,,,,,,
367,fda-approves-merck?s-keytruda-pembrolizumab-for-the-treatment-of-adult-and-pediatric-patients-with-recurrent-locally-advanced-or-metastatic-merkel-cell-carcinoma-a-rare-form-of-skin-cancer,20-12-2018 00:00,,,,,,
368,bristol-myers-squibb-announces-offer-from-taisho-pharmaceutical-holdings-co-ltd-to-purchase-upsa,20-12-2018 00:00,,,,,,
369,lynparza-olaparib-approved-by-fda-for-first-line-maintenance-therapy-in-brca-mutated-advanced-ovarian-cancer-astrazeneca-and-merck?s-lynparza-reduced-the-risk-of-disease-progression-or-death-by-70-percent-compared-to-placebo-following-response-to-platinum-based-chemotherapy-first-parp-inhibitor-approved-in-first-line-maintenance-for-brcam-advanced-ovarian-cancer,20-12-2018 00:00,,,,,,
370,albireo-granted-orphan-designation-by-european-commission-for-lead-product-candidate-a4250-for-treatment-of-biliary-atresia,19-12-2018 00:00,,,,,,
371,boston-scientific-announces-recommended-offer-to-acquire-btg-plc,19-12-2018 00:00,,,,,,
372,alcon-announces-acquisition-of-tear-film-innovations-inc,19-12-2018 00:00,,,,,,
373,lilly-and-aduro-biotech-announce-research-collaboration-and-license-agreement-to-develop-novel-immunotherapies,19-12-2018 00:00,,,,,,
374,amgen-and-molecular-partners-announce-strategic-collaboration-in-immuno-oncology,19-12-2018 00:00,,,,,,
375,bristol-myers-squibb-receives-positive-chmp-opinion-recommending-sprycel-dasatinib-for-pediatric-patients-with-newly-diagnosed-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia,18-12-2018 00:00,,,,,,
376,ligand-acquires-milestone-and-royalty-rights-to-ptx-022-from-palvella-therapeutics,18-12-2018 00:00,,,,,,
377,european-commission-approves-merck?s-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma,18-12-2018 00:00,,,,,,
378,lilly-to-acquire-pre-clinical-pain-program-from-hydra-biosciences,17-12-2018 00:00,,,,,,
379,merck-to-acquire-privately-held-antelliq-group,17-12-2018 00:00,,,,,,
380,merck-to-acquire-privately-held-antelliq-group,17-12-2018 00:00,,,,,,
381,novartis-receives-european-commission-approval-for-self-administration-of-xolair-across-all-indications,14-12-2018 00:00,,,,,,
382,health-canada-grants-market-authorization-for-orkambi?-lumacaftorivacaftor-for-children-with-cystic-fibrosis-aged-2-to-5-years-old-with-most-common-form-of-the-disease,14-12-2018 00:00,,,,,,
383,axovant-licenses-investigational-gene-therapies-for-gm1-gangliosidosis-tay-sachs-and-sandhoff-diseases-from-university-of-massachusetts-medical-school,14-12-2018 00:00,,,,,,
384,fda-grants-fast-track-designation-to-the-baricitinib-development-program-for-the-treatment-of-systemic-lupus-erythematosus-sle,14-12-2018 00:00,,,,,,
385,fda-approves-vaxelis-sanofi-and-msd?s-pediatric-hexavalent-combination-vaccine,13-12-2018 00:00,,,,,,
386,lilly-and-ac-immune-announce-license-and-collaboration-agreement,13-12-2018 00:00,,,,,,
387,merck-and-instituto-butantan-announce-collaboration-agreement-to-develop-vaccines-to-protect-against-dengue-infections,13-12-2018 00:00,,,,,,
388,oxford-biotherapeutics-expands-strategic-collaboration-with-wuxi-biologics-and-licenses-wuxibody?-platform-for-five-bispecific-antibody-programs-for-up-to-450-million,13-12-2018 00:00,,,,,,
389,cormedix-inc-announces-highly-statistically-significant-topline-results-for-neutrolin?-from-the-interim-analysis-of-the-phase-3-lock-it-100-study,18-01-2019 00:00,,,,,,
390,thyas-obtains-exclusive-rights-to-manufacture-induced-pluripotent-stem-cells-derived-killer-t-cells-for-autologous-immunotherapy,18-01-2019 00:00,,,,,,
391,us-fda-approves-ontruzant-trastuzumab-dttb-samsung-bioepis?-first-oncology-medicine-in-the-united-states,21-01-2019 00:00,,,,,,
392,vertex-announces-european-commission-approval-for-orkambi-lumacaftorivacaftor-for-treatment-of-children-with-cystic-fibrosis-aged-2-to-5-years-old-with-most-common-form-of-the-disease,21-01-2019 00:00,,,,,,
393,obsidian-therapeutics-announces-strategic-collaboration-with-celgene-to-develop-novel-cell-therapies-with-tunable-immunomodulatory-factors-opening-potential-for-car-t-and-other-cellular-medicines-in-new-settings,21-01-2019 00:00,,,,,,
394,sandoz-canada-receives-health-canada-approval-for-erelzi-etanercept-in-the-treatment-of-psoriatic-arthritis-psa-in-adult-patients,22-01-2019 00:00,,,,,,
395,verily-study-watch-receives-fda-510k-clearance-for-ecg,22-01-2019 00:00,,,,,,
396,lilly-phase-3-reach-2-trial-data-published-in-the-lancet-oncology-shows-improvement-in-overall-survival-with-cyramza?-ramucirumab-in-second-line-afp-high-hepatocellular-carcinoma-patients,22-01-2019 00:00,,,,,,
397,crispr-therapeutics-and-probiogen-sign-collaboration-and-license-agreement-to-develop-novel-in-vivo-delivery-technologies,22-01-2019 00:00,,,,,,
398,lilly-reports-results-of-phase-3-soft-tissue-sarcoma-study-of-lartruvo,22-01-2019 00:00,,,,,,
399,european-commission-approves-blincyto-blinatumomab-in-patients-with-philadelphia-chromosome-negative-minimal-residual-disease-positive-b-cell-precursor-acute-lymphoblastic-leukemia,23-01-2019 00:00,,,,,,
400,albireo-granted-orphan-drug-designation-by-fda-for-lead-product-candidate-a4250-for-treatment-of-biliary-atresia,23-01-2019 00:00,,,,,,
401,klaria-signs-exclusive-development-agreement-with-purdue-pharma-for-acute-adrenaline-treatment-of-allergic-reaction,23-01-2019 00:00,,,,,,
402,ema-grants-orphan-drug-designation-to-tlc178-for-the-treatment-of-soft-tissue-sarcoma,23-01-2019 00:00,,,,,,
403,abbott-offers-a-new-option-for-physicians-treating-patients-with-atrial-fibrillation,23-01-2019 00:00,,,,,,
404,b-mogen-biotechnologies-and-cytosen-therapeutics-partner-on-research-collaboration-to-develop-next-generation-natural-killer-cells-for-human-therapeutics,24-01-2019 00:00,,,,,,
405,athersys-announces-positive-results-from-its-exploratory-clinical-study-of-multistem?-cell-therapy-for-treatment-of-acute-respiratory-distress-syndrome-ards,24-01-2019 00:00,,,,,,
406,rigel-pharmaceuticals-enters-collaboration-and-license-agreement-with-grifols-sa-to-commercialize-fostamatinib-in-europe,24-01-2019 00:00,,,,,,
407,23andme-receives-fda-clearance-for-genetic-health-risk-report-that-looks-at-a-hereditary-colorectal-cancer-syndrome,24-01-2019 00:00,,,,,,
408,philogen-announces-collaboration-with-celgene,24-01-2019 00:00,,,,,,
409,govt-may-fix-trade-margins-on-expensive-orphan-cancer-drugs,25-01-2019 00:00,,,,,,
410,q-biomed-technology-partner-mannin-research-enters-into-collaboration-with-mcmaster-university-for-glaucoma-drug-candidate-man-01,28-01-2019 00:00,,,,,,
411,merck-grants-exclusive-license-to-vertex-for-two-dna-damage-response-inhibitors,28-01-2019 00:00,,,,,,
412,medtronic-to-acquire-epix-therapeutics-expanding-its-cardiac-ablation-portfolio,28-01-2019 00:00,,,,,,
413,clovis-oncology-announces-european-commission-authorization-of-rubraca-rucaparib-tablets-as-maintenance-treatment-for-women-with-relapsed-ovarian-cancer,25-01-2019 00:00,,,,,,
414,dr-reddys-laboratories-and-its-us-subsidiary-promius-pharma-announce-fda-approval-for-tosymra?-sumatriptan-nasal-spray-10-mg-in-the-us-market,28-01-2019 00:00,,,,,,
415,amgen-receives-nmpa-approval-for-repatha-evolocumab-in-china-to-reduce-the-risk-of-cardiovascular-events,24-01-2019 00:00,,,,,,
416,basilea-announces-collaboration-to-study-derazantinib-and-atezolizumab-tecentriq?-in-urothelial-cancer,25-01-2019 00:00,,,,,,
417,amgen-and-allergan-announce-positive-top-line-results-from-phase-1-phase-3-study-of-abp-798-biosimilar-candidate-to-rituximab,24-01-2019 00:00,,,,,,
418,zimmer-biomet-receives-fda-clearance-for-rosa-knee-system-for-robotically-assisted-surgeries,28-01-2019 00:00,,,,,,
419,abbvie-announces-us-fda-approval-of-imbruvica-ibrutinib-plus-obinutuzumab-gazyva?-?-first-chemotherapy-free-anti-cd20-combination-regimen-approved-for-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-cllsll-in-previously-untreated-patients,28-01-2019 00:00,,,,,,
420,alexion-announces-positive-top-line-results-from-phase-3-study-of-ultomiris?-ravulizumab-cwvz-in-complement-inhibitor-na?ve-patients-with-atypical-hemolytic-uremic-syndrome-ahus,29-01-2019 00:00,,,,,,
421,purdue-pharma-lp-and-alivio-therapeutics-enter-into-partnership-to-advance-alv-107-a-non-opioid-interstitial-cystitisbladder-pain-syndrome-treatment,29-01-2019 00:00,,,,,,
422,nmpa-accepts-new-drug-application-for-ibi-305-a-biosimilar-product-candidate-of-bevacizumab-avastin?,29-01-2019 00:00,,,,,,
423,health-canada-grants-market-authorization-for-kalydeco-ivacaftor-in-children-ages-12-to,29-01-2019 00:00,,,,,,
424,medtronic-announces-us-commercial-launch-of-mazor-x-stealthtm-edition-for-robotic-assisted-spine-surgery,29-01-2019 00:00,,,,,,
425,priority-review-granted-to-zai-lab?s-nda-application-for-zejula-niraparib-in-china,29-01-2019 00:00,,,,,,
426,pfizer-and-lilly-announce-top-line-results-from-second-phase-3-study-of-tanezumab-in-osteoarthritis-pain,30-01-2019 00:00,,,,,,
427,takeda?s-dengue-vaccine-candidate-meets-primary-endpoint-in-pivotal-phase-3-efficacy-trial,30-01-2019 00:00,,,,,,
428,sumitomo-dainippon-pharma-announces-the-approval-of-atypical-antipsychotic-latuda?-lurasidone-hcl-for-the-treatment-of-patients-with-schizophrenia-in-china,30-01-2019 00:00,,,,,,
429,key-eu-medicines-regulator-closes-london-office-with-loss-of-900-jobs,30-01-2019 00:00,,,,,,
430,neurocrine-biosciences-and-voyager-therapeutics-form-strategic-development-and-commercialization-collaboration-for-parkinson?s-disease-and-friedreich?s-ataxia,30-01-2019 00:00,,,,,,
431,roche-to-discontinue-phase-iii-cread-1-and-2-clinical-studies-of-crenezumab-in-early-alzheimer?s-disease-ad-?-other-company-programmes-in-ad-continue,31-01-2019 00:00,,,,,,
432,us-fda-approves-lumoxiti-moxetumomab-pasudotox-tdfk-for-certain-patients-with-relapsed-or-refractory-hairy-cell-leukaemia,14-09-2018 00:00,,,,,,
433,fda-approves-subcutaneous-formulation-of-actemra-for-use-in-active-systemic-juvenile-idiopathic-arthritis-sjia-a-rare-form-of-juvenile-arthritis,14-09-2018 00:00,,,,,,
434,exelixis?-partner-ipsen-announces-health-canada?s-approval-of-cabometyx-cabozantinib-tablets-for-the-treatment-of-adults-with-previously-treated-advanced-renal-cell-carcinoma,20-09-2018 00:00,,,,,,
435,merck-receives-positive-chmp-opinion-for-delstrigo-doravirinelamivudinetenofovir-disoproxil-fumarate-and-pifeltro?-doravirine-in-the-european-union-for-the-treatment-of-hiv-1-infection,21-09-2018 00:00,,,,,,
436,coherus-biosciences-receives-european-commission-approval-for-udenyca-pegfilgrastim-biosimilar,26-09-2018 00:00,,,,,,
437,anaeropharma-science-signs-collaborative-research-agreement-with-astellas-on-creation-of-novel-anti-tumor-drugs-using-bifidobacterium,26-09-2018 00:00,,,,,,
438,i-mab-biopharma-expands-strategic-collaboration-with-wuxi-biologics-and-licenses-wuxibody?-platform-for-three-bispecific-antibody-programs,27-09-2018 00:00,,,,,,
439,fda-approves-libtayo-cemiplimab-rwlc-as-first-and-only-treatment-for-advanced-cutaneous-squamous-cell-carcinoma,01-10-2018 00:00,,,,,,
440,kite-and-hifibio-therapeutics-announce-a-research-collaboration-to-develop-technology-for-the-potential-discovery-of-neoantigen-reactive-t-cell-receptors-tcrs-for-the-treatment-of-cancer,03-10-2018 00:00,,,,,,
441,health-canada-approves-tresiba-for-children-with-type-1-diabetes,03-10-2018 00:00,,,,,,
442,eagle-pharmaceuticals-enters-into-agreement-with-usamricd-to-evaluate-neuroprotective-effects-of-ryanodex-secondary-to-nerve-agent-exposure,04-10-2018 00:00,,,,,,
443,xbrane-biopharma-tillk?nnager-resultat-fr?n-in-vivo-studie-som-p?visar-ekvivalent-tolerabilitet-och-farmakokinetisk-profil-f?r-xlucane-j?mf?rt-med-lucentis?,04-10-2018 00:00,,,,,,
444,meiragtx-announces-acquisition-of-vector-neurosciences-gains-phase-2-gene-therapy-program-for-parkinson?s-disease,10-10-2018 00:00,,,,,,
445,new-analyses-from-pivotal-phase-3-trials-of-oral-ozanimod-to-be-presented-at-ectrims-2018,11-10-2018 00:00,,,,,,
446,myriad-announces-new-laboratory-agreement-with-pfizer,12-10-2018 00:00,,,,,,
447,dr-reddys-laboratories-announces-the-sale-of-its-api-manufacturing-business-unit-in-jeedimetla-hyderabad,15-10-2018 00:00,,,,,,
448,themis-bioscience-announces-exclusive-licensing-agreement-with-max-planck-innovation-to-develop-and-commercialize-oncolytic-virotherapie,15-10-2018 00:00,,,,,,
449,myriad-announces-new-laboratory-agreement-with-pfizer,17-10-2018 00:00,,,,,,
450,mylan-launches-hulio-biosimilar-adalimumab-in-markets-across-europe,22-10-2018 00:00,,,,,,
451,mylan-and-biocon-announce-positive-chmp-opinion-for-ogivri-biosimilar-trastuzumab,22-10-2018 00:00,,,,,,
452,pfizer-presents-overall-survival-data-from-paloma-3-trial-of-ibrance-palbociclib-in-patients-with-hr-her2-metastatic-breast-cancer,22-10-2018 00:00,,,,,,
453,novartis-combi-ad-study-of-tafinlar-mekinist-continues-to-demonstrate-relapse-free-survival-benefit-in-patients-with-braf-v600-mutant-stage-iii-melanoma,22-10-2018 00:00,,,,,,
454,bimekizumab-showed-sustained-improvements-in-both-joint-and-skin-outcomes-for-psoriatic-arthritis-patients,24-10-2018 00:00,,,,,,
455,roche-announces-fda-approval-of-xofluza-baloxavir-marboxil-for-influenza,25-10-2018 00:00,,,,,,
456,medtronic-receives-fda-approval-for-valiant-navion-thoracic-stent-graft-system,26-10-2018 00:00,,,,,,
457,eylea-aflibercept-injection-improves-diabetic-retinopathy-and-reduces-vision-threatening-complications-in-phase-3-trial,26-10-2018 00:00,,,,,,
458,esperion-announces-completion-of-phase-3-ldl-c-lowering-development-program-of-bempedoic-acid-and-positive-cumulative-results,29-10-2018 00:00,,,,,,
459,lilly-and-dicerna-announce-rnai-licensing-and-research-collaboration,29-10-2018 00:00,,,,,,
460,g3-pharmaceuticals-signs-exclusive-license-and-option-agreement-for-treating-diastolic-heart-failure-hfpef-by-inhibiting-galectin-3,31-10-2018 00:00,,,,,,
461,gilead-sciences-and-tango-therapeutics-have-entered-into-a-global-collaboration-to-discover-develop-and-commercialize-a-pipeline-of-targeted-immuno-oncology-treatments-for-cancer,01-11-2018 00:00,,,,,,
462,sandoz-receives-us-fda-approval-for-biosimilar-hyrimoz?-adalimumab-adaz,01-11-2018 00:00,,,,,,
463,phase-iii-data-showed-that-venclextavenclyxto-plus-gazyvagazyvaro-reduced-the-risk-of-disease-worsening-or-death-in-people-with-previously-untreated-chronic-lymphocytic-leukaemia-with-co-morbidities,01-11-2018 00:00,,,,,,
464,roche-announces-eu-approval-of-venclyxto-plus-mabthera-for-people-with-previously-treated-chronic-lymphocytic-leukaemia,01-11-2018 00:00,,,,,,
465,sanofi-and-denali-therapeutics-to-develop-treatments-for-neurological-and-inflammatory-diseases,01-11-2018 00:00,,,,,,
466,vertex-announces-european-authorization-for-third-cystic-fibrosis-medicine-symkevi-tezacaftorivacaftor-to-be-used-in-combination-with-ivacaftor-kalydeco?-for-people-with-cf-aged-12-and-older-with-certain-mutations-in-the-cftr-gene,02-11-2018 00:00,,,,,,
467,aileron-therapeutics-announces-clinical-trial-collaboration-with-dana-farberboston-children?s-cancer-and-blood-disorders-center,02-11-2018 00:00,,,,,,
468,bioarctic?s-partner-abbvie-exercises-its-option-to-license-the-alpha-synuclein-antibody-portfolio-for-parkinson?s-disease,02-11-2018 00:00,,,,,,
469,illumina-to-acquire-pacific-biosciences-for-approximately-12-billion-broadening-access-to-long-read-sequencing-and-accelerating-scientific-discovery,02-11-2018 00:00,,,,,,
470,sage-therapeutics-announces-fda-advisory-committee-votes-17-1-in-support-of-benefit-risk-profile-of-zulresso-brexanolone-injection-for-treatment-of-postpartum-depression,05-11-2018 00:00,,,,,,
471,lilly-and-nextcure-announce-collaboration-to-discover-and-develop-novel-immuno-oncology-medicines,06-11-2018 00:00,,,,,,
472,amgen-announces-presentation-of-research-reinforcing-the-long-term-safety-and-efficacy-of-repatha?-evolocumab-in-high-risk-patients-at-aha-scientific-sessions-2018,06-11-2018 00:00,,,,,,
473,amgen-and-provention-bio-announce-co-development-collaboration-in-celiac-disease,05-11-2018 00:00,,,,,,
474,new-data-from-investigational-study-of-lenvima-lenvatinib-and-keytruda-pembrolizumab-combination-in-three-different-tumor-types-presented-at-the-society-for-immunotherapy-of-cancer?s-33rd-annual-meeting,12-11-2018 00:00,,,,,,
475,amgen-presents-results-highlighting-the-long-term-safety-and-efficacy-of-repatha-evolocumab-in-the-longest-duration-study-of-a-pcsk9-inhibitor-to-date-at-aha-scientific-sessions-2018,13-11-2018 00:00,,,,,,
476,novartis-announces-eu-approval-of-gilenya-for-children-and-adolescents-with-ms-making-it-the-first-and-only-oral-disease-modifying-treatment-for-these-patients-in-europe,30-11-2018 00:00,,,,,,
477,janssen-announces-erleada-apalutamide-phase-3-titan-study-unblinded-as-dual-primary-endpoints-achieved-in-clinical-program-evaluating-treatment-of-patients-with-metastatic-castration-sensitive-prostate-cancer,31-01-2019 00:00,,,,,,
478,merck-receives-breakthrough-therapy-designation-from-fda-for-v114-the-company?s-investigational-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-infants-children-and-adolescents,31-01-2019 00:00,,,,,,
479,columbia-engineers-translate-brain-signals-directly-into-speech,31-01-2019 00:00,,,,,,
480,fda-expands-lillys-alimta-pemetrexed-label-with-combination-of-keytruda?-pembrolizumab-and-platinum-chemotherapy-for-the-first-line-treatment-of-metastatic-nonsquamous-non-small-cell-lung-cancer,31-01-2019 00:00,,,,,,
481,janssen-enters-worldwide-collaboration-and-license-agreement-with-meiragtx-to-develop-gene-therapy-programs-for-inherited-retinal-diseases,01-02-2019 00:00,,,,,,
482,bayer-and-kyoto-university-form-research-alliance-to-discover-new-treatment-approaches-against-lung-diseases,01-02-2019 00:00,,,,,,
483,alexion-and-caelum-biosciences-announce-collaboration-to-develop-targeted-therapy-for-light-chain-al-amyloidosis,01-02-2019 00:00,,,,,,
484,audentes-therapeutics-announces-next-steps-in-the-development-of-at132-to-treat-xlmtm-following-collaborative-initial-meeting-with-fda-under-rmat-designation,01-02-2019 00:00,,,,,,
485,repare-therapeutics-announces-a-strategic-partnership-agreement-with-ono-pharmaceutical-co-ltd-for-repare?s-pol-inhibitor-program-in-japan-and-selected-territories-in-asia,01-02-2019 00:00,,,,,,
486,fda-warns-patients-and-doctors-about-recall-of-home-use-test-strips-used-with-device-to-monitor-blood-thinner-warfarin-not-authorized-for-sale-in-us,04-02-2019 00:00,,,,,,
487,evolus-receives-fda-approval-for-jeuveau-prabotulinumtoxina-xvfs-for-injection,04-02-2019 00:00,,,,,,
488,nice-recommends-another-revolutionary-car-t-cell-therapy-for-adults-with-lymphoma,04-02-2019 00:00,,,,,,
489,european-medicines-agency-adopts-positive-opinion-for-merck?s-keytruda?-pembrolizumab-in-combination-with-chemotherapy-for-first-line-treatment-of-adults-with-metastatic-squamous-non-small-cell-lung-cancer-nsclc,04-02-2019 00:00,,,,,,
490,argenx-and-halozyme-enter-global-collaboration-and-license-agreement-for-enhanze-technology,05-02-2019 00:00,,,,,,
491,lilly-announces-top-line-phase-3-results-for-baricitinib-in-patients-with-moderate-to-severe-atopic-dermatitis,05-02-2019 00:00,,,,,,
492,biolinerx-receives-orphan-drug-designation-from-the-fda-for-its-lead-therapeutic-candidate-bl-8040-for-the-treatment-of-pancreatic-cancer,05-02-2019 00:00,,,,,,
493,lilly-announces-top-line-phase-3-results-for-baricitinib-in-patients-with-moderate-to-severe-atopic-dermatitis,05-02-2019 00:00,,,,,,
494,us-fda-grants-breakthrough-therapy-designation-for-potential-next-generation-rsv-medicine-medi8897,05-02-2019 00:00,,,,,,
495,novartis-enters-agreement-to-acquire-avexis-inc-for-usd-87-bn-to-transform-care-in-sma-and-expand-position-as-a-gene-therapy-and-neuroscience-leader,09-04-2018 00:00,,,,,,
496,celgene-corporation-to-acquire-juno-therapeutics-inc,06-02-2018 00:00,,,,,,
497,sanofi-to-acquire-bioverativ-for-116-billion,22-01-2018 00:00,,,,,,
498,celgene-provides-regulatory-update-on-ozanimod-for-the-treatment-of-relapsing-multiple-sclerosis-conference-call-scheduled-for-today-at-530-pm-et,27-02-2018 00:00,,,,,,
499,gsk-announces-major-3-part-transaction-with-novartis-to-drive-sustainable-sales-growth-improve-long-term-earnings-and-deliver-increasing-returns-to-shareholders,22-04-2018 00:00,,,,,,
500,xencor-to-develop-and-commercialize-novel-il-15-immune-activating-cytokines-with-genentech,06-02-2019 00:00,,,,,,
501,lilly-announces-detailed-results-of-the-phase-3-solanezumab-expedition-studies-following-a-presentation-of-the-independent-analyses-by-the-alzheimers-disease-cooperative-study-adcs,06-12-2018 00:00,,,,,,
502,novo-nordisk-to-cut-250-jobs-in-the-united-states,03-11-2018 00:00,,,,,,
503,hisamitsu-pharmaceutical-and-kyowa-hakko-kirin-sign-commercialization-agreement-for-hp-3000-a-potential-new-transdermal-patch-for-parkinsons-disease-in-japan,06-02-2019 00:00,,,,,,
504,pfizer-names-albert-bourla-chief-operating-officer,06-09-2018 00:00,,,,,,
505,fda-accepts-for-review-new-drug-application-nda-for-merck?s-investigational-combination-of-imipenemcilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and-tazobactam,06-02-2019 00:00,,,,,,
506,glaxosmithkline-plc-and-pfizer-inc-to-form-new-world-leading-consumer-healthcare-joint-venture-transaction-provides-a-unique-opportunity-to-accelerate-gsk?s-strategy-and-create-substantial-value-for-shareholders-lays-foundation-for-separation-of-gsk-to-create-two-new-uk-based-global-companies-focused-on-pharmaceuticalsvaccines-and-consumer-healthcare,19-12-2018 00:00,,,,,,
507,isatuximab-phase-3-trial-meets-primary-endpoint-of-prolonging-progression-free-survival-in-patients-with-relapsedrefractory-multiple-myeloma,06-02-2019 00:00,,,,,,
508,pfizer?s-biosimilar-retacrit-epoetin-alfa-epbx-approved-by-us-fda,15-05-2018 00:00,,,,,,
509,us-fda-approves-pfizer?s-biosimilar-nivestym-filgrastim-aafi-nivestym-a-biosimilar-to-neupogen-filgrastim-is-pfizer?s-fourth-biosimilar-to-be-approved-by-the-fda,15-07-2018 00:00,,,,,,
510,celltrion-and-teva-announce-fda-approval-of-truxima-rituximab-abbs-a-biosimilar-to-rituxan-for-three-non-hodgkin?s-lymphoma-indications,29-11-2018 00:00,,,,,,
511,celltrion-and-teva-announce-fda-approval-of-herzuma-trastuzumab-pkrb-a-biosimilar-to-herceptin-for-the-treatment-of-her2-overexpressing-breast-cancer-for-certain-indications,14-12-2018 00:00,,,,,,
512,european-commission-approves-amgen-and-allergans-mvasi-biosimilar-bevacizumab-for-the-treatment-of-certain-types-of-cancer,18-01-2019 00:00,,,,,,
513,celltrion?s-herzuma-biosimilar-trastuzumab-approved-in-europe,14-02-2018 00:00,,,,,,
514,amgen-and-allergan-receive-positive-chmp-opinion-for-abp-980-biosimilar-herceptin-for-the-treatment-of-three-types-of-cancer,23-03-2018 00:00,,,,,,
515,sandoz-receives-european-commission-approval-for-zessly-infliximab-in-gastroenterological-rheumatological-and-dermatological-diseases,24-05-2018 00:00,,,,,,
516,sandoz-receives-european-commission-approval-for-biosimilar-hyrimoz-adalimumab,27-07-2018 00:00,,,,,,
517,biocon-and-mylan-announce-positive-chmp-opinion-for-fulphila-biosimilar-pegfilgrastim,21-09-2018 00:00,,,,,,
518,mylan-and-biocon-receive-approvals-from-the-european-commission-and-tga-australia-for-semglee-biosimilar-insulin-glargine,28-03-2018 00:00,,,,,,
519,gsk-and-merck-kgaa-darmstadt-germany-announce-global-alliance-to-jointly-develop-and-commercialise-m7824-a-novel-immunotherapy-with-potential-in-multiple-difficult-to-treat-cancers,06-02-2019 00:00,,,,,,
520,fda-approves-cablivi-caplacizumab-yhdp-the-first-nanobody-based-medicine-for-adults-with-acquired-thrombotic-thrombocytopenic-purpura-attp,07-02-2019 00:00,,,,,,
521,new-england-journal-of-medicine-publishes-results-from-pivotal-phase-3-studies-of-paratek?s-nuzyra-omadacycline-for-pneumonia-and-skin-infections,07-02-2019 00:00,,,,,,
522,recordati-obtains-exclusive-license-for-juxtapid-in-japan,07-02-2019 00:00,,,,,,
523,us-fda-grants-fasenra-orphan-drug-designation-for-hypereosinophilic-syndrome,07-02-2019 00:00,,,,,,
524,pg-acquires-this-is-l-one-of-the-fastest-growing-feminine-care-brands-in-the-us,07-02-2019 00:00,,,,,,
525,medtronic-receives-fda-approval-on-expanded-indication-for-pipeline-flex-embolization-device,08-02-2019 00:00,,,,,,
526,biomarin-announces-ongoing-study-demonstrates-durable-treatment-benefit-from-brineura-cerliponase-alfa-for-3-years,08-02-2019 00:00,,,,,,
527,ligand-announces-omniab-partnership-with-genagon-therapeutics,08-02-2019 00:00,,,,,,
528,orthofix-announces-fda-approval-of-the-m6-c-artificial-cervical-disc-to-treat-patients-with-cervical-disc-degeneration,08-02-2019 00:00,,,,,,
529,evotec-and-galapagos-enter-into-collaboration-in-the-field-of-fibrosis,08-02-2019 00:00,,,,,,
530,samsung-bioepis-and-c-bridge-capital-to-develop-and-commercialize-next-generation-biosimilars-in-china,11-02-2019 00:00,,,,,,
531,one-year-results-from-positive-phase-3-eylea-trial-in-diabetic-retinopathy-presented-at-angiogenesis-symposium,11-02-2019 00:00,,,,,,
532,about-ambaro-combination-tablets-pfizer-voluntary-recall-class-i,11-02-2019 00:00,,,,,,
533,finch-therapeutics?-investigational-drug-cp101-granted-breakthrough-therapy-designation-from-fda-for-recurrent-c-difficile-infection,11-02-2019 00:00,,,,,,
534,opdivo-nivolumab-plus-low-dose-yervoy-ipilimumab-demonstrates-continued-survival-benefit-at-30-month-follow-up-in-patients-with-previously-untreated-advanced-or-metastatic-renal-cell-carcinoma,12-02-2019 00:00,,,,,,
535,"phase-3-arches-trial-shows-xtandi-enzalutamide-significantly-improved-radiographic-progression-free-survival-in-men-with-metastatic-hormone-sensitive-prostate-cancer
-",12-02-2019 00:00,,,,,,
536,moberg-pharma-and-bayer-sign-exclusive-license-agreement-for-mob-015-in-europe,12-02-2019 00:00,,,,,,
537,european-commission-approves-adcetris-brentuximab-vedotin-with-avd-the-first-new-treatment-in-decades-for-adults-with-previously-untreated-cd30-stage-iv-hodgkin-lymphoma,12-02-2019 00:00,,,,,,
538,genmab-announces-us-fda-approval-of-darzalex-daratumumab-split-dosing-regimen,12-02-2019 00:00,,,,,,
539,gilead-announces-topline-data-from-phase-3-stellar-4-study-of-selonsertib-in-compensated-cirrhosis-f4-due-to-nonalcoholic-steatohepatitis-nash,13-02-2019 00:00,,,,,,
540,abbvie-and-teneobio-announce-a-strategic-transaction-to-develop-a-new-treatment-for-multiple-myeloma,13-02-2019 00:00,,,,,,
541,fda-advisory-committee-recommends-approval-of-spravato-esketamine-nasal-spray-c-iii-for-adults-with-treatment-resistant-depression,13-02-2019 00:00,,,,,,
542,almirall-and-dermira-enter-into-option-and-license-agreement-for-european-rights-to-lebrikizumab,13-02-2019 00:00,,,,,,
543,mithra-signs-exclusive-license-and-supply-agreement-for-commercialization-of-myring-in-the-middle-east,13-02-2019 00:00,,,,,,
544,novartis-receives-fda-approval-for-egaten-for-the-treatment-of-fascioliasis-a-neglected-tropical-disease,14-02-2019 00:00,,,,,,
545,johnson-johnson-announces-agreement-to-acquire-auris-health-inc,14-02-2019 00:00,,,,,,
546,clinigen-to-acquire-us-rights-to-proleukin,14-02-2019 00:00,,,,,,
547,abilita-bio-and-amgen-enter-into-a-multi-target-collaboration,14-02-2019 00:00,,,,,,
548,vaccibody-announces-collaboration-to-study-vb1016-and-atezolizumab-tecentriq-in-advanced-cervical-cancer,14-02-2019 00:00,,,,,,
549,bayer?s-darolutamide-plus-androgen-deprivation-therapy-adt-significantly-extends-metastasis-free-survival-with-a-favorable-safety-profile-compared-to-placebo-plus-adt-in-non-metastatic-castration-resistant-prostate-cancer,15-02-2019 00:00,,,,,,
550,codexis-announces-nestl?-health-science-exercises-option-for-exclusive-global-license-to-cdx-6114-for-the-management-of-phenylketonuria,15-02-2019 00:00,,,,,,
551,opdivo-nivolumab-plus-yervoy-ipilimumab-shows-response-in-pre-treated-patients-with-metastatic-castration-resistant-prostate-cancer,15-02-2019 00:00,,,,,,
552,abcellera-announces-multi-target-partnership-agreement-with-a-top-5-global-pharma,15-02-2019 00:00,,,,,,
553,newly-formed-arvelle-therapeutics-acquires-exclusive-rights-from-sk-biopharmaceuticals-to-develop-and-commercialize-cenobamate-in-europe,15-02-2019 00:00,,,,,,
554,keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-reduced-risk-of-death-by-nearly-half-compared-to-sunitinib-as-first-line-treatment-for-advanced-renal-cell-carcinoma-rcc,18-02-2019 00:00,,,,,,
555,bayer-exercised-option-to-obtain-full-licensing-rights-for-larotrectinib-and-bay-2731954-loxo-195,18-02-2019 00:00,,,,,,
556,medtronic-inc-recalls-dual-chamber-implantable-pulse-generators-ipgs-due-to-possible-circuit-error,18-02-2019 00:00,,,,,,
557,medtronic-announces-preliminary-prodigy-results-a-global-study-to-identify-patients-at-high-risk-for-opioid-induced-respiratory-compromise,18-02-2019 00:00,,,,,,
558,pivotal-phase-iii-data-for-bavencio-avelumab-plus-inlyta-axitinib-in-advanced-renal-cell-carcinoma-published-in-the-new-england-journal-of-medicine,19-02-2019 00:00,,,,,,
559,japan-approves-test-of-ips-cells-for-treating-spinal-injuries,19-02-2019 00:00,,,,,,
560,fda-grants-priority-review-to-roche?s-personalised-medicine-entrectinib,19-02-2019 00:00,,,,,,
561,aveo-oncology-announces-oral-presentation-of-tivo-3-trial-topline-results-at-the-2019-asco-genitourinary-cancers-symposium,19-02-2019 00:00,,,,,,
562,aveo-oncology-announces-oral-presentation-of-tivo-3-trial-topline-results-at-the-2019-asco-genitourinary-cancers-symposium,19-02-2019 00:00,,,,,,
563,fda-approves-merck?s-keytruda-pembrolizumab-for-the-adjuvant-treatment-of-patients-with-melanoma-with-involvement-of-lymph-nodes-following-complete-resection,20-02-2019 00:00,,,,,,
564,novo-nordisk-receives-us-fda-approval-of-esperoct-turoctocog-alfa-pegol-n8-gp,20-02-2019 00:00,,,,,,
565,alkermes-and-clovis-oncology-initiate-research-collaboration-to-explore-combination-cancer-therapies,20-02-2019 00:00,,,,,,
566,pfizer-and-lilly-announce-top-line-results-from-phase-3-study-of-tanezumab-in-chronic-low-back-pain,20-02-2019 00:00,,,,,,
567,bausch-health-acquires-eton-pharmaceuticals-em-100-investigational-eye-drop-for-the-treatment-of-itchy-eyes-associated-with-allergies,20-02-2019 00:00,,,,,,
568,merck-provides-update-on-keynote-240-a-phase-3-study-of-keytruda-pembrolizumab-in-previously-treated-patients-with-advanced-hepatocellular-carcinoma,21-02-2019 00:00,,,,,,
569,mustang-bio-and-nationwide-children?s-hospital-enter-into-exclusive-worldwide-license-agreement-for-oncolytic-virus-c134-to-treat-glioblastoma-multiforme,21-02-2019 00:00,,,,,,
570,abbott-and-novo-nordisk-enter-partnership-to-provide-integrated-digital-solution-to-people-with-diabetes-using-insulin,21-02-2019 00:00,,,,,,
571,abbvies-humira-adalimumab-approved-by-health-canada-to-treat-pediatric-patients-with-chronic-non-infectious-anterior-uveitis,21-02-2019 00:00,,,,,,
572,merck-to-acquire-immune-design,21-02-2019 00:00,,,,,,
573,abbvie-and-eisai-announce-fully-human-anti-tnf-a-monoclonal-antibody-humira-is-the-first-in-japan-to-be-approved-for-the-treatment-of-hidradenitis-suppurativa,22-02-2019 00:00,,,,,,
574,amgen-cytokinetics-and-servier-announce-start-of-meteoric-hf-the-second-phase-3-clinical-trial-of-omecamtiv-mecarbil-in-patients-with-heart-failure,22-02-2019 00:00,,,,,,
575,morphic-therapeutic-enters-into-integrin-research-and-development-collaboration-with-janssen,22-02-2019 00:00,,,,,,
576,morphic-therapeutic-enters-into-integrin-research-and-development-collaboration-with-janssen,22-02-2019 00:00,,,,,,
577,mallinckrodt-announces-results-from-the-phase-3-clinical-trial-interim-analysis-for-therakos?-platform-for-the-treatment-of-pediatric-patients-with-steroid-refractory-acute-graft-versus-host-disease,22-02-2019 00:00,,,,,,
578,brilinta?s-phase-iii-themis-trial-met-primary-endpoint-in-patients-with-established-coronary-artery-disease-and-type-2-diabetes,25-02-2019 00:00,,,,,,
579,roche-enters-into-definitive-merger-agreement-to-acquire-spark-therapeutics,25-02-2019 00:00,,,,,,
580,santhera?s-syros-study-shows-long-term-efficacy-with-idebenone-in-slowing-respiratory-function-loss-in-patients-with-duchenne-muscular-dystrophy,25-02-2019 00:00,,,,,,
581,abbvie-and-voyager-therapeutics-announce-collaboration-to-develop-vectorized-antibodies-to-treat-parkinsons-disease-and-other-synucleinopathies,25-02-2019 00:00,,,,,,
582,danaher-to-acquire-the-biopharma-business-of-general-electric-life-sciences-for-214-billion,26-02-2019 00:00,,,,,,
583,akcea-apoa-lrx-advances-as-leading-pharmaceutical-company-exercises-option-to-license,26-02-2019 00:00,,,,,,
584,ipsen-to-acquire-clementia-pharmaceuticals-to-significantly-boost-rare-disease-portfolio,26-02-2019 00:00,,,,,,
585,jury-upholds-amgens-patents-on-repatha-evolocumab,26-02-2019 00:00,,,,,,
586,genmab-announces-positive-topline-results-in-phase-iii-columba-study-of-subcutaneous-daratumumab,26-02-2019 00:00,,,,,,
587,lynparza-significantly-delayed-disease-progression-as-1st-line-maintenance-treatment-in-germline-brca-mutated-metastatic-pancreatic-cancer,27-02-2019 00:00,,,,,,
588,immatics-announces-clinical-trial-collaboration-in-immunotherapy-for-solid-cancers,27-02-2019 00:00,,,,,,
589,imbrium-therapeutics-and-tetragenetics-announce-strategic-research-collaboration-and-license-option-to-develop-novel-biologic-therapeutics-for-pain,27-02-2019 00:00,,,,,,
590,medtronic-resolutetm-drug-eluting-stent-des-platform-receives-expanded-indication-for-treatment-of-chronic-total-occlusion-cto,27-02-2019 00:00,,,,,,
591,sarepta-exercises-option-to-acquire-myonexus-therapeutics,27-02-2019 00:00,,,,,,
592,us-fda-approves-expanded-farxiga-and-xigduo-xr-labels-for-use-in-patients-with-type-2-diabetes-and-moderate-renal-impairment,28-02-2019 00:00,,,,,,
593,janssen-announces-us-fda-approval-of-novel-tremfya-guselkumab-one-press-patient-controlled-injector-for-adults-with-moderate-to-severe-plaque-psoriasis,28-02-2019 00:00,,,,,,
595,blackstone-life-sciences-and-novartis-launch-anthos-therapeutics-to-develop-innovative-medicines-for-cardiovascular-disease,28-02-2019 00:00,,,,,,
596,fda-approves-galafold-migalastat-for-the-treatment-of-certain-adult-patients-with-fabry-disease,10-08-2018 00:00,,,,,,
597,abcellera-and-denali-therapeutics-sign-expanded-multi-year-multi-target-deal-to-discover-therapeutic-antibodies-for-neurological-diseases,28-02-2019 00:00,,,,,,
598,fda-approves-longer-acting-calaspargase-pegol-mknl-for-all,20-12-2018 00:00,,,,,,
599,fda-approves-shire?s-motegrity-prucalopride-the-only-serotonin-4-receptor-agonist-for-adults-with-chronic-idiopathic-constipation-cic,17-12-2018 00:00,,,,,,
600,fda-approves-first-treatment-for-lambert-eaton-myasthenic-syndrome-a-rare-autoimmune-disorder,20-10-2018 00:00,,,,,,
601,fda-approves-herceptin-hylecta-for-subcutaneous-injection-in-certain-her2-positive-breast-cancers,01-03-2019 00:00,,,,,,
602,biogen-further-expands-presence-in-china-with-approval-of-spinraza-nusinersen-the-first-and-only-treatment-for-spinal-muscular-atrophy,01-03-2019 00:00,,,,,,
603,antolrx-announces-pfizer-exercises-option-to-license-immune-tolerance-therapy-for-potential-treatment-of-type-1-diabetes,11-10-2018 00:00,,,,,,
604,fda-approves-gamifant-emapalumab-the-first-and-only-treatment-for-primary-haemophagocytic-lymphohistiocytosis-hlh,20-11-2018 00:00,,,,,,
605,us-fda-approves-lorbrena-lorlatinib-for-previously-treated-alk-positive-metastatic-nsclc,20-11-2018 00:00,,,,,,
606,pfenex-and-alvogen-expand-development-and-commercialization-collaboration-for-pf708-a-therapeutic-equivalent-candidate-to-forteoforsteo-to-the-eu-mena-and-row,01-03-2019 00:00,,,,,,
607,fda-approves-talazoparib-for-gbrcam-her2-negative-locally-advanced-or-metastatic-breast-cancer,11-10-2018 00:00,,,,,,
608,tegsedi-is-an-effective-treatment-choice-that-allows-self-administration-at-a-time-and-place-that-works-for-the-patient,05-10-2018 00:00,,,,,,
609,adorx-therapeutics-announces-collaboration-with-johnson-johnson-innovation-to-develop-novel-lung-cancer-therapeutics,01-03-2019 00:00,,,,,,
610,fda-approves-revcovi-a-new-enzyme-replacement-therapy-developed-by-leadiant-biosciences-for-the-treatment-of-ada-scid-in-pediatric-and-adult-patients,05-10-2018 00:00,,,,,,
611,paratek-announces-fda-approval-of-nuzyra-omadacycline,02-10-2018 00:00,,,,,,
612,fda-approves-new-hiv-treatment-for-patients-who-have-limited-treatment-options,06-03-2018 00:00,,,,,,
613,fda-approves-seysara-sarecycline-for-the-treatment-of-moderate-to-severe-acne,02-10-2018 00:00,,,,,,
614,verastem-oncology-receives-fda-approval-of-copiktra-duvelisib-capsules,24-09-2018 00:00,,,,,,
615,rigel-announces-fda-approval-of-tavalisse?-fostamatinib-disodium-hexahydrate-for-chronic-immune-thrombocytopenia-itp-in-adult-patients,06-03-2018 00:00,,,,,,
616,fda-approves-merck?s-pifeltro-doravirine-for-the-treatment-of-hiv-1-in-appropriate-patients,30-08-2018 00:00,,,,,,
617,therapeuticsmd-announces-fda-approval-of-annovera-segesterone-acetateethinyl-estradiol-vaginal-system-for-birth-control,10-08-2018 00:00,,,,,,
618,tetraphase-pharmaceuticals-announces-fda-approval-of-xerava-eravacycline-for-complicated-intra-abdominal-infections-ciai,27-08-2018 00:00,,,,,,
619,fda-approves-olumiant-baricitinib-2-mg-tablets-for-the-treatment-of-adults-with-moderately-to-severely-active-rheumatoid-arthritis,06-06-2018 00:00,,,,,,
620,us-fda-approves-krintafel-tafenoquine-for-the-radical-cure-of-p-vivax-malaria,20-07-2018 00:00,,,,,,
621,lokelma-approved-in-the-us-for-the-treatment-of-adults-with-hyperkalaemia,18-05-2018 00:00,,,,,,
622,fda-approves-aimovig-erenumab-aooe-a-novel-treatment-developed-specifically-for-migraine-prevention,17-05-2018 00:00,,,,,,
623,fda-grants-approval-of-tibsovo-the-first-oral-targeted-therapy-for-adult-patients-with-relapsedrefractory-acute-myeloid-leukemia-and-an-idh1-mutation,20-07-2018 00:00,,,,,,
624,erleada-apalutamide-a-next-generation-androgen-receptor-inhibitor-granted-us-fda-approval-for-the-treatment-of-patients-with-non-metastatic-castration-resistant-prostate-cancer,14-02-2018 00:00,,,,,,
625,helsinn-group-announces-the-fda-approval-of-the-iv-formulation-of-akynzeo-fosnetupitantpalonosetron-in-the-united-states,20-04-2018 00:00,,,,,,
626,us-food-and-drug-administration-approves-siga-technologies?-tpoxx-tecovirimat-for-the-treatment-of-smallpox,13-07-2018 00:00,,,,,,
627,biomarin-receives-standard-approval-for-palynziq-pegvaliase-pqpz-injection-for-treatment-of-adults-with-phenylketonuria-pku-a-rare-genetic-disease,24-05-2018 00:00,,,,,,
628,zemdri-plazomicin-approved-by-fda-for-the-treatment-of-adults-with-complicated-urinary-tract-infections-cuti,26-06-2018 00:00,,,,,,
629,gw-pharmaceuticals-plc-and-its-us-subsidiary-greenwich-biosciences-announce-fda-approval-of-epidiolex-cannabidiol-oral-solution-?-the-first-plant-derived-cannabinoid-prescription-medicine,25-06-2018 00:00,,,,,,
630,us-fda-approves-moxidectin-for-the-treatment-of-river-blindness,13-06-2018 00:00,,,,,,
631,novavax-announces-topline-results-from-phase-3-preparetm-trial-of-resvax-for-prevention-of-rsv-disease-in-infants-via-maternal-immunization,01-03-2019 00:00,,,,,,
632,fda-approves-diacomit-stiripentol-for-the-treatment-of-seizures-associated-with-dravet-syndrome-ds-in-patients-2-years-of-age-and-older-taking-clobazam,02-08-2018 00:00,,,,,,
633,chmp-recommends-zynquistatm-sotagliflozin-for-the-treatment-of-adults-with-type-1-diabetes,04-03-2019 00:00,,,,,,
634,novartis-data-confirm-rapid-response-and-high-efficacy-of-cosentyx-in-psoriasis-patients-for-first-time-in-china,04-03-2019 00:00,,,,,,
635,lupus-therapeutics-partners-with-takeda-to-test-potential-treatment-for-lupus,04-03-2019 00:00,,,,,,
636,biogen-announces-agreement-to-acquire-nightstar-therapeutics-to-establish-clinical-pipeline-of-gene-therapy-candidates-in-ophthalmology,04-03-2019 00:00,,,,,,
637,verastem-oncology-presents-phase-3-duo-data-evaluating-copiktra-duvelisib-in-patients-with-cllsll-who-have-progressed-following-two-prior-lines-of-therapy,05-03-2019 00:00,,,,,,
639,ascendis-pharma-announces-once-weekly-transcon?-growth-hormone-demonstrated-superiority-on-primary-endpoint-compared-to-a-daily-growth-hormone-in-phase-3-height-trial-for-pediatric-growth-hormone-deficiency,05-03-2019 00:00,,,,,,
640,bioxcel-therapeutics-announces-addition-of-merck-kgaa-darmstadt-germany-and-pfizer-to-clinical-collaboration-with-nektar-for-development-of-triple-combination-therapy-in-pancreatic-cancer,05-03-2019 00:00,,,,,,
641,nantkwest-signs-worldwide-license-agreement-with-promab-biotechnologies-to-exclusively-develop-select-next-generation-targeted-natural-killer-cell-therapeutics,05-03-2019 00:00,,,,,,
642,us-fda-grants-priority-review-for-fedratinib-new-drug-application-in-myelofibrosis,06-03-2019 00:00,,,,,,
643,fda-accepts-genentech?s-supplemental-new-drug-application-for-xofluza-baloxavir-marboxil-for-the-treatment-of-influenza-in-people-at-high-risk-of-complications,06-03-2019 00:00,,,,,,
644,pacira-to-acquire-myoscience-adding-fda-approved-iovera-system-for-non-opioid-pain-control,06-03-2019 00:00,,,,,,
645,acceleron-receives-fda-orphan-drug-designation-for-ace-083-in-charcot-marie-tooth-disease,06-03-2019 00:00,,,,,,
646,antolrx-announces-pfizer-exercises-option-to-license-immune-tolerance-therapy-for-potential-treatment-of-type-1-diabetes,06-03-2019 00:00,,,,,,
647,allergan-announces-phase-3-results-for-rapastinel-as-an-adjunctive-treatment-of-major-depressive-disorder-mdd,07-03-2019 00:00,,,,,,
648,ambrx-and-beigene-announce-global-research-and-development-collaboration-to-develop-next-generation-biologics,07-03-2019 00:00,,,,,,
649,two-phase-3-studies-of-the-triple-combination-of-vx-445-tezacaftor-and-ivacaftor-met-primary-endpoint-of-improvement-in-lung-function-ppfev1-in-people-with-cystic-fibrosis,07-03-2019 00:00,,,,,,
650,alnylam-reports-positive-topline-results-from-envision-phase-3-study-of-givosiran-in-acute-hepatic-porphyria,07-03-2019 00:00,,,,,,
651,baxter-announces-us-fda-approval-and-launch-of-ready-to-use-cardiovascular-medicine-eptifibatide,07-03-2019 00:00,,,,,,
652,akili-and-shionogi-announce-strategic-partnership-to-develop-and-commercialize-digital-therapeutics-in-key-asian-markets,08-03-2019 00:00,,,,,,
653,gtx-and-oncternal-therapeutics-enter-into-definitive-merger-agreement,08-03-2019 00:00,,,,,,
654,janssen-announces-results-of-two-phase-3-studies-which-showed-long-acting-injectable-hiv-treatment-regimen-of-rilpivirine-and-cabotegravir-demonstrated-comparable-safety-and-efficacy-to-daily-oral-hiv-therapy,08-03-2019 00:00,,,,,,
655,zeiss-receives-fda-clearance-for-epithelial-thickness-mapping-for-cirrus-hd-oct-enabling-more-detailed-assessment-of-refractive-surgery-patients,08-03-2019 00:00,,,,,,
656,bayer-submits-european-marketing-authorization-application-for-darolutamide,08-03-2019 00:00,,,,,,
657,roche?s-ventana-pd-l1-sp142-assay-approved-as-first-companion-diagnostic-to-identify-triple-negative-breast-cancer-patients-eligible-for-treatment-with-tecentriq-in-combination-with-abraxane,11-03-2019 00:00,,,,,,
658,pioneering-pain-research-leads-to-landmark-deal,11-03-2019 00:00,,,,,,
659,nice-provisionally-approves-almiralls-ilumetri-tildrakizumab-as-a-cost-effective-option-for-adults-with-moderate-to-severe-plaque-psoriasis,11-03-2019 00:00,,,,,,
660,fda-grants-roche?s-tecentriq-in-combination-with-abraxane-accelerated-approval-for-people-with-pd-l1-positive-metastatic-triple-negative-breast-cancer,11-03-2019 00:00,,,,,,
661,seres-therapeutics-announces-microbiome-immuno-oncology-focused-collaboration-with-astrazeneca,12-03-2019 00:00,,,,,,
662,us-fda-approves-pfizer?s-oncology-biosimilar-trazimeratrastuzumab-qyyp-a-biosimilar-to-herceptin?1,12-03-2019 00:00,,,,,,
663,allergan-announces-fda-acceptance-of-new-drug-application-for-ubrogepant-for-the-acute-treatment-of-migraine,12-03-2019 00:00,,,,,,
664,biogen-enters-into-an-agreement-to-sell-its-large-scale-biologics-manufacturing-site-in-hiller?d-denmark-to-fujifilm,12-03-2019 00:00,,,,,,
665,fda-grants-breakthrough-designation-to-paigeai,12-03-2019 00:00,,,,,,
666,lillys-cyramza-ramucirumab-phase-3-relay-trial-met-primary-endpoint-significantly-improving-progression-free-survival-in-first-line-treatment-of-patients-with-metastatic-egfr-mutated-non-small-cell-lung-cancer,12-03-2019 00:00,,,,,,
667,vertex-receives-approval-for-symdeko-tezacaftorivacaftor-and-ivacaftor-in-australia-to-treat-the-underlying-cause-of-cystic-fibrosis-in-people-aged-12-and-older-with-certain-cftr-gene-mutations,13-03-2019 00:00,,,,,,
668,secura-bio-acquires-global-rights-to-farydak,13-03-2019 00:00,,,,,,
669,akebia-therapeutics-announces-positive-top-line-results-from-two-pivotal-phase-3-studies-of-vadadustat-in-japanese-patients-with-anemia-due-to-chronic-kidney-disease,13-03-2019 00:00,,,,,,
670,exactech-acquires-xpandortho,13-03-2019 00:00,,,,,,
671,hitgen-and-sparc-enter-dna-encoded-library-based-innovative-drug-discovery-research-collaboration,13-03-2019 00:00,,,,,,
672,ema-grants-orphan-medicinal-product-designation-for-retrotope?s-rt001-in-the-treatment-of-infantile-neuroaxonal-dystrophy-inad-a-pla2g6-associated-neurodegeneration-plan,14-03-2019 00:00,,,,,,
673,smith-nephew-expands-in-high-growth-regenerative-medicine-market-through-acquisition-of-osiris-therapeutics-inc,14-03-2019 00:00,,,,,,
674,european-commission-approves-roche?s-hemlibra-for-people-with-severe-haemophilia-a-without-factor-viii-inhibitors,14-03-2019 00:00,,,,,,
675,hoth-therapeutics-enters-into-commercial-licensing-agreement-with-university-of-maryland-baltimore-and-isoprene-pharmaceuticals-inc,14-03-2019 00:00,,,,,,
676,european-commission-approves-merck?s-keytruda-pembrolizumab-in-combination-with-chemotherapy-for-first-line-treatment-of-adults-with-metastatic-squamous-non-small-cell-lung-cancer-nsclc,14-03-2019 00:00,,,,,,
677,merck-kgaa-darmstadt-germany-announces-collaboration-with-iktos-for-generative-artificial-intelligence-ai-technology,15-03-2019 00:00,,,,,,
678,phase-iii-clinical-trial-with-bayer?s-nifurtimox-demonstrates-the-safety-and-efficacy-of-new-formulation-to-treat-children-with-chagas-disease,15-03-2019 00:00,,,,,,
679,european-commission-approves-roche?s-mabthera-rituximab-for-a-rare-autoimmune-disease,15-03-2019 00:00,,,,,,
680,abbott-receives-fda-approval-for-expanded-indication-for-mitraclip-device,15-03-2019 00:00,,,,,,
681,abcellera-signs-agreement-with-global-health-foundation-to-fight-infectious-disease,15-03-2019 00:00,,,,,,
682,augustus-demonstrates-favorable-safety-results-of-eliquis-versus-vitamin-k-antagonists-in-non-valvular-atrial-fibrillation-patients-with-acute-coronary-syndrome-andor-undergoing-percutaneous-coronary-intervention,18-03-2019 00:00,,,,,,
683,alcon-announces-acquisition-of-powervision-inc,18-03-2019 00:00,,,,,,
684,novartis-late-breaking-data-further-support-initiation-of-entresto-in-hospital-and-as-a-first-choice-systolic-heart-failure-therapy-in-stabilized-patients,18-03-2019 00:00,,,,,,
685,organoid-news-cellesce-announces-license-agreement-with-hubrecht-organoid-technology-hub-for-the-expansion-of-breast-cancer-organoids-at-scale,18-03-2019 00:00,,,,,,
686,declare-timi-58-sglt2i-reduces-hf-hospitalization-cv-death-in-t2d-and-hf,19-03-2019 00:00,,,,,,
687,baxter-and-biom?rieux-announce-collaboration-to-improve-identification-and-treatment-of-acute-kidney-injury,19-03-2019 00:00,,,,,,
688,jazz-pharmaceuticals-announces-us-fda-approval-of-sunosi-solriamfetol-for-excessive-daytime-sleepiness-associated-with-narcolepsy-or-obstructive-sleep-apnea,22-03-2019 00:00,,,,,,
689,mylan-institutional-llc-initiates-voluntary-nationwide-recall-of-levoleucovorin-injection-due-to-the-presence-of-particulate-matter,19-03-2019 00:00,,,,,,
690,merck-and-ngm-bio-announce-extension-of-broad-multi-year-strategic-collaboration-to-2022,22-03-2019 00:00,,,,,,
691,fda-approves-roche?s-tecentriq-in-combination-with-chemotherapy-for-the-initial-treatment-of-adults-with-extensive-stage-small-cell-lung-cancer,19-03-2019 00:00,,,,,,
692,biogen-and-eisai-to-discontinue-phase-3-engage-and-emerge-trials-of-aducanumab-in-alzheimer?s-disease,22-03-2019 00:00,,,,,,
693,th?a-and-olix-announce-collaboration-to-develop-rnai-therapies-for-the-treatment-of-amd,19-03-2019 00:00,,,,,,
694,merck-and-ngm-bio-announce-extension-of-broad-multi-year-strategic-collaboration-to-2022,20-03-2019 00:00,,,,,,
695,celgene-and-exscientia-enter-3-year-ai-drug-discovery-collaboration-focused-on-accelerating-drug-discovery-in-oncology-and-autoimmunity,22-03-2019 00:00,,,,,,
696,novartis-plans-for-alcon-spin-off-on-april-9-2019,22-03-2019 00:00,,,,,,
697,abbvie-provides-update-on-venclexta?venclyxto?-venetoclax-multiple-myeloma-program,20-03-2019 00:00,,,,,,
698,merck-to-collaborate-with-genscript-to-accelerate-cell-and-gene-therapy-industrialization-in-china,20-03-2019 00:00,,,,,,
699,sage-therapeutics-announces-fda-approval-of-zulresso-brexanolone-injection-the-first-and-only-treatment-specifically-indicated-for-postpartum-depression,20-03-2019 00:00,,,,,,
700,evotec-and-gardp-announce-new-partnership-to-discover-novel-antibiotics,20-03-2019 00:00,,,,,,
701,kyowa-hakko-kirin-enters-new-development-and-commercialisation-agreements-with-astrazeneca-for-all-benralizumab-indications-beyond-copd-and-asthma-in-asia-inclusive-of-japan,26-03-2019 00:00,,,,,,
702,thermo-fisher-scientific-to-acquire-brammer-bio-a-leader-in-viral-vector-manufacturing,25-03-2019 00:00,,,,,,
703,hitgen-and-almirall-enter-dna-encoded-library-based-innovative-drug-discovery-research-collaboration,26-03-2019 00:00,,,,,,
704,lupin-and-yl-biologics-receives-pmda-approval-for-etanercept-biosimilar-in-japan,26-03-2019 00:00,,,,,,
705,abbvie-announces-first-regulatory-approval-of-skyrizi-risankizumab-for-the-treatment-of-plaque-psoriasis-generalized-pustular-psoriasis-and-erythrodermic-psoriasis-and-psoriatic-arthritis-in-japan,26-03-2019 00:00,,,,,,
706,celgene-submits-application-to-fda-for-ozanimod-for-the-treatment-of-relapsing-forms-of-multiple-sclerosis,26-03-2019 00:00,,,,,,
707,novartis-receives-fda-approval-for-mayzent-siponimod-the-first-oral-drug-to-treat-secondary-progressive-ms-with-active-disease,27-03-2019 00:00,,,,,,
708,lilly-and-immunext-announce-licensing-and-research-collaboration,27-03-2019 00:00,,,,,,
709,forxiga-approved-in-japan-for-type-1-diabetes,27-03-2019 00:00,,,,,,
710,japan?s-ministry-of-health-labour-and-welfare-approves-gilead?s-biktarvy-bictegravir-emtricitabine-and-tenofovir-alafenamide-for-treatment-of-hiv-1-infection,27-03-2019 00:00,,,,,,
711,jazz-pharmaceuticals-announces-positive-top-line-results-from-phase-3-study-of-jzp-258-in-adult-narcolepsy-patients-with-cataplexy-and-excessive-daytime-sleepiness,27-03-2019 00:00,,,,,,
712,legochem-biosciences-and-takeda-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates-in-immuno-oncology,25-03-2019 00:00,,,,,,
713,cerveau-technologies-inc-signs-research-agreement-with-eisai-inc-for-novel-tau-imaging-agent,25-03-2019 00:00,,,,,,
714,forxiga-approved-in-europe-for-type-1-diabetes,25-03-2019 00:00,,,,,,
715,biolinerx-announces-successful-engraftment-data-from-phase-3-genesis-trial-for-bl-8040-in-multiple-myeloma-patients,28-03-2019 00:00,,,,,,
716,chugai-receives-orphan-drug-designation-for-risdiplam-in-spinal-muscular-atrophy,28-03-2019 00:00,,,,,,
717,cancer-research-uk-lifearc-and-ono-pharma-form-cancer-immunotherapy-alliance,28-03-2019 00:00,,,,,,
718,ecg-app-and-irregular-rhythm-notification-on-apple-watch-available-today-across-europe-and-hong-kong,28-03-2019 00:00,,,,,,
719,johnson-johnson-vision-announces-availability-of-acuvue-oasys-with-transitions-light-intelligent-technology-in-the-us,28-03-2019 00:00,,,,,,
720,proteonic-biotechnology-licenses-protein-production-technology-to-bayer,29-03-2019 00:00,,,,,,
721,gilead-and-galapagos-announce-filgotinib-meets-primary-endpoint-in-the-phase-3-finch-3-study-in-methotrexate-na?ve-rheumatoid-arthritis-patients,29-03-2019 00:00,,,,,,
722,astrazeneca-and-daiichi-sankyo-enter-collaboration-for-novel-her2-targeting-antibody-drug-conjugate,29-03-2019 00:00,,,,,,
723,mitsubishi-tanabe-pharma-america-announces-collaboration-with-massachusetts-general-hospital-on-als-biomarker-study,29-03-2019 00:00,,,,,,
724,stridebio-and-takeda-sign-collaboration-and-license-agreement-to-advance-novel-gene-therapies-for-neurological-diseases,29-03-2019 00:00,,,,,,
725,bluebird-bio-receives-positive-opinion-from-chmp-for-zynteglo?-autologous-cd34-cells-encoding-?a-t87q-globin-gene-gene-therapy-for-patients-12-years-and-older-with-transfusion-dependent-?-thalassemia-tdt-who-do-not-have-?0?0-genotype,01-04-2019 00:00,,,,,,
726,novartis-to-acquire-ifm-tre-to-develop-first-in-class-nlrp3-antagonist-portfolio-targeting-innate-immune-system,01-04-2019 00:00,,,,,,
727,boehringer-ingelheim-enhances-oncology-rd-with-novel-macrodel-delivery-technology-via-acquisition-of-icd-therapeutics,01-04-2019 00:00,,,,,,
728,roche?s-ipatasertib-in-combination-with-tecentriq-and-chemotherapy-shows-promising-anti-tumour-activity-in-triple-negative-breast-cancer-in-early-phase-tria,01-04-2019 00:00,,,,,,
729,positive-pilot-phase-3-data-position-vistagens-ph94b-neuroactive-nasal-spray-for-pivotal-phase-3-development-as-a-novel-as-needed-treatment-for-social-anxiety-disorder,02-04-2019 00:00,,,,,,
730,avexis-expands-world-leading-gene-therapy-manufacturing-capacity-with-purchase-of-advanced-biologics-therapy-manufacturing-campus-in-longmont-colorado,02-04-2019 00:00,,,,,,
731,merck?s-keytruda-pembrolizumab-approved-in-china-for-first-line-treatment-of-metastatic-nonsquamous-non-small-cell-lung-cancer-nsclc-in-combination-with-chemotherapy,02-04-2019 00:00,,,,,,
732,novartis-first-in-class-cosentyx-approved-in-china-for-psoriasis-patients,02-04-2019 00:00,,,,,,
733,sangamo-announces-agreement-securing-access-to-large-scale-commercial-grade-manufacturing-capacity-at-brammer-bio,02-04-2019 00:00,,,,,,
734,allergan-and-molecular-partners-announce-topline-safety-results-from-maple-study-of-abicipar-pegol,03-04-2019 00:00,,,,,,
735,xencor-and-astellas-enter-collaboration-for-novel-bispecific-antibody-program,03-04-2019 00:00,,,,,,
736,encore-dermatology-inc-acquires-sernivo-trianex-and-promiseb,03-04-2019 00:00,,,,,,
737,esperare-partners-its-pivotal-program-in-xlhed,03-04-2019 00:00,,,,,,
738,channel-medsystems-receives-us-fda-approval-of-the-cerene-cryotherapy-device-for-the-treatment-of-heavy-menstrual-bleeding,03-04-2019 00:00,,,,,,
739,liquidia-technologies-presents-phase-3-trial-data-for-liq861-at-the-ishlt-39th-annual-meeting-scientific-sessions,04-04-2019 00:00,,,,,,
740,fresenius-kabi-receives-european-commission-approval-for-adalimumab-biosimilar-idacio,04-04-2019 00:00,,,,,,
741,editas-medicine-and-bluerock-therapeutics-enter-strategic-research-collaboration-and-cross-licensing-agreement-to-combine-genome-editing-and-cell-therapy-platforms,04-04-2019 00:00,,,,,,
742,genmab-announces-phase-iii-study-exploring-daratumumab-as-maintenance-treatment-in-newly-diagnosed-multiple-myeloma,04-04-2019 00:00,,,,,,
743,positive-results-from-fasenra-phase-ii-trial-in-hypereosinophilic-syndrome-published-in-new-england-journal-of-medicine,04-04-2019 00:00,,,,,,
744,oncology-venture-obtains-option-to-in-license-the-european-rights-to-the-fda-approved-ixabepilone,05-04-2019 00:00,,,,,,
745,myriad-astrazeneca-and-merck-expand-companion-diagnostic-partnership,05-04-2019 00:00,,,,,,
746,banyan-provides-non-exclusive-license-of-traumatic-brain-injury-tbi-biomarkers-to-abbott-for-use-on-its-core-laboratory-instruments,05-04-2019 00:00,,,,,,
747,sinovant-and-roivant-launch-cytovant-sciences-in-partnership-with-medigene-to-develop-cellular-therapies-in-asia,05-04-2019 00:00,,,,,,
748,introducing-new-alexa-healthcare-skills,05-04-2019 00:00,,,,,,
749,novartis-kisqali-received-fda-breakthrough-therapy-designation-for-initial-endocrine-based-treatment-in-premenopausal-women-with-hrher2-advanced-breast-cancer,03-01-2018 00:00,,,,,,
750,fda-grants-breakthrough-therapy-designation-for-genentech?s-hemlibra-emicizumab-kxwh-in-hemophilia-a-without-inhibitors,17-04-2018 00:00,,,,,,
751,fda-grants-breakthrough-therapy-designation-for-roche?s-tecentriq-in-combination-with-avastin-as-first-line-treatment-for-advanced-or-metastatic-hepatocellular-carcinoma-hcc,18-07-2018 00:00,,,,,,
752,proteostasis-therapeutics-announces-fda-grants-breakthrough-therapy-designation-for-pti-428-in-cystic-fibrosis,12-03-2018 00:00,,,,,,
753,novartis-drug-promacta-receives-fda-breakthrough-therapy-designation-for-first-line-use-in-severe-aplastic-anemia-saa,04-01-2018 00:00,,,,,,
754,fda-grants-breakthrough-therapy-designation-to-adcetris-brentuximab-vedotin-for-frontline-peripheral-t-cell-lymphomas,15-11-2018 00:00,,,,,,
755,compass-pathways-receives-fda-breakthrough-therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression,23-10-2018 00:00,,,,,,
756,sage-therapeutics-receives-fda-breakthrough-therapy-designation-for-sage-217-for-the-treatment-of-major-depressive-disorder,07-02-2018 00:00,,,,,,
757,avita-medical-announces-presentation-at-aba-meeting-highlighting-results-of-study-using-recell-system-to-treat-third-degree-burns-in-pediatric-patients,08-04-2019 00:00,,,,,,
758,celgene-corporation-and-acceleron-pharma-announce-submission-of-luspatercept-biologics-license-application-to-us-fda,08-04-2019 00:00,,,,,,
759,sanofi-and-alnylam-conclude-research-and-option-phase-of-2014-rare-disease-alliance,08-04-2019 00:00,,,,,,
760,xoma-acquires-royalty-rights-to-five-hematology-candidates,08-04-2019 00:00,,,,,,
761,alnylam-and-regeneron-announce-broad-collaboration-to-discover-develop-and-commercialize-rnai-therapeutics-focused-on-ocular-and-central-nervous-system-cns-diseases,09-04-2019 00:00,,,,,,
762,us-fda-approves-viiv-healthcare?s-dovato-dolutegravirlamivudine-the-first-once-daily-single-tablet-two-drug-regimen-for-treatment-na?ve-hiv-1-adults,09-04-2019 00:00,,,,,,
763,uniqure-receives-fda-fast-track-designation-for-amt-130-gene-therapy-for-thetreatment-of-huntington?s-disease,09-04-2019 00:00,,,,,,
764,audentes-therapeutics-announces-expansion-of-aav-technology-platform-and-pipeline-with-new-development-programs-for-duchenne-muscular-dystrophy-and-myotonic-dystrophy,09-04-2019 00:00,,,,,,
765,bioatla-and-beigene-form-worldwide-collaboration-to-develop-and-commercialize-novel-conditionally-active-biologic-ctla-4-therapy,09-04-2019 00:00,,,,,,
766,fda-approves-evenity-romosozumab-aqqg-for-the-treatment-of-osteoporosis-in-postmenopausal-women-at-high-risk-for-fracture,10-04-2019 00:00,,,,,,
767,arcdia-has-entered-into-an-exclusive-license-agreement-with-xinhua-healthcare-for-the-commercialisation-of-arcdia?s-maripoc-technology-in-china,10-04-2019 00:00,,,,,,
768,lynparza-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer,10-04-2019 00:00,,,,,,
769,alkermes-announces-positive-topline-results-from-innovative-study-of-aristada-and-invega-sustenna-for-the-treatment-of-schizophrenia,10-04-2019 00:00,,,,,,
770,reneuron-partners-with-fosun-pharma-in-china,10-04-2019 00:00,,,,,,
771,astellas-and-concerto-healthai-to-launch-real-world-evidence-initiative-on-acute-myeloid-leukemia-focused-on-improving-patient-treatment-and-outcomes,11-04-2019 00:00,,,,,,
772,synaffix-announces-125m-license-agreement-with-shanghai-miracogenapril-10-2019,11-04-2019 00:00,,,,,,
773,sandoz-drives-differentiated-portfolio-with-deal-to-commercialize-new-treatment-for-opioid-induced-constipation-in-key-european-countries,11-04-2019 00:00,,,,,,
774,cognoa-licenses-innovative-digital-therapeutic-technology,11-04-2019 00:00,,,,,,
775,biodelivery-sciences-acquires-us-commercial-rights-to-symproic,11-04-2019 00:00,,,,,,
776,fda-approves-expanded-monotherapy-label-for-merck?s-keytruda-pembrolizumab,12-04-2019 00:00,,,,,,
777,evotec-and-indivumed-announce-strategic-drug-discovery-collaboration-on-precision-medicine-for-colorectal-cancer,12-04-2019 00:00,,,,,,
778,moleculin-announces-agreement-with-emory-university-to-conduct-pediatric-brain-tumor-trial,12-04-2019 00:00,,,,,,
779,gilead-sciences-and-novo-nordisk-announce-intent-to-initiate-a-clinical-collaboration-in-nash,12-04-2019 00:00,,,,,,
780,omron-healthcare-announces-april-15th-pre-order-availability-of-complete-the-first-blood-pressure-monitor-with-ekg-capability,12-04-2019 00:00,,,,,,
781,alnylam-presents-positive-complete-results-from-envision-phase-3-study-of-givosiran-an-investigational-rnai-therapeutic-for-the-treatment-of-acute-hepatic-porphyria,15-04-2019 00:00,,,,,,
782,tracon-pharmaceuticals-announces-termination-of-phase-3-tappas-trial-based-on-the-recommendation-of-the-independent-data-monitoring-committee,15-04-2019 00:00,,,,,,
783,dr-reddys-laboratories-announces-acquisitionof-anda-portfolio,15-04-2019 00:00,,,,,,
784,santhera-to-present-long-term-efficacy-results-with-idebenone-in-dmd-at-the-2019-mda-clinical-and-scientific-conference,15-04-2019 00:00,,,,,,
785,generium-launches-first-biosimilar-of-eculizumab-becomes-fifth-marketed-product-using-selexis-suretechnology-platform,09-04-2019 00:00,,,,,,
786,novartis-announces-fda-filing-acceptance-and-priority-review-of-brolucizumab-rth258-for-patients-with-wet-amd,16-04-2019 00:00,,,,,,
787,fibrocell-announces-collaboration-with-castle-creek-pharmaceuticals-to-develop-and-commercialize-fcx-007-gene-therapy,16-04-2019 00:00,,,,,,
788,eagle-pharmaceuticals-inc-expands-licensing-agreement-for-bendeka-with-teva-pharmaceuticals-international-gmbh,16-04-2019 00:00,,,,,,
789,morphosys-announces-that-its-licensee-janssen-has-expanded-clinical-development-of-guselkumab-tremfyar-into-familial-adenomatous-polyposis,16-04-2019 00:00,,,,,,
790,alnylam-initiates-illuminate-b-phase-3-pediatric-study-of-lumasiran-for-the-treatment-of-primary-hyperoxaluria-type-1-and-presents-new-positive-results-from-phase-2-open-label-extension-study,16-04-2019 00:00,,,,,,
791,tessa-therapeutics-announces-collaboration-with-msd-investigating-the-combination-of-keytrudapembrolizumab-and-virus-specific-t-cell-therapy-targeting-human-papillomavirus-in-cervical-cancer,17-04-2019 00:00,,,,,,
792,avexis-data-reinforce-effectiveness-of-zolgensma-in-treating-spinal-muscular-atrophy-sma-type-1,17-04-2019 00:00,,,,,,
793,fda-takes-action-to-protect-women?s-health-orders-manufacturers-of-surgical-mesh-intended-for-transvaginal-repair-of-pelvic-organ-prolapse-to-stop-selling-all-devices,17-04-2019 00:00,,,,,,
794,thermo-fisher-scientific-announces-collaboration-to-advance-noninvasive-risk-assessments-of-pregnancy-outcomes,17-04-2019 00:00,,,,,,
795,gilead-and-insitro-announce-strategic-collaboration-to-discover-and-develop-novel-therapies-for-nonalcoholic-steatohepatitis,17-04-2019 00:00,,,,,,
796,puretech-health-announces-collaboration-with-boehringer-ingelheim-to-advance-immuno-oncology-product-candidates-using-its-lymphatic-targeting-platform,18-04-2019 00:00,,,,,,
797,casi-pharmaceuticals-in-licenses-exclusive-worldwide-rights-to-novel-anti-cd38-monoclonal-antibody-program-from-black-belt-therapeutics,18-04-2019 00:00,,,,,,
798,medtronic-venasealtm-closure-system-demonstrates-durable-and-consistent-outcomes-at-five-years-in-patients-with-chronic-venous-disease,18-04-2019 00:00,,,,,,
799,oncosec-announces-collaborative-research-agreement-in-her2-breast-cancer-evaluating-the-use-of-tavo-in-combination-with-plasmid-dna-vaccines-with-a-world-leading-academic-medical-center,18-04-2019 00:00,,,,,,
800,who-releases-first-guideline-on-digital-health-interventions,18-04-2019 00:00,,,,,,
801,pfizer-and-lilly-announce-top-line-results-from-long-term-phase-3-study-of-tanezumab-in-patients-with-osteoarthritis,19-04-2019 00:00,,,,,,
802,health-canada-approves-skyrizi-risankizumab-for-the-treatment-of-moderate-to-severe-plaque-psoriasis,19-04-2019 00:00,,,,,,
803,tb-alliance-and-mylan-announce-global-collaboration-to-commercialize-investigational-drug-pretomanid-as-part-of-two-regimens-to-treat-tuberculosis-tb,19-04-2019 00:00,,,,,,
804,nice-publishes-final-recommendation-for-almiralls-ilumetri-tildrakizumab-as-a-cost-effective-option-for-adults-with-moderate-to-severe-plaque-psoriasis,19-04-2019 00:00,,,,,,
805,almac-group-partner-with-queen?s-researchers-to-pioneer-potentially-life-changing-oesophageal-cancer-test,19-04-2019 00:00,,,,,,
806,alvogen-inc-issues-voluntary-nationwide-recall-of-fentanyl-transderma,22-04-2019 00:00,,,,,,
807,tela-bio-announces-510k-clearance-for-restella-reconstructive-bioscaffolds-for-reconstructive-surgery,22-04-2019 00:00,,,,,,
808,lilly-and-avidity-biosciences-announce-licensing-and-research-collaboration,22-04-2019 00:00,,,,,,
809,fda-approves-merck?s-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc,22-04-2019 00:00,,,,,,
810,lilly-announces-positive-top-line-results-for-coast-x-a-52-week-placebo-controlled-study-of-taltz?-ixekizumab-in-patients-with-non-radiographic-axial-spondyloarthritis,23-04-2019 00:00,,,,,,
811,roche-launches-new-ventana-her2-dual-ish-companion-diagnostic-test-for-breast-and-gastric-cancer-patients-eligible-for-targeted-therapy,23-04-2019 00:00,,,,,,
812,lilly-announces-sale-of-legacy-antibiotics-brands-and-manufacturing-facility-in-china,23-04-2019 00:00,,,,,,
813,us-food-and-drug-administration-accepts-biologics-license-application-for-eptinezumab,23-04-2019 00:00,,,,,,
814,clinical-study-demonstrates-nuvasive-cohere-porous-peek-spinal-interbody-promotes-improved-early-outcomes-over-structural-allograft-and-smooth-peek,23-04-2019 00:00,,,,,,
815,baronova-announces-fda-approval-of-the-transpyloric-shuttle-tps-device,24-04-2019 00:00,,,,,,
816,teva-announces-update-on-fremanezumab-clinical-development-for-use-in-episodic-cluster-headache,24-04-2019 00:00,,,,,,
817,oncosec-announces-triple-combination-immunotherapy-clinical-trial-of-tavo-epacadostat-and-keytruda-in-squamous-cell-head-and-neck-scchn-cancer,24-04-2019 00:00,,,,,,
818,abbvie-expands-immunology-portfolio-in-the-us-with-fda-approval-of-skyrizi-risankizumab-rzaa-for-moderate-to-severe-plaque-psoriasis,24-04-2019 00:00,,,,,,
819,fulcrum-therapeutics-acquires-global-rights-to-losmapimod-a-potential-disease-modifying-therapyfor-facioscapulohumeral-muscular-dystrophy,24-04-2019 00:00,,,,,,
820,emendo-biotherapeutics-enters-into-licensing-option-agreement-with-takeda-for-its-omni-nuclease-program,25-04-2019 00:00,,,,,,
821,sensus-healthcare-signs-rd-agreement-to-collaborate-with-perelman-school-of-medicine-at-the-university-of-pennsylvania-on-worlds-first-sculptura-intraoperative-radiation-therapy-system,24-04-2019 00:00,,,,,,
822,adc-therapeutics-and-adagene-announce-license-agreement,25-04-2019 00:00,,,,,,
823,lilly-to-establish-an-access-program-for-patients-as-it-prepares-to-withdraw-lartruvo-from-the-global-market,25-04-2019 00:00,,,,,,
824,b-braun-launches-the-first-fda-approved-heparin-sodium-prefilled-syringe-with-attached-safety-needle,25-04-2019 00:00,,,,,,
825,salix-enters-into-exclusive-license-agreement-with-mitsubishi-tanabe-pharma-to-develop-and-commercialize-late-stage-investigational-s1p-modulator-for-the-treatment-of-inflammatory-bowel-disease,26-04-2019 00:00,,,,,,
826,merck-provides-update-on-phase-3-keynote-062-trial-evaluating-keytruda?-pembrolizumab-as-monotherapy-and-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-advanced-gastric-or-gastroesophageal-junction-adenocarcinoma,26-04-2019 00:00,,,,,,
827,exelixis?-partner-takeda-announces-filing-of-new-drug-application-in-japan-for-cabometyx-cabozantinib-for-advanced-renal-cell-carcinoma,26-04-2019 00:00,,,,,,
828,gilead-announces-topline-data-from-phase-3-stellar-3-study-of-selonsertib-in-bridging-fibrosis-f3-due-to-nonalcoholic-steatohepatitis-nash,26-04-2019 00:00,,,,,,
829,novo-nordisk-files-for-eu-regulatory-approval-of-oral-semaglutide-for-the-treatment-of-type-2-diabetes,26-04-2019 00:00,,,,,,
830,lynparza-receives-positive-eu-chmp-opinion-for-1st-line-maintenance-treatment-of-brca-mutated-advanced-ovarian-cancer,29-04-2019 00:00,,,,,,
831,zynquista-now-approved-in-the-european-union-for-treatment-of-adults-with-type-1-diabetes,29-04-2019 00:00,,,,,,
832,acutus-medical?s-new-contact-mapping-software-receives-ce-mark,29-04-2019 00:00,,,,,,
833,novo-nordisk-receives-positive-opinion-from-the-european-regulatory-authorities-for-esperoct-turoctocog-alfa-pegol-n8-gp-for-the-treatment-of-haemophilia-a,29-04-2019 00:00,,,,,,
834,sandoz-enters-agreement-for-proposed-trastuzumab-biosimilar-currently-in-phase-iii-development-to-treat-selected-her2-positive-cancer-tumors,30-04-2019 00:00,,,,,,
835,viiv-healthcare-submits-new-drug-application-to-us-fda-for-the-first-monthly-injectable-two-drug-regimen-of-cabotegravir-and-rilpivirine-for-treatment-of-hiv,30-04-2019 00:00,,,,,,
836,iktos-announces-research-collaboration-with-janssen-to-utilize-iktos?-artificial-intelligence-technology-to-increase-speed-efficiency-of-small-molecule-drug-discovery,30-04-2019 00:00,,,,,,
837,astrazeneca-starts-artificial-intelligence-collaboration-to-accelerate-drug-discovery,30-04-2019 00:00,,,,,,
838,new-study-finds-abbott-blood-test-can-help-predict-future-cardiac-events-in-adults-with-no-known-heart-disease,30-04-2019 00:00,,,,,,
839,fda-approves-kalydeco-ivacaftor-as-first-and-only-cftr-modulator-to-treat-eligible-infants-with-cf-as-early-as-six-months-of-age,01-05-2019 00:00,,,,,,
840,fda-approves-first-treatment-for-all-genotypes-of-hepatitis-c-in-pediatric-patients,01-05-2019 00:00,,,,,,
841,nimble-therapeutics-spins-out-from-roche-to-commercialize-novel-drug-discovery-technology-with-financing-from-telegraph-hill-partners,01-05-2019 00:00,,,,,,
842,european-commission-approves-skyrizi-risankizumab-for-the-treatment-of-moderate-to-severe-plaque-psoriasis,01-05-2019 00:00,,,,,,
843,medtronic-announces-us-commercial-launch-of-solitairetm-x-revascularization-device,01-05-2019 00:00,,,,,,
844,exelixis-initiating-phase-3-pivotal-trial-cosmic-313-of-cabozantinib-in-combination-with-nivolumab-and-ipilimumab-versus-nivolumab-and-ipilimumab-in-previously-untreated-advanced-renal-cell-carcinoma,02-05-2019 00:00,,,,,,
845,medtronic-receives-fda-approval-for-worlds-first-quadripolar-active-fixation-left-heart-lead,02-05-2019 00:00,,,,,,
846,eisai-and-purdue-pharma-announce-buy-out-of-purdue?s-rights-in-worldwide-collaboration-to-develop-and-commercialize-lemborexant,02-05-2019 00:00,,,,,,
847,tmunity-and-uc-san-francisco-announce-exclusive-license-and-research-collaboration-to-advance-tcr-t-cell-therapies-for-pediatric-cancers,02-05-2019 00:00,,,,,,
848,first-fda-approved-vaccine-for-the-prevention-of-dengue-disease-in-endemic-regions,02-05-2019 00:00,,,,,,
849,transgene-and-astrazeneca-enter-into-a-collaboration-and-exclusive-license-option-agreement-for-innovative-inviriotm-based-armed-oncolytic-immunotherapies,03-05-2019 00:00,,,,,,
850,phase-iii-captain-study-of-trelegy-ellipta-in-patients-with-asthma-meets-primary-endpoint,03-05-2019 00:00,,,,,,
851,amal-therapeutics-enters-clinical-collaboration-with-boehringer-ingelheim-to-evaluate-atp128-in-combination-with-bi754091,03-05-2019 00:00,,,,,,
852,presage-announces-collaboration-with-celgene-to-investigate-novel-agents-with-civo?-technology,03-05-2019 00:00,,,,,,
853,qternmet-xr-approved-in-the-us-for-the-treatment-of-type-2-diabetes,03-05-2019 00:00,,,,,,
854,fda-approves-roche?s-kadcyla-for-adjuvant-treatment-of-people-with-her2-positive-early-breast-cancer-with-residual-invasive-disease-after-neoadjuvant-treatment,06-05-2019 00:00,,,,,,
855,lundbeck-to-acquire-abide-therapeutics-adding-a-unique-discovery-platform-and-a-lead-compound-in-an-exploratory-phase-iia-program-for-tourette?s,06-05-2019 00:00,,,,,,
856,new-data-show-mirabegron-reduced-oab-symptoms-in-men-with-benign-prostatic-hyperplasia-currently-treated-with-tamsulosin,06-05-2019 00:00,,,,,,
857,us-fda-approves-vyndaqel-and-vyndamax-for-use-in-patients-with-transthyretin-amyloid-cardiomyopathy-a-rare-and-fatal-disease,06-05-2019 00:00,,,,,,
858,aan-2019-pooled-analyses-of-two-emgality-galcanezumab-gnlm-phase-3-studies-show-reduction-in-monthly-migraine-headache-days-in-low-and-high-frequency-episodic-migraine-subgroups,07-05-2019 00:00,,,,,,
859,roche-presents-data-from-the-risdiplam-pivotal-firefish-and-sunfish-studies-in-spinal-muscular-atrophy-at-the-2019-aan-annual-meeting,07-05-2019 00:00,,,,,,
860,european-commission-approves-palynziq-pegvaliase-injection-for-treatment-of-phenylketonuria-pku-in-patients-aged-16-years-or-older,07-05-2019 00:00,,,,,,
861,skyhawk-therapeutics-announces-agreement-with-takeda-to-develop-novel-small-molecule-rna-splicing-modifiers-for-neurodegenerative-diseases,07-05-2019 00:00,,,,,,
862,novartis-presents-first-of-its-kind-algorithm-based-tool-to-help-ms-patients-and-physicians-evaluate-and-discuss-early-signs-of-progression-to-secondary-progressive-ms,07-05-2019 00:00,,,,,,
863,calquence-phase-iii-ascend-trial-met-primary-endpoint-at-interim-analysis-in-relapsed-or-refractory-chronic-lymphocytic-leukaemia-and-will-stop-early,08-05-2019 00:00,,,,,,
864,roche-to-present-new-ocrevus-ocrelizumab-data-analyses-showing-significant-reduction-of-disability-progression-in-relapsing-and-primary-progressive-multiple-sclerosis-at-the-aan-annual-meeting,08-05-2019 00:00,,,,,,
865,dupixent-dupilumab-approved-for-severe-asthma-by-european-commission,08-05-2019 00:00,,,,,,
866,trastuzumab-deruxtecan-demonstrated-clinically-meaningful-response-in-patients-with-refractory-her2-positive-metastatic-breast-cancer-a-population-with-high-unmet-need,08-05-2019 00:00,,,,,,
867,fda-alerts-providers-and-patients-to-check-for-premature-battery-depletion-in-certain-medtronic-pacemakers-fda-safety-communication,08-05-2019 00:00,,,,,,
868,pfizer-acquires-clinical-stage-biotech-therachon,08-05-2019 00:00,,,,,,
869,novartis-to-acquire-xiidra-expanding-front-of-eye-portfolio-and-strengthening-leadership-in-eye-care,09-05-2019 00:00,,,,,,
870,new-study-demonstrates-safety-and-effectiveness-of-the-minimedtm-640g-system-reducing-hypoglycemia-compared-with-insulin-pump-therapy-without-cgm-in-type-1-diabetes,09-05-2019 00:00,,,,,,
871,protagonist-therapeutics-expands-ptg-200-collaboration-agreement-with-janssen-to-include-second-generation-oral-il-23-receptor-antagonists,09-05-2019 00:00,,,,,,
872,gilead-sciences-and-goldfinch-bio-announce-strategic-collaboration-to-develop-novel-therapies-for-kidney-disease,09-05-2019 00:00,,,,,,
873,curadev-announces-licensing-agreement-with-takeda-for-novel-sting-agonist,09-05-2019 00:00,,,,,,
874,takeda-simplifies-portfolio-and-accelerates-deleveraging-through-two-divestitures,09-05-2019 00:00,,,,,,
875,bristol-myers-squibb-announces-phase-3-checkmate-498-study-did-not-meet-primary-endpoint-of-overall-survival-with-opdivo-nivolumab-plus-radiation-in-patients-with-newly-diagnosed-mgmt-unmethylated-glioblastoma-multiforme,10-05-2019 00:00,,,,,,
876,us-food-drug-administration-accepts-takeda?s-biologics-license-application-for-a-subcutaneous-formulation-of-vedolizumab-entyvio-for-maintenance-therapy-in-moderately-to-severely-active-ulcerative-colitis,10-05-2019 00:00,,,,,,
877,us-food-drug-administration-accepts-takeda?s-biologics-license-application-for-a-subcutaneous-formulation-of-vedolizumab-entyvio-for-maintenance-therapy-in-moderately-to-severely-active-ulcerative-colitis,10-05-2019 00:00,,,,,,
878,boston-scientific-announces-agreement-to-acquire-vertiflex-inc,10-05-2019 00:00,,,,,,
879,pooled-analyses-of-the-roxadustat-global-phase-iii-programme-confirmed-cardiovascular-safety,10-05-2019 00:00,,,,,,
880,fda-approves-ramucirumab-for-hepatocellular-carcinoma,13-05-2019 00:00,,,,,,
881,novartis-issues-voluntary-nationwide-recall-of-promacta-125-mg-for-oral-suspension-due-to-potential-peanut-contamination,13-05-2019 00:00,,,,,,
882,late-breaking-trial-data-highlight-continued-clinical-success-of-boston-scientific-emblem?-s-icd-system,13-05-2019 00:00,,,,,,
883,statement-from-acting-fda-commissioner-ned-sharpless-md-on-policy-advancements-to-help-bring-interchangeable-biosimilars-to-market,13-05-2019 00:00,,,,,,
884,new-roche-test-aids-clinicians-in-accelerating-tuberculosis-diagnosis-and-treatment-by-detecting-antimicrobial-resistance-within-the-world?s-leading-cause-of-infectious-disease-deaths,14-05-2019 00:00,,,,,,
885,fda-approves-eylea-aflibercept-injection-for-diabetic-retinopathy,14-05-2019 00:00,,,,,,
886,exelixis?-collaborator-daiichi-sankyo-launches-minnebro?-esaxerenone-tablets-in-japan,14-05-2019 00:00,,,,,,
887,fda-grants-first-ever-clearance-for-six-lead-personal-ecg-device,14-05-2019 00:00,,,,,,
888,onconova-therapeutics-announces-license-agreement-with-hanx-biopharmaceuticals-to-develop-and-commercialize-rigosertib-in-greater-china,14-05-2019 00:00,,,,,,
889,myovant-sciences-announces-positive-phase-3-results-from-liberty-1-study-evaluating-once-daily-relugolix-combination-therapy-in-women-with-uterine-fibroids,15-05-2019 00:00,,,,,,
890,fda-approves-bavencio-avelumab-plus-inlyta-axitinib-combination-for-patients-with-advanced-renal-cell-carcinoma,15-05-2019 00:00,,,,,,
891,abbott-partners-with-nih-on-brain-initiative-to-advance-research-or-neurological-disorders,15-05-2019 00:00,,,,,,
892,progenics-pharmaceuticals-and-rotop-pharmaka-gmbh-announce-european-collaboration-for-prostate-cancer-imaging-agent-1404,15-05-2019 00:00,,,,,,
893,regenxbio-to-launch-new-manufacturing-facility-for-nav-technology-based-aav-gene-therapies,15-05-2019 00:00,,,,,,
894,roche-announces-fda-approval-for-venclexta-plus-gazyva-for-people-with-previously-untreated-chronic-lymphocytic-leukaemia,16-05-2019 00:00,,,,,,
895,vertex-and-kymera-therapeutics-establish-strategic-collaboration-to-discover-and-develop-targeted-protein-degradation-medicines-for-serious-diseases,16-05-2019 00:00,,,,,,
896,takeda-and-frazier-healthcare-partners-announce-collaboration-to-launch-phathom-pharmaceuticals,16-05-2019 00:00,,,,,,
897,neuclone-to-initiate-phase-i-clinical-trial-of-stelara-ustekinumab-biosimilar-the-second-biosimilar-from-the-10-product-portfolio-with-serum-institute,16-05-2019 00:00,,,,,,
898,zymeworks-and-gsk-expand-2016-azymetric?-bispecific-agreement,16-05-2019 00:00,,,,,,
899,updated-libtayo?-cemiplimab-rwlc-results-reinforce-durable-and-substantial-response-rates-in-advanced-cutaneous-squamous-cell-carcinoma,17-05-2019 00:00,,,,,,
900,thermo-fisher-scientific-to-acquire-manufacturing-site-in-cork-ireland-from-gsk,17-05-2019 00:00,,,,,,
901,fda-approves-first-anticoagulant-blood-thinner-for-pediatric-patients-to-treat-potentially-life-threatening-blood-clots,17-05-2019 00:00,,,,,,
902,exelixis-and-iconic-therapeutics-enter-into-exclusive-option-and-license-agreement-for-novel-antibody-drug-conjugate-program,17-05-2019 00:00,,,,,,
903,parvus-therapeutics-enters-into-worldwide-collaboration-and-license-agreement-with-genentech-to-develop-navacim?-therapeutics-for-the-treatment-of-autoimmune-diseases,17-05-2019 00:00,,,,,,
904,abbvie-provides-update-on-depatuxizumab-mafodotin-depatux-m-an-investigational-medicine-for-newly-diagnosed-glioblastoma-an-aggressive-form-of-brain-cancer,20-05-2019 00:00,,,,,,
905,new-exploratory-data-from-varsity-the-first-head-to-head-ulcerative-colitis-biologic-study-which-demonstrated-superiority-of-vedolizumab-to-adalimumab-in-clinical-remission-at-week-52-presented-at-2019-digestive-disease-week?,20-05-2019 00:00,,,,,,
906,ethicon-recalls-circular-staplers-for-insufficient-firing-and-failure-to-completely-form-staples,20-05-2019 00:00,,,,,,
907,us-fda-approves-gattex-teduglutide-for-children-1-year-of-age-and-older-with-short-bowel-syndrome-sbs,20-05-2019 00:00,,,,,,
908,ucb-announces-nayzilam-midazolam-nasal-spray-now-approved-by-fda-to-treat-intermittent-stereotypic-episodes-of-frequent-seizure-activity-in-people-living-with-epilepsy-in-the-us,21-05-2019 00:00,,,,,,
909,santhera-starts-collaboration-in-gene-therapy-research-for-congenital-muscular-dystrophy-with-the-biozentrum-university-of-basel-co-financedby-innosuisse,21-05-2019 00:00,,,,,,
910,merck-provides-update-on-phase-3-keynote-119-study-of-keytruda?-pembrolizumab-monotherapy-in-previously-treated-patients-with-metastatic-triple-negative-breast-cancer,21-05-2019 00:00,,,,,,
911,new-data-show-symbicort-reduces-attacks-in-mild-asthma-when-used-as-an-anti-inflammatory-reliever,21-05-2019 00:00,,,,,,
912,clovis-oncology-presents-patient-centered-outcomes-data-from-phase-3-ariel3-study-for-rubraca?-in-advanced-ovarian-cancer,21-05-2019 00:00,,,,,,
913,merck-to-acquire-peloton-therapeutics-bolstering-oncology-pipeline,22-05-2019 00:00,,,,,,
914,verily-forms-strategic-alliances-with-novartis-otsuka-pfizer-and-sanofi-to-transformclinical-research,22-05-2019 00:00,,,,,,
915,array-biopharma-announces-braftovi-mektovi-cetuximab-meet-primary-endpoints-of-orr-and-os-in-phase-3-beacon-crc-trial-interim-analysis-for-the-treatment-of-brafv600e-mutant-metastatic-colorectal-cancer,22-05-2019 00:00,,,,,,
916,triluminate-study-shows-treatment-with-abbotts-first-of-its-kind-minimally-invasive-device-reduces-tricuspid-heart-valve-leaks,22-05-2019 00:00,,,,,,
917,results-announced-from-two-renal-denervation-studies-at-europcr-show-positive-outcomes-in-high-risk-hypertensive-patients,22-05-2019 00:00,,,,,,
918,health-canada-approves-biocon-and-mylan?s-ogivri-the-first-trastuzumab-biosimilar-for-the-treatment-of-her2-positive-breast-and-gastric-cancers,22-05-2019 00:00,,,,,,
919,entyvio-vedolizumab-approved-in-japan-for-the-treatment-of-patients-with-moderately-to-severely-active-crohns-disease,23-05-2019 00:00,,,,,,
920,santhera-enters-into-license-agreement-with-chiesi-group-for-raxone-in-lhon-valued-at-up-to-chf-105-million,23-05-2019 00:00,,,,,,
921,oncosec-provides-encouraging-interim-data-from-ongoing-keynote-890-study-of-tavo-in-combination-with-keytruda-for-the-treatment-of-heavily-pretreated-chemotherapyradiotherapy-refractory-metastatic-triple-negative-breast-cancer,23-05-2019 00:00,,,,,,
922,synlogic-announces-clinical-collaboration-to-evaluate-synb1891-in-combination-with-pd-l1-checkpoint-inhibitor-in-patients-with-advanced-solid-tumors,23-05-2019 00:00,,,,,,
923,boston-scientific-initiates-trial-comparing-left-atrial-appendage-closure-to-direct-oral-anticoagulants-for-stroke-risk-reduction-post-afib-ablation,23-05-2019 00:00,,,,,,
924,gsk-announces-approval-of-shingrix-in-china-for-prevention-of-shingles-in-adults-aged-50-and-over,24-05-2019 00:00,,,,,,
925,celltrion-announces-approval-of-herzuma-trastuzumab-pkrb-in-brazil,24-05-2019 00:00,,,,,,
926,fda-clears-first-diagnostic-tests-for-extragenital-testing-for-chlamydia-and-gonorrhea,24-05-2019 00:00,,,,,,
927,roche-receives-fda-clearance-to-expand-testing-menu-on-cobas-68008800-systems-for-sexually-transmitted-diseases,24-05-2019 00:00,,,,,,
928,brightinsight-announces-the-launch-of-a-ce-marked-dosing-calculator-for-emicizumab,24-05-2019 00:00,,,,,,
929,fda-approves-novartis-piqray?-?-the-first-and-only-treatment-specifically-for-patients-with-a-pik3ca-mutation-in-hrher2-advanced-breast-cancer,27-05-2019 00:00,,,,,,
930,pfizer-announces-top-line-results-from-phase-3-trial-of-lyrica?-pregabalin-in-primary-generalized-tonic-clonic-seizures,27-05-2019 00:00,,,,,,
931,avexis-receives-fda-approval-for-zolgensma?-the-first-and-only-gene-therapy-for-pediatric-patients-with-spinal-muscular-atrophy-sma,27-05-2019 00:00,,,,,,
932,calecim-collaborates-with-menarini-asia-pacific-to-expand-the-worldwide-sales-of-its-product,27-05-2019 00:00,,,,,,
933,santhera-submits-marketing-authorization-application-to-the-europeanmedicines-agency-for-puldysa?-idebenone-in-duchenne-muscular-dystrophy,28-05-2019 00:00,,,,,,
934,matas-signs-agreement-to-acquire-kosmolet-as,28-05-2019 00:00,,,,,,
935,anobiotix-announces-the-launch-of-curadigm-a-new-nanotechnology-platform-for-healthcare,28-05-2019 00:00,,,,,,
936,biomarin-announces-that-phase-3-cohort-of-valoctocogene-roxaparvovec-gene-therapy-study-in-severe-hemophilia-a-met-pre-specified-criteria-for-regulatory-submissions-in-the-us-and-europe,28-05-2019 00:00,,,,,,
937,lilly-announces-licensing-agreement-for-non-opioid-pain-asset-from-centrexion-therapeutics,28-05-2019 00:00,,,,,,
938,fda-approves-revlimid-lenalidomide-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-previously-treated-follicular-lymphoma-or-marginal-zone-lymphoma,29-05-2019 00:00,,,,,,
939,european-medicines-agency-accepts-marketing-authorisation-application-for-prestige-biopharma?s-trastuzumab-biosimilar-hd201-for-review,29-05-2019 00:00,,,,,,
940,sensible-medical-innovations-licenses-reds-technology-to-bayer,29-05-2019 00:00,,,,,,
941,arvinas-receives-fast-track-designation-for-its-targeted-protein-degrader-arv-110-as-a-treatment-for-men-with-metastatic-castration-resistant-prostate-cancer,29-05-2019 00:00,,,,,,
942,ziopharm-oncology-announces-exclusive-license-with-national-cancer-institute-to-identify-and-use-t-cell-receptors-targeting-neoantigens-for-cancer-with-sleeping-beauty-platform,29-05-2019 00:00,,,,,,
943,bayer-and-foundation-medicine-announce-global-collaboration-to-develop-next-generation-sequencing-ngs-based-companion-diagnostics-cdx-in-oncology,29-05-2019 00:00,,,,,,
944,novartis-phase-iii-quartz-study-of-new-investigational-inhaled-combination-treatment-qmf149-meets-primary-and-key-secondary-endpoints-in-patients-with-inadequately-controlled-asthma,30-05-2019 00:00,,,,,,
945,roche?s-tecentriq-atezolizumab-combination-therapy-receives-health-canada?s-approval-for-metastatic-non-squamous-non-small-cell-lung-cancer-in-adults,30-05-2019 00:00,,,,,,
946,medtronic-gains-us-fda-clearance-for-new-catheter-system-for-his-bundle-pacing,30-05-2019 00:00,,,,,,
947,darzalex?-daratumumab-phase-3-maia-study-results-published-in-the-new-england-journal-of-medicine-show-combination-therapy-increases-progression-free-survival-in-newly-diagnosed-patients-with-multiple-myeloma-who-are-transplant-ineligible,30-05-2019 00:00,,,,,,
948,sumitomo-dainippon-pharma-signs-a-co-promotion-and-sales-collaboration-agreement-for-diabetes-treatments-equa-and-equmet-in-japan,31-05-2019 00:00,,,,,,
949,roche-and-ge-healthcare-launch-navify-tumor-board-with-medical-imaging-capabilities-to-enable-more-personalised-treatment-decisions-in-cancer-care,31-05-2019 00:00,,,,,,
950,pfenex-and-alvogen-announce-european-medicines-agency-accepts-marketing-authorization-application-for-pf708,01-06-2019 00:00,,,,,,
951,merck?s-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivotal-phase-3-keynote-048-trial,31-05-2019 00:00,,,,,,
952,us-fda-grants-priority-review-for-daratumumab-in-combination-with-bortezomib-thalidomide-and-dexamethasone-in-frontline-multiple-myeloma,31-05-2019 00:00,,,,,,
953,xolair-omalizumab-significantly-reduced-nasal-polyps-and-congestion-symptoms-in-adults-with-chronic-rhinosinusitis-with-nasal-polyps-in-two-phase-iii-studies,03-06-2019 00:00,,,,,,
954,phase-3-trial-of-isatuximab-combination-therapy-showed-40-reduction-in-the-risk-of-disease-progression-or-death-for-patients-with-relapsedrefractory-multiple-myeloma,03-06-2019 00:00,,,,,,
955,novartis-kisqali-significantly-extends-life-in-women-with-hrher2-advanced-breast-cancer-in-monaleesa-7-trial,03-06-2019 00:00,,,,,,
956,novartis-shows-growing-strength-in-lung-cancer-innovation-with-new-capmatinib-investigational-data-and-novel-canakinumab-clinical-trials,04-06-2019 00:00,,,,,,
957,xolair-omalizumab-significantly-reduced-nasal-polyps-and-congestion-symptoms-in-adults-with-chronic-rhinosinusitis-with-nasal-polyps-in-two-phase-iii-studies,04-06-2019 00:00,,,,,,
958,fda-approves-merck?s-zerbaxa-ceftolozane-and-tazobactam-3g-dose-for-the-treatment-of-adults-with-hospital-acquired-and-ventilator-associated-bacterial-pneumonia-habpvabp,04-06-2019 00:00,,,,,,
959,fresenius-kabi-launches-biosimilar-adalimumab-idacio-in-germany,03-05-2019 00:00,,,,,,
960,bc-expands-use-of-biosimilars-to-offer-coverage-for-more-treatment-options,27-05-2019 00:00,,,,,,
961,fda-issues-draft-guidance-for-industry-on-the-design-and-evaluation-of-comparative-analytical-studies-for-biosimilarity,21-05-2019 00:00,,,,,,
962,fda-issues-draft-guidance-for-industry-on-the-design-and-evaluation-of-comparative-analytical-studies-for-biosimilarity,21-05-2019 00:00,,,,,,
963,abbvie-resolves-humira-adalimumab-us-patent-litigation-with-boehringer-ingelheim,14-05-2019 00:00,,,,,,
964,phase-iii-study-showed-xofluza-baloxavir-marboxil-is-effective-at-preventing-influenza-infection,04-06-2019 00:00,,,,,,
965,new-ad-hoc-analysis-of-phase-3-help-study-evaluates-prevention-of-hae-attacks-with-takhzyro-lanadelumab-during-early-treatment-phase,04-06-2019 00:00,,,,,,
966,celgene-corporation-and-acceleron-pharma-announce-us-fda-accepts-luspatercept-biologics-license-application-in-myelodysplastic-syndromes-and-beta-thalassemia,04-06-2019 00:00,,,,,,
967,astellas-and-seattle-genetics-announce-antibody-drug-conjugate-enfortumab-vedotin-produced-tumor-response-rate-of-44-percent-in-patients-with-most-common-type-of-advanced-urothelial-bladder-cancer,04-06-2019 00:00,,,,,,
968,fda-approves-emgality-galcanezumab-gnlm-as-the-first-and-only-medication-for-the-treatment-of-episodic-cluster-headache-that-reduces-the-frequency-of-attacks,05-06-2019 00:00,,,,,,
969,pivotal-phase-iii-cll14-results-for-venclextavenclyxto-in-combination-with-gazyvagazyvaro-for-chronic-lymphocytic-leukaemia-presented-at-asco-2019-and-published-in-the-new-england-journal-of-medicine,05-06-2019 00:00,,,,,,
970,puma-biotechnology-presents-results-from-phase-iii-nala-trial-of-neratinib-in-patients-with-her2-positive-metastatic-breast-cancer-at-the-asco-2019-annual-meeting,05-06-2019 00:00,,,,,,
971,biomarin-announces-approval-of-vimizim-elosulfase-alfa-in-china-for-treatment-of-morquio-a-syndrome,05-06-2019 00:00,,,,,,
972,bayer-and-arvinas-inc-to-develop-novel-proteolysis-targeting-chimera-candidates-for-humans-and-plants,05-06-2019 00:00,,,,,,
973,ibm-watson-health-presents-new-data-demonstrating-real-world-progress-of-ai-in-oncology-at-2019-asco-annual-meeting,05-06-2019 00:00,,,,,,
974,takeda-provides-update-on-tourmaline-al1-phase-3-trial-in-al-amyloidosis,06-06-2019 00:00,,,,,,
975,enzyvant-announces-fda-acceptance-of-biologics-license-application-bla-and-priority-review-status-for-rvt-802-a-novel-investigational-tissue-based-regenerative-therapy-for-pediatric-congenital-athymia,06-06-2019 00:00,,,,,,
976,oncolytics-biotech-announces-study-to-investigate-combination-of-pelareorep-and-avelumab-in-metastatic-breast-cancer-in-collaboration-with-merck-kgaa-darmstadt-germany-and-pfizer,06-06-2019 00:00,,,,,,
977,oncolytics-biotech-announces-study-to-investigate-combination-of-pelareorep-and-avelumab-in-metastatic-breast-cancer-in-collaboration-with-merck-kgaa-darmstadt-germany-and-pfizer,06-06-2019 00:00,,,,,,
978,calquence-phase-iii-elevate-tn-trial-met-primary-endpoint-at-interim-analysis-in-previously-untreated-chronic-lymphocytic-leukaemia,06-06-2019 00:00,,,,,,
979,nucala-mepolizumab-gains-fda-approval-for-two-new-self-administration-options,07-06-2019 00:00,,,,,,
980,novartis-presents-first-of-its-kind-histology-data-with-iscalimab-cfz533-suggesting-the-extended-survival-of-transplanted-organs-may-be-possible,07-06-2019 00:00,,,,,,
981,advanced-accelerator-applications-receives-positive-chmp-opinion-for-lysakare,07-06-2019 00:00,,,,,,
982,vertex-expands-into-new-disease-areas-and-enhances-gene-editing-capabilities-through-expanded-collaboration-with-crispr-therapeutics-and-acquisition-of-exonics-therapeutics,07-06-2019 00:00,,,,,,
983,stada-to-acquire-branded-otc-portfolio-from-gsk-to-strengthen-skin-care-business-in-europe,07-06-2019 00:00,,,,,,
984,lillys-ultra-rapid-lispro-provided-similar-a1c-reductions-compared-to-humalog-insulin-lispro-with-superior-post-meal-blood-glucose-reductions,10-06-2019 00:00,,,,,,
985,therapeuticsmd-and-theramex-enter-into-exclusive-license-and-supply-agreement-to-commercialize-bijuva?-and-imvexxy?-outside-the-united-states,10-06-2019 00:00,,,,,,
986,merck-gains-portfolio-of-investigational-antibodies-modulating-tgf?,10-06-2019 00:00,,,,,,
987,medtronic-and-tidepool-work-together-on-interoperable-automated-insulin-pump-system-for-diabetes-management,10-06-2019 00:00,,,,,,
988,innovate-biopharmaceuticals-announces-the-start-of-the-first-phase-3-clinical-trial-in-celiac-disease,10-06-2019 00:00,,,,,,
989,fda-grants-roche?s-polivy-accelerated-approval-for-people-with-previously-treated-aggressive-lymphoma,11-06-2019 00:00,,,,,,
990,present-5-year-sustained-efficacy-and-safety-results-for-taltz-ixekizumab-in-patients-with-plaque-psoriasis-at-the-world-congress-lilly-to-of-dermatology,11-06-2019 00:00,,,,,,
991,fda-gives-first-ever-indication-for-device-to-be-used-for-patients-with-functional-abdominal-pain-associated-with-irritable-bowel-syndrome-ibs,11-06-2019 00:00,,,,,,
992,new-two-year-data-at-the-24th-world-congress-of-dermatology-shows-skyrizi-risankizumab-maintains-complete-skin-clearance,11-06-2019 00:00,,,,,,
993,detailed-findings-from-carolina-outcome-trial-support-long-term-cardiovascular-safety-profile-of-tradjenta?,11-06-2019 00:00,,,,,,
994,fda-approves-two-new-indications-for-merck?s-keytruda-pembrolizumab,11-06-2019 00:00,,,,,,
995,invokana-canagliflozin-significantly-reduced-major-cardiovascular-events-and-kidney-failure-in-patients-with-type-2-diabetes-and-chronic-kidney-disease-in-new-credence-analysis,12-06-2019 00:00,,,,,,
996,genmab-signs-agreement-with-janssen-for-next-generation-cd38-antibody-hexabody-cd38,12-06-2019 00:00,,,,,,
997,biogen-to-present-new-safety-and-efficacy-data-on-biosimilars-and-estimates-18-billion-euros-in-savings-for-the-european-healthcare-system-in-2019,12-06-2019 00:00,,,,,,
998,fda-grants-priority-review-to-genentech?s-rituxan-rituximab-in-children-with-two-rare-blood-vessel-disorders,12-06-2019 00:00,,,,,,
999,oral-semaglutide-demonstrated-cardiovascular-safety-in-people-with-type-2-diabetes-and-established-cardiovascular-disease-or-high-cardiovascular-risk-in-pioneer-6-trial,12-06-2019 00:00,,,,,,
1000,new-long-term-data-from-upadacitinib-phase-3-studies-in-rheumatoid-arthritis-including-results-on-clinical-remission-at-48-weeks-presented-at-eular,13-06-2019 00:00,,,,,,
1001,phase-iii-pemphix-study-showed-that-genentech?s-rituxan-rituximab-is-superior-to-standard-of-care-in-achieving-sustained-remission-in-patients-with-pemphigus-vulgaris,13-06-2019 00:00,,,,,,
1002,pfizer-announces-results-from-xeljanz-xr-tofacitinib-oral-shift-study-the-first-phase-3b4-study-to-evaluate-methotrexate-withdrawal-with-a-jak-inhibitor,13-06-2019 00:00,,,,,,
1003,new-subcutaneous-formulation-of-celltrion-healthcare?s-ct-p13-biosimilar-infliximab-shows-positive-results-for-the-treatment-of-rheumatoid-arthritis-ra-in-data-presented-at-the-annual-european-congress-of-rheumatology-eular-2019,13-06-2019 00:00,,,,,,
1004,sobi-strengthens-focus-and-increases-investments-in-late-stage-development-in-haematology-and-immunology,13-06-2019 00:00,,,,,,
1005,fda-approves-amgen-and-allergans-kanjinti-trastuzumab-anns-a-biosimilar-to-herceptin?-trastuzumab,14-06-2019 00:00,,,,,,
1006,new-mechanistic-study-explores-the-relationship-between-a-key-genetic-marker-and-clinical-efficacy-of-orencia-abatacept-or-adalimumab-in-moderate-to-severe-early-rheumatoid-arthritis-patients,14-06-2019 00:00,,,,,,
1007,beigene-announces-updated-results-from-a-pivotal-phase-2-study-of-tislelizumab-in-chinese-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-at-the-24th-congress-of-the-european-hematology-association-eha,14-06-2019 00:00,,,,,,
1008,lilly-presents-positive-results-for-taltz-ixekizumab-vs-humira-adalimumab-in-a-head-to-head-spirit-h2h-superiority-study-in-patients-with-active-psoriatic-arthritis-at-the-european-congress-of-rheumatology,14-06-2019 00:00,,,,,,
1009,dr-reddy?s-laboratories-announces-entering-into-a-definitive-agreement-tosell-its-neurology-branded-products-to-upsher-smith-laboratories-llc,14-06-2019 00:00,,,,,,
1010,lokelma-demonstrated-efficacy-in-treating-hyperkalaemia-in-patients-with-end-stage-renal-disease-on-haemodialysis,14-06-2019 00:00,,,,,,
1011,janssen-reports-top-line-phase-3-results-for-tremfya-guselkumab-in-adults-with-active-psoriatic-arthritis,17-06-2019 00:00,,,,,,
1012,immunophotonics-and-clinical-laserthermia-systems-announce-immuno-oncology-research-collaboration-and-clinical-trials-for-cancer-patients-with-solid-tumors,17-06-2019 00:00,,,,,,
1013,pfizer-to-acquire-array-biopharma,17-06-2019 00:00,,,,,,
1014,calquence-significantly-prolonged-the-time-patients-lived-without-disease-progression-in-relapsed-or-refractory-chronic-lymphocytic-leukaemia,17-06-2019 00:00,,,,,,
1015,fda-approves-victoza-for-the-treatment-of-type-2-diabetes-in-children-and-adolescents-aged-10-17-years,18-06-2019 00:00,,,,,,
1016,beigene-regains-full-global-rights-to-its-investigational-anti-pd-1-antibody-tislelizumab,18-06-2019 00:00,,,,,,
1017,japan-becomes-the-first-country-to-approve-roche?s-personalised-medicine-rozlytrek,18-06-2019 00:00,,,,,,
1018,lynparza-approved-in-the-eu-for-1st-line-maintenance-treatment-of-brca-mutated-advanced-ovarian-cancer,18-06-2019 00:00,,,,,,
1019,abbott-launches-first-ever-rapid-point-of-care-hba1c-test-to-aid-in-the-diagnosis-of-diabetes,18-06-2019 00:00,,,,,,
1020,fda-approves-merck?s-keytruda-pembrolizumab-as-monotherapy-for-patients-with-metastatic-small-cell-lung-cancer-sclc-with-disease-progression-on-or-after-platinum-based-chemotherapy-and-at-least-one-other-prior-line-of-therapy,19-06-2019 00:00,,,,,,
1021,ironwood-and-allergan-report-positive-topline-data-from-phase-iiib-trial-of-linzess-linaclotide-in-adults-with-irritable-bowel-syndrome-with-constipation-ibs-c,19-06-2019 00:00,,,,,,
1022,breztri-aerosphere-pt010-approved-in-japan-for-patients-with-chronic-obstructive-pulmonary-disease,19-06-2019 00:00,,,,,,
1023,health-canada-approves-hemlibra-for-hemophilia-a-patients-without-factor-viii-inhibitors,19-06-2019 00:00,,,,,,
1024,catalent-to-purchase-bristol-myers-squibb-manufacturing-facility-in-anagni-italy,19-06-2019 00:00,,,,,,
1025,sanofi-and-google-to-develop-new-healthcare-innovation-lab,19-06-2019 00:00,,,,,,
1026,gilead-and-nurix-establish-strategic-collaboration-to-develop-novel-therapies-for-cancer-and-other-diseases,20-06-2019 00:00,,,,,,
1027,amgen-and-the-institute-for-protein-design-ipd-at-university-of-washington-announce-unique-strategic-research-partnership,20-06-2019 00:00,,,,,,
1028,?alexa-monitor-my-heart?-researchers-develop-first-contactless-cardiac-arrest-ai-system-for-smart-speakers,20-06-2019 00:00,,,,,,
1029,resolution-advancing-development-of-cell-free-dna-companion-diagnostic-for-prostate-cancer-through-collaboration-with-janssen,20-06-2019 00:00,,,,,,
1030,ultomiris-ravulizumab-receives-marketing-authorization-from-japan?s-ministry-of-health-labour-and-welfare-mhlw-for-the-treatment-of-adults-with-paroxysmal-nocturnal-hemoglobinuria-pnh,20-06-2019 00:00,,,,,,
1031,esperoct-turoctocog-alfa-pegol-n8-gp-approved-in-the-eu,21-06-2019 00:00,,,,,,
1032,ibri-in-license-agreement-for-access-to-lilly?s-fab-phage-display-library,21-06-2019 00:00,,,,,,
1033,valneva-announces-mutual-agreement-with-gsk-to-end-strategic-alliance-agreement-regains-control-of-rd,21-06-2019 00:00,,,,,,
1034,bayer-initiates-phase-iii-trial-of-aflibercept-to-prevent-blindness-in-premature-infants,21-06-2019 00:00,,,,,,
1035,sanofi-and-regeneron-announce-positive-topline-phase-2-results-for-il-33-antibody-in-asthma,21-06-2019 00:00,,,,,,
1036,fda-approves-botox-onabotulinumtoxina-for-pediatric-patients-with-upper-limb-spasticity,24-06-2019 00:00,,,,,,
1037,european-commission-approves-talzenna-talazoparib-for-patients-with-inherited-germline-brca-mutated-locally-advanced-or-metastatic-breast-cancer,24-06-2019 00:00,,,,,,
1038,european-medicines-agency-accepted-first-china-developed-biosimilar-?-henlius-hlx02-marketing-authorization-application-for-review,24-06-2019 00:00,,,,,,
1039,bristol-myers-squibb-announces-results-from-checkmate-459-study-evaluating-opdivo-nivolumab-as-a-first-line-treatment-for-patients-with-unresectable-hepatocellular-carcinoma,24-06-2019 00:00,,,,,,
1040,allergan-receives-fda-clearance-for-cooltone-device,24-06-2019 00:00,,,,,,
1041,gilead-and-carna-biosciences-announce-research-and-development-collaboration-to-develop-novel-immuno-oncology-therapies,25-06-2019 00:00,,,,,,
1042,glenmark-to-partner-with-novartis-to-promote-commercialize-and-distribute-threerespiratory-products-in-brazil,25-06-2019 00:00,,,,,,
1043,abbvie-to-acquire-allergan-in-transformative-move-for-both-companies,25-06-2019 00:00,,,,,,
1044,bristol-myers-squibb-provides-update-on-pending-merger-with-celgene,25-06-2019 00:00,,,,,,
1045,c4x-discovery-and-phoremost-collaboration-to-accelerate-parkinson?s-disease-drug-discovery-pipeline,25-06-2019 00:00,,,,,,
1046,almirall-exercises-its-option-with-dermira-to-license-rights-to-lebrikizumab-in-europe-for-atopic-dermatitis,26-06-2019 00:00,,,,,,
1047,tilt-biotherapeutics-initiates-collaboration-with-merck-kgaa-darmstadt-germany-and-pfizer-investigating-the-combination-of-oncolytic-virus-tilt-123-and-anti-pdl1-antibody-avelumab,26-06-2019 00:00,,,,,,
1048,eisai-presents-data-to-assess-seizure-freedom-with-fycompa-monotherapy-in-newly-diagnosed-or-untreated-patients-with-partial-onset-seizures,26-06-2019 00:00,,,,,,
1049,lillys-award-11-trial-studying-higher-investigational-doses-of-trulicity-dulaglutide-demonstrated-superiority-in-a1c-reduction-in-people-with-type-2-diabetes,26-06-2019 00:00,,,,,,
1050,us-fda-grants-fast-track-designation-to-empagliflozin-for-the-treatment-of-chronic-heart-failure,26-06-2019 00:00,,,,,,
1051,daiichi-sankyo-to-transfer-marketing-authorization-rights-for-four-diagnostic-imaging-agents-in-japan-to-ge-healthcare,26-06-2019 00:00,,,,,,
1052,louisiana-launches-hepatitis-c-innovative-payment-model-with-asegua-therapeutics-aiming-to-eliminate-the-disease,27-06-2019 00:00,,,,,,
1053,fda-approves-dupixent-dupilumab-for-chronic-rhinosinusitis-with-nasal-polyposis,27-06-2019 00:00,,,,,,
1054,imfinzi-improves-overall-survival-at-interim-analysis-in-the-phase-iii-caspian-trial-in-1st-line-extensive-stage-small-cell-lung-cancer,27-06-2019 00:00,,,,,,
1055,fda-to-review-menquadfitm-a-meningococcal-vaccine-candidate,27-06-2019 00:00,,,,,,
1056,liquidia-and-gsk-restructure-collaboration-agreement,27-06-2019 00:00,,,,,,
1057,janssen-announces-us-fda-approval-of-darzalex-daratumumab-in-combination-with-lenalidomide-and-dexamethasone-for-newly-diagnosed-patients-with-multiple-myeloma-who-are-transplant-ineligible,28-06-2019 00:00,,,,,,
1058,alexion-receives-fda-approval-of-soliris-eculizumab-for-the-treatment-of-adults-with-neuromyelitis-optica-spectrum-disorder-nmosd-who-are-anti-aquaporin-4-aqp4-antibody-positive,28-06-2019 00:00,,,,,,
1059,purchase-includes-one-drop?s-wireless-glucose-monitoring-system-and-one-year-of-unlimited-access-to-certified-diabetes-coaches-for-247-support,28-06-2019 00:00,,,,,,
1060,chmp-recommends-approval-of-dupixent-dupilumab-for-moderate-to-severe-atopic-dermatitis-in-adolescents,28-06-2019 00:00,,,,,,
1061,nmpa-accepts-new-drug-application-for-ibi301-a-biosimilar-product-candidate-of-rituximab-mabtherarituxan,28-06-2019 00:00,,,,,,
1062,pfizer-receives-us-fda-approval-for-its-oncology-biosimilar-zirabev-bevacizumab-bvzr,28-06-2019 00:00,,,,,,
1063,pfizer-announces-results-from-phase-3-trial-of-revatio-sildenafil-citrate-in-newborns-with-persistent-pulmonary-hypertension,01-07-2019 00:00,,,,,,
1064,forxiga-receives-positive-eu-chmp-opinion-for-declare-timi-58-cardiovascular-outcomes-data,01-07-2019 00:00,,,,,,
1065,janssen-receives-positive-chmp-opinion-recommending-expanded-use-of-imbruvica-ibrutinib-in-two-indications-in-europe,01-07-2019 00:00,,,,,,
1066,chmp-recommends-eu-approval-of-roche?s-tecentriq-in-combination-with-abraxane-as-an-initial-treatment-for-people-with-pd-l1-positive-metastatic-triple-negative-breast-cancer,01-07-2019 00:00,,,,,,
1067,biogen-announces-new-data-further-establishing-spinraza?-nusinersen-as-a-foundation-of-care-in-spinal-muscular-atrophy-for-a-broad-range-of-patients,02-07-2019 00:00,,,,,,
1068,libtayo-cemiplimab-approved-for-advanced-cutaneous-squamous-cell-carcinoma-in-the-european-union,02-07-2019 00:00,,,,,,
1069,teva-presents-positive-results-showing-improvement-in-disability-and-quality-of-life-from-the-phase-iiib-focus-study-of-fremanezumab-in-adults-with-migraine,02-07-2019 00:00,,,,,,
1070,it-strengthens-its-presence-in-the-market-for-bio-like-products,13-06-2019 00:00,,,,,,
1071,withdrawal-of-application-for-the-marketing-authorisation-of-abp-710-infliximab,28-06-2019 00:00,,,,,,
1072,boehringer-ingelheim-expands-nonalcoholic-steatohepatitis-nash-rd-pipeline-with-new-first-in-class-compound-from-yuhan-corporation,02-07-2019 00:00,,,,,,
1073,foundation-medicine-expands-indication-for-foundationone?cdx-as-a-companion-diagnostic-for-lynparza?-olaparib,02-07-2019 00:00,,,,,,
1074,varian-to-expand-interventional-oncology-portfolio-with-purchase-of-embolic-bead-asset,02-07-2019 00:00,,,,,,
1075,genentech-announces-positive-results-for-first-global-phase-iii-study-investigating-one-dose-xofluza-baloxavir-marboxil-in-children-with-the-flu,03-07-2019 00:00,,,,,,
1076,sandoz-launches-oncology-generic-gefitinib-in-13-eu-countries-at-loss-of-market-exclusivity-expanding-access-to-essential-medicine,03-07-2019 00:00,,,,,,
1077,viiv-healthcare-receives-eu-marketing-authorisation-for-dovato-dolutegravirlamivudine-a-new-once-daily-single-pill-two-drug-regimen-for-the-treatment-of-hiv-1-infection,03-07-2019 00:00,,,,,,
1078,gsk-announces-phase-iii-start-for-its-anti-gm-csf-antibody-otilimab-in-patients-with-rheumatoid-arthritis-ra,03-07-2019 00:00,,,,,,
1079,asieris-and-photocure-enter-into-a-license-agreement-for-world-wide-development-and-commercialization-of-cevira,03-07-2019 00:00,,,,,,
1080,joint-stipulation-of-dismissal,04-07-2019 00:00,,,,,,
1081,ultomiris-ravulizumab-receives-marketing-authorization-from-european-commission-for-adults-with-paroxysmal-nocturnal-hemoglobinuria-pnh,04-07-2019 00:00,,,,,,
1082,karyopharm-announces-fda-approval-of-xpovio-selinexor-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma,04-07-2019 00:00,,,,,,
1083,samsung-bioepis-announces-eu-label-update-for-imraldi-adalimumab-with-extended-storage-conditions,28-06-2019 00:00,,,,,,
1084,nosopharm-and-evotec-enter-into-collaboration-to-accelerate-development-of-novel-antibiotics,04-07-2019 00:00,,,,,,
1085,janssen-returns-obesity-and-diabetes-treatment-rights-to-hanmi-pharmaceutical,04-07-2019 00:00,,,,,,
1086,sifi-announces-expansion-on-the-french-market-with-the-acquisition-of-dacudoses?-and-novoptine?,05-07-2019 00:00,,,,,,
1087,grifols-announces-fda-approval-of-xembify-20-subcutaneous-immunoglobulin-for-primary-immunodeficiencies,05-07-2019 00:00,,,,,,
1088,precise-navigation-through-the-vascular-system,05-07-2019 00:00,,,,,,
1089,using-machine-learning-models-to-better-predict-bladder-cancer-stages,05-07-2019 00:00,,,,,,
1090,fresenius-kabi-issues-voluntary-nationwide-recall-of-two-lots-of-fluorouracil-injection-due-to-the-potential-for-glass-particulate,05-07-2019 00:00,,,,,,
1091,priority-review-granted-to-beigene?s-supplemental-new-drug-application-in-china-for-tislelizumab-in-urothelial-carcinoma,08-07-2019 00:00,,,,,,
1092,sepsis-can-be-detected-early-using-new-technology-enabling-patients-to-receive-timely-treatment,08-07-2019 00:00,,,,,,
1093,new-data-show-nonacog-beta-pegol-n9-gp-is-effective-and-well-tolerated-for-the-prevention-and-treatment-of-bleeding-in-children-with-haemophilia-bnew-data-show-nonacog-beta-pegol-n9-gp-is-effective-and-well-tolerated-for-the-prevention-and-treatment-of-bleeding-in-children-with-haemophilia-b,08-07-2019 00:00,,,,,,
1094,takeda-unveil-new-data-from-the-propel-study-at-isth-2019-reinforcing-the-potential-benefit-for-personalized-prophylaxis-with-adynovate-in-severe-hemophilia-a,08-07-2019 00:00,,,,,,
1095,viiv-healthcare-announces-start-of-first-ever-study-to-identify-and-evaluate-approaches-to-implementing-its-once-monthly-injectable-hiv-treatment-in-clinical-practice,08-07-2019 00:00,,,,,,
1096,rivaroxaban-demonstrates-strong-efficacy-and-safety-profile-in-phase-iii-study-in-children-with-thromboembolism,09-07-2019 00:00,,,,,,
1097,roche-presents-a-broad-range-of-data-for-hemlibra-demonstrating-continued-benefits-for-people-with-haemophilia-a-at-the-isth-2019-congress,09-07-2019 00:00,,,,,,
1098,siga-awarded-department-of-defense-contract-to-develop-expanded-indication-for-tpoxx-as-post-exposure-prophylactic-for-smallpox,09-07-2019 00:00,,,,,,
1099,fda-accepts-merck?s-supplemental-biologics-license-applications-for-keytruda?-pembrolizumab-six-week-dosing-schedule-for-melanoma-and-multiple-other-indications,09-07-2019 00:00,,,,,,
1100,new-data-show-efficacy-and-safety-of-pradaxa-in-the-management-of-vte-in-children,09-07-2019 00:00,,,,,,
1101,fda-to-review-isatuximab-as-a-potential-treatment-forrelapsedrefractory-multiple-myeloma,10-07-2019 00:00,,,,,,
1102,viiv-healthcare-announces-phase-iii-study-meets-primary-endpoint-demonstrating-the-ability-to-control-hiv-1-with-a-2-drug-regimen-of-dolutegravir-plus-lamivudine-in-virally-suppressed-patients-switching-from-a-taf-containing-3-drug-regimen,10-07-2019 00:00,,,,,,
1103,mirati-announces-clinical-collaboration-to-evaluate-mrtx849-in-combination-with-shp2-inhibitor-tno155,10-07-2019 00:00,,,,,,
1104,celsius-therapeutics-signs-collaboration-agreement-with-janssen-to-identify-response-biomarkers-for-ulcerative-colitis,10-07-2019 00:00,,,,,,
1105,jazz-pharmaceuticals-acquires-pre-clinical-pan-raf-inhibitor-program-from-redx-pharma,10-07-2019 00:00,,,,,,
1106,sandoz-extends-symjepi-epinephrine-injection-launch-to-us-pharmacies-to-help-improve-patient-access-to-life-saving-medicine,10-07-2019 00:00,,,,,,
1107,health-canada-approves-pomalyst-based-triplet-combination-for-patients-with-multiple-myeloma,11-07-2019 00:00,,,,,,
1108,glenmark-torrent-sign-licensing-agreement-for-co-marketing-of-remogliflozin-etabonate-in-india,11-07-2019 00:00,,,,,,
1109,health-canada-has-authorized-vyvanse-lisdexamfetamine-dimesylate-the-first-and-only-chewable-tablet-for-the-treatment-of-attention-deficithyperactivity-disorder-adhd,11-07-2019 00:00,,,,,,
1110,nhs-health-information-available-through-amazons-alexa,11-07-2019 00:00,,,,,,
1111,new-england-journal-of-medicine-publishes-positive-phase-3-data-for-emgality?-galcanezumab-gnlm-in-episodic-cluster-headache,11-07-2019 00:00,,,,,,
1112,macrogenics-and-i-mab-announce-exclusive-collaboration-and-license-agreement-to-develop-and-commercialize-enoblituzumab-in-greater-china,11-07-2019 00:00,,,,,,
1113,novartis-amgen-and-banner-alzheimers-institute-discontinue-clinical-program-with-bace-inhibitor-cnp520-for-alzheimers-prevention,12-07-2019 00:00,,,,,,
1114,abbott-announces-fda-approval-of-the-alinity-s-system-the-latest-technology-for-screening-and-protecting-the-us-blood-and-plasma-supply,12-07-2019 00:00,,,,,,
1115,forty-seven-inc-and-ono-pharmaceutical-co-ltd-sign-regional-license-agreement-to-develop-manufacture-and-commercialize-5f9-in-japan-south-korea-taiwan-and-select-countries-in-southeast-asia,12-07-2019 00:00,,,,,,
1116,newron?s-commercialization-partner-zambon-and-valeo-pharma-announce-the-launch-of-onstryv-safinamide-for-parkinson?s-disease-in-canada,12-07-2019 00:00,,,,,,
1117,ahs-2019-post-hoc-analyses-of-phase-3-pivotal-studies-of-emgality-galcanezumab-gnlm-show-improvements-in-daily-functioning-and-reductions-in-disability-in-patients-with-chronic-and-episodic-migraine,12-07-2019 00:00,,,,,,
1118,gsk-announces-positive-headline-results-in-phase-3-prima-study-of-zejula-niraparib-for-patients-with-ovarian-cancer-in-the-first-line-maintenance-setting,15-07-2019 00:00,,,,,,
1119,gilead-and-galapagos-enter-into-transformative-research-and-development-collaboration,15-07-2019 00:00,,,,,,
1120,janssen-submits-application-to-us-fda-seeking-approval-of-new-darzalex-daratumumab-subcutaneous-formulation,15-07-2019 00:00,,,,,,
1121,abbvie-enhances-early-stage-oncology-pipeline-with-acquisition-of-mavupharma,15-07-2019 00:00,,,,,,
1122,boehringer-ingelheim-acquires-amal-therapeutics-significantly-enriching-its-cancer-immunology-portfolio-with-novel-cancer-vaccines-platform,16-07-2019 00:00,,,,,,
1123,abbott-receives-us-approval-of-next-generation-mitraclip-bringing-new-enhancements-to-abbotts-leading-mitraclip-platform,16-07-2019 00:00,,,,,,
1124,fda-approves-bayers-gadavist-as-first-and-only-contrast-agent-for-use-in-cardiac-mri-in-patients-with-coronary-artery-disease,16-07-2019 00:00,,,,,,
1125,first-ipsc-derived-car-t-cell-therapy-created-by-kyoto-university-cira-and-takeda-collaboration-enters-process-development-toward-clinical-testing,16-07-2019 00:00,,,,,,
1126,fda-accepts-file-and-accelerates-review-of-novartis-sickle-cell-disease-medicine-crizanlizumab-seg101,16-07-2019 00:00,,,,,,
1127,skyhawk-therapeutics-announces-agreement-with-genentech-to-discover-and-develop-small-molecule-rna-splicing-modifiers-for-oncology-and-neurodegenerative-diseases,17-07-2019 00:00,,,,,,
1128,convelo-therapeutics-enters-into-collaboration-and-option-to-acquire-agreement-with-genentech-to-discover-novel-remyelinating-therapies,17-07-2019 00:00,,,,,,
1129,puma-biotechnology?s-licensing-partner-knight-therapeutics-receives-regulatory-approval-from-health-canada-to-commercialize-nerlynx-neratinib-for-extended-adjuvant-treatment-of-hormone-receptor-positive-her2-positive-early-stage-breast-cancer,17-07-2019 00:00,,,,,,
1130,fda-approves-merck?s-recarbrio-imipenem-cilastatin-and-relebactam-for-the-treatment-of-adults-with-complicated-urinary-tract-and-complicated-intra-abdominal-bacterial-infections-where-limited-or-no-alternative-treatment-options-are-available,17-07-2019 00:00,,,,,,
1131,us-fda-accepts-allergans-new-drug-application-for-bimatoprost-sustained-release-in-patients-with-open-angle-glaucoma-or-ocular-hypertension,17-07-2019 00:00,,,,,,
1132,sosei-heptares-enters-into-multi-target-research-collaboration-and-license-agreement-with-genentech,17-07-2019 00:00,,,,,,
1133,macrogenics-provides-update-on-flotetuzumab-program-in-acute-myeloid-leukemia,18-07-2019 00:00,,,,,,
1134,breast-cancer-patients-to-have-further-nice-approved-drug-combination-option-on-cancer-drugs-fund,18-07-2019 00:00,,,,,,
1135,paragon-biosciences-launches-qlarity-imaging-to-advance-the-first-fda-cleared-artificial-intelligence-breast-cancer-diagnosis-system,18-07-2019 00:00,,,,,,
1136,bayer-bristol-myers-squibb-and-ono-pharmaceutical-enter-into-a-clinical-collaboration-agreement-to-investigate-stivarga?-regorafenib-and-opdivo?-nivolumab-as-combination-therapy-in-patients-with-metastatic-colorectal-cancer,18-07-2019 00:00,,,,,,
1137,astellas-and-frequency-therapeutics-enter-into-license-agreement-for-fx-322-a-regenerative-treatment-candidate-for-hearing-loss,18-07-2019 00:00,,,,,,
1138,chembio-diagnostics-and-takeda-pharmaceutical-company-enter-collaboration-to-develop-point-of-care-diagnostic-test,18-07-2019 00:00,,,,,,
1139,interpace-diagnostics-enters-agreement-with-predictive-oncology-to-enhance-diagnosis-of-thyroid-cancer-via-ai-driven-analysis,19-07-2019 00:00,,,,,,
1140,boehringer-ingelheim-expands-idiopathic-pulmonary-fibrosis-ipf-pipeline-through-collaboration-and-license-agreement-with-bridge-biotherapeutics,19-07-2019 00:00,,,,,,
1141,boehringer-ingelheim-expands-idiopathic-pulmonary-fibrosis-ipf-pipeline-through-collaboration-and-license-agreement-with-bridge-biotherapeutics,19-07-2019 00:00,,,,,,
1142,mallinckrodt-and-silence-therapeutics-announce-collaboration-to-develop-and-commercialize-rnai-therapeutics-for-complement-mediated-diseases,19-07-2019 00:00,,,,,,
1143,amgen-and-allergans-mvasi-bevacizumab-awwb-and-kanjinti-trastuzumab-anns-now-available-in-the-united-states,19-07-2019 00:00,,,,,,
1144,gilead-sciences-licenses-respiratory-and-herpes-antiviral-research-programs-from-novartis,19-07-2019 00:00,,,,,,
1145,sandoz-announces-first-patient-enrolled-in-clinical-study-for-proposed-biosimilar-denosumab-in-osteoporosis,22-07-2019 00:00,,,,,,
1146,fda-approves-otezla-apremilast-for-the-treatment-of-oral-ulcers-associated-with-beh?et?s-disease,22-07-2019 00:00,,,,,,
1147,investigational-subcutaneous-formulation-of-vedolizumab-meets-primary-endpoint-in-achieving-clinical-remission-at-week-52-in-patients-with-moderately-to-severely-active-crohns-disease,22-07-2019 00:00,,,,,,
1148,medtronic-partners-with-vizai-to-accelerate-adoption-of-new-artificial-intelligence-software-in-us-stroke-centers,22-07-2019 00:00,,,,,,
1149,durect-and-gilead-enter-into-license-agreement-for-long-acting-injectable-hiv-investigational-product,22-07-2019 00:00,,,,,,
1150,baxter-announces-us-fda-approval-of-myxredlin-the-first-and-only-ready-to-use-insulin-for-iv-infusion,23-07-2019 00:00,,,,,,
1151,sanofi-signs-strategic-deal-for-exclusive-us-over-the-counter-rights-to-tamiflu-in-flu-care,23-07-2019 00:00,,,,,,
1152,viiv-healthcare-presents-positive-96-week-data-from-phase-iii-study-of-investigational-fostemsavir-in-heavily-treatment-experienced-patients-with-hiv-at-ias-2019,23-07-2019 00:00,,,,,,
1153,imfinzi?-durvalumab-us-label-updated-with-overall-survival-data-in-unresectable-stage-iii-non-small-cell-lung-cancer,23-07-2019 00:00,,,,,,
1154,designation-granted-for-potential-first-line-treatment-of-patients-with-advanced-unresectable-hepatocellular-carcinoma-not-amenable-to-locoregional-treatment,23-07-2019 00:00,,,,,,
1155,chiasma-announces-positive-phase-3-top-line-results-from-chiasma-optimal-clinical-trial-of-mycapssa-for-the-maintenance-treatment-of-adults-with-acromegaly,23-07-2019 00:00,,,,,,
1156,fda-approves-pfizer?s-biosimilar-ruxience-rituximab-pvvr-for-certain-cancers-and-autoimmune-conditions,24-07-2019 00:00,,,,,,
1157,fda-approves-samsung-bioepis-hadlima?-adalimumab-bwwd,24-07-2019 00:00,,,,,,
1158,ligand-acquires-ab-initio-biotherapeutics-an-antigen-discovery-company,24-07-2019 00:00,,,,,,
1159,medtronic-requests-approval-of-non-adjunctive-labeling-from-fda,24-07-2019 00:00,,,,,,
1160,gilead-presents-new-findings-on-profile-of-descovy-for-potential-use-as-hiv-pre-exposure-prophylaxis-compared-with-truvada?,24-07-2019 00:00,,,,,,
1161,celgene-and-the-multiple-sclerosis-association-of-america-bring-ms-mindshift-initiative-and-?brain-bulb?-hot-air-balloon-to-festival-to-raise-awareness-of-multiple-sclerosis-and-brain-health,24-07-2019 00:00,,,,,,
1162,syapse-announces-collaboration-with-pfizer-in-oncology-precision-medicine-focused-on-outcomes-research-using-real-world-evidence,24-07-2019 00:00,,,,,,
1163,baqsimi-glucagon-nasal-powder-3-mg-the-first-and-only-nasally-administered-glucagon-to-treat-severe-hypoglycemia-in-adults-and-children-with-diabetes-ages-four-years-and-older-approved-by-fda,25-07-2019 00:00,,,,,,
1164,bristol-myers-squibb-announces-checkmate-227-part-1a-meets-co-primary-endpoint-of-overall-survival,25-07-2019 00:00,,,,,,
1165,jounce-therapeutics-announces-update-on-strategic-collaboration-with-celgene-corporation,25-07-2019 00:00,,,,,,
1166,allergan-voluntarily-recalls-biocell-textured-breast-implants-and-tissue-expanders,25-07-2019 00:00,,,,,,
1167,regenxbio-and-neurimmune-announce-collaboration-to-develop-vectorized-antibodies-for-the-treatment-of-neurodegenerative-diseases,25-07-2019 00:00,,,,,,
1168,verastem-oncology-signs-an-exclusive-license-agreement-with-sanofi-for-the-development-and-commercialization-of-copiktra?-duvelisib-in-russia-and-cis-turkey-the-middle-east-and-africa,26-07-2019 00:00,,,,,,
1169,boehringer-ingelheim-today-announced-that-the-fdas-arthritis-advisory-committee-recommended-10-7-vote-to-approve-ofev-nintedanib-for-the-treatment-of-systemic-sclerosis-associated-interstitial-lung-disease-or-ssc-ild,26-07-2019 00:00,,,,,,
1170,janssen-reports-positive-top-line-phase-3-results-for-ponesimod-in-adults-with-relapsing-multiple-sclerosis,26-07-2019 00:00,,,,,,
1171,bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-of-empliciti-elotuzumab-plus-pomalidomide-and-low-dose-dexamethasone-for-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma,26-07-2019 00:00,,,,,,
1172,chmp-recommends-eu-approval-of-roche?s-tecentriq-in-combination-with-chemotherapy-as-an-initial-treatment-of-adults-with-extensive-stage-small-cell-lung-cancer,26-07-2019 00:00,,,,,,
1173,epizyme-announces-fda-filing-acceptance-of-new-drug-application-and-priority-review-for-tazemetostat-for-the-treatment-of-epithelioid-sarcoma,26-07-2019 00:00,,,,,,
1174,viiv-healthcare-submits-regulatory-application-to-european-medicines-agency-for-investigational-cabotegravir-to-be-used-in-combination-with-rilpivirine-as-the-first-monthly-injectable-treatment-for-hiv,29-07-2019 00:00,,,,,,
1175,pfizer-nears-deal-to-combine-off-patent-drug-business-with-mylan,29-07-2019 00:00,,,,,,
1176,mylan-and-upjohn-a-division-of-pfizer-to-combine-creating-a-new-champion-for-global-health-uniquely-positioned-to-fulfill-the-world?s-need-for-medicine,29-07-2019 00:00,,,,,,
1177,sanofi-provides-update-on-zynquista-sotagliflozin-type-2-diabetes-phase-3-program-and-collaboration-with-lexicon,29-07-2019 00:00,,,,,,
1178,baxter-launches-prismax-in-us-to-maximize-care-for-critically-ill-patients,30-07-2019 00:00,,,,,,
1179,merck?s-keytruda-pembrolizumab-in-combination-with-chemotherapy-met-primary-endpoint-of-pathological-complete-response-pcr-in-pivotal-phase-3-keynote-522-trial-in-patients-with-triple-negative-breast-cancer-tnbc,30-07-2019 00:00,,,,,,
1180,exact-sciences-and-genomic-health-to-combine-creating-leading-global-cancer-diagnostics-company,30-07-2019 00:00,,,,,,
1181,lillys-verzenio-abemaciclib-significantly-extended-life-in-women-with-hr-her2-advanced-breast-cancer-in-monarch-2,30-07-2019 00:00,,,,,,
1182,merck-receives-positive-eu-chmp-opinion-for-zerbaxa?-3g-dose-ceftolozane-and-tazobactam-for-the-treatment-of-adults-with-hospital-acquired-pneumonia-hap-including-ventilator-associated-pneumonia-vap,30-07-2019 00:00,,,,,,
1183,novartis-receives-positive-chmp-opinion-for-lucentis?-treatment-in-preterm-infants-with-retinopathy-of-prematurity-rop-a-disease-causing-visual-impairment-and-blindness,30-07-2019 00:00,,,,,,
1184,us-fda-approves-darolutamide-a-new-treatment-for-men-with-non-metastatic-castration-resistant-prostate-cancer,31-07-2019 00:00,,,,,,
1185,diroximel-fumarate-demonstrated-significantly-improved-gastrointestinal-tolerability-profile-compared-to-dimethyl-fumarate-in-patients-with-multiple-sclerosis,31-07-2019 00:00,,,,,,
1186,lyndra-therapeutics-to-develop-once-monthly-oral-contraceptive,31-07-2019 00:00,,,,,,
1187,health-canada-approves-vitrakvi-larotrectinib-the-first-tumour-agnostic-cancer-treatment-for-advanced-solid-tumours-harbouring-an-ntrk-gene-fusion,31-07-2019 00:00,,,,,,
1188,fda-approves-new-monotherapy-indication-for-merck?s-keytruda-pembrolizumab,31-07-2019 00:00,,,,,,
1189,regenxbio-announces-new-license-agreement-with-pfizer-for-the-treatment-of-friedreichs-ataxia-using-nav-aav9-vector,31-07-2019 00:00,,,,,,
1190,novartis-kisqali-significantly-prolongs-life-in-women-with-hrher2-advanced-breast-cancer-now-in-two-distinct-phase-iii-trials,01-08-2019 00:00,,,,,,
1191,chimerix-announces-exclusive-worldwide-license-of-phase-3-ready-cx-01-for-development-in-acute-myeloid-leukemia,01-08-2019 00:00,,,,,,
1192,exelixis-and-aurigene-enter-into-exclusive-collaboration-option-and-license-agreement-to-discover-and-develop-novel-therapies-for-cancer,01-08-2019 00:00,,,,,,
1193,leo-pharma-inc-announces-us-food-and-drug-administration-fda-expandedregulatory-approvals-for-enstilar-foam-and-taclonex-topical-suspension-in-treatment-of-plaque-psoriasis,01-08-2019 00:00,,,,,,
1194,sun-pharma-announces-regulatory-filing-of-tildrakizumab-in-japan,01-08-2019 00:00,,,,,,
1195,nucala-receives-eu-approval-for-self-administration-by-patients-with-severe-eosinophilic-asthma,02-08-2019 00:00,,,,,,
1196,nektar-therapeutics-and-bristol-myers-squibb-announce-us-fda-breakthrough-therapy-designation-for-bempegaldesleukin-nktr-214-in-combination-with-opdivo-nivolumab-for-the-treatment-of-patients-with-untreated-advanced-melanoma,02-08-2019 00:00,,,,,,
1197,pfenex-and-arcellx-announce-a-development-evaluation-and-license-agreement,02-08-2019 00:00,,,,,,
1198,mylan-and-biocon-launch-first-trastuzumab-biosimilar-ogivri-in-australia,02-08-2019 00:00,,,,,,
1199,voluntis-announces-market-authorization-for-oleena-first-digital-therapeutic-in-oncology,02-08-2019 00:00,,,,,,
1200,canadian-government-sponsored-collaboration-targets-standardized-cancer-testing,02-08-2019 00:00,,,,,,
1201,abbvies-maviret-glecaprevirpibrentasvir-approved-by-european-commission-to-shorten-treatment-duration-to-eight-weeks-for-treatment-na?ve-patients-with-chronic-hepatitis-c-and-compensated-cirrhosis,02-08-2019 00:00,,,,,,
1202,fda-approves-daiichi-sankyo?s-turalio-pexidartinib-for-the-treatment-of-select-patients-with-tgct-a-rare-and-debilitating-tumor,05-08-2019 00:00,,,,,,
1203,roche?s-tecentriq-plus-platinum-based-chemotherapy-reduced-the-risk-of-disease-worsening-or-death-in-people-with-previously-untreated-advanced-bladder-cancer,05-08-2019 00:00,,,,,,
1204,sosei-heptares-and-takeda-enter-into-new-strategic-multi-target-research-development-and-commercialization-partnership,05-08-2019 00:00,,,,,,
1205,label-updated-with-positive-cardiovascular-outcomes-and-renal-data-from-the-declare-timi-58-trial,05-08-2019 00:00,,,,,,
1206,pfizer-announces-phase-3-top-line-results-for-rivipansel-in-patients-with-sickle-cell-disease-experiencing-a-vaso-occlusive-crisis,05-08-2019 00:00,,,,,,
1207,squeak-of-cancer-scientists-from-nust-misis-develop-a-new-ultrasound-tomography-system-for-cancer-diagnosis,05-08-2019 00:00,,,,,,
1208,alvotech-and-cipla-gulf-enter-into-a-partnership-for-the-commercialization-of-key-biosimilar-in-select-emerging-markets,23-07-2019 00:00,,,,,,
1209,coherus-biosciences-reports-victory-in-pegfilgrastim-patent-dispute,29-07-2019 00:00,,,,,,
1210,celltrion-enters-phase-1-clinical-trial-of-?-ct-p39-,15-07-2019 00:00,,,,,,
1211,lilly-announces-positive-results-for-emgality-galcanezumab-gnlm-from-the-conquer-study-in-patients-who-failed-previous-migraine-preventive-treatments,05-08-2019 00:00,,,,,,
1212,chong-kun-dang-dong-a-st-to-launch-nesp-biosimilars-in-japan-in-h2,21-07-2019 00:00,,,,,,
1213,mundipharma-announces-exclusive-license-and-supply-agreement-with-prestige-biopharma-for-tuznue-hd201,02-07-2019 00:00,,,,,,
1214,dupixent-dupilumab-approved-by-european-commission-for-adolescents-with-moderate-to-severe-atopic-dermatitis,06-08-2019 00:00,,,,,,
1215,lifeomic-launches-the-life-extend-app-to-disrupt-healthcare-and-empower-people-to-increase-their-healthspan-with-five-health-pillars,06-08-2019 00:00,,,,,,
1216,mannkind-and-one-drop-sign-collaboration-agreement-to-integrate-bluetooth-connected-inhaler-with-dose-detection-into-the-one-drop-platform,06-08-2019 00:00,,,,,,
1217,innovent-and-shenogen-announce-collaboration-to-evaluate-tyvyt-sintilimab-injection-in-combination-with-sng1005-for-the-treatment-of-patients-with-advanced-cancer,06-08-2019 00:00,,,,,,
1218,gsk-grants-exclusive-technology-license-for-clinical-stage-ebola-vaccines-to-sabin-vaccine-institute,06-08-2019 00:00,,,,,,
1219,astellas-initiates-phase-3-clinical-trials-for-fezolinetant-in-postmenopausal-women-with-vasomotor-symptoms,06-08-2019 00:00,,,,,,
1220,molecular-partners?-strategic-partner-allergan-announced-today-that-ema-has-validated-the-marketing-authorisation-application-for-abicipar,07-08-2019 00:00,,,,,,
1221,spring-bank-announces-collaborative-research-agreement-with-university-of-texas-southwestern-medical-school-for-evaluation-of-sting-antagonist-compounds,07-08-2019 00:00,,,,,,
1222,lynparza-phase-iii-profound-trial-in-hrr-mutation-selected-metastatic-castration-resistant-prostate-cancer-met-primary-endpoint,07-08-2019 00:00,,,,,,
1223,adc-therapeutics-and-sophia-genetics-partner-for-biomarker-discovery-in-pivotal-phase-ii-clinical-trial,07-08-2019 00:00,,,,,,
1224,luca-biologics-launches-to-develop-live-biotherapeutics-for-womens-health-starting-with-urinary-tract-infection-uti,07-08-2019 00:00,,,,,,
1225,zenith-epigenetics-and-china-based-newsoara-biopharma-announce-licensing-agreement-for-zen-3694,07-08-2019 00:00,,,,,,
1226,aevi-genomic-medicine-enters-into-license-agreement-with-astrazeneca-for-anti-il-18-antibody,08-08-2019 00:00,,,,,,
1227,stoke-therapeutics-granted-fda-orphan-drug-designation-for-stk-001-an-investigational-new-treatment-for-dravet-syndrome,08-08-2019 00:00,,,,,,
1228,myriad-will-seek-fda-approval-of-bracanalysis-cdx?-as-a-companion-diagnostic-for-lynparza-olaparib-in-men-with-metastatic-castrate-resistant-prostate-cancer,08-08-2019 00:00,,,,,,
1229,new-england-journal-of-medicine-publishes-results-from-pivotal-study-of-waylivra-volanesorsen-in-patients-with-familial-chylomicronemia-syndrome,08-08-2019 00:00,,,,,,
1230,gilead-sciences-statement-on-us-food-and-drug-administration-advisory-committee?s-recommendation-on-descovy-for-prep?,08-08-2019 00:00,,,,,,
1231,nmpa-approved-japan-originated-als-treatment-edaravone-in-china,08-08-2019 00:00,,,,,,
1232,bayer-acquires-bluerock-therapeutics-to-build-leading-position-in-cell-therapy,09-08-2019 00:00,,,,,,
1233,lilly-evidation-health-and-apple-study-shows-personal-digital-devices-may-help-in-the-identification-of-mild-cognitive-impairment-and-mild-alzheimers-disease-dementia,09-08-2019 00:00,,,,,,
1234,takeda-submits-new-drug-application-for-a-subcutaneous-formulation-of-vedolizumab-for-patients-with-moderately-to-severely-active-ulcerative-colitis-in-japan,09-08-2019 00:00,,,,,,
1235,tagrisso-significantly-improves-overall-survival-in-the-phase-iii-flaura-trial-for-1st-line-egfr-mutated-non-small-cell-lung-cancer,09-08-2019 00:00,,,,,,
1236,ziopharm-oncology-receives-positive-opinion-for-orphan-drug-designation-from-the-european-medicines-agency-for-ad-rts-hil-12-plus-veledimex-for-the-treatment-of-glioma,09-08-2019 00:00,,,,,,
1237,china-national-medical-products-administration-approves-biktarvy-bictegravir-emtricitabine-and-tenofovir-alafenamide-for-treatment-of-hiv-1-infection,12-08-2019 00:00,,,,,,
1238,cytovation-and-sms-oncology-sign-agreement-on-conduct-of-phase-iii-trial-with-cypep-1-in-solid-tumors,12-08-2019 00:00,,,,,,
1239,atricure-enters-into-definitive-agreement-to-acquire-sentreheart,12-08-2019 00:00,,,,,,
1240,oncologie-inc-announces-clinical-trial-collaboration-with-merck-to-evaluate-bavituximab-in-combination-with-keytruda-pembrolizumab-in-advanced-gastric-or-gastroesophageal-cancer,12-08-2019 00:00,,,,,,
1241,china-national-medical-products-administration-grants-innovative-medical-device-designation-for-optune-in-china,12-08-2019 00:00,,,,,,
1242,boehringer-ingelheim-and-md-anderson-form-unique-virtual-research-and-development-center-to-rapidly-advance-new-cancer-therapies,13-08-2019 00:00,,,,,,
1243,baxter-launches-prismax-in-canada-to-maximize-treatment-in-the-intensive-care-unit,13-08-2019 00:00,,,,,,
1244,pharming-acquires-exclusive-license-to-cdz173-a-late-stage-drug-forthe-treatment-of-apds,13-08-2019 00:00,,,,,,
1245,jazz-pharmaceuticals-announces-acquisition-of-cavion-inc,13-08-2019 00:00,,,,,,
1246,lilly-announces-superiority-of-taltz-ixekizumab-versus-tremfya-guselkumab-in-delivering-total-skin-clearance-at-week-12-in-topline-results-from-head-to-head-ixora-r-trial-in-people-living-with-moderate-to-severe-plaque-psoriasis,13-08-2019 00:00,,,,,,
1247,health-canada-approves-tecentriq-atezolizumab-first-new-treatment-in-20-years-for-aggressive-form-of-lung-cancer1,13-08-2019 00:00,,,,,,
1248,innovate-biopharmaceuticals-inc-announces-first-patient-dosed-in-the-first-phase-3-clinical-trial-for-patients-with-celiac-disease,13-08-2019 00:00,,,,,,
1249,janssen-announces-european-commission-approval-of-imbruvica-ibrutinib-for-expanded-use-in-two-indications,14-08-2019 00:00,,,,,,
1250,calquence-granted-us-breakthrough-therapy-designation-for-chronic-lymphocytic-leukaemia,14-08-2019 00:00,,,,,,
1251,leo-pharma-as-acquires-rights-to-develop-and-market-brodalumab-for-moderate-to-severe-psoriasis-outside-of-europe,14-08-2019 00:00,,,,,,
1252,lynparza-phase-iii-paola-1-trial-met-primary-endpoint-as-1st-line-maintenance-treatment-with-bevacizumab-for-advanced-ovarian-cancer,14-08-2019 00:00,,,,,,
1253,fda-approves-eylea-aflibercept-injection-prefilled-syringe,14-08-2019 00:00,,,,,,
1254,regeneron-announces-positive-topline-results-from-phase-3-trial-of-evinacumab-in-patients-with-severe-inherited-form-of-high-cholesterol,14-08-2019 00:00,,,,,,
1255,fda-approves-genentech?s-rozlytrek-entrectinib-for-people-with-ros1-positive-metastatic-non-small-cell-lung-cancer-and-ntrk-gene-fusion-positive-solid-tumors,16-08-2019 00:00,,,,,,
1256,ultragenyx-announces-partnership-with-genetx-to-advance-treatment-for-angelman-syndrome,16-08-2019 00:00,,,,,,
1257,european-medicines-agency-validates-marketing-application-for-filgotinib-for-the-treatment-of-rheumatoid-arthritis,16-08-2019 00:00,,,,,,
1258,baxter-and-cosmed-announce-partnership-to-bring-next-generation-indirect-calorimetry-device-q-nrg-to-support-clinical-nutrition-globally,16-08-2019 00:00,,,,,,
1259,mallinckrodt-announces-positive-top-line-results-from-its-pivotal-phase-3-confirm-trial-of-terlipressin-in-patients-with-hepatorenal-syndrome-type-1-hrs-1,16-08-2019 00:00,,,,,,
1260,profound-medical-receives-us-fda-510k-clearance-for-tulsa-pro?,16-08-2019 00:00,,,,,,
1261,abbvie-receives-fda-approval-of-rinvoq-upadacitinib-an-oral-jak-inhibitor-for-the-treatment-of-moderate-to-severe-rheumatoid-arthritis,19-08-2019 00:00,,,,,,
1262,us-fda-approves-inrebic-fedratinib-as-first-new-treatment-in-nearly-a-decade-for-patients-with-myelofibrosis,19-08-2019 00:00,,,,,,
1263,alcon-to-launch-precision1-daily-disposable-contact-lenses-as-it-continues-to-deliver-on-vision-care-pipeline,19-08-2019 00:00,,,,,,
1264,cvrx-receives-fda-approval-for-worlds-first-heart-failure-neuromodulation-device,19-08-2019 00:00,,,,,,
1265,glenmark-receives-approval-for-combination-of-remogliflozin-etabonate-andmetformin-hydrochloride-for-adults-with-type-2-diabetes-in-india,19-08-2019 00:00,,,,,,
1266,dr-reddys-laboratories-announces-the-launch-of-versavo?-bevacizumab-biosimilar-in-india,20-08-2019 00:00,,,,,,
1267,farxiga-met-primary-endpoint-in-landmark-phase-iii-dapa-hf-trial-for-the-treatment-of-patients-with-heart-failure,20-08-2019 00:00,,,,,,
1268,boston-scientific-announces-fda-approval-of-imageready-mri-for-vercise-gevia-deep-brain-stimulation-system,20-08-2019 00:00,,,,,,
1269,nabriva-therapeutics-receives-us-fda-approval-of-xenleta-lefamulin-to-treat-community-acquired-bacterial-pneumonia-cabp,20-08-2019 00:00,,,,,,
1270,elanco-announces-agreement-to-acquire-bayer?s-animal-health-business,20-08-2019 00:00,,,,,,
1271,richter-launched-terrosa-its-biosimilar-teriparatide-across-europe,20-08-2019 00:00,,,,,,
1272,alligator-bioscience-signs-antibody-agreement-for-greater-china-with-biotheus-inc,21-08-2019 00:00,,,,,,
1273,update-on-the-phase-iii-neptune-trial-of-imfinzi-plus-tremelimumab-in-stage-iv-non-small-cell-lung-cancer,21-08-2019 00:00,,,,,,
1274,gsk-submits-first-regulatory-application-for-daprodustat-in-japan-for-patients-with-renal-anaemia-due-to-chronic-kidney-disease,21-08-2019 00:00,,,,,,
1275,bioinvent-will-conduct-phase-llla-trial-with-bi-1206-in-combination-with-pembrolizumab-keytruda-in-solid-tumors,21-08-2019 00:00,,,,,,
1276,orexo-signs-partnership-agreement-with-gaia-to-develop-and-commercialize-a-new-digital-therapy-for-the-treatment-of-opioid-use-disorder,21-08-2019 00:00,,,,,,
1277,new-pilot-clinical-study-results-demonstrate-that-addition-of-vivus?-qsymia-to-gastric-sleeve-surgery-significantly-improves-weight-loss-compared-with-surgery-alone,21-08-2019 00:00,,,,,,
1278,pfizer-invests-half-billion-dollars-to-advance-state-of-the-art-gene-therapy-facility-in-sanford-north-carolina,22-08-2019 00:00,,,,,,
1279,biocons-malaysia-insulin-glargine-manufacturing-facility-receives-eu-gmp-certification-provides-fillip-to-its-capacity,22-08-2019 00:00,,,,,,
1280,clarus-therapeutics-receives-us-fda-approval-of-jatenzo-testosterone-undecanoate-capsules-for-oral-use-ciii-for-testosterone-replacement-therapy-in-certain-adult-men,27-03-2019 00:00,,,,,,
1281,fda-approves-mavenclad-cladribine-tablets-as-first-and-only-short-course-oral-treatment-for-relapsing-remitting-and-active-secondary-progressive-multiple-sclerosis,29-03-2019 00:00,,,,,,
1282,balversa-erdafitinib-receives-us-fda-approval-for-the-treatment-of-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma-with-certain-fgfr-genetic-alterations,12-04-2019 00:00,,,,,,
1283,fda-approves-corlanor-ivabradine-to-reduce-the-risk-of-hospitalization-for-worsening-heart-failure-in-patients-with-chronic-heart-failure,15-04-2019 00:00,,,,,,
1284,fda-approves-bausch-healths-duobrii-halobetasol-propionate-and-tazarotene-lotion-0010045-for-plaque-psoriasis-in-adults,25-04-2019 00:00,,,,,,
1285,genmab-announces-approval-of-darzalex-daratumumab-in-frontline-multiple-myeloma-in-japan,22-08-2019 00:00,,,,,,
1286,fda-approves-eticovo-etanercept-ykro-samsung-bioepis-second-anti-tnf-medicine-in-the-united-states,29-04-2019 00:00,,,,,,
1287,fda-approves-first-treatment-for-children-with-lambert-eaton-myasthenic-syndrome-a-rare-autoimmune-disorder,06-05-2019 00:00,,,,,,
1288,astrazeneca-agrees-to-buy-us-fda-priority-review-voucher-from-sobi,22-08-2019 00:00,,,,,,
1289,exeltis-usa-inc-announces-the-approval-of-slynd-the-first-and-only-progestin-only-pill-providing-pregnancy-prevention-with-a-244-dosing-regimen-and-24-hour-missed-pill-window,06-06-2019 00:00,,,,,,
1290,innovent-enters-a-licensing-agreement-with-lilly-to-develop-commercialize-a-novel-diabetes-medicine-in-china,22-08-2019 00:00,,,,,,
1291,roxadustat-approved-in-china-for-the-treatment-of-anaemia-in-non-dialysis-dependent-patients-with-chronic-kidney-disease,22-08-2019 00:00,,,,,,
1292,fda-approves-new-drug-application-for-vyleesi-bremelanotide-injection,22-06-2019 00:00,,,,,,
1293,themis-bioscience-announces-exclusive-license-and-research-collaboration-agreement-with-msd-to-develop-vaccine-candidates,23-08-2019 00:00,,,,,,
1294,amgen-and-allergan-announce-positive-top-line-results-from-comparative-clinical-study-of-abp-798-biosimilar-candidate-to-rituxan?-rituximab,23-08-2019 00:00,,,,,,
1295,tecentriq-an-anti-pd-l1-antibody-receives-approval-for-additional-indication-of-extensive-stage-small-cell-lung-cancer,23-08-2019 00:00,,,,,,
1296,cantargia-and-biowa-extend-ongoing-collaboration-around-the-potelligent?technology,23-08-2019 00:00,,,,,,
1297,iconic-therapeutics-signs-ophthalmology-option-agreement,23-08-2019 00:00,,,,,,
1298,oxthera-receives-positive-decision-from-ema-on-paediatric-investigational-plan-pip-for-treatment-of-primary-hyperoxaluria-with-oxalobacter-formigenes,23-08-2019 00:00,,,,,,
1299,bristol-myers-squibb-announces-agreement-between-celgene-and-amgen-to-divest-otezla-for-134-billion,26-08-2019 00:00,,,,,,
1300,miracor-medical-granted-fda-breakthrough-device-designationfor-the-picso-impulse-system,26-08-2019 00:00,,,,,,
1301,zogenix-announces-acquisition-of-modis-therapeutics-inc,26-08-2019 00:00,,,,,,
1302,lilly-announces-top-line-phase-3-results-for-oral-jak-inhibitor-baricitinib-in-combination-with-topical-corticosteroids-in-adult-patients-with-moderate-to-severe-atopic-dermatitis,26-08-2019 00:00,,,,,,
1303,vasq-external-support-demonstrates-significant-improvement-in-fistula-usability-in-the-newly-published-multi-center-randomized-controlled-study,26-08-2019 00:00,,,,,,
1304,adc-therapeutics-and-freenome-enter-biomarker-development-collaboration,27-08-2019 00:00,,,,,,
1305,lilly-receives-us-fda-approval-for-taltz-ixekizumab-for-the-treatment-of-active-ankylosing-spondylitis-radiographic-axial-spondyloarthritis,27-08-2019 00:00,,,,,,
1306,alcon-introduces-acrysof-iq-panoptix-trifocal-iol-in-the-us-the-first-and-only-fda-approved-trifocal-lens,27-08-2019 00:00,,,,,,
1307,new-study-finds-abbotts-blood-test-technology-could-help-detect-brain-injury-quickly-even-if-ct-scan-is-normal,27-08-2019 00:00,,,,,,
1308,"fda-grants-fast-track-designation-for-farxiga-in-chronic-kidney-disease
-tuba-khan",27-08-2019 00:00,,,,,,
1309,ionis-licenses-hepatitis-b-program-to-gsk,27-08-2019 00:00,,,,,,
1310,everyday-health-group-acquires-babycenter-the-leading-global-digital-parenting-resource,27-08-2019 00:00,,,,,,
1311,presage-announces-collaboration-with-bristol-myers-squibb-for-phase-o-studies-of-novel-cancer-agents-utilizing-civo-technology,28-08-2019 00:00,,,,,,
1312,european-commission-approves-soliris-eculizumab-for-the-treatment-of-adults-with-neuromyelitis-optica-spectrum-disorder-nmosd,28-08-2019 00:00,,,,,,
1313,breztri-aerosphere-phase-iii-ethos-trial-met-its-primary-endpoint-in-chronic-obstructive-pulmonary-disease,28-08-2019 00:00,,,,,,
1314,european-commission-approves-empliciti-elotuzumab-plus-pomalidomide-and-low-dose-dexamethasone-epd-for-the-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma,28-08-2019 00:00,,,,,,
1315,fasenra-granted-us-orphan-drug-designation-for-eosinophilic-oesophagitis,28-08-2019 00:00,,,,,,
1316,kyowa-kirin-announces-fda-approval-of-nourianztm-istradefyllinefor-use-in-parkinson?s-disease,28-08-2019 00:00,,,,,,
1317,arrowhead-collaborator-janssen-begins-reef-1-phase-2b-combination-study-in-patients-with-chronic-hepatitis-b-infection,28-08-2019 00:00,,,,,,
1318,immatics-and-celgene-enter-strategic-collaboration-to-develop-novel-adoptive-cell-therapiesimmatics-and-celgene-enter-strategic-collaboration-to-develop-novel-adoptive-cell-therapies,29-08-2019 00:00,,,,,,
1319,phase-3-clinical-trial-evaluating-continuous-subcutaneous-carbidopalevodopa-nd0612-initiated-in-the-united-states-for-parkinsons-disease-with-motor-fluctuations,29-08-2019 00:00,,,,,,
1320,european-commission-approves-roche?s-tecentriq-in-combination-with-abraxane-for-people-with-pd-l1-positive-metastatic-triple-negative-breast-cancer,29-08-2019 00:00,,,,,,
1321,anifrolumab-phase-iii-trial-meets-primary-endpoint-in-systemic-lupus-erythematosus,29-08-2019 00:00,,,,,,
1322,roche-launches-ventana-pd-l1-sp142-assay-in-ce-markets-as-first-companion-diagnostic-to-identify-triple-negative-breast-cancer-patients-eligible-for-treatment-with-tecentriq,29-08-2019 00:00,,,,,,
1323,abbvie-discontinues-rovalpituzumab-tesirine-rova-t-research-and-development-program,29-08-2019 00:00,,,,,,
1324,novartis-ofatumumab-demonstrates-superiority-versus-aubagio-in-two-head-to-head-phase-iii-multiple-sclerosis-studies,30-08-2019 00:00,,,,,,
1325,sandoz-recalls-losartan-potassium-and-ezetimibe-prescription-drug-bottles-due-to-failure-to-meet-child-resistant-closure-requirements,30-08-2019 00:00,,,,,,
1327,innovent-biologics-study-results-of-ibi303-in-patients-with-ankylosing-spondylitis-was-published-in-the-lancet-rheumatology,30-08-2019 00:00,,,,,,
1328,updated-phase-3-results-for-ct-p6-demonstrate-the-biosimilars-safety-and-efficacy-in-adjuvant-setting,21-08-2019 00:00,,,,,,
1329,unitedhealthcare-will-prefer-amgens-anticancer-biosimilars-beginning-in-october,16-08-2019 00:00,,,,,,
1330,lindacare-partners-with-philips,30-08-2019 00:00,,,,,,
1331,the-lancet-infectious-diseases-publishes-results-from-paratek?s-phase-3-oral-only-dosing-study-of-nuzyra-omadacycline-for-skin-infections,30-08-2019 00:00,,,,,,
1332,roche-presents-positive-phase-iii-study-results-for-one-dose-xofluza-in-children-with-flu,02-09-2019 00:00,,,,,,
1333,novartis-paragon-hf-trial-suggests-entresto-benefit-in-hfpef-patients-but-narrowly-misses-primary-endpoint,02-09-2019 00:00,,,,,,
1334,research-breakthrough-to-safely-monitor-pre-term-babies,02-09-2019 00:00,,,,,,
1335,brilinta-reduced-the-risk-of-cardiovascular-events-in-patients-with-coronary-artery-disease-and-type-2-diabetes-in-phase-iii-themis-trial,02-09-2019 00:00,,,,,,
1336,chugai-files-for-additional-indication-for-anti-her2-antibody-drug-conjugate-kadcyla-for-adjuvant-therapy-of-her2-positive-early-breast-cance,02-09-2019 00:00,,,,,,
1337,detailed-results-from-phase-iii-dapa-hf-trial-showed-farxiga-significantly-reduced-both-the-incidence-of-cardiovascular-death-and-the-worsening-of-heart-failure,02-09-2019 00:00,,,,,,
1338,helsinn-signs-exclusive-distribution-and-license-agreements-with-blanver-and-varifarma-for-pracinostat-in-south-america,03-09-2019 00:00,,,,,,
1339,federal-circuit-will-not-halt-sales-of-amgen?s-mvasi-bevacizumab-awws-before-it-resolves-genentech?s-appeal,16-08-2019 00:00,,,,,,
1340,sandoz-announces-global-deal-to-commercialize-proposed-biosimilar-natalizumab-a-key-multiple-sclerosis-medicine,03-09-2019 00:00,,,,,,
1341,xarelto-25-mg-plus-aspirin-recommended-for-patients-at-high-risk-of-heart-attacks-strokes-and-death-due-to-chronic-coronary-syndromes,03-09-2019 00:00,,,,,,
1342,boehringer-ingelheim-and-zealand-pharma-advance-dual-acting-glp-1glucagon-agonist-bi-456906-to-phase-2-clinical-testing-in-obesitydiabetes,03-09-2019 00:00,,,,,,
1343,inotrem-announces-fast-track-designation-granted-by-us-fda-to-nangibotide-development-program-for-the-treatment-of-septic-shock,03-09-2019 00:00,,,,,,
1344,vertex-to-acquire-semma-therapeutics-with-a-goal-of-developing-curative-cell-based-treatments-for-type-1-diabetes,03-09-2019 00:00,,,,,,
1345,celltrion-and-lonza-sign-contract-to-manufacture-remsima-drug-substance,04-09-2019 00:00,,,,,,
1346,stada-teriparatide-biosimilar-movymia-for-treatment-of-osteoporosis-launched-in-24-countries,20-08-2019 00:00,,,,,,
1347,tagrisso-approved-in-china-as-a-1st-line-treatment-for-egfr-mutated-non-small-cell-lung-cancer,04-09-2019 00:00,,,,,,
1348,boehringer-ingelheim-enters-into-a-licensing-agreement-with-lupin-to-expand-its-kras-cancer-program,04-09-2019 00:00,,,,,,
1349,self-monitoring-solution-in-mobile-app-can-help-uncontrolled-asthma,04-09-2019 00:00,,,,,,
1350,european-commission-approves-merck?s-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc,04-09-2019 00:00,,,,,,
1351,janssen-announces-us-fda-breakthrough-therapy-designation-for-investigational-prophylactic-vaccine-for-the-prevention-of-respiratory-syncytial-virus-in-older-adults,04-09-2019 00:00,,,,,,
1352,biomotiv-and-bristol-myers-squibb-form-strategic-partnership,04-09-2019 00:00,,,,,,
1353,regenxbio-announces-exclusive-worldwide-option-and-license-agreement-with-clearside-biomedical-for-evaluation-of-in-office-delivery-platform-for-rgx-314,04-09-2019 00:00,,,,,,
1354,entry-into-a-material-definitive-agreement,22-08-2019 00:00,,,,,,
1355,samsung-bioepis-begins-recruiting-patients-for-phase-3-trial-of-eculizumab-biosimilar-sb12,16-08-2019 00:00,,,,,,
1356,2019-update-of-the-american-college-of-rheumatology-spondylitis-association-of-americaspondyloarthritis-research-and-treatment-network-recommendations-for-the-treatment-of-ankylosing-spondylitis-and-nonradiographic-axial-spondyloarthritis,22-08-2019 00:00,,,,,,
1357,schr?dinger-announces-collaboration-with-astrazeneca-to-deploy-advanced-computing-technology-for-drug-discovery,05-09-2019 00:00,,,,,,
1358,cochlear-and-gn-hearing-become-world?s-first-to-support-direct-android-streaming-to-hearing-devices-using-bluetooth-low-energy,05-09-2019 00:00,,,,,,
1359,biontech-announces-new-collaboration-to-develop-hiv-and-tuberculosis-programs,05-09-2019 00:00,,,,,,
1360,european-commission-approves-expanded-use-of-janssen?s-stelara-ustekinumab-for-the-treatment-of-moderately-to-severely-active-ulcerative-colitis-in-the-european-union,05-09-2019 00:00,,,,,,
1361,idera-pharmaceuticals-announces-immuno-oncology-clinical-research-collaboration-with-abbvie,05-09-2019 00:00,,,,,,
1362,ifm-therapeutics-announces-collaboration-and-exclusive-option-agreement-for-cgassting-focused-subsidiary-ifm-due,05-09-2019 00:00,,,,,,
1363,takeda-issues-us-recall-of-natpara-parathyroid-hormone-for-injection-due-to-the-potential-for-rubber-particulate,06-09-2019 00:00,,,,,,
1364,theragnostics-signs-agreement-with-astrazeneca,06-09-2019 00:00,,,,,,
1365,speedx-receives-ce-ivd-clearance-for-resistanceplus-mg-flexible,06-09-2019 00:00,,,,,,
1366,bristol-myers-squibb-provides-update-on-phase-3-opdivo-nivolumab-checkmate-548-trial-in-patients-with-newly-diagnosed-mgmt-methylated-glioblastoma-multiforme,06-09-2019 00:00,,,,,,
1367,european-commission-approves-roche?s-new-tecentriq-based-combination-therapy-as-an-initial-treatment-for-most-common-form-of-advanced-lung-cancer,06-09-2019 00:00,,,,,,
1368,oncocyte-announces-definitive-agreement-to-acquire-razor-genomics,06-09-2019 00:00,,,,,,
1369,european-commission-approves-roche?s-tecentriq-in-combination-with-chemotherapy-for-the-initial-treatment-of-people-with-extensive-stage-small-cell-lung-cancer,06-09-2019 00:00,,,,,,
1370,sumitomo-dainippon-pharma-and-roivant-sciences-enter-into-a-memorandum-of-understanding-to-create-broad-strategic-alliance-to-deliver-promising-new-medicines-to-patients,09-09-2019 00:00,,,,,,
1371,thermo-fisher-scientific-signs-agreement-with-lilly-oncology-for-companion-diagnostic-to-be-used-with-ret-inhibitor,09-09-2019 00:00,,,,,,
1372,imfinzi-is-first-immunotherapy-to-show-both-significant-survival-benefit-and-improved-durable-responses-in-extensive-stage-small-cell-lung-cancer,09-09-2019 00:00,,,,,,
1373,abbott-launches-worlds-first-pivotal-trial-to-test-new-approach-for-repairing-leaky-tricuspid-heart-valves,09-09-2019 00:00,,,,,,
1374,allergan-and-molecular-partners-announce-acceptance-of-us-fda-biologics-license-application-and-validation-of-ema-marketing-authorisation-for-abicipar-pegol-in-patients-with-neovascular-wet-age-related-macular-degeneration,09-09-2019 00:00,,,,,,
1375,genmab-and-tempus-enter-into-strategic-collaboration-agreement,10-09-2019 00:00,,,,,,
1376,alexion-and-bridgebio-announce-japanese-license-agreement-for-eidos?-transthyretin-amyloidosis-attr-investigational-medicine,10-09-2019 00:00,,,,,,
1377,medtronic-announces-reimbursement-in-germany-for-minimed-670g-insulin-pump-system-for-individuals-with-type-1-diabetes,10-09-2019 00:00,,,,,,
1378,bristol-myers-squibb-announces-pooled-five-year-survival-results-for-opdivo-nivolumab-in-previously-treated-advanced-non-small-cell-lung-cancer-patients,10-09-2019 00:00,,,,,,
1379,mallinckrodt-agrees-to-sell-biovectra-inc-to-hig-capital-for-250-million,10-09-2019 00:00,,,,,,
1380,baxter-announces-acquisition-of-cheetah-medical-to-expand-specialized-patient-monitoring-portfolio,10-09-2019 00:00,,,,,,
1381,lexicon-pharmaceuticals-announces-termination-of-alliance-and-settlement-with-sanofi,11-09-2019 00:00,,,,,,
1382,xeris-pharmaceuticals-receives-us-fda-approval-for-gvoke-glucagon-the-first-ready-to-use-stable-liquid-glucagon-for-severe-hypoglycemia,11-09-2019 00:00,,,,,,
1383,mayo-clinic-selects-google-as-strategic-partner-for-health-care-innovation-cloud-computing,11-09-2019 00:00,,,,,,
1384,samsung-bioepis-continues-global-expansion-enters-brazilian-biopharmaceutical-market-with-brenzys-etanercept,11-09-2019 00:00,,,,,,
1385,merck-kgaa-darmstadt-germany-announces-fda-breakthrough-therapy-designation-for-investigational-therapy-tepotinib-in-patients-with-metastatic-nsclc-with-metex14-skipping-alterations,11-09-2019 00:00,,,,,,
1386,apple-announces-three-groundbreaking-health-studies,11-09-2019 00:00,,,,,,
1387,avalon-ventures-and-coi-pharmaceuticals-announce-acquisition-of-sitari-pharmaceuticals-by-gsk,12-09-2019 00:00,,,,,,
1388,teva-canada-announces-the-approval-of-herzuma-a-biosimilar-to-herceptin-for-the-treatment-of-adult-patients-with-early-breast-cancer-metastatic-breast-cancer-and-metastatic-gastric-cancer,12-09-2019 00:00,,,,,,
1389,roche?s-satralizumab-significantly-reduced-relapse-risk-in-second-positive-phase-iii-study-for-neuromyelitis-optica-spectrum,12-09-2019 00:00,,,,,,
1390,zentiva-enhances-its-global-manufacturing-footprint-by-signing-an-agreement-to-acquire-manufacturing-site-in-ankleshwar-india,12-09-2019 00:00,,,,,,
1391,new-head-to-head-phase-3-study-data-show-ponesimod-superiority-versus-aubagio-teriflunomide-14-mg-in-adults-with-relapsing-multiple-sclerosis-ms,12-09-2019 00:00,,,,,,
1392,atomwise-announces-largest-china-us-collaboration-for-ai-drug-discovery,12-09-2019 00:00,,,,,,
1393,vertex-announces-new-access-agreement-with-scottish-government-for-orkambi-lumacaftorivacaftor-and-symkevi-tezacaftorivacaftor,12-09-2019 00:00,,,,,,
1394,aytu-bioscience-announces-definitive-agreement-to-acquire-innovus-pharmaceuticals,13-09-2019 00:00,,,,,,
1395,roche?s-fixed-dose-subcutaneous-combination-of-perjeta-and-herceptin-showed-non-inferiority-when-compared-to-intravenous-formulations-for-people-with-her2-positive-breast-cancer,13-09-2019 00:00,,,,,,
1396,nucala-is-the-first-biologic-approved-in-the-us-for-six-to-11-year-old-children-with-severe-eosinophilic-asthma,13-09-2019 00:00,,,,,,
1397,celgene-announces-phase-3-quazar-aml-001-study-of-cc-486-as-maintenance-therapy-in-patients-with-newly-diagnosed-acute-myeloid-leukemia-met-primary-and-key-secondary-endpoints,13-09-2019 00:00,,,,,,
1398,ge-healthcare-receives-fda-clearance-of-first-artificial-intelligence-algorithms-embedded-on-device-to-prioritize-critical-chest-x-ray-review,13-09-2019 00:00,,,,,,
1399,eisai-and-biogen-to-discontinue-phase-iii-clinical-studies-of-bace-inhibitor-elenbecestat-in-early-alzheimers-disease,13-09-2019 00:00,,,,,,
1400,lundbeck-to-acquire-alder-bio-pharmaceuticals-for-195b,16-09-2019 00:00,,,,,,
1401,sanofi-and-abbott-partner-to-integrate-glucose-sensing-and-insulin-delivery-technologies-to-help-change-the-way-diabetes-is-managed,16-09-2019 00:00,,,,,,
1402,medtronic-and-novo-nordisk-enter-agreement-to-provide-integrated-digital-solutions-for-people-with-diabetes,16-09-2019 00:00,,,,,,
1403,fda-grants-fast-track-designation-for-farxiga-in-heart-failure,16-09-2019 00:00,,,,,,
1404,oncoheroes-biosciences-inc-and-boehringer-ingelheim-international-gmbh-sign-exclusive-licensing-agreement-for-volasertib,16-09-2019 00:00,,,,,,
1405,janssen-submits-application-to-us-fda-seeking-first-in-class-approval-of-tremfya-guselkumab-for-treatment-of-adults-with-active-psoriatic-arthritis,17-09-2019 00:00,,,,,,
1406,seattle-genetics-and-astellas-announce-us-fda-grants-priority-review-for-enfortumab-vedotin-biologics-license-application-in-locally-advanced-or-metastatic-urothelial-cancer,17-09-2019 00:00,,,,,,
1407,medtronic-introduces-envision-pro-continuous-glucose-monitoring-cgm-system-in-europe,17-09-2019 00:00,,,,,,
1408,acceleron-announces-topline-results-from-the-phase-2-trial-of-ace-083-in-patients-with-facioscapulohumeral-muscular-dystrophy,17-09-2019 00:00,,,,,,
1409,glenmark-receives-orphan-drug-designation-for-gbr-1342-a-bispecific-antibody-candidate-under-evaluation-for-the-treatment-of-multiple-myeloma,17-09-2019 00:00,,,,,,
1410,fda-accepts-merck?s-biologics-license-application-bla-and-grants-priority-review-for-v920-the-company?s-investigational-vaccine-for-ebola-zaire-virus,17-09-2019 00:00,,,,,,
1411,bayer-and-informed-data-systems-inc-to-develop-one-drop-digital-therapeutics-platform-for-multiple-therapeutic-areas,17-09-2019 00:00,,,,,,
1412,mylan-expands-oncology-portfolio-with-launch-of-generic-faslodex-injection-a-treatment-for-advanced-breast-cancer,18-09-2019 00:00,,,,,,
1413,generium-launches-first-biosimilar-of-dornase-alfa-becomes-sixth-approved-product-using-selexis-suretechnology-platform,18-09-2019 00:00,,,,,,
1414,new-agreement-gives-astrazeneca-full-responsibility-for-developing-manufacturing-and-commercialising-linzess-in-china,18-09-2019 00:00,,,,,,
1415,fda-grants-breakthrough-therapy-designation-for-roche?s-gazyva-obinutuzumab-in-lupus-nephritis,18-09-2019 00:00,,,,,,
1416,educational-campaign-helps-teens-and-their-caregivers-tackle-everyday-challenges-of-living-with-moderate-to-severe-atopic-dermatitis,18-09-2019 00:00,,,,,,
1417,fda-takes-first-action-under-new-international-collaboration-with-australia-and-canada-designed-to-provide-a-framework-for-concurrent-review-of-cancer-therapies-approving-treatment-for-patients-with-endometrial-carcinoma,18-09-2019 00:00,,,,,,
1418,fda-approves-keytruda-pembrolizumab-plus-lenvima-lenvatinib-combination-treatment-for-patients-with-certain-types-of-endometrial-carcinoma,18-09-2019 00:00,,,,,,
1419,novigenix-and-biolizard-sign-collaboration-agreement-for-development-of-ngs-based-diagnostic-algorithm,19-09-2019 00:00,,,,,,
1420,roche-renews-its-commitment-to-the-primary-healthcare-phelophepa-trains-marking-the-25th-anniversary,19-09-2019 00:00,,,,,,
1421,positive-results-from-novartis-five-year-verify-study-in-type-2-diabetes-demonstrate-long-term-clinical-benefits-of-early-combination-treatment-with-galvus?-and-metformin,19-09-2019 00:00,,,,,,
1422,biogen-advances-spinal-muscular-atrophy-sma-clinical-research-with-new-study-evaluating-a-higher-dose-of-spinraza-nusinersen-and-additional-data-in-a-broad-range-of-patients,19-09-2019 00:00,,,,,,
1423,fda-approves-new-treatment-for-highly-drug-resistant-forms-of-tuberculosis,15-08-2019 00:00,,,,,,
1424,harmony-biosciences-announces-fda-approval-of-wakix-pitolisant-a-first-in-class-medication-for-the-treatment-of-excessive-daytime-sleepiness-in-adult-patients-with-narcolepsy,15-08-2019 00:00,,,,,,
1425,tresiba-showed-an-overall-lower-risk-of-hypoglycaemia-and-significantly-lower-hba1c-when-compared-to-insulin-glargine-u300-in-people-with-type-2-diabetes,19-09-2019 00:00,,,,,,
1426,addition-of-kisqali-to-drug-plan-in-quebec-expands-access-to-treatment-for-metastatic-breast-cancer,19-09-2019 00:00,,,,,,
1427,y-trap-enters-collaboration-with-merck-kgaa-darmstadt-germany-to-develop-novel-antibody-ligand-traps-for-immuno-oncology,20-09-2019 00:00,,,,,,
1428,fda-approves-cobas-babesia-roche?s-first-whole-blood-test-for-donor-screening,20-09-2019 00:00,,,,,,
1429,takeda-and-lundbeck-announce-ministry-of-health-labour-and-welfare-mhlw-approval-of-trintellix?-in-japan,20-09-2019 00:00,,,,,,
1430,chmp-issues-positive-opinion-to-expand-trulicity-dulaglutide-label-to-include-results-from-rewind-cardiovascular-outcomes-trial,20-09-2019 00:00,,,,,,
1431,evrenzo-roxadustat-tablets-approved-in-japan-for-the-treatment-of-anemia-associated-with-chronic-kidney-disease-in-dialysis-patients,20-09-2019 00:00,,,,,,
1432,boehringer-ingelheim-partners-with-inflammasome-therapeutics-to-develop-novel-therapies-for-patients-with-retinal-diseases,20-09-2019 00:00,,,,,,
1433,qtrilmet-recommended-for-approval-in-eu-by-chmp-for-the-treatment-of-type-2-diabetes,23-09-2019 00:00,,,,,,
1434,fda-approves-rybelsus-semaglutide-the-first-glp-1-analog-treatment-available-in-a-pill-for-adults-with-type-2-diabetes,23-09-2019 00:00,,,,,,
1435,clovis-oncology-acquires-rights-to-fap-targeted-radiopharmaceutical-program-from-3b-pharmaceuticals,23-09-2019 00:00,,,,,,
1436,interferon-beta-treatments-including-plegridy-peginterferon-beta-1a-and-avonex-interferon-beta-1a-receive-positive-chmp-opinion-for-use-during-pregnancy-and-breastfeeding,23-09-2019 00:00,,,,,,
1437,mallinckrodt-announces-positive-top-line-results-from-pivotal-phase-3-clinical-trial-of-stratagraft-regenerative-tissue-in-patients-with-deep-partial-thickness-thermal-burns,23-09-2019 00:00,,,,,,
1438,celltrion-healthcare-receives-chmp-positive-opinion-for-novel-subcutaneous-formulation-of-ct-p13-biosimilar-infliximab-for-the-treatment-of-people-with-rheumatoid-arthritis,23-09-2019 00:00,,,,,,
1439,i-mab-biopharma-announces-clinical-collaboration-to-evaluate-tjc4-in-combination-with-keytruda-pembrolizumab-in-patients-with-multiple-cancer-types,24-09-2019 00:00,,,,,,
1440,vitrakvi-larotrectinib-receives-first-tumor-agnostic-approval-in-eu,24-09-2019 00:00,,,,,,
1441,sandoz-inc-issues-voluntary-recall-of-ranitidine-hydrochloride-capsules-150mg-and-300mg-due-to-an-elevated-amount-of-unexpected-impurity-n-nitrosodimethylamine-ndma-in-the-product,24-09-2019 00:00,,,,,,
1442,bayer-brigham-and-women?s-hospital-and-massachusetts-general-hospital-open-joint-lab-for-research-of-new-treatments-for-chronic-lung-diseases,24-09-2019 00:00,,,,,,
1443,evotec-and-takeda-enter-collaboration-agreement-to-discover-clinical-candidates-across-multiple-therapeutic-areas,24-09-2019 00:00,,,,,,
1444,bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-of-opdivo-nivolumab-four-week-dosing-schedule-for-the-adjuvant-treatment-of-adult-patients-with-melanoma-with-involvement-of-lymph-nodes-or-metastatic-disease-who-have?,24-09-2019 00:00,,,,,,
1445,aldeyra-therapeutics-receives-fast-track-designation-for-adx-2191-for-the-prevention-of-proliferative-vitreoretinopathy,24-09-2019 00:00,,,,,,
1446,biocon-biologics-expands-its-rd-footprint-through-acquisition,25-09-2019 00:00,,,,,,
1447,pfizer-and-flatiron-health-announce-expanded-strategic-collaboration-to-unlock-power-of-real-world-evidence-in-oncology,25-09-2019 00:00,,,,,,
1448,amgen-announces-positive-results-from-two-phase-3-blincyto-blinatumomab-studies-in-pediatric-patients-with-relapsed-acute-lymphoblastic-leukemia,25-09-2019 00:00,,,,,,
1449,bavarian-nordic-announces-us-fda-approval-of-jynneos-smallpox-and-monkeypox-vaccine-live-non-replicating-for-prevention-of-smallpox-and-monkeypox-disease-in-adults,25-09-2019 00:00,,,,,,
1450,achillion-receives-breakthrough-therapy-designation-from-fda-for-danicopan-for-treatment-of-paroxysmal-nocturnal-hemoglobinuria,25-09-2019 00:00,,,,,,
1451,ethicon-launches-industry?s-first-powered-circular-stapler-for-colorectal-gastric-and-thoracic-surgery,25-09-2019 00:00,,,,,,
1452,first-head-to-head-biologic-study-in-ulcerative-colitis-published-in-the-new-england-journal-of-medicine-highlights-benefit-of-vedolizumab-vs-adalimumab,26-09-2019 00:00,,,,,,
1453,us-fda-clears-abbotts-high-sensitivity-troponin-i-blood-test-that-aids-doctors-in-diagnosing-heart-attacks-faster-and-more-accurately,26-09-2019 00:00,,,,,,
1454,thermo-fisher-scientific-expands-clinical-trials-capabilities-and-announces-collaboration-with-frontier-biotechnologies-inc,26-09-2019 00:00,,,,,,
1455,jazz-pharmaceuticals-presents-positive-jzp-258-phase-3-study-data-at-world-sleep-2019,26-09-2019 00:00,,,,,,
1456,monalizumab-to-advance-to-phase-iii-in-head-and-neck-cancer,26-09-2019 00:00,,,,,,
1457,medtronic-announces-new-clinical-trial-to-study-infuse-bone-graft-in-tlif-spine-procedures,26-09-2019 00:00,,,,,,
1458,abbvie-receives-fda-approval-of-mavyret?-glecaprevirpibrentasvir-to-shorten-treatment-duration-to-eight-weeks-for-treatment-na?ve-patients-with-chronic-hepatitis-c-and-compensated-cirrhosis-across-all-genotypes,27-09-2019 00:00,,,,,,
1459,genmab-announces-us-fda-approval-of-darzalex-daratumumab-in-combination-with-bortezomib-thalidomide-and-dexamethasone-for-frontline-multiple-myeloma,27-09-2019 00:00,,,,,,
1460,resolute-onyx-des-meets-primary-endpoint-in-first-ever-clinical-study-comparing-drug-eluting-stents-in-high-bleeding-risk-hbr-patients-with-one-month-dapt,27-09-2019 00:00,,,,,,
1461,ieso-launches-eight-billion-minds-to-address-unmet-global-mental-health-needs,27-09-2019 00:00,,,,,,
1462,simcere-and-jw-pharmaceutical-announce-collaboration-and-license-agreement-for-anti-gout-drug-candidate-urc-102-in-china,27-09-2019 00:00,,,,,,
1463,pfizer-announces-positive-top-line-results-from-second-pivotal-phase-3-study-of-investigational-oral-jak1-candidate-abrocitinib-in-patients-aged-12-and-older-with-moderate-to-severe-atopic-dermatitis,27-09-2019 00:00,,,,,,
1464,incyte-announces-positive-updated-results-from-phase-2-trial-of-pemigatinib-in-patients-with-previously-treated-advanced-cholangiocarcinoma,27-09-2019 00:00,,,,,,
1465,sobi-to-acquire-dova-pharmaceuticals-creating-a-global-growth-platform-in-haematology,30-09-2019 00:00,,,,,,
1466,fda-approves-roche?s-rituxan-rituximab-in-children-with-two-rare-blood-vessel-disorders,30-09-2019 00:00,,,,,,
1467,nucala-significantly-reduces-exacerbations-in-first-global-prospective-real-world-study-of-a-biologic-in-severe-eosinophilic-asthma,30-09-2019 00:00,,,,,,
1468,pivotal-restore-imi-2-phase-3-study-of-merck?s-recarbrio-imipenem-cilastatin-and-relebactam-in-hospital-acquired-and-ventilator-associated-bacterial-pneumonia-habpvabp-met-primary-endpoint,30-09-2019 00:00,,,,,,
1469,celltrion-healthcare-australia-and-juno-pharmaceuticals-australia-partnership,30-09-2019 00:00,,,,,,
1470,fresenius-kabi-expands-biosimilar-research-activities-?-inauguration-of-state-of-the-art-rd-center-in-eysins-switzerland,18-09-2019 00:00,,,,,,
1471,vertex-and-ribometrix-establish-strategic-collaboration-to-discover-and-develop-rna-targeted-small-molecule-therapeutics,30-09-2019 00:00,,,,,,
1472,mochida-obtains-marketing-approval-for-teriparatide-biosimilar-in-japan,20-09-2019 00:00,,,,,,
1473,chimerix-announces-exclusive-global-license-agreement-with-symbio-pharmaceuticals-for-brincidofovir,01-10-2019 00:00,,,,,,
1474,indian-biosimilar-of-rituximab-to-undergo-test-in-korea,17-09-2019 00:00,,,,,,
1475,agreement-supports-astrazeneca?s-focus-on-three-main-therapy-areas,01-10-2019 00:00,,,,,,
1476,us-fda-approves-invokana-canagliflozin-to-treat-diabetic-kidney-disease-dkd-and-reduce-the-risk-of-hospitalization-for-heart-failure-in-patients-with-type-2-diabetes-t2d-and-dkd,01-10-2019 00:00,,,,,,
1477,roche-presents-positive-phase-iii-results-for-tecentriq-atezolizumab-in-combination-with-platinum-based-chemotherapy-in-people-with-previously-untreated-advanced-bladder-cancer,01-10-2019 00:00,,,,,,
1478,pfizer-confirms-it-plans-to-launch-bevacizumab-biosimilar-on-december-31,01-10-2019 00:00,,,,,,
1479,moberg-pharma-and-taisho-sign-exclusive-license-agreement-for-mob-015-in-japan,01-10-2019 00:00,,,,,,
1480,numab-and-eisai-enter-into-a-global-research-and-option-agreement-to-discover-and-develop-multi-specific-antibody-immunotherapies-for-cancer,01-10-2019 00:00,,,,,,
1481,novartis-and-microsoft-announce-collaboration-to-transform-medicine-with-artificial-intelligence,03-10-2019 00:00,,,,,,
1482,biocon-and-mylan-launch-first-insulin-glargine-biosimilar-semglee-in-australia,03-10-2019 00:00,,,,,,
1483,philips-teams-with-air-ambulance-kent-surrey-sussex-in-first-of-its-kind-emergency-response-collaboration-in-the-uk,03-10-2019 00:00,,,,,,
1484,new-head-to-head-data-show-taltz-ixekizumab-superiority-versus-tremfya-guselkumab-in-people-with-moderate-to-severe-plaque-psoriasis,03-10-2019 00:00,,,,,,
1485,merck?s-keytruda-pembrolizumab-now-approved-as-monotherapy-in-china-for-first-line-treatment-of-certain-patients-with-advanced-non-small-cell-lung-cancer-nsclc-whose-tumors-express-pd-l1,03-10-2019 00:00,,,,,,
1486,emgality-galcanezumab-now-available-in-canada-for-preventive-treatment-of-migraine,03-10-2019 00:00,,,,,,
1487,novo-nordisk-and-noom-to-partner-around-digital-health-solutions-to-help-people-with-obesity-lose-weight-and-keep-it-off,03-10-2019 00:00,,,,,,
1488,goldfinch-bio-announces-licensing-agreement-with-takeda-for-cb1-monoclonal-antibody-for-the-treatment-of-rare-and-metabolic-kidney-diseases,04-10-2019 00:00,,,,,,
1489,us-food-and-drug-administration-approves-descovy-for-hiv-pre-exposure-prophylaxis-prep,04-10-2019 00:00,,,,,,
1490,fasenra-approved-in-the-us-for-self-administration-in-a-new-pre-filled-auto-injector-the-fasenra-pen,04-10-2019 00:00,,,,,,
1491,silvercloud-health-collaborates-with-microsoft-in-pioneering-artificial-intelligence-research-to-deliver-more-effective-digital-mental-healthcare,04-10-2019 00:00,,,,,,
1492,arbutus-announces-decision-to-discontinue-development-of-ab-506-an-oral-capsid-inhibitor-for-the-treatment-of-chronic-hepatitis-b,04-10-2019 00:00,,,,,,
1493,janssen-announces-us-fda-breakthrough-therapy-designation-granted-for-niraparib-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer,04-10-2019 00:00,,,,,,
1494,avexis-presents-updated-strong-data-at-wms-demonstrating-a-higher-mean-increase-in-hammersmith-functional-motor-scale-expanded-hfmse-scores-among-older-sma-type-2-patients-following-one-time-intrathecal-administration-of-avxs-101,07-10-2019 00:00,,,,,,
1495,prometheus-biosciences-inc-enters-into-multi-target-strategic-collaboration-with-takeda-to-develop-targeted-therapies-for-inflammatory-bowel-disease,07-10-2019 00:00,,,,,,
1496,lillys-cyramza-ramucirumab-phase-3-data-in-first-line-egfr-mutated-non-small-cell-lung-cancer-published-in-the-lancet-oncology,07-10-2019 00:00,,,,,,
1497,pfenex-receives-us-fda-approval-for-pf708-to-treat-osteoporosis,07-10-2019 00:00,,,,,,
1498,akcea-and-pfizer-inc-announce-licensing-agreement-for-investigative-antisense-therapy-akcea-angptl3-lrx,07-10-2019 00:00,,,,,,
1499,biofourmis-biovitals-analytics-engine-receives-fda-clearance-for-ambulatory-physiologic-monitoring,07-10-2019 00:00,,,,,,
1500,innovate-biopharmaceuticals-to-merge-with-rdd-pharma-creating-new-gastroenterology-company-focused-on-specialty-rare-and-orphan-diseases,08-10-2019 00:00,,,,,,
1501,allergan-expands-refresh-portfolio-with-new-refresh-relieva-lubricant-eye-drop-product-line,08-10-2019 00:00,,,,,,
1502,4d-pharma-collaborates-with-msd-to-develop-live-biotherapeutics-for-vaccines,08-10-2019 00:00,,,,,,
1503,medtronic-initiates-worldwide-pivotal-study-of-a-new-approach-to-treating-dangerously-fast-heart-rhythms,08-10-2019 00:00,,,,,,
1504,novartis-receives-fda-approval-for-beovu-offering-wet-amd-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept,08-10-2019 00:00,,,,,,
1505,gilead-sciences-submits-new-drug-application-for-filgotinib-for-the-treatment-of-adults-with-rheumatoid-arthritis-in-japan,08-10-2019 00:00,,,,,,
1506,gsk-and-lyell-immunopharma-join-forces-to-develop-the-next-generation-of-cancer-cell-therapies,09-10-2019 00:00,,,,,,
1507,health-canada-approves-calquence-acalabrutinib-for-adult-patients-with-previously-treated-mantle-cell-lymphoma-mcl,09-10-2019 00:00,,,,,,
1508,prevail-therapeutics-and-lonza-establish-strategic-collaboration-to-develop-and-manufacture-prevails-novel-aav9-gene-therapy-programs-for-patients-with-neurodegenerative-diseases,09-10-2019 00:00,,,,,,
1509,health-canada-approves-evenity-for-the-treatment-of-osteoporosis-in-postmenopausal-women-at-high-risk-for-fracture,09-10-2019 00:00,,,,,,
1510,ge-healthcare-and-theragnostics-announce-global-commercial-partnership-for-late-stage-psma-diagnostic-for-prostate-cancer,09-10-2019 00:00,,,,,,
1511,samsung-bioepis-presents-real-world-data-of-benepali-etanercept-in-patients-with-psoriasis-at-european-academy-of-dermatology-and-venereology-eadv-congress,09-10-2019 00:00,,,,,,
1512,bluebird-bio-and-novo-nordisk-enter-into-research-agreement-to-develop-in-vivo-genome-editing-candidates-for-haemophilia-and-other-severe-genetic-diseases,09-10-2019 00:00,,,,,,
1513,viela-bio-enters-strategic-collaboration-with-mitsubishi-tanabe-pharma-to-develop-and-commercialize-inebilizumab-for-autoimmune-diseases-in-japan-and-other-asia-regions,10-10-2019 00:00,,,,,,
1514,evotec-and-celmatix-enter-into-strategic-collaboration,10-10-2019 00:00,,,,,,
1515,new-data-showed-ofev-nintedanib-slows-decline-of-lung-function-in-broad-range-of-chronic-fibrosing-interstitial-lung-diseases-with-a-progressive-phenotype1,10-10-2019 00:00,,,,,,
1516,bayer-launches-lifehub-uk-focused-on-artificial-intelligence-to-optimize-data-driven-drug-discovery-and-disease-diagnosis,10-10-2019 00:00,,,,,,
1517,sun-pharma-presents-long-term-study-results-that-show-significant-skin-clearance-with-ilumya-tildrakizumabasmn-maintained-over-four-years-in-people-with-moderate-to-severe-plaque-psoriasis,10-10-2019 00:00,,,,,,
1518,ucb-agrees-to-acquire-ra-pharmaceuticals-joining-forces-to-improve-treatment-options-for-people-living-with-myasthenia-gravis-and-other-rare-diseases,10-10-2019 00:00,,,,,,
1519,reata-pharmaceuticals-reacquires-rights-from-abbvie-to-develop-and-commercialize-bardoxolone-methyl-omaveloxolone-and-all-next-generation-nrf2-activators,10-10-2019 00:00,,,,,,
1520,aclaris-therapeutics-announces-divestiture-of-rhofade,11-10-2019 00:00,,,,,,
1521,bayer-inks-deals-with-eleven-startups-under-g4a-digital-health-partnerships-program,11-10-2019 00:00,,,,,,
1522,fda-grants-ofev-breakthrough-therapy-designation-for-chronic-fibrosing-ilds-with-a-progressive-phenotype,11-10-2019 00:00,,,,,,
1523,just-?-evotec-biologics-biocon-biologics-sign-licensing-deal-for-a-biosimilar-asset,11-10-2019 00:00,,,,,,
1524,alexion-and-stealth-announce-agreement-for-option-to-co-develop-and-commercialize-late-stage-therapy-for-mitochondrial-diseases,11-10-2019 00:00,,,,,,
1525,fda-allows-marketing-of-first-rapid-diagnostic-test-for-detecting-ebola-virus-antigens,11-10-2019 00:00,,,,,,
1526,alnylam-announces-filing-for-marketing-authorization-of-onpattro-patisiran-in-brazil-for-the-treatment-of-hereditary-attr-amyloidosis-with-polyneuropathy,11-10-2019 00:00,,,,,,
1527,imaginab-signs-multi-party-collaboration-agreement-with-three-global-pharmaceutical-companies-to-help-further-develop-companys-cd8-immunopet-technology,14-10-2019 00:00,,,,,,
1528,phase-iii-pemphix-study-shows-roche?s-mabtherarituxan-rituximab-superior-to-mycophenolate-mofetil-in-patients-with-pemphigus-vulgaris,14-10-2019 00:00,,,,,,
1529,lillys-reyvow-lasmiditan-the-first-and-only-medicine-in-a-new-class-of-acute-treatment-for-migraine-receives-fda-approval,14-10-2019 00:00,,,,,,
1530,exact-sciences-and-mayo-clinic-initiate-150-000-patient-7-year-study-to-evaluate-real-world-impact-of-cologuard,14-10-2019 00:00,,,,,,
1531,aytu-bioscience-acquires-124-million-prescription-product-portfolio,14-10-2019 00:00,,,,,,
1532,sanofi-opens-its-first-digitally-enabled-continuous-manufacturing-facility-ushers-in-next-generation-of-biotech-manufacturing,15-10-2019 00:00,,,,,,
1533,takeda-agrees-to-divest-select-otc-and-non-core-assets-to-acino-for-over-200-million-usd,15-10-2019 00:00,,,,,,
1534,abbott-and-omada-health-partner-to-offer-integrated-digital-health-and-coaching-experience-for-people-with-type-2-diabetes,15-10-2019 00:00,,,,,,
1535,us-fda-approves-rivaroxaban-to-help-prevent-blood-clots-in-acutely-ill-medical-patients,15-10-2019 00:00,,,,,,
1536,kyowa-kirin-announces-nourianz-istradefylline-now-available-in-the-us-for-treatment-of-parkinson?s-disease-?off?-episodes,15-10-2019 00:00,,,,,,
1537,crispr-therapeutics-and-ksq-therapeutics-announce-license-agreement-to-advance-companies?-respective-cell-therapy-programs-in-oncology,15-10-2019 00:00,,,,,,
1538,reata-announces-positive-topline-results-from-the-moxie-registrational-trial-of-omaveloxolone-in-patients-with-friedreich?s-ataxia,15-10-2019 00:00,,,,,,
1539,abbott-and-tandem-diabetes-care-exploring-new-integrated-solutions-to-improve-diabetes-management,16-10-2019 00:00,,,,,,
1540,sanofi-and-kaken-pharmaceutical-terminate-the-co-marketing-agreement-for-the-anticoagulant-clexane,16-10-2019 00:00,,,,,,
1541,daiichi-sankyo-announces-transfer-from-astellas-pharma-of-three-products-in-asia,16-10-2019 00:00,,,,,,
1542,proqr-receives-rare-pediatric-disease-designation-from-fda-for-sepofarsen-for-the-treatment-of-lca10,16-10-2019 00:00,,,,,,
1543,alexion-to-acquire-achillion,16-10-2019 00:00,,,,,,
1544,lilly-announces-phase-3-study-in-patients-with-metastatic-pancreatic-cancer-did-not-meet-primary-endpoint-of-overall-survival,16-10-2019 00:00,,,,,,
1545,sandoz-and-pear-therapeutics-announce-pear-will-solely-commercialize-reset?-and-reset-o,17-10-2019 00:00,,,,,,
1546,petagene-announces-collaboration-with-astrazeneca-to-deploy-its-genomic-data-compression-software-in-core-genomics-initiative,17-10-2019 00:00,,,,,,
1547,trastuzumab-deruxtecan-granted-fda-priority-review-for-treatment-of-patients-with-her2-positive-metastatic-breast-cancer,17-10-2019 00:00,,,,,,
1548,sun-pharma-launches-drizalma-sprinkle-in-the-us,17-10-2019 00:00,,,,,,
1549,ipsen-and-blueprint-medicines-announce-exclusive-global-license-agreement-to-develop-and-commercialize-blu-782-for-the-treatment-of-fibrodysplasia-ossificans-progressiva-fop,17-10-2019 00:00,,,,,,
1550,bimekizumab-phase-3-psoriasis-study-meets-all-endpoints-achieving-significantly-greater-efficacy-versus-placebo-and-ustekinumab,17-10-2019 00:00,,,,,,
1551,the-bristol-myers-squibb-pfizer-alliance-and-fitbit-collaborate-to-address-gaps-in-atrial-fibrillation-detection-with-the-aim-of-accelerating-diagnosis,18-10-2019 00:00,,,,,,
1552,roche-announces-fda-approval-of-xofluza-baloxavir-marboxil-for-people-at-high-risk-of-developing-influenza-related-complications,18-10-2019 00:00,,,,,,
1553,evenity-romosozumab-receives-positive-chmp-opinion-for-the-treatment-of-severe-osteoporosis-in-postmenopausal-women-at-high-risk-of-fracture,18-10-2019 00:00,,,,,,
1554,cipla-acquires-novel-anti-infective-elores-to-further-anti-microbial-stewardship-in-critical-care-in-india,18-10-2019 00:00,,,,,,
1555,merck-receives-eu-chmp-positive-opinion-for-investigational-v920-ebola-zaire-vaccine-for-protection-against-ebola-virus-disease,18-10-2019 00:00,,,,,,
1556,abbvie-receives-chmp-positive-opinion-for-upadacitinib-rinvoq-for-the-treatment-of-adults-with-moderate-to-severe-active-rheumatoid-arthritis,18-10-2019 00:00,,,,,,
1557,johnson-johnson-consumer-inc-to-voluntarily-recall-a-single-lot-of-johnson?s-baby-powder-in-the-united-states,18-10-2019 00:00,,,,,,
1558,roche?s-tecentriq-in-combination-with-avastin-increased-overall-survival-and-progression-free-survival-in-people-with-unresectable-hepatocellular-carcinoma,21-10-2019 00:00,,,,,,
1559,gsk-agrees-to-divest-rabies-and-tick-borne-encephalitis-vaccines-to-bavarian-nordic,21-10-2019 00:00,,,,,,
1560,farxiga-approved-in-the-us-to-reduce-the-risk-of-hospitalisation-for-heart-failure-in-patients-with-type-2-diabetes,21-10-2019 00:00,,,,,,
1561,sartorius-signs-agreement-to-acquire-select-danaher-life-science-platform-businesses,21-10-2019 00:00,,,,,,
1562,janssen-announces-us-fda-approval-of-stelara-ustekinumab-for-the-treatment-of-adults-with-moderately-to-severely-active-ulcerative-colitis,21-10-2019 00:00,,,,,,
1563,humana-and-microsoft-announce-multiyear-strategic-partnership-to-reimagine-health-for-aging-populations-and-their-care-teams,22-10-2019 00:00,,,,,,
1564,crispr-therapeutics-and-bayer-announce-an-update-on-casebia-therapeutics,22-10-2019 00:00,,,,,,
1565,takeda-acquires-license-for-first-in-class-celiac-disease-therapy-from-cour-pharmaceuticals-following-positive-phase-2a-proof-of-concept-study,22-10-2019 00:00,,,,,,
1566,opko-and-pfizer-announce-positive-phase-3-top-line-results-for-somatrogon-an-investigational-long-acting-human-growth-hormone-to-treat-children-with-growth-hormone-deficiency,22-10-2019 00:00,,,,,,
1567,fda-approves-trikafta-elexacaftortezacaftorivacaftor-and-ivacaftor-to-treat-the-underlying-cause-of-cystic-fibrosis-in-people-ages-12-and-older-who-have-at-least-one-f508del-mutation,22-10-2019 00:00,,,,,,
1568,checkmate-9la-a-phase-3-trial-evaluating-opdivo-nivolumab-plus-low-dose-yervoy-ipilimumab-combined-with-chemotherapy-meets-primary-endpoint-demonstrating-superior-overall-survival-compared-to-chemotherapy-alone-in-first-line-lung-cancer,22-10-2019 00:00,,,,,,
1569,alvogen-announces-exclusive-commercialization-agreements-in-south-korea-israel,23-10-2019 00:00,,,,,,
1570,fda-approves-fiasp-for-use-in-insulin-infusion-pumps-for-adults-with-type-1-or-type-2-diabetes,23-10-2019 00:00,,,,,,
1571,biogen-plans-regulatory-filing-for-aducanumab-in-alzheimer?s-disease-based-on-new-analysis-of-larger-dataset-from-phase-3-studies,23-10-2019 00:00,,,,,,
1572,bergenbio-receives-fda-approval-of-fast-track-designation-for-bemcentinib,23-10-2019 00:00,,,,,,
1573,qpex-biopharma-and-brii-biosciences-enter-into-a-strategic-collaboration-to-develop-and-commercialize-antibiotics-for-drug-resistant-infections-in-china,23-10-2019 00:00,,,,,,
1574,biomica-to-collaborate-with-weizmann-institute-of-science-to-develop-a-selective-treatment-against-antibiotic-resistant-bacteria,23-10-2019 00:00,,,,,,
1575,pliant-therapeutics-announces-strategic-collaboration-to-develop-novel-therapies-for-nash-and-fibrotic-diseases,24-10-2019 00:00,,,,,,
1576,gsk-announces-us-food-and-drug-administration-approval-of-additional-indication-for-zejula-niraparib-for-late-line-treatment-for-women-with-recurrent-ovarian-cancer,24-10-2019 00:00,,,,,,
1577,bausch-health-licenses-clearside-biomedicals-xipere-triamcinolone-acetonide-suprachoroidal-injectable-suspension-an-investigational-treatment-for-macular-edema-associated-with-uveitis,24-10-2019 00:00,,,,,,
1578,ambrx-and-novocodex-form-second-collaboration-to-develop-and-commercialize-ambrxs-antibody-drug-conjugates,24-10-2019 00:00,,,,,,
1579,who-signs-mou-with-international-generic-and-biosimilar-medicines-association-to-promote-access,24-10-2019 00:00,,,,,,
1580,abbvie-announces-collaboration-with-cystic-fibrosis-foundation,25-10-2019 00:00,,,,,,
1581,fda-approves-botox-onabotulinumtoxina-for-pediatric-patients-with-lower-limb-spasticity-excluding-spasticity-caused-by-cerebral-palsy,25-10-2019 00:00,,,,,,
1582,european-commission-approves-astellas?-xospata-gilteritinib-as-a-monotherapy-for-patients-with-relapsed-or-refractory-acute-myeloid-leukemia-with-a-flt3-mutation,25-10-2019 00:00,,,,,,
1583,zentiva-acquires-central-and-eastern-european-business-of-alvogen,25-10-2019 00:00,,,,,,
1584,vertex-announces-agreement-with-nhs-england-for-access-to-all-licensed-cystic-fibrosis-medicines,25-10-2019 00:00,,,,,,
1585,anixa-biosciences-announces-collaboration-with-urology-san-antonio-on-cchek-prostate-cancer-study,25-10-2019 00:00,,,,,,
1586,gilead-and-glympse-bio-announce-strategic-collaboration-for-use-of-biomarker-technology-in-nash-clinical-development,29-10-2019 00:00,,,,,,
1587,imfinzi-and-imfinzi-plus-tremelimumab-delayed-disease-progression-in-phase-iii-poseidon-trial-for-1st-line-treatment-of-stage-iv-non-small-cell-lung-cancer,29-10-2019 00:00,,,,,,
1588,european-commission-approves-bavencio-avelumab-plus-axitinib-combination-for-first-line-treatment-of-patients-with-advanced-renal-cell-carcinoma,29-10-2019 00:00,,,,,,
1589,gsk-candidate-vaccine-demonstrates-sustained-level-of-protection-against-active-pulmonary-tuberculosis,29-10-2019 00:00,,,,,,
1590,mor106-clinical-development-in-atopic-dermatitis-stopped-for-futility,29-10-2019 00:00,,,,,,
1591,astellas?-asp1128-receives-the-us-fda?s-fast-track-designation-for-patients-at-high-risk-of-acute-kidney-injury,29-10-2019 00:00,,,,,,
1592,boehringer-ingelheim-joins-forces-with-the-defeat-ncd-partnership-to-fight-non-communicable-diseases,30-10-2019 00:00,,,,,,
1593,intravenous-benlysta-is-the-first-biologic-treatment-to-be-approved-for-children-with-lupus-in-europe,30-10-2019 00:00,,,,,,
1594,astrazeneca-divests-rights-to-seroquel-and-seroquel-xr-in-europe-and-russia,30-10-2019 00:00,,,,,,
1595,roche?s-marketing-applications-for-satralizumab-in-neuromyelitis-optica-spectrum-disorder-accepted-for-review-by-ema-and-fda,30-10-2019 00:00,,,,,,
1596,novartis-announces-avxs-101-intrathecal-study-update,30-10-2019 00:00,,,,,,
1597,leo-pharma-enters-into-option-agreement-with-ubiquigent-for-access-to-novel-compounds,30-10-2019 00:00,,,,,,
1598,biogen-and-alkermes-announce-fda-approval-of-vumerity-diroximel-fumarate-for-multiple-sclerosis,30-10-2019 00:00,,,,,,
1599,pear-therapeutics-announces-agreement-with-ironwood-pharmaceuticals-to-evaluate-prescription-digital-therapeutics-for-patients-with-gi-indications,31-10-2019 00:00,,,,,,
1600,pandion-and-astellas-announce-collaboration-to-deliver-pancreas-targeted-immunomodulators,31-10-2019 00:00,,,,,,
1601,johnson-johnson-vision-launches-tecnis-eyhance-monofocal-intraocular-lens-in-india,31-10-2019 00:00,,,,,,
1602,alivecor-and-huami-partner-to-deliver-the-next-generation-of-medical-wearables,31-10-2019 00:00,,,,,,
1603,dicerna-enters-agreement-with-roche-to-develop-and-commercialize-dcr-hbvs-for-the-treatment-of-chronic-hepatitis-b-virus-hbv-infection,31-10-2019 00:00,,,,,,
1604,janssen-announces-health-canada-approval-of-darzalex-daratumumab-in-combination-with-lenalidomide-and-dexamethasone-for-newly-diagnosed-patients-with-multiple-myeloma-who-are-transplant-ineligible,31-10-2019 00:00,,,,,,
1605,beigene-announces-global-strategic-oncology-collaboration-with-amgen,01-11-2019 00:00,,,,,,
1606,pfizer-announces-launch-dates-for-2-more-anticancer-biosimilars-ruxience-and-trazimera,29-10-2019 00:00,,,,,,
1607,formycon-announces-start-of-phase-i-clinical-trial-with-ustekinumab-biosimilar-candidate-fyb202,28-10-2019 00:00,,,,,,
1608,pfenex-reports-positive-results-for-pf708-comparative-use-human-factors-study,14-10-2019 00:00,,,,,,
1609,neuclone-announces-first-human-dose-of-stelara-ustekinumab-biosimilar-candidate-in-phase-i-clinical-trial,01-11-2019 00:00,,,,,,
1610,novartis-cosentyx-shows-encouraging-results-versus-humira-from-first-of-its-kind-head-to-head-trial-in-psoriatic-arthritis,01-11-2019 00:00,,,,,,
1611,rinvoq-upadacitinib-meets-primary-and-all-ranked-secondary-endpoints-in-phase-3-study-in-psoriatic-arthritis,01-11-2019 00:00,,,,,,
1612,phase-3-results-from-two-studies-of-trikafta-elexacaftortezacaftorivacaftor-and-ivacaftor-triple-combination-treatment-for-cystic-fibrosis-concurrently-published-in-the-new-england-journal-of-medicine-and-the-lancet,01-11-2019 00:00,,,,,,
1613,mundipharma-receives-positive-chmp-opinion-for-pegfilgrastim-biosimilar,18-10-2019 00:00,,,,,,
1614,beam-therapeutics-announces-collaboration-and-exclusive-license-agreement-with-prime-medicine-for-prime-editing-technology,01-11-2019 00:00,,,,,,
1615,medtronic-announces-shonin-approval-and-launch-of-the-valiant-navion-thoracic-stent-graft-system-in-japan,01-11-2019 00:00,,,,,,
1616,helping-more-people-with-wearables-google-to-acquire-fitbit,04-11-2019 00:00,,,,,,
1617,sanofi-positive-results-in-phase-3-trial-for-toujeo-in-children-and-adolescents-with-type-1-diabetes,04-11-2019 00:00,,,,,,
1618,vifor-pharma-enters-into-commercial-collaboration-in-the-us-with-janssen,04-11-2019 00:00,,,,,,
1619,yas-holding-invests-in-alvotech-and-agrees-on-a-strategic-partnership-for-biosimilar-candidates,04-11-2019 00:00,,,,,,
1620,halozyme-announces-halo-301-phase-3-study-fails-to-meet-primary-endpoint,04-11-2019 00:00,,,,,,
1621,boehringer-ingelheim-and-lilly-modernise-alliance-to-focus-full-expertise-on-jardiance,05-11-2019 00:00,,,,,,
1622,sandoz-receives-us-fda-approval-for-long-acting-oncology-supportive-care-biosimilar-ziextenzo-pegfilgrastim-bmez,05-11-2019 00:00,,,,,,
1623,takeda-continues-strategic-divestitures-with-sale-of-select-otc-and-non-core-assets-to-stada-for-660-million-usd,05-11-2019 00:00,,,,,,
1624,fda-approves-fluzone-high-dose-quadrivalent-influenza-vaccine-for-adults-65-years-of-age-and-older,05-11-2019 00:00,,,,,,
1625,ascentage-pharma-and-henlius-form-a-combination-therapy-strategic-collaboration,05-11-2019 00:00,,,,,,
1626,stryker-announces-definitive-agreement-to-acquire-wright-medical,05-11-2019 00:00,,,,,,
1627,seattle-genetics-and-beigene-announce-global-license-agreement-for-advanced-preclinical-product-candidate,06-11-2019 00:00,,,,,,
1628,takeda-and-md-anderson-announce-collaboration-to-accelerate-the-development-of-clinical-stage-off-the-shelf-car-nk-cell-therapy-platform,06-11-2019 00:00,,,,,,
1629,biolinerx-announces-bl-8040-in-combination-with-keytruda-shows-clinical-activity-in-heavily-pretreated-metastatic-pancreatic-cancer-patients,06-11-2019 00:00,,,,,,
1630,fda-grants-de-novo-designation-to-vela-diagnostics?-next-generation-sequencing-hiv-1-genotyping-assay,06-11-2019 00:00,,,,,,
1631,evotec-and-vifor-pharma-form-joint-venture-for-early-development-in-nephrology,06-11-2019 00:00,,,,,,
1632,eisai-transfers-rights-to-receive-royalties-outside-of-japan-for-ezh2-inhibitor-tazemetostat-to-royalty-pharma,06-11-2019 00:00,,,,,,
1633,regeneron-and-vyriad-announce-strategic-agreement-for-discovery-and-development-of-new-oncolytic-virus-treatments-for-cancer,06-11-2019 00:00,,,,,,
1634,biogen-to-expand-biosimilars-portfolio-and-gain-access-to-additional-markets-through-new-transaction-with-samsung-bioepis,07-11-2019 00:00,,,,,,
1635,coherus-acquires-commercial-rights-for-leading-lucentis-biosimilar-in-the-united-states,07-11-2019 00:00,,,,,,
1636,promega-enters-global-collaboration-with-merck-to-develop-microsatellite-instability-msi-companion-diagnostic-for-use-with-keytruda?,07-11-2019 00:00,,,,,,
1637,novo-nordisk-obtains-exclusive-worldwide-licence-to-potential-nash-candidate-ud-014-from-ube-industries,07-11-2019 00:00,,,,,,
1638,alvotech-and-stada-agree-on-strategic-biosimilar-partnership,07-11-2019 00:00,,,,,,
1639,new-global-rd-centre-ai-innovation-centre-and-a-joint-investment-fund-with-cicc-to-underpin-next-phase-of-growth-and-support-transformation-of-healthcare-in-china,07-11-2019 00:00,,,,,,
1640,china-nmpa-approves-bio-thera-solutions?-qletli-a-biosimilar-to-humira-adalimumab,07-11-2019 00:00,,,,,,
1641,teva-and-celltrion-announce-the-availability-of-truxima-rituximab-abbs-injection-the-first-biosimilar-to-rituxan-rituximab-in-the-united-states,07-11-2019 00:00,,,,,,
1642,roxadustat-significantly-increased-haemoglobin-levels-for-chronic-kidney-disease-patients-with-anaemia-in-phase-iii-olympus-and-rockies-trials,08-11-2019 00:00,,,,,,
1643,sierra-oncology-and-gilead-sciences-agree-on-amendments-to-asset-purchase-agreement-for-momelotinib,08-11-2019 00:00,,,,,,
1644,phase-3-trial-of-ninlaro-ixazomib-as-first-line-maintenance-therapy-met-primary-endpoint-in-multiple-myeloma-patients-not-treated-with-stem-cell-transplantation,08-11-2019 00:00,,,,,,
1645,south-korean-company-yuhan-pharmaceuticals-partners-with-cyclica-to-advance-rd-across-two-separate-programs-for-oncology,08-11-2019 00:00,,,,,,
1646,triumvira-immunologics-announces-fast-track-designation-for-its-first-tac-t-cell-therapeutic-product-candidate-tac01-cd19,08-11-2019 00:00,,,,,,
1647,johnson-johnson-announces-submission-of-european-marketing-authorisation-applications-for-janssen?s-investigational-ebola-vaccine-regimen,08-11-2019 00:00,,,,,,
1648,sandoz-announces-agreement-to-acquire-aspen?s-japanese-operations-and-associated-assets-strengthening-position-in-world?s-third-largest-generics-market,11-11-2019 00:00,,,,,,
1649,roxadustat-phase-iii-programme-pooled-analyses-showed-positive-efficacy-and-no-increased-cardiovascular-risk-in-patients-with-anaemia-from-chronic-kidney-disease,11-11-2019 00:00,,,,,,
1650,roche?s-risdiplam-meets-primary-endpoint-in-pivotal-sunfish-trial-in-people-with-type-2-or-3-spinal-muscular-atrophy,11-11-2019 00:00,,,,,,
1651,fda-approves-first-therapy-to-treat-patients-with-rare-blood-disorder,11-11-2019 00:00,,,,,,
1652,roche?s-gazyva-obinutuzumab-in-combination-with-standard-of-care-more-than-doubles-the-percentage-of-lupus-nephritis-patients-achieving-complete-renal-response-compared-to-standard-of-care-alone,11-11-2019 00:00,,,,,,
1653,new-study-shows-promise-in-treating-more-patients-with-world?s-smallest-pacemaker,12-11-2019 00:00,,,,,,
1654,merck?s-ervebo-ebola-zaire-vaccine-rvsv-g-zebov-gp-live-granted-conditional-approval-in-the-european-union,12-11-2019 00:00,,,,,,
1655,lupin-enters-into-agreement-to-divest-its-stake-in-kyowa-to-unison,12-11-2019 00:00,,,,,,
1656,us-food-and-drug-administration-accepts-for-priority-review-bristol-myers-squibb?s-application-for-opdivo-nivolumab-plus-yervoy-ipilimumab-combination-for-patients-with-previously-treated-advanced-hepatocellular-carcinoma,12-11-2019 00:00,,,,,,
1657,tremfya-guselkumab-a-first-in-class-il-23-p19-subunit-inhibitor-meets-primary-endpoints-of-superior-acr20-responses-versus-placebo-at-week-24-in-phase-3-psoriatic-arthritis-studies,12-11-2019 00:00,,,,,,
1658,bluebird-bio-and-forty-seven-announce-a-research-collaboration-to-study-an-all-antibody-conditioning-regimen-for-use-in-combination-with-autologous-lentiviral-vector-hematopoietic-stem-cell-gene-therapy,12-11-2019 00:00,,,,,,
1659,mylan-and-pfizer-announce-viatris-as-the-new-company-name-in-the-planned-mylan-upjohn-combination,13-11-2019 00:00,,,,,,
1660,editas-medicine-and-celgene-corporation-amend-existing-collaboration-to-develop-and-commercialize-autologous-and-allogeneic-t-cell-medicines-for-the-treatment-of-cancer-and-autoimmune-diseases,13-11-2019 00:00,,,,,,
1661,skyhawk-therapeutics-announces-a-second-multi-target-collaboration-agreement-with-celgene-to-discover-and-develop-novel-small-molecules-that-modulate-rna-splicing,13-11-2019 00:00,,,,,,
1662,new-positive-data-for-rinvoq-upadacitinib-on-signs-and-symptoms-in-patients-with-ankylosing-spondylitis-presented-at-2019-acrarp-annual-meeting,13-11-2019 00:00,,,,,,
1663,boehringer-ingelheim-and-lilly-initiate-first-ever-study-to-assess-jardiance-in-people-hospitalized-for-acute-heart-failure-who-have-been-stabilized,13-11-2019 00:00,,,,,,
1664,nucala-mepolizumab-is-the-first-treatment-to-show-a-significant-reduction-in-flares-for-patients-with-hypereosinophilic-syndrome-hes,13-11-2019 00:00,,,,,,
1665,coi-pharmaceuticals-announces-acquisition-of-calporta-by-merck,14-11-2019 00:00,,,,,,
1666,centogene-signs-data-access-and-collaboration-agreement-with-pfizer-inc,14-11-2019 00:00,,,,,,
1667,cytotron-granted-breakthrough-device-designation-by-us-fda-for-treatment-of-breast-liver-and-pancreatic-cancers,31-10-2019 00:00,,,,,,
1668,boehringer-ingelheim-and-lilly-announce-outcome-of-fda-advisory-committee-meeting-for-empagliflozin-25-mg-as-adjunct-to-insulin-for-adults-with-type-1-diabetes,14-11-2019 00:00,,,,,,
1669,finch-therapeutics-takeda-expand-collaboration-to-develop-microbiome-therapeutics-using-finch?s-human-first-discovery-platform,14-11-2019 00:00,,,,,,
1670,aquestive-therapeutics-licenses-riluzole-oral-film-to-zambon-for-development-and-commercialization-in-the-eu-for-patients-with-als,14-11-2019 00:00,,,,,,
1671,fda-approves-scenesse-for-genetic-disorder,08-10-2019 00:00,,,,,,
1672,bayer-and-dewpoint-therapeutics-partner-to-research-new-treatments-for-cardiovascular-and-gynecological-diseases,14-11-2019 00:00,,,,,,
1673,galderma-receives-fda-approval-for-aklief-trifarotene-cream-0005-the-first-new-retinoid-molecule-for-the-treatment-of-acne-in-over-20-years,04-10-2019 00:00,,,,,,
1674,ardelyx-receives-fda-approval-for-ibsrela-tenapanor-an-nhe3-sodium-transport-inhibitor-for-the-treatment-of-irritable-bowel-syndrome-with-constipation,12-09-2019 00:00,,,,,,
1675,foamix-receives-fda-approval-of-amzeeq-topical-minocycline-treatment-for-millions-of-moderate-to-severe-acne-sufferers,18-10-2019 00:00,,,,,,
1676,exicure-and-allergan-enter-into-collaboration-option-and-license-agreement-to-discover-and-develop-sna-based-treatments-for-hair-loss-disorders,15-11-2019 00:00,,,,,,
1677,ozobax-baclofen-?-new-drug-approval,18-09-2019 00:00,,,,,,
1678,astrazeneca-and-msd?s-selumetinib-would-become-the-first-medicine-indicated-for-the-treatment-of-paediatric-patients-with-nf1-plexiform-neurofibromas-if-approved,15-11-2019 00:00,,,,,,
1679,us-fda-grants-beigene?s-brukinsa-zanubrutinib-accelerated-approval-to-treat-adult-patients-with-mantle-cell-lymphoma-who-received-at-least-one-prior-therapy,15-11-2019 00:00,,,,,,
1680,fetroja-cefiderocol-approved-by-the-fda-for-treatment-of-complicated-urinary-tract-infections-cuti-in-adult-patients-with-limited-or-no-alternative-treatment-options,15-11-2019 00:00,,,,,,
1681,sarepta-and-stridebio-announce-multi-target-strategic-collaboration-to-advance-novel-gene-therapies,15-11-2019 00:00,,,,,,
1682,through-apple-heart-study-stanford-medicine-researchers-show-wearable-technology-can-help-detect-atrial-fibrillation,15-11-2019 00:00,,,,,,
1683,chmp-recommends-eu-approval-of-roche?s-kadcyla-for-the-adjuvant-treatment-of-people-with-her2-positive-early-breast-cancer-with-residual-invasive-disease-after-neoadjuvant-treatment,15-11-2019 00:00,,,,,,
1684,promedior-enters-into-definitive-merger-agreement-to-be-acquired-by-roche,18-11-2019 00:00,,,,,,
1685,statement-from-sarah-yim-md-acting-director-of-the-office-of-therapeutic-biologics-and-biosimilars-in-the-fda?s-center-for-drug-evaluation-and-research-on-fda?s-continued-progress-facilitating-competition-in-the-biologic-marketplace-with-approval-of-25th-biosimilar-product,18-11-2019 00:00,,,,,,
1686,new-novartis-medicine-adakveo-crizanlizumab-approved-by-fda-to-reduce-frequency-of-pain-crises-in-individuals-living-with-sickle-cell-disease,18-11-2019 00:00,,,,,,
1687,dicerna-and-novo-nordisk-enter-agreement-to-discover-and-develop-rnai-therapies-for-liver-related-cardio-metabolic-diseases,18-11-2019 00:00,,,,,,
1688,aerie-pharmaceuticals-announces-agreement-to-acquire-avizorex-pharma-sl-to-advance-its-dry-eye-program,18-11-2019 00:00,,,,,,
1689,merck-and-bayer?s-investigational-drug-vericiguat-meets-primary-endpoint-in-phase-3-study-of-patients-with-worsening-chronic-heart-failure,18-11-2019 00:00,,,,,,
1690,biofourmis-forms-alliance-with-global-healthcare-company-to-offer-digital-therapeutics-for-patients-with-heart-failure,19-11-2019 00:00,,,,,,
1691,alkermes-to-acquire-rodin-therapeutics,19-11-2019 00:00,,,,,,
1692,santhera-announces-publication-of-long-term-idebenone-data-from-syros-study-in-duchenne-muscular-dystrophy,19-11-2019 00:00,,,,,,
1693,janssen-leverages-wearable-technology-to-reimagine-clinical-trial-design,19-11-2019 00:00,,,,,,
1694,vertex-and-molecular-templates-establish-collaboration-to-discover-and-develop-novel-targeted-conditioning-regimens-to-enhance-hematopoietic-stem-cell-transplants,19-11-2019 00:00,,,,,,
1695,fda-accepts-samsung-bioepis?-bla-for-sb8-bevacizumab-biosimilar-candidate,19-11-2019 00:00,,,,,,
1696,personalis-inc-announces-collaboration-with-merck-kgaa-darmstadt-germany-to-identify-and-develop-novel-biomarkers-for-cancer-therapies,20-11-2019 00:00,,,,,,
1697,crispr-therapeutics-and-vertex-announce-positive-safety-and-efficacy-data-from-first-two-patients-treated-with-investigational-crisprcas9-gene-editing-therapy-ctx001-for-severe-hemoglobinopathies,20-11-2019 00:00,,,,,,
1698,myovant-sciences-announces-97-response-rate-in-positive-phase-3-hero-study-of-once-daily-oral-relugolix-in-men-with-advanced-prostate-cancer,20-11-2019 00:00,,,,,,
1699,janssen-receives-eu-marketing-authorisation-for-darzalex-daratumumab-in-combination-with-lenalidomide-and-dexamethasone-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-ineligible,20-11-2019 00:00,,,,,,
1700,fda-grants-breakthrough-device-designation-status-for-bioventrix-revivent-tc-transcatheter-ventricular-enhancement-system-for-heart-failure,20-11-2019 00:00,,,,,,
1701,european-commission-approves-two-new-regimens-of-merck?s-keytrudapembrolizumab-as-first-line-treatment-for-metastatic-or-unresectable-recurrent-head-and-neck-squamous-cell-carcinoma-hnscc,20-11-2019 00:00,,,,,,
1702,bristol-myers-squibb-announces-update-on-checkmate-915-for-opdivo-nivolumab-plus-yervoy-ipilimumab-versus-opdivo-alone-in-patients-with-resected-high-risk-melanoma-and-pd-l1,20-11-2019 00:00,,,,,,
1703,dragonfly-therapeutics-announces-collaboration-with-abbvie-for-autoimmune-diseases-and-oncology,21-11-2019 00:00,,,,,,
1704,fda-approves-first-treatment-for-inherited-rare-disease,21-11-2019 00:00,,,,,,
1705,novartis-establishes-strategic-alliance-with-mila,21-11-2019 00:00,,,,,,
1706,sanofi-and-aetion-launch-enterprise-wide-collaboration-to-advance-regulatory-submissions-using-real-world-evidence,21-11-2019 00:00,,,,,,
1707,promedior-enters-into-definitive-merger-agreement-to-be-acquired-by-roche,18-11-2019 00:00,,,,,,
1708,statement-from-sarah-yim-md-acting-director-of-the-office-of-therapeutic-biologics-and-biosimilars-in-the-fda?s-center-for-drug-evaluation-and-research-on-fda?s-continued-progress-facilitating-competition-in-the-biologic-marketplace-with-approval-of-25th-biosimilar-product,18-11-2019 00:00,,,,,,
1709,new-novartis-medicine-adakveo-crizanlizumab-approved-by-fda-to-reduce-frequency-of-pain-crises-in-individuals-living-with-sickle-cell-disease,18-11-2019 00:00,,,,,,
1710,dicerna-and-novo-nordisk-enter-agreement-to-discover-and-develop-rnai-therapies-for-liver-related-cardio-metabolic-diseases,18-11-2019 00:00,,,,,,
1711,aerie-pharmaceuticals-announces-agreement-to-acquire-avizorex-pharma-sl-to-advance-its-dry-eye-program,18-11-2019 00:00,,,,,,
1712,merck-and-bayer?s-investigational-drug-vericiguat-meets-primary-endpoint-in-phase-3-study-of-patients-with-worsening-chronic-heart-failure,18-11-2019 00:00,,,,,,
1713,biofourmis-forms-alliance-with-global-healthcare-company-to-offer-digital-therapeutics-for-patients-with-heart-failure,19-11-2019 00:00,,,,,,
1714,alkermes-to-acquire-rodin-therapeutics,19-11-2019 00:00,,,,,,
1715,santhera-announces-publication-of-long-term-idebenone-data-from-syros-study-in-duchenne-muscular-dystrophy,19-11-2019 00:00,,,,,,
1716,janssen-leverages-wearable-technology-to-reimagine-clinical-trial-design,19-11-2019 00:00,,,,,,
1717,vertex-and-molecular-templates-establish-collaboration-to-discover-and-develop-novel-targeted-conditioning-regimens-to-enhance-hematopoietic-stem-cell-transplants,19-11-2019 00:00,,,,,,
1718,fda-accepts-samsung-bioepis?-bla-for-sb8-bevacizumab-biosimilar-candidate,19-11-2019 00:00,,,,,,
1719,personalis-inc-announces-collaboration-with-merck-kgaa-darmstadt-germany-to-identify-and-develop-novel-biomarkers-for-cancer-therapies,20-11-2019 00:00,,,,,,
1720,crispr-therapeutics-and-vertex-announce-positive-safety-and-efficacy-data-from-first-two-patients-treated-with-investigational-crisprcas9-gene-editing-therapy-ctx001-for-severe-hemoglobinopathies,20-11-2019 00:00,,,,,,
1721,myovant-sciences-announces-97-response-rate-in-positive-phase-3-hero-study-of-once-daily-oral-relugolix-in-men-with-advanced-prostate-cancer,20-11-2019 00:00,,,,,,
1722,janssen-receives-eu-marketing-authorisation-for-darzalex-daratumumab-in-combination-with-lenalidomide-and-dexamethasone-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-ineligible,20-11-2019 00:00,,,,,,
1723,fda-grants-breakthrough-device-designation-status-for-bioventrix-revivent-tc-transcatheter-ventricular-enhancement-system-for-heart-failure,20-11-2019 00:00,,,,,,
1724,european-commission-approves-two-new-regimens-of-merck?s-keytrudapembrolizumab-as-first-line-treatment-for-metastatic-or-unresectable-recurrent-head-and-neck-squamous-cell-carcinoma-hnscc,20-11-2019 00:00,,,,,,
1725,bristol-myers-squibb-announces-update-on-checkmate-915-for-opdivo-nivolumab-plus-yervoy-ipilimumab-versus-opdivo-alone-in-patients-with-resected-high-risk-melanoma-and-pd-l1,20-11-2019 00:00,,,,,,
1726,dragonfly-therapeutics-announces-collaboration-with-abbvie-for-autoimmune-diseases-and-oncology,21-11-2019 00:00,,,,,,
1727,fda-approves-first-treatment-for-inherited-rare-disease,21-11-2019 00:00,,,,,,
1728,novartis-establishes-strategic-alliance-with-mila,21-11-2019 00:00,,,,,,
1729,sanofi-and-aetion-launch-enterprise-wide-collaboration-to-advance-regulatory-submissions-using-real-world-evidence,21-11-2019 00:00,,,,,,
1730,astellas-and-welldoc-enter-into-strategic-alliance-for-digital-therapeutics-?-develop-and-commercialize-digital-health-solutions-globally-for-multiple-therapeutic-areas-including-in-japan-for-diabetes-patients,21-11-2019 00:00,,,,,,
1731,aerie-pharmaceuticals-receives-european-commission-approval-for-rhokiinsa?netarsudil-ophthalmic-solution-002,21-11-2019 00:00,,,,,,
1732,harpoon-therapeutics-and-abbvie-announce-licensing-and-option-collaboration-to-advance-hpn217-harpoon?s-bcma-targeting-tritac-and-expand-existing-discovery-collaboration,21-11-2019 00:00,,,,,,
1733,onconova-therapeutics-announces-exclusive-license-agreement-with-knight-therapeutics-for-rigosertib-in-canada,22-11-2019 00:00,,,,,,
1734,fda-takes-second-action-under-international-collaboration-approves-new-treatment-option-for-patients-with-chronic-lymphocytic-leukemia,22-11-2019 00:00,,,,,,
1735,viiv-healthcare-announces-exclusive-licensing-agreement-with-the-national-institutes-of-health-for-investigational-?bnab?-with-potential-for-long-acting-hiv-treatment-and-prevention,22-11-2019 00:00,,,,,,
1736,medtronic-drug-coated-balloon-receives-us-fda-approval-to-treat-arteriovenous-fistula-lesions,22-11-2019 00:00,,,,,,
1737,biomarin-submits-marketing-authorization-application-to-european-medicines-agency-for-valoctocogene-roxaparvovec-to-treat-severe-hemophilia-a,22-11-2019 00:00,,,,,,
1738,lupin-launches-?adhero-?-first-of-its-kind-connected-smart-device-in-india-to-support-treatment-of-respiratory-disease,22-11-2019 00:00,,,,,,
1739,novartis-to-acquire-the-medicines-company-for-usd-97-bn-adding-inclisiran-a-potentially-transformational-investigational-cholesterol-lowering-therapy-to-address-leading-global-cause-of-death,25-11-2019 00:00,,,,,,
1740,fda-grants-priority-review-to-roche?s-risdiplam-for-spinal-muscular-atrophy,25-11-2019 00:00,,,,,,
1741,takhzyro-lanadelumab-injection-receives-positive-recommendation-from-cadths-canadian-drug-expert-committee-cdec-for-the-routine-prevention-of-hereditary-angioedema-hae-attacks,25-11-2019 00:00,,,,,,
1742,roche-presents-pivotal-data-demonstrating-tecentriq-in-combination-with-avastin-improves-overall-survival-in-people-with-the-most-common-form-of-liver-cancer,25-11-2019 00:00,,,,,,
1743,takeda-presents-long-term-data-in-alk-nsclc-showing-alunbrig-brigatinib-continues-to-demonstrate-superiority-in-the-first-line-after-two-years-of-follow-up,25-11-2019 00:00,,,,,,
1744,ferring-and-blackstone-life-sciences-invest-over-570-million-usd-in-novel-gene-therapy-for-bladder-cancer-patients,26-11-2019 00:00,,,,,,
1745,zogenix-announces-fda-acceptance-for-filing-of-new-drug-application-and-priority-review-for-fintepla-for-the-treatment-of-dravet-syndrome,26-11-2019 00:00,,,,,,
1746,bayer-submits-application-to-ema-for-use-of-rivaroxaban-in-children-with-venous-thromboembolism,26-11-2019 00:00,,,,,,
1747,ardelyx-and-kyowa-kirin-expand-partnership-with-two-additional-agreements,26-11-2019 00:00,,,,,,
1748,alvogen-and-yas-holding-announce-license-and-distribution-agreement-to-commercialize-generics-portfolio-in-mena-region,26-11-2019 00:00,,,,,,
1749,merck?s-keytruda-pembrolizumab-now-approved-in-china-for-first-line-treatment-of-metastatic-squamous-non-small-cell-lung-cancer-nsclc-in-combination-with-chemotherapy,26-11-2019 00:00,,,,,,
1750,novoheart-to-co-develop-first-of-its-kind-human-heart-in-a-jar-model-of-heart-failure-with-astrazeneca,27-11-2019 00:00,,,,,,
1751,usfda-approves-biocon?s-sbla-for-pegfilgrastim-new-manufacturing-facility,27-11-2019 00:00,,,,,,
1752,celltrion-healthcare-receives-eu-marketing-authorisation-for-world?s-first-subcutaneous-formulation-of-infliximab-remsima-sc-for-the-treatment-of-people-with-rheumatoid-arthritis,27-11-2019 00:00,,,,,,
1753,elsevier-acquires-3d4medical-creator-of-world-leading-3d-anatomy-technology,27-11-2019 00:00,,,,,,
1754,new-ways-to-manage-your-medications-at-home-using-alexa,27-11-2019 00:00,,,,,,
1755,astellas-announces-the-approval-of-xtandi?-enzalutamide-by-the-china-national-medical-products-administration-nmpa-approval-based-on-asian-prevail-study-of-men-with-metastatic-castration-resistant-prostate-cancer,27-11-2019 00:00,,,,,,
1756,incyte-announces-acceptance-and-priority-review-of-nda-for-pemigatinib-as-a-treatment-for-patients-with-cholangiocarcinoma,27-11-2019 00:00,,,,,,
1757,abbvie-uk-announces-collaboration-with-northwest-ehealth-to-generate-real-world-evidence-to-drive-improvements-in-patient-care,28-11-2019 00:00,,,,,,
1758,the-nhi-drug-price-listing-and-launch-of-teriparatide-bs-mochida-a-treatment-for-osteoporosis-in-japan,28-11-2019 00:00,,,,,,
1759,health-canada-approves-ofev-nintedanib-the-first-and-only-therapy-in-canada-to-slow-the-rate-of-decline-in-pulmonary-function-in-patients-with-systemic-sclerosis-associated-ild,28-11-2019 00:00,,,,,,
1760,chugai-launches-tecentriq-intravenous-infusion-840-mg-as-an-optimal-formulation-for-the-treatment-of-pd-l1-positive-inoperable-or-metastatic-triple-negative-breast-cancer,28-11-2019 00:00,,,,,,
1761,chugai-and-jw-pharmaceutical-agree-to-make-cc-research-laboratories-a-joint-venture-in-korea-a-wholly-owned-subsidiary-of-jw-pharmaceutical,28-11-2019 00:00,,,,,,
1762,simcere-and-gi-innovation-announce-collaboration-and-exclusive-license-agreement-for-immunotherapy-drugs-in-china,28-11-2019 00:00,,,,,,
1763,immupharma-and-avion-pharmaceuticals-sign-exclusive-licence,29-11-2019 00:00,,,,,,
1764,health-canada-approves-kadcyla-trastuzumab-emtansine-for-the-treatment-of-her2-positive-early-breast-cancer-after-surgery,29-11-2019 00:00,,,,,,
1765,wuxi-atu-and-genemedicine-sign-development-and-manufacturing-agreement-for-oncolytic-virus-products,29-11-2019 00:00,,,,,,
1766,imfinzi-granted-fda-priority-review-for-the-treatment-of-patients-with-extensive-stage-small-cell-lung-cancer,29-11-2019 00:00,,,,,,
1767,combining-forces-the-multinational-pharmaceutical-company-astrazeneca-plc-and-jerusalem-venture-partners-jvp-have-signed-a-cooperation-agreement-to-identify-develop-and-invest-in-digital-health-in-israel,29-11-2019 00:00,,,,,,
1768,ono-submits-an-application-for-manufacturing-and-marketing-approval-in-japan-for-tirabrutinib-hydrochloride-ono-4059-a-btk-inhibitor-for-the-treatment-of-waldenstrom-macroglobulinemia-and-lymphoplasmacytic-lymphoma,29-11-2019 00:00,,,,,,
1769,positive-phase-iii-results-for-roche?s-satralizumab-in-neuromyelitis-optica-spectrum-disorder-published-in-the-new-england-journal-of-medicine,02-12-2019 00:00,,,,,,
1770,y-mabs-initiates-rolling-submission-of-biologics-license-application-to-us-fda-for-naxitamab-for-treatment-of-neuroblastoma,02-12-2019 00:00,,,,,,
1771,fosun-pharma?s-new-development-leukemia-drug-fn-1501-receives-fda-orphan-drug-designation,02-12-2019 00:00,,,,,,
1772,national-medical-products-administration-nmpa-approves-chipscreen-biosciences-chidamide-epidaza-for-breast-cancer-indication,02-12-2019 00:00,,,,,,
1773,fda-grants-priority-review-to-merck?s-supplemental-biologics-license-application-sbla-for-keytruda?-pembrolizumab-in-certain-patients-with-high-risk-non-muscle-invasive-bladder-cancer-nmibc,02-12-2019 00:00,,,,,,
1774,mylan-and-biocon-launch-trastuzumab-biosimilar-ogivri-trastuzumab-dkst-in-the-us,02-12-2019 00:00,,,,,,
1775,neurocrine-biosciences-and-xenon-pharmaceuticals-announce-agreement-to-develop-first-in-class-treatments-for-epilepsy,02-12-2019 00:00,,,,,,
1776,baxter-to-expand-advanced-surgery-portfolio-with-acquisition-of-seprafilm-adhesion-barrier,02-12-2019 00:00,,,,,,
1777,astellas-enters-into-definitive-agreement-to-acquire-audentes-therapeutics,03-12-2019 00:00,,,,,,
1778,stada-to-become-a-major-pharma-player-in-ukraine-by-acquiring-biopharma?s-pharmaceutical-prescription-and-consumer-health-business,03-12-2019 00:00,,,,,,
1779,astrazeneca-divests-rights-to-seroquel-and-seroquel-xr-in-the-us-and-canada,03-12-2019 00:00,,,,,,
1780,announcement-of-joint-development-agreement-of-aflibercept-biosimilars-with-kishi-kasei-co-ltd,03-12-2019 00:00,,,,,,
1781,seattle-genetics-and-astellas-announce-clinical-trial-collaboration-with-merck-to-evaluate-enfortumab-vedotin-in-combination-with-keytruda-pembrolizumab-in-patients-with-metastatic-urothelial-cancer,03-12-2019 00:00,,,,,,
1782,affidea-and-ge-healthcare-sign-a-100-million-technology-partnership-agreement-for-innovative-imaging-fleet-digital-workflow-solutions-and-contrast-media,03-12-2019 00:00,,,,,,
1783,kamada-enters-into-partnership-with-alvotech-for-commercialization-of-six-biosimilar-products-in-israel,03-12-2019 00:00,,,,,,
1784,stemonix-collaborates-with-atomwise-to-form-joint-venture-targeting-rett-syndrome,03-12-2019 00:00,,,,,,
1785,ethicon-launches-vistaseal-fibrin-sealant-human-to-manage-bleeding-during-surgery,04-12-2019 00:00,,,,,,
1786,lupin-to-launch-etanercept-and-pegfilgrastim-biosimilars-in-the-us,28-11-2019 00:00,,,,,,
1787,qilu-starts-phase-iii-trial-for-denosumab-copy-biological,22-11-2019 00:00,,,,,,
1788,merck-and-ping-an-good-doctor-form-strategic-collaboration-to-advance-intelligent-healthcare-in-china,04-12-2019 00:00,,,,,,
1789,approval-based-on-the-phase-iii-impower130-study-showing-the-tecentriq-plus-chemotherapy-combination-demonstrated-a-significant-overall-survival-and-progression-free-survival-benefit,04-12-2019 00:00,,,,,,
1790,johnson-johnson-vision-introduces-tecnis-toric-ii-1-piece-iol-as-new-monofocal-option-for-cataract-patients-with-astigmatism-launching-multi-center-post-market-clinical-trials-across-us,04-12-2019 00:00,,,,,,
1791,nanostring-announces-exclusive-license-of-ncounter-diagnostic-assets-and-rights-to-veracyte,04-12-2019 00:00,,,,,,
1792,eris-lifesciences-acquires-trademark-zomelis-from-novartis-ag-for-india-market,04-12-2019 00:00,,,,,,
1793,bristol-myers-squibb-announces-us-fda-breakthrough-therapy-designation-for-orencia-abatacept-to-help-prevent-acute-graft-versus-host-disease-a-potentially-life-threatening-complication-after-stem-cell-transplant,04-12-2019 00:00,,,,,,
1794,leo-pharma-and-portal-instruments-announce-collaboration-to-develop-needle-free-drug-delivery-device,04-12-2019 00:00,,,,,,
1795,lannett-announces-positive-results-from-human-clinical-trial-of-biosimilar-insulin-glargine-versus-us-lantus,04-12-2019 00:00,,,,,,
1796,aws-announces-strategic-collaboration-with-novartis-to-accelerate-digital-transformation-of-its-business-operations,05-12-2019 00:00,,,,,,
1797,novartis-expects-to-sustain-long-term-growth-with-a-robust-pipeline-of-25-potential-blockbusters-highlighted-at-rd-day,05-12-2019 00:00,,,,,,
1798,takeda-and-enzyre-to-develop-diagnostic-device-allowing-hemophilia-patients-to-determine-their-coagulation-status-at-home,05-12-2019 00:00,,,,,,
1799,lynparza-approved-in-china-as-a-1st-line-maintenance-therapy-in-brca-mutated-advanced-ovarian-cancer,05-12-2019 00:00,,,,,,
1800,philips-and-humana-team-up-to-improve-care-for-at-risk-medicare-advantage-members,05-12-2019 00:00,,,,,,
1801,bayer-enters-into-collaboration-with-childrens-hospital-of-philadelphia-to-research-novel-small-molecule-therapies-for-the-oral-treatment-of-hemophilia,05-12-2019 00:00,,,,,,
1802,gatehouse-bio-collaborates-with-astrazeneca-to-accelerate-new-drug-discovery,05-12-2019 00:00,,,,,,
1803,cerecor-to-acquire-aevi-genomic-medicine,06-12-2019 00:00,,,,,,
1804,fda-launches-app-for-health-care-professionals-to-report-novel-uses-of-existing-medicines-for-patients-with-difficult-to-treat-infectious-diseases,06-12-2019 00:00,,,,,,
1805,clinical-immunogenicity-considerations-for-biosimilar-2-and-interchangeable-insulin-products,25-11-2019 00:00,,,,,,
1806,novartis-phase-iii-data-on-new-inhaled-dual-combination-qmf149-show-significant-improvement-across-key-asthma-outcomes-versus-monotherapy,06-12-2019 00:00,,,,,,
1807,y-mabs-and-the-european-medicines-agency-pediatric-committee-reach-agreement-on-the-pediatric-investigation-plan-for-omburtamab,06-12-2019 00:00,,,,,,
1808,simulations-plus-partners-with-bayer-ag-to-develop-new-cheminformatics-capabilities-in-admet-predictor,06-12-2019 00:00,,,,,,
1809,bio-thera-solutions-announces-nmpa-approval-of-ind-application-to-initiate-phase-i-clinical-trial-for-bat2206-a-proposed-biosimilar-of-stelara-ustekinumab,06-12-2019 00:00,,,,,,
1810,sage-therapeutics-reports-topline-results-from-pivotal-phase-3-mountain-study-of-sage-217-in-major-depressive-disorder,06-12-2019 00:00,,,,,,
1811,sanofi-to-acquire-synthorx-to-bolster-its-immuno-oncology-pipeline-for-25-billion,09-12-2019 00:00,,,,,,
1812,janssen-to-acquire-investigational-bermekimab-from-xbiotech,09-12-2019 00:00,,,,,,
1813,results-from-a-survey-with-patients-with-immune-thrombocytopenia-itp-demonstrates-disease-burden-and-impact-for-patients-with-itp,09-12-2019 00:00,,,,,,
1814,"cambridge-uk-?-9-december-2019-?-healx-the-ai-powered-biotechnology-company-focused-on-developing-breakthrough-treatments-for-rare-diseases-today-announces-it-has-entered-into-an-agreement-with-boehringer-ingelheim-to-identify-indications-related-to-rare-neurological-diseases
-the-project-will-leverage-healx?s-comprehensive-ai-based-drug-discovery-platform-healnet-and-expertise-in-rare-diseases-and-pharmacology-to-identify-potential-new-indications-for-assets-from-boehringer-ingelheim?s-pipeline
-healx-will-use-their-data-analysis-and-technological-capabilities-to-assist-boehringer-ingelheim?s-efforts-in-prioritising-selected-indications-for-further-research-their-ai-platform-which-draws-upon-the-most-comprehensive-knowledge-graph-of-rare-disease-data-to-intelligently-predict-and-match-treatments-to-rare-diseases-will-play-a-key-part-in-the-collaborative-effort
-in-addition-healx-has-significant-experience-in-the-area-of-rare-neurological-disorders-such-as-fragile-x-syndrome-as-well-as-pitt-hopkins-syndrome-healx?s-ai-based-drug-discovery-platform-healnet-has-proven-success-in-that-it-identified-eight-repurposing-drug-candidates-with-potential-benefits-for-fragile-x-syndrome-which-were-not-considered-for-the-condition-prior-to-healx?s-involvement-as-a-result-several-candidates-have-demonstrated-efficacy-in-vivo-and-one-candidate-is-now-progressing-toward-a-phase-2a-trial
-in-another-project-carried-out-in-collaboration-with-the-pitt-hopkins-research-foundation-healnet-was-successfully-used-to-investigate-predict-and-progress-novel-treatment-options-for-the-ultra-rare-neurodevelopmental-disorder-pitt-hopkins-syndrome
-dr-tim-guilliams-founder-and-ceo-of-healx-commented-?healx-is-dedicated-to-transforming-the-lives-of-rare-disease-patients-by-intelligently-matching-and-developing-potential-drug-treatments-to-their-conditions-we-believe-that-sophisticated-technologies-such-as-ai-and-machine-learning-methods-will-be-fundamental-to-any-drug-discovery-and-development-project-in-the-future
-the-project-with-boehringer-ingelheim-presents-an-opportunity-for-further-innovation-in-identifying-rare-disease-candidates-for-patients-whose-medical-needs-are-not-currently-met-harnessing-bi?s-expertise-for-drug-development-especially-in-rare-neurological-conditions-in-combination-with-our-ai-powered-drug-discovery-platform-will-enable-faster-identification-of-potential-new-treatments?
-
-
-more-than-7-000-rare-diseases-have-been-identified-to-date-diseases-affecting-fewer-than-1-in-2-000-people-with-250-new-rare-diseases-classified-annually-collectively-this-impacts-over-400-million-individuals-worldwide-with-less-than-5-of-these-rare-diseases-having-approved-treatments-there-is-therefore-a-substantial-unmet-medical-need1
-healx?s-mission-is-to-use-its-ai-platform-deep-pharmacological-expertise-and-extensive-patient-engagement-to-improve-the-quality-of-life-and-care-for-patients-with-rare-diseases-its-business-model-is-to-develop-its-own-pipeline-of-proprietary-drug-candidates-as-well-as-to-work-in-partnership-with-a-range-of-organisations-to-explore-novel-pharmacological-routes-and-indication-expansion-opportunities
-the-project-with-boehringer-ingelheim-adds-to-healx?s-portfolio-of-agreements-and-collaborations-with-pharmaceutical-and-biotechnology-companies-academia-clinical-institutes-and-rare-disease-charities-since-its-foundation-in-2014
-references
-1-rare-neurological-disease-special-report-neurology-reviews-march-2019
-please-click-here-to-download-the-full-press-release",09-12-2019 00:00,,,,,,
1815,fda-approves-amgens-avsola-infliximab-axxq-for-the-same-indications-as-remicade-infliximab,09-12-2019 00:00,,,,,,
1816,calquence-significantly-prolonged-the-time-patients-lived-without-disease-progression-or-death-in-previously-untreated-chronic-lymphocytic-leukaemia,09-12-2019 00:00,,,,,,
1817,merck-to-acquire-arqule-advancing-leadership-in-oncology,09-12-2019 00:00,,,,,,
1818,deepmatter-announces-collaboration-with-astrazeneca-focused-on-improving-productivity-of-compound-synthesis-using-digital-technologies-enabled-with-machine-learning-and-artificial-intelligence,10-12-2019 00:00,,,,,,
1819,roche-receives-ce-mark-for-its-accu-chek-sugarview-app,10-12-2019 00:00,,,,,,
1820,abbvie-and-scripps-research-announce-collaboration-to-develop-a-broad-range-of-new-therapeutics,10-12-2019 00:00,,,,,,
1821,seven-and-eight-biopharmaceuticals-inc-announces-clinical-collaboration-to-evaluate-bdb001-in-combination-with-keytruda-pembrolizumab-in-patients-with-advanced-solid-tumors,10-12-2019 00:00,,,,,,
1822,adaptive-and-abbvie-partner-across-multiple-myeloma-trials-to-measure-minimal-residual-disease-using-the-clonoseq-assay,10-12-2019 00:00,,,,,,
1823,engitix-and-morphic-enter-research-collaboration-to-identify-ecm-related-targets-in-fibrostenotic-inflammatory-bowel-disease-ibd,10-12-2019 00:00,,,,,,
1824,sanofi-ceo-unveils-new-strategy-to-drive-innovation-and-growth,10-12-2019 00:00,,,,,,
1825,regeneron-and-sanofi-announce-intent-to-restructure-antibody-collaboration-for-kevzara-sarilumab-and-praluent-alirocumab,11-12-2019 00:00,,,,,,
1826,fda-accepts-supplemental-biologics-license-application-for-xolair-omalizumab-for-the-treatment-of-nasal-polyps,11-12-2019 00:00,,,,,,
1827,affamed-therapeutics-receives-nmpa-approval-to-initiate-phase-iii-clinical-trial-in-china-with-herceptin-trastuzumab-biosimilar-candidate-amt901,11-12-2019 00:00,,,,,,
1828,vertex-announces-european-commission-approval-for-kalydeco-ivacaftor-in-infants-with-cystic-fibrosis-ages-6-months-to-less-than-12-months-with-certain-mutations-in-the-cftr-gene,11-12-2019 00:00,,,,,,
1829,amgen-data-from-phase-3-candor-study-combining-kyprolis-carfilzomib-and-darzalex-daratumumab-to-be-presented-during-late-breaking-session-at-american-society-of-hematology-annual-meeting,11-12-2019 00:00,,,,,,
1830,dermira-receives-fast-track-designation-from-fda-for-lebrikizumab-for-the-treatment-of-atopic-dermatitis,,,,,,,
1831,kite-and-kiniksa-pharmaceuticals-announce-clinical-collaboration-evaluating-investigational-combination-of-yescarta-and-mavrilimumab-in-relapsed-or-refractory-large-b-cell-lymphoma,12-12-2019 00:00,,,,,,
1832,kite-submits-biologics-license-application-to-us-food-and-drug-administration-for-company?s-second-car-t-cell-therapy,12-12-2019 00:00,,,,,,
1833,karolinska-development?s-portfolio-company-forendo-pharma-enters-license-and-collaboration-agreement-with-leading-pharma-company,12-12-2019 00:00,,,,,,
1834,iktos-and-almirall-announce-research-collaboration-in-artificial-intelligence-for-new-drug-design,12-12-2019 00:00,,,,,,
1835,roche?s-fixed-dose-subcutaneous-combination-of-perjeta-and-herceptin-comparable-to-intravenous-formulations-in-people-with-her2-positive-breast-cancer,12-12-2019 00:00,,,,,,
1836,european-commission-approves-evenity-romosozumab-for-the-treatment-of-severe-osteoporosis-in-postmenopausal-women-at-high-risk-of-fracture,12-12-2019 00:00,,,,,,
1837,astrazeneca-and-daiichi-sankyo?s-trastuzumab-deruxtecan-demonstrated-an-impressive-148-month-median-duration-of-response-and-164-month-median-progression-free-survival,12-12-2019 00:00,,,,,,
1838,imfinzi-approved-in-china-for-the-treatment-of-unresectable-stage-iii-non-small-cell-lung-cancer-based-on-the-phase-iii-pacific-trial,12-12-2019 00:00,,,,,,
1839,assertio-therapeutics-announces-sale-of-gralise-for-total-transaction-value-of-1275-million,12-12-2019 00:00,,,,,,
1840,iteos-therapeutics-announces-collaboration-with-merck-investigating-the-combination-of-its-a2a-antagonist-with-keytruda,13-12-2019 00:00,,,,,,
1841,fda-authorizes-first-test-to-aid-in-newborn-screening-for-duchenne-muscular-dystrophy,13-12-2019 00:00,,,,,,
1842,roche-announces-positive-phase-iii-study-results-for-tecentriq-plus-cotellic-and-zelboraf-in-people-with-previously-untreated-braf-v600-mutation-positive-advanced-melanoma,13-12-2019 00:00,,,,,,
1843,biocon-equillium-expand-exclusive-licensing-agreement-for-itolizumab-to-include-australia-and-new-zealand,13-12-2019 00:00,,,,,,
1844,fda-approves-xeljanz-xr-tofacitinib-extended-release-tablets-for-the-treatment-of-ulcerative-colitis,13-12-2019 00:00,,,,,,
1845,fda-approves-xcopri?-cenobamate-tablets-an-anti-epileptic-drug-aed-from-sk-biopharmaceuticals-co-ltd-and-us-subsidiary-sk-life-science-inc,21-11-2019 00:00,,,,,,
1846,fda-approves-oxbryta-voxelotor-the-first-medicine-specifically-targeting-the-root-cause-of-sickle-cell-disease,25-11-2019 00:00,,,,,,
1847,redhill-biopharma-announces-fda-approval-of-talicia-for-treatment-of-h-pylori-in-adults,04-11-2019 00:00,,,,,,
1848,viiv-healthcare-files-submissions-to-the-fda-and-ema-for-the-first-ever-dispersible-formulation-of-dolutegravir-dtg-for-children-living-with-hiv,13-12-2019 00:00,,,,,,
1849,absorica-ld-isotretinoin-?-new-formulation-approval,05-11-2019 00:00,,,,,,
1850,aquestive-therapeutics-receives-fda-approval-for-exservan-riluzole-oral-film,13-11-2019 00:00,,,,,,
1851,cumberland-pharmaceuticals-receives-fda-approval-for-reditrex-product-line,13-12-2019 00:00,,,,,,
1852,chmp-issues-positive-opinion-recommending-darzalex-daratumumab-in-combination-with-bortezomib-thalidomide-and-dexamethasone-in-frontline-multiple-myeloma,13-12-2019 00:00,,,,,,
1853,amsparity,13-12-2019 00:00,,,,,,
1854,roche-launches-cobas-zika-blood-screening-test-to-markets-accepting-the-ce-mark,16-12-2019 00:00,,,,,,
1855,fda-authorizes-first-interoperable-automated-insulin-dosing-controller-designed-to-allow-more-choices-for-patients-looking-to-customize-their-individual-diabetes-management-device-system,16-12-2019 00:00,,,,,,
1856,novartis-provides-update-on-luster-phase-iii-studies-in-patients-with-uncontrolled-gina-45-asthma,16-12-2019 00:00,,,,,,
1857,boehringer-ingelheim-and-lilly-provide-update-on-jardiance-phase-iii-exercise-ability-studies-in-chronic-heart-failure,16-12-2019 00:00,,,,,,
1858,sanbio-and-sumitomo-dainippon-pharma-announce-a-termination-of-a-joint-development-and-license-agreement-for-regenerative-cell-medicine-sb623-for-chronic-stroke-in-north-america,16-12-2019 00:00,,,,,,
1859,lilly-to-integrate-dexcom-cgm-into-personalized-diabetes-management-system,16-12-2019 00:00,,,,,,
1860,charles-river-laboratories-to-acquire-hemacare-corporation,16-12-2019 00:00,,,,,,
1861,medtronic-and-christianacare-collaborate-to-improve-patient-outcomes-and-reduce-cost-of-care-in-delaware,17-12-2019 00:00,,,,,,
1862,alexion-exercises-option-for-two-additional-galxc-rnai-programs-for-complement-mediated-targets-under-collaboration-with-dicerna,17-12-2019 00:00,,,,,,
1863,eagle-pharmaceuticals-granted-orphan-drug-designation-for-ryanodex-dantrolene-sodium-for-treatment-of-organophosphate-exposure-nerve-agents,17-12-2019 00:00,,,,,,
1864,beigene-announces-results-of-phase-3-aspen-trial-of-zanubrutinib-compared-to-ibrutinib-for-the-treatment-of-patients-with-waldenstr?m?s-macroglobulinemia,17-12-2019 00:00,,,,,,
1865,health-canada-approves-new-indication-for-erleada-apalutamide-for-the-treatment-of-metastatic-castration-sensitive-prostate-cancer-mcspc,17-12-2019 00:00,,,,,,
1866,sangamo-highlights-advancements-in-genomic-medicine-pipeline-and-expanded-rd-and-manufacturing-capabilities-at-rd-day,17-12-2019 00:00,,,,,,
1867,sangamo-highlights-advancements-in-genomic-medicine-pipeline-and-expanded-rd-and-manufacturing-capabilities-at-rd-day,17-12-2019 00:00,,,,,,
1868,medtronic-acquires-klue,18-12-2019 00:00,,,,,,
1869,fda-oncologic-drugs-advisory-committee-odac-recommends-keytruda-pembrolizumab-for-the-treatment-of-certain-patients-with-high-risk-non-muscle-invasive-bladder-cancer-nmibc,18-12-2019 00:00,,,,,,
1870,cerevance-enters-research-collaboration-with-takeda-to-advance-new-treatments-for-gastrointestinal-disorders,18-12-2019 00:00,,,,,,
1871,bioinvent-has-entered-into-a-clinical-trial-collaboration-and-supply-agreement-to-evaluate-bi-1206-in-combination-with-keytruda-in-advanced-solid-tumors,18-12-2019 00:00,,,,,,
1872,lynparza-recommended-by-fda-advisory-committee-for-1st-line-maintenance-treatment-of-germline-brca-mutated-metastatic-pancreatic-cancer,18-12-2019 00:00,,,,,,
1873,bioarctic-announces-research-collaboration-with-eisai-regarding-ban2401,18-12-2019 00:00,,,,,,
1874,zafgen-and-chondrial-therapeutics-announce-definitive-merger-agreement,18-12-2019 00:00,,,,,,
1875,arcus-biosciences-in-collaboration-with-genentech-announces-two-randomized-clinical-studies-to-advance-ab928-a-dual-adenosine-receptor-antagonist-into-novel-combinations-for-colorectal-and-pancreatic-cancers,19-12-2019 00:00,,,,,,
1876,gsk-announces-positive-headline-results-in-phase-3-study-of-benlysta-in-patients-with-lupus-nephritis,19-12-2019 00:00,,,,,,
1877,onconova-therapeutics-announces-exclusive-license-agreement-with-specialised-therapeutics-for-rigosertib-in-australia-and-new-zealand,19-12-2019 00:00,,,,,,
1878,abbvie-receives-european-commission-approval-of-rinvoq?-upadacitinib-for-the-treatment-of-adults-with-moderate-to-severe-active-rheumatoid-arthritis,19-12-2019 00:00,,,,,,
1879,akcea-retains-rights-to-akcea-apociii-lrx,19-12-2019 00:00,,,,,,
1880,ionis-licenses-investigational-alzheimers-therapy,19-12-2019 00:00,,,,,,
1881,exelixis-enters-into-a-clinical-collaboration-for-three-phase-3-combination-trials-for-patients-with-advanced-solid-tumors,19-12-2019 00:00,,,,,,
1882,genmab-and-curevac-enter-strategic-partnership-to-develop-mrna-based-antibody-therapeutics,20-12-2019 00:00,,,,,,
1883,amgen-and-allergan-submit-biologics-license-application-for-abp-798-biosimilar-candidate-to-rituxan?-rituximab-to-us-food-and-drug-administration,20-12-2019 00:00,,,,,,
1884,smiths-medical-asd-inc-recalls-medfusion?-4000-syringe-pumps-due-to-malfunctioning-alarms-and-potential-interruption-of-therapy,20-12-2019 00:00,,,,,,
1885,first-fda-approved-vaccine-for-the-prevention-of-ebola-virus-disease-marking-a-critical-milestone-in-public-health-preparedness-and-response,20-12-2019 00:00,,,,,,
1886,gilead-submits-filgotinib-new-drug-application-to-us-food-and-drug-administration-under-priority-review-for-rheumatoid-arthritis-treatment,20-12-2019 00:00,,,,,,
1887,university-of-virginia-center-for-diabetes-technology-and-novo-nordisk-enter-into-research-collaboration-to-develop-virtual-patient-modelling-for-type-2-diabetes,20-12-2019 00:00,,,,,,
1888,astrazeneca-divests-rights-to-arimidex-and-casodex-in-europe-and-certain-additional-countries,20-12-2019 00:00,,,,,,
1889,rheos-medicines-announces-worldwide-collaboration-with-roche-to-discover-and-develop-novel-medicines-in-the-field-of-immunometabolism,23-12-2019 00:00,,,,,,
1890,sarepta-therapeutics-announces-partnership-with-roche-in-territories-outside-the-united-states-for-its-investigational-micro-dystrophin-gene-therapy-for-duchenne-muscular-dystrophy-srp-9001,23-12-2019 00:00,,,,,,
1891,bristol-myers-squibb-receives-european-commission-approval-for-revlimid?-lenalidomide-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-previously-treated-follicular-lymphoma,23-12-2019 00:00,,,,,,
1892,johnson-johnson-acquires-taris-biomedical-with-focus-on-transforming-the-treatment-of-bladder-cancer,23-12-2019 00:00,,,,,,
1893,china-national-medical-products-administration-approves-vosevi?-sofosbuvir-velpatasvir-and-voxilaprevir-for-people-with-chronic-hepatitis-c-infection-who-require-re-treatment,23-12-2019 00:00,,,,,,
1894,theravance-biopharma-and-pfizer-inc-enter-global-license-agreement-for-skin-targeted-locally-acting-pan-janus-kinase-jak-inhibitor-program,26-12-2019 00:00,,,,,,
1895,gilead-and-eisai-enter-into-agreement-in-japan-for-the-co-promotion-of-the-investigational-rheumatoid-arthritis-therapy-filgotinib-pending-regulatory-approval,26-12-2019 00:00,,,,,,
1896,allergan-receives-us-fda-approval-for-ubrelvy-for-the-acute-treatment-of-migraine-with-or-without-aura-in-adults,26-12-2019 00:00,,,,,,
1897,astrazeneca?s-triple-combination-therapy-approved-in-china-for-patients-with-copd,26-12-2019 00:00,,,,,,
1898,bioinvent-announces-selection-of-second-target-and-extension-of-the-research-collaboration-and-license-agreement-with-pfizer-inc,26-12-2019 00:00,,,,,,
1899,enhertu-trastuzumab-deruxtecan-approved-in-the-us-for-her2-positive-unresectable-or-metastatic-breast-cancer-following-two-or-more-prior-anti-her2-based-regimens,26-12-2019 00:00,,,,,,
1900,obi-pharma-granted-fda-orphan-drug-designation-for-the-treatment-of-pancreatic-cancer-for-its-antibody-drug-conjugate-adc-targeted-cancer-therapy-obi-999,26-12-2019 00:00,,,,,,
1901,astellas-strengthens-immuno-oncology-pipeline-with-acquisition-of-xyphos-biosciences-inc,27-12-2019 00:00,,,,,,
1902,kadmon-and-meiji-announce-collaboration-to-develop-and-commercialize-kd025-in-japan,27-12-2019 00:00,,,,,,
1903,ono-and-bmskk-submit-supplemental-application-for-approval-of-opdivo-and-yervoy-combination-therapy-to-expand-the-use-for-first-line-treatment-of-unresectable-advanced-or-recurrent-non-small-cell-lung-cancer-in-japan,27-12-2019 00:00,,,,,,
1904,chugai-obtains-approval-for-expanded-use-of-foundationone-cdx-cancer-genomic-profile-as-a-companion-diagnostic-of-rozlytrek-for-ros1-positive-lung-cancer,27-12-2019 00:00,,,,,,
1905,immunomedics-announces-fda-acceptance-for-filing-of-biologics-license-application-resubmission-for-sacituzumab-govitecan-to-treat-metastatic-triple-negative-breast-cancer,27-12-2019 00:00,,,,,,
1906,luye-pharma-submits-new-drug-application-in-the-us-for-its-antidepressant-drug-ly03005,27-12-2019 00:00,,,,,,
1907,pharming-reacquires-ruconest-licensed-territories-from-sobi,30-12-2019 00:00,,,,,,
1908,pivotal-phase-3-study-of-dayvigo-lemborexant-for-the-treatment-of-insomnia-disorder-published-in-jama-network-open,30-12-2019 00:00,,,,,,
1909,zai-lab-announces-nmpa-approval-of-zejula?-niraparib-in-china-as-maintenance-therapy-for-patients-with-recurrent-ovarian-cancer,30-12-2019 00:00,,,,,,
1910,lynparza-approved-in-the-us-as-a-1st-line-maintenance-treatment-of-germline-brca-mutated-metastatic-pancreatic-cancer,30-12-2019 00:00,,,,,,
1911,lilly-opens-phase-3-clinical-trial-in-ret-mutant-medullary-thyroid-cancer,30-12-2019 00:00,,,,,,
1912,china-national-medical-products-administration-approves-beigene?s-tislelizumab-for-patients-with-classical-hodgkin?s-lymphoma-who-have-received-at-least-two-prior-therapies,31-12-2019 00:00,,,,,,
1913,acceleron-and-fulcrum-therapeutics-announce-pulmonary-research-and-discovery-collaboration-agreement,31-12-2019 00:00,,,,,,
1914,genscript-and-selecxine-enter-into-strategic-cooperation-agreement,31-12-2019 00:00,,,,,,
1915,clover-biopharmaceuticals-initiates-phase-iii-study-of-etanercept-biosimilar-candidate-scb-808-in-china,31-12-2019 00:00,,,,,,
1916,morphosys-announces-submission-of-biologics-license-application-for-tafasitamab-in-rr-dlbcl-to-the-fda,31-12-2019 00:00,,,,,,
1917,axsome-therapeutics-announces-axs-07-achieves-co-primary-and-key-secondary-endpoints-in-momentum-phase-3-migraine-trial-in-patients-with-history-of-inadequate-response,02-01-2020 00:00,,,,,,
1918,regulation-fd-disclosure,02-01-2020 00:00,,,,,,
1919,sensyne-health-enters-into-a-research-collaboration-to-apply-ai-for-clinical-trial-design,02-01-2020 00:00,,,,,,
1920,sol-gel-announces-positive-top-line-phase-3-trial-results-of-twyneo-for-the-treatment-of-acne-vulgaris,02-01-2020 00:00,,,,,,
1921,amgen-commences-strategic-collaboration-with-beigene-to-expand-oncology-presence-in-chin,03-01-2020 00:00,,,,,,
1922,pulmatrix-announces-kinase-inhibitor-licensing-agreement-with-lung-cancer-initiative-at-johnson-johnson,03-01-2020 00:00,,,,,,
1923,arena-pharmaceuticals-and-beacon-discovery-expand-strategic-relationship-focusing-on-multiple-immune-and-inflammatory-targets,03-01-2020 00:00,,,,,,
1924,incyte-reports-results-of-itacitinib-in-gravitas-301-p-iii-study-for-patients-with-treatment-naive-acute-graft-versus-host-disease,03-01-2020 00:00,,,,,,
1925,the-european-medicines-agency-accepts-the-regulatory-submission-for-lumoxiti-in-relapsed-or-refractory-hairy-cell-leukemia,03-01-2020 00:00,,,,,,
1926,redhill-biopharma-regains-rights-to-its-proprietary-bowel-preparation-rhb-106,03-01-2020 00:00,,,,,,
1927,leap-therapeutics-and-beigene-announce-exclusive-option-and-license-agreement-for-dkn-01-and-leap-announces-27-million-equity-financing,06-01-2020 00:00,,,,,,
1928,farxiga-granted-fda-priority-review-for-patients-with-heart-failure-with-reduced-ejection-fraction,06-01-2020 00:00,,,,,,
1929,kyowa-kirin-announces-marketing-authorisation-application-for-istradefylline-validated-by-european-medicines-agency,06-01-2020 00:00,,,,,,
1930,lokelma-approved-in-china-for-the-treatment-of-adult-patients-with-hyperkalaemia,06-01-2020 00:00,,,,,,
1931,i-mab-biopharma-announces-dosing-of-first-patient-in-a-pivotal-study-of-tj202mor202-in-multiple-myeloma-in-mainland-china,06-01-2020 00:00,,,,,,
1932,merck-establishes-strategic-oncology-collaboration-with-taiho-and-astex,06-01-2020 00:00,,,,,,
1933,inxmed-announces-clinical-collaboration-with-msd-to-evaluate-in10018-in-combination-with-pembrolizumab,07-01-2020 00:00,,,,,,
1934,sorrento-announces-filing-for-approval-of-infliximab-biobetter-antibody-by-its-partner-mabpharm-in-china,07-01-2020 00:00,,,,,,
1935,merck?s-keytruda-pembrolizumab-in-combination-with-chemotherapy-significantly-improved-progression-free-survival-compared-to-chemotherapy-alone-as-first-line-treatment-for-extensive-stage-small-cell-lung-cancer,07-01-2020 00:00,,,,,,
1936,mundipharma-announces-exclusive-deal-for-biosolutions-cartilifer-in-south-korea,07-01-2020 00:00,,,,,,
1937,bavencio-significantly-improved-overall-survival-in-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma,07-01-2020 00:00,,,,,,
1938,mithra-signs-lsa-with-alvogen-for-commercialization-of-estelle?-in-hong-kong-and-taiwan,07-01-2020 00:00,,,,,,
1939,evotec-and-bristol-myers-squibb-expand-ipsc-collaboration,07-01-2020 00:00,,,,,,
1940,bicycle-therapeutics-and-cancer-research-uk-to-collaborate-on-development-of-new-bicycle-immuno-oncology-candidate-bt7401,08-01-2020 00:00,,,,,,
1941,mina-therapeutics-announces-research-collaboration-with-astrazeneca-in-metabolic-diseases,08-01-2020 00:00,,,,,,
1942,tyme-technologies-and-eagle-pharmaceuticals-announce-strategic-collaboration-to-advance-innovative-oral-sm-88-for-the-treatment-of-patients-with-cancer,08-01-2020 00:00,,,,,,
1943,innovent-and-sirnaomics-entered-strategic-collaboration-to-conduct-clinical-oncology-studies-combining-sintilimab-and-rnai-in-the-us,08-01-2020 00:00,,,,,,
1944,fda-approves-less-invasive-surgical-approach-for-abbotts-heart-pump-to-help-patients-avoid-open-heart-surgery,08-01-2020 00:00,,,,,,
1945,phoremost-and-boehringer-ingelheim-enter-multi-project-drug-discovery-collaboration,08-01-2020 00:00,,,,,,
1946,xencor-and-gilead-enter-license-agreement-for-use-of-xmab?-antibody-technologies-in-investigational-agents-for-hiv,08-01-2020 00:00,,,,,,
1947,veracyte-announces-biopharmaceutical-collaboration-with-acerta-pharma,09-01-2020 00:00,,,,,,
1948,fda-approves-merck?s-keytruda?-pembrolizumab-for-patients-with-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer-with-carcinoma-in-situ-with-or-without-papillary-tumors-who-are-ineligible-for-or-have-elected-not-to-undergo-cystectomy,09-01-2020 00:00,,,,,,
1949,almirall-signs-a-strategic-agreement-with-23andme-to-license-rights-of-a-bispecific-monoclonal-antibody-that-blocks-all-three-isoforms-of-il-36-cytokine,09-01-2020 00:00,,,,,,
1950,mylan-initiates-voluntary-nationwide-recall-of-three-lots-of-nizatidine-capsules-usp-due-to-the-detection-of-trace-amounts-of-ndma-n-nitrosodimethylamine-impurity-found-in-the-active-pharmaceutical-ingredient-manufactured-by-solara-active-pharma-sciences-limited,09-01-2020 00:00,,,,,,
1951,bayer-and-evotec-form-new-strategic-alliance-focusing-on-polycystic-ovary-syndrome,09-01-2020 00:00,,,,,,
1952,biomed-x-starts-new-research-program-in-autoimmune-diseases-with-merck,09-01-2020 00:00,,,,,,
1953,gilead-sciences-licenses-portfolio-of-hiv-antibodies-from-the-rockefeller-university,10-01-2020 00:00,,,,,,
1954,kaleido-biosciences-announces-collaboration-with-janssen-to-explore-the-potential-for-microbiome-metabolic-therapies-mmt?-to-prevent-childhood-onset-of-atopic-immune-and-metabolic-conditions-by-promoting-healthy-function-of-the-gut-microbiome,10-01-2020 00:00,,,,,,
1955,effector-enters-into-agreement-with-pfizer-inc-to-develop-novel-first-in-class-inhibitors-of-eif4e-to-treat-multiple-cancer-types,10-01-2020 00:00,,,,,,
1956,immunic-exercises-its-option-for-the-exclusive-worldwide-license-to-imu-856-from-daiichi-sankyo-co-ltd,10-01-2020 00:00,,,,,,
1957,bayer-and-exscientia-collaborate-to-leverage-the-potential-of-artificial-intelligence-in-cardiovascular-and-oncology-drug-discovery,10-01-2020 00:00,,,,,,
1958,lilly-announces-agreement-to-acquire-dermira,10-01-2020 00:00,,,,,,
1959,nektar-therapeutics-and-bristol-myers-squibb-amend-strategic-collaboration-agreement-for-bempegaldesleukin-plus-opdivo-nivolumab,10-01-2020 00:00,,,,,,
1960,iovance-biotherapeutics-obtains-license-to-develop-and-commercialize-a-novel-il-2-analog,13-01-2020 00:00,,,,,,
1961,lynparza-regulatory-submission-granted-priority-review-in-the-us-for-1st-line-maintenance-treatment-with-bevacizumab-in-advanced-ovarian-cancer,13-01-2020 00:00,,,,,,
1962,morphosys-and-incyte-sign-global-collaboration-and-license-agreement-for-tafasitamab,13-01-2020 00:00,,,,,,
1963,amunix-pharmaceuticals-announces-technology-licensing-agreement-with-roche-to-advance-novel-therapeutics-outside-oncology,13-01-2020 00:00,,,,,,
1964,mundipharma-enters-partnership-with-samsung-bioepis-to-expand-biosimilars-into-hong-kong-and-taiwan,13-01-2020 00:00,,,,,,
1965,biogen-to-acquire-novel-clinical-stage-asset-with-application-in-alzheimer?s-disease-and-parkinson?s-disease-from-pfizer-inc,13-01-2020 00:00,,,,,,
1966,eusa-pharma-and-beigene-announce-exclusive-development-and-commercialization-agreement-for-sylvant-and-qarziba-in-greater-china,13-01-2020 00:00,,,,,,
1967,coherus-acquires-commercial-rights-for-avastin-biosimilar-in-the-united-states,14-01-2020 00:00,,,,,,
1968,just-?-evotec-biologics-enters-into-multi-year-collaboration-with-msd-around-facility-of-the-future,14-01-2020 00:00,,,,,,
1969,roche-and-illumina-partner-to-broaden-patient-access-to-genomic-testing,14-01-2020 00:00,,,,,,
1970,astellas-and-adaptimmune-enter-into-agreement-to-co-develop-and-co-commercialize-stem-cell-derived-allogeneic-car-t-and-tcr-t-cell-therapies,14-01-2020 00:00,,,,,,
1971,amgen-announces-global-diagnostic-collaborations-to-expand-molecular-testing-for-patients-with-non-small-cell-lung-cancer,14-01-2020 00:00,,,,,,
1972,axsome-therapeutics-enters-into-exclusive-license-agreement-with-pfizer-inc-for-pfizer?s-reboxetine-clinical-and-nonclinical-data-and-for-new-phase-3-esreboxetine-product-candidate,14-01-2020 00:00,,,,,,
1973,bayer-and-dar?-bioscience-enter-into-an-exclusive-license-agreement-for-us-commercial-rights-to-investigational-hormone-free-monthly-contraceptive-ovaprene,14-01-2020 00:00,,,,,,
1974,charles-river-and-takeda-announce-scientific-collaboration-to-identify-and-develop-preclinical-candidates,14-01-2020 00:00,,,,,,
1975,genome-company-announces-a-clinical-trial-collaboration-and-supply-agreement-with-merck-kgaa-darmstadt-germany-and-pfizer,15-01-2020 00:00,,,,,,
1976,health-canada-approves-astellas-xospata-gilteritinib-for-patients-with-relapsed-or-refractory-acute-myeloid-leukemia-with-a-flt3-mutation,15-01-2020 00:00,,,,,,
1977,dovato-dolutegravirlamivudine-the-once-daily-single-pill-2-drug-regimen-for-the-treatment-of-hiv-1-infection-granted-marketing-approval-by-japan-ministry-of-health-labour-and-welfare,15-01-2020 00:00,,,,,,
1978,insilico-enters-into-research-collaboration-with-pfizer-inc-to-explore-novel-data-and-artificial-intelligence-system-for-potential-therapeutic-targets,15-01-2020 00:00,,,,,,
1979,jamp-pharma-group-signs-a-landmark-partnership-agreement-for-the-commercialization-of-five-biosimilar-medicines-in-canada,15-01-2020 00:00,,,,,,
1980,alexion-announces-planned-initiation-of-pivotal-phase-3-study-of-ultomiris-ravulizumab-in-als,15-01-2020 00:00,,,,,,
1981,hitgen-enters-into-dna-encoded-library-based-drug-discovery-research-collaboration-with-kymera,15-01-2020 00:00,,,,,,
1982,biolinerx-receives-orphan-drug-designation-for-motixafortide-bl-8040-for-the-treatment-of-pancreatic-cancer-in-europe,15-01-2020 00:00,,,,,,
1983,fibrocor-and-galapagos-sign-expanded-collaboration-in-fibrosis,16-01-2020 00:00,,,,,,
1984,dermavant-enters-into-exclusive-license-agreement-with-jt-for-development-and-commercialization-of-tapinarof-in-japan,16-01-2020 00:00,,,,,,
1985,livongo-and-dexcom-partner-to-integrate-dexcom?s-g6-continuous-glucose-monitoring-system-into-livongo?s-applied-health-signals-platform,16-01-2020 00:00,,,,,,
1986,bayer-and-wuxi-biologics-enter-into-an-agreement-on-a-leverkusen-drug-product-plant,16-01-2020 00:00,,,,,,
1987,cimzia-certolizumab-pegol-now-approved-in-canada-for-the-treatment-of-non-radiographic-axial-spondyloarthritis,16-01-2020 00:00,,,,,,
1988,us-food-and-drug-administration-accepts-for-priority-review-bristol-myers-squibb?s-application-for-opdivo-nivolumab-plus-yervoy-ipilimumab-in-first-line-non-small-cell-lung-cancer,16-01-2020 00:00,,,,,,
1989,sun-pharma-and-rockwell-medical-enter-into-licensing-agreement-for-triferic-in-india,16-01-2020 00:00,,,,,,
1990,meiji-seika-pharma-and-dong-a-socio-holdings-initiate-phase-i-clinical-trial-of-dmb-3115-a-ustekinumab-biosimilar-candidate,16-12-2019 00:00,,,,,,
1991,biosimilar-bi-695501-comparable-to-reference-product-in-crohn-disease,17-12-2019 00:00,,,,,,
1992,biontech-to-acquire-neon-to-strengthen-global-leadership-position-in-t-cell-therapies,17-01-2020 00:00,,,,,,
1993,celltrion-unveils-long-term-p3-trial-results-for-truxima-in-us,12-12-2019 00:00,,,,,,
1994,clover-initiates-phase-iii-study-of-etanercept-biosimilar-candidate-scb-808-in-china,30-12-2019 00:00,,,,,,
1995,clover-initiates-phase-iii-study-of-etanercept-biosimilar-candidate-scb-808-in-china,30-12-2019 00:00,,,,,,
1996,who-prequalifies-samsung-bioepis-biosimilar-trastuzumab,20-12-2019 00:00,,,,,,
1997,fda-approves-ozempic-for-cardiovascular-risk-reduction-in-adults-with-type-2-diabetes-and-known-heart-disease-updates-rybelsus-label,17-01-2020 00:00,,,,,,
1998,just-?-evotec-biologics-announces-product-development-and-manufacturing-agreement-with-oncoresponse,17-01-2020 00:00,,,,,,
1999,a-new-standard-for-wound-care-introducing-our-digital-wound-management-solution,17-01-2020 00:00,,,,,,
2000,genomics-form-a-strategic-alliance-to-provide-bioinformatics-driven-drug-discovery-and-safety-assessment,17-01-2020 00:00,,,,,,
2001,fda-grants-fast-track-designation-to-arena-pharmaceuticals-apd418-for-development-in-decompensated-heart-failure-patients,17-01-2020 00:00,,,,,,
2002,lynparza-regulatory-submission-granted-priority-review-in-the-us-for-hrr-mutated-metastatic-castration-resistant-prostate-cancer,20-01-2020 00:00,,,,,,
2003,imfinzi-and-tremelimumab-granted-orphan-drug-designation-in-the-us-for-liver-cancer,20-01-2020 00:00,,,,,,
2004,cyclica-and-aum-biosciences-to-partner-on-developing-novel-cancer-therapies-with-greater-precision-and-speed-under-project-nexus,20-01-2020 00:00,,,,,,
2005,zydus-and-china-medical-system-holdings-enter-into-a-license-agreement-for-desidustat-in-greater-china,20-01-2020 00:00,,,,,,
2006,astellas-announces-construction-of-new-manufacturing-facility-for-active-pharmaceutical-ingredient-of-prograf-in-toyama-technology-center,20-01-2020 00:00,,,,,,
2007,tb-alliance-announces-partnership-with-hongqi-pharma-to-commercialize-new-therapy-for-highly-drug-resistant-forms-of-tb-in-china,20-01-2020 00:00,,,,,,
2008,novartis-announces-eu-approval-of-mayzent-siponimod-for-adult-patients-with-secondary-progressive-multiple-sclerosis-spms-with-active-disease,21-01-2020 00:00,,,,,,
2009,european-commission-approves-roche?s-polivy-for-people-with-previously-treated-aggressive-lymphoma,21-01-2020 00:00,,,,,,
2010,pharming-receives-ema-approval-of-new-facility-for-expansion-of-ruconest-production,21-01-2020 00:00,,,,,,
2011,jazz-pharmaceuticals-receives-eu-marketing-authorisation-for-sunosi-solriamfetol-for-excessive-daytime-sleepiness-in-adults-with-narcolepsy-or-obstructive-sleep-apnea,21-01-2020 00:00,,,,,,
2012,inotrem-secures-strategic-licensing-agreement-for-a-companion-diagnostics-test-in-septic-shock,21-01-2020 00:00,,,,,,
2013,phoremost-enters-multi-project-drug-discovery-collaboration-with-otsuka-pharmaceutical,21-01-2020 00:00,,,,,,
2014,european-commission-approves-darzalex-daratumumab-in-combination-with-bortezomib-thalidomide-and-dexamethasone-vtd-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-eligible,21-01-2020 00:00,,,,,,
2015,obi-pharma-granted-us-fda-orphan-drug-designation-for-the-treatment-of-gastric-cancer-for-its-antibody-drug-conjugate-adc-targeted-cancer-therapy-obi-999,21-01-2020 00:00,,,,,,
2016,bellicum-pharmaceuticals-enters-into-asset-purchase-and-master-services-agreements-with-md-anderson,22-01-2020 00:00,,,,,,
2017,three-industry-leaders-form-new-venture-to-create-scalable-manufacturing-platforms-for-cell-and-gene-therapies,22-01-2020 00:00,,,,,,
2018,fda-approves-tepezza-teprotumumab-trbw-for-the-treatment-of-thyroid-eye-disease-ted,22-01-2020 00:00,,,,,,
2019,fda-approves-medtronic-micra-av-the-world?s-smallest-pacemaker-which-can-now-treat-av-block,22-01-2020 00:00,,,,,,
2020,theramex-acquires-commercial-rights-for-oral-contraceptive-zoely,22-01-2020 00:00,,,,,,
2021,us-food-and-drug-administration-fda-grants-priority-review-of-belantamab-mafodotin-for-patients-with-relapsed-or-refractory-multiple-myeloma,22-01-2020 00:00,,,,,,
2022,genialis-and-oncologie-collaborate-on-precision-medicine-initiative-in-gastric-cancer,23-01-2020 00:00,,,,,,
2023,roche?s-risdiplam-meets-primary-endpoint-in-pivotal-firefish-trial-in-infants-with-type-1-spinal-muscular-atrophy,23-01-2020 00:00,,,,,,
2024,bayer-receives-approval-for-darolutamide-in-japan,23-01-2020 00:00,,,,,,
2025,bayer-submits-application-to-european-medicines-agency-for-pre-filled-syringe-to-administer-eye-medication-eylea,23-01-2020 00:00,,,,,,
2026,evotec-and-indivumed-announce-second-joint-drug-discovery-programme,23-01-2020 00:00,,,,,,
2027,approval-based-on-results-of-keynote-426-where-keytruda-in-combination-with-axitinib-reduced-the-risk-of-death-by-nearly-half-compared-to-sunitinib,23-01-2020 00:00,,,,,,
2028,roche-reports-results-of-tecentriq-atezolizumab-in-p-iii-imvigor010-study-for-patients-with-muscle-invasive-urothelial-cancer,24-01-2020 00:00,,,,,,
2029,roche-provides-an-update-on-phase-iii-study-of-tecentriq-in-people-with-muscle-invasive-urothelial-cancer,24-01-2020 00:00,,,,,,
2030,pfizer-brings-three-new-bosimilars-to-us-patients-at-substantial-discounts,24-01-2020 00:00,,,,,,
2031,evoke-pharma-enters-commercialization-agreement-with-eversana-life-sciences-for-gimoti,24-01-2020 00:00,,,,,,
2032,epizyme-announces-us-fda-accelerated-approval-of-tazverik-tazemetostat-for-the-treatment-of-patients-with-epithelioid-sarcoma,24-01-2020 00:00,,,,,,
2033,abbvie-and-allergan-announce-agreements-to-divest-brazikumab-and-zenpep,27-01-2020 00:00,,,,,,
2034,astrazeneca-divests-rights-to-established-hypertension-medicines,27-01-2020 00:00,,,,,,
2035,roche-submits-supplemental-biologics-license-application-to-the-fda-for-tecentriq-in-combination-with-avastin-for-the-most-common-form-of-liver-cancer,27-01-2020 00:00,,,,,,
2036,brilinta-reduced-the-risk-of-the-composite-of-stroke-and-death-after-an-acute-ischaemic-stroke-or-transient-ischaemic-attack,27-01-2020 00:00,,,,,,
2037,fda-approves-merck?s-dificid-fidaxomicin-to-treat-clostridioides-difficile-in-children-aged-six-months-and-older,27-01-2020 00:00,,,,,,
2038,fda-accepts-for-priority-review-dupixent-dupilumab-for-children-aged-6-to-11-years-with-moderate-to-severe-atopic-dermatitis,28-01-2020 00:00,,,,,,
2039,gsk-licenses-tuberculosis-vaccine-candidate-to-the-bill-melinda-gates-medical-research-institute-for-continued-development,28-01-2020 00:00,,,,,,
2040,us-fda-approves-only-triple-combination-tablet-with-jardiance-for-adults-with-type-2-diabetes,28-01-2020 00:00,,,,,,
2041,bausch-lomb-and-terracycle-partner-to-launch-canadas-first-and-only-contact-lens-recycling-program,28-01-2020 00:00,,,,,,
2042,ningbo-newbay-medical-technology-co-ltd-announces-a-license-agreement-with-genentech,28-01-2020 00:00,,,,,,
2043,alkermes-announces-us-food-and-drug-administration-acceptance-of-alks-3831-new-drug-application-for-treatment-of-schizophrenia-and-bipolar-i-disorder,28-01-2020 00:00,,,,,,
2044,biopharmx-and-timber-pharmaceuticals-announce-entry-into-merger-agreement,29-01-2020 00:00,,,,,,
2045,exelixis-announces-partner-takeda-files-new-drug-application-in-japan-for-cabometyx-cabozantinib-for-advanced-hepatocellular-carcinoma,29-01-2020 00:00,,,,,,
2046,european-medicines-agency-validates-kite?s-marketing-application-for-company?s-second-car-t-cell-therapy,29-01-2020 00:00,,,,,,
2047,lilly-receives-fda-priority-review-for-the-selpercatinib-new-drug-application,29-01-2020 00:00,,,,,,
2048,verastem-oncology-announces-dosing-of-first-patient-in-cspc?s-chinese-study-evaluating-copiktra-duvelisib-in-patients-with-relapsed-or-refractory-follicular-lymphoma,29-01-2020 00:00,,,,,,
2049,akcea-and-ionis-report-positive-topline-phase-2-study-results-of-akcea-angptl3-lrx,29-01-2020 00:00,,,,,,
2050,johnson-johnson-launches-multi-pronged-response-to-coronavirus-global-public-health-threat,30-01-2020 00:00,,,,,,
2051,sanofi-positive-topline-results-demonstrated-by-olipudase-alfa-first-and-only-investigational-therapy-in-late-stage-development-for-acid-sphingomyelinase-deficiency,30-01-2020 00:00,,,,,,
2052,astellas-submits-supplemental-new-drug-application-for-approval-of-evrenzo-roxadustat-for-the-treatment-of-anemia-associated-with-chronic-kidney-disease-in-non-dialysis-dependent-patients-in-japan,30-01-2020 00:00,,,,,,
2053,sorrento-and-celularity-to-initiate-emergency-allogeneic-natural-killer-nk-cell-therapy-development-for-coronavirus-infection,30-01-2020 00:00,,,,,,
2054,janssen-announces-european-commission-approval-for-expanded-use-of-erleada-apalutamide-for-treatment-of-patients-with-metastatic-hormone-sensitive-prostate-cancer,30-01-2020 00:00,,,,,,
2055,nubeqa-darolutamide-plus-androgen-deprivation-therapy-achieved-the-secondary-endpoint-of-overall-survival-os-in-men-with-non-metastatic-castration-resistant-prostate-cancer,30-01-2020 00:00,,,,,,
2056,spring-bank-discontinues-development-of-inarigivir-for-the-treatment-of-hbv,30-01-2020 00:00,,,,,,
2057,inovio-collaborating-with-beijing-advaccine-to-advance-ino-4800-vaccine-against-new-coronavirus-in-china,31-01-2020 00:00,,,,,,
2058,abbotts-tendyne-device-receives-worlds-first-ce-mark-for-transcatheter-mitral-valve-implantation,31-01-2020 00:00,,,,,,
2059,microsoft-launches-new-ai-for-good-program-ai-for-health-to-accelerate-global-health-initiatives,31-01-2020 00:00,,,,,,
2060,accenture-and-google-cloud-collaborate-to-help-life-sciences-companies-advance-the-discovery-development-and-delivery-of-innovative-therapies,31-01-2020 00:00,,,,,,
2061,proqr-receives-rare-pediatric-disease-designation-from-fda-for-qr-421a,31-01-2020 00:00,,,,,,
2062,alnylam-receives-positive-chmp-opinion-for-givlaari-givosiran-for-the-treatment-of-acute-hepatic-porphyria-in-adults-and-adolescents,31-01-2020 00:00,,,,,,
2063,chmp-recommends-approval-of-lillys-new-fast-acting-mealtime-insulin-to-improve-glycemic-control-in-adults-with-diabetes,31-01-2020 00:00,,,,,,
2064,cepi-and-gsk-announce-collaboration-to-strengthen-the-global-effort-to-develop-a-vaccine-for-the-2019-ncov-virus,03-02-2020 00:00,,,,,,
2065,lillys-reyvow-lasmiditan-c-v-the-first-and-only-medicine-in-a-new-class-of-acute-treatment-for-migraine-ditan-now-available-for-prescription,03-02-2020 00:00,,,,,,
2066,teva-announces-positive-top-line-results-from-ajovy-fremanezumab-clinical-trials-in-japan,03-02-2020 00:00,,,,,,
2067,pfizer-receives-positive-chmp-opinion-for-oncology-biosimilar-ruxience-rituximab,03-02-2020 00:00,,,,,,
2068,amgen-launches-biosimilar-for-the-treatment-of-inflammatory-diseases,03-02-2020 00:00,,,,,,
2069,danaher-gets-conditional-skorean-regulatory-nod-for-21-bln-ge-biopharma-unit-deal,04-02-2020 00:00,,,,,,
2070,imidomics-and-gossamer-bio-enter-into-a-strategic-collaboration-to-advance-the-development-of-novel-treatments-for-patients-with-immune-mediated-inflammatory-diseases,04-02-2020 00:00,,,,,,
2071,genialis-and-oncologie-collaborate-on-precision-medicine-initiative-in-gastric-cancer,23-01-2020 00:00,,,,,,
2072,bio-thera-solutions-announces-positive-top-line-results-for-bat1706-a-proposed-biosimilar-to-avastin,04-02-2020 00:00,,,,,,
2073,roche?s-risdiplam-meets-primary-endpoint-in-pivotal-firefish-trial-in-infants-with-type-1-spinal-muscular-atrophy,23-01-2020 00:00,,,,,,
2074,kyowa-kirin-announces-termination-of-agreement-with-zeria-pharmaceutical-on-asacol?,04-02-2020 00:00,,,,,,
2075,bayer-receives-approval-for-darolutamide-in-japan,23-01-2020 00:00,,,,,,
2076,bayer-submits-application-to-european-medicines-agency-for-pre-filled-syringe-to-administer-eye-medication-eylea,23-01-2020 00:00,,,,,,
2077,evotec-and-indivumed-announce-second-joint-drug-discovery-programme,23-01-2020 00:00,,,,,,
2078,approval-based-on-results-of-keynote-426-where-keytruda-in-combination-with-axitinib-reduced-the-risk-of-death-by-nearly-half-compared-to-sunitinib,23-01-2020 00:00,,,,,,
2079,roche-reports-results-of-tecentriq-atezolizumab-in-p-iii-imvigor010-study-for-patients-with-muscle-invasive-urothelial-cancer,24-01-2020 00:00,,,,,,
2080,cellink-announces-extension-of-collaboration-with-astrazeneca-to-use-cellinks?-3d-bioprinting-and-associated-technology-for-drug-discovery,04-02-2020 00:00,,,,,,
2081,roche-provides-an-update-on-phase-iii-study-of-tecentriq-in-people-with-muscle-invasive-urothelial-cancer,24-01-2020 00:00,,,,,,
2082,new-study-further-supports-the-benefits-of-spiriva-respimat-in-the-treatment-of-asthma,04-02-2020 00:00,,,,,,
2083,pfizer-brings-three-new-bosimilars-to-us-patients-at-substantial-discounts,24-01-2020 00:00,,,,,,
2084,gsk-announces-european-medicines-agency-ema-accepted-marketing-authorisation-application-for-belantamab-mafodotin-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma,04-02-2020 00:00,,,,,,
2085,evoke-pharma-enters-commercialization-agreement-with-eversana-life-sciences-for-gimoti,24-01-2020 00:00,,,,,,
2086,regeneron-announces-expanded-collaboration-with-hhs-to-develop-antibody-treatments-for-new-coronavirus,05-02-2020 00:00,,,,,,
2087,epizyme-announces-us-fda-accelerated-approval-of-tazverik-tazemetostat-for-the-treatment-of-patients-with-epithelioid-sarcoma,24-01-2020 00:00,,,,,,
2088,biomotiv-and-bristol-myers-squibb-announce-the-launch-of-anteros-pharmaceuticals,05-02-2020 00:00,,,,,,
2089,abbvie-and-allergan-announce-agreements-to-divest-brazikumab-and-zenpep,27-01-2020 00:00,,,,,,
2090,anvisa-approves-rinvoq-upadacitinib-jak1-inhibitor-for-the-treatment-of-rheumatoid-arthritis-ra,05-02-2020 00:00,,,,,,
2091,fda-takes-significant-step-in-coronavirus-response-efforts-issues-emergency-use-authorization-for-the-first-2019-novel-coronavirus-diagnostic,05-02-2020 00:00,,,,,,
2092,astrazeneca-divests-rights-to-established-hypertension-medicines,27-01-2020 00:00,,,,,,
2093,roche-submits-supplemental-biologics-license-application-to-the-fda-for-tecentriq-in-combination-with-avastin-for-the-most-common-form-of-liver-cancer,27-01-2020 00:00,,,,,,
2094,merck-to-focus-on-key-growth-pillars-through-spinoff-of-women?s-health-trusted-legacy-brands-and-biosimilars-products-into-new-company-?newco?,05-02-2020 00:00,,,,,,
2095,brilinta-reduced-the-risk-of-the-composite-of-stroke-and-death-after-an-acute-ischaemic-stroke-or-transient-ischaemic-attack,27-01-2020 00:00,,,,,,
2096,seqirus-announces-us-fda-approval-of-its-first-ever-adjuvanted-cell-based-pandemic-influenza-a-h5n1-vaccine,05-02-2020 00:00,,,,,,
2097,navrogen-and-levena-announce-collaboration-to-develop-antibody-drug-conjugates-adcs-to-treat-humoral-immuno-suppressed-cancers,05-02-2020 00:00,,,,,,
2098,fda-approves-merck?s-dificid-fidaxomicin-to-treat-clostridioides-difficile-in-children-aged-six-months-and-older,27-01-2020 00:00,,,,,,
2099,alector-announces-fda-fast-track-designation-granted-to-al101-for-the-treatment-of-patients-with-frontotemporal-dementia,05-02-2020 00:00,,,,,,
2100,fda-accepts-for-priority-review-dupixent-dupilumab-for-children-aged-6-to-11-years-with-moderate-to-severe-atopic-dermatitis,28-01-2020 00:00,,,,,,
2101,atreca-announces-strategic-research-collaboration-with-merck-to-identify-novel-antibody-targets-in-oncology,06-02-2020 00:00,,,,,,
2102,gsk-licenses-tuberculosis-vaccine-candidate-to-the-bill-melinda-gates-medical-research-institute-for-continued-development,28-01-2020 00:00,,,,,,
2103,sanofi-sanofi-brain-penetrant-btk-inhibitor-meets-primary-endpoint-of-phase-2-trial-in-relapsing-multiple-sclerosis,06-02-2020 00:00,,,,,,
2104,us-fda-approves-only-triple-combination-tablet-with-jardiance-for-adults-with-type-2-diabetes,28-01-2020 00:00,,,,,,
2105,fresenius-kabi-introduces-glucagon-emergency-medicine-kit-to-treat-life-threatening-episodes-of-low-blood-sugar,06-02-2020 00:00,,,,,,
2106,bausch-lomb-and-terracycle-partner-to-launch-canadas-first-and-only-contact-lens-recycling-program,28-01-2020 00:00,,,,,,
2107,roche?s-risdiplam-showed-significant-improvement-in-motor-function-in-people-aged-2-25-with-type-2-or-3-spinal-muscular-atrophy,06-02-2020 00:00,,,,,,
2108,ningbo-newbay-medical-technology-co-ltd-announces-a-license-agreement-with-genentech,28-01-2020 00:00,,,,,,
2109,valbiotis-announces-a-global-strategic-partnership-with-nestl?-health-science-for-the-development-and-commercialization-of-totum-63-a-plant-derived-active-substance-with-clinically-demonstrated-metabolic-health-benefits-on-prediabetics,06-02-2020 00:00,,,,,,
2110,alkermes-announces-us-food-and-drug-administration-acceptance-of-alks-3831-new-drug-application-for-treatment-of-schizophrenia-and-bipolar-i-disorder,28-01-2020 00:00,,,,,,
2111,bridge-biotherapeutics-acquires-a-new-drug-development-candidate-for-back-eye-diseases,06-02-2020 00:00,,,,,,
2112,biopharmx-and-timber-pharmaceuticals-announce-entry-into-merger-agreement,29-01-2020 00:00,,,,,,
2113,almirall-partners-with-plug-and-play-to-accelerate-digital-innovation-in-dermatology,07-02-2020 00:00,,,,,,
2114,exelixis-announces-partner-takeda-files-new-drug-application-in-japan-for-cabometyx-cabozantinib-for-advanced-hepatocellular-carcinoma,29-01-2020 00:00,,,,,,
2115,roche-to-present-new-data-on-tecentriq-in-combination-with-avastin-that-shows-improvement-in-overall-survival-for-chinese-patients-with-the-most-common-form-of-liver-cancer,07-02-2020 00:00,,,,,,
2116,european-medicines-agency-validates-kite?s-marketing-application-for-company?s-second-car-t-cell-therapy,29-01-2020 00:00,,,,,,
2117,aduro-biotech-announces-milestone-achieved-under-merck-collaboration-for-initiation-of-phase-2-trial-of-anti-cd27-agonist-mk-5890-in-non-small-cell-lung-cancer,07-02-2020 00:00,,,,,,
2118,lilly-receives-fda-priority-review-for-the-selpercatinib-new-drug-application,29-01-2020 00:00,,,,,,
2119,collegium-to-acquire-us-rights-to-nucynta-franchise,07-02-2020 00:00,,,,,,
2120,verastem-oncology-announces-dosing-of-first-patient-in-cspc?s-chinese-study-evaluating-copiktra-duvelisib-in-patients-with-relapsed-or-refractory-follicular-lymphoma,29-01-2020 00:00,,,,,,
2121,novo-nordisk-invests-dkk-800-million-in-upgrading-and-expanding-production-facilities-in-kalundborg,07-02-2020 00:00,,,,,,
2122,akcea-and-ionis-report-positive-topline-phase-2-study-results-of-akcea-angptl3-lrx,29-01-2020 00:00,,,,,,
2123,curis-and-aurigene-announce-amendment-of-collaboration-for-the-development-and-commercialization-of-ca-170,07-02-2020 00:00,,,,,,
2124,johnson-johnson-launches-multi-pronged-response-to-coronavirus-global-public-health-threat,30-01-2020 00:00,,,,,,
2125,who-to-accelerate-research-and-innovation-for-new-coronavirus,07-02-2020 00:00,,,,,,
2126,sanofi-positive-topline-results-demonstrated-by-olipudase-alfa-first-and-only-investigational-therapy-in-late-stage-development-for-acid-sphingomyelinase-deficiency,30-01-2020 00:00,,,,,,
2127,lilly-announces-topline-results-for-solanezumab-from-the-dominantly-inherited-alzheimer-network-trials-unit-dian-tu-study,10-02-2020 00:00,,,,,,
2128,astellas-submits-supplemental-new-drug-application-for-approval-of-evrenzo-roxadustat-for-the-treatment-of-anemia-associated-with-chronic-kidney-disease-in-non-dialysis-dependent-patients-in-japan,30-01-2020 00:00,,,,,,
2129,sorrento-and-celularity-to-initiate-emergency-allogeneic-natural-killer-nk-cell-therapy-development-for-coronavirus-infection,30-01-2020 00:00,,,,,,
2130,eylea-aflibercept-injection-reduced-risk-of-developing-vision-threatening-events-by-75-after-two-years-in-patients-with-diabetic-retinopathy,10-02-2020 00:00,,,,,,
2131,janssen-announces-european-commission-approval-for-expanded-use-of-erleada-apalutamide-for-treatment-of-patients-with-metastatic-hormone-sensitive-prostate-cancer,30-01-2020 00:00,,,,,,
2132,valeritas-announces-agreement-for-zealand-pharma-to-acquire-business-and-retain-employees,10-02-2020 00:00,,,,,,
2133,nubeqa-darolutamide-plus-androgen-deprivation-therapy-achieved-the-secondary-endpoint-of-overall-survival-os-in-men-with-non-metastatic-castration-resistant-prostate-cancer,30-01-2020 00:00,,,,,,
2134,bayer-announces-phase-iii-trials-with-new-aflibercept-8mg-formulation,10-02-2020 00:00,,,,,,
2135,spring-bank-discontinues-development-of-inarigivir-for-the-treatment-of-hbv,30-01-2020 00:00,,,,,,
2136,roche-provides-topline-results-from-investigator-led-phase-iiiii-trial-with-gantenerumab-in-rare-inherited-form-of-alzheimer?s-disease,10-02-2020 00:00,,,,,,
2137,inovio-collaborating-with-beijing-advaccine-to-advance-ino-4800-vaccine-against-new-coronavirus-in-china,31-01-2020 00:00,,,,,,
2138,biointellisense-announces-fda-clearance-of-the-biosticker-the-first-single-use-medical-device-enabling-30-days-of-continuous-vital-signs-monitoring,11-02-2020 00:00,,,,,,
2139,abbotts-tendyne-device-receives-worlds-first-ce-mark-for-transcatheter-mitral-valve-implantation,31-01-2020 00:00,,,,,,
2140,axim-biotechnologies-acquiree-sapphire-biotech-inc-signs-sponsored-research-agreement-with-arizona-state-university-to-develop-metastatic-cancer-inhibitor,11-02-2020 00:00,,,,,,
2141,microsoft-launches-new-ai-for-good-program-ai-for-health-to-accelerate-global-health-initiatives,31-01-2020 00:00,,,,,,
2142,us-fda-grants-priority-review-for-kite?s-kte-x19-biologics-license-application-bla-in-relapsed-or-refractory-mantle-cell-lymphoma-february-10-2020-at-830-am-est,11-02-2020 00:00,,,,,,
2143,accenture-and-google-cloud-collaborate-to-help-life-sciences-companies-advance-the-discovery-development-and-delivery-of-innovative-therapies,31-01-2020 00:00,,,,,,
2144,bayer-and-nuvisan-create-new-research-unit-in-berlin,11-02-2020 00:00,,,,,,
2145,proqr-receives-rare-pediatric-disease-designation-from-fda-for-qr-421a,31-01-2020 00:00,,,,,,
2146,eagle-pharmaceuticals-receives-final-fda-approval-for-pemfexy?-pemetrexed-for-injection,11-02-2020 00:00,,,,,,
2147,alnylam-receives-positive-chmp-opinion-for-givlaari-givosiran-for-the-treatment-of-acute-hepatic-porphyria-in-adults-and-adolescents,31-01-2020 00:00,,,,,,
2148,novartis-announces-met-inhibitor-capmatinib-inc280-the-first-potential-treatment-for-metex14-mutated-advanced-non-small-cell-lung-cancer-granted-priority-fda-review,11-02-2020 00:00,,,,,,
2149,chmp-recommends-approval-of-lillys-new-fast-acting-mealtime-insulin-to-improve-glycemic-control-in-adults-with-diabetes,31-01-2020 00:00,,,,,,
2150,janssen-announces-submission-to-us-fda-for-new-darzalex?-daratumumab-based-combination-regimen-for-patients-with-relapsedrefractory-multiple-myeloma,11-02-2020 00:00,,,,,,
2151,cepi-and-gsk-announce-collaboration-to-strengthen-the-global-effort-to-develop-a-vaccine-for-the-2019-ncov-virus,03-02-2020 00:00,,,,,,
2152,fda-grants-caption-health-landmark-authorization-for-first-ai-guided-image-acquisition-system,11-02-2020 00:00,,,,,,
2153,lillys-reyvow-lasmiditan-c-v-the-first-and-only-medicine-in-a-new-class-of-acute-treatment-for-migraine-ditan-now-available-for-prescription,03-02-2020 00:00,,,,,,
2154,johnson-johnson-announces-collaboration-with-us-department-of-health-human-services-to-accelerate-development-of-a-potential-novel-coronavirus-vaccine,12-02-2020 00:00,,,,,,
2155,teva-announces-positive-top-line-results-from-ajovy-fremanezumab-clinical-trials-in-japan,03-02-2020 00:00,,,,,,
2157,pfizer-receives-positive-chmp-opinion-for-oncology-biosimilar-ruxience-rituximab,03-02-2020 00:00,,,,,,
2158,novo-nordisk-launches-esperoct-in-the-us-for-the-treatment-of-people-with-hemophilia-a,12-02-2020 00:00,,,,,,
2159,amgen-launches-biosimilar-for-the-treatment-of-inflammatory-diseases,03-02-2020 00:00,,,,,,
2160,health-canada-has-approved-taltz-ixekizumab-for-the-treatment-of-active-ankylosing-spondylitis-radiographic-axial-spondyloarthritis,12-02-2020 00:00,,,,,,
2161,danaher-gets-conditional-skorean-regulatory-nod-for-21-bln-ge-biopharma-unit-deal,04-02-2020 00:00,,,,,,
2162,autism-learning-partners-and-cognoa-announce-partnership-to-enable-earlier-access-to-care,12-02-2020 00:00,,,,,,
2163,imidomics-and-gossamer-bio-enter-into-a-strategic-collaboration-to-advance-the-development-of-novel-treatments-for-patients-with-immune-mediated-inflammatory-diseases,04-02-2020 00:00,,,,,,
2164,xtandi-enzalutamide-demonstrates-significant-improvement-in-overall-survival-in-phase-3-prosper-trial-of-patients-with-nmcrpc,12-02-2020 00:00,,,,,,
2165,bio-thera-solutions-announces-positive-top-line-results-for-bat1706-a-proposed-biosimilar-to-avastin,04-02-2020 00:00,,,,,,
2166,merck?s-keytruda-pembrolizumab-in-combination-with-chemotherapy-met-primary-endpoint-of-progression-free-survival-pfs-as-first-line-treatment-for-metastatic-triple-negative-breast-cancer-mtnbc,12-02-2020 00:00,,,,,,
2167,kyowa-kirin-announces-termination-of-agreement-with-zeria-pharmaceutical-on-asacol?,04-02-2020 00:00,,,,,,
2168,dr-reddy?s-laboratories-to-acquire-select-business-divisions-of-wockhardt-in-india,13-02-2020 00:00,,,,,,
2169,deciphera-pharmaceuticals-announces-us-food-and-drug-administration-acceptance-of-new-drug-application-and-priority-review-for-ripretinib-in-patients-with-advanced-gastrointestinal-stromal-tumors,13-02-2020 00:00,,,,,,
2170,vizient-comments-support-fda?s-efforts-to-expedite-biosimilar-insulin-development,28-01-2020 00:00,,,,,,
2171,alvotech-and-jamp-pharma-enter-into-an-exclusive-partnership-for-the-commercialization-of-key-biosimilars-in-canada,14-01-2020 00:00,,,,,,
2172,medtronic-recalls-minimed-insulin-pumps-for-incorrect-insulin-dosing,13-02-2020 00:00,,,,,,
2173,benevolentai-announces-scientific-collaboration-with-uc-san-diego-to-investigate-cerebral-cavernous-malformations,13-02-2020 00:00,,,,,,
2174,medtronic-to-advance-solutions-and-capabilities-in-surgical-data-and-analytics-with-acquisition-of-digital-surgery,13-02-2020 00:00,,,,,,
2175,cellink-announces-extension-of-collaboration-with-astrazeneca-to-use-cellinks?-3d-bioprinting-and-associated-technology-for-drug-discovery,04-02-2020 00:00,,,,,,
2176,amgen-canada-receives-approval-of-marketing-authorization-transfer-of-otezla-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-and-psoriatic-arthritis,13-02-2020 00:00,,,,,,
2177,new-study-further-supports-the-benefits-of-spiriva-respimat-in-the-treatment-of-asthma,04-02-2020 00:00,,,,,,
2178,gsk-announces-european-medicines-agency-ema-accepted-marketing-authorisation-application-for-belantamab-mafodotin-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma,04-02-2020 00:00,,,,,,
2179,us-food-and-drug-administration-fda-accepts-for-priority-review-bristol-myers-squibb?s-biologics-license-application-bla-for-lisocabtagene-maraleucel-liso-cel-for-adult-patients-with-relapsed-or-refractory-large-b-cell-lymphoma,13-02-2020 00:00,,,,,,
2180,thermo-fisher-scientific-announces-collaboration-to-develop-highly-sensitive-analytical-workflow-for-infectious-disease-diagnosis-and-patient-monitoring,14-02-2020 00:00,,,,,,
2181,regeneron-announces-expanded-collaboration-with-hhs-to-develop-antibody-treatments-for-new-coronavirus,05-02-2020 00:00,,,,,,
2182,biomotiv-and-bristol-myers-squibb-announce-the-launch-of-anteros-pharmaceuticals,05-02-2020 00:00,,,,,,
2183,china-national-medical-products-administration-grants-approval-of-roche?s-tecentriq-in-combination-with-chemotherapy-as-first-line-treatment-of-people-with-extensive-stage-small-cell-lung-cancer,14-02-2020 00:00,,,,,,
2184,anvisa-approves-rinvoq-upadacitinib-jak1-inhibitor-for-the-treatment-of-rheumatoid-arthritis-ra,05-02-2020 00:00,,,,,,
2185,orthofix-announces-fda-approval-of-stim-ontrack-21-mobile-app-for-bone-growth-stimulators,14-02-2020 00:00,,,,,,
2186,codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19,14-02-2020 00:00,,,,,,
2187,fda-takes-significant-step-in-coronavirus-response-efforts-issues-emergency-use-authorization-for-the-first-2019-novel-coronavirus-diagnostic,05-02-2020 00:00,,,,,,
2188,fda-grants-soligenix-fast-track-designation-for-rivax-in-the-prevention-of-ricin-poisoning,14-02-2020 00:00,,,,,,
2189,merck-to-focus-on-key-growth-pillars-through-spinoff-of-women?s-health-trusted-legacy-brands-and-biosimilars-products-into-new-company-?newco?,05-02-2020 00:00,,,,,,
2190,epizyme-announces-fda-acceptance-of-new-drug-application-for-filing-with-priority-review-for-tazverik-tazemetostat-for-the-treatment-of-follicular-lymphoma,14-02-2020 00:00,,,,,,
2191,seqirus-announces-us-fda-approval-of-its-first-ever-adjuvanted-cell-based-pandemic-influenza-a-h5n1-vaccine,05-02-2020 00:00,,,,,,
2192,international-childhood-cancer-day-announcement-global-hope-teva-and-direct-relief-partner-to-bring-medicines-to-help-improve-the-lives-of-children-with-cancer-in-africa,17-02-2020 00:00,,,,,,
2193,navrogen-and-levena-announce-collaboration-to-develop-antibody-drug-conjugates-adcs-to-treat-humoral-immuno-suppressed-cancers,05-02-2020 00:00,,,,,,
2194,ervebo-ebola-zaire-vaccine-live-now-registered-in-four-african-countries-within-90-days-of-reference-country-approval-and-who-prequalification,17-02-2020 00:00,,,,,,
2195,alector-announces-fda-fast-track-designation-granted-to-al101-for-the-treatment-of-patients-with-frontotemporal-dementia,05-02-2020 00:00,,,,,,
2196,pharmamar-and-jazz-pharmaceuticals-announce-fda-acceptance-and-priority-review-of-new-drug-application-for-lurbinectedin-in-relapsed-small-cell-lung-cancer,17-02-2020 00:00,,,,,,
2197,atreca-announces-strategic-research-collaboration-with-merck-to-identify-novel-antibody-targets-in-oncology,06-02-2020 00:00,,,,,,
2198,celltrion-healthcare-showcases-positive-1-year-results-for-novel-subcutaneous-formulation-of-infliximab-in-patients-with-active-crohn?s-disease-and-ulcerative-colitis-presented-at-the-european-crohns-and-colitis-organisation-ecco-annual-congress,17-02-2020 00:00,,,,,,
2199,sanofi-sanofi-brain-penetrant-btk-inhibitor-meets-primary-endpoint-of-phase-2-trial-in-relapsing-multiple-sclerosis,06-02-2020 00:00,,,,,,
2200,novartis-receives-ec-approval-for-beovu-a-next-generation-anti-vegf-treatment-for-wet-amd-a-leading-cause-of-blindness-worldwide,17-02-2020 00:00,,,,,,
2201,fresenius-kabi-introduces-glucagon-emergency-medicine-kit-to-treat-life-threatening-episodes-of-low-blood-sugar,06-02-2020 00:00,,,,,,
2202,zydus-cadila-launches-a-fast-tracked-programme-to-develop-vaccine-for-the-novel-coronavirus-2019-ncov-covid-19,17-02-2020 00:00,,,,,,
2203,roche?s-risdiplam-showed-significant-improvement-in-motor-function-in-people-aged-2-25-with-type-2-or-3-spinal-muscular-atrophy,06-02-2020 00:00,,,,,,
2204,changes-to-marketing-arrangements-of-the-sglt2-inhibitor-tofogliflozin-hydrate-in-japan,18-02-2020 00:00,,,,,,
2205,valbiotis-announces-a-global-strategic-partnership-with-nestl?-health-science-for-the-development-and-commercialization-of-totum-63-a-plant-derived-active-substance-with-clinically-demonstrated-metabolic-health-benefits-on-prediabetics,06-02-2020 00:00,,,,,,
2206,fda-approves-gsk?s-voltaren-arthritis-pain-for-over-the-counter-use-in-the-united-states,18-02-2020 00:00,,,,,,
2207,bridge-biotherapeutics-acquires-a-new-drug-development-candidate-for-back-eye-diseases,06-02-2020 00:00,,,,,,
2208,noxopharm-alliance-with-genesiscare,18-02-2020 00:00,,,,,,
2209,almirall-partners-with-plug-and-play-to-accelerate-digital-innovation-in-dermatology,07-02-2020 00:00,,,,,,
2210,taiwan-firm-teams-up-with-us-to-develop-covid-19-vaccine,18-02-2020 00:00,,,,,,
2211,roche-to-present-new-data-on-tecentriq-in-combination-with-avastin-that-shows-improvement-in-overall-survival-for-chinese-patients-with-the-most-common-form-of-liver-cancer,07-02-2020 00:00,,,,,,
2212,headaterm-tens-therapy-proves-to-be-a-fast-and-effective-treatment-for-acute-migraine-a-randomized-controlled-trial,18-02-2020 00:00,,,,,,
2213,aduro-biotech-announces-milestone-achieved-under-merck-collaboration-for-initiation-of-phase-2-trial-of-anti-cd27-agonist-mk-5890-in-non-small-cell-lung-cancer,07-02-2020 00:00,,,,,,
2214,european-commission-approves-vyndaqel-the-first-treatment-in-the-eu-for-transthyretin-amyloid-cardiomyopathy-attr-cm,18-02-2020 00:00,,,,,,
2215,collegium-to-acquire-us-rights-to-nucynta-franchise,07-02-2020 00:00,,,,,,
2216,chugai-receives-orphan-drug-designation-for-rg6042-in-huntingtons-disease-from-the-mhlw,18-02-2020 00:00,,,,,,
2217,novo-nordisk-invests-dkk-800-million-in-upgrading-and-expanding-production-facilities-in-kalundborg,07-02-2020 00:00,,,,,,
2218,sanofi-joins-forces-with-us-department-of-health-and-human-services-to-advance-a-novel-coronavirus-vaccine,19-02-2020 00:00,,,,,,
2219,curis-and-aurigene-announce-amendment-of-collaboration-for-the-development-and-commercialization-of-ca-170,07-02-2020 00:00,,,,,,
2220,fda-grants-priority-review-to-roche?s-tecentriq-monotherapy-as-first-line-treatment-of-certain-people-with-advanced-non-small-cell-lung-cancer,19-02-2020 00:00,,,,,,
2221,who-to-accelerate-research-and-innovation-for-new-coronavirus,07-02-2020 00:00,,,,,,
2222,world?s-first-bedside-mri-system-receives-fda-510k-clearance,19-02-2020 00:00,,,,,,
2223,lilly-announces-topline-results-for-solanezumab-from-the-dominantly-inherited-alzheimer-network-trials-unit-dian-tu-study,10-02-2020 00:00,,,,,,
2224,abbott-introduces-next-generation-heart-rhythm-management-devices-in-europe-featuring-state-of-the-art-patient-app-and-bluetooth-connectivity,19-02-2020 00:00,,,,,,
2225,eylea-aflibercept-injection-reduced-risk-of-developing-vision-threatening-events-by-75-after-two-years-in-patients-with-diabetic-retinopathy,10-02-2020 00:00,,,,,,
2226,johnson-johnson-to-expand-partnership-with-us-department-of-health-human-services-to-accelerate-the-discovery-of-potential-covid-19-treatments,19-02-2020 00:00,,,,,,
2227,valeritas-announces-agreement-for-zealand-pharma-to-acquire-business-and-retain-employees,10-02-2020 00:00,,,,,,
2228,sarepta-therapeutics-announces-fda-approval-of-vyondys-53-golodirsen-injection-for-the-treatment-of-duchenne-muscular-dystrophy-dmd-in-patients-amenable-to-skipping-exon-53,12-12-2019 00:00,,,,,,
2229,bayer-announces-phase-iii-trials-with-new-aflibercept-8mg-formulation,10-02-2020 00:00,,,,,,
2230,abbott-collaborates-with-insulet-to-integrate-glucose-sensing-technology-with-automated-insulin-delivery-system-for-seamless-diabetes-care,19-02-2020 00:00,,,,,,
2231,roche-provides-topline-results-from-investigator-led-phase-iiiii-trial-with-gantenerumab-in-rare-inherited-form-of-alzheimer?s-disease,10-02-2020 00:00,,,,,,
2232,fda-grants-accelerated-approval-to-astellas-and-seattle-genetics-padcev-enfortumab-vedotin-ejfv-for-people-with-locally-advanced-or-metastatic-urothelial-cancer-the-most-common-type-of-bladder-cancer,18-12-2019 00:00,,,,,,
2233,biointellisense-announces-fda-clearance-of-the-biosticker-the-first-single-use-medical-device-enabling-30-days-of-continuous-vital-signs-monitoring,11-02-2020 00:00,,,,,,
2234,wuxi-vaccines-signed-long-term-vaccine-manufacturing-contract-with-a-global-vaccine-leader,19-02-2020 00:00,,,,,,
2235,axim-biotechnologies-acquiree-sapphire-biotech-inc-signs-sponsored-research-agreement-with-arizona-state-university-to-develop-metastatic-cancer-inhibitor,11-02-2020 00:00,,,,,,
2236,merck-divests-allergopharma-to-dermapharm-holding-se,20-02-2020 00:00,,,,,,
2237,us-fda-grants-priority-review-for-kite?s-kte-x19-biologics-license-application-bla-in-relapsed-or-refractory-mantle-cell-lymphoma-february-10-2020-at-830-am-est,11-02-2020 00:00,,,,,,
2238,astellas-and-seattle-genetics-receive-fda-breakthrough-therapy-designation-for-padcev-enfortumab-vedotin-ejfv-in-combination-with-pembrolizumab-in-first-line-advanced-bladder-cancer,20-02-2020 00:00,,,,,,
2239,bayer-and-nuvisan-create-new-research-unit-in-berlin,11-02-2020 00:00,,,,,,
2240,fda-approves-intra-cellular-therapies?-novel-antipsychotic-caplyta?-lumateperone-for-the-treatment-of-schizophrenia-in-adults,23-01-2020 00:00,,,,,,
2241,eagle-pharmaceuticals-receives-final-fda-approval-for-pemfexy?-pemetrexed-for-injection,11-02-2020 00:00,,,,,,
2242,novartis-announces-met-inhibitor-capmatinib-inc280-the-first-potential-treatment-for-metex14-mutated-advanced-non-small-cell-lung-cancer-granted-priority-fda-review,11-02-2020 00:00,,,,,,
2243,blueprint-medicines-announces-fda-approval-of-ayvakit-avapritinib-for-the-treatment-of-adults-with-unresectable-or-metastatic-pdgfra-exon-18-mutant-gastrointestinal-stromal-tumor,09-01-2020 00:00,,,,,,
2244,janssen-announces-submission-to-us-fda-for-new-darzalex?-daratumumab-based-combination-regimen-for-patients-with-relapsedrefractory-multiple-myeloma,11-02-2020 00:00,,,,,,
2245,vifor-pharma-and-fresenius-kabi-create-joint-venture-in-china-for-iv-iron-portfolio,20-02-2020 00:00,,,,,,
2246,fda-grants-caption-health-landmark-authorization-for-first-ai-guided-image-acquisition-system,11-02-2020 00:00,,,,,,
2247,us-fda-approves-eisai?s-dayvigo?-lemborexant-for-treatment-of-insomnia-in-adult-patients,23-12-2019 00:00,,,,,,
2248,johnson-johnson-announces-collaboration-with-us-department-of-health-human-services-to-accelerate-development-of-a-potential-novel-coronavirus-vaccine,12-02-2020 00:00,,,,,,
2249,abbott-vascular-recalls-nc-trek-rx-and-nc-traveler-rx-coronary-dilatation-catheters-due-to-failure-of-balloon-diameter-40mm-45mm-and-500mm-to-deflate,20-02-2020 00:00,,,,,,
2251,nimble-announces-collaboration-with-genentech-to-discover-and-develop-novel-peptide-based-therapeutics,20-02-2020 00:00,,,,,,
2252,novo-nordisk-launches-esperoct-in-the-us-for-the-treatment-of-people-with-hemophilia-a,12-02-2020 00:00,,,,,,
2253,roche-presents-rochediabetes-insulinstart-a-new-service-to-help-you-get-started-with-insulin-therapy,20-02-2020 00:00,,,,,,
2254,health-canada-has-approved-taltz-ixekizumab-for-the-treatment-of-active-ankylosing-spondylitis-radiographic-axial-spondyloarthritis,12-02-2020 00:00,,,,,,
2255,immatics-and-gsk-partner-to-develop-novel-adoptive-cell-therapies,21-02-2020 00:00,,,,,,
2256,autism-learning-partners-and-cognoa-announce-partnership-to-enable-earlier-access-to-care,12-02-2020 00:00,,,,,,
2257,biomarins-biologics-license-application-for-valoctocogene-roxaparvovec-accepted-for-priority-review-by-fda-with-review-action-date-of-august-21-2020,21-02-2020 00:00,,,,,,
2258,xtandi-enzalutamide-demonstrates-significant-improvement-in-overall-survival-in-phase-3-prosper-trial-of-patients-with-nmcrpc,12-02-2020 00:00,,,,,,
2259,vbl-therapeutics-announces-the-launch-of-a-new-clinical-trial-of-vb-111-combined-with-the-checkpoint-inhibitor-nivolumab-in-metastatic-colorectal-cancer,21-02-2020 00:00,,,,,,
2260,merck?s-keytruda-pembrolizumab-in-combination-with-chemotherapy-met-primary-endpoint-of-progression-free-survival-pfs-as-first-line-treatment-for-metastatic-triple-negative-breast-cancer-mtnbc,12-02-2020 00:00,,,,,,
2261,teva-announces-registration-trials-of-deutetrabenazine-in-pediatric-patients-with-tourette-syndrome-did-not-meet-the-primary-endpoint,21-02-2020 00:00,,,,,,
2262,chugai-obtains-approval-for-additional-indication-of-rozlytrek-for-ros1-fusion-positive-non-small-cell-lung-cancer,21-02-2020 00:00,,,,,,
2263,dr-reddy?s-laboratories-to-acquire-select-business-divisions-of-wockhardt-in-india,13-02-2020 00:00,,,,,,
2264,esperion-announces-fda-approval-of-nexletol-bempedoic-acid-tablet-an-oral-once-daily-non-statin-ldl-cholesterol-lowering-medicine,24-02-2020 00:00,,,,,,
2265,deciphera-pharmaceuticals-announces-us-food-and-drug-administration-acceptance-of-new-drug-application-and-priority-review-for-ripretinib-in-patients-with-advanced-gastrointestinal-stromal-tumors,13-02-2020 00:00,,,,,,
2266,novartis-announces-fda-and-ema-filing-acceptance-of-ofatumumab-a-novel-b-cell-therapy-for-patients-with-relapsing-forms-of-multiple-sclerosis-rms,24-02-2020 00:00,,,,,,
2267,vizient-comments-support-fda?s-efforts-to-expedite-biosimilar-insulin-development,28-01-2020 00:00,,,,,,
2268,alvotech-and-jamp-pharma-enter-into-an-exclusive-partnership-for-the-commercialization-of-key-biosimilars-in-canada,14-01-2020 00:00,,,,,,
2269,trulicity?-dulaglutide-is-the-first-and-only-type-2-diabetes-medicine-approved-to-reduce-cardiovascular-events-in-adults-with-and-without-established-cardiovascular-disease,24-02-2020 00:00,,,,,,
2270,medtronic-recalls-minimed-insulin-pumps-for-incorrect-insulin-dosing,13-02-2020 00:00,,,,,,
2271,fda-approves-lundbeck?s-vyepti-eptinezumab-jjmr-?-the-first-and-only-intravenous-preventive-treatment-for-migraine,24-02-2020 00:00,,,,,,
2272,benevolentai-announces-scientific-collaboration-with-uc-san-diego-to-investigate-cerebral-cavernous-malformations,13-02-2020 00:00,,,,,,
2273,fda-authorizes-marketing-of-the-first-genetic-test-to-aid-in-the-diagnosis-of-fragile-x-syndrome,24-02-2020 00:00,,,,,,
2274,medtronic-to-advance-solutions-and-capabilities-in-surgical-data-and-analytics-with-acquisition-of-digital-surgery,13-02-2020 00:00,,,,,,
2275,paratek-announces-license-grant-to-almirall-for-seysara?-sarecycline-for-greater-china-region,24-02-2020 00:00,,,,,,
2276,amgen-canada-receives-approval-of-marketing-authorization-transfer-of-otezla-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-and-psoriatic-arthritis,13-02-2020 00:00,,,,,,
2277,clover-and-gsk-announce-research-collaboration-to-evaluate-coronavirus-covid-19-vaccine-candidate-with-pandemic-adjuvant-system,24-02-2020 00:00,,,,,,
2278,us-food-and-drug-administration-fda-accepts-for-priority-review-bristol-myers-squibb?s-biologics-license-application-bla-for-lisocabtagene-maraleucel-liso-cel-for-adult-patients-with-relapsed-or-refractory-large-b-cell-lymphoma,13-02-2020 00:00,,,,,,
2279,sanofi-to-create-new-industry-leading-european-company-to-provide-active-pharmaceutical-ingredients-api,25-02-2020 00:00,,,,,,
2280,thermo-fisher-scientific-announces-collaboration-to-develop-highly-sensitive-analytical-workflow-for-infectious-disease-diagnosis-and-patient-monitoring,14-02-2020 00:00,,,,,,
2281,fda-accepts-roche?s-biologics-license-application-for-fixed-dose-subcutaneous-combination-of-perjeta-and-herceptin-for-her2-positive-breast-cancer,25-02-2020 00:00,,,,,,
2282,china-national-medical-products-administration-grants-approval-of-roche?s-tecentriq-in-combination-with-chemotherapy-as-first-line-treatment-of-people-with-extensive-stage-small-cell-lung-cancer,14-02-2020 00:00,,,,,,
2283,license-to-redhill-biopharma-supports-astrazeneca?s-focus-on-main-therapy-areas,25-02-2020 00:00,,,,,,
2284,orthofix-announces-fda-approval-of-stim-ontrack-21-mobile-app-for-bone-growth-stimulators,14-02-2020 00:00,,,,,,
2285,codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19,14-02-2020 00:00,,,,,,
2286,stada-becomes-a-major-consumer-healthcare-player-by-acquiring-15-well-established-gsk-brands,25-02-2020 00:00,,,,,,
2287,fda-grants-soligenix-fast-track-designation-for-rivax-in-the-prevention-of-ricin-poisoning,14-02-2020 00:00,,,,,,
2288,takeda-announces-that-the-fda-has-granted-a-priority-assessment-to-the-additional-request-for-a-new-drug-for-alunbrig-brigatinib,25-02-2020 00:00,,,,,,
2289,epizyme-announces-fda-acceptance-of-new-drug-application-for-filing-with-priority-review-for-tazverik-tazemetostat-for-the-treatment-of-follicular-lymphoma,14-02-2020 00:00,,,,,,
2290,fda-clears-novalung-for-treatment-of-acute-respiratory-and-cardiopulmonary-failure,25-02-2020 00:00,,,,,,
2291,international-childhood-cancer-day-announcement-global-hope-teva-and-direct-relief-partner-to-bring-medicines-to-help-improve-the-lives-of-children-with-cancer-in-africa,17-02-2020 00:00,,,,,,
2292,bicycle-therapeutics-announces-exclusive-strategic-collaboration-with-genentech-to-develop-and-commercialize-bicycle?-based-immuno-oncology-therapies,25-02-2020 00:00,,,,,,
2293,ervebo-ebola-zaire-vaccine-live-now-registered-in-four-african-countries-within-90-days-of-reference-country-approval-and-who-prequalification,17-02-2020 00:00,,,,,,
2294,novartis-and-dndi-to-collaborate-on-the-development-of-a-new-oral-drug-to-treat-visceral-leishmaniasis,26-02-2020 00:00,,,,,,
2295,pharmamar-and-jazz-pharmaceuticals-announce-fda-acceptance-and-priority-review-of-new-drug-application-for-lurbinectedin-in-relapsed-small-cell-lung-cancer,17-02-2020 00:00,,,,,,
2296,wuxi-biologics-and-vir-biotechnology-announce-collaboration-for-global-development-of-antibodies-to-treat-covid-19,26-02-2020 00:00,,,,,,
2297,celltrion-healthcare-showcases-positive-1-year-results-for-novel-subcutaneous-formulation-of-infliximab-in-patients-with-active-crohn?s-disease-and-ulcerative-colitis-presented-at-the-european-crohns-and-colitis-organisation-ecco-annual-congress,17-02-2020 00:00,,,,,,
2298,takeda-acquires-pvp-biologics-following-results-of-a-phase-1-study-of-tak-062-kuma062-for-the-treatment-of-celiac-disease,26-02-2020 00:00,,,,,,
2299,novartis-receives-ec-approval-for-beovu-a-next-generation-anti-vegf-treatment-for-wet-amd-a-leading-cause-of-blindness-worldwide,17-02-2020 00:00,,,,,,
2300,johnson-johnson-launches-heartline?-the-first-of-its-kind-virtual-study-designed-to-explore-if-a-new-iphone-app-and-apple-watch-can-help-reduce-the-risk-of-stroke,26-02-2020 00:00,,,,,,
2301,zydus-cadila-launches-a-fast-tracked-programme-to-develop-vaccine-for-the-novel-coronavirus-2019-ncov-covid-19,17-02-2020 00:00,,,,,,
2302,fda-in-brief-fda-enhances-purple-book-to-support-transparency-in-biosimilars,26-02-2020 00:00,,,,,,
2303,changes-to-marketing-arrangements-of-the-sglt2-inhibitor-tofogliflozin-hydrate-in-japan,18-02-2020 00:00,,,,,,
2304,eisai-and-fuji-yakuhin-conclude-license-agreement-concerning-the-development-and-distribution-of-dotinurad-a-treatment-for-hyperuricemia-and-gout-in-china,26-02-2020 00:00,,,,,,
2305,fda-approves-gsk?s-voltaren-arthritis-pain-for-over-the-counter-use-in-the-united-states,18-02-2020 00:00,,,,,,
2306,gilead-sciences-initiates-two-phase-3-studies-of-investigational-antiviral-remdesivir-for-the-treatment-of-covid-19,27-02-2020 00:00,,,,,,
2307,noxopharm-alliance-with-genesiscare,18-02-2020 00:00,,,,,,
2308,taiwan-firm-teams-up-with-us-to-develop-covid-19-vaccine,18-02-2020 00:00,,,,,,
2309,gemini-therapeutics-and-singapore-eye-research-institute-enter-into-research-collaboration-to-explore-new-targets-for-age-related-macular-degeneration,27-02-2020 00:00,,,,,,
2310,headaterm-tens-therapy-proves-to-be-a-fast-and-effective-treatment-for-acute-migraine-a-randomized-controlled-trial,18-02-2020 00:00,,,,,,
2311,hikma-and-glenmark-pharmaceuticals-enter-into-exclusive-licensing-agreement-for-commercialising-ryaltris-seasonal-allergic-rhinitis-nasal-spray-in-the-us,27-02-2020 00:00,,,,,,
2312,european-commission-approves-vyndaqel-the-first-treatment-in-the-eu-for-transthyretin-amyloid-cardiomyopathy-attr-cm,18-02-2020 00:00,,,,,,
2313,esperion-announces-fda-approval-of-the-nexlizetbempedoic-acid-and-ezetimibe-tablet-an-oral-once-daily-non-statin-ldl-cholesterol-lowering-medicine,27-02-2020 00:00,,,,,,
2314,chugai-receives-orphan-drug-designation-for-rg6042-in-huntingtons-disease-from-the-mhlw,18-02-2020 00:00,,,,,,
2315,european-medicines-agency-accepts-submission-of-gsk?s-marketing-authorisation-application-for-zejula-niraparib-in-first-line-maintenance-treatment-for-women-with-platinum-responsive-advanced-ovarian-cancer,27-02-2020 00:00,,,,,,
2316,sanofi-joins-forces-with-us-department-of-health-and-human-services-to-advance-a-novel-coronavirus-vaccine,19-02-2020 00:00,,,,,,
2317,co-diagnostics-inc-receives-ce-mark-for-novel-coronavirus-test,27-02-2020 00:00,,,,,,
2318,fda-grants-priority-review-to-roche?s-tecentriq-monotherapy-as-first-line-treatment-of-certain-people-with-advanced-non-small-cell-lung-cancer,19-02-2020 00:00,,,,,,
2319,celltrion-approved-for-domestic-sales-of-remshima-sc-drug-for-autoimmune-diseases,28-02-2020 00:00,,,,,,
2320,world?s-first-bedside-mri-system-receives-fda-510k-clearance,19-02-2020 00:00,,,,,,
2321,biogen-and-sangamo-announce-global-collaboration-to-develop-gene-regulation-therapies-for-alzheimer?s-parkinson?s-neuromuscular-and-other-neurological-diseases,28-02-2020 00:00,,,,,,
2322,abbott-introduces-next-generation-heart-rhythm-management-devices-in-europe-featuring-state-of-the-art-patient-app-and-bluetooth-connectivity,19-02-2020 00:00,,,,,,
2323,boehringer-ingelheim-enters-discovery-stage-collaboration-with-trutino-biosciences-to-grow-its-cancer-immunology-portfolio-with-novel-cytokine-platform,28-02-2020 00:00,,,,,,
2324,johnson-johnson-to-expand-partnership-with-us-department-of-health-human-services-to-accelerate-the-discovery-of-potential-covid-19-treatments,19-02-2020 00:00,,,,,,
2325,fujifilm-acquires-ce-mark-and-launches-cad-eye-a-function-of-colonic-polyp-detection-utilizing-ai-technology-in-europe,28-02-2020 00:00,,,,,,
2326,sarepta-therapeutics-announces-fda-approval-of-vyondys-53-golodirsen-injection-for-the-treatment-of-duchenne-muscular-dystrophy-dmd-in-patients-amenable-to-skipping-exon-53,12-12-2019 00:00,,,,,,
2327,first-of-its-kind-global-collaboration-launched-to-develop-transformative-treatment-regimens-for-tuberculosis,28-02-2020 00:00,,,,,,
2328,abbott-collaborates-with-insulet-to-integrate-glucose-sensing-technology-with-automated-insulin-delivery-system-for-seamless-diabetes-care,19-02-2020 00:00,,,,,,
2329,takeda-receives-positive-chmp-opinion-for-subcutaneous-formulation-of-vedolizumab-for-use-as-maintenance-therapy-in-adults-with-moderately-to-severely-active-ulcerative-colitis-or-crohn?s-disease,28-02-2020 00:00,,,,,,
2330,fda-grants-accelerated-approval-to-astellas-and-seattle-genetics-padcev-enfortumab-vedotin-ejfv-for-people-with-locally-advanced-or-metastatic-urothelial-cancer-the-most-common-type-of-bladder-cancer,18-12-2019 00:00,,,,,,
2331,fda-clears-inpen-diabetes-management-system-for-fixed-dosing-and-meal-estimation,28-02-2020 00:00,,,,,,
2332,wuxi-vaccines-signed-long-term-vaccine-manufacturing-contract-with-a-global-vaccine-leader,19-02-2020 00:00,,,,,,
2333,erbitux-approved-for-first-line-use-in-china-in-patients-with-recurrent-andor-metastatic-squamous-cell-carcinoma-of-the-head-and-neck-rm-scchn,02-03-2020 00:00,,,,,,
2334,merck-divests-allergopharma-to-dermapharm-holding-se,20-02-2020 00:00,,,,,,
2335,boehringer-ingelheim-receives-positive-chmp-opinion-for-nintedanib-for-the-treatment-of-systemic-sclerosis-associated-interstitial-lung-disease,02-03-2020 00:00,,,,,,
2336,astellas-and-seattle-genetics-receive-fda-breakthrough-therapy-designation-for-padcev-enfortumab-vedotin-ejfv-in-combination-with-pembrolizumab-in-first-line-advanced-bladder-cancer,20-02-2020 00:00,,,,,,
2337,medexus-expands-its-us-product-portfolio-by-acquiring-the-hematology-asset-ixinity,02-03-2020 00:00,,,,,,
2338,fda-approves-intra-cellular-therapies?-novel-antipsychotic-caplyta?-lumateperone-for-the-treatment-of-schizophrenia-in-adults,23-01-2020 00:00,,,,,,
2339,gilead-to-acquire-forty-seven-for-49-billion,02-03-2020 00:00,,,,,,
2340,takeda-agrees-to-divest-select-otc-and-non-core-assets-in-latin-america-to-hypera-pharma-for-825-million-usd,02-03-2020 00:00,,,,,,
2341,blueprint-medicines-announces-fda-approval-of-ayvakit-avapritinib-for-the-treatment-of-adults-with-unresectable-or-metastatic-pdgfra-exon-18-mutant-gastrointestinal-stromal-tumor,09-01-2020 00:00,,,,,,
2342,us-fda-accepts-regulatory-submission-for-tanezumab-a-potential-first-in-class-treatment-for-patients-with-chronic-pain-due-to-moderate-to-severe-osteoarthritis,02-03-2020 00:00,,,,,,
2343,vifor-pharma-and-fresenius-kabi-create-joint-venture-in-china-for-iv-iron-portfolio,20-02-2020 00:00,,,,,,
2344,uniqure-and-gen-x-enter-into-research-collaboration-and-license-agreement-for-the-development-of-novel-synthetic-promoters,03-03-2020 00:00,,,,,,
2345,us-fda-approves-eisai?s-dayvigo?-lemborexant-for-treatment-of-insomnia-in-adult-patients,23-12-2019 00:00,,,,,,
2346,fda-approves-sarclisa-isatuximab-irfc-for-patients-with-relapsed-refractory-multiple-myeloma,03-03-2020 00:00,,,,,,
2347,abbott-vascular-recalls-nc-trek-rx-and-nc-traveler-rx-coronary-dilatation-catheters-due-to-failure-of-balloon-diameter-40mm-45mm-and-500mm-to-deflate,20-02-2020 00:00,,,,,,
2348,thermo-fisher-scientific-to-acquire-qiagen-nv,03-03-2020 00:00,,,,,,
2349,nimble-announces-collaboration-with-genentech-to-discover-and-develop-novel-peptide-based-therapeutics,20-02-2020 00:00,,,,,,
2350,insulet-provides-update-on-pivotal-study-of-omnipod-horizon,03-03-2020 00:00,,,,,,
2351,roche-presents-rochediabetes-insulinstart-a-new-service-to-help-you-get-started-with-insulin-therapy,20-02-2020 00:00,,,,,,
2352,fda-grants-breakthrough-therapy-designation-for-genentech?s-esbriet-pirfenidone-in-unclassifiable-interstitial-lung-disease,03-03-2020 00:00,,,,,,
2353,immatics-and-gsk-partner-to-develop-novel-adoptive-cell-therapies,21-02-2020 00:00,,,,,,
2354,pavmed-subsidiary-lucid-diagnostics-partners-with-university-of-pennsylvania-to-evaluate-esocheck-in-eosinophilic-esophagitis-eoe-patients,03-03-2020 00:00,,,,,,
2355,biomarins-biologics-license-application-for-valoctocogene-roxaparvovec-accepted-for-priority-review-by-fda-with-review-action-date-of-august-21-2020,21-02-2020 00:00,,,,,,
2356,novartis-receives-health-canada-approval-for-mayzent-siponimod-to-treat-secondary-progressive-multiple-sclerosis-with-active-disease,03-03-2020 00:00,,,,,,
2357,vbl-therapeutics-announces-the-launch-of-a-new-clinical-trial-of-vb-111-combined-with-the-checkpoint-inhibitor-nivolumab-in-metastatic-colorectal-cancer,21-02-2020 00:00,,,,,,
2358,voluntis-and-bristol-myers-squibb-to-co-develop-digital-therapeutics-for-oncology,04-03-2020 00:00,,,,,,
2359,teva-announces-registration-trials-of-deutetrabenazine-in-pediatric-patients-with-tourette-syndrome-did-not-meet-the-primary-endpoint,21-02-2020 00:00,,,,,,
2360,chugai-obtains-approval-for-additional-indication-of-rozlytrek-for-ros1-fusion-positive-non-small-cell-lung-cancer,21-02-2020 00:00,,,,,,
2361,esperion-announces-fda-approval-of-nexletol-bempedoic-acid-tablet-an-oral-once-daily-non-statin-ldl-cholesterol-lowering-medicine,24-02-2020 00:00,,,,,,
2362,novartis-announces-fda-and-ema-filing-acceptance-of-ofatumumab-a-novel-b-cell-therapy-for-patients-with-relapsing-forms-of-multiple-sclerosis-rms,24-02-2020 00:00,,,,,,
2363,trulicity?-dulaglutide-is-the-first-and-only-type-2-diabetes-medicine-approved-to-reduce-cardiovascular-events-in-adults-with-and-without-established-cardiovascular-disease,24-02-2020 00:00,,,,,,
2364,fda-approves-lundbeck?s-vyepti-eptinezumab-jjmr-?-the-first-and-only-intravenous-preventive-treatment-for-migraine,24-02-2020 00:00,,,,,,
2365,fda-authorizes-marketing-of-the-first-genetic-test-to-aid-in-the-diagnosis-of-fragile-x-syndrome,24-02-2020 00:00,,,,,,
2366,paratek-announces-license-grant-to-almirall-for-seysara?-sarecycline-for-greater-china-region,24-02-2020 00:00,,,,,,
2367,clover-and-gsk-announce-research-collaboration-to-evaluate-coronavirus-covid-19-vaccine-candidate-with-pandemic-adjuvant-system,24-02-2020 00:00,,,,,,
2368,sanofi-to-create-new-industry-leading-european-company-to-provide-active-pharmaceutical-ingredients-api,25-02-2020 00:00,,,,,,
2369,fda-accepts-roche?s-biologics-license-application-for-fixed-dose-subcutaneous-combination-of-perjeta-and-herceptin-for-her2-positive-breast-cancer,25-02-2020 00:00,,,,,,
2370,license-to-redhill-biopharma-supports-astrazeneca?s-focus-on-main-therapy-areas,25-02-2020 00:00,,,,,,
2371,stada-becomes-a-major-consumer-healthcare-player-by-acquiring-15-well-established-gsk-brands,25-02-2020 00:00,,,,,,
2372,takeda-announces-that-the-fda-has-granted-a-priority-assessment-to-the-additional-request-for-a-new-drug-for-alunbrig-brigatinib,25-02-2020 00:00,,,,,,
2373,fda-clears-novalung-for-treatment-of-acute-respiratory-and-cardiopulmonary-failure,25-02-2020 00:00,,,,,,
2374,bicycle-therapeutics-announces-exclusive-strategic-collaboration-with-genentech-to-develop-and-commercialize-bicycle?-based-immuno-oncology-therapies,25-02-2020 00:00,,,,,,
2375,novartis-and-dndi-to-collaborate-on-the-development-of-a-new-oral-drug-to-treat-visceral-leishmaniasis,26-02-2020 00:00,,,,,,
2376,wuxi-biologics-and-vir-biotechnology-announce-collaboration-for-global-development-of-antibodies-to-treat-covid-19,26-02-2020 00:00,,,,,,
2377,takeda-acquires-pvp-biologics-following-results-of-a-phase-1-study-of-tak-062-kuma062-for-the-treatment-of-celiac-disease,26-02-2020 00:00,,,,,,
2378,johnson-johnson-launches-heartline?-the-first-of-its-kind-virtual-study-designed-to-explore-if-a-new-iphone-app-and-apple-watch-can-help-reduce-the-risk-of-stroke,26-02-2020 00:00,,,,,,
2379,fda-in-brief-fda-enhances-purple-book-to-support-transparency-in-biosimilars,26-02-2020 00:00,,,,,,
2380,eisai-and-fuji-yakuhin-conclude-license-agreement-concerning-the-development-and-distribution-of-dotinurad-a-treatment-for-hyperuricemia-and-gout-in-china,26-02-2020 00:00,,,,,,
2381,gilead-sciences-initiates-two-phase-3-studies-of-investigational-antiviral-remdesivir-for-the-treatment-of-covid-19,27-02-2020 00:00,,,,,,
2382,gemini-therapeutics-and-singapore-eye-research-institute-enter-into-research-collaboration-to-explore-new-targets-for-age-related-macular-degeneration,27-02-2020 00:00,,,,,,
2383,hikma-and-glenmark-pharmaceuticals-enter-into-exclusive-licensing-agreement-for-commercialising-ryaltris-seasonal-allergic-rhinitis-nasal-spray-in-the-us,27-02-2020 00:00,,,,,,
2384,esperion-announces-fda-approval-of-the-nexlizetbempedoic-acid-and-ezetimibe-tablet-an-oral-once-daily-non-statin-ldl-cholesterol-lowering-medicine,27-02-2020 00:00,,,,,,
2385,european-medicines-agency-accepts-submission-of-gsk?s-marketing-authorisation-application-for-zejula-niraparib-in-first-line-maintenance-treatment-for-women-with-platinum-responsive-advanced-ovarian-cancer,27-02-2020 00:00,,,,,,
2386,co-diagnostics-inc-receives-ce-mark-for-novel-coronavirus-test,27-02-2020 00:00,,,,,,
2387,celltrion-approved-for-domestic-sales-of-remshima-sc-drug-for-autoimmune-diseases,28-02-2020 00:00,,,,,,
2388,biogen-and-sangamo-announce-global-collaboration-to-develop-gene-regulation-therapies-for-alzheimer?s-parkinson?s-neuromuscular-and-other-neurological-diseases,28-02-2020 00:00,,,,,,
2389,boehringer-ingelheim-enters-discovery-stage-collaboration-with-trutino-biosciences-to-grow-its-cancer-immunology-portfolio-with-novel-cytokine-platform,28-02-2020 00:00,,,,,,
2390,fujifilm-acquires-ce-mark-and-launches-cad-eye-a-function-of-colonic-polyp-detection-utilizing-ai-technology-in-europe,28-02-2020 00:00,,,,,,
2391,first-of-its-kind-global-collaboration-launched-to-develop-transformative-treatment-regimens-for-tuberculosis,28-02-2020 00:00,,,,,,
2392,takeda-receives-positive-chmp-opinion-for-subcutaneous-formulation-of-vedolizumab-for-use-as-maintenance-therapy-in-adults-with-moderately-to-severely-active-ulcerative-colitis-or-crohn?s-disease,28-02-2020 00:00,,,,,,
2393,fda-clears-inpen-diabetes-management-system-for-fixed-dosing-and-meal-estimation,28-02-2020 00:00,,,,,,
2394,erbitux-approved-for-first-line-use-in-china-in-patients-with-recurrent-andor-metastatic-squamous-cell-carcinoma-of-the-head-and-neck-rm-scchn,02-03-2020 00:00,,,,,,
2395,boehringer-ingelheim-receives-positive-chmp-opinion-for-nintedanib-for-the-treatment-of-systemic-sclerosis-associated-interstitial-lung-disease,02-03-2020 00:00,,,,,,
2396,medexus-expands-its-us-product-portfolio-by-acquiring-the-hematology-asset-ixinity,02-03-2020 00:00,,,,,,
2397,gilead-to-acquire-forty-seven-for-49-billion,02-03-2020 00:00,,,,,,
2398,takeda-agrees-to-divest-select-otc-and-non-core-assets-in-latin-america-to-hypera-pharma-for-825-million-usd,02-03-2020 00:00,,,,,,
2399,us-fda-accepts-regulatory-submission-for-tanezumab-a-potential-first-in-class-treatment-for-patients-with-chronic-pain-due-to-moderate-to-severe-osteoarthritis,02-03-2020 00:00,,,,,,
2400,uniqure-and-gen-x-enter-into-research-collaboration-and-license-agreement-for-the-development-of-novel-synthetic-promoters,03-03-2020 00:00,,,,,,
2401,fda-approves-sarclisa-isatuximab-irfc-for-patients-with-relapsed-refractory-multiple-myeloma,03-03-2020 00:00,,,,,,
2402,thermo-fisher-scientific-to-acquire-qiagen-nv,03-03-2020 00:00,,,,,,
2403,insulet-provides-update-on-pivotal-study-of-omnipod-horizon,03-03-2020 00:00,,,,,,
2404,fda-grants-breakthrough-therapy-designation-for-genentech?s-esbriet-pirfenidone-in-unclassifiable-interstitial-lung-disease,03-03-2020 00:00,,,,,,
2405,pavmed-subsidiary-lucid-diagnostics-partners-with-university-of-pennsylvania-to-evaluate-esocheck-in-eosinophilic-esophagitis-eoe-patients,03-03-2020 00:00,,,,,,
2406,novartis-receives-health-canada-approval-for-mayzent-siponimod-to-treat-secondary-progressive-multiple-sclerosis-with-active-disease,03-03-2020 00:00,,,,,,
2407,voluntis-and-bristol-myers-squibb-to-co-develop-digital-therapeutics-for-oncology,04-03-2020 00:00,,,,,,
2408,fda-grants-breakthrough-device-designation-for-roches-elecsys-galad-score-to-support-earlier-diagnosis-of-hepatocellular-carcinoma,04-03-2020 00:00,,,,,,
2409,takeda-initiates-development-of-a-plasma-derived-therapy-for-covid-19,04-03-2020 00:00,,,,,,
2410,gilead-sciences-announces-two-phase-3-randomised-studies-to-evaluate-the-safety-and-antiviral-activity-of-remdesivir-gs-5734-in-participants-with-moderate-to-severe-covid-19,02-04-2020 00:00,,,,,,
2411,merck-announces-keytruda-pembrolizumab-significantly-improved-progression-free-survival-as-first-line-treatment-for-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer,02-04-2020 00:00,,,,,,
2412,vir-and-alnylam-expand-collaboration-to-advance-investigational-rnai-therapeutics-targeting-host-factors-for-the-treatment-of-covid-19,02-04-2020 00:00,,,,,,
2413,pfizer-receives-european-approval-for-oncology-biosimilar-ruxience-rituximab,03-04-2020 00:00,,,,,,
2414,celularity-announces-fda-clearance-of-ind-application-for-cynk-001-in-coronavirus-first-in-cellular-therapy,03-04-2020 00:00,,,,,,
2415,amgen-and-adaptive-biotechnologies-announce-strategic-partnership-to-develop-a-therapeutic-to-prevent-or-treat-covid-19,03-04-2020 00:00,,,,,,
2416,novartis-announces-plan-to-initiate-clinical-study-of-jakavi-in-severe-covid-19-patients-and-establish-international-compassionate-use-program,03-04-2020 00:00,,,,,,
2417,celltrion?s-covid-19-antiviral-treatment-enters-the-next-phase-of-development,03-04-2020 00:00,,,,,,
2418,sorrento-to-provide-manufacturing-support-to-celularity-as-cynk-001-nk-cell-trial-for-covid-19-begins-enrolling-patients,03-04-2020 00:00,,,,,,
2419,update-on-gsk-actions-to-support-the-global-response-to-covid-19,06-04-2020 00:00,,,,,,
2420,ema-provides-recommendations-on-compassionate-use-of-remdesivir-for-covid-19,06-04-2020 00:00,,,,,,
2421,fate-therapeutics-announces-worldwide-collaboration-with-janssen-for-novel-ipsc-derived-cell-based-cancer-immunotherapies,06-04-2020 00:00,,,,,,
2422,gilead-sciences-and-second-genome-announce-strategic-collaboration-in-biomarker-and-inflammatory-bowel-disease-drug-discovery,06-04-2020 00:00,,,,,,
2423,evotec-and-takeda-enter-into-multi-year-gene-therapy-research-alliance,06-04-2020 00:00,,,,,,
2424,sanofi-finalizes-praluent-alirocumab-restructuring-with-regeneron,07-04-2020 00:00,,,,,,
2425,alnylam-and-dicerna-form-rnai-therapeutics-collaboration-on-alpha-1-antitrypsin-deficiency-associated-liver-disease-and-complete-cross-license-agreement-for-primary-hyperoxaluria-programs,07-04-2020 00:00,,,,,,
2426,gsk-and-vir-biotechnology-enter-collaboration-to-find-coronavirus-solutions,07-04-2020 00:00,,,,,,
2427,european-commission-approves-takeda?s-alunbrig-brigatinib-as-a-first-line-treatment-for-alk-nsclc,07-04-2020 00:00,,,,,,
2428,cytodyn-collaborating-with-uk?s-department-of-health-to-provide-emergency-access-to-leronlimab-for-severe-and-critically-ill-covid-19-patients,07-04-2020 00:00,,,,,,
2429,merck-receives-priority-review-from-fda-for-second-application-for-keytruda?-pembrolizumab-based-on-biomarker-regardless-of-tumor-type,07-04-2020 00:00,,,,,,
2430,roche-provides-regulatory-update-on-risdiplam-for-the-treatment-of-spinal-muscular-atrophy-sma,08-04-2020 00:00,,,,,,
2431,oxford-biomedica-joins-consortium-to-rapidly-develop-a-covid-19-vaccine-candidate,08-04-2020 00:00,,,,,,
2432,bristol-myers-squibb-expands-patient-support-programs-to-help-newly-uninsured-patients-in-the-us,08-04-2020 00:00,,,,,,
2433,bayer-launches-pre-filled-syringe-to-administer-eye-medication-eylea-in-europe,08-04-2020 00:00,,,,,,
2434,regeneron-and-zai-lab-announce-regional-strategic-collaboration-for-regn1979-cd20xcd3-bispecific-antibody,08-04-2020 00:00,,,,,,
2435,insulin-gains-new-pathway-to-increased-competition,23-03-2020 00:00,,,,,,
2436,russian-antitumor-drugs-first-time-received-a-registration-certificate-in-europe,30-03-2020 00:00,,,,,,
2437,arrakis-therapeutics-enters-strategic-collaboration-and-license-agreement-with-roche-for-multi-target-program-utilizing-rna-targeted-small-molecule-drug-discovery-platform,08-04-2020 00:00,,,,,,
2438,researching-antibodies-to-target-covid-19,09-04-2020 00:00,,,,,,
2439,chugai-starts-phase-iii-clinical-trial-of-actemra-for-covid-19-pneumonia-in-japan,09-04-2020 00:00,,,,,,
2440,novavax-identifies-coronavirus-vaccine-candidate-accelerates-initiation-of-first-in-human-trial-to-mid-may,09-04-2020 00:00,,,,,,
2441,physicians-urge-fda-to-waive-interchangeability-standard-for-insulin-biosimilars,09-04-2020 00:00,,,,,,
2442,emd-serono-and-pfizer-receive-us-fda-breakthrough-therapy-designation-and-submit-application-for-bavencio-for-first-line-maintenance-treatment-of-locally-advanced-or-metastatic-urothelial-carcinoma,09-04-2020 00:00,,,,,,
2443,supporting-uk-national-effort-to-boost-covid-19-testing,09-04-2020 00:00,,,,,,
2444,pfizer-and-biontech-announce-further-details-on-collaboration-to-accelerate-global-covid-19-vaccine-development,09-04-2020 00:00,,,,,,
2445,astellas-announces-acceptance-of-xospata?-gilteritinib-for-regulatory-review-in-china-by-the-national-medical-products-administration,10-04-2020 00:00,,,,,,
2446,neoimmunetech-announces-clinical-collaboration-with-bristol-myers-squibb-to-evaluate-nt-i7-hyleukin-7?-in-combination-with-nivolumab,10-04-2020 00:00,,,,,,
2447,cipla-receives-final-approval-for-generic-version-of-proventil?-hfa-inhalation-aerosol-albuterol-sulfate-inhalation-aerosol-90mcg-baseactuation,10-04-2020 00:00,,,,,,
2448,abbott?s-triclip?-becomes-first-device-of-its-kind-to-receive-ce-mark-for-minimally-invasive-tricuspid-valve-repair,10-04-2020 00:00,,,,,,
2449,samsung-biologics-and-vir-biotechnology-enter-into-agreement-for-large-scale-manufacture-of-sars-cov-2-antibodies-for-potential-covid-19-treatment,10-04-2020 00:00,,,,,,
2450,amgen-e-adaptive-biotecnologies-anunciam-parceria-para-desenvolver-anticorpos-com-potencial-de-prevenir-ou-tratar-a-covid-19,10-04-2020 00:00,,,,,,
2451,revance-provides-corporate-update-and-anticipated-milestones-for-2020,30-03-2020 00:00,,,,,,
2452,apple-and-google-partner-on-covid-19-contact-tracing-technology,13-04-2020 00:00,,,,,,
2453,lilly-begins-clinical-testing-of-therapies-for-covid-19,13-04-2020 00:00,,,,,,
2454,terumo-bct-and-marker-therapeutics-received-the-first-device-fda-emergency-use-authorization-eua-to-treat-acute-respiratory-failure-in-covid-19-patients,13-04-2020 00:00,,,,,,
2455,koselugo-selumetinib-approved-in-us-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas,13-04-2020 00:00,,,,,,
2456,bausch-health-initiates-virazole-ribavirin-for-inhalation-solution-usp-clinical-study-in-patients-with-covid-19,13-04-2020 00:00,,,,,,
2457,blackstone-and-alnylam-enter-into-2-billion-strategic-financing-collaboration-to-accelerate-the-advancement-of-rnai-therapeutics,14-04-2020 00:00,,,,,,
2458,biocon-and-mylan-launch-fulphila-biosimilar-pegfilgrastim-in-australia,14-04-2020 00:00,,,,,,
2459,celltrion-completes-neutralisation-test-on-candidate-monoclonal-antibodies-mabs-for-covid-19-antiviral-antibody-treatment,14-04-2020 00:00,,,,,,
2460,bd-announces-second-fda-emergency-use-authorization-ce-mark-for-new-covid-19-molecular-diagnostic-for-global-use,14-04-2020 00:00,,,,,,
2461,sanofi-and-gsk-to-join-forces-in-unprecedented-vaccine-collaboration-to-fight-covid-19,14-04-2020 00:00,,,,,,
2462,b-braun-receives-fda-emergency-use-authorization-for-use-of-infusion-pumps-with-nebulizers-to-treat-covid-19-patients,14-04-2020 00:00,,,,,,
2463,alnylam-receives-fast-track-designation-for-vutrisiran-for-the-treatment-of-the-polyneuropathy-of-hattr-amyloidosis,14-04-2020 00:00,,,,,,
2464,astrazeneca-initiates-calavi-clinical-trial-with-calquence-against-covid-19,15-04-2020 00:00,,,,,,
2465,insilico-enters-into-a-research-collaboration-with-boehringer-ingelheim-to-apply-novel-generative-artificial-intelligence-system-for-discovery-of-potential-therapeutic-targets,15-04-2020 00:00,,,,,,
2466,sosei-heptares-to-apply-its-structure-based-drug-design-expertise-in-new-covid-19-rd-program,15-04-2020 00:00,,,,,,
2467,merck-announces-us-launch-of-ontruzant-trastuzumab-dttb-a-biosimilar-of-herceptin-trastuzumab,15-04-2020 00:00,,,,,,
2468,ortho?s-total-antibody-test-for-covid-19-receives-emergency-use-authorization-from-fda,15-04-2020 00:00,,,,,,
2469,abbott-launches-third-covid-19-test-a-laboratory-based-antibody-blood-test-that-will-ship-in-the-us-starting-tomorrow,15-04-2020 00:00,,,,,,
2470,ge-healthcare-deploys-remote-patient-data-monitoring-technology-to-help-clinicians-support-most-critical-covid-19-patients-across-the-health-system,16-04-2020 00:00,,,,,,
2471,vanda-pharmaceuticals-announces-initiation-of-?calypso?-to-study-the-role-of-genetic-variation-in-covid-19-infections-in-collaboration-with-university-of-washington-medicine,16-04-2020 00:00,,,,,,
2472,qiagen-launches-therascreen-braf-test-as-companion-diagnostic-to-a-braftovi?encorafenib-based-regimen-in-metastatic-colorectal-cancer,16-04-2020 00:00,,,,,,
2473,novavax-to-commence-covid-19-vaccine-trial-with-nucleus-network,16-04-2020 00:00,,,,,,
2474,dynavax-and-sinovac-announce-collaboration-to-develop-a-coronavirus-covid-19-vaccine,16-04-2020 00:00,,,,,,
2475,fda-accepts-for-priority-review-biologics-license-application-for-regn-eb3-to-treat-ebola,16-04-2020 00:00,,,,,,
2476,sanofi-and-luminostics-to-join-forces-on-developing-breakthrough-covid-19-smartphone-based-self-testing-solution,17-04-2020 00:00,,,,,,
2477,roche-develops-new-serology-test-to-detect-covid-19-antibodies,17-04-2020 00:00,,,,,,
2478,moderna-announces-award-from-us-government-agency-barda-for-up-to-483-million-to-accelerate-development-of-mrna-vaccine-mrna-1273-against-novel-coronavirus,17-04-2020 00:00,,,,,,
2479,chi-med-announces-surufatinib-granted-us-fda-fast-track-designations-for-the-treatment-of-both-pancreatic-and-non-pancreatic-neuroendocrine-tumors,17-04-2020 00:00,,,,,,
2480,1healthio-launches-the-first-covid-19-telehealth-supervised-self-collection-kit-50-000-test-kits-will-ship-immediately-ramping-up-to-300-000-kits-monthly-by-may,17-04-2020 00:00,,,,,,
2481,"sinovac-announces-commencement-of-phase-i-human-clinical-trial-for-vaccine-candidate-against-covid-19beijing?business-wire?sinovac-biotech-ltd-nasdaqsva-?sinovac?-or-the-?company?-a-leading-provider-of-biopharmaceutical-products-in-china-today-announced-that-the-company-has-commenced-phase-i-clinical-trial-a-randomized-double-blinded-placebo-controlled-study-for-its-vaccine-candidate-against-covid-19-enrollment-of-the-first-group-of-volunteers-and-the-first-dose-of-vaccination-for-these-volunteers-have-been-completed
-
-this-study-is-to-evaluate-the-safety-tolerance-and-preliminary-immunogenicity-of-the-company?s-sars-cov-2-vaccine-by-vaccinating-144-healthy-adults-aged-from-18-to-59-with-two-different-dosages-of-the-vaccine-candidate-two-thirds-of-the-volunteers-will-be-vaccinated-with-the-investigational-vaccine-while-one-third-of-volunteers-will-be-administered-with-the-placebo-the-trial-is-being-conducted-in-jiangsu-province
-
-on-april-13-2020-the-randomized-double-blinded-placebo-controlled-phase-iii-clinical-trials-of-the-inactivated-sars-cov-2-vaccine-developed-by-sinovac-was-approved-by-china?s-national-medical-products-administration-nmpa-to-evaluate-the-vaccine-candidate?s-safety-and-immunogenicity
-
-mr-weidong-yin-chairman-president-and-ceo-said-?the-vaccine-is-critical-to-the-eventual-prevention-of-the-spread-of-covid-19-commencing-our-human-trial-is-another-milestone-achieved-by-our-scientists-together-with-our-vaccine-development-partners-sinovac-will-accelerate-the-progress-of-our-research-in-order-to-support-the-worldwide-fight-against-covid-19?
-
-about-sinovac
-
-sinovac-biotech-ltd-is-a-china-based-biopharmaceutical-company-that-focuses-on-the-research-development-manufacturing-and-commercialization-of-vaccines-that-protect-against-human-infectious-diseases-sinovac?s-product-portfolio-includes-vaccines-against-enterovirus71-ev71-hepatitis-a-and-b-seasonal-influenza-h5n1-pandemic-influenza-avian-flu-h1n1-influenza-swine-flu-varicella-vaccine-and-mumps-healive-the-hepatitis-a-vaccine-manufactured-by-the-company-has-passed-the-assessment-under-who-prequalification-procedures-in-2017-the-ev71-vaccine-an-innovative-vaccine-developed-by-sinovac-against-hand-foot-and-mouth-disease-caused-by-ev71-was-commercialized-in-china-in-2016-in-2009-sinovac-was-the-first-company-worldwide-to-receive-approval-for-its-h1n1-influenza-vaccine-which-it-has-supplied-to-the-chinese-government?s-vaccination-campaign-and-stockpiling-program-the-company-is-also-the-only-supplier-of-the-h5n1-pandemic-influenza-vaccine-to-the-chinese-government?s-stockpiling-program-the-company-is-developing-a-number-of-new-products-including-a-sabin-strain-inactivated-polio-vaccine-pneumococcal-polysaccharides-vaccine-a-quadrivalent-influenza-vaccine-and-a-sars-cov-2-commonly-referred-to-as-covid-19-vaccine-sinovac-primarily-sells-its-vaccines-in-china-while-also-exploring-growth-opportunities-in-international-markets-the-company-is-registering-its-products-in-over-30-countries-outside-of-china-for-more-information-please-see-the-company?s-website-at-wwwsinovaccom
-
-safe-harbor-statement
-
-this-press-release-contains-?forward-looking-statements?-within-the-meaning-of-the-united-states-federal-securities-laws-such-statements-involve-known-and-unknown-risks-uncertainties-and-other-factors-that-may-cause-our-actual-results-levels-of-activity-performance-or-achievements-to-differ-materially-from-any-future-results-levels-of-activity-performance-or-achievements-expressed-or-implied-by-these-forward-looking-statements-factors-that-might-cause-such-a-difference-include-our-inability-to-compete-successfully-in-the-competitive-and-rapidly-changing-marketplace-in-which-we-operate-failure-to-retain-key-employees-cancellation-or-delay-of-projects-failure-to-satisfy-regulatory-and-other-requirements-disapproval-or-delay-in-approval-of-new-products-by-regulatory-bodies-disruptions-to-our-operations-the-results-of-any-pending-litigation-including-litigation-relating-to-the-2018-annual-general-meeting-the-validity-of-our-rights-agreement-and-the-issuance-of-the-exchange-shares-nasdaq?s-halt-in-trading-of-the-company?s-securities-and-any-future-action-taken-by-nasdaq-regarding-the-trading-of-the-company?s-securities-the-effects-of-natural-disasters-pandemics-and-outbreaks-of-contagious-diseases-and-other-adverse-public-health-developments-such-as-sars-cov-2-commonly-referred-to-as-covid-19-and-adverse-general-economic-conditions-in-china-the-united-states-and-elsewhere-these-risks-and-other-factors-include-those-listed-under-?risk-factors?-and-elsewhere-in-our-annual-report-on-form-20-f-as-filed-with-the-securities-and-exchange-commission-in-some-cases-you-can-identify-forward-looking-statements-by-terminology-such-as-?may-?-?will-?-?should-?-?expects-?-?intends-?-?plans-?-?anticipates-?-?believes-?-?estimates-?-?predicts-?-?potential-?-?continue-?-or-the-negative-of-these-terms-or-other-comparable-terminology-although-we-believe-that-the-expectations-reflected-in-the-forward-looking-statements-are-reasonable-we-cannot-guarantee-future-results-levels-of-activity-performance-or-achievements-the-company-assumes-no-obligation-to-update-the-forward-looking-information-contained-in-this-release
-
-
-
-contacts
-sinovac-biotech-ltd
-helen-yang
-tel-86-10-8279-9871-or
-86-10-5693-1897
-fax-86-10-6296-6910
-email-irsinovaccom
-
-icr-inc
-bill-zima
-us-1-646-308-1707
-email-williamzimaicrinccom",17-04-2020 00:00,,,,,,
2482,novartis-to-sponsor-large-clinical-trial-of-hydroxychloroquine-in-hospitalized-covid-19-patients,20-04-2020 00:00,,,,,,
2483,us-fda-and-ema-accept-applications-for-roche?s-ocrevus-ocrelizumab-shorter-2-hour-infusion-time,20-04-2020 00:00,,,,,,
2484,incyte-announces-initiation-of-phase-3-ruxcovid-study-evaluating-ruxolitinib-jakafi-as-a-treatment-for-patients-with-covid-19-associated-cytokine-storm,20-04-2020 00:00,,,,,,
2485,fosun-pharma-receives-the-us-fda?s-eua-for-its-covid-19-rt-pcr-detection-kit,20-04-2020 00:00,,,,,,
2486,esperion-announces-agreement-with-otsuka-pharmaceutical-co-ltd-for-development-and-commercialization-of-nexletol-bempedoic-acid-and-nexlizet-bempedoic-acid-and-ezetimibe-tablets-in-japan,20-07-2020 00:00,,,,,,
2487,alexion-announces-plans-to-initiate-phase-3-study-of-ultomiris-ravulizumab-cwvz-in-hospitalized-patients-with-severe-covid-19,20-04-2020 00:00,,,,,,
2488,redhill-biopharma-announces-agreement-with-niaid-to-evaluate-rhb-107-against-covid-19,21-04-2020 00:00,,,,,,
2489,cue-biopharma-announces-clinical-trial-collaboration-agreement-with-merck-to-evaluate-cue-101-in-combination-with-keytruda-pembrolizumab-as-first-line-treatment-for-hpv-recurrentmetastatic-head-and-neck-cancer,21-04-2020 00:00,,,,,,
2490,roche-receives-fda-approval-for-cobas-hpv-test-for-use-on-the-cobas-68008800-systems-to-identify-women-at-risk-for-cervical-cancer,21-04-2020 00:00,,,,,,
2491,approval-to-be-sought-for-covid-19-clinical-study-in-us,21-04-2020 00:00,,,,,,
2492,mogrify-and-sangamo-announce-collaboration-and-exclusive-license-agreement-for-mogrify?s-ipsc-and-esc-derived-regulatory-t-cells,21-04-2020 00:00,,,,,,
2493,novartis-announces-new-mayzent-siponimod-data-show-sustained-effect-in-delaying-disability-for-up-to-five-years-in-patients-with-secondary-progressive-multiple-sclerosis-spms,21-04-2020 00:00,,,,,,
2494,bayer-partners-with-population-health-research-institute-phri-on-global-clinical-research-evaluating-covid-19-treatments,22-04-2020 00:00,,,,,,
2495,gilead-kite-and-onko-innate-announce-research-collaboration-to-discover-cancer-immunotherapies-focused-on-natural-killer-nk-cells,22-04-2020 00:00,,,,,,
2496,novartis-kymriah-receives-fda-regenerative-medicine-advanced-therapy-designation-in-follicular-lymphoma,22-04-2020 00:00,,,,,,
2497,hope-biosciences-announces-third-fda-approved-clinical-trial-for-covid-19,22-04-2020 00:00,,,,,,
2498,biontech-and-pfizer-announce-regulatory-approval-from-german-authority-paul-ehrlich-institut-to-commence-first-clinical-trial-of-covid-19-vaccine-candidates,22-04-2020 00:00,,,,,,
2499,sobi-affiliate-florio-gmbh-launches-a-new-digital-platform-aiming-to-improve-the-lives-of-people-with-haemophilia,22-04-2020 00:00,,,,,,
2500,valneva-and-dynavax-announce-collaboration-to-advance-vaccine-development-for-covid-19,23-04-2020 00:00,,,,,,
2501,mergers-commission-approves-the-merger-of-mylan-and-pfizer?s-upjohn-division-subject-to-conditions,23-04-2020 00:00,,,,,,
2502,astrazeneca-and-saint-luke?s-mid-america-heart-institute-initiate-phase-iii-dare-19-trial-with-farxiga-in-covid-19-patients,23-04-2020 00:00,,,,,,
2503,labcorp-covid-19-at-home-test-kit-receives-fda-emergency-use-authorization,23-04-2020 00:00,,,,,,
2504,novodiag-covid-19-a-fully-automated-molecular-diagnostic-test-granted-emergency-use-authorization-in-finland-for-novel-coronavirus,23-04-2020 00:00,,,,,,
2505,theravance-biopharma-announces-first-subject-dosed-in-phase-1-study-of-td-0903-in-development-for-the-treatment-of-hospitalized-patients-with-acute-lung-injury-caused-by-covid-19,23-04-2020 00:00,,,,,,
2506,johnson-johnson-announces-collaboration-to-expand-manufacturing-capabilities-for-its-covid-19-vaccine-candidate-in-support-of-the-company?s-goal-to-supply-more-than-one-billion-vaccine-doses-globally,24-04-2020 00:00,,,,,,
2507,merck-resubmits-supplemental-biologics-license-applications-sblas-for-keytruda-pembrolizumab-six-week-dosing-schedule,24-04-2020 00:00,,,,,,
2508,lynparza-demonstrated-overall-survival-benefit-in-phase-iii-profound-trial-for-brca12-or-atm-mutated-metastatic-castration-resistant-prostate-cancer,24-04-2020 00:00,,,,,,
2509,takeda-continues-divestiture-strategy-with-sale-of-select-otc-and-non-core-assets-in-europe-to-orifarm-for-up-to-approximately-670m-usd,24-04-2020 00:00,,,,,,
2510,fda-approves-menquadfi-the-latest-innovation-in-meningococcal-menacwy-vaccination,24-04-2020 00:00,,,,,,
2511,santhera-and-cold-spring-harbor-laboratory-to-investigate-lonodelestat-pol6014-in-covid-19-related-acute-respiratory-distress-syndrome-ards,27-04-2020 00:00,,,,,,
2512,janssen-announces-submission-of-two-applications-to-us-fda-seeking-approval-of-simponi-aria-golimumab-for-the-treatment-of-polyarticular-juvenile-idiopathic-arthritis-and-juvenile-psoriatic-arthritis,27-04-2020 00:00,,,,,,
2513,positive-results-from-the-second-phase-iii-sakurastar-study-for-chugai?s-satralizumab-in-neuromyelitis-optica-spectrum-disorder-nmosd-published-in-the-lancet-neurology,27-04-2020 00:00,,,,,,
2514,regeneron-and-sanofi-provide-update-of-p-iiiii-adaptive-designed-trial-of-kevzara-in-hospitalized-patients-with-covid-19-in-the-us,27-04-2020 00:00,,,,,,
2515,clinical-trial-approved-to-help-the-nhs-treat-covid-19-patients-using-plasma,27-04-2020 00:00,,,,,,
2516,merck-and-institute-for-systems-biology-collaborate-to-define-molecular-mechanisms-of-sars-cov-2-infection-and-identify-potential-prognostic-biomarkers,28-04-2020 00:00,,,,,,
2517,roche?s-risdiplam-shows-significant-improvement-in-survival-and-motor-milestones-in-infants-with-type-1-spinal-muscular-atrophy-sma,28-04-2020 00:00,,,,,,
2518,cepi-announces-covid-19-vaccine-development-partnership-with-clover-biopharmaceuticals?-australian-subsidiary,28-04-2020 00:00,,,,,,
2519,takeda-announces-us-fda-breakthrough-therapy-designation-for-mobocertinib-tak-788-for-the-treatment-of-nsclc-patients-with-egfr-exon-20-insertion-mutations,28-04-2020 00:00,,,,,,
2520,abbott-receives-health-canada-authorization-under-interim-order-to-use-freestyle?-libre-system-for-hospitalized-patients-during-covid-19-pandemic,28-04-2020 00:00,,,,,,
2521,moderna-announces-ind-submitted-to-us-fda-for-phase-2-study-of-mrna-vaccine-mrna-1273-against-novel-coronavirus,28-04-2020 00:00,,,,,,
2522,biocon-and-mylan-launch-fulphila-biosimilar-pegfilgrastim-in-canada,28-04-2020 00:00,,,,,,
2523,sarepta-therapeutics-announces-research-agreement-with-us-department-of-defense-to-evaluate-multiple-constructs-from-its-proprietary-rna-platform-as-treatments-for-covid-19,29-04-2020 00:00,,,,,,
2524,novartis-cosentyx-gains-fourth-indication-in-eu-with-first-in-class-approval-in-axial-spondyloarthritis-spectrum,29-04-2020 00:00,,,,,,
2525,biontech-and-pfizer-announce-completion-of-dosing-for-first-cohort-of-phase-12-trial-of-covid-19-vaccine-candidates-in-germany,29-04-2020 00:00,,,,,,
2526,astellas-and-harvard-establish-strategic-research-alliance,29-04-2020 00:00,,,,,,
2527,novartis-announces-plan-to-initiate-clinical-trial-of-canakinumab-for-patients-with-covid-19-pneumonia,29-04-2020 00:00,,,,,,
2528,fda-approves-merck?s-keytruda-pembrolizumab-for-use-at-an-additional-recommended-dose-of-400-mg-every-six-weeks-for-all-approved-adult-indications,29-04-2020 00:00,,,,,,
2529,catalent-signs-agreement-with-johnson-johnson-to-be-us-manufacturing-partner-for-lead-covid-19-vaccine-candidate,30-04-2020 00:00,,,,,,
2530,gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19,30-04-2020 00:00,,,,,,
2531,astrazeneca-and-oxford-university-announce-landmark-agreement-for-covid-19-vaccine,30-04-2020 00:00,,,,,,
2532,fda-approves-zejula-niraparib-as-the-only-once-daily-parp-inhibitor-in-first-line-monotherapy-maintenance-treatment-for-women-with-platinum-responsive-advanced-ovarian-cancer-regardless-of-biomarker-status,30-04-2020 00:00,,,,,,
2533,curium-announces-approval-of-pulmotechtm-maa-kit-for-the-preparation-of-technetium-tc-99m-albumin-aggregated-injection-by-the-us-food-and-drug-administration,24-03-2020 00:00,,,,,,
2534,bergenbio?s-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative,30-04-2020 00:00,,,,,,
2535,rockwell-medical-inc-receives-fda-approval-for-triferic?-avnu-ferric-pyrophosphate-citrate-intravenous-formulation-of-triferic-for-replacement-of-iron-and-maintenance-of-hemoglobin-in-hemodialysis-patients,27-03-2020 00:00,,,,,,
2536,almac-discovery-to-collaborate-with-msd-on-selected-dub-therapeutic-targets,30-04-2020 00:00,,,,,,
2537,valneva-and-pfizer-announce-collaboration-to-co-develop-and-commercialize-lyme-disease-vaccine-vla15,01-05-2020 00:00,,,,,,
2538,moderna-and-lonza-announce-worldwide-strategic-collaboration-to-manufacture-moderna?s-vaccine-mrna-1273-against-novel-coronavirus,01-05-2020 00:00,,,,,,
2539,novartis-receives-chmp-positive-opinion-for-enerzair-breezhaler-qvm149-a-potential-first-in-class-inhaled-labalamaics-combination-for-uncontrolled-asthma,01-05-2020 00:00,,,,,,
2540,wuxi-biologics-and-aravive-form-strategic-collaboration-to-develop-novel-high-affinity-bispecific-antibodies-targeting-cancer-and-fibrosis-using-the-wuxibody-platform,01-05-2020 00:00,,,,,,
2541,gilead?s-investigational-antiviral-remdesivir-receives-us-food-and-drug-administration-emergency-use-authorization-for-the-treatment-of-covid-19,04-05-2020 00:00,,,,,,
2542,revance-and-mylan-biosimilar-to-botox?-program-decision-to-extend-beyond-april-30-2020,04-05-2020 00:00,,,,,,
2543,japan-health-ministry-expediting-remdesivir-for-covid-19-patients,04-05-2020 00:00,,,,,,
2544,roche?s-covid-19-antibody-test-receives-fda-emergency-use-authorization-and-is-available-in-markets-accepting-the-ce-mark,04-05-2020 00:00,,,,,,
2545,teva-and-celltrion-healthcare-announce-the-launch-of-truximarituximab-abbs-injection-for-rheumatoid-arthritis-the-only-biosimilar-to-rituxan-rituximab-available-in-the-united-states-for-this-indication,05-05-2020 00:00,,,,,,
2546,lilly-and-junshi-biosciences-to-co-develop-antibody-therapies-for-the-prevention-and-treatment-of-covid-19,05-05-2020 00:00,,,,,,
2547,vir-and-alnylam-identify-rnai-therapeutic-development-candidate-vir-2703-aln-cov-targeting-sars-cov-2-for-the-treatment-of-covid-19,05-05-2020 00:00,,,,,,
2548,alexion-to-acquire-portola,05-05-2020 00:00,,,,,,
2549,bio-rad-receives-fda-emergency-use-authorization-for-droplet-digital-pcr-sars-cov-2-test-kit,05-05-2020 00:00,,,,,,
2550,pfizer-and-biontech-dose-first-participants-in-the-us-as-part-of-global-covid-19-mrna-vaccine-development-program,06-05-2020 00:00,,,,,,
2551,neogenomics-and-bayer-collaborate-to-offer-ntrk-testing-for-certain-colorectal-and-thyroid-cancer-patients,06-05-2020 00:00,,,,,,
2552,regeneron-reports-first-quarter-2020-financial-and-operating-results,06-05-2020 00:00,,,,,,
2553,bavarian-nordic-enters-agreement-with-adaptvac-to-advance-covid-19-vaccine-program,06-05-2020 00:00,,,,,,
2554,libtayo-cemiplimab-shows-clinically-meaningful-and-durable-responses-in-second-line-advanced-basal-cell-carcinoma,06-05-2020 00:00,,,,,,
2555,ibio-supporting-azargen-biotechnologies?-development-of-a-rituximab-biosimilar,26-03-2020 00:00,,,,,,
2556,ptc-therapeutics-to-acquire-censa-pharmaceuticals,07-05-2020 00:00,,,,,,
2557,novartis-announces-fda-approval-of-met-inhibitor-tabrecta-for-metastatic-non-small-cell-lung-cancer-with-metex14,07-05-2020 00:00,,,,,,
2558,bausch-lomb-licenses-exclusive-rights-from-stada-and-xbrane-to-a-biosimilar-candidate-for-lucentis-ranibizumab-in-the-united-states-and-canada,07-05-2020 00:00,,,,,,
2559,amgen-announces-positive-top-line-results-from-otezla?-apremilast-phase-3-advance-study-in-mild-to-moderate-plaque-psoriasis,07-05-2020 00:00,,,,,,
2560,laurent-pharmaceuticals-receives-health-canada?s-approval-to-initiate-covid-19-clinical-trial-montreal-qc-canada-?-may-6th-2020,07-05-2020 00:00,,,,,,
2561,richter-entered-into-an-asset-purchase-agreement-with-mycenax-for-the-biosimilar-tocilizumab,29-04-2020 00:00,,,,,,
2562,henlius-receives-eu-gmp-certificate-for-hlx02-trastuzumab-for-injection,23-04-2020 00:00,,,,,,
2563,henlius-received-ind-approval-for-its-ipilimumab-biosimilar-hlx13-from-nmpa,08-04-2020 00:00,,,,,,
2564,xlucane-is-still-on-track-towards-regulatory-approval-ahead-of-lucentis-patent-expiration-in-eu-july-2022-despite-the-impact-of-covid-19-on-the-phase-iii-study-xplore,02-04-2020 00:00,,,,,,
2565,gilead-announces-approval-of-veklury-remdesivir-in-japan-for-patients-with-severe-covid-19,08-05-2020 00:00,,,,,,
2566,insulin-aspart-sanofi,30-04-2020 00:00,,,,,,
2567,alnylam-announces-approval-of-givlaari-givosiran-in-the-european-union-for-the-treatment-of-acute-hepatic-porphyria-ahp-in-adults-and-adolescents,04-03-2020 00:00,,,,,,
2568,iktos-and-sri-international-announce-collaboration-to-combine-artificial-intelligence-and-novel-automated-discovery-platform-for-accelerated-development-of-new-anti-viral-therapies,04-03-2020 00:00,,,,,,
2569,janssen-submits-european-marketing-authorisation-application-for-ponesimod-for-treatment-of-adults-with-relapsing-multiple-sclerosis,04-03-2020 00:00,,,,,,
2570,vir-and-alnylam-expand-collaboration-to-advance-rnai-therapeutics-for-the-treatment-of-coronavirus-infection-including-covid-19,05-03-2020 00:00,,,,,,
2571,allergan-and-editas-medicine-announce-dosing-of-first-patient-in-landmark-phase-12-clinical-trial-of-crispr-medicine-agn-151587-edit-101-for-the-treatment-of-lca10,05-03-2020 00:00,,,,,,
2572,fda-and-ftc-announce-new-efforts-to-further-deter-anti-competitive-business-practices-support-competitive-market-for-biological-products-to-help-americans,03-02-2020 00:00,,,,,,
2573,biosimilars-and-interchangeable-biosimilars-licensure-for-fewer-than-all-conditions-of-use-for-which-the-reference-product-has-been-licensed,07-02-2020 00:00,,,,,,
2574,alopexx-oncology-announces-licensing-agreement-with-beijing-shenogen-pharma-group-for-development-and-commercialization-of-novel-immunocytokine-for-the-treatment-of-b-cell-lymphomas-in-chinaasia,05-03-2020 00:00,,,,,,
2575,china-approves-use-of-roche-drug-in-battle-against-coronavirus-complications,05-03-2020 00:00,,,,,,
2576,mabxience-inaugurates-new-monoclonal-antibody-biosimilar-plant-in-argentina,24-02-2020 00:00,,,,,,
2577,zuellig-pharma-acquires-alliance-pharma-cambodge-in-cambodia-to-strengthen-indochina-presence,05-03-2020 00:00,,,,,,
2578,fda-informs-patients-providers-and-manufacturers-about-potential-cybersecurity-vulnerabilities-in-certain-medical-devices-with-bluetooth-low-energy,05-03-2020 00:00,,,,,,
2579,heat-biologics-announces-research-collaboration-with-university-of-miami-to-develop-vaccine-designed-to-protect-against-covid-19-coronavirus,06-03-2020 00:00,,,,,,
2580,digital-health-company-baysient-announces-cdshcei-software-to-reduce-healthcare-cost-in-the-biosimilar-market,28-02-2020 00:00,,,,,,
2581,orionis-biosciences-debuts-with-major-pharmaceutical-collaboration-to-tackle-industry?s-most-challenging-protein-targets,06-03-2020 00:00,,,,,,
2582,zydus-announces-world?s-first-drug-for-the-treatment-of-non-cirrhotic-nash,06-03-2020 00:00,,,,,,
2583,allergan-receives-fda-approval-for-durysta-bimatoprost-implant-the-first-and-only-intracameral-biodegradable-sustained-release-implant-to-lower-intraocular-pressure-in-open-angle-glaucoma-or-ocular-hypertension-patients,06-03-2020 00:00,,,,,,
2584,update-on-phase-iii-danube-trial-for-imfinzi-and-tremelimumab-in-unresectable-stage-iv-bladder-cancer,06-03-2020 00:00,,,,,,
2585,mount-sinai-and-harbour-biomed-collaborate-to-advance-novel-biotherapies-for-the-treatment-of-cancer-and-coronavirus-covid-19,06-03-2020 00:00,,,,,,
2586,tetra-therapeutics-and-shionogi-announce-expanded-alliance,09-03-2020 00:00,,,,,,
2587,fda-approves-new-treatment-for-adults-with-cushing?s-disease,09-03-2020 00:00,,,,,,
2588,european-commission-grants-abbvie-marketing-authorization-shortening-maviret-glecaprevirpibrentasvir-treatment-duration-to-eight-weeks-for-treatment-na?ve-chronic-hcv-patients-with-genotype-3-and-compensated-cirrhosis,09-03-2020 00:00,,,,,,
2589,zydus-and-xoma-announce-il-2-based-immuno-oncology-therapy-licensing-agreement,09-03-2020 00:00,,,,,,
2590,bristol-myers-squibb-reports-primary-results-of-eloquent-1-study-evaluating-empliciti-elotuzumab-plus-revlimid-lenalidomide-and-dexamethasone-in-patients-with-newly-diagnosed-untreated-multiple-myeloma,09-03-2020 00:00,,,,,,
2591,us-fda-accepts-biologics-license-application-bla-for-mylan-and-biocons-proposed-biosimilar-bevacizumab-for-review,09-03-2020 00:00,,,,,,
2592,abbvie-partnering-with-global-authorities-to-determine-efficacy-of-hiv-drug-in-treating-covid-19,10-03-2020 00:00,,,,,,
2593,celltrion-applies-for-european-approval-of-humira-biosimilar,10-03-2020 00:00,,,,,,
2594,viiv-healthcare-and-unc-chapel-hill-announce-five-year-renewal-of-innovative-hiv-cure-partnership,10-03-2020 00:00,,,,,,
2595,boehringer-ingelheim?s-ofev-nintedanib-as-the-first-treatment-for-chronic-fibrosing-ilds-with-progressive-phenotype,10-03-2020 00:00,,,,,,
2596,health-canada-approves-fast-acting-mealtime-insulin-fiasp-for-children-with-diabetes,10-03-2020 00:00,,,,,,
2597,bora-pharmaceuticals-to-acquire-gsk-mississauga-based-facility,10-03-2020 00:00,,,,,,
2598,cepi-expands-investment-in-covid-19-vaccine-development,11-03-2020 00:00,,,,,,
2599,roche-receives-fda-approval-for-cintec-plus-cytology-test-to-aid-clinicians-in-improving-cervical-cancer-prevention,11-03-2020 00:00,,,,,,
2600,atomwise-and-bridge-biotherapeutics-sign-1b-deal-to-unlock-blockbuster-potential-in-inflammation,11-03-2020 00:00,,,,,,
2601,janssen-announces-us-fda-breakthrough-therapy-designation-granted-for-jnj-6372-for-the-treatment-of-non-small-cell-lung-cancer,11-03-2020 00:00,,,,,,
2602,takeda-provides-update-on-tourmaline-mm2-phase-3-trial,11-03-2020 00:00,,,,,,
2603,us-food-and-drug-administration-approves-opdivo-nivolumab-yervoy-ipilimumab-for-patients-with-hepatocellular-carcinoma-hcc-previously-treated-with-sorafenib,11-03-2020 00:00,,,,,,
2604,vir-biotechnology-announces-research-collaboration-with-the-national-institutes-of-health-vaccine-research-center-on-antibodies-against-coronaviruses,12-03-2020 00:00,,,,,,
2605,henlius-received-acceptance-notification-for-clinical-trial-application-from-nmpa-for-its-denosumab-biosimilar-hlx14,12-03-2020 00:00,,,,,,
2606,positive-recommendation-by-nice-for-first-anti-cgrp-migraine-therapy-ajovy-fremanezumab,12-03-2020 00:00,,,,,,
2607,calquence-granted-us-breakthrough-therapy-designation-for-chronic-lymphocytic-leukaemia,14-08-2019 00:00,,,,,,
2608,novavax-and-serum-institute-of-india-to-develop-and-commercialize-malaria-vaccine-candidate,12-03-2020 00:00,,,,,,
2609,selumetinib-granted-us-breakthrough-therapy-designation-in-neurofibromatosis-type-1,01-04-2019 00:00,,,,,,
2610,f2g-receives-us-fda-breakthrough-therapy-designation-for-olorofim,11-11-2019 00:00,,,,,,
2611,abbvie-receives-european-commission-approval-of-venclyxto-combination-regimen-for-patients-with-previously-untreated-chronic-lymphocytic-leukemia,12-03-2020 00:00,,,,,,
2612,thermo-fisher-scientific-signs-agreement-with-janssen-to-co-develop-companion-diagnostic-for-cancer,12-03-2020 00:00,,,,,,
2613,bayer-receives-us-fda-breakthrough-therapy-designation-for-aliqopa?-copanlisib-for-the-treatment-of-marginal-zone-lymphoma,29-05-2019 00:00,,,,,,
2614,merck-and-eisai-receive-third-breakthrough-therapy-designation-from-fda-for-keytruda?-pembrolizumab-plus-lenvima?-lenvatinib-combination-treatment,23-07-2019 00:00,,,,,,
2615,novartis-investigational-lung-cancer-therapy-capmatinib-inc280-granted-fda-breakthrough-therapy-designation-for-patients-with-met-mutated-advanced-non-small-cell-lung-cancer,06-09-2019 00:00,,,,,,
2616,chugai?s-nemolizumab-receives-fda-breakthrough-therapy-designation-for-the-treatment-of-pruritus-associated-with-prurigo-nodularis,09-12-2019 00:00,,,,,,
2617,agios-receives-fda-breakthrough-therapy-designation-for-tibsovo-ivosidenib-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-myelodysplastic-syndrome-with-an-idh1-mutation,16-12-2019 00:00,,,,,,
2618,abcellera-and-lilly-to-co-develop-antibody-therapies-for-the-treatment-of-covid-19,13-03-2020 00:00,,,,,,
2619,roche?s-cobas-sars-cov-2-test-to-detect-novel-coronavirus-receives-fda-emergency-use-authorization-and-is-available-in-markets-accepting-the-ce-mark,13-03-2020 00:00,,,,,,
2620,fda-grants-breakthrough-therapy-designation-to-usona-institutes-psilocybin-program-for-major-depressive-disorder,22-11-2019 00:00,,,,,,
2621,update-on-phase-iii-gy004-trial-for-cediranib-added-to-lynparza-in-platinum-sensitive-relapsed-ovarian-cancer,13-03-2020 00:00,,,,,,
2622,us-fda-grants-fast-track-designation-to-jardiance-for-the-treatment-of-chronic-kidney-disease,13-03-2020 00:00,,,,,,
2623,emd-serono-and-pfizer-provide-update-on-phase-iii-javelin-head-and-neck-100-study,13-03-2020 00:00,,,,,,
2624,i-mab-biopharma-announces-development-of-tjm2-to-treat-cytokine-release-syndrome-associated-with-severe-and-critically-ill-patients-with-coronavirus-disease-covid-19,13-03-2020 00:00,,,,,,
2625,johnson-johnson-announces-collaboration-with-the-beth-israel-deaconess-medical-center-to-accelerate-covid-19-vaccine-development,16-03-2020 00:00,,,,,,
2626,biontech-and-fosun-pharma-form-covid-19-vaccine-strategic-alliance-in-china,16-03-2020 00:00,,,,,,
2627,lilly-receives-fda-breakthrough-therapy-designation-for-baricitinib-for-the-treatment-of-alopecia-areata,16-03-2020 00:00,,,,,,
2628,vir-biotechnology-announces-intent-to-collaborate-with-biogen-on-manufacturing-of-antibodies-to-potentially-treat-covid-19,16-03-2020 00:00,,,,,,
2629,sanofi-and-regeneron-begin-global-kevzara-sarilumab-clinical-trial-program-in-patients-with-severe-covid-19,16-03-2020 00:00,,,,,,
2630,teva-and-celltrion-healthcare-announce-us-availability-of-herzuma-trastuzumab-pkrb-for-injection,17-03-2020 00:00,,,,,,
2631,pfizer-and-biontech-to-co-develop-potential-covid-19-vaccine,17-03-2020 00:00,,,,,,
2632,novo-nordisk-pauses-the-clinical-trials-investigating-concizumab-anti-tfpi-mab-in-haemophilia-a-and-b-with-or-without-inhibitors,17-03-2020 00:00,,,,,,
2633,acelrx-pharmaceuticals-to-acquire-tetraphase-pharmaceuticals,17-03-2020 00:00,,,,,,
2634,imfinzi-confirmed-a-sustained-overall-survival-benefit-in-final-analysis-of-the-phase-iii-caspian-trial-in-1st-line-extensive-stage-small-cell-lung-cancer,17-03-2020 00:00,,,,,,
2635,verily?s-coronavirus-screening-site-is-already-out-of-testing-appointments,17-03-2020 00:00,,,,,,
2636,nucala-is-approved-in-canada-for-use-in-adolescents-and-children-aged-6-years-and-above-with-severe-eosinophilic-asthma,17-03-2020 00:00,,,,,,
2637,nih-clinical-trial-of-investigational-vaccine-for-covid-19-begins,17-03-2020 00:00,,,,,,
2638,moleculin-signs-agreement-with-utmb-to-test-wp1122-on-a-range-of-viruses-including-coronavirus,18-03-2020 00:00,,,,,,
2639,merck-announces-top-line-results-from-phase-3-trials-evaluating-gefapixant-an-investigational-treatment-for-refractory-or-unexplained-chronic-cough,18-03-2020 00:00,,,,,,
2640,nuprobe-announces-strategic-collaboration-with-qiagen-completes-multiple-ce-ivd-product-registrations,18-03-2020 00:00,,,,,,
2641,regeneron-announces-important-advances-in-novel-covid-19-antibody-program,18-03-2020 00:00,,,,,,
2642,ideaya-and-pfizer-enter-clinical-trial-collaboration-and-supply-agreement-to-evaluate-clinical-combination-of-ide196-and-binimetinib-in-solid-tumors-harboring-gnaq-or-gna11-hotspot-mutations,18-03-2020 00:00,,,,,,
2643,samsung-biologics-expands-presence-in-greater-china-region-with-cdo-partnership-for-alzheimers-candidate,18-03-2020 00:00,,,,,,
2644,oxford-biomedica-signs-license-clinical-supply-agreement-with-juno-therapeutics-inc-a-bristol-myers-squibb-company-for-lentivector?-platform-for-car-t-and-tcr-t-therapeutics,19-03-2020 00:00,,,,,,
2645,roche-initiates-phase-iii-clinical-trial-of-actemraroactemra-in-hospitalised-patients-with-severe-covid-19-pneumonia,19-03-2020 00:00,,,,,,
2646,novartis?-zolgensma-onasemnogene-abeparvovec-receives-mhlw?s-approval-for-spinal-muscular-atrophy,19-03-2020 00:00,,,,,,
2647,lilly-indiana-state-department-of-health-partner-to-accelerate-covid-19-testing-using-lilly-research-laboratories,19-03-2020 00:00,,,,,,
2648,lynparza-granted-orphan-drug-designation-in-japan-for-brca-mutated-metastatic-pancreatic-cancer,19-03-2020 00:00,,,,,,
2649,updated-who-now-doesnt-recommend-avoiding-ibuprofen-for-covid-19-symptoms,19-03-2020 00:00,,,,,,
2650,janssen-submits-ponesimod-new-drug-application-to-the-us-fda-for-treatment-of-adults-with-relapsing-multiple-sclerosis,19-03-2020 00:00,,,,,,
2651,cepi-partners-with-university-of-hong-kong-to-develop-covid-19-vaccine,20-03-2020 00:00,,,,,,
2652,us-food-and-drug-administration-approves-epclusa-sofosbuvirvelpatasvir-for-children-ages-6-and-older-or-weighing-at-least-17-kg-with-chronic-hepatitis-c-infection,20-03-2020 00:00,,,,,,
2653,abbott-receives-fda-emergency-use-authorization-and-launches-test-to-detect-novel-coronavirus,20-03-2020 00:00,,,,,,
2654,fda-advises-patients-on-use-of-non-steroidal-anti-inflammatory-drugs-nsaids-for-covid-19,20-03-2020 00:00,,,,,,
2655,bgi?s-rt-pcr-sars-cov-2-test-now-commercially-available-for-clinical-use-in-the-united-states,20-03-2020 00:00,,,,,,
2656,dragonfly-therapeutics-announces-multi-target-expansion-of-its-collaboration-with-merck-to-use-dragonflys-proprietary-trinket-platform-to-develop-novel-therapeutic-candidates-in-the-fields-of-oncology-infectious-disease-and-immune-disorders,20-03-2020 00:00,,,,,,
2657,takeda-receives-approval-of-entyvio-vedolizumab-in-china-for-the-treatment-of-patients-with-moderate-to-severe-active-ulcerative-colitis-uc-and-crohns-disease-cd,23-03-2020 00:00,,,,,,
2658,bayer-and-curadev-sign-research-collaboration-and-license-agreement-to-develop-novel-sting-antagonists-across-indications,23-03-2020 00:00,,,,,,
2659,adaptive-biotechnologies-and-microsoft-expand-partnership-to-decode-covid-19-immune-response-and-provide-open-data-access,23-03-2020 00:00,,,,,,
2660,sorrento-develops-sti-4398-covidtrap-protein-for-potential-prevention-and-treatment-of-sars-cov-2-coronavirus-disease-covid-19,23-03-2020 00:00,,,,,,
2661,celltrion-accelerates-development-of-covid-19-antiviral-treatment-and-aims-to-launch-rapid-self-testing-kit,23-03-2020 00:00,,,,,,
2662,codexis-signs-strategic-collaboration-and-license-agreement-with-takeda-to-advance-novel-gene-therapies-for-rare-genetic-disorders,23-03-2020 00:00,,,,,,
2663,amgen-and-the-amgen-foundation-commit-up-to-125-million-to-support-covid-19-relief-efforts,24-03-2020 00:00,,,,,,
2664,roche-response-to-covid-19-pandemic,24-03-2020 00:00,,,,,,
2665,sorrento-and-smartpharm-to-collaborate-to-develop-novel-gene-encoded-antibody-vaccine-intended-to-protect-against-covid-19,24-03-2020 00:00,,,,,,
2666,genentech-announces-fda-approval-of-clinical-trial-for-actemra-to-treat-hospitalized-patients-with-severe-covid-19-pneumonia,24-03-2020 00:00,,,,,,
2667,qiagen-releases-qiastat-dx-test-kit-to-the-us-as-first-syndromic-test-for-detection-of-sars-cov-2-coronavirus-under-new-fda-policy,24-03-2020 00:00,,,,,,
2668,cytomx-therapeutics-and-astellas-announce-strategic-collaboration-to-develop-probody-t-cell-engaging-bispecific-therapies-for-treatment-of-cancer,24-03-2020 00:00,,,,,,
2669,sorrento-collaborates-with-mabpharm-on-development-and-commercialization-of-ace-mab-to-potentially-treat-covid-19,25-03-2020 00:00,,,,,,
2670,oasmia-and-elevar-sign-a-global-strategic-partnership-for-the-commercialization-of-apealea-with-an-upfront-payment-of-usd-20-million-milestone-payments-with-a-potential-of-up-to-usd-678-million-and-double-digit-royalties,25-03-2020 00:00,,,,,,
2671,alvotech-and-dksh-partner-to-bring-key-biosimilar-to-asia,25-03-2020 00:00,,,,,,
2672,horizon-therapeutics-plc-announces-us-fda-approval-of-new-dosage-form-for-procysbi?-cysteamine-bitartrate-delayed-release-oral-granules,18-02-2020 00:00,,,,,,
2673,samsung-bioepis-announces-fda-approval-of-420-mg-multi-dose-vial-of-ontruzant-trastuzumab-dttb,25-03-2020 00:00,,,,,,
2674,tepmetko-tepotinib-approved-in-japan-for-advanced-nsclc-with-metex14-skipping-alterations,25-03-2020 00:00,,,,,,
2675,silence-therapeutics-announces-collaboration-with-astrazeneca-to-discover-and-develop-sirna-therapeutics-for-cardiovascular-renal-metabolic-and-respiratory-diseases,25-03-2020 00:00,,,,,,
2676,fda-approves-agile-therapeutics-inc?s-twirla-levonorgestrel-and-ethinyl-estradiol-transdermal-system-?-a-new-weekly-contraceptive-patch-delivering-a-30-mcg-daily-dose-of-estrogen-and-120-mcg-daily-dose-of-progestin,14-02-2020 00:00,,,,,,
2677,biohavens-nurtec?-odt-rimegepant-receives-fda-approval-for-the-acute-treatment-of-migraine-in-adults,27-02-2020 00:00,,,,,,
2678,sorrento-launches-novel-i-cell-covid-19-cellular-vaccine-program,26-03-2020 00:00,,,,,,
2679,baudax-bio-announces-fda-approval-of-anjeso-for-the-management-of-moderate-to-severe-pain,20-02-2020 00:00,,,,,,
2680,esperion-announces-fda-approval-of-the-nexlizet?-bempedoic-acid-and-ezetimibe-tablet-an-oral-once-daily-non-statin-ldl-cholesterol-lowering-medicine,26-02-2020 00:00,,,,,,
2681,fda-approves-gsks-advil-dual-action-with-acetaminophen-for-over-the-counter-use-in-the-united-states,28-02-2020 00:00,,,,,,
2682,xencor-and-vir-biotechnology-enter-license-agreement-for-use-of-xtend-xmab-antibody-technology-in-investigational-antibodies-to-treat-covid-19,26-03-2020 00:00,,,,,,
2683,acacia-pharma-announces-us-fda-approval-of-barhemsys?-amisulpride-for-the-treatment-and-prevention-of-postoperative-nausea-and-vomiting-ponv,27-02-2020 00:00,,,,,,
2684,lokelma-approved-in-japan-for-the-treatment-of-hyperkalaemia,26-03-2020 00:00,,,,,,
2685,novartis-and-life-sciences-companies-commit-expertise-and-assets-to-the-fight-against-covid-19-pandemic-alongside-bill-melinda-gates-foundation,26-03-2020 00:00,,,,,,
2686,pra-health-sciences-launches-covid-19-monitoring-program,26-03-2020 00:00,,,,,,
2687,saniona-enters-into-second-collaboration-agreement-with-boehringer-ingelheim-in-schizophrenia,27-03-2020 00:00,,,,,,
2688,us-food-and-drug-administration-approves-bristol-myers-squibb?s-zeposia-ozanimod-a-new-oral-treatment-for-relapsing-forms-of-multiple-sclerosis,27-03-2020 00:00,,,,,,
2689,sanofi-receives-positive-chmp-opinion-for-sarclisa-isatuximab-for-the-treatment-of-relapsed-and-refractory-multiple-myeloma,27-03-2020 00:00,,,,,,
2690,quidel?s-lyra-sars-cov-2-assay-receives-authorization-for-expanded-use-for-molecular-detection-of-covid-19-also-receives-ce-mark-health-canada-authorization,27-03-2020 00:00,,,,,,
2691,medopad-offers-support-for-global-covid-19-pandemic,27-03-2020 00:00,,,,,,
2692,mylan-and-pfizer-provide-update-regarding-proposed-combination-of-mylan-and-upjohn,27-03-2020 00:00,,,,,,
2693,sanofi-and-translate-bio-collaborate-to-develop-novel-mrna-vaccine-candidate-against-covid-19,30-03-2020 00:00,,,,,,
2694,first-patient-outside-us-treated-in-global-kevzara-sarilumab-clinical-trial-program-for-patients-with-severe-covid-19,30-03-2020 00:00,,,,,,
2695,mylan-and-lupin-announce-positive-chmp-opinion-for-nepexto-biosimilar-etanercept,30-03-2020 00:00,,,,,,
2696,imfinzi-approved-in-the-us-for-extensive-stage-small-cell-lung-cancer,30-03-2020 00:00,,,,,,
2697,lillys-taltz-ixekizumab-receives-us-fda-approval-for-the-treatment-of-pediatric-patients-with-moderate-to-severe-plaque-psoriasis,30-03-2020 00:00,,,,,,
2698,bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-of-zeposia-ozanimod-for-the-treatment-of-adult-patients-with-relapsing-remitting-multiple-sclerosis-with-active-disease,30-03-2020 00:00,,,,,,
2699,johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-us-department-of-health-human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use,31-03-2020 00:00,,,,,,
2700,detect-covid-19-in-as-little-as-5-minutes,31-03-2020 00:00,,,,,,
2701,nubeqa-darolutamide-receives-eu-approval-as-a-new-treatment-for-men-with-non-metastatic-castration-resistant-prostate-cancer,31-03-2020 00:00,,,,,,
2702,coronavirus-covid-19-update-daily-roundup-march-30-2020,31-03-2020 00:00,,,,,,
2703,lokelma-recommended-for-approval-in-eu-for-patients-with-hyperkalaemia-on-stable-haemodialysis,31-03-2020 00:00,,,,,,
2704,lilly-and-sitryx-announce-licensing-and-research-collaboration-to-discover-and-develop-new-immunometabolic-medicines,31-03-2020 00:00,,,,,,
2705,sorrento-and-the-university-of-texas-medical-branch-at-galveston-enter-into-preclinical-testing-agreement-for-covid-19-therapeutic-candidates,01-04-2020 00:00,,,,,,
2706,amgen-update-regarding-covid-19-for-media,01-04-2020 00:00,,,,,,
2707,vivus-accelerates-the-launch-of-telemedicine-and-remote-monitoring-modules-to-facilitate-effective-patient-care-during-?social-distancing?,01-04-2020 00:00,,,,,,
2708,amgen-establishes-wholly-owned-affiliate-in-japan,01-04-2020 00:00,,,,,,
2709,ultragenyx-enters-into-strategic-partnership-with-daiichi-sankyo-for-gene-therapy-manufacturing-technology,01-04-2020 00:00,,,,,,
2710,qiagen-receives-us-fda-eua-for-qiastat-dx-test-kit-first-and-only-syndromic-solution-integrating-detection-of-sars-cov-2-coronavirus,01-04-2020 00:00,,,,,,
2711,bd-biomedomics-announce-launch-of-rapid-serology-test-to-detect-exposure-to-covid-19,01-04-2020 00:00,,,,,,
2712,medical-professionals-across-merck-co-inc-pfizer-inc-and-eli-lilly-and-company-activate-to-support-health-systems-first-responders-and-patients-amid-covid-19-pandemic,02-04-2020 00:00,,,,,,
2713,y-mabs-announces-submission-of-naxitamab-biologics-license-application-to-us-fda,02-04-2020 00:00,,,,,,
2714,fda-launches-program-to-speed-development-of-covid-19-treatments,02-04-2020 00:00,,,,,,
2715,moderna-reports-first-quarter-2020-financial-results-and-provides-business-updates,08-05-2020 00:00,,,,,,
2716,covig-19-plasma-alliance-builds-strong-momentum-through-expanded-membership-and-clinical-trial-collaboration-may-7-2020,08-05-2020 00:00,,,,,,
2718,celltrion-healthcare-launches-?ramshima-sc?-in-the-netherlands,08-05-2020 00:00,,,,,,
2719,fitbit-launches-heart-study-to-validate-its-wearable-technology-for-identifying-atrial-fibrillation,08-05-2020 00:00,,,,,,
2720,astrazeneca-recovery-of-global-rights-to-brazikumab-medi2070-from-allergan-completed,11-05-2020 00:00,,,,,,
2721,sorrento-and-mount-sinai-health-system-to-jointly-develop-covi-shield-antibody-therapy-targeting-sars-cov-2-infection-covid-19,11-05-2020 00:00,,,,,,
2722,regeneron-and-colorado-center-for-personalized-medicine-announce-major-new-human-genetics-research-collaboration,11-05-2020 00:00,,,,,,
2723,lilly-receives-us-fda-approval-for-retevmo-selpercatinib-the-first-therapy-specifically-for-patients-with-advanced-ret-driven-lung-and-thyroid-cancers,11-05-2020 00:00,,,,,,
2724,sarclisa?-isatuximab-phase-3-ikema-trial-meets-primary-endpoint-early-in-patients-with-relapsed-multiple-myeloma,12-05-2020 00:00,,,,,,
2725,neurocrine-biosciences-exercises-option-to-license-idorsia?s-novel-treatment-for-rare-pediatric-epilepsy,12-05-2020 00:00,,,,,,
2726,pharmamar-and-megapharm-sign-a-licensing-agreement-for-lurbinectedin-in-israel,12-05-2020 00:00,,,,,,
2727,dyno-therapeutics-announces-ocular-collaboration-with-novartis-to-develop-improved-gene-therapies-with-aav-vectors-based-on-ai-technology,12-05-2020 00:00,,,,,,
2728,abbott-receives-fda-emergency-use-authorization-for-covid-19-antibody-blood-test-on-alinity-i-system,12-05-2020 00:00,,,,,,
2729,gryt-health-and-bristol-myers-squibb-team-up-to-launch-covid-advocacy-exchange-for-patient-advocates,12-05-2020 00:00,,,,,,
2730,voluntary-licensing-agreements-for-remdesivir,13-05-2020 00:00,,,,,,
2731,moderna-receives-fda-fast-track-designation-for-mrna-vaccine-mrna-1273-against-novel-coronavirus,13-05-2020 00:00,,,,,,
2732,alvotech-announces-positive-top-line-results-for-two-comparative-studies-for-avt02-a-proposed-biosimilar-to-humira-adalimumab,13-05-2020 00:00,,,,,,
2733,skyhawk-therapeutics-announces-expansion-of-its-collaboration-agreement-with-merck-to-discover-and-develop-novel-small-molecules-that-modulate-rna-splicing,13-05-2020 00:00,,,,,,
2734,lifescan-and-noom-to-launch-digital-diabetes-and-weight-loss-management-pilot-program,13-05-2020 00:00,,,,,,
2735,bristol-myers-squibb-and-bluebird-bio-provide-regulatory-update-on-idecabtagene-vicleucel-ide-cel-bb2121-for-the-treatment-of-patients-with-multiple-myeloma,14-05-2020 00:00,,,,,,
2736,fda-grants-priority-review-of-sutimlimab-potential-first-approved-treatment-of-hemolysis-in-adult-patients-with-cold-agglutinin-disease,14-05-2020 00:00,,,,,,
2737,china-nmpa-approves-optune-for-the-treatment-of-newly-diagnosed-and-recurrent-glioblastoma,14-05-2020 00:00,,,,,,
2738,roche-to-present-first-clinical-data-on-novel-anti-tigit-cancer-immunotherapy-tiragolumab-at-asco,14-05-2020 00:00,,,,,,
2739,tyvyt-sintilimab-injection-orient-2-study-met-its-primary-endpoint-of-overall-survival-in-the-second-line-treatment-of-patients-with-advanced-or-metastatic-esophageal-squamous-cell-carcinoma,14-05-2020 00:00,,,,,,
2740,boehringer-ingelheim-acquires-northern-biologics?-preclinical-cancer-antibody-pipeline-expanding-immuno-oncology-portfolio,15-05-2020 00:00,,,,,,
2741,seattle-genetics-announces-us-fda-approval-of-tukysa-tucatinib-for-people-with-advanced-unresectable-or-metastatic-her2-positive-breast-cancer,17-04-2020 00:00,,,,,,
2742,fda-grants-accelerated-approval-for-immunomedics?-trodelvy-in-previously-treated-metastatic-triple-negative-breast-cancer,22-04-2020 00:00,,,,,,
2743,urogen-pharma-receives-us-fda-expedited-approval-for-jelmyto?-the-first-and-only-non-surgical-treatment-for-patients-with-low-grade-upper-tract-urothelial-cancer,15-04-2020 00:00,,,,,,
2744,fda-approves-incyte?s-pemazyre?-pemigatinib-as-first-targeted-treatment-for-adults-with-previously-treated-unresectable-locally-advanced-or-metastatic-cholangiocarcinoma,17-04-2020 00:00,,,,,,
2745,sanofi-says-covid-19-vaccine-will-be-available-worldwide-simultaneously,15-05-2020 00:00,,,,,,
2746,roche-launches-new-blood-gas-digital-solution-designed-to-improve-patient-care,15-05-2020 00:00,,,,,,
2747,recursion-enters-into-global-licensing-agreement-with-takeda-to-develop-tak-733-in-hereditary-cancer-syndrome,15-05-2020 00:00,,,,,,
2748,samsung-bioepis-announces-four-year-follow-up-data-for-biosimilar-ontruzanttrastuzumab-dttb-in-early-or-locally-advanced-her2-positive-breast-cancer,15-05-2020 00:00,,,,,,
2749,janssen?s-bcma-car-t-therapy-jnj-4528-showed-early-deep-and-durable-responses-in-heavily-pretreated-patients-with-multiple-myeloma,15-05-2020 00:00,,,,,,
2750,enhertu-granted-breakthrough-therapy-designation-in-the-us-for-her2-mutant-metastatic-non-small-cell-lung-cancer,18-05-2020 00:00,,,,,,
2751,first-approval-in-china-of-a-fixed-dose-long-acting-dual-bronchodilator-in-a-pressurised-metered-dose-inhaler-device,18-05-2020 00:00,,,,,,
2752,remdesivir-close-to-eu?s-initial-authorisation-as-covid-19-treatment,18-05-2020 00:00,,,,,,
2753,moderna-announces-positive-interim-phase-1-data-for-its-mrna-vaccine-mrna-1273-against-novel-coronavirus,18-05-2020 00:00,,,,,,
2754,fda-approves-genentech?s-tecentriq-as-a-first-line-monotherapy-for-certain-people-with-metastatic-non-small-cell-lung-cancer,19-05-2020 00:00,,,,,,
2755,china-approves-austedo-for-treating-chorea-associated-with-huntington?s-disease-and-tardive-dyskinesia-in-adults,19-05-2020 00:00,,,,,,
2756,samsung-bioepis-announces-24-week-interim-results-from-a-phase-3-trial-of-sb11-proposed-ranibizumab-biosimilar,19-05-2020 00:00,,,,,,
2757,vividion-therapeutics-announces-drug-discovery-collaboration-with-roche-focused-on-novel-e3-ligases,19-05-2020 00:00,,,,,,
2758,innovent-biologics-and-md-anderson-announce-a-strategic-collaboration-to-develop-anti-pd-1-therapy-tyvyt-sintilimab-injection-in-rare-cancers,19-05-2020 00:00,,,,,,
2759,avexis-receives-ec-approval-and-activates-?day-one?-access-program-for-zolgensma-the-only-gene-therapy-for-spinal-muscular-atrophy-sma,20-05-2020 00:00,,,,,,
2760,biocon-biologics-receives-eu-gmp-certification-for-multiple-biosimilars-manufacturing-facilities-in-bengaluru-expands-its-manufacturing-capacity,20-05-2020 00:00,,,,,,
2761,roche-highly-accurate-antibody-test-for-covid-19-goes-live-at-more-than-20-initial-lab-sites-in-the-us,20-05-2020 00:00,,,,,,
2762,eiger-biopharmaceuticals-announces-fda-acceptance-of-nda-for-filing-with-priority-review-of-zokinvy-lonafarnib-for-treatment-of-progeria-and-progeroid-laminopathies,20-05-2020 00:00,,,,,,
2763,aldeyra-therapeutics-to-advance-adx-1612-an-investigational-new-hsp90-inhibitor-with-potential-nanomolar-potency-against-sars-cov-2-to-clinical-testing-for-covid-19-adx-629-accepted-for-barda-coronawatch-meeting,20-05-2020 00:00,,,,,,
2764,european-medicines-agency-accepts-astellas?-marketing-authorization-application-for-roxadustat-submission-for-the-treatment-of-anemia-in-adult-patients-with-chronic-kidney-disease,21-05-2020 00:00,,,,,,
2765,exposure-notification-api-launches-to-support-public-health-agencies,21-05-2020 00:00,,,,,,
2766,astrazeneca-advances-response-to-global-covid-19-challenge-as-it-receives-first-commitments-for-oxford?s-potential-new-vaccine,21-05-2020 00:00,,,,,,
2767,synlogic-announces-termination-of-abbvie-collaboration-agreement,21-05-2020 00:00,,,,,,
2768,gilead-and-galapagos-announce-positive-topline-results-of-phase-2b3-trial-of-filgotinib-in-moderately-to-severely-active-ulcerative-colitis,21-05-2020 00:00,,,,,,
2769,roche-acquires-stratos-genomics-to-further-develop-dna-based-sequencing-for-diagnostic-use,22-05-2020 00:00,,,,,,
2770,gsk-partners-with-samsung-biologics-to-secure-additional-manufacturing-capacity-for-innovative-biopharmaceutical-portfolio,22-05-2020 00:00,,,,,,
2771,enhertu-granted-orphan-drug-designation-in-the-us-for-gastric-cancer,22-05-2020 00:00,,,,,,
2772,bayer-submits-larotrectinib-for-marketing-authorization-in-japan-for-the-treatment-of-trk-fusion-cancer,22-05-2020 00:00,,,,,,
2773,us-pharma-firm-gilead-sciences-likely-to-seek-nod-to-market-anti-viral-drug-remdesivir-in-india,22-05-2020 00:00,,,,,,
2774,european-medicines-agency-validates-bristol-myers-squibb?s-applications-for-idecabtagene-vicleucel-ide-cel-bb2121-and-cc-486,22-05-2020 00:00,,,,,,
2775,fresenius-kabi?s-regulatory-submission-for-pegfilgrastim-biosimilar-accepted-for-review-by-ema,25-05-2020 00:00,,,,,,
2776,abcellera-will-use-its-world-leading-antibody-drug-discovery-platform-in-a-multi-year-collaboration-to-identify-antibodies-against-up-to-nine-targets,25-05-2020 00:00,,,,,,
2777,astrazeneca-advances-response-to-global-covid-19-challenge-as-it-receives-first-commitments-for-oxford?s-potential-new-vaccine,25-05-2020 00:00,,,,,,
2778,us-fda-approves-evofem-biosciences?-phexxi?-lactic-acid-citric-acid-and-potassium-bitartrate-the-first-and-only-non-hormonal-prescription-gel-for-the-prevention-of-pregnancy,25-05-2020 00:00,,,,,,
2779,dupixent?-dupilumab-eosinophilic-esophagitis-trial-meets-both-co-primary-endpoints,25-05-2020 00:00,,,,,,
2780,novavax-initiates-phase-12-clinical-trial-of-covid-19-vaccine,26-05-2020 00:00,,,,,,
2781,astrazeneca-collaborates-with-archerdx-to-use-personalised-cancer-assays-to-detect-minimal-residual-disease-in-lung-cancer-trials,26-05-2020 00:00,,,,,,
2782,chi-med-and-beigene-enter-into-clinical-collaboration-to-evaluate-combinations-of-surufatinib-and-fruquintinib-with-tislelizumab,26-05-2020 00:00,,,,,,
2783,neogenomics-enters-strategic-collaboration-with-inivata-to-commercialize-invisionfirst-lung-liquid-biopsy-test,26-05-2020 00:00,,,,,,
2784,merck-to-acquire-themis,26-05-2020 00:00,,,,,,
2785,algernon-submits-investigational-new-drug-ind-application-with-us-fda-for-multinational-phase-2b3-human-study-to-evaluate-ifenprodil-for-covid-19,26-05-2020 00:00,,,,,,
2786,boehringer-ingelheim-and-lilly-to-collaborate-with-duke-clinical-research-institute-on-a-pragmatic-trial-examining-jardiance?s-effects-following-an-acute-myocardial-infarction,26-05-2020 00:00,,,,,,
2787,tetra-therapeutics-enters-into-definitive-merger-agreement-to-be-acquired-by-shionogi,27-05-2020 00:00,,,,,,
2788,glenmark-to-commence-another-new-phase-3-clinical-trial-on-a-combination-of-two-anti-viral-drugs-favipiravir-and-umifenovir-in-hospitalized-patients-of-moderate-covid-19-in-india,27-05-2020 00:00,,,,,,
2789,port-delivery-system-with-ranibizumab-shows-positive-phase-iii-results-in-neovascular-age-related-macular-degeneration,27-05-2020 00:00,,,,,,
2790,sanofi-fda-approves-dupixent-dupilumab-as-first-biologic-medicine-for-children-aged-6-to-11-years-with-moderate-to-severe-atopic-dermatitis,27-05-2020 00:00,,,,,,
2791,repare-therapeutics-announces-multi-target-discovery-collaboration-with-bristol-myers-squibb,27-05-2020 00:00,,,,,,
2792,nature-publishes-preclinical-characterization-and-primate-efficacy-data-on-junshi-biosciences?-covid-19-neutralizing-antibodies,27-05-2020 00:00,,,,,,
2793,gilead-sciences-and-arcus-biosciences-establish-10-year-partnership-to-co-develop-and-co-commercialize-next-generation-cancer-immunotherapies,28-05-2020 00:00,,,,,,
2794,roche?s-ocrevus-ocrelizumab-shorter-2-hour-infusion-time-approved-in-europe,28-05-2020 00:00,,,,,,
2795,roche?s-ocrevus-ocrelizumab-shorter-2-hour-infusion-time-approved-in-europe,28-05-2020 00:00,,,,,,
2796,acelrx-pharmaceuticals-announces-revised-merger-agreement-with-tetraphase,28-05-2020 00:00,,,,,,
2797,fda-accepts-for-review-fresenius-kabi?s-first-biosimilar-regulatory-submission-for-msb11455-a-biosimilar-candidate-of-pegfilgrastim,28-05-2020 00:00,,,,,,
2798,atriva-therapeutics-to-develop-atr-002-for-treatment-of-patients-with-covid-19-in-phase-ii-study,28-05-2020 00:00,,,,,,
2799,astrazeneca-takes-next-steps-towards-broad-and-equitable-access-to-oxford-university?s-covid-19-vaccine,05-06-2020 00:00,,,,,,
2800,fresenius-kabi-enters-marketing-agreement-for-biosimilar-product,29-05-2020 00:00,,,,,,
2801,lilly-receives-us-fda-approval-of-tauvid?-flortaucipir-f-18-injection-for-use-in-patients-being-evaluated-for-alzheimer?s-disease,29-05-2020 00:00,,,,,,
2802,updated-data-demonstrate-roche?s-alecensa-increases-overall-survival-rate-for-people-with-alk-positive-non-small-cell-lung-cancer,29-05-2020 00:00,,,,,,
2803,first-subjects-dosed-in-australian-phase-i-clinical-study-of-a-denosumab-biosimilar,18-05-2020 00:00,,,,,,
2804,european-commission-releases-takeda-from-commitment-to-divest-shire?s-pipeline-compound-shp647,29-05-2020 00:00,,,,,,
2805,celltrion-healthcare?truxima?-launched-in-brazil-direct-marketing-activities-to-expand-the-latin-american-market,27-05-2020 00:00,,,,,,
2806,genmab-announces-positive-topline-results-in-phase-iii-andromeda-study-of-daratumumab-in-light-chain-al-amyloidosis,29-05-2020 00:00,,,,,,
2807,amgen-presents-new-amg-510-clinical-data-across-multiple-solid-tumors-during-asco20-virtual-scientific-program,01-06-2020 00:00,,,,,,
2808,celltrion-healthcare?truxima?-launched-in-brazil-direct-marketing-activities-to-expand-the-latin-american-market,27-05-2020 00:00,,,,,,
2809,abbvie-and-jacobio-announce-strategic-collaboration-to-advance-shp2-inhibitors,01-06-2020 00:00,,,,,,
2810,immunotherapy-avelumab-shows-potential-in-rare-gynecologic-cancer-resistant-to-chemotherapy,01-06-2020 00:00,,,,,,
2811,seattle-genetics-announces-positive-results-from-exploratory-analyses-of-her2climb-for-tukysa?-tucatinib-in-brain-metastases-patients-with-her2-positive-breast-cancer,01-06-2020 00:00,,,,,,
2812,mycenax-announces-the-sale-of-lusinex-to-gedeon-richter,28-05-2020 00:00,,,,,,
2813,daewon-pharmaceutical-launches-terrosa-in-republic-of-korea,26-05-2020 00:00,,,,,,
2814,merck?s-keytruda?-pembrolizumab-superior-to-standard-of-care-chemotherapy-in-patients-with-msi-h-colorectal-cancer,01-06-2020 00:00,,,,,,
2815,takeda-to-present-data-from-the-iclusig?-ponatinib-clinical-trial-program-that-could-prove-practice-changing-for-the-treatment-of-chronic-phase-cml,01-06-2020 00:00,,,,,,
2816,tagrisso-demonstrated-unprecedented-disease-free-survival-in-the-adjuvant-treatment-of-stage-ib-iiia-patients-with-egfr-mutated-lung-cancer,01-06-2020 00:00,,,,,,
2817,enhertu-fam-trastuzumab-deruxtecan-nxki-achieved-a-tumor-response-rate-of-453-in-patients-with-her2-positive-metastatic-colorectal-cancer-in-phase-ii-destiny-crc01,01-06-2020 00:00,,,,,,
2818,lilly-begins-world?s-first-study-of-a-potential-covid-19-antibody-treatment-in-humans,02-06-2020 00:00,,,,,,
2819,mylan-and-lupin-receive-european-marketing-authorization-for-nepexto?-biosimilar-etanercept,04-06-2020 00:00,,,,,,
2820,inovio-and-ivi-partner-with-seoul-national-university-hospital-to-start-phase-12-clinical-trial-of-inovio?s-covid-19-dna-vaccine-ino-4800-in-south-korea,04-06-2020 00:00,,,,,,
2821,accent-therapeutics-and-astrazeneca-to-discover-and-develop-novel-cancer-therapeutics-in-new-collaboration,04-06-2020 00:00,,,,,,
2822,roche?s-elecsys-il-6-test-receives-fda-emergency-use-authorisation-to-help-in-identifying-patients-at-high-risk-of-severe-inflammatory-response,04-06-2020 00:00,,,,,,
2823,formycon-announces-update-on-biosimilar-programs,15-05-2020 00:00,,,,,,
2824,celltrion-poonglim-pharmatech-selected?national-no-1?insulin-pen-type-injection-drug-as-a-national-project,03-06-2020 00:00,,,,,,
2825,eular-2020-lilly-shares-new-data-for-olumiant?-in-rheumatoid-arthritis-and-systemic-lupus-erythematosus,03-06-2020 00:00,,,,,,
2826,eular-2020-lilly?s-taltz?-ixekizumab-continues-to-show-robust-and-consistent-efficacy-in-psoriatic-arthritis,03-06-2020 00:00,,,,,,
2827,personalis-announces-scientific-collaboration-with-sarepta-therapeutics-on-immune-response-to-precision-genetic-therapeutics,03-06-2020 00:00,,,,,,
2828,novartis-provides-update-on-fda-review-of-ofatumumab-a-self-administered-targeted-b-cell-therapy-for-patients-with-relapsing-multiple-sclerosis,03-06-2020 00:00,,,,,,
2829,intravacc-and-epivax-team-up-in-development-of-covid-19-emerging-vaccine,03-06-2020 00:00,,,,,,
2830,y-mabs-announces-us-fda-acceptance-of-biologics-license-application-for-danyelza?-naxitamab-for-the-treatment-of-neuroblastoma-for-priority-review,03-06-2020 00:00,,,,,,
2831,regeneron-and-intellia-therapeutics-expand-collaboration-to-develop-crisprcas9-based-treatments,02-06-2020 00:00,,,,,,
2832,european-commission-approves-sarclisa?-isatuximab-for-adults-with-relapsed-and-refractory-multiple-myeloma,02-06-2020 00:00,,,,,,
2833,fda-approves-roche?s-tecentriq-in-combination-with-avastin-for-people-with-the-most-common-form-of-liver-cancer,02-06-2020 00:00,,,,,,
2834,european-commission-approves-sarclisa?-isatuximab-for-adults-with-relapsed-and-refractory-multiple-myeloma,02-06-2020 00:00,,,,,,
2835,henlius-and-accord-receive-positive-chmp-opinion-for-oncology-biosimilar-hlx02-trastuzumab,02-06-2020 00:00,,,,,,
2836,melinta-therapeutics-to-acquire-tetraphase-pharmaceuticals,05-06-2020 00:00,,,,,,
2837,novartis-phase-iiib-argon-study-meets-primary-endpoint-in-a-comparison-of-enerzair-breezhaler-qvm149-versus-a-free-combination-of-two-existing-inhaled-treatments-in-uncontrolled-asthma,05-06-2020 00:00,,,,,,
2838,astrazeneca-approaches-gilead-about-potential-merger,08-06-2020 00:00,,,,,,
2839,abbvie-harbour-biomed-utrecht-university-and-erasmus-medical-center-announce-collaboration-to-develop-monoclonal-antibody-therapy-to-prevent-and-treat-covid-19,08-06-2020 00:00,,,,,,
2840,oxford-biomedica-signs-five-year-collaboration-agreement-with-the-vaccines-manufacturing-and-innovation-centre,08-06-2020 00:00,,,,,,
2841,calquence-showed-promising-clinical-improvement-in-majority-of-19-hospitalised-covid-19-patients,08-06-2020 00:00,,,,,,
2842,lilly-announces-start-of-a-phase-1-study-for-its-second-potential-covid-19-antibody-treatment,08-06-2020 00:00,,,,,,
2843,alphamab-oncology-and-sanofi-enter-collaboration-on-kn026-in-her2-breast-cancer,09-06-2020 00:00,,,,,,
2844,innovent-and-roche-enter-into-a-strategic-collaboration-to-discover-and-develop-multiple-products-including-cellular-therapies-and-bispecific-antibodies,09-06-2020 00:00,,,,,,
2845,roxadustat-demonstrates-non-inferiority-to-darbepoetin-in-phase-3-dolomites-study-of-anemia-in-non-dialysisdependent-adult-patients-with-chronic-kidney-disease,09-06-2020 00:00,,,,,,
2846,mallinckrodt-completes-rolling-submission-of-biologics-license-application-for-stratagraft?-regenerative-skin-tissue-to-us-food-and-drug-administration,09-06-2020 00:00,,,,,,
2847,first-patient-dose-delivered-for-lilly?s-tirzepatide-cardiovascular-outcomes-trial,09-06-2020 00:00,,,,,,
2848,evox-therapeutics-announces-a-multi-target-rnai-and-antisense-research-collaboration-and-license-agreement-with-lilly,09-06-2020 00:00,,,,,,
2849,denali-therapeutics-provides-broad-update-on-its-ripk1-program-partnered-with-sanofi,10-06-2020 00:00,,,,,,
2850,sandoz-canada-receives-health-canada-approval-to-launch-two-oncology-biosimilars-ziextenzo-and-riximyo,10-06-2020 00:00,,,,,,
2851,advancing-our-discovery-of-novel-coronavirus-neutralising-antibodies-against-covid-19,10-06-2020 00:00,,,,,,
2852,genmab-and-abbvie-announce-broad-oncology-collaboration,10-06-2020 00:00,,,,,,
2853,ubivac-announces-clinical-trial-collaboration-with-bristol-myers-squibb-on-combination-immunotherapy-for-advanced-triple-negative-breast-cancer,10-06-2020 00:00,,,,,,
2854,debiopharm?s-novel-microbiome-remodeling-program-licensed-to-takeda-for-the-treatment-of-gastrointestinal-disorders,10-06-2020 00:00,,,,,,
2855,dexcom?s-dxcm-g6-cgm-system-gets-ce-marking-in-europe,10-06-2020 00:00,,,,,,
2856,johnson-johnson-announces-acceleration-of-its-covid-19-vaccine-candidate-phase-12a-clinical-trial-to-begin-in-second-half-of-july,11-06-2020 00:00,,,,,,
2857,redhill-biopharma-submits-covid-19-clinical-trial-application-for-phase-23-study-with-opaganib,11-06-2020 00:00,,,,,,
2858,#NAME?,11-06-2020 00:00,,,,,,
2859,us-food-and-drug-administration-approves-opdivo-nivolumab-for-the-treatment-of-patients-with-advanced-esophageal-squamous-cell-carcinoma-escc-after-prior-fluoropyrimidine-and-platinum-based-chemotherapy,11-06-2020 00:00,,,,,,
2860,sorrento-announces-it-has-submitted-an-emergency-use-authorization-eua-application-for-the-covi-track-diagnostic-test-for-the-detection-of-antibodies-to-sars-cov-2,11-06-2020 00:00,,,,,,
2861,fda-approves-pfizer?s-oncology-supportive-care-biosimilar-nyvepria?-pegfilgrastim-apgf,11-06-2020 00:00,,,,,,
2862,first-drugs-announced-in-major-covid-19-drugs-trial,11-06-2020 00:00,,,,,,
2863,novo-nordisk-to-acquire-corvidia-therapeutics-and-expand-presence-in-cardiovascular-disease,12-06-2020 00:00,,,,,,
2864,mylan-and-biocon-announce-us-fda-approval-of-semglee-insulin-glargine-injection,12-06-2020 00:00,,,,,,
2865,moderna-advances-late-stage-development-of-its-vaccine-mrna-1273-against-covid-19,12-06-2020 00:00,,,,,,
2866,lannett-provides-update-on-clinical-advancement-of-biosimilar-insulin-glargine-following-fda-meeting,12-06-2020 00:00,,,,,,
2867,regeneron-begins-first-clinical-trials-of-anti-viral-antibody-cocktail-regn-cov2-for-the-treatment-and-prevention-of-covid-19-,12-06-2020 00:00,,,,,,
2868,takeda-to-divest-otc-and-select-non-core-assets-in-asia-pacific-to-celltrion-for-up-to-278-million-usd,12-06-2020 00:00,,,,,,
2869,medtronic-secures-ce-mark-for-minimed-780g-advanced-hybrid-closed-loop-system-designed-to-further-simplify-type-1-diabetes-management,12-06-2020 00:00,,,,,,
2870,astrazeneca-to-supply-europe-with-up-to-400-million-doses-of-oxford-university?s-vaccine-at-no-profit,15-06-2020 00:00,,,,,,
2871,zydus-signs-a-non-exclusive-licensing-agreement-with-gilead-sciences-inc-to-manufacture-and-market-remdesivir,15-06-2020 00:00,,,,,,
2872,lilly-begins-a-phase-3-clinical-trial-with-baricitinib-for-hospitalized-covid-19-patients,15-06-2020 00:00,,,,,,
2873,fda-approves-merck?s-gardasil-9-for-the-prevention-of-certain-hpv-related-head-and-neck-cancers,15-06-2020 00:00,,,,,,
2874,foundation-medicine-acquires-lexent-bio-inc-to-accelerate-liquid-biopsy-research-and-development-and-advance-cancer-care,15-06-2020 00:00,,,,,,
2875,catalent-signs-agreement-with-astrazeneca-to-manufacture-covid-19-vaccine-candidate,16-06-2020 00:00,,,,,,
2876,akili-announces-fda-clearance-of-endeavorrx-for-children-with-adhd-the-first-prescription-treatment-delivered-through-a-video-game,16-06-2020 00:00,,,,,,
2877,celltrion-to-expand-covid-19-testing-portfolio-to-include-both-antigen-and-antibody-testing-kits,16-06-2020 00:00,,,,,,
2878,bayer-partners-with-massbio-to-launch-joint-mentoring-program-to-support-startups-in-china-and-asia,16-06-2020 00:00,,,,,,
2879,new-phase-ii-data-indicate-regimen-of-truxima-biosimilar-rituximab-lenalidomide-and-acalabrutinib-r2a-may-be-well-tolerated-and-effective-in-relapsedrefractory-aggressive-b-cell-lymphoma,16-06-2020 00:00,,,,,,
2880,sun-pharma-and-hikma-enter-into-exclusive-licensing-agreement-for-ilumya?-for-middle-east-north-africa-regions,16-06-2020 00:00,,,,,,
2881,neurocrine-biosciences-and-takeda-announce-collaboration-to-develop-and-commercialize-potential-therapies-for-psychiatric-disorders,17-06-2020 00:00,,,,,,
2882,merck-and-pfizer?s-sglt2-inhibitor-steglatro-ertugliflozin-meets-primary-endpoint-in-vertis-cv-trial-for-patients-with-type-2-diabetes-and-atherosclerotic-cardiovascular-disease,17-06-2020 00:00,,,,,,
2883,ideaya-and-gsk-announce-a-broad-partnership-in-synthetic-lethality-an-emerging-field-in-precision-medicine-oncology,17-06-2020 00:00,,,,,,
2884,novartis-cosentyx-receives-fda-approval-for-new-indication-to-treat-active-non-radiographic-axial-spondyloarthritis,17-06-2020 00:00,,,,,,
2885,sanofi?s-investigational-enzyme-replacement-therapy-shows-clinically-meaningful-improvement-in-critical-manifestations-of-late-onset-pompe-disease,17-06-2020 00:00,,,,,,
2886,fda-grants-full-approval-of-deciphera-pharmaceuticals?-qinloc-ripretinib-for-the-treatment-of-fourth-line-gastrointestinal-stromal-tumor,15-05-2020 00:00,,,,,,
2887,zionexa-usa-and-petnet-solutions-announce-fda-approval-of-cerianna-fluoroestradiol-f-18,28-05-2020 00:00,,,,,,
2888,amivas-us-llc-announces-fda-approval-of-artesunate-for-injection-for-treatment-of-severe-malaria,27-05-2020 00:00,,,,,,
2889,fda-approves-fensolvi?-leuprolide-acetate-for-injectable-suspension-for-pediatric-patients-with-central-precocious-puberty,04-05-2020 00:00,,,,,,
2890,cobra-biologics-signs-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine-candidate,17-06-2020 00:00,,,,,,
2891,gilead-sciences-statement-on-phase-23-clinical-trial-of-remdesivir-in-pediatric-patients-hospitalized-with-covid-19,18-06-2020 00:00,,,,,,
2892,roche?s-tecentriq-in-combination-with-chemotherapy-including-abraxane-meets-primary-endpoint-of-improved-pathological-complete-response-regardless-of-pd-l1-status-as-initial-treatment-for-people-with-early-triple-negative-breast-cancer,18-06-2020 00:00,,,,,,
2893,samsung-launches-the-samsung-health-monitor-application-with-blood-pressure-measurement,18-06-2020 00:00,,,,,,
2894,uk-start-up-gendius-partners-with-astrazeneca-to-develop-diabetes-management-support-for-patients-in-the-gulf-region,18-06-2020 00:00,,,,,,
2895,genmab-announces-us-fda-approval-of-subcutaneous-formulation-of-daratumumab-darzalex-faspro?-daratumumab-and-hyaluronidase-fihj-for-the-treatment-of-patients-with-multiple-myeloma,01-05-2020 00:00,,,,,,
2896,fda-approves-second-biomarker-based-indication-for-merck?s-keytruda-pembrolizumab-regardless-of-tumor-type,18-06-2020 00:00,,,,,,
2897,dr-reddy?s-laboratories-received-approval-for-their-nda-elyxyb?-celecoxib-oral-solution-25-mgml-in-the-us,06-05-2020 00:00,,,,,,
2898,sunovion-announces-us-fda-approval-of-kynmobi?-apomorphine-hydrochloride-sublingual-film-for-the-treatment-of-parkinson?s-disease-off-episodes,21-05-2020 00:00,,,,,,
2899,pra-teams-with-microsoft-to-enhance-covid-19-monitoring,18-06-2020 00:00,,,,,,
2900,fda-approves-vesicare-ls?-solifenacin-succinate-oral-suspension-for-pediatric-patients,27-05-2020 00:00,,,,,,
2901,fda-approves-the-first-oral-medication-for-the-management-of-heavy-menstrual-bleeding-due-to-uterine-fibroids-in-pre-menopausal-women,29-05-2020 00:00,,,,,,
2902,alpine-immune-sciences-and-abbvie-announce-option-and-license-agreement-for-the-development-and-commercialization-of-alpn-101,19-06-2020 00:00,,,,,,
2903,cipla-expands-partnership-with-roche-pharma-india-to-further-improve-access-to-key-oncology-medicines,19-06-2020 00:00,,,,,,
2904,redhill-biopharma-expands-opaganib-covid-19-phase-23-study-with-clinical-trial-applications-in-italy-and-uk,19-06-2020 00:00,,,,,,
2905,innovent-announces-the-nmpa-granted-marketing-approval-for-byvasda-bevacizumab-biosimilar-in-china,19-06-2020 00:00,,,,,,
2906,pfizer-and-sangamo-announce-updated-phase-12-results-showing-sustained-factor-viii-activity-levels-and-no-bleeding-events-or-factor-usage-in-3e13-vgkg-cohort-following-giroctocogene-fitelparvovec-sb-525-gene-therapy,19-06-2020 00:00,,,,,,
2907,ultragenyx-and-kyowa-kirin-announce-us-fda-approval-of-crysvita-burosumab-for-the-treatment-of-tumor-induced-osteomalacia-tio,19-06-2020 00:00,,,,,,
2908,glenmark-becomes-the-first-pharmaceutical-company-in-india-to-receive-regulatory-approval-for-oral-antiviral-favipiravir-for-the-treatment-of-mild-to-moderate-covid-19,22-06-2020 00:00,,,,,,
2909,european-medicines-agency-validates-application-for-bavencio-avelumab-for-first-line-maintenance-treatment-of-locally-advanced-or-metastatic-urothelial-carcinoma,22-06-2020 00:00,,,,,,
2910,novartis-discontinues-hydroxychloroquine-clinical-trial-based-on-slow-enrollment-remains-committed-to-pandemic-research-efforts,22-06-2020 00:00,,,,,,
2911,cipla-launches-cipremi-remdesivir-lyophilised-powder-for-injection-100-mg-the-only-us-fda-approved-emergency-use-authorisation-eua-treatment-for-patients-with-severe-covid-19-disease,22-06-2020 00:00,,,,,,
2912,merck?s-keytruda-pembrolizumab-approved-in-china-for-second-line-treatment-of-patients-with-locally-advanced-or-metastatic-esophageal-squamous-cell-carcinoma-whose-tumors-express-pd-l1-cps-10,22-06-2020 00:00,,,,,,
2913,an-open-letter-from-daniel-o?day-chairman-ceo-gilead-sciences,23-06-2020 00:00,,,,,,
2914,sanofi-and-translate-bio-expand-collaboration-to-develop-mrna-vaccines-across-all-infectious-disease-areas,23-06-2020 00:00,,,,,,
2915,fda-accepts-supplemental-biologics-license-application-sbla-for-botox-onabotulinumtoxina-for-the-treatment-of-pediatric-patients-with-neurogenic-detrusor-overactivity,23-06-2020 00:00,,,,,,
2916,atai-launches-introspect-digital-therapeutics-appoints-veteran-software-engineer-david-keene-as-ceo,23-06-2020 00:00,,,,,,
2917,bioinvent-enrolls-first-patient-in-phase-iiia-trial-of-bi-1206-in-combination-with-keytruda-for-the-treatment-of-patients-with-solid-tumors,23-06-2020 00:00,,,,,,
2918,schr?dinger-expands-discovery-efforts-for-covid-19-alliance-with-advanced-molecular-simulation-leveraging-high-powered-parallel-computing-on-google-cloud,23-06-2020 00:00,,,,,,
2919,sanofi?s-virtual-rd-day-event-to-highlight-capabilities-platforms-and-expertise-in-disease-pathways-to-deliver-potentially-transformative-treatments-to-patients,24-06-2020 00:00,,,,,,
2920,gilead-sciences-secures-exclusive-option-to-acquire-pionyr-immunotherapeutics,24-06-2020 00:00,,,,,,
2921,sarepta-therapeutics-and-codiak-biosciences-collaborate-to-research-and-develop-exosome-based-therapeutics-for-rare-diseases,24-06-2020 00:00,,,,,,
2922,symbiosis-and-astrazeneca-sign-supply-agreement-for-sterile-manufacture-of-covid-19-vaccine-for-clinical-trials,24-06-2020 00:00,,,,,,
2923,fda-announces-first-of-its-kind-pilot-program-to-communicate-patient-reported-outcomes-from-cancer-clinical-trials,24-06-2020 00:00,,,,,,
2924,fibrogen-announces-first-patient-enrolled-in-pamrevlumab-clinical-trial-in-patients-hospitalized-in-us-with-acute-covid-19,24-06-2020 00:00,,,,,,
2925,csl-behring-agrees-to-acquire-novel-late-stage-gene-therapy-candidate-for-hemophilia-b-patients-from-uniqure,25-06-2020 00:00,,,,,,
2926,merck-collaborates-with-yumanity-to-accelerate-the-development-of-two-therapies-targeting-neurodegenerative-diseases,25-06-2020 00:00,,,,,,
2927,breztri-aerosphere-significantly-reduced-rate-of-moderate-or-severe-copd-exacerbations-in-phase-iii-ethos-trial,25-06-2020 00:00,,,,,,
2928,fda-approves-merck?s-keytruda-pembrolizumab-for-the-treatment-of-patients-with-recurrent-or-metastatic-cutaneous-squamous-cell-carcinoma-cscc-that-is-not-curable-by-surgery-or-radiation,25-06-2020 00:00,,,,,,
2929,fulcrum-therapeutics-announces-initiation-of-multi-center-phase-3-losvid-trial-with-losmapimod-for-hospitalized-covid-19-patients,25-06-2020 00:00,,,,,,
2930,theravance-biopharma-announces-first-patient-dosed-in-phase-2-study-of-td-0903-for-the-treatment-of-hospitalized-patients-with-acute-lung-injury-caused-by-covid-19,25-06-2020 00:00,,,,,,
2931,sosei-heptares-and-abbvie-announce-new-discovery-collaboration-targeting-inflammatory-diseases,26-06-2020 00:00,,,,,,
2932,fda-approves-fintepla-fenfluramine-for-the-treatment-of-seizures-associated-with-dravet-syndrome,26-06-2020 00:00,,,,,,
2933,first-covid-19-treatment-recommended-for-eu-authorisation,26-06-2020 00:00,,,,,,
2934,roche-improves-speed-and-accuracy-of-non-small-cell-lung-cancer-diagnosis-with-launch-of-automated-digital-pathology-algorithm,26-06-2020 00:00,,,,,,
2935,sandoz-canada-launches-the-biosimilars-generation,26-06-2020 00:00,,,,,,
2936,fda-approves-first-of-its-kind-percept-pc-neurostimulator-with-brainsense-technology,26-06-2020 00:00,,,,,,
2937,livogiva,26-06-2020 00:00,,,,,,
2938,daiichi-sankyo-announces-start-of-discussions-with-astrazeneca-regarding-supply-in-japan-of-novel-corona-virus-vaccine,29-06-2020 00:00,,,,,,
2939,novartis-receives-simultaneous-approval-for-five-new-products-from-japanese-ministry-of-health-labour-and-welfare-offering-japanese-patients-a-broad-range-of-novel-treatment-options,29-06-2020 00:00,,,,,,
2940,ultomiris-ravulizumab-receives-marketing-authorization-from-european-commission-for-adults-and-children-with-atypical-hemolytic-uremic-syndrome-ahus,29-06-2020 00:00,,,,,,
2941,roche?s-enspryng-satralizumab-approved-in-japan-for-adults-and-children-with-neuromyelitis-optica-spectrum-disorder,29-06-2020 00:00,,,,,,
2942,samsung-bioepis-receives-positive-chmp-opinion-for-aybintio-bevacizumab,29-06-2020 00:00,,,,,,
2943,an-open-letter-from-daniel-o?day-chairman-ceo-gilead-sciences,30-06-2020 00:00,,,,,,
2944,abbott-and-tandem-diabetes-care-advance-development-of-integrated-technologies-for-future-automated-insulin-delivery-systems,30-06-2020 00:00,,,,,,
2945,india?s-1st-covid-19-vaccine-?-covaxin-developed-by-bharat-biotech-gets-dcgi-approval-for-phase-i-ii-human-clinical-trials,30-06-2020 00:00,,,,,,
2946,selumetinib-granted-orphan-drug-designation-in-japan-for-neurofibromatosis-type-1,30-06-2020 00:00,,,,,,
2947,fda-approves-roche?s-phesgo-fixed-dose-combination-of-perjeta-and-herceptin-for-subcutaneous-injection-for-her2-positive-breast-cancer,30-06-2020 00:00,,,,,,
2948,celltrion-healthcare-receives-positive-chmp-opinion-for-an-additional-five-indications-for-remsima-sc-including-for-use-in-inflammatory-bowel-disease-and-ankylosing-spondylitis,30-06-2020 00:00,,,,,,
2949,carmine-therapeutics-and-takeda-collaborate-to-discover-and-develop-rare-disease-gene-therapies-using-novel-red-blood-cell-extracellular-vesicles-platform,01-07-2020 00:00,,,,,,
2950,g1-therapeutics-and-boehringer-ingelheim-announce-co-promotion-agreement-for-trilaciclib-in-small-cell-lung-cancer-in-the-united-states-and-puerto-rico,01-07-2020 00:00,,,,,,
2951,samsung-bioepis-initiates-phase-3-clinical-trial-for-sb15-proposed-biosimilar-to-eylea-aflibercept,01-07-2020 00:00,,,,,,
2952,fda-approves-bavencio-as-first-line-maintenance-treatment-for-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma,01-07-2020 00:00,,,,,,
2953,boston-scientific-receives-fda-510k-clearance-for-the-lux-dx-insertable-cardiac-monitor-system,01-07-2020 00:00,,,,,,
2954,quralis-announces-agreement-to-strengthen-als-pipeline,01-07-2020 00:00,,,,,,
2955,pfizer-and-biontech-announce-early-positive-data-from-an-ongoing-phase-12-study-of-mrna-based-vaccine-candidate-against-sars-cov-2,02-07-2020 00:00,,,,,,
2956,dr-reddy?s-partners-with-fujifilm-and-global-response-aid-for-avigan-favipiravir-a-potential-treatment-of-covid-19,02-07-2020 00:00,,,,,,
2957,sorrento-announces-selection-of-t-viva-19-as-targeted-protein-vaccine-candidate-for-sars-cov-2,02-07-2020 00:00,,,,,,
2958,johnson-johnson-announces-european-commission-approval-for-janssen?s-preventive-ebola-vaccine,02-07-2020 00:00,,,,,,
2959,phase-3-trial-of-henlius-bevacizumab-biosimilar-hlx04-in-metastatic-colorectal-cancer-met-study-primary-endpoint,16-06-2020 00:00,,,,,,
2960,yuhan-in-licenses-gi-innovation?s-allergy-treatment-pipeline-for-12b,02-07-2020 00:00,,,,,,
2961,fujifilm-kyowa-kirin-biologics-announces-approval-of-?adalimumab-genetical-recombination-adalimumab-biosimilar-1?-in-japan,29-06-2020 00:00,,,,,,
2962,massachusetts-eye-and-ear-enters-licensing-agreement-with-biogen-to-develop-treatment-for-inherited-retinal-disorder,02-07-2020 00:00,,,,,,
2963,helsinn-group-and-mei-pharma-discontinue-the-phase-3-study-with-pracinostat-in-aml-after-completing-interim-analysis,03-07-2020 00:00,,,,,,
2964,sarepta-therapeutics-signs-agreement-with-hansa-biopharma-for-imlifidase,03-07-2020 00:00,,,,,,
2965,sanofi-and-regeneron-provide-update-on-kevzara-sarilumab-phase-3-us-trial-in-covid-19-patients,03-07-2020 00:00,,,,,,
2966,zydus?-vaccine-for-covid-19-zycov-d-successfully-completes-preclinical-development-and-receives-permission-to-initiate-human-clinical-trials,03-07-2020 00:00,,,,,,
2967,viiv-healthcare-announces-us-fda-approval-for-rukobia-fostemsavir-a-first-in-class-treatment-for-hiv-in-adults-with-few-treatment-options-available,03-07-2020 00:00,,,,,,
2968,the-european-commission-has-granted-orphan-medicinal-product-designation-in-the-eu-for-miv-818,03-07-2020 00:00,,,,,,
2969,cytodyn-announces-execution-of-exclusive-agreement-with-american-regent-for-distribution-and-supply-of-leronlimab-for-treatment-of-covid-19-in-united-states,06-07-2020 00:00,,,,,,
2970,ascentage-pharma-announces-clinical-trial-collaboration-agreement-with-msd-to-evaluate-apg-115-in-combination-with-keytruda-pembrolizumab-in-advanced-solid-tumors,06-07-2020 00:00,,,,,,
2971,mylan-secures-regulatory-approval-for-remdesivir-lyophilized-powder-for-injection-100-mgvial-in-india-for-restricted-emergency-use-in-covid-19-patients,06-07-2020 00:00,,,,,,
2972,regeneron-announces-start-of-regn-cov2-phase-3-covid-19-prevention-trial-in-collaboration-with-national-institute-of-allergy-and-infectious-diseases-niaid,06-07-2020 00:00,,,,,,
2973,esperare-receives-fda-breakthrough-therapy-designation-for-investigational-prenatal-treatment-er-004-in-x-linked-hypohidrotic-ectodermal-dysplasia-xlhed,06-07-2020 00:00,,,,,,
2974,emergent-biosolutions-signs-five-year-agreement-for-large-scale-drug-substance-manufacturing-for-johnson-johnson?s-lead-covid-19-vaccine-candidate,07-07-2020 00:00,,,,,,
2975,bd-launches-portable-rapid-point-of-care-antigen-test-to-detect-sars-cov-2-in-15-minutes-dramatically-expanding-access-to-covid-19-testing,07-07-2020 00:00,,,,,,
2976,dragonfly-therapeutics-announces-new-research-collaboration-with-bristol-myers-squibb-to-develop-novel-therapeutic-candidates-for-multiple-sclerosis-and-neuro-inflammation-targets,07-07-2020 00:00,,,,,,
2977,abbott-receives-fda-approval-for-new-heart-rhythm-devices-featuring-bluetooth-connectivity-and-continuous-remote-monitoring,07-07-2020 00:00,,,,,,
2978,novartis-receives-ec-approval-for-enerzair?-breezhaler?-including-the-first-digital-companion-sensor-and-app-that-can-be-prescribed-alongside-a-treatment-for-uncontrolled-asthma-in-the-eu,07-07-2020 00:00,,,,,,
2979,ema-validates-and-grants-accelerated-assessment-for-trastuzumab-deruxtecan-for-the-treatment-of-her2-positive-metastatic-breast-cancer,07-07-2020 00:00,,,,,,
2980,regeneron-announces-manufacturing-and-supply-agreement-for-barda-and-us-department-of-defense-for-regn-cov2-anti-viral-antibody-cocktail,08-07-2020 00:00,,,,,,
2981,gsk-and-medicago-announce-collaboration-to-develop-a-novel-adjuvanted-covid-19-candidate-vaccine,08-07-2020 00:00,,,,,,
2982,angion-initiates-phase-2-clinical-trial-of-ang-3777-in-patients-with-acute-lung-injury-associated-with-covid-19-pneumonia,08-07-2020 00:00,,,,,,
2983,turning-point-therapeutics-and-zai-lab-announce-exclusive-license-agreement-for-repotrectinib-in-greater-china,08-07-2020 00:00,,,,,,
2984,lynparza-approved-in-the-eu-for-brca-mutated-metastatic-pancreatic-cancer,08-07-2020 00:00,,,,,,
2985,foghorn-therapeutics-announces-collaboration-with-merck-to-discover-and-develop-novel-oncology-therapeutics-against-transcription-factor-target,08-07-2020 00:00,,,,,,
2986,biogen-completes-submission-of-biologics-license-application-to-fda-for-aducanumab-as-a-treatment-for-alzheimer?s-disease,09-07-2020 00:00,,,,,,
2987,reverie-labs-enters-multi-target-collaboration-agreement-with-roche,09-07-2020 00:00,,,,,,
2988,brilinta-granted-fda-priority-review-for-the-reduction-of-subsequent-stroke-in-patients-who-had-an-acute-ischemic-stroke-or-transient-ischemic-attack,09-07-2020 00:00,,,,,,
2989,eu-secures-potential-covid-19-drugs-from-roche-germany?s-merck-?-source,09-07-2020 00:00,,,,,,
2990,mylan-and-fujifilm-kyowa-kirin-biologics-announce-us-fda-approval-of-hulio-adalimumab-fkjp,09-07-2020 00:00,,,,,,
2991,cipla-prices-its-generic-remdesivir-at-5334-per-vial-below-rivals,10-07-2020 00:00,,,,,,
2992,kymera-therapeutics-and-sanofi-enter-into-strategic-partnership-to-advance-novel-protein-degrader-therapies-to-patients,10-07-2020 00:00,,,,,,
2993,bayer?s-finerenone-meets-primary-endpoint-in-phase-iii-fidelio-dkd-renal-outcomes-study-in-patients-with-chronic-kidney-disease-and-type-2-diabetes,10-07-2020 00:00,,,,,,
2994,proteinqure-collaborates-with-astrazeneca-to-design-novel-peptide-therapeutics,10-07-2020 00:00,,,,,,
2995,philips-and-biointellisense-form-strategic-collaboration-to-enhance-remote-patient-monitoring-for-at-risk-patients-from-the-hospital-into-the-home,10-07-2020 00:00,,,,,,
2996,leo-pharma-announces-us-food-and-drug-administration-fda-acceptance-of-biologics-license-application-bla-for-tralokinumab-for-the-treatment-of-adults-with-moderate-to-severe-atopic-dermatitis,10-07-2020 00:00,,,,,,
2997,biocon?s-breakthrough-drug-itolizumab-receives-dcgi-nod-for-its-use-in-moderate-to-severe-covid-19-patients,13-07-2020 00:00,,,,,,
2998,roche-provides-update-on-phase-iii-study-of-tecentriq-in-women-with-advanced-stage-ovarian-cancer,13-07-2020 00:00,,,,,,
2999,samsung-biologics-signs-additional-development-and-manufacturing-agreement-with-stcube,13-07-2020 00:00,,,,,,
3000,pfizer-and-biontech-granted-fda-fast-track-designation-for-two-investigational-mrna-based-vaccine-candidates-against-sars-cov-2,13-07-2020 00:00,,,,,,
3001,australia?s-first-covid-treatment-approved,13-07-2020 00:00,,,,,,
3002,paige-secures-additional-15m-from-goldman-sachs-for-a-total-series-b-funding-round-of-70m,14-07-2020 00:00,,,,,,
3003,roche-collaborates-with-blueprint-medicines-to-bring-a-new-treatment-to-people-with-ret-altered-cancers,14-07-2020 00:00,,,,,,
3004,fda-grants-breakthrough-therapy-designation-for-roche?s-cd20xcd3-bispecific-cancer-immunotherapy-mosunetuzumab-recognising-its-potential-in-follicular-lymphoma,14-07-2020 00:00,,,,,,
3005,immunomedics-expands-collaboration-with-roche-evaluating-trodelvy-sacituzumab-govitecan-hziy-in-combination-with-tecentriq-atezolizumab-into-urothelial-and-non-small-cell-lung-cancers,14-07-2020 00:00,,,,,,
3006,dewpoint-therapeutics-collaborates-with-merck-to-evaluate-novel-approach-for-the-treatment-of-hiv,14-07-2020 00:00,,,,,,
3007,sanofi-and-md-anderson-announce-strategic-collaboration-to-accelerate-oncology-research-and-development,14-07-2020 00:00,,,,,,
3008,an-mrna-vaccine-against-sars-cov-2-?-preliminary-report,15-07-2020 00:00,,,,,,
3009,samsung-biologics-and-immuneoncia-sign-multi-product-development-and-manufacturing-agreement,15-07-2020 00:00,,,,,,
3010,3m-and-mit-researchers-developing-a-rapid-diagnostic-test-for-covid-19,15-07-2020 00:00,,,,,,
3011,gsk-announces-fda-advisory-committee-votes-in-favour-of-positive-benefitrisk-profile-for-belantamab-mafodotin-for-patients-with-relapsedrefractory-multiple-myeloma,15-07-2020 00:00,,,,,,
3012,positive-news-is-coming-on-oxford-covid-19-vaccine-writes-robert-peston,15-07-2020 00:00,,,,,,
3013,medtronic-to-acquire-medicrea,16-07-2020 00:00,,,,,,
3014,novartis-launches-first-of-its-kind-not-for-profit-portfolio-of-medicines-for-symptomatic-treatment-of-covid-19,16-07-2020 00:00,,,,,,
3015,brilinta-significantly-reduced-the-rate-of-the-composite-of-stroke-and-death-in-patients-who-had-an-acute-ischaemic-stroke-or-transient-ischaemic-attack-in-the-phase-iii-thales-trial,16-07-2020 00:00,,,,,,
3016,zydus-starts-human-dosing-of-its-vaccine-?zycov-d?,16-07-2020 00:00,,,,,,
3017,nccn-explores-adoption-of-biosimilars-in-oncology-in-collaboration-with-pfizer,16-07-2020 00:00,,,,,,
3018,novocure-announces-clinical-trial-collaboration-with-msd-to-evaluate-tumor-treating-fields-together-with-keytruda-pembrolizumab-in-non-small-cell-lung-cancer,16-07-2020 00:00,,,,,,
3019,fda-grants-priority-review-to-merck?s-new-drug-application-for-vericiguat,16-07-2020 00:00,,,,,,
3020,kronos-bio-and-gilead-sciences-enter-into-asset-purchase-agreement-for-gilead?s-syk-inhibitor-portfolio,17-07-2020 00:00,,,,,,
3021,merck-kgaa-darmstadt-germany-takes-an-early-option-in-immuno-oncology-collaboration,17-07-2020 00:00,,,,,,
3022,kiniksa-announces-us-orphan-drug-designation-for-rilonacept-for-the-treatment-of-pericarditis,17-07-2020 00:00,,,,,,
3023,thermo-fisher-scientific-and-qiagen-nv-agree-on-amended-terms-to-acquisition-agreement,17-07-2020 00:00,,,,,,
3024,lilly?s-mirikizumab-superior-to-cosentyx-secukinumab-in-a-phase-3-study-for-patients-with-moderate-to-severe-plaque-psoriasis,17-07-2020 00:00,,,,,,
3025,oncorus-initiates-first-in-human-phase-1-study-of-oncr-177-for-the-treatment-of-adult-subjects-with-advanced-andor-refractory-cutaneous-subcutaneous-or-metastatic-nodal-solid-tumors,17-07-2020 00:00,,,,,,
3026,celltrion-launches-human-clinical-trial-of-potential-covid-19-antiviral-antibody-treatment-following-positive-pre-clinical-results,20-07-2020 00:00,,,,,,
3027,gsk-and-curevac-announce-strategic-mrna-technology-collaboration,20-07-2020 00:00,,,,,,
3028,picnichealth-announces-strategic-partnership-with-roche-to-generate-scientific-insights-from-real-world-data,20-07-2020 00:00,,,,,,
3029,fda-authorizes-quest-diagnostics-covid-19-diagnostic-testing-for-specimen-pooling-for-emergency-use,20-07-2020 00:00,,,,,,
3030,ptc-therapeutics-announces-agreement-to-monetize-a-portion-of-the-risdiplam-royalty-stream-for-650-million,20-07-2020 00:00,,,,,,
3031,covid-19-vaccine-azd1222-showed-robust-immune-responses-in-all-participants-in-phase-iii-trial,21-07-2020 00:00,,,,,,
3032,pfizer-and-biontech-announce-early-positive-update-from-german-phase-12-covid-19-vaccine-study-including-first-t-cell-response-data,21-07-2020 00:00,,,,,,
3033,mylan-initiates-supply-of-remdesivir-in-india-under-brand-name-desrem,21-07-2020 00:00,,,,,,
3034,jnana-therapeutics-enters-collaboration-with-roche-to-discover-novel-medicines-that-target-key-regulators-of-cellular-metabolism-to-treat-immune-mediated-and-neurological-diseases,21-07-2020 00:00,,,,,,
3035,exclusive-?game-changing?-coronavirus-antibody-test-passes-first-major-trials,21-07-2020 00:00,,,,,,
3036,paige-receives-fda-clearance-for-the-fullfocus-viewer-for-digital-pathology,21-07-2020 00:00,,,,,,
3037,biocon-biologics-and-voluntis-join-hands-for-global-collaboration-on-digital-therapeutics-for-insulins,22-07-2020 00:00,,,,,,
3038,gilead-sciences-secures-exclusive-option-to-acquire-tizona-therapeutics-for-300-million,22-07-2020 00:00,,,,,,
3039,boston-scientific-receives-fda-approval-for-next-generation-watchman-flx-left-atrial-appendage-closure-device,22-07-2020 00:00,,,,,,
3040,evotec-enters-partnership-with-quantro-therapeutics,22-07-2020 00:00,,,,,,
3041,rinvoq-upadacitinib-monotherapy-meets-all-primary-and-secondary-endpoints-in-second-phase-3-study-for-atopic-dermatitis,22-07-2020 00:00,,,,,,
3042,viela-bio-announces-us-fda-approval-of-uplizna?-inebilizumab-cdon-for-the-treatment-of-neuromyelitis-optica-spectrum-disorder-nmosd,11-06-2020 00:00,,,,,,
3043,fda-grants-accelerated-approval-to-lurbinectedin-for-metastatic-small-cell-lung-cancer,15-06-2020 00:00,,,,,,
3044,ultragenyx-announces-us-fda-approval-of-dojolvi?-ux007triheptanoin-the-first-fda-approved-therapy-for-the-treatment-of-long-chain-fatty-acid-oxidation-disorders,15-06-2020 00:00,,,,,,
3045,viiv-healthcare-announces-us-fda-approval-of-the-first-ever-dispersible-tablet-formulation-of-dolutegravir-tivicay-pd-a-once-daily-treatment-for-children-living-with-hiv,12-06-2020 00:00,,,,,,
3046,daiichi-sankyo-and-gustave-roussy-enter-innovative-research-collaboration-for-dxd-adcs-ds-1062-and-patritumab-deruxtecan,23-07-2020 00:00,,,,,,
3047,glenmark-announces-top-line-results-from-phase-3-clinical-trial-of-favipiravir-in-patients-with-mild-to-moderate-covid-19,23-07-2020 00:00,,,,,,
3048,phase-iii-data-show-port-delivery-system-with-ranibizumab-enabled-over-98-of-patients-to-go-six-months-between-treatments-for-neovascular-age-related-macular-degeneration,23-07-2020 00:00,,,,,,
3049,ovid-therapeutics-and-university-of-connecticut-enter-into-strategic-research-collaboration-to-accelerate-the-development-of-next-generation-genetic-therapy-for-angelman-syndrome,23-07-2020 00:00,,,,,,
3050,biomarin-submits-marketing-authorization-application-to-european-medicines-agency-for-vosoritide-to-treat-children-with-achondroplasia,24-07-2020 00:00,,,,,,
3051,zydus-receives-approval-from-usfda-to-initiate-clinical-trials-of-desidustat-in-cancer-patients-receiving-chemotherapy,24-07-2020 00:00,,,,,,
3052,synaffix-announces-expansion-of-collaboration-with-adc-therapeutics,24-07-2020 00:00,,,,,,
3053,pfizer-and-biontech-choose-lead-mrna-vaccine-candidate-against-covid-19-and-commence-pivotal-phase-23-global-study,28-07-2020 00:00,,,,,,
3054,chi-med-and-lilly-to-collaborate-in-commercializing-elunate-in-china,28-07-2020 00:00,,,,,,
3055,lilly?s-p-tau217-blood-test-shows-high-accuracy-in-diagnosis-of-alzheimer?s-disease-in-data-published-in-jama,29-07-2020 00:00,,,,,,
3056,roche-provides-an-update-on-the-phase-iii-covacta-trial-of-actemraroactemra-in-hospitalised-patients-with-severe-covid-19-associated-pneumonia,29-07-2020 00:00,,,,,,
3057,third-pivotal-phase-3-study-shows-rinvoq-upadacitinib-plus-topical-corticosteroids-improves-skin-and-itch-symptoms-in-atopic-dermatitis-patients,29-07-2020 00:00,,,,,,
3058,baxter-and-ayogo-announce-partnership-for-unique-digital-health-solutions-for-home-dialysis,29-07-2020 00:00,,,,,,
3059,barda-procures-regeneron?s-regn-eb3-investigational-ebola-treatment-for-national-preparedness,30-07-2020 00:00,,,,,,
3060,health-canada-approves-brivlera?-brivaracetam-to-treat-partial-onset-seizures-in-pediatric-epilepsy-patients,30-07-2020 00:00,,,,,,
3061,henlius-and-accord-healthcare-receive-ema-approval-for-zercepac?-trastuzumab-biosimilar,30-07-2020 00:00,,,,,,
3062,tagrisso-granted-breakthrough-therapy-designation-in-the-us-for-the-adjuvant-treatment-of-patients-with-stage-ib-iiia-egfr-mutated-lung-cancer,30-07-2020 00:00,,,,,,
3063,jardiance?-meets-primary-endpoint-in-reducing-risk-of-cardiovascular-death-or-hospitalization-for-heart-failure-in-phase-iii-trial-in-adults-with-and-without-diabetes,30-07-2020 00:00,,,,,,
3064,sangamo-announces-global-collaboration-with-novartis-to-develop-genomic-medicines-for-autism-and-other-neurodevelopmental-disorders,30-07-2020 00:00,,,,,,
3065,single-dose-of-johnson-johnson-covid-19-vaccine-candidate-demonstrates-robust-protection-in-pre-clinical-studies,31-07-2020 00:00,,,,,,
3066,oxford-biomedica-signs-three-year-clinical-supply-agreement-with-axovant-gene-therapies-for-manufacture-and-supply-of-axo-lenti-pd,31-07-2020 00:00,,,,,,
3067,fda-approves-monjuvi-tafasitamab-cxix-in-combination-with-lenalidomide-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-dlbcl,03-08-2020 00:00,,,,,,
3068,immunic-inc-reports-positive-top-line-data-from-phase-2-emphasis-trial-of-imu-838-in-patients-with-relapsing-remitting-multiple-sclerosis,03-08-2020 00:00,,,,,,
3069,biontech-announces-strategic-collaboration-with-regeneron-to-advance-fixvac-and-libtayo-cemiplimab-combination-in-melanoma,03-08-2020 00:00,,,,,,
3070,rozlytrek-roche?s-first-tumour-agnostic-therapy-approved-in-europe-for-people-with-ntrk-fusion-positive-solid-tumours-and-for-people-with-ros1-positive-advanced-non-small-cell-lung-cancer,03-08-2020 00:00,,,,,,
3071,redhill-biopharma-announces-new-agreement-with-daiichi-sankyo-for-movantik,04-08-2020 00:00,,,,,,
3072,novartis-announces-kymriah-meets-primary-endpoint-at-interim-analysis-of-pivotal-study-in-follicular-lymphoma,04-08-2020 00:00,,,,,,
3073,redx-signs-out-licensing-agreement-with-astrazeneca,05-08-2020 00:00,,,,,,
3074,leo-pharma-announces-us-food-and-drug-administration-fast-track-designation-for-delgocitinib-cream-for-the-treatment-of-adults-with-moderate-to-severe-chronic-hand-eczema,05-08-2020 00:00,,,,,,
3075,voyager-therapeutics-provides-update-on-abbvie-vectorized-antibody-collaborations,05-08-2020 00:00,,,,,,
3076,roche-announces-fda-authorisation-for-the-first-epstein-barr-virus-quantitative-test-on-the-cobas-68008800-systems-to-improve-care-for-transplant-patients,05-08-2020 00:00,,,,,,
3077,biontech-and-fosun-pharma-announce-start-of-clinical-trial-of-mrna-based-covid-19-vaccine-candidate-in-china,05-08-2020 00:00,,,,,,
3078,european-commission-grants-marketing-authorisation-for-world?s-first-subcutaneous-formulation-of-infliximab-remsima?-sc-for-an-additional-five-indic,27-07-2020 00:00,,,,,,
3079,bio-thera-solutions-partners-with-pharmapark-to-market-bat2506-in-russia-and-other-cis-countries,17-07-2020 00:00,,,,,,
3080,lundbeck-discontinues-phase-ii-proof-of-concept-study-of-lu-af11167-in-patients-with-negative-symptoms-of-schizophrenia,06-08-2020 00:00,,,,,,
3081,cimzia-is-the-first-and-only-biologic-approved-in-europe-with-the-option-for-a-reduced-maintenance-dose-for-patients-across-the-full-axial-spondyloarthritis-spectrum,06-08-2020 00:00,,,,,,
3082,moderna-prices-covid-19-vaccine-at-32-37-per-dose-for-smaller-volume-deals,06-08-2020 00:00,,,,,,
3083,evotec-signs-agreement-with-sanofi-to-advance-early-stage-academic-research-into-novel-therapeutic-candidates,05-10-2018 00:00,,,,,,
3084,emergent-biosolutions-completes-acquisition-of-specialty-vaccines-company-paxvax,05-10-2018 00:00,,,,,,
3086,objectivefield-a-ground-breaking-fda-510k-cleared-objective-perimeter-announced-by-konan-medical-usa,11-10-2018 00:00,,,,,,
3087,palette-life-sciences-and-nestl?-skin-health-enter-into-global-licensing-agreement-for-deflux-solesta-and-barrigel,17-10-2018 00:00,,,,,,
3088,johnson-johnson-announces-offer-to-acquire-ciz-holdings-co-ltd,24-10-2018 00:00,,,,,,
3089,novartis-receives-approval-for-cosentyx-label-update-in-europe-to-include-dosing-flexibility-in-psoriatic-arthritis,26-10-2018 00:00,,,,,,
3090,astrazeneca-to-divest-us-synagis-rights-to-sobi,13-11-2018 00:00,,,,,,
3091,once-daily-trelegy-ellipta-gains-expanded-copd-indication-in-europe,13-11-2018 00:00,,,,,,
3092,dragonfly-therapeutics-announces-expansion-of-its-strategic-collaboration-with-celgene-doubling-the-number-of-programs-and-including-targets-for-solid-tumor-indications,15-11-2018 00:00,,,,,,
3093,arena-pharmaceuticals-and-united-therapeutics-announce-global-license-agreement-for-ralinepag,16-11-2018 00:00,,,,,,
3094,fda-issues-emergency-use-authorization-to-vela-diagnostics?-coronavirus-pcr-test,07-08-2020 00:00,,,,,,
3095,fda-approves-lyumjev-insulin-lispro-aabc-injection-lilly?s-new-rapid-acting-insulin,15-06-2020 00:00,,,,,,
3096,fda-approves-evoke?s-gimoti?,19-06-2020 00:00,,,,,,
3097,chugai-and-biofourmis-partner-to-develop-an-objective-assessment-of-pain-using-digital-technology,23-07-2020 00:00,,,,,,
3098,abbott-receives-fda-approval-for-ios-compatible-app-allowing-people-living-with-chronic-pain-and-movement-disorders-to-personalize-therapy-via-their-mobile-device,24-07-2020 00:00,,,,,,
3099,breztri-aerosphere-approved-in-the-us-for-the-maintenance-treatment-of-copd,24-07-2020 00:00,,,,,,
3100,gilead-and-galapagos-announce-positive-european-chmp-opinion-for-jyseleca-filgotinib-for-the-treatment-of-adults-with-moderate-to-severe-rheumatoid-arthritis,24-07-2020 00:00,,,,,,
3101,sorrento-enters-into-letter-of-intent-to-acquire-smartpharm-and-develop-pipeline-of-gene-encoded-therapeutic-antibodies-starting-with-neutralizing-antibodies-to-treat-covid-19-and-cancer-therapeutics,27-07-2020 00:00,,,,,,
3102,daiichi-sankyo-and-astrazeneca-enter-new-global-development-and-commercialization-collaboration-for-daiichi-sankyo?s-adc-ds-1062,27-07-2020 00:00,,,,,,
3103,equidacent,27-07-2020 00:00,,,,,,
3104,us-fda-approves-kite?s-tecartus-the-first-and-only-car-t-treatment-for-relapsed-or-refractory-mantle-cell-lymphoma,27-07-2020 00:00,,,,,,
3105,cadila-pharmaceuticals-expands-oncology-portfolio-with-biosimilar-cancer-drug-bevaro,22-07-2020 00:00,,,,,,
3106,cipla-receives-regulatory-approval-for-launch-of-ciplenza-favipiravir-200-mg-in-india-to-treat-mild-to-moderate-covid-19,27-07-2020 00:00,,,,,,
3107,emergent-biosolutions-signs-agreement-with-astrazeneca-to-expand-manufacturing-for-covid-19-vaccine-candidate,28-07-2020 00:00,,,,,,
3108,farxiga-met-all-primary-and-secondary-endpoints-in-groundbreaking-phase-iii-dapa-ckd-trial-for-the-treatment-of-patients-with-chronic-kidney-disease,28-07-2020 00:00,,,,,,
3109,zebra-medical-vision-secures-its-first-fda-clearance-in-oncology-boosting-early-detection-of-breast-cancer-in-mammograms,28-07-2020 00:00,,,,,,
3110,ucb-enters-into-collaboration-with-roche-to-develop-antibody-treatment-for-people-living-with-alzheimer?s-disease,29-07-2020 00:00,,,,,,
3111,sanofi-and-gsk-agree-with-the-uk-government-to-supply-up-to-60-million-doses-of-covid-19-vaccine,29-07-2020 00:00,,,,,,
3112,fda-grants-breakthrough-therapy-designation-to-merck?s-novel-hif-2a-inhibitor-mk-6482-for-treatment-of-certain-patients-with-von-hippel-lindau-disease-associated-renal-cell-carcinoma,29-07-2020 00:00,,,,,,
3113,cadila-pharmaceuticals-launches-biosimilar-rituximab-drug-ritucad,29-07-2020 00:00,,,,,,
3114,fda-approves-roche?s-tecentriq-plus-cotellic-and-zelboraf-for-people-with-advanced-melanoma,31-07-2020 00:00,,,,,,
3115,takeda-announces-us-fda-breakthrough-therapy-designation-granted-for-pevonedistat-for-the-treatment-of-patients-with-higher-risk-myelodysplastic-syndromes-hr-mds,31-07-2020 00:00,,,,,,
3116,fda-approves-roche?s-new-ventana-her2-dual-ish-test-as-companion-diagnostic-to-identify-breast-cancer-patients-eligible-for-targeted-therapy,31-07-2020 00:00,,,,,,
3117,sanofi-and-gsk-in-advanced-discussions-with-european-union-to-supply-up-to-300-million-doses-of-covid-19-vaccine,03-08-2020 00:00,,,,,,
3118,lilly-initiates-phase-3-trial-of-ly-cov555-for-prevention-of-covid-19-at-long-term-care-facilities-in-partnership-with-the-national-institute-of-allergy-and-infectious-diseases-niaid,04-08-2020 00:00,,,,,,
3119,varian-to-combine-with-siemens-healthineers-in-164-billion-all-cash-transaction,04-08-2020 00:00,,,,,,
3120,merck-and-hanmi-pharmaceutical-enter-into-licensing-agreement-to-develop-efinopegdutide-an-investigational-once-weekly-therapy-for-nonalcoholic-steatohepatitis-nash,04-08-2020 00:00,,,,,,
3121,janssen-announces-health-canada-approval-of-darzalex-sc-a-new-subcutaneous-formulation-for-the-treatment-of-patients-with-multiple-myeloma,04-08-2020 00:00,,,,,,
3122,lupin-launches-favipiravir-drug-covihalt-for-treatment-of-mild-to-moderate-covid-19,05-08-2020 00:00,,,,,,
3123,teva-and-alvotech-announce-strategic-partnership-to-collaborate-in-the-us-biosimilar-market,05-08-2020 00:00,,,,,,
3124,johnson-johnson-announces-agreement-with-us-government-for-100-million-doses-of-investigational-covid-19-vaccine,06-08-2020 00:00,,,,,,
3125,eko-announces-global-collaboration-with-astrazeneca-to-improve-diagnosis-of-heart-failure,06-08-2020 00:00,,,,,,
3126,novartis-announces-nejm-publication-of-phase-iii-asclepios-trials-demonstrating-superior-efficacy-of-ofatumumab-in-patients-with-relapsing-multiple-sclerosis,06-08-2020 00:00,,,,,,
3127,biogen-and-denali-to-collaborate-on-lrrk2-program-for-parkinson?s-disease-and-certain-tv-platform-enabled-programs-for-neurodegenerative-diseases,07-08-2020 00:00,,,,,,
3128,roche-provides-update-on-phase-iii-study-of-tecentriq-in-combination-with-paclitaxel-for-people-with-metastatic-triple-negative-breast-cancer,07-08-2020 00:00,,,,,,
3129,daiichi-sankyo-announces-clinical-trial-collaboration-with-astrazeneca-to-evaluate-patritumab-deruxtecan-u3-1402-in-combination-with-tagrisso-in-egfr-mutated-non-small-cell-lung-cancer,07-08-2020 00:00,,,,,,
3130,bausch-health-to-spin-off-its-eye-health-business,07-08-2020 00:00,,,,,,
3131,elanco-announces-european-commission-approval-of-pending-acquisition-of-bayer-animal-health,08-06-2020 00:00,,,,,,
3132,merck-animal-health-to-acquire-us-rights-to-sentinel-brand-of-combination-parasiticides-for-companion-animals,13-05-2020 00:00,,,,,,
3133,elanco-receives-us-federal-trade-commission-approval-for-acquisition-of-bayer-animal-health,15-07-2020 00:00,,,,,,
3134,merck-animal-health-receives-us-fda-approval-of-bravecto-fluralaner-monthly-chews,09-07-2020 00:00,,,,,,
3135,boehringer-ingelheim?s-china-developed-classical-swine-fever-live-vaccine-approved,10-06-2020 00:00,,,,,,
3136,elanco-announces-agreement-to-acquire-bayer?s-animal-health-business,20-08-2019 00:00,,,,,,
3137,cadila-pharma-launches-osteoporosis-biosimilar-in-india,07-08-2020 00:00,,,,,,
3138,fda-approves-roche?s-evrysdi-risdiplam-for-treatment-of-spinal-muscular-atrophy-sma-in-adults-and-children-2-months-and-older,10-08-2020 00:00,,,,,,
3139,boehringer-ingelheim-acquires-gst-to-strengthen-its-stem-cell-capabilities-in-animal-health,10-08-2020 00:00,,,,,,
3140,fda-approves-first-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test,10-08-2020 00:00,,,,,,
3141,roche-provides-update-on-phase-iii-studies-of-etrolizumab-in-people-with-moderately-to-severely-active-ulcerative-colitis,10-08-2020 00:00,,,,,,
3142,samsung-bioepis-announces-launch-of-ontruzant-trastuzumab-in-brazil-for-early-and-metastatic-her2-overexpressing-breast-cancer,11-08-2020 00:00,,,,,,
3143,gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-veklury?-remdesivir-for-the-treatment-of-covid-19,11-08-2020 00:00,,,,,,
3144,olympus-announces-acquisition-of-arc-medical-design-limited-from-norgine-bv,11-08-2020 00:00,,,,,,
3145,bayer-to-acquire-uk-based-biotech-kandy-therapeutics-ltd,11-08-2020 00:00,,,,,,
3146,ligand-to-acquire-pfenex-inc,11-08-2020 00:00,,,,,,
3147,medtronic-to-acquire-smart-insulin-pen-company-companion-medical,12-08-2020 00:00,,,,,,
3148,health-canada-approves-opdivo-nivolumab-plus-yervoy-ipilimumab-combined-with-limited-chemotherapy-for-the-treatment-of-metastatic-non-small-cell-lung-cancer,12-08-2020 00:00,,,,,,
3149,sarepta-therapeutics-and-university-of-florida-announce-collaboration-to-accelerate-the-discovery-and-development-of-therapies-for-rare-genetic-diseases,12-08-2020 00:00,,,,,,
3150,innovent-and-eli-lilly-announce-acceptance-of-a-supplemental-new-drug-application-of-tyvyt-sintilimab-injection-in-combination-with-gemcitabine-and-platinum-as-first-line-therapy-in-squamous-non-small-cell-lung-cancer-in-china,12-08-2020 00:00,,,,,,
3151,celleron-therapeutics-enters-into-a-license-agreement-with-roche-to-improve-the-lives-of-patients-living-with-tenosynovial-giant-cell-tumour,12-08-2020 00:00,,,,,,
3152,fda-accepts-evinacumab-biologics-license-application-for-priority-review-as-a-treatment-for-patients-with-hofh-an-ultra-rare-inherited-form-of-high-cholesterol,13-08-2020 00:00,,,,,,
3153,fda-accepts-application-for-xolair-omalizumab-prefilled-syringe-for-self-administration-across-all-indications,13-08-2020 00:00,,,,,,
3154,verily-stands-up-clia-certified-lab-focused-on-covid-19-testing-an-interview-with-deb-hanks-md-verily?s-head-of-pathology,13-08-2020 00:00,,,,,,
3155,zydus-launches-remdac-remdesivir-for-the-treatment-of-covid-19-in-india,13-08-2020 00:00,,,,,,
3156,novo-nordisk-resumes-the-phase-3-clinical-trials-investigating-concizumab-anti-tfpi-mab-in-haemophilia-a-and-b-with-or-without-inhibitors,13-08-2020 00:00,,,,,,
3157,strata-oncology-announces-partnership-to-broaden-enrollment-in-mirati-therapeutics?-clinical-trial-of-mrtx849-a-novel-kras-g12c-selective-inhibitor,13-08-2020 00:00,,,,,,
3158,astrazeneca-set-to-start-making-400-million-covid-19-vaccines-for-latam-early-in-2021,14-08-2020 00:00,,,,,,
3159,commission-concludes-further-talks-to-secure-future-vaccine,14-08-2020 00:00,,,,,,
3160,novavax-and-sk-bioscience-announce-collaboration-for-novavax?-covid-19-vaccine-candidate,14-08-2020 00:00,,,,,,
3161,novavax-and-uk-government-announce-collaboration-and-purchase-agreement-for-novavax?-covid-19-vaccine-candidate,14-08-2020 00:00,,,,,,
3162,isofol-enters-licensing-agreement-with-solasia-to-develop-and-commercialize-arfolitixorin-in-japan,14-08-2020 00:00,,,,,,
3163,sanofi-to-acquire-principia-biopharma,17-08-2020 00:00,,,,,,
3164,fda-approves-roche?s-enspryng-for-neuromyelitis-optica-spectrum-disorder-nmosd,17-08-2020 00:00,,,,,,
3165,dragonfly-therapeutics-and-bristol-myers-squibb-announce-exclusive-global-license-for-dragonfly?s-il-12-investigational-immunotherapy-program,17-08-2020 00:00,,,,,,
3166,abeona-therapeutics-and-taysha-gene-therapies-enter-into-licensing-and-inventory-purchase-agreements-for-abo-202-a-clinical-stage-novel-one-time-gene-therapy-for-cln1-disease,17-08-2020 00:00,,,,,,
3167,china?s-first-trastuzumab-biosimilar-approved-by-nmpa,17-08-2020 00:00,,,,,,
3168,gilead-sciences-and-tango-therapeutics-to-expand-strategic-oncology-collaboration,18-08-2020 00:00,,,,,,
3169,mabxience-enters-into-an-agreement-with-astrazeneca-to-produce-covid-19-vaccine,18-08-2020 00:00,,,,,,
3170,ptc-announces-the-acceptance-of-the-european-marketing-authorization-application-for-evrysdi-risdiplam-for-the-treatment-of-spinal-muscular-atrophy,18-08-2020 00:00,,,,,,
3171,imfinzi-granted-fda-priority-review-for-less-frequent-fixed-dose-use,18-08-2020 00:00,,,,,,
3172,g1-therapeutics-announces-acceptance-and-priority-review-of-nda-for-trilaciclib-for-patients-with-small-cell-lung-cancer,18-08-2020 00:00,,,,,,
3173,lilly-and-innovent-announce-global-expansion-of-tyvyt-licensing-agreement,18-08-2020 00:00,,,,,,
3174,roche-and-regeneron-collaborate-to-significantly-increase-global-supply-of-regn-cov2-investigational-antibody-combination-for-covid-19,19-08-2020 00:00,,,,,,
3175,evotec-and-novo-nordisk-form-strategic-alliance-to-develop-novel-therapies-for-kidney-diseases,19-08-2020 00:00,,,,,,
3176,dupixent-dupilumab-injection-now-approved-by-health-canada-for-severe-chronic-rhinosinusitis-with-nasal-polyposis,19-08-2020 00:00,,,,,,
3177,johnson-johnson-to-acquire-momenta-pharmaceuticals-inc-expanding-janssen?s-leadership-in-novel-treatments-for-autoimmune-diseases,19-08-2020 00:00,,,,,,
3178,gilead-receives-complete-response-letter-for-filgotinib-for-the-treatment-of-moderately-to-severely-active-rheumatoid-arthritis,19-08-2020 00:00,,,,,,
3179,health-canada-grants-market-authorization-for-tecentriq-in-combination-with-bevacizumab-the-first-immunotherapy-combination-treatment-for-the-most-common-form-of-liver-cancer,19-08-2020 00:00,,,,,,
3180,early-findings-from-fitbit-covid-19-study-suggest-fitbit-devices-can-identify-signs-of-disease-at-its-earliest-stages,20-08-2020 00:00,,,,,,
3181,qiagen-expands-integrated-coronavirus-ngs-and-software-solutions-to-accelerate-covid-19-research,20-08-2020 00:00,,,,,,
3182,sorrento-announces-fda-ind-filing-today-for-covi-guard-neutralizing-and-high-potency-antibody-against-sars-cov-2,20-08-2020 00:00,,,,,,
3183,precision-biosciences-receives-fast-track-disease-designation-from-us-food-and-drug-administration-for-pbcar0191-investigational-allogeneic-car-t-cell-therapy,20-08-2020 00:00,,,,,,
3184,biosymetrics-collaborates-with-janssen-and-sema4-to-predict-the-onset-of-covid-19,20-08-2020 00:00,,,,,,
3185,evotec-and-centogene-expand-collaboration-into-gaucher-disease,20-08-2020 00:00,,,,,,
3186,fda-approves-novartis-kesimpta-ofatumumab-the-first-and-only-self-administered-targeted-b-cell-therapy-for-patients-with-relapsing-multiple-sclerosis,21-08-2020 00:00,,,,,,
3187,jazz-pharmaceuticals-announces-us-fda-approval-of-xywavcalcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-cataplexy-or-excessive-daytime-sleepiness-associated-with-narcolepsy,22-07-2020 00:00,,,,,,
3188,mc2-therapeutics-announces-us-food-and-drug-administration-approval-of-wynzora?-cream-calcipotriene-and-betamethasone-dipropionate-ww-00050064-for-adults-with-plaque-psoriasis,22-07-2020 00:00,,,,,,
3189,osmotica-pharmaceuticals-plc-receives-fda-approval-for-upneeq?-oxymetazoline-hydrochloride-ophthalmic-solution-01-for-acquired-blepharoptosis-droopy-eyelid-in-adults,09-07-2020 00:00,,,,,,
3190,pfizer-and-biontech-share-positive-early-data-on-lead-mrna-vaccine-candidate-bnt162b2-against-covid-19,21-08-2020 00:00,,,,,,
3191,imfinzi-approved-in-japan-for-the-treatment-of-extensive-stage-small-cell-lung-cancer,21-08-2020 00:00,,,,,,
3192,acacia-pharma-announces-us-fda-approval-of-byfavo?-remimazolam-for-injection-for-the-induction-and-maintenance-of-procedural-sedation,02-07-2020 00:00,,,,,,
3193,us-fda-approves-new-darzalex-daratumumab-based-combination-regimen-for-patients-with-relapsedrefractory-multiple-myeloma,21-08-2020 00:00,,,,,,
3194,junshi-biosciences-and-impact-therapeutics-establish-joint-venture-to-develop-parp-inhibitor-senaparib-imp4297-in-china,21-08-2020 00:00,,,,,,
3195,biomarin-submits-new-drug-application-to-us-food-and-drug-administration-for-vosoritide-to-treat-children-with-achondroplasia,21-08-2020 00:00,,,,,,
3196,renalytixai-to-collaborate-with-astrazeneca-to-improve-outcomes-for-patients-with-chronic-disease,24-08-2020 00:00,,,,,,
3197,european-commission-approves-kaftrio-ivacaftortezacaftorelexacaftor-in-combination-with-ivacaftor-to-treat-cystic-fibrosis-in-people-ages-12-years-and-older,24-08-2020 00:00,,,,,,
3198,chugai-obtains-approval-for-additional-indication-of-kadcyla-for-adjuvant-therapy-of-her2-positive-early-breast-cancer,24-08-2020 00:00,,,,,,
3199,takeda-to-divest-its-japan-consumer-health-care-business-unit-to-blackstone-for-jpy-2420-billion,24-08-2020 00:00,,,,,,
3200,reithera?s-covid-19-vaccine-candidate-enters-phase-1-clinical-study-with-first-healthy-volunteer-dosed-in-italy,24-08-2020 00:00,,,,,,
3201,bristol-myers-squibb-enters-agreement-to-acquire-forbius-adding-lead-tgf-beta-asset-to-portfolio,24-08-2020 00:00,,,,,,
3202,bayer-and-informed-data-systems-inc-one-drop-join-forces-to-jointly-develop-digital-health-products-across-therapeutic-areas,24-08-2020 00:00,,,,,,
3203,novartis-provides-update-on-phase-iii-study-evaluating-investigational-spartalizumab-pdr001-in-combination-with-tafinlar-mekinist-in-advanced-melanoma,25-08-2020 00:00,,,,,,
3204,bionano-genomics-acquires-diagnostics-services-provider-lineagen-inc-to-accelerate-clinical-adoption-of-saphyr-for-digital-cytogenetics,25-08-2020 00:00,,,,,,
3205,merck?s-keytruda-pembrolizumab-receives-two-new-approvals-in-japan,25-08-2020 00:00,,,,,,
3206,phase-i-clinical-trial-initiated-for-monoclonal-antibody-combination-for-the-prevention-and-treatment-of-covid-19,25-08-2020 00:00,,,,,,
3207,bio-thera-solutions-and-beigene-announce-license-distribution-and-supply-agreement-for-avastin-bevacizumab-biosimilar-bat1706-in-china,25-08-2020 00:00,,,,,,
3208,morphic-announces-that-abbvie-exercises-license-option-to-v-6-integrin-inhibitor-program-including-morf-720-for-fibrotic-diseases,25-08-2020 00:00,,,,,,
3209,abbvie-harvard-university-form-research-alliance-to-address-emergent-viral-diseases,25-08-2020 00:00,,,,,,
3210,acadia-pharmaceuticals-acquires-cersci-therapeutics-adds-novel-pain-program-to-portfolio,26-08-2020 00:00,,,,,,
3211,phase-2-elektra-study-of-soticlestat-tak-935ov935-meets-primary-endpoint-reducing-seizure-frequency-in-children-with-dravet-syndrome-or-lennox-gastaut-syndrome,26-08-2020 00:00,,,,,,
3212,novartis-investigational-novel-stamp-inhibitor-asciminib-abl001-meets-primary-endpoint-of-phase-iii-chronic-myeloid-leukemia-study,26-08-2020 00:00,,,,,,
3213,qiagen-to-launch-easy-to-use-digital-test-in-the-us-for-rapid-detection-of-sars-cov-2-antibodies-following-fda-emergency-use-authorization,26-08-2020 00:00,,,,,,
3214,philips-and-b-braun-receive-fda-clearance-for-breakthrough-onvision-needle-tip-tracking-technology-for-regional-anesthesia,26-08-2020 00:00,,,,,,
3215,engitix-signs-collaboration-and-licensing-agreement-with-takeda-to-develop-anti-fibrotic-therapies-in-advanced-liver-diseases,26-08-2020 00:00,,,,,,
3216,lupin-and-mylan-launch-nepexto-biosimilar-etanercept-in-germany,27-08-2020 00:00,,,,,,
3217,european-commission-approves-blenrep-belantamab-mafodotin-for-the-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma,27-08-2020 00:00,,,,,,
3218,celltrion-receives-korean-mfds-approval-to-initiate-phase-i-trial-of-covid-19-antiviral-antibody-treatment-candidate-ct-p59-in-patients,27-08-2020 00:00,,,,,,
3219,fdc-limited-launches-two-variants-of-favipiravir-drug-for-covid-19,27-08-2020 00:00,,,,,,
3220,abbott?s-fast-5-15-minute-easy-to-use-covid-19-antigen-test-receives-fda-emergency-use-authorization-mobile-app-displays-test-results-to-help-our-return-to-daily-life-ramping-production-to-50-million-tests-a-month,27-08-2020 00:00,,,,,,
3221,beigene-announces-exclusive-license-agreement-for-neutralizing-covid-19-antibodies-developed-by-singlomics-biopharmaceuticals,27-08-2020 00:00,,,,,,
3222,otsuka-announces-simultaneous-regulatory-approvals-by-us-fda-and-health-canada-of-inqovi?-an-oral-hypomethylating-agent-hma-therapy-for-mds-and-cmml,20-07-2020 00:00,,,,,,
3223,introducing-amazon-halo-and-amazon-halo-band?a-new-service-that-helps-customers-improve-their-health-and-wellness,28-08-2020 00:00,,,,,,
3224,biontech-and-fosun-pharma-to-potentially-supply-10-million-doses-of-biontech?s-bnt162-mrna-based-vaccine-candidate-against-sars-cov-2-to-hong-kong-sar-and-macao-sar,28-08-2020 00:00,,,,,,
3225,philips-to-expand-its-image-guided-therapy-devices-portfolio-through-acquisition-of-intact-vascular,28-08-2020 00:00,,,,,,
3226,galecto-inc-receives-us-and-eu-orphan-drug-designations-for-gb0139-in-idiopathic-pulmonary-fibrosis,28-08-2020 00:00,,,,,,
3227,bayer-submits-vericiguat-for-marketing-authorization-in-china-for-the-treatment-of-chronic-heart-failure,28-08-2020 00:00,,,,,,
3228,taysha-gene-therapies-receives-orphan-drug-designation-and-rare-pediatric-disease-designation-for-tsha-101-for-gm2-gangliosidosis,28-08-2020 00:00,,,,,,
3229,novartis-announces-positive-results-from-phase-ii-study-of-lnp023-in-patients-with-paroxysmal-nocturnal-hemoglobinuria-pnh,31-08-2020 00:00,,,,,,
3230,asia?s-first-prescription-?digital-therapeutic?-approved-in-japan-nicotine-addiction-treatment-app-with-co-checker-receives-regulatory-approval-?-cureapp-inc,31-08-2020 00:00,,,,,,
3231,farxiga-is-the-first-medicine-to-significantly-prolong-survival-in-a-renal-outcomes-trial-in-patients-with-chronic-kidney-disease-with-and-without-type-2-diabetes,31-08-2020 00:00,,,,,,
3232,cadila-pharmaceuticals-launches-cadalimab-adalimumab-biosimilar-for-india,31-08-2020 00:00,,,,,,
3233,mylan-and-biocon-biologics-announce-launch-of-semglee-insulin-glargine-injection-in-the-us-to-expand-access-for-patients-living-with-diabetes,31-08-2020 00:00,,,,,,
3234,ionis-pharmaceuticals-to-acquire-remaining-stake-in-akcea-therapeutics,31-08-2020 00:00,,,,,,
3235,johnson-johnson-announces-agreement-in-principle-with-government-of-canada-to-supply-its-covid-19-vaccine-candidate,01-09-2020 00:00,,,,,,
3236,development-of-covid-19-vaccine-azd1222-expands-into-us-phase-iii-clinical-trial-across-all-adult-age-groups,01-09-2020 00:00,,,,,,
3237,vir-biotechnology-and-gsk-start-phase-23-study-of-covid-19-antibody-treatment,01-09-2020 00:00,,,,,,
3238,oxford-biomedica-signs-supply-agreement-with-astrazeneca-to-expand-manufacturing-support-of-covid-19-vaccine-candidate-azd1222,01-09-2020 00:00,,,,,,
3239,health-canada-authorizes-enspryng-for-canadians-living-with-neuromyelitis-optica-spectrum-disorder,01-09-2020 00:00,,,,,,
3240,roche-receives-fda-approval-for-first-hiv-1hiv-2-qualitative-test-on-the-cobas-68008800-systems-in-the-fight-against-hivaids,01-09-2020 00:00,,,,,,
3241,gilead-sciences-and-jounce-therapeutics-announce-exclusive-license-agreement-for-novel-immunotherapy-program,02-09-2020 00:00,,,,,,
3242,imfinzi-approved-in-the-eu-for-the-treatment-of-extensive-stage-small-cell-lung-cancer,02-09-2020 00:00,,,,,,
3243,aimmune-agrees-to-be-acquired-by-nestl?-health-science,02-09-2020 00:00,,,,,,
3244,medtronic-announces-fda-approval-for-minimed-770g-insulin-pump-system-with-smartphone-connectivity-for-people-with-type-1-diabetes,02-09-2020 00:00,,,,,,
3245,us-food-and-drug-administration-approves-onureg-azacitidine-a-new-oral-therapy-as-continued-treatment-for-adults-in-first-remission-with-acute-myeloid-leukemia,02-09-2020 00:00,,,,,,
3246,celltrion-to-start-p1-trial-of-prolia-biosimilar,14-08-2020 00:00,,,,,,
3247,santhera-exercises-option-to-obtain-worldwide-rights-to-vamorolone-in-duchenne-muscular-dystrophy-and-all-other-indications,02-09-2020 00:00,,,,,,
3248,formycon-and-bioeq-enroll-first-patient-in-phase-iii-study-with-aflibercept-biosimilar-fyb203,24-08-2020 00:00,,,,,,
3249,samsung-bioepis-acquires-european-sales-license-for-anticancer-drug?avincio-sb8?,21-08-2020 00:00,,,,,,
3250,cadila-pharmaceuticals-launches-cadalimab-adalimumab-biosimilar-for-india,28-08-2020 00:00,,,,,,
3251,sandoz-canada-launches-two-new-biosimilars-ziextenzo?-and-riximyo?,19-08-2020 00:00,,,,,,
3252,biomx-enters-collaboration-with-boehringer-ingelheim-with-the-goal-of-discovering-microbiome-based-biomarkers-for-inflammatory-bowel-disease,03-09-2020 00:00,,,,,,
3253,sanofi-and-gsk-initiate-phase-12-clinical-trial-of-covid-19-adjuvanted-recombinant-protein-based-vaccine-candidate,03-09-2020 00:00,,,,,,
3254,highlight-therapeutics-announces-second-phase-ii-oncology-collaboration-with-merck,03-09-2020 00:00,,,,,,
3255,janssen-to-discontinue-pimodivir-influenza-development-program,03-09-2020 00:00,,,,,,
3256,baxter-announces-us-fda-de-novo-authorization-for-theranova-dialyzers-enabling-hdx-therapy,03-09-2020 00:00,,,,,,
3257,bicycle-therapeutics-announces-first-patient-dosed-in-phase-iia-trial-of-bicycle-toxin-conjugate-bt1718,03-09-2020 00:00,,,,,,
3258,bio-thera-solutions-initiates-phase-i-clinical-trial-for-bat2206-a-proposed-biosimilar-of-stelara-ustekinumab,04-09-2020 00:00,,,,,,
3259,fda-approves-additional-doses-of-trulicity-dulaglutide-for-the-treatment-of-type-2-diabetes,04-09-2020 00:00,,,,,,
3260,roche-receives-fda-emergency-use-authorization-for-the-cobas-sars-cov-2-influenza-ab-test-for-use-on-the-cobas-68008800-systems,04-09-2020 00:00,,,,,,
3261,innovent-announces-nmpa-granted-marketing-approval-for-sulinno-adalimumab-injection-in-china,04-09-2020 00:00,,,,,,
3262,abbott-announces-start-of-trial-to-evaluate-the-new-esprit-btk-drug-eluting-resorbable-scaffold,04-09-2020 00:00,,,,,,
3263,kite-and-hifibio-therapeutics-partner-to-discover-novel-targets-and-antibodies-against-acute-myeloid-leukemia,04-09-2020 00:00,,,,,,
3264,abbvie-and-i-mab-enter-into-global-strategic-partnership-for-differentiated-immuno-oncology-therapy,04-09-2020 00:00,,,,,,
3265,chi-med-initiates-fresco-2-a-global-phase-iii-trial-of-fruquintinib-in-metastatic-colorectal-cancer,07-09-2020 00:00,,,,,,
3266,kite-submits-supplemental-biologics-license-application-to-us-food-and-drug-administration-for-yescarta-in-relapsed-or-refractory-indolent-non-hodgkin-lymphomas,07-09-2020 00:00,,,,,,
3267,roche-announces-fda-approval-of-gavreto-pralsetinib-for-the-treatment-of-adults-with-metastatic-ret-fusion-positive-non-small-cell-lung-cancer,07-09-2020 00:00,,,,,,
3268,new-analyses-from-breztri-aerosphere-phase-iii-ethos-trial-to-be-presented-at-the-european-respiratory-society-international-congress-2020,07-09-2020 00:00,,,,,,
3269,grifols-to-acquire-alkahest-to-enhance-discovery-research-and-development-to-identify-innovative-therapies-for-age-related-diseases-based-upon-an-understanding-of-the-human-plasma-proteome,07-09-2020 00:00,,,,,,
3270,project-als-granted-fda-orphan-drug-designation-for-prosetin-for-the-treatment-of-amyotrophic-lateral-sclerosis,07-09-2020 00:00,,,,,,
3271,boehringer-ingelheim-discontinues-development-of-bi-1467335-for-diabetic-retinopathy,08-09-2020 00:00,,,,,,
3272,mylan-to-acquire-aspen?s-thrombosis-business-in-europe,08-09-2020 00:00,,,,,,
3273,dupixent-dupilumab-long-term-data-show-sustained-improvement-in-lung-function-and-reduction-in-severe-exacerbations-in-adults-and-adolescents-with-moderate-to-severe-asthma,08-09-2020 00:00,,,,,,
3274,roche-receives-fda-clearance-for-bk-virus-quantitative-test-on-cobas-68008800-systems-to-support-better-care-for-transplant-patients,08-09-2020 00:00,,,,,,
3275,silence-therapeutics-provides-research-and-development-update,08-09-2020 00:00,,,,,,
3276,janssen-announces-european-commission-decision-for-expanded-use-of-imbruvica-ibrutinib-in-combination-with-rituximab-for-previously-untreated-patients-with-chronic-lymphocytic-leukaemia-cll,08-09-2020 00:00,,,,,,
3277,roche-expands-its-multiple-sclerosis-portfolio-with-investigational-btk-inhibitor-fenebrutinib-and-initiates-novel-clinical-trials-for-ocrevus-ocrelizumab,09-09-2020 00:00,,,,,,
3278,takeda-divests-select-non-core-assets-in-europe-to-cheplapharm-for-approximately-562-million-usd,09-09-2020 00:00,,,,,,
3279,nerivio-smartphone-controlled-wearable-for-acute-treatment-of-migraine-granted-ce-mark-for-use-in-europe,09-09-2020 00:00,,,,,,
3280,merck?s-gefapixant-45-mg-twice-daily-significantly-decreased-cough-frequency-compared-to-placebo-at-week-12-and-24-in-patients-with-refractory-or-unexplained-chronic-cough,09-09-2020 00:00,,,,,,
3281,regenxbio-announces-dosing-of-first-patient-in-phase-ii-aaviate-trial-of-rgx-314-for-the-treatment-of-wet-amd-using-suprachoroidal-delivery,09-09-2020 00:00,,,,,,
3282,sanofi-genzyme-continues-research-to-improve-the-lives-of-patients-with-multiple-sclerosis-with-new-data-presented-at-msvirtual2020,09-09-2020 00:00,,,,,,
3283,bayer-collaborates-with-recursion-to-strengthen-digital-drug-discovery-and-advance-new-therapies-for-fibrotic-diseases,10-09-2020 00:00,,,,,,
3284,fasenra-met-both-co-primary-endpoints-of-reduced-nasal-polyp-size-and-blockage-in-the-ostro-phase-iii-trial-for-patients-with-chronic-rhinosinusitis-with-nasal-polyps,10-09-2020 00:00,,,,,,
3285,pfizer-and-biontech-to-potentially-supply-the-eu-with-200-million-doses-of-mrna-based-vaccine-candidate-against-sars-cov-2,10-09-2020 00:00,,,,,,
3286,new-data-show-genentech?s-enspryng-significantly-reduces-severity-and-risk-of-relapse-in-neuromyelitis-optica-spectrum-disorder,10-09-2020 00:00,,,,,,
3287,jazz-pharmaceuticals-announces-new-research-collaboration-with-redx-pharma-to-discover-and-develop-two-targeted-cancer-therapies,10-09-2020 00:00,,,,,,
3288,takeda-announces-results-from-phase-3-clinical-trial-evaluating-ninlaro?-ixazomib-in-newly-diagnosed-multiple-myeloma,10-09-2020 00:00,,,,,,
3289,henlius-bevacizumab-biosimilar-received-nda-acceptance-notification-from-nmpa,11-09-2020 00:00,,,,,,
3290,new-data-further-reinforce-roche?s-ocrevus-ocrelizumab-as-a-highly-effective-treatment-for-people-with-multiple-sclerosis,11-09-2020 00:00,,,,,,
3291,fda-approves-trelegy-ellipta-as-the-first-once-daily-single-inhaler-triple-therapy-for-the-treatment-of-both-asthma-and-copd-in-the-us,11-09-2020 00:00,,,,,,
3292,chugai-and-takeda-to-join-a-clinical-collaboration-for-global-phase-iii-studies-for-the-combination-therapy-with-multiple-tumor-types-in-japan,11-09-2020 00:00,,,,,,
3293,janssen-submits-application-seeking-us-fda-approval-of-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-for-the-treatment-of-patients-with-light-chain-al-amyloidosis,11-09-2020 00:00,,,,,,
3294,tremfya-guselkumab-approved-by-us-food-and-drug-administration-as-the-first-selective-interleukin-il-23-inhibitor-for-active-psoriatic-arthritis,11-09-2020 00:00,,,,,,
3295,gilead-sciences-to-acquire-immunomedics,14-09-2020 00:00,,,,,,
3296,covid-19-vaccine-azd1222-clinical-trials-resumed-in-the-uk,14-09-2020 00:00,,,,,,
3297,fda-grants-dupixent-dupilumab-breakthrough-therapy-designation-for-eosinophilic-esophagitis,14-09-2020 00:00,,,,,,
3298,novartis-reports-positive-topline-results-from-the-first-phase-iii-trial-of-beovu-versus-aflibercept-in-patients-with-diabetic-macular-edema-dme,14-09-2020 00:00,,,,,,
3299,boehringer-ingelheim-and-click-therapeutics-enter-into-collaboration-to-develop-and-commercialize-ct-155-a-novel-prescription-digital-therapeutic-to-aid-in-the-treatment-of-schizophrenia,14-09-2020 00:00,,,,,,
3300,seattle-genetics-and-merck-announce-two-strategic-oncology-collaborations,14-09-2020 00:00,,,,,,
3301,fitbit-receives-regulatory-clearance-in-both-the-united-states-and-europe-for-ecg-app-to-identify-atrial-fibrillation-afib,15-09-2020 00:00,,,,,,
3302,lilly-incyte?s-olumiant-cuts-recovery-time-when-added-to-veklury-in-hospitalized-covid-19-patients,15-09-2020 00:00,,,,,,
3303,springworks-therapeutics-announces-clinical-collaboration-with-janssen-to-evaluate-nirogacestat-in-combination-with-teclistamab-in-patients-with-relapsed-or-refractory-multiple-myeloma,15-09-2020 00:00,,,,,,
3304,european-medicines-agency-ema-approves-safety-label-update-for-novartis-beovu,15-09-2020 00:00,,,,,,
3305,mallinckrodt-receives-a-complete-response-letter-from-the-us-food-and-drug-administration-fda-for-terlipressin-for-the-treatment-of-hepatorenal-syndrome-type-1-hrs-1,15-09-2020 00:00,,,,,,
3306,phase-ii-trial-results-demonstrated-improvement-in-cognition-with-bi-425809-in-adult-patients-with-schizophrenia,15-09-2020 00:00,,,,,,
3307,brenzys-etanercept-injection-now-indicated-for-the-treatment-of-plaque-psoriasis-psoriatic-arthritis-and-juvenile-idiopathic-arthritis,16-09-2020 00:00,,,,,,
3308,obsidian-therapeutics-announces-bristol-myers-squibb-opt-in-of-cytodrive?-cell-therapy-candidate,16-09-2020 00:00,,,,,,
3309,gilead?s-magrolimab-an-investigational-anti-cd47-monoclonal-antibody-receives-fda-breakthrough-therapy-designation-for-treatment-of-myelodysplastic-syndrome,16-09-2020 00:00,,,,,,
3310,takeda-to-divest-tachosil-to-corza-health-for-?350-million,16-09-2020 00:00,,,,,,
3311,roche-receives-fda-approval-for-expanded-use-of-the-cintec-plus-cytology-test-to-aid-clinicians-in-preventing-cervical-cancer,16-09-2020 00:00,,,,,,
3312,lilly-announces-proof-of-concept-data-for-neutralizing-antibody-ly-cov555-in-the-covid-19-outpatient-setting,16-09-2020 00:00,,,,,,
3313,baxter-announces-exclusive-distribution-agreement-with-biom?rieux-for-novel-acute-kidney-injury-diagnostic-test-in-europe-and-us,17-09-2020 00:00,,,,,,
3314,novartis-tafinlar-mekinist-demonstrates-long-term-relapse-free-survival-benefit-for-high-risk-stage-iii-melanoma-patients-in-study-published-in-nejm,17-09-2020 00:00,,,,,,
3315,samsung-bioepis-announces-phase-3-exploratory-analyses-results-of-aybintio-bevacizumab-at-the-european-society-for-medical-oncology-esmo-virtual-congress-2020,17-09-2020 00:00,,,,,,
3316,sorrento-receives-us-fda-clearance-to-proceed-with-phase-1-clinical-trial-of-sti-1499-covi-guard-neutralizing-antibody-in-covid-19-positive-patients,17-09-2020 00:00,,,,,,
3317,junshi-biosciences-and-wigen-biomedicine-enter-global-development-and-commercialization-collaboration-for-four-small-molecule-cancer-drug-candidates,17-09-2020 00:00,,,,,,
3318,roche-to-present-a-broad-range-of-data-across-multiple-cancer-types-at-the-esmo-virtual-congress-2020,17-09-2020 00:00,,,,,,
3319,ns-pharma?s-viltepso?-viltolarsen-injection-now-fda-approved-in-the-us-for-the-treatment-of-duchenne-muscular-dystrophy-in-patients-amenable-to-exon-53-skipping-therapy,12-08-2020 00:00,,,,,,
3320,us-food-and-drug-administration-approves-lampit?-nifurtimox-for-the-treatment-of-chagas-disease-in-children,07-08-2020 00:00,,,,,,
3321,trevena-announces-fda-approval-of-olinvyk?-oliceridine-injection,10-08-2020 00:00,,,,,,
3322,fda-approves-once-weekly-sogroya?-for-the-treatment-of-adult-growth-hormone-deficiency,28-08-2020 00:00,,,,,,
3323,cassiopea-receives-fda-approval-for-winlevi?-clascoterone-cream-1-first-in-class-topical-acne-treatment-targeting-the-androgen-receptor,27-08-2020 00:00,,,,,,
3324,us-fda-approves-cystadrops?-cysteamine-ophthalmic-solution-037-a-new-practical-treatment-option-for-the-ocular-manifestations-of-cystinosis,25-08-2020 00:00,,,,,,
3325,fda-approves-xaracoll?-bupivacaine-hcl-implant-a-non-opioid-drug-device-treatment-option-for-acute-postsurgical-pain-relief-for-up-to-24-hours-following-open-inguinal-hernia-repair-in-adults,31-08-2020 00:00,,,,,,
3326,fda-approves-gsk?s-blenrep-belantamab-mafodotin-blmf-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma,06-08-2020 00:00,,,,,,
3327,dogma-therapeutics-announces-global-acquisition-of-oral-pcsk9-inhibitor-program-by-astrazeneca,18-09-2020 00:00,,,,,,
3328,lilly-and-amgen-announce-manufacturing-collaboration-for-covid-19-antibody-therapies,18-09-2020 00:00,,,,,,
3329,roche-launches-new-quantitative-antibody-test-to-measure-sars-cov-2-antibodies-to-support-the-evaluation-of-vaccines,18-09-2020 00:00,,,,,,
3330,lynparza-improved-median-time-patients-lived-without-disease-progression-to-over-four-and-half-years-in-brca-mutated-advanced-ovarian-cancer-vs-just-over-one-year-with-placebo,18-09-2020 00:00,,,,,,
3331,roche?s-phase-iii-empacta-study-showed-actemraroactemra-reduced-the-likelihood-of-needing-mechanical-ventilation-in-hospitalised-patients-with-covid-19-associated-pneumonia,18-09-2020 00:00,,,,,,
3332,imfinzi-demonstrated-unprecedented-survival-in-unresectable-stage-iii-non-small-cell-lung-cancer-with-an-estimated-50-of-patients-surviving-four-years,18-09-2020 00:00,,,,,,
3333,tagrisso-reduced-the-risk-of-disease-recurrence-in-the-brain-by-82-in-the-adjuvant-treatment-of-early-stage-egfr-mutated-lung-cancer,21-09-2020 00:00,,,,,,
3334,foundation-medicine-and-takeda-announce-collaboration-to-develop-foundationone-cdx-and-foundationone-liquid-cdx-as-companion-diagnostics-for-takeda?s-late-stage-lung-cancer-portfolio,21-09-2020 00:00,,,,,,
3335,inflazome-announces-acquisition-by-roche,21-09-2020 00:00,,,,,,
3336,lynparza-recommended-for-approval-in-eu-by-chmp-as-1st-line-maintenance-treatment-with-bevacizumab-for-hrd-positive-advanced-ovarian-cancer,21-09-2020 00:00,,,,,,
3337,bausch-health-to-acquire-option-to-purchase-all-ophthalmology-assets-of-allegro-ophthalmics,21-09-2020 00:00,,,,,,
3338,roche-presents-new-data-from-multiple-phase-iii-studies-of-tecentriq-in-triple-negative-breast-cancer-at-esmo-virtual-congress-2020,21-09-2020 00:00,,,,,,
3339,chmp-recommends-approval-of-lilly?s-baricitinib-for-the-treatment-of-adults-with-moderate-to-severe-atopic-dermatitis,21-09-2020 00:00,,,,,,
3340,novartis-kisqali-receives-the-highest-rating-of-any-cdk46-inhibitor-on-the-esmo-magnitude-of-clinical-benefit-scal,22-09-2020 00:00,,,,,,
3341,scenic-biotech-enters-into-genetic-modifier-collaboration-with-genentech,22-09-2020 00:00,,,,,,
3342,alexion-receives-chmp-positive-opinion-for-new-advanced-formulation-of-ultomiris-ravulizumab-with-significantly-reduced-infusion-time,22-09-2020 00:00,,,,,,
3343,illumina-to-acquire-grail-to-launch-new-era-of-cancer-detection,22-09-2020 00:00,,,,,,
3344,health-canada-approves-inrebic-fedratinib-first-new-treatment-in-nearly-a-decade-for-patients-living-with-myelofibrosis,22-09-2020 00:00,,,,,,
3345,ucb-achieves-important-regulatory-milestone-for-bimekizumab,23-09-2020 00:00,,,,,,
3346,novartis-provides-update-on-avxs-101-intrathecal-clinical-development-program,23-09-2020 00:00,,,,,,
3347,us-food-and-drug-administration-fda-accepts-for-priority-review-bristol-myers-squibb-and-bluebird-bio-application-for-anti-bcma-car-t-cell-therapy-idecabtagene-vicleucel-ide-cel-bb2121,23-09-2020 00:00,,,,,,
3348,micreos-initiates-clinical-trial-to-evaluate-world?s-first-endolysin-drug-as-a-therapy-for-atopic-dermatitis,23-09-2020 00:00,,,,,,
3349,chmp-recommends-approval-of-supemtek-quadrivalent-recombinant-influenza-vaccine-for-the-prevention-of-influenza-in-adults-aged-18-years-and-older,23-09-2020 00:00,,,,,,
3350,fda-accepts-supplemental-new-drug-application-for-pfizer?s-xalkori-crizotinib-for-the-treatment-of-pediatric-alk-positive-anaplastic-large-cell-lymphoma,23-09-2020 00:00,,,,,,
3351,johnson-johnson-initiates-pivotal-global-phase-3-clinical-trial-of-janssen?s-covid-19-vaccine-candidate,24-09-2020 00:00,,,,,,
3352,siemens-healthineers-announces-collaboration-agreement-for-assay-development-with-an-initial-focus-on-multiple-sclerosis,24-09-2020 00:00,,,,,,
3353,ac-immune-reports-top-line-results-from-tauriel-phase-2-trial-evaluating-semorinemab-in-early-alzheimer?s-disease,24-09-2020 00:00,,,,,,
3354,pear-therapeutics-announces-availability-of-reset-and-reset-o-to-wellpath-community-care-center-patients-wellpath-to-bring-prescription-digital-therapeutics-for-addiction-to-new-outpatient-treatment-centers,24-09-2020 00:00,,,,,,
3355,verona-pharma-initiates-phase-3-clinical-trials-with-nebulized-ensifentrine-for-the-maintenance-treatment-of-copd,24-09-2020 00:00,,,,,,
3356,ideaya-and-pfizer-expand-clinical-trial-collaboration-and-supply-agreement-to-evaluate-clinical-combination-of-ide196-and-crizotinib-in-solid-tumors-harboring-gnaq-or-gna11-mutations,24-09-2020 00:00,,,,,,
3357,accord-healthcare-launches-zercepac-trastuzumab-biosimilar-in-the-uk,25-09-2020 00:00,,,,,,
3358,novavax-initiates-phase-3-efficacy-trial-of-covid-19-vaccine-in-the-united-kingdom,25-09-2020 00:00,,,,,,
3359,health-canada-grants-market-authorization-to-polivy-polatuzumab-vedotin-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma,25-09-2020 00:00,,,,,,
3360,medtronic-evaluates-insertable-cardiac-monitor-in-identifying-patients-at-high-risk-of-worsening-heart-failure,25-09-2020 00:00,,,,,,
3361,opdivo-nivolumab-significantly-improves-disease-free-survival-vs-placebo-as-adjuvant-therapy-for-patients-with-high-risk-muscle-invasive-urothelial-carcinoma-in-phase-3-checkmate-274-trial,25-09-2020 00:00,,,,,,
3362,philips-expands-peripheral-vascular-disease-portfolio-with-the-quickclear-mechanical-thrombectomy-system-for-blood-clot-removal,25-09-2020 00:00,,,,,,
3363,roche-presents-new-2-year-data-for-evrysdi-risdiplam-in-infants-with-type-1-spinal-muscular-atrophy-sma,28-09-2020 00:00,,,,,,
3364,jyseleca-filgotinib-approved-in-japan-for-rheumatoid-arthritis,28-09-2020 00:00,,,,,,
3365,chugai-obtains-approval-for-additional-indication-of-tecentriq-and-avastin-as-the-first-cancer-immunotherapy-for-unresectable-hepatocellular-carcinoma,28-09-2020 00:00,,,,,,
3366,fda-approves-nucala-as-the-first-and-only-biologic-treatment-for-hypereosinophilic-syndrome-hes,28-09-2020 00:00,,,,,,
3367,tyvytsintilimab-injection-in-combination-with-byvasda?-bevacizumab-injection-orient-32-study-met-its-primary-endpoints-of-progression-free-survival-and-overall-survival-in-the-first-line-treatment-of-patients-with-advanced-hepatocellular-carcinoma-hcc,28-09-2020 00:00,,,,,,
3368,sosei-heptares-announces-that-a-second-novel-drug-candidate-from-its-multi-target-drug-discovery-collaboration-with-pfizer-has-started-clinical-trials,28-09-2020 00:00,,,,,,
3369,sarepta-therapeutics-reports-sustained-functional-improvement-two-years-after-treatment-with-srp-9001-its-investigational-micro-dystrophin-gene-therapy-for-duchenne-muscular-dystrophy,29-09-2020 00:00,,,,,,
3370,abbvie-receives-orphan-drug-and-fast-track-designations-from-the-us-food-and-drug-administration-for-elezanumab-an-investigational-monoclonal-antibody-rgma-inhibitor-for-the-treatment-of-spinal-cord-injury,29-09-2020 00:00,,,,,,
3371,us-fda-approves-pfizer?s-xeljanz-tofacitinib-for-the-treatment-of-active-polyarticular-course-juvenile-idiopathic-arthritis,29-09-2020 00:00,,,,,,
3372,us-food-and-drug-administration-approves-haegarda-c1-esterase-inhibitor-subcutaneous-human-for-prevention-of-hereditary-angioedema-hae-attacks-in-pediatric-patient,29-09-2020 00:00,,,,,,
3373,boston-scientific-launches-acurate-neo2-aortic-valve-system-in-europe,29-09-2020 00:00,,,,,,
3374,inovio-reports-fda-partial-clinical-hold-for-planned-phase-2-3-trial-of-covid-19-vaccine-candidate-ino-4800,29-09-2020 00:00,,,,,,
3375,regeneron?s-regn-cov2-antibody-cocktail-reduced-viral-levels-and-improved-symptoms-in-non-hospitalized-covid-19-patients,30-09-2020 00:00,,,,,,
3376,health-canada-approves-reblozyl-luspatercept-new-class-of-treatment-for-adult-patients-living-with-beta-thalassemia,30-09-2020 00:00,,,,,,
3377,abbott?s-freestyle-libre-3-system-receives-ce-mark-?-features-world?s-smallest-thinnest-sensor-with-best-in-class-performance-at-the-same-low-cost-for-people-with-diabetes,30-09-2020 00:00,,,,,,
3378,galapagos-announces-first-dosing-with-toledo-compound-glpg3970-in-psoriasis-trial,30-09-2020 00:00,,,,,,
3379,jupiter-02-phase-iii-global-study-of-toripalimab-at-the-interim-analysis-met-pre-specified-primary-endpoint-of-progression-free-survival-in-recurrent-or-metastatic-nasopharyngeal-carcinoma,30-09-2020 00:00,,,,,,
3380,medtronic-to-acquire-avenu-medical,30-09-2020 00:00,,,,,,
3381,sanofi-pasteur-launches-tetraxim-the-first-full-dose-dtap-booster-vaccine-in-india-for-preschoolers,01-10-2020 00:00,,,,,,
3382,henlius-granted-exclusive-development-and-commercialisation-rights-of-hlx02-in-the-us-and-canada-to-accord,01-10-2020 00:00,,,,,,
3383,janssen-submits-new-drug-application-nda-to-us-fda-for-uptravi-selexipag-injection-for-intravenous-use-to-treat-pulmonary-arterial-hypertension-pah,01-10-2020 00:00,,,,,,
3384,lotus-announces-exclusive-commercialization-agreement-with-ckd-for-biosimilar-darbepoetin-alfa,18-09-2020 00:00,,,,,,
3385,alnylam-reports-positive-topline-results-from-illuminate-b-phase-3-study-of-lumasiran-for-the-treatment-of-primary-hyperoxaluria-type-1-in-children-under-the-age-of-six,01-10-2020 00:00,,,,,,
3386,moderna-announces-publication-in-the-new-england-journal-of-medicine-of-interim-results-from-older-adult-age-cohorts-in-phase-1-study-of-its-mrna-vaccine-against-covid-19-mrna-1273,01-10-2020 00:00,,,,,,
3387,sobi-and-selecta-biosciences-announce-topline-data-of-sel-212-from-the-phase-2-compare-study-supporting-the-potential-for-important-clinical-improvement-in-patients-with-chronic-refractory-gout,01-10-2020 00:00,,,,,,
3388,alvotech-and-dksh-extend-partnership-in-asia,22-09-2020 00:00,,,,,,
3389,first-patient-dosed-in-phase-1-clinical-trial-of-henlius-pertuzumab-biosimilar-hlx11,20-09-2020 00:00,,,,,,
3390,henlius-released-phase-3-study-data-of-its-bevacizumab-biosimilar-hlx04-at-csco-2020,20-09-2020 00:00,,,,,,
3391,the-updated-multi-centre-phase-3-clinical-study-data-of-trastuzumab-released-in-esmo,17-09-2020 00:00,,,,,,
3392,neuclone-discloses-two-biosimilars-referencing-opdivo-and-keytruda,01-09-2020 00:00,,,,,,
3393,covid-19-vaccine-azd1222-clinical-trial-resumed-in-japan-follows-restart-of-trials-in-the-uk-brazil-south-africa-and-india,05-10-2020 00:00,,,,,,
3394,amgen-announces-five-year-data-that-reinforce-the-safety-and-efficacy-profile-of-aimovig-erenumab-aooe-in-adult-patients-with-episodic-migraine,05-10-2020 00:00,,,,,,
3395,zolgensma-data-including-patients-with-more-severe-sma-at-baseline-further-demonstrate-therapeutic-benefit-including-prolonged-event-free-survival-increased-motor-function-and-milestone-achievement,05-10-2020 00:00,,,,,,
3396,designation-follows-dapa-ckd-phase-iii-trial-results-in-which-farxiga-demonstrated-unprecedented-reduction-in-the-risk-of-kidney-failure-and-cardiovascular-or-renal-death-in-patients-with-chronic-kidney-disease,05-10-2020 00:00,,,,,,
3397,stada-expands-specialty-footprint-through-acquisition-of-innovative-therapy-for-treating-advanced-parkinson?s-disease,05-10-2020 00:00,,,,,,
3398,bristol-myers-squibb-to-acquire-myokardia-for-131-billion-in-cash,05-10-2020 00:00,,,,,,
3399,gsk-astrazeneca-guy?s-and-st-thomas?-nhs-foundation-trust-king?s-college-london-oxford-nanopore-to-tap-nvidia?s-new-?cambridge-1?-ai-supercomputer,06-10-2020 00:00,,,,,,
3400,new-phase-iii-analysis-demonstrates-novartis-beovu-showed-improvement-in-best-corrected-visual-acuity-in-wet-amd-patients-with-early-persistent-fluid,06-10-2020 00:00,,,,,,
3401,springworks-therapeutics-announces-clinical-collaboration-with-pfizer-inc-to-evaluate-nirogacestat-in-combination-with-pf-06863135-in-patients-with-relapsed-or-refractory-multiple-myeloma,06-10-2020 00:00,,,,,,
3402,amgen-announces-positive-topline-phase-2-results-for-investigational-kras-g12c-inhibitor-sotorasib-in-advanced-non-small-cell-lung-cancer,06-10-2020 00:00,,,,,,
3403,zejula-is-approved-in-canada-for-first-line-maintenance-treatment-of-women-with-advanced-ovarian-cancer,06-10-2020 00:00,,,,,,
3404,santhera-to-discontinue-phase-3-sideros-study-and-development-of-puldysa-in-duchenne-muscular-dystrophy-dmd-and-focus-on-vamorolone,06-10-2020 00:00,,,,,,
3405,qiagen-to-complement-covid-19-testing-portfolio-with-novel-kit-that-simplifies-and-accelerates-pcr-analysis-for-research-applications,06-10-2020 00:00,,,,,,
3406,phasebio-doses-first-patients-in-canada-as-part-of-the-reverse-it-global-phase-3-trial-of-bentracimab-for-reversal-of-the-antiplatelet-effects-of-ticagrelor,07-10-2020 00:00,,,,,,
3407,merck-announces-out-licensing-agreement-for-phase-ii-ready-anti-adamts5-nanobody-for-osteoarthritis,07-10-2020 00:00,,,,,,
3408,biontech-and-pfizer-initiate-rolling-submission-to-european-medicines-agency-for-sars-cov-2-vaccine-candidate-bnt162b2,07-10-2020 00:00,,,,,,
3409,samsung-bioepis-and-biogen-announce-ema-filing-acceptance-of-sb11-a-proposed-biosimilar-referencing-lucentis?-ranibizumab,07-10-2020 00:00,,,,,,
3410,gsk-and-vir-biotechnology-enter-collaboration-to-find-coronavirus-solutions,07-10-2020 00:00,,,,,,
3411,exact-sciences-and-pfizer-extend-and-amend-cologuard?-promotion-agreement,07-10-2020 00:00,,,,,,
3412,lilly-provides-comprehensive-update-on-progress-of-sars-cov-2-neutralizing-antibody-programs,08-10-2020 00:00,,,,,,
3413,polarean-imaging-plc-?polarean?-or-the-?company?-nda-submission,08-10-2020 00:00,,,,,,
3414,opdivo-nivolumab-plus-chemotherapy-shows-statistically-significant-improvement-in-pathologic-complete-response-as-neoadjuvant-treatment-of-resectable-non-small-cell-lung-cancer-in-phase-3-checkmate-816-trial,08-10-2020 00:00,,,,,,
3415,lilly-and-dexcom-team-up-on-new-program-to-help-improve-diabetes-management,08-10-2020 00:00,,,,,,
3416,health-canada-approves-zeposia?-an-oral-treatment-for-relapsing-remitting-multiple-sclerosis,08-10-2020 00:00,,,,,,
3417,biomarin-pioneer-in-rare-disease-treatments-for-phenylketonuria-pku-receives-fda-approval-of-label-expansion-to-allow-maximum-dose-of-60-mg-for-palynziq?-pegvaliase-pqpz-injection-for-treatment-of-adults-with-pku,08-10-2020 00:00,,,,,,
3418,baricitinib-has-significant-effect-on-recovery-time-most-impactful-in-covid-19-patients-requiring-oxygen,09-10-2020 00:00,,,,,,
3419,neurocrine-biosciences-to-present-new-data-analyses-of-once-daily-ongentys?-opicapone-in-patients-with-parkinson?s-disease-at-the-american-neurological-association-2020-virtual-meeting,28-09-2020 00:00,,,,,,
3420,imbio-partners-with-genentech-to-develop-imaging-diagnostics-for-lung-diseases,09-10-2020 00:00,,,,,,
3421,johnson-johnson-announces-european-commission-approval-of-agreement-to-supply-200-million-doses-of-janssen?s-covid-19-vaccine-candidate,09-10-2020 00:00,,,,,,
3422,amgen-cytokinetics-and-servier-announce-topline-results-from-galactic-hf-a-phase-3-trial-of-omecamtiv-mecarbil-in-patients-with-heart-failure,09-10-2020 00:00,,,,,,
3423,regeneron-asks-fda-to-approve-emergency-use-of-regn-cov2-for-covid-19,09-10-2020 00:00,,,,,,
3424,takeda-and-arrowhead-collaborate-to-co-develop-and-co-commercialize-aro-aat-for-alpha-1-antitrypsin-associated-liver-disease,09-10-2020 00:00,,,,,,
3425,penelope-b-trial-of-ibrance?-palbociclib-in-early-breast-cancer-did-not-meet-primary-endpoint,12-10-2020 00:00,,,,,,
3426,covid-19-long-acting-antibody-laab-combination-azd7442-rapidly-advances-into-phase-iii-clinical-trials,12-10-2020 00:00,,,,,,
3427,true-digital-surgery-and-aesculap-inc-launch-the-aesculap-aeos?-robotic-digital-microscope,16-09-2020 00:00,,,,,,
3428,innovent-and-lilly-jointly-announce-the-nmpa-granted-marketing-approval-for-halpryza?-rituximab-injection-in-china,12-10-2020 00:00,,,,,,
3429,novartis-received-european-medicines-agency-ema-prime-designation-for-iptacopan-lnp-in-c3-glomerulopathy-c3g,12-10-2020 00:00,,,,,,
3430,tremfya?-guselkumab-induces-clinical-and-endoscopic-improvements-in-patients-with-moderately-to-severely-active-crohn?s-disease-based-on-interim-results-from-phase-2-study,12-10-2020 00:00,,,,,,
3431,stelara?-ustekinumab-five-year-results-presented-from-long-term-extension-study-of-clinical-response-and-remission-in-patients-with-moderate-to-severe-crohn?s-disease,12-10-2020 00:00,,,,,,
3432,safety-and-efficacy-of-subcutaneous-entyvio?-vedolizumab-sustained-during-long-term-maintenance-therapy-in-adults-with-moderately-to-severely-active-ulcerative-colitis,13-10-2020 00:00,,,,,,
3433,mirikizumab-shows-continued-symptom-improvement-and-reduction-of-intestinal-inflammation-in-patients-with-crohn?s-disease-in-52-week-phase-2-trial,13-10-2020 00:00,,,,,,
3434,abbott-receives-fda-emergency-use-authorization-for-its-covid-19-igm-antibody-blood-test,13-10-2020 00:00,,,,,,
3435,phase-2b3-trial-shows-efficacy-of-filgotinib-for-the-induction-and-maintenance-of-remission-in-moderately-and-severely-active-ulcerative-colitis,13-10-2020 00:00,,,,,,
3436,phase-2b3-trial-shows-efficacy-of-filgotinib-for-the-induction-and-maintenance-of-remission-in-moderately-and-severely-active-ulcerative-colitis,13-10-2020 00:00,,,,,,
3437,roche-to-launch-laboratory-sars-cov-2-antigen-test-to-support-high-volume-testing-of-suspected-covid-19-patients,13-10-2020 00:00,,,,,,
3438,johnson-johnson-temporarily-pauses-all-dosing-in-our-janssen-covid-19-vaccine-candidate-clinical-trials,14-10-2020 00:00,,,,,,
3439,linnaeus-therapeutics-announces-first-patient-dosed-in-its-clinical-trial-of-lns8801-in-combination-with-keytruda?-pembrolizumab-in-patients-with-advanced-cancer,14-10-2020 00:00,,,,,,
3440,celltrion-initiates-post-exposure-prophylaxis-clinical-trial-of-an-anti-covid-19-monoclonal-antibody-treatment-candidate-ct-p59,14-10-2020 00:00,,,,,,
3441,moderna-announces-initiation-of-rolling-submission-to-health-canada-for-mrna-vaccine-against-covid-19-mrna-1273,14-10-2020 00:00,,,,,,
3442,prestige-biopharma-receives-positive-ema-opinion-on-orphan-designation-for-pbp1510-for-treatment-of-pancreatic-cancer,14-10-2020 00:00,,,,,,
3443,iaslc-naclc-2020-boehringer-ingelheim-presents-new-data-for-gilotrif?-in-metastatic-squamous-cell-carcinoma-of-the-lung-and-in-egfr-mutation-positive-nsclc,14-10-2020 00:00,,,,,,
3444,dyno-therapeutics-enters-collaboration-and-license-agreement-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-cns-diseases-and-liver-directed-therapies,15-10-2020 00:00,,,,,,
3445,regeneron?s-antibody-cocktail-regn-eb3-inmazeb?-is-first-fda-approved-treatment-for-ebola-zaire-ebolavirus,15-10-2020 00:00,,,,,,
3446,takeda-accelerates-digital-transformation-with-accenture-and-aws,15-10-2020 00:00,,,,,,
3447,aliqopa?-copanlisib-in-combination-with-rituximab-meets-primary-endpoint-in-patients-with-relapsed-indolent-non-hodgkin?s-lymphoma,15-10-2020 00:00,,,,,,
3448,radiomedix-and-curium-announce-fda-approval-of-detectnet-copper-cu-64-dotatate-injection-in-the-us,03-09-2020 00:00,,,,,,
3449,us-fda-approves-athena-bioscience?s-new-drug-application-nda-for-qdolo?-tramadol-hydrochloride-oral-solution,01-09-2020 00:00,,,,,,
3450,brazilian-health-regulatory-agency-anvisa-authorizes-sorrento-therapeutics?-large-phase-2-clinical-trial-of-abivertinib-in-mild-moderate-and-severe-covid-19-patients,15-10-2020 00:00,,,,,,
3451,eton-pharmaceuticals-announces-fda-approval-of-orphan-drug-alkindi?-sprinkle-hydrocortisone-as-replacement-therapy-in-pediatric-patients-with-adrenocortical-insufficiency,29-09-2020 00:00,,,,,,
3452,lilly-statement-on-the-niaid-decision-to-pause-enrollment-in-activ-3-clinical-trial,15-10-2020 00:00,,,,,,
3453,lilly-announces-agreement-to-acquire-disarm-therapeutics,16-10-2020 00:00,,,,,,
3454,fda-approves-expanded-indication-for-merck?s-keytruda?-pembrolizumab-in-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-chl,16-10-2020 00:00,,,,,,
3455,chugai-files-a-new-drug-application-for-risdiplam-as-the-first-oral-drug-for-spinal-muscular-atrophy-in-japan,16-10-2020 00:00,,,,,,
3456,sanofi-and-translate-bio-mrna-covid-19-vaccine-candidate-induced-high-antibody-levels-in-preclinical-studies,16-10-2020 00:00,,,,,,
3457,galapagos-and-servier-report-topline-results-for-roccella-phase-2-clinical-trial-with-glpg1972s201086-in-knee-osteoarthritis-patients,16-10-2020 00:00,,,,,,
3458,health-canada-approves-first-ever-gene-replacement-therapy-luxturna?,16-10-2020 00:00,,,,,,
3459,novartis-receives-positive-chmp-opinion-for-leqvio?-inclisiran-a-potential-first-in-class-sirna-for-the-treatment-of-high-cholesterol,19-10-2020 00:00,,,,,,
3460,venclexta?-venetoclax-receives-fda-full-approval-for-acute-myeloid-leukemia-aml,19-10-2020 00:00,,,,,,
3461,henlius-and-essex-enter-into-a-global-co-development-and-exclusive-license-agreement-to-jointly-develop-bevacizumab-to-treat-ophthalmic-diseases,19-10-2020 00:00,,,,,,
3462,trixeo-aerosphere-recommended-for-approval-in-the-eu-by-chmp-for-the-maintenance-treatment-of-copd,19-10-2020 00:00,,,,,,
3463,janssen-receives-chmp-positive-opinion-for-expanded-use-of-tremfya?-guselkumab-in-the-treatment-of-active-psoriatic-arthritis-psa-in-the-european-union-eu,19-10-2020 00:00,,,,,,
3464,nice-recommends-sarclisa?-isatuximab-for-patients-with-multiple-myeloma-an-incurable-progressive-blood-cancer1,19-10-2020 00:00,,,,,,
3465,genesis-therapeutics-enters-ai-driven-multi-target-drug-discovery-partnership-with-genentech,20-10-2020 00:00,,,,,,
3466,immunogen-and-huadong-medicine-announce-strategic-collaboration-to-develop-and-commercialize-mirvetuximab-soravtansine-in-greater-china,20-10-2020 00:00,,,,,,
3467,abbvie-submits-regulatory-applications-to-fda-and-ema-for-rinvoq?-upadacitinib-in-atopic-dermatitis,20-10-2020 00:00,,,,,,
3468,endo-to-acquire-biospecifics-to-enhance-profitability-of-xiaflex?-and-qwo,20-10-2020 00:00,,,,,,
3469,tagrisso-granted-priority-review-in-the-us-for-the-adjuvant-treatment-of-patients-with-early-stage-egfr-mutated-lung-cancer,20-10-2020 00:00,,,,,,
3470,tagrisso-granted-priority-review-in-the-us-for-the-adjuvant-treatment-of-patients-with-early-stage-egfr-mutated-lung-cancer,20-10-2020 00:00,,,,,,
3471,samsung-biologics-inks-development-partnership-with-dinona-for-potential-covid-19-treatment,21-10-2020 00:00,,,,,,
3472,health-canada-has-approved-taltz?-ixekizumab-for-the-treatment-of-non-radiographic-axial-spondyloarthritis-nr-axspa,21-10-2020 00:00,,,,,,
3473,roche-and-prothena-will-advance-prasinezumab-into-late-stage-clinical-development-study-in-parkinson?s-disease,21-10-2020 00:00,,,,,,
3474,neuclone-announces-positive-results-from-phase-i-study-of-stelara?-ustekinumab-biosimilar-candidate,21-10-2020 00:00,,,,,,
3475,stagebio-expands-its-global-presence-with-acquisition-of-tpl-path-labs,21-10-2020 00:00,,,,,,
3476,jazz-pharmaceuticals-announces-sleep-publication-of-phase-3-xywav?-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-study-in-cataplexy-or-excessive-daytime-sleepiness-in-patients-with-narcolepsy,21-10-2020 00:00,,,,,,
3477,teva-amazon-web-services-and-onica-announce-collaboration-to-support-teva?s-digihaler?-portfolio,22-10-2020 00:00,,,,,,
3478,chugai-enters-into-a-license-agreement-for-chugai?s-antibody-engineering-technologies-with-novo-nordisk,22-10-2020 00:00,,,,,,
3479,novartis-receives-us-food-and-drug-administration-fda-orphan-drug-designation-for-branaplam-lmi070-in-huntington?s-disease-hd,22-10-2020 00:00,,,,,,
3480,viiv-healthcare-announces-analysis-showing-no-antiretroviral-therapy-interruptions-due-to-covid-19-across-its-clinical-development-programme-for-investigational-long-acting-cabotegravir-and-rilpivirine,22-10-2020 00:00,,,,,,
3481,roche-announces-collaboration-with-atea-pharmaceuticals-to-develop-a-potential-oral-treatment-for-covid-19-patients,22-10-2020 00:00,,,,,,
3482,gsk-presents-positive-clinical-data-on-maternal-and-older-adults-rsv-candidate-vaccines,22-10-2020 00:00,,,,,,
3483,dicerna-presents-positive-new-interim-data-from-phyox?3-long-term-open-label-extension-study-of-nedosiran-for-treatment-of-primary-hyperoxaluria-ph,23-10-2020 00:00,,,,,,
3484,us-food-and-drug-administration-approves-gilead?s-antiviral-veklury?-remdesivir-for-treatment-of-covid-19,23-10-2020 00:00,,,,,,
3485,ucb?s-anti-epileptic-drug-vimpat?-lacosamide-receives-eu-chmp-positive-opinion-for-primary-generalised-tonic-clonic-seizures,23-10-2020 00:00,,,,,,
3486,daiichi-sankyo-initiates-phase-1-trial-with-immuno-oncology-therapy-ds-1055-targeting-garp-on-activated-regulatory-t-cells,23-10-2020 00:00,,,,,,
3487,sanifit-presents-new-data-for-snf472-in-treatment-of-vascular-calcification-at-asn-kidney-week-2020,23-10-2020 00:00,,,,,,
3488,akebia-presents-results-from-its-inno2vate-global-phase-3-program-demonstrated-efficacy-and-cardiovascular-safety-of-vadadustat-for-the-treatment-of-anemia-due-to-chronic-kidney-disease-in-adult-patients-on-dialysis,23-10-2020 00:00,,,,,,
3489,fda-authorises-restart-of-the-covid-19-azd1222-vaccine-us-phase-iii-trial,26-10-2020 00:00,,,,,,
3490,eisai-and-cogstate-expand-agreement-for-global-development-and-commercialization-of-digital-cognitive-assessment-technologies,26-10-2020 00:00,,,,,,
3491,jardiance-shows-consistent-cardio-renal-benefits-in-adults-with-heart-failure-with-left-ventricular-ejection-fraction-over-40-regardless-of-chronic-kidney-disease-status,26-10-2020 00:00,,,,,,
3492,farxiga-dapa-ckd-phase-iii-trial-reduced-worsening-of-kidney-function-risk-of-cardiovascular-or-renal-death-in-patients-with-chronic-kidney-disease-irrespective-of-underlying-cause,26-10-2020 00:00,,,,,,
3493,foundationone?cdx-receives-fda-approval-as-a-companion-diagnostic-for-vitrakvi?larotrectinib-to-identify-patients-with-ntrk-fusions-across-all-solid-tumors,26-10-2020 00:00,,,,,,
3494,bayer-acquires-asklepios-biopharmaceutical-to-broaden-innovation-base-in-cell-and-gene-therapy,26-10-2020 00:00,,,,,,
3495,jazz-pharmaceuticals-acquires-springworks-therapeutics?-faah-inhibitor-program,27-10-2020 00:00,,,,,,
3496,samsung-bioepis-announces-first-real-world-data-on-renflexis?-infliximab-abda-with-ibd-patients-from-veterans-affairs-healthcare-system-at-the-american-college-of-gastroenterology-acg-2020,27-10-2020 00:00,,,,,,
3497,dupixent?-dupilumab-late-breaking-pivotal-data-showing-significant-improvement-in-eosinophilic-esophagitis-signs-and-symptoms-presented-for-the-first-time-at-scientific-meetings,27-10-2020 00:00,,,,,,
3498,novartis-presents-promising-interim-phase-ii-data-of-potential-first-in-class-oral-therapy-iptacopan-lnp023-in-rare-renal-disease-c3-glomerulopathy-c3g,27-10-2020 00:00,,,,,,
3499,cstone-and-eqrx-enter-global-strategic-partnership-for-two-immune-checkpoint-inhibitors-sugemalimab-anti-pd-l1-and-cs1003-anti-pd-1,27-10-2020 00:00,,,,,,
3500,exact-sciences-to-acquire-thrive-earlier-detection-becoming-a-leader-in-blood-based-multi-cancer-screening,28-10-2020 00:00,,,,,,
3501,olipudase-alfa-demonstrated-significant-improvement-in-lung-function-and-spleen-volume-in-patients-with-asmd,28-10-2020 00:00,,,,,,
3502,novartis-announces-collaboration-with-molecular-partners-to-develop-two-darpin?-therapies-designed-for-potential-use-against-covid-19,28-10-2020 00:00,,,,,,
3503,thermo-fisher-scientific-expands-direct-to-patient-clinical-trials-service-offerings,28-10-2020 00:00,,,,,,
3504,forxiga-cardiovascular-outcomes-benefit-approved-in-china,28-10-2020 00:00,,,,,,
3505,dermavant?s-pivotal-phase-3-psoaring-data-for-tapinarof-cream-in-adults-with-plaque-psoriasis-selected-as-late-breaking-oral-presentation-at-the-29th-european-academy-of-dermatology-and-venereology-eadv-virtual-congress,28-10-2020 00:00,,,,,,
3506,insitro-announces-five-year-discovery-collaboration-with-bristol-myers-squibb-to-discover-and-develop-novel-treatments-for-amyotrophic-lateral-sclerosis-and-frontotemporal-dementia,29-10-2020 00:00,,,,,,
3507,data-for-lilly?s-bamlanivimab-ly-cov555-in-covid-19-outpatients-published-in-new-england-journal-of-medicine,29-10-2020 00:00,,,,,,
3508,novartis-acquires-vedere-bio-a-novel-optogenetics-aav-gene-therapy-company,29-10-2020 00:00,,,,,,
3509,cstone-and-legochem-biosciences-enter-global-licensing-agreement-for-new-antibody-drug-conjugate,29-10-2020 00:00,,,,,,
3510,boehringer-ingelheim-begins-phase-2-clinical-trial-of-a-targeted-therapy-to-help-people-with-severe-respiratory-illness-from-covid-19,29-10-2020 00:00,,,,,,
3511,roche?s-tecentriq-in-combination-with-avastin-approved-in-china-for-people-with-the-most-common-form-of-liver-cancer,30-10-2020 00:00,,,,,,
3512,fasenra-eliminated-oral-corticosteroid-use-in-a-majority-of-ocs-dependent-patients-with-asthma-in-ponente-phase-iiib-trial,30-10-2020 00:00,,,,,,
3513,sanofi-to-evaluate-the-safety-and-efficacy-of-novel-investigational-candidate-thor-707-and-keytruda?-pembrolizumab-in-pursuit-of-establishing-a-new-treatment-option-in-oncology,30-10-2020 00:00,,,,,,
3514,new-data-show-skyrizi-?-risankizumab-maintains-completely-clear-skin-for-over-three-years-in-nearly-two-thirds-of-patients-with-moderate-to-severe-plaque-psoriasis,30-10-2020 00:00,,,,,,
3515,european-commission-approves-zejula-niraparib-as-first-line-monotherapy-maintenance-treatment-in-advanced-ovarian-cancer,30-10-2020 00:00,,,,,,
3516,atacand-to-be-divested-to-cheplapharm-in-more-than-70-countries,30-10-2020 00:00,,,,,,
3517,bimekizumab-phase-3-data-shows-superior-skin-clearance-over-humira?-in-moderate-to-severe-psoriasis-patients,02-11-2020 00:00,,,,,,
3518,regeneron-provides-update-on-the-garetosmab-phase-2-lumina-1-trial-in-fibrodysplasia-ossificans-progressiva-fop,02-11-2020 00:00,,,,,,
3519,medtronic-expands-ent-portfolio-with-fda-clearance-of-nim-vital?-next-generation-intraoperative-nerve-monitoring-system-and-acquisiton-of-ai-biomed-corp,02-11-2020 00:00,,,,,,
3520,sun-pharma-announces-5-year-sustained-efficacy-and-safety-results-for-ilumya?-tildrakizumab-asmn-in-patients-with-moderate-to-severe-plaque-psoriasis,02-11-2020 00:00,,,,,,
3521,novartis-announces-positive-results-from-a-phase-iv-study-showing-superior-tolerability-and-efficacy-of-aimovig?-erenumab-compared-with-topiramate-in-migraine-prevention,02-11-2020 00:00,,,,,,
3522,sanofi-offers-to-acquire-kiadis-a-clinical-stage-company-developing-cell-based-immunotherapy-products,02-11-2020 00:00,,,,,,
3523,janssen-submits-paliperidone-palmitate-6-month-pp6m-supplemental-new-drug-application-to-us-fda-for-treatment-of-schizophrenia-in-adults,03-11-2020 00:00,,,,,,
3524,tetra-therapeutics-announces-positive-topline-results-from-phase-2-study-of-bpn14770-in-patients-with-fragile-x-syndrome,03-11-2020 00:00,,,,,,
3525,fusion-pharmaceuticals-announces-collaboration-with-astrazeneca-to-develop-and-commercialize-next-generation-radiopharmaceuticals-and-combination-therapies,03-11-2020 00:00,,,,,,
3526,celltrion-healthcare-presents-positive-top-line-efficacy-and-safety-results-for-ct-p17-in-the-treatment-of-rheumatoid-arthritis,03-11-2020 00:00,,,,,,
3527,european-commission-approves-roche?s-tecentriq-in-combination-with-avastin-for-the-treatment-of-people-with-the-most-common-form-of-liver-cancer,03-11-2020 00:00,,,,,,
3528,novartis?-monaleesa-7-kisqali-ribociclib-study-demonstrated-statistically-significant-improvement-in-overall-survival-in-pre-and-perimenopausal-women-with-hrher2-advanced-breast-cancer,03-11-2020 00:00,,,,,,
3529,bristol-myers-squibb-announces-deucravacitinib-bms-986165-demonstrated-superiority-to-placebo-and-otezla?-apremilast-in-pivotal-phase-3-psoriasis-study,04-11-2020 00:00,,,,,,
3530,somalogic-announces-new-collaboration-with-fda-to-advance-biosimilar-development,29-10-2020 00:00,,,,,,
3531,cepi-extends-partnership-with-clover-biopharmaceuticals-to-fund-covid-19-vaccine-candidate-through-global-phase-23-study-to-licensure,04-11-2020 00:00,,,,,,
3532,boston-scientific-receives-fda-approval-for-the-ranger?-drug-coated-balloon,04-11-2020 00:00,,,,,,
3533,food-and-drug-administration-accepts-biomarin?s-new-drug-application-for-vosoritide-to-treat-children-with-achondroplasia,04-11-2020 00:00,,,,,,
3534,jounce-therapeutics-announces-update-on-vopratelimab-program,04-11-2020 00:00,,,,,,
3535,abbott-introduces-next-generation-3d-cardiac-mapping-platform-in-europe-and-australia,04-11-2020 00:00,,,,,,
3536,medicure-announces-an-agreement-with-reliance-life-sciences-for-the-marketing-rights-of-a-cardiovascular-biosimilar,05-10-2020 00:00,,,,,,
3537,the-results-of-the-phase-3-study-of-henlius?-adalimumab-biosimilar-hlx03-presented-on-eadv-2020,29-10-2020 00:00,,,,,,
3538,bioinvent-presents-promising-new-clinical-and-preclinical-data-on-anti-fc-rllb-antibody-bi-1206-at-the-ash-annual-meeting,05-11-2020 00:00,,,,,,
3539,innovent-and-lilly-jointly-announce-results-of-seven-clinical-studies-of-tyvyt?-sintilimab-injection-to-be-presented-at-the-esmo-asia-congress-2020,05-11-2020 00:00,,,,,,
3540,novartis-cosentyx-shows-early-synovitis-reduction-in-patients-with-psoriatic-arthritis-in-first-of-its-kind-study,05-11-2020 00:00,,,,,,
3541,novavax-and-commonwealth-of-australia-announce-agreement-in-principle-for-acquisition-of-novavax-covid-19-vaccine,05-11-2020 00:00,,,,,,
3542,coloplast-acquires-nine-continents-medical-inc,05-11-2020 00:00,,,,,,
3543,merck-to-acquire-velosbio,05-11-2020 00:00,,,,,,
3544,forxiga-approved-in-the-eu-for-heart-failure,06-11-2020 00:00,,,,,,
3545,iktos-announces-additional-collaboration-with-merck-kgaa-darmstadt-germany-in-ai-for-new-drug-design,06-11-2020 00:00,,,,,,
3546,lynparza-approved-in-the-eu-as-1st-line-maintenance-treatment-with-bevacizumab-for-hrd-positive-advanced-ovarian-cancer,06-11-2020 00:00,,,,,,
3547,formycon-informs-about-the-modified-bla-submission-strategy-for-its-lucentisr-biosimilar-candidate-fyb201,06-11-2020 00:00,,,,,,
3548,novo-nordisk-to-acquire-emisphere-technologies-and-obtain-ownership-of-the-eligen-snac-oral-delivery-technology,06-11-2020 00:00,,,,,,
3549,brilinta-approved-in-the-us-to-reduce-the-risk-of-stroke-in-patients-with-an-acute-ischaemic-stroke-or-high-risk-transient-ischaemic-attack,06-11-2020 00:00,,,,,,
3550,merck-and-transcenta-collaborate-to-advance-continuous-biomanufacturing-make-the-?facility-of-the-future?-a-reality,09-11-2020 00:00,,,,,,
3551,update-on-fda-advisory-committee?s-meeting-on-aducanumab-in-alzheimer?s-disease,09-11-2020 00:00,,,,,,
3552,eisai-announces-new-investigational-data-evaluating-tki-mtor-inhibitor-regimen-lenvima?-lenvatinib-plus-everolimus-in-advanced-renal-cell-carcinoma-rcc-at-ikcs-2020,09-11-2020 00:00,,,,,,
3553,alvotech-and-cipla-partner-to-ensure-access-to-biosimilars-in-south-africa,09-11-2020 00:00,,,,,,
3554,celltrion-presents-efficacy-and-safety-data-for-potential-covid-19-treatment-candidate-ct-p59-in-patients-with-mild-symptoms,09-11-2020 00:00,,,,,,
3555,novartis-provides-update-on-can-covid-trial-in-hospitalized-patients-with-covid-19-pneumonia-and-cytokine-release-syndrome-crs,09-11-2020 00:00,,,,,,
3556,calquence-approved-in-the-eu-for-the-treatment-of-chronic-lymphocytic-leukaemia,10-11-2020 00:00,,,,,,
3557,pfizer-and-biontech-announce-vaccine-candidate-against-covid-19-achieved-success-in-first-interim-analysis-from-phase-3-study,10-11-2020 00:00,,,,,,
3558,lilly?s-neutralizing-antibody-bamlanivimab-ly-cov555-receives-fda-emergency-use-authorization-for-the-treatment-of-recently-diagnosed-covid-19,10-11-2020 00:00,,,,,,
3559,bayer-submits-marketing-authorization-applications-for-finerenone-in-the-us-and-the-eu-for-patients-with-chronic-kidney-disease-and-type-2-diabetes,10-11-2020 00:00,,,,,,
3560,tezepelumab-navigator-phase-iii-trial-met-primary-endpoint-of-a-statistically-significant-and-clinically-meaningful-reduction-in-exacerbations-in-a-broad-population-of-patients-with-severe-asthma,10-11-2020 00:00,,,,,,
3561,novavax-covid-19-vaccine-granted-fast-track-designation-by-us-fda,10-11-2020 00:00,,,,,,
3562,first-patient-dosed-in-phase-1-clinical-trial-of-henlius-denosumab-biosimilar-hlx14,11-11-2020 00:00,,,,,,
3563,fda-permits-marketing-of-new-device-designed-to-reduce-sleep-disturbance-related-to-nightmares-in-certain-adults,11-11-2020 00:00,,,,,,
3564,abbott-announces-the-us-launch-of-the-ionicrf?-generator-for-use-in-patients-living-with-chronic-pain,11-11-2020 00:00,,,,,,
3565,samsung-bioepis-initiates-phase-1-clinical-trial-for-sb16-proposed-biosimilar-to-prolia?-denosumab,11-11-2020 00:00,,,,,,
3566,prestige-biopharma-and-teva-israel-announce-license-and-supply-agreement-to-commercialize-prestige?s-trastuzumab-biosimilar-tuznue?-in-israel,11-11-2020 00:00,,,,,,
3567,curevac-publishes-detailed-interim-phase-1-data-of-its-covid-19-vaccine-candidate-cvncov,11-11-2020 00:00,,,,,,
3568,johnson-johnson-resumes-all-clinical-trials-of-its-janssen-covid-19-vaccine-candidate-in-europe,12-11-2020 00:00,,,,,,
3569,moderna-announces-clinical-updates-on-personalized-cancer-vaccine-program,12-11-2020 00:00,,,,,,
3570,pfizer-announces-positive-results-from-fifth-phase-3-trial-of-abrocitinib-evaluating-safety-and-efficacy-across-different-dosing-regimens,12-11-2020 00:00,,,,,,
3571,pfizer-and-biontech-reach-an-agreement-to-supply-the-eu-with-200-million-doses-of-their-bnt162b2-mrna-based-vaccine-candidate-against-sars-cov-2,12-11-2020 00:00,,,,,,
3572,tscan-therapeutics-announces-partnership-with-qiagen-to-develop-t-cell-based-laboratory-test-for-comprehensive-covid-19-immune-response,12-11-2020 00:00,,,,,,
3573,update-on-calavi-phase-ii-trials-for-calquence-in-patients-hospitalised-with-respiratory-symptoms-of-covid-19,12-11-2020 00:00,,,,,,
3574,medtronic-launches-inpen?-with-real-time-guardian?-connect-cgm-data-?-the-first-integrated-smart-insulin-pen-for-people-with-diabetes-on-mdi,13-11-2020 00:00,,,,,,
3575,ucb-strengthens-its-gene-therapy-activities-with-additional-pipeline-programs-capabilities-and-platforms,13-11-2020 00:00,,,,,,
3576,integrating-fitbit-wearable-devices-into-diabetes-care-leads-to-significant-improvements-in-blood-glucose-and-hba1c-finds-health2sync-clinical-study-in-taiwan,13-11-2020 00:00,,,,,,
3577,medicago-and-gsk-announce-start-of-phase-23-clinical-trials-of-adjuvanted-covid-19-vaccine-candidate,13-11-2020 00:00,,,,,,
3578,qiagen-launches-portable-digital-sars-cov-2-antigen-test-that-can-accurately-analyze-over-30-samples-per-hour,13-11-2020 00:00,,,,,,
3579,bd-acquires-the-medical-business-assets-of-cubex-llc-broadening-automated-dispensing-portfolio-across-care-continuum,13-11-2020 00:00,,,,,,
3580,twist-bioscience-illumina-and-western-digital-form-alliance-with-microsoft-to-advance-data-storage-in-dna,16-11-2020 00:00,,,,,,
3581,johnson-johnson-and-us-department-of-health-human-services-expand-agreement-to-support-next-phase-of-covid-19-vaccine-candidate-research-and-development,16-11-2020 00:00,,,,,,
3582,eisai-receives-approval-for-indication-expansion-of-anti-epileptic-agent-fycompa?-for-use-in-pediatric-patients,16-11-2020 00:00,,,,,,
3583,chmp-recommends-eu-approval-of-roche?s-xofluza?-baloxavir-marboxil-for-the-treatment-of-influenza,16-11-2020 00:00,,,,,,
3584,beyondspring-subsidiary-seed-therapeutics-announces-research-collaboration-and-license-agreement-with-lilly,16-11-2020 00:00,,,,,,
3585,the-ind-application-of-henlius-daratumumab-biosimilar-accepted-by-nmpa,16-11-2020 00:00,,,,,,
3586,bharat-biotech-starts-phase-iii-trials-for-covaxin,17-11-2020 00:00,,,,,,
3587,moderna?s-covid-19-vaccine-candidate-meets-its-primary-efficacy-endpoint-in-the-first-interim-analysis-of-the-phase-3-cove-study,17-11-2020 00:00,,,,,,
3588,zymeworks-and-alx-oncology-announce-clinical-collaboration-evaluating-zanidatamab-with-the-cd47-blocker-alx148-in-patients-with-advanced-her2-expressing-breast-cancer,17-11-2020 00:00,,,,,,
3589,lead-pharma-enters-into-a-research-collaboration-and-license-agreement-with-roche-to-develop-oral-small-molecules-for-immune-mediated-diseases,17-11-2020 00:00,,,,,,
3590,johnson-johnson-initiates-second-global-phase-3-clinical-trial-of-its-janssen-covid-19-vaccine-candidate,17-11-2020 00:00,,,,,,
3591,fda-approves-registration-of-stelfonta?,17-11-2020 00:00,,,,,,
3592,finerenone-showed-consistent-benefits-on-cardiovascular-outcomes-in-patients-with-chronic-kidney-disease-and-type-2-diabetes-with-or-without-history-of-cardiovascular-disease,18-11-2020 00:00,,,,,,
3593,viiv-healthcare-receives-fda-breakthrough-therapy-designation-for-investigational-long-acting-cabotegravir-for-hiv-prevention,18-11-2020 00:00,,,,,,
3594,fda-grants-priority-review-for-avalglucosidase-alfa-a-potential-new-therapy-for-pompe-disease,18-11-2020 00:00,,,,,,
3595,pfizer-update-on-our-us-covid-19-vaccine-candidate-distribution-preparedness,18-11-2020 00:00,,,,,,
3596,biomarin-and-deep-genomics-to-collaborate-on-advancing-programs-identified-using-artificial-intelligence,18-11-2020 00:00,,,,,,
3597,samsung-bioepis-and-biogen-announce-fda-filing-acceptance-of-sb11-a-proposed-biosimilar-referencing-lucentis?-ranibizumab,18-11-2020 00:00,,,,,,
3598,european-commission-approves-supemtek-quadrivalent-recombinant-influenza-vaccine-for-the-prevention-of-influenza-in-adults-aged-18-years-and-older,19-11-2020 00:00,,,,,,
3599,pfizer-and-biontech-conclude-phase-3-study-of-covid-19-vaccine-candidate-meeting-all-primary-efficacy-endpoints,19-11-2020 00:00,,,,,,
3600,pear-therapeutics-launches-somryst-for-chronic-insomnia-via-an-end-to-end-virtual-care-experience,19-11-2020 00:00,,,,,,
3601,viiv-healthcare-announces-results-of-the-progress-study-demonstrating-that-the-inclusion-of-patient-reported-outcomes-into-clinical-practice-can-improve-hiv-care,19-11-2020 00:00,,,,,,
3602,bayer-initiates-new-g4a-digital-health-partnerships-program,19-11-2020 00:00,,,,,,
3603,coronavirus-covid-19-update-fda-authorizes-first-covid-19-test-for-self-testing-at-home,19-11-2020 00:00,,,,,,
3604,nevakar-announces-fda-approval-for-ephedrine-sulfate-injection-as-ready-to-use-vials,22-10-2020 00:00,,,,,,
3605,kala-pharmaceuticals-receives-fda-approval-of-dry-eye-disease-treatment-eysuvis,27-10-2020 00:00,,,,,,
3606,chiesi-usa-inc-announces-fda-approval-of-bronchitol?-mannitol-inhalation-powder,19-11-2020 00:00,,,,,,
3607,alvotech-announces-that-the-us-fda-and-ema-have-accepted-regulatory-submissions-for-avt02-a-proposed-biosimilar-to-humira?-adalimumab,20-11-2020 00:00,,,,,,
3608,novartis-secures-exclusive-rights-for-potential-acute-respiratory-distress-syndrome-cell-therapy,20-11-2020 00:00,,,,,,
3609,baricitinib-receives-emergency-use-authorization-from-the-fda-for-the-treatment-of-hospitalized-patients-with-covid-19,20-11-2020 00:00,,,,,,
3610,lilly-and-ypsomed-collaborate-to-advance-an-automated-insulin-delivery-system-for-people-with-diabetes,20-11-2020 00:00,,,,,,
3611,pfizer-and-lianbio-announce-strategic-collaboration-to-expand-development-of-novel-therapeutics-in-greater-china,20-11-2020 00:00,,,,,,
3612,imfinzi-approved-in-the-us-for-less-frequent-fixed-dose-use,20-11-2020 00:00,,,,,,
3613,regeneron?s-casirivimab-and-imdevimab-antibody-cocktail-for-covid-19-is-first-combination-therapy-to-receive-fda-emergency-use-authorization,23-11-2020 00:00,,,,,,
3614,lilly?s-neutralizing-antibody-bamlanivimab-ly-cov555-receives-interim-authorization-from-health-canada-as-a-treatment-for-covid-19,23-11-2020 00:00,,,,,,
3615,innovent-releases-phase-3-results-of-tyvyt?-sintilimab-injection-in-combination-with-byvasda?-bevacizumab-biosimilar-injection-as-first-line-treatment-in-patients-with-advanced-hepatocellular-carcinoma-hcc-at-esmo-asia-virtual-congress-2020,23-11-2020 00:00,,,,,,
3616,eiger-biopharmaceuticals-announces-fda-approval-of-zokinvy?-lonafarnib-the-first-treatment-for-hutchinson-gilford-progeria-syndrome-and-processing-deficient-progeroid-laminopathies,23-11-2020 00:00,,,,,,
3617,lilly-and-precision-biosciences-announce-genome-editing-research-collaboration-and-license-agreement,23-11-2020 00:00,,,,,,
3618,azd1222-vaccine-met-primary-efficacy-endpoint-in-preventing-covid-19,23-11-2020 00:00,,,,,,
3619,merck-to-acquire-oncoimmune,24-11-2020 00:00,,,,,,
3620,schr?dinger-announces-a-multi-target-drug-discovery-development-and-commercialization-collaboration-with-bristol-myers-squibb,24-11-2020 00:00,,,,,,
3621,baxter-announces-us-fda-510k-clearance-of-homechoice-claria-with-sharesource,24-11-2020 00:00,,,,,,
3622,roche-announces-fda-approval-of-xofluza-for-the-prevention-of-influenza-following-contact-with-an-infected-person,24-11-2020 00:00,,,,,,
3623,targovax-demonstrates-encouraging-survival-data-for-oncos-102-in-mesothelioma,24-11-2020 00:00,,,,,,
3624,selvita-to-acquire-fidelta-from-galapagos,24-11-2020 00:00,,,,,,
3625,bristol-myers-squibb-receives-european-commission-approval-for-opdivo-nivolumab-as-second-line-treatment-for-unresectable-advanced-recurrent-or-metastatic-esophageal-squamous-cell-carcinoma,25-11-2020 00:00,,,,,,
3626,alnylam-announces-us-food-and-drug-administration-fda-approval-of-oxlumo?-lumasiran-the-first-and-only-treatment-approved-for-primary-hyperoxaluria-type-1-to-lower-urinary-oxalate-levels-in-pediatric-and-adult-patients,25-11-2020 00:00,,,,,,
3627,alvotech-alvotech-ccht-biopharmaceutical-and-yangtze-river-pharmaceutical-agree-on-an-exclusive-biosimilar-partnership-in-china,25-11-2020 00:00,,,,,,
3628,second-interim-analysis-of-clinical-trial-data-showed-a-914-efficacy-for-the-sputnik-v-vaccine-on-day-28-after-the-first-dose-vaccine-efficacy-is-over-95-42-days-after-the-first-dose,25-11-2020 00:00,,,,,,
3629,evotec-and-rappta-therapeutics-enter-discovery-and-development-partnership-focused-on-oncology-target,25-11-2020 00:00,,,,,,
3630,bausch-health-initiates-second-phase-3-study-for-nov03-investigational-treatment-for-dry-eye-disease-associated-with-meibomian-gland-dysfunction,25-11-2020 00:00,,,,,,
3631,european-commission-approves-janssen?s-tremfya?-guselkumab-a-first-in-class-treatment-for-active-psoriatic-arthritis-psa,26-11-2020 00:00,,,,,,
3632,bio-thera-solutions-submits-marketing-authorization-application-maa-for-bat1706-a-proposed-biosimilar-to-avastin?-to-european-medicines-agency-ema,26-11-2020 00:00,,,,,,
3633,urovant-sciences-announces-topline-data-from-phase-2a-study-of-vibegron-for-the-treatment-of-irritable-bowel-syndrome-ibs-pain-did-not-meet-primary-endpoint,26-11-2020 00:00,,,,,,
3634,biontech-and-fosun-pharma-announce-the-start-of-a-phase-2-clinical-trial-of-lead-mrna-covid-19-vaccine-bnt162b2-in-china,26-11-2020 00:00,,,,,,
3635,corticometrics-announces-fda-510k-clearance-of-thinq?-for-mri-brain-volumetric-reporting,26-11-2020 00:00,,,,,,
3636,fda-approves-y-mabs?-danyelza?-naxitamab-gqgk-for-the-treatment-of-neuroblastoma,26-11-2020 00:00,,,,,,
3637,european-medicines-agency-validates-application-for-tepotinib-for-the-treatment-of-advanced-nsclc-with-metex14-skipping-alterations,27-11-2020 00:00,,,,,,
3638,egle-therapeutics-identifies-first-novel-regulatory-t-cell-targets-in-research-alliance-with-takeda,27-11-2020 00:00,,,,,,
3639,digitalization-of-production-merck-and-siemens-collaborate,27-11-2020 00:00,,,,,,
3640,co-diagnostics-jv-cosara-receives-clearance-from-indian-fda-for-covid-19-2-gene-multiplex-test,27-11-2020 00:00,,,,,,
3641,postera-and-neurolucent-collaborate-on-identifying-small-molecule-therapeutics-for-alzheimer?s-disease,27-11-2020 00:00,,,,,,
3642,base10-and-dna-link-partners-on-research-to-support-authorization-of-antibody-test-at-the-point-of-care,27-11-2020 00:00,,,,,,
3643,dr-reddy?s-to-acquire-select-anti-allergy-brands-from-glenmark-in-russia-ukraine-kazakhstan-and-uzbekistan,30-11-2020 00:00,,,,,,
3644,moderna-announces-amendment-to-current-supply-agreement-with-united-kingdom-government-for-an-additional-2-million-doses-of-mrna-vaccine-against-covid-19-mrna-1273,30-11-2020 00:00,,,,,,
3645,shionogi-announces-supplemental-new-drug-application-for-xofluza?-in-japan-for-the-post-exposure-prophylaxis-of-influenza-virus-infection-was-approved,30-11-2020 00:00,,,,,,
3646,shionogi-and-nagasaki-university-entered-into-strategic-research-collaboration-for-antimalarial-drugs-with-the-kitasato-institute,30-11-2020 00:00,,,,,,
3647,abbvie-and-eisai-announce-an-approval-for-additional-indication-of-humira?-a-fully-human-anti-tnfa-monoclonal-antibody-for-the-treatment-of-pyoderma-gangrenosum-for-the-first-time-in-the-world,30-11-2020 00:00,,,,,,
3648,forxiga-approved-in-japan-for-chronic-heart-failure,30-11-2020 00:00,,,,,,
3649,moderna-announces-primary-efficacy-analysis-in-phase-3-cove-study-for-its-covid-19-vaccine-candidate-and-filing-today-with-us-fda-for-emergency-use-authorization,01-12-2020 00:00,,,,,,
3650,dupixent?-dupilumab-approved-by-european-commission-as-first-and-only-biologic-medicine-for-children-aged-6-to-11-years-with-severe-atopic-dermatitis,01-12-2020 00:00,,,,,,
3651,world?s-leading-life-science-companies-now-enrolling-community-a-global-platform-trial-for-hospitalized-patients-with-covid-19,01-12-2020 00:00,,,,,,
3652,kaia-health-copd-pulmonary-rehabilitation-app-to-be-commercialized-in-europe,01-12-2020 00:00,,,,,,
3653,ionis-announces-astrazeneca?s-initiation-of-the-phase-2b-clinical-study-of-its-antisense-medicine-targeting-pcsk9-to-lower-ldl-cholesterol,01-12-2020 00:00,,,,,,
3654,eisai-and-wren-therapeutics-enter-into-research-collaboration-agreement-for-drug-discovery-for-synucleinopathies,01-12-2020 00:00,,,,,,
3655,novartis-announces-fda-approval-of-xolair?-omalizumab-for-adults-with-nasal-polyps,02-12-2020 00:00,,,,,,
3656,pfizer-and-biontech-submitted-application-for-conditional-marketing-authorization-for-covid-19-vaccine-to-the-ema,02-12-2020 00:00,,,,,,
3657,boston-scientific-signs-definitive-agreement-to-divest-btg-specialty-pharmaceuticals-business,02-12-2020 00:00,,,,,,
3658,penn-medicine-collaborates-with-regeneron-to-investigate-delivery-of-covid-19-antibody-cocktail-via-gene-therapy-platform,02-12-2020 00:00,,,,,,
3659,gr?nenthal-agrees-to-acquire-european-rights-to-crestor?-rosuvastatin-from-astrazeneca,02-12-2020 00:00,,,,,,
3660,pfizer-receives-european-approval-for-oncology-supportive-care-biosimilar-nyvepriatm-pegfilgrastim,20-11-2020 00:00,,,,,,
3661,roche-announces-fda-approval-of-gavreto-pralsetinib-for-people-with-advanced-or-metastatic-ret-mutant-and-ret-fusion-positive-thyroid-cancers,02-12-2020 00:00,,,,,,
3662,new-fda-draft-guidance-on-biosimilarity-and-interchangeability,19-11-2020 00:00,,,,,,
3663,samsung-biologics-and-astrazeneca-dissolve-rituximab-partnership,20-11-2020 00:00,,,,,,
3665,formycon-and-bioeq-announce-launch-of-phase-iii-study-of-fyb202-a-biosimilar-candidate-for-stelarar-ustekinumab,09-11-2020 00:00,,,,,,
3666,xbrane-announces-that-last-patient-has-been-enrolled-into-the-pivotal-phase-iii-trial-xplore,11-11-2020 00:00,,,,,,
3667,pfizer-and-biontech-achieve-first-authorization-in-the-world-for-a-vaccine-to-combat-covid-19,03-12-2020 00:00,,,,,,
3668,samsung-bioepis-announces-one-year-results-from-phase-3-study-of-sb11-a-proposed-biosimilar-to-lucentis?-ranibizumab-at-the-american-academy-of-ophthalmology-aao-2020-virtual,11-11-2020 00:00,,,,,,
3669,roche-receives-fda-emergency-use-authorization-for-new-test-to-measure-the-level-of-sars-cov-2-antibodies,03-12-2020 00:00,,,,,,
3670,samsung-bioepis-and-biogen-announce-fda-filing-acceptance-of-sb11-a-proposed-biosimilar-referencing-lucentis?-ranibizumab,18-11-2020 00:00,,,,,,
3671,henlius-released-phase-3-study-data-of-its-bevacizumab-biosimilar-hlx04-at-esmo-asia-2020,20-11-2020 00:00,,,,,,
3672,abbvie-and-frontier-medicines-establish-global-partnership-to-discover-and-develop-novel-therapies-and-e3-degraders-against-difficult-to-drug-targets,03-12-2020 00:00,,,,,,
3673,innovent-announces-nmpa-granted-new-indication-approval-for-sulinno?-adalimumab-injection-in-china-for-the-treatment-of-polyarticular-juvenile-idiopathic-arthritis,23-11-2020 00:00,,,,,,
3674,astrazeneca-demonstrates-growing-leadership-in-breast-cancer-at-sabcs-with-data-from-its-innovative-medicines-and-robust-pipeline,03-12-2020 00:00,,,,,,
3675,janssen-acquires-rights-to-novel-gene-therapy-pioneering-treatment-solutions-for-late-stage-age-related-macular-degeneration,03-12-2020 00:00,,,,,,
3676,merck-kgaa-darmstadt-germany-and-artios-pharma-announce-a-global-strategic-collaboration-on-novel-dna-damage-response-targets-in-oncology,03-12-2020 00:00,,,,,,
3677,janssen-submits-application-to-us-fda-seeking-approval-of-amivantamab-for-the-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations,04-12-2020 00:00,,,,,,
3678,richter-announces-the-acquisition-of-janssen?s-evra?-transdermal-contraceptive-patch-assets,04-12-2020 00:00,,,,,,
3679,jazz-pharmaceuticals-and-pharmamar-announce-results-of-atlantis-phase-3-study-evaluating-zepzelca?-in-combination-with-doxorubicin-for-patients-with-small-cell-lung-cancer-following-one-prior-platinum-containing-line,04-12-2020 00:00,,,,,,
3680,remynd-commences-first-in-human-trial-of-res19-t-alzheimer?s-program,04-12-2020 00:00,,,,,,
3681,abbott?s-freestyle-libre-2-now-approved-for-adults-and-children-with-diabetes-in-canada-featuring-unsurpassed-14-day-accuracy-and-optional-alarms,04-12-2020 00:00,,,,,,
3682,exactech-acquires-muvr-innovative-patient-wearable-and-communication-solutions-for-orthopaedic-practices,04-12-2020 00:00,,,,,,
3683,new-data-demonstrate-long-term-benefit-of-imbruvica?-ibrutinib-as-first-line-treatment-for-high-risk-chronic-lymphocytic-leukaemia,07-12-2020 00:00,,,,,,
3684,yescarta?-is-first-car-t-cell-therapy-to-demonstrate-high-response-rates-and-durable-clinical-benefit-in-a-pivotal-indolent-non-hodgkin-lymphoma-study,07-12-2020 00:00,,,,,,
3685,roche-announces-new-data-reinforcing-the-long-term-benefit-of-venclextavenclyxto-based-combination-for-people-with-relapsed-or-refractory-chronic-lymphocytic-leukaemia,07-12-2020 00:00,,,,,,
3686,calquence-shows-long-term-efficacy-and-tolerability-at-three-years-for-patients-with-relapsed-or-refractory-mantle-cell-lymphoma,07-12-2020 00:00,,,,,,
3687,new-follow-up-phase-iii-data-reinforce-the-long-term-benefit-of-roche?s-hemlibra-for-people-with-haemophilia-a,07-12-2020 00:00,,,,,,
3688,new-data-presented-at-ash-2020-reinforces-the-benefitrisk-profile-of-fixed-duration-polivy-plus-bendamustine-and-mabtherarituxan-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma,07-12-2020 00:00,,,,,,
3689,combined-data-from-multiple-phase-3-studies-of-imbruvica?-ibrutinib-show-efficacy-and-safety-in-high-risk-previously-untreated-chronic-lymphocytic-leukemia-cll-and-real-world-data-indicating-low-biomarker-testing-rates-for-these-patients,08-12-2020 00:00,,,,,,
3690,nektar-therapeutics-announces-presentation-of-preclinical-data-for-nktr-255-its-novel-il-15-agonist-at-the-american-society-of-hematology-ash-2020-annual-meeting,08-12-2020 00:00,,,,,,
3691,bayer-and-atara-biotherapeutics-enter-strategic-collaboration-for-mesothelin-targeted-car-t-cell-therapies-for-solid-tumors,08-12-2020 00:00,,,,,,
3692,"hilden-germany-germantown-md?business-wire?qiagen-nv-nyse-qgen-frankfurt-prime-standard-qia-announced-today-the-launch-of-its-quantiferon-sars-cov-2-ruo-solution-that-can-detect-t-cell-responses-of-the-human-immune-system-to-the-pathogen-that-causes-covid-19-which-could-help-researchers-find-out-more-about-immunity-levels-and-disease-progression
-
-studies-suggest-that-t-cell-response-to-sars-cov-2-declines-much-more-slowly-than-antibody-response-which-presents-several-benefits-to-researchers-who-want-to-push-beyond-the-existing-detection-of-active-infections-to-screen-for-potential-courses-of-the-illness-and-long-term-immune-responses-to-it-qiagen?s-quantiferon-sars-cov-2-research-use-only-ruo-solution-could-be-a-valuable-tool-in-this-research
-
-there-is-also-growing-evidence-that-t-cell-response-gives-a-reliable-indication-of-how-severe-the-course-of-an-illness-triggered-by-sars-cov-2-will-be-in-infected-patients-and-how-immune-those-who-have-recovered-remain-months-?-possibly-even-years-?-after-having-been-infected
-
-quantiferon-sars-cov-2-ruo-is-a-flexible-modular-system-designed-to-meet-a-wide-range-of-research-demands-it-is-based-on-qiagen?s-easy-to-use-quantiferon-technology-pioneered-in-the-quantiferon-tb-gold-plus-test-for-latent-tuberculosis-and-recognized-worldwide-for-its-ability-to-detect-interferon-gamma-that-t-cells-release-upon-contact-with-certain-pathogens
-
-quantiferon-sars-cov-2-ruo-is-a-crucial-addition-to-qiagen?s-growing-covid-19-portfolio-that-already-provides-sample-preparation-technology-infection-testing-with-polymerase-chain-reaction-pcr-technology-antibody-and-antigen-tests-enzymes-and-automation-solutions
-
-please-find-the-full-press-release-here
-
-
-
-contacts
-qiagen
-investor-relations
-john-gilardi
-49-2103-29-11711
-
-phoebe-loh
-49-2103-29-11457
-e-mail-irqiagencom
-
-public-relations
-thomas-theuringer
-49-2103-29-11826
-
-robert-reitze
-49-2103-29-11676
-e-mail-prqiagencom",08-12-2020 00:00,,,,,,
3693,kalivir-immunotherapeutics-and-astellas-enter-worldwide-exclusive-licensing-agreement-for-development-and-commercialization-of-vet2-l2-novel-oncolytic-virus,08-12-2020 00:00,,,,,,
3694,retinai-announces-collaboration-with-novartis-to-provide-artificial-intelligence-solutions-in-ophthalmology,08-12-2020 00:00,,,,,,
3695,novartis-investigational-stamp-inhibitor-asciminib-abl001-shows-superior-mmr-rate-to-bosulif?-in-chronic-myeloid-leukemia-trial,09-12-2020 00:00,,,,,,
3696,azd1222-oxford-phase-iii-trials-interim-analysis-results-published-in-the-lancet,09-12-2020 00:00,,,,,,
3697,medtronic-launches-the-first-and-only-pediatric-and-neonatal-acute-dialysis-machine-in-the-us,09-12-2020 00:00,,,,,,
3698,amgen?s-sotorasib-granted-breakthrough-therapy-designation-for-advanced-or-metastatic-non-small-cell-lung-cancer-patients-with-kras-g12c-mutation,09-12-2020 00:00,,,,,,
3699,roche-presents-new-data-from-its-bispecific-antibody-portfolio-across-a-range-of-blood-cancers,09-12-2020 00:00,,,,,,
3700,elsevier-acquires-shadow-health-a-leading-provider-of-best-in-class-healthcare-simulations,09-12-2020 00:00,,,,,,
3701,boehringer-ingelheim-to-acquire-labor-dr-merk-kollegen-to-strengthen-its-next-generation-cancer-immunology-program,10-12-2020 00:00,,,,,,
3702,lilly?s-tirzepatide-significantly-reduced-a1c-and-body-weight-in-people-with-type-2-diabetes,10-12-2020 00:00,,,,,,
3703,roche-partners-with-moderna-to-include-sars-cov-2-antibody-test-in-ongoing-covid-19-vaccine-trials,10-12-2020 00:00,,,,,,
3704,novartis-kisqali?-demonstrates-nearly-five-years-median-overall-survival-in-metastatic-breast-cancer,10-12-2020 00:00,,,,,,
3705,advancing-health-research-with-google-health-studies,10-12-2020 00:00,,,,,,
3706,pfizer-and-biontech-achieve-health-canada-authorization-for-their-vaccine-to-combat-covid-19,10-12-2020 00:00,,,,,,
3707,boehringer-ingelheim-to-acquire-nbe-therapeutics-for-eur-118-billion-significantly-enhancing-its-cancer-pipeline-portfolio-with-novel-antibody-drug-conjugates,11-12-2020 00:00,,,,,,
3708,gilead-sciences-to-acquire-myr-gmbh,11-12-2020 00:00,,,,,,
3709,biogen-files-new-drug-application-for-aducanumab-in-japan,11-12-2020 00:00,,,,,,
3710,roche-presents-exploratory-data-from-the-phase-iii-imvigor010-study-in-early-bladder-cancer-at-the-esmo-immuno-oncology-virtual-congress-2020,11-12-2020 00:00,,,,,,
3711,roche-launches-laboratory-sars-cov-2-antigen-test-to-support-high-volume-testing-of-suspected-covid-19-patients,11-12-2020 00:00,,,,,,
3712,chugai-in-licenses-antibody-cocktail-for-covid-19-from-roche,11-12-2020 00:00,,,,,,
3713,astrazeneca-to-acquire-alexion-accelerating-the-company?s-strategic-and-financial-development,14-12-2020 00:00,,,,,,
3714,pfizer-and-biontech-celebrate-historic-first-authorization-in-the-us-of-vaccine-to-prevent-covid-19,14-12-2020 00:00,,,,,,
3715,alvotech-and-fuji-pharma-extend-biosimilar-partnership-in-japan,14-12-2020 00:00,,,,,,
3716,trixeo-aerosphere-approved-in-the-eu-for-maintenance-treatment-of-copd,14-12-2020 00:00,,,,,,
3717,novartis-provides-update-on-ruxcovid-study-of-ruxolitinib-for-hospitalized-patients-with-covid-19,14-12-2020 00:00,,,,,,
3718,trastuzumab-deruxtecan-recommended-for-approval-in-the-eu-by-chmp-for-her2-positive-metastatic-breast-cancer,14-12-2020 00:00,,,,,,
3719,fda-approves-genentech?s-ocrevus-ocrelizumab-shorter-2-hour-infusion-for-relapsing-and-primary-progressive-multiple-sclerosis,15-12-2020 00:00,,,,,,
3720,relay-therapeutics-announces-a-worldwide-license-and-collaboration-agreement-withrelay-therapeutics-for-rly-1971,15-12-2020 00:00,,,,,,
3721,samsung-bioepis-initiates-phase-3-clinical-trial-for-sb16-proposed-biosimilar-to-prolia-denosumab,15-12-2020 00:00,,,,,,
3722,roche-launches-cobas-pik3ca-mutation-test-for-patients-with-advanced-or-metastatic-breast-cancer-in-countries-accepting-the-ce-mark,15-12-2020 00:00,,,,,,
3723,curevac-commences-global-pivotal-phase-2b3-trial-for-covid-19-vaccine-candidate-cvncov,15-12-2020 00:00,,,,,,
3724,imfinzi-recommended-for-approval-in-the-eu-by-chmp-for-less-frequent-fixed-dose-use-in-unresectable-non-small-cell-lung-cancer,15-12-2020 00:00,,,,,,
3725,lilly-announces-agreement-to-acquire-prevail-therapeutics,15-12-2020 00:00,,,,,,
3726,sedor-pharmaceuticals-receives-fda-approval-for-sesquient?-fosphenytoin-sodium-for-the-treatment-of-status-epilepticus-in-adult-and-pediatric-patients,09-11-2020 00:00,,,,,,
3727,rhythm-pharmaceuticals-announces-fda-approval-of-imcivree?-setmelanotide-as-first-ever-therapy-for-chronic-weight-management-in-patients-with-obesity-due-to-pomc-pcsk1-or-lepr-deficiency,27-11-2020 00:00,,,,,,
3728,gilead-and-galapagos-announce-new-commercialization-and-development-agreement-for-jyseleca?-filgotinib,16-12-2020 00:00,,,,,,
3729,athenex-announces-fda-approval-of-klisyri?-tirbanibulin-for-the-treatment-of-actinic-keratosis-on-the-face-or-scalp,16-12-2020 00:00,,,,,,
3730,us-food-and-drug-administration-accepts-new-drug-application-for-review-grants-priority-review-for-takeda?s-tak-721-budesonide-oral-suspension-for-the-treatment-of-eosinophilic-esophagitis,16-12-2020 00:00,,,,,,
3731,osteoporosis-prevention-product-wins-fda-breakthrough-device-designation,16-12-2020 00:00,,,,,,
3732,fda-authorizes-ellume-covid-19-home-test-as-first-over-the-counter-fully-at-home-diagnostic-test,16-12-2020 00:00,,,,,,
3733,abbott-receives-ce-mark-for-its-covid-19-igg-quantitative-antibody-blood-test,16-12-2020 00:00,,,,,,
3734,novartis-announces-positive-fda-advisory-committee-recommendation-for-use-of-entresto?-to-treat-patients-with-hfpef,17-12-2020 00:00,,,,,,
3735,novo-nordisk-to-enter-phase-3-development-in-alzheimer?s-disease-with-oral-semaglutide,17-12-2020 00:00,,,,,,
3736,health-canada-approves-zolgensma?-the-one-time-gene-therapy-for-pediatric-patients-with-spinal-muscular-atrophy-sma,17-12-2020 00:00,,,,,,
3737,amgen-submits-sotorasib-new-drug-application-to-us-fda-for-advanced-or-metastatic-non-small-cell-lung-cancer-with-kras-g12c-mutation,17-12-2020 00:00,,,,,,
3738,kite?s-tecartus?-kte-x19-granted-conditional-marketing-authorization-for-the-treatment-of-relapsed-or-refractory-mantle-cell-lymphoma-in-europe,17-12-2020 00:00,,,,,,
3739,cadent-therapeutics-enters-agreement-to-be-acquired-by-novartis,17-12-2020 00:00,,,,,,
3740,moderna-receives-fda-advisory-committee-vote-supporting-emergency-use-for-moderna?s-vaccine-against-covid-19-in-the-united-states,18-12-2020 00:00,,,,,,
3741,surface-oncology-announces-exclusive-license-agreement-with-gsk-for-novel-immunotherapy-program,18-12-2020 00:00,,,,,,
3742,fda-approves-gsk?s-benlysta-as-the-first-medicine-for-adult-patients-with-active-lupus-nephritis-in-the-us,18-12-2020 00:00,,,,,,
3743,sandoz-canada-receives-authorization-from-health-canada-to-launch-new-biosimilar-hyrimoz?-adalimumab,18-12-2020 00:00,,,,,,
3744,fda-approves-amgen?s-riabni?-rituximab-arrx-a-biosimilar-to-rituxan?-rituximab,18-12-2020 00:00,,,,,,
3745,self-contained-rapid-adexusdx?-covid-19-antibody-fingerstick-test-receives-ce-mark-for-deployment-across-european-union,18-12-2020 00:00,,,,,,
3746,sosei-heptares-and-gsk-enter-global-collaboration-and-license-agreement-targeting-immune-disorders-of-the-digestive-system,21-12-2020 00:00,,,,,,
3747,janux-therapeutics-announces-collaboration-with-merck-to-develop-novel-drug-candidates-for-immuno-oncology-using-t-cell-engager-tractr-technology,21-12-2020 00:00,,,,,,
3748,philips-to-become-a-global-leader-in-patient-care-management-solutions-for-the-hospital-and-the-home-through-the-acquisition-of-biotelemetry-inc,21-12-2020 00:00,,,,,,
3749,viiv-healthcare-announces-the-marketing-authorisation-of-the-first-complete-long-acting-injectable-hiv-treatment-in-europe,21-12-2020 00:00,,,,,,
3750,ultragenyx-and-mereo-biopharma-announce-collaboration-and-license-agreement-for-setrusumab-in-osteogenesis-imperfecta,21-12-2020 00:00,,,,,,
3751,moderna-announces-fda-authorization-of-moderna-covid-19-vaccine-in-us,21-12-2020 00:00,,,,,,
3752,adding-multimedia-tagrisso-approved-in-the-us-for-the-adjuvant-treatment-of-patients-with-early-stage-egfr-mutated-lung-cancer,22-12-2020 00:00,,,,,,
3753,roche?s-faricimab-meets-primary-endpoint-and-shows-strong-durability-across-two-global-phase-iii-studies-for-diabetic-macular-edema-a-leading-cause-of-blindness,22-12-2020 00:00,,,,,,
3754,servier-to-acquire-agios-pharmaceuticals?-oncology-business,22-12-2020 00:00,,,,,,
3755,the-european-commission-grants-marketing-authorization-for-plegridy?-peginterferon-beta-1a-intramuscular-administration-for-relapsing-remitting-multiple-sclerosis,22-12-2020 00:00,,,,,,
3756,pfizer-and-biontech-receive-authorization-in-the-european-union-for-covid-19-vaccine,22-12-2020 00:00,,,,,,
3757,update-on-source-phase-iii-trial-for-tezepelumab-in-patients-with-severe-oral-corticosteroid-dependent-asthma,22-12-2020 00:00,,,,,,
3758,janssen-announces-health-canada-approval-of-darzalex?-combination-regimen-for-newly-diagnosed-transplant-eligible-patients-with-multiple-myeloma,23-12-2020 00:00,,,,,,
3759,voyager-therapeutics-provides-update-on-nbib-1817-vy-aadc-gene-therapy-program,23-12-2020 00:00,,,,,,
3760,janssen-initiates-rolling-submission-of-a-biologics-license-application-to-us-fda-for-bcma-car-t-therapy-ciltacabtagene-autoleucel-cilta-cel-for-the-treatment-of-relapsed-andor-refractory-multiple-myeloma,23-12-2020 00:00,,,,,,
3761,ocular-therapeutix?-announces-submission-to-the-fda-of-a-supplemental-new-drug-application-for-dextenza?-dexamethasone-ophthalmic-insert-for-the-treatment-of-ocular-itching-associated-with-allergic-conjunctivitis,23-12-2020 00:00,,,,,,
3762,amo-pharma-announces-initiation-of-pivotal-reach-cdm-clinical-trial-for-amo-02-in-treatment-of-congenital-myotonic-dystrophy,23-12-2020 00:00,,,,,,
3763,european-commission-approves-roche?s-phesgo-fixed-dose-combination-of-perjeta-and-herceptin-for-subcutaneous-injection-for-people-with-her2-positive-breast-cancer,23-12-2020 00:00,,,,,,
3764,innovent-announces-nmpa-granted-new-indication-approvals-for-sulinno?-adalimumab-injection-for-the-treatment-of-pediatric-plaque-psoriasis-and-non-infectious-uveitis,28-12-2020 00:00,,,,,,
3765,innovent-announces-the-nmpa-granted-new-indication-approval-for-byvasda?-bevacizumab-biosimilar-for-the-treatment-of-adult-recurrent-glioblastoma,28-12-2020 00:00,,,,,,
3766,aurobindo-pharma-and-covaxx-sign-an-exclusive-agreement-to-develop-and-commercialize-covid-19-vaccine-ub-612-for-india-and-unicef,28-12-2020 00:00,,,,,,
3767,amryt-granted-orphan-drug-designation-by-the-fda-for-ap103,28-12-2020 00:00,,,,,,
3768,casi-pharmaceuticals-announces-cnct19-cd19-car-t-receives-china-breakthrough-therapy-designation,28-12-2020 00:00,,,,,,
3769,algernon-pharmaceuticals-announces-last-patient-out-in-multinational-phase-2b3-human-study-of-ifenprodil-for-covid-19,28-12-2020 00:00,,,,,,
3770,janssen-submits-european-marketing-authorisation-application-for-amivantamab-for-the-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations,29-12-2020 00:00,,,,,,
3771,zai-lab-and-cullinan-oncology-announce-strategic-collaboration-and-license-agreement-for-cln-081-in-greater-china,29-12-2020 00:00,,,,,,
3772,myovant-sciences-and-pfizer-announce-collaboration-to-develop-and-commercialize-relugolix-in-oncology-and-women?s-health,29-12-2020 00:00,,,,,,
3773,biocon-expands-generic-formulations-portfolio-with-the-launch-of-tacrolimus-capsules-in-the-us,29-12-2020 00:00,,,,,,
3774,lorbrena-lorlatinib-snda-in-previously-untreated-alk-positive-lung-cancer-accepted-for-priority-review-by-us-fda,29-12-2020 00:00,,,,,,
3775,alligator-bioscience-submits-cta-for-the-mitazalimab-phase-ii-study-optimize-1,29-12-2020 00:00,,,,,,
3776,chi-med-initiates-rolling-submission-of-nda-to-us-fda-for-surufatinib-for-the-treatment-of-advanced-neuroendocrine-tumors,30-12-2020 00:00,,,,,,
3777,novo-nordisk-files-for-eu-regulatory-approval-of-once-weekly-semaglutide-20-mg-for-the-treatment-of-type-2-diabetes,30-12-2020 00:00,,,,,,
3778,skyhawk-and-vertex-establish-a-strategic-collaboration-to-discover-and-develop-novel-small-molecules-that-modulate-rna-splicing-for-serious-diseases,30-12-2020 00:00,,,,,,
3779,astrazeneca?s-covid-19-vaccine-authorised-for-emergency-supply-in-the-uk,30-12-2020 00:00,,,,,,
3780,regeneron-announces-encouraging-initial-data-from-covid-19-antibody-cocktail-trial-in-hospitalized-patients-on-low-flow-oxygen,30-12-2020 00:00,,,,,,
3781,zydus-cadila-submits-phase-iii-clinical-trial-data-of-zycov-d-seeks-nod-to-start-phase-iii-clinical-trials,30-12-2020 00:00,,,,,,
3782,sinopharm-china-bio-beijing-company?s-new-coronavirus-inactivated-vaccine-phase-iii,31-12-2020 00:00,,,,,,
3783,according-to-the-statistical-analysis-of-sinopharm-china-biotech-the-results-of-the-interim-analysis-of-the-new-coronavirus-inactivated-vaccine-phase-iii-clinical-trial-showed-that-the-safety-of-the-new-coronavirus-inactivated-vaccine-of-sinopharm-china-bio-beijing-company-is-good-after-inoculation-after-two-injections-of-the-immunization-program-the-vaccine-group-will-be-vaccinated-all-patients-produced-high-titer-antibodies-the-neutralizing-antibody-positive-conversion-rate-was-9952-and-the-vaccine?s-protective-efficacy-against-the-disease-caused-by-the-new-coronavirus-infection-covid-19-was-7934-the-data-results-reached-the-relevant-technical-standards-of-the-world-health-organization-and-the-country-the-?guiding-principles-for-clinical-evaluation-of-new-coronavirus-preventive-vaccines-trial?-issued-by-the-food-and-drug-administration-is-required-by-relevant-standards-at-present-sinopharm-china-biotech-beijing-has-formally-submitted-a-conditional-listing-application-to-the-state-food-and-drug-administration,31-12-2020 00:00,,,,,,
3784,quanterix-receives-fda-emergency-use-authorization-for-semi-quantitative-antibody-test,31-12-2020 00:00,,,,,,
3785,sorrento-announces-the-submission-of-a-marketing-authorization-application-to-cofepris-mexico-for-covi-stix?-rapid-detection-test-of-sars-cov-2-viral-antigen,31-12-2020 00:00,,,,,,
3786,statement-on-the-uk-authorization-of-the-astrazeneca?s-covid-19-vaccine,31-12-2020 00:00,,,,,,
3787,incyte-and-cellenkos-enter-into-global-development-collaboration-agreement-for-ck0804,31-12-2020 00:00,,,,,,
3788,redhill-biopharma-announces-positive-top-line-safety-and-efficacy-data-from-phase-2-covid-19-study-of-opaganib,04-01-2021 00:00,,,,,,
3789,india-approves-astrazeneca?s-covid-19-vaccine,04-01-2021 00:00,,,,,,
3790,antengene-submits-nda-for-atg-010-selinexor-in-south-korea-for-rrmm-and-rrdlbcl,04-01-2021 00:00,,,,,,
3791,tiziana-announces-completion-of-the-clinical-trial-with-nasally-administered-foralumab-its-proprietary-fully-human-anti-cd3-monoclonal-antibody-for-the-treatment-of-covid-19-patients-in-brazil,04-01-2021 00:00,,,,,,
3792,how-oura-ring-data-could-help-identify-early-covid-19-symptoms,04-01-2021 00:00,,,,,,
3793,provention-bio-announces-us-fda-filing-of-a-biologics-license-application-bla-and-priority-review-for-teplizumab-for-the-delay-or-prevention-of-clinical-type-1-diabetes-in-at-risk-individuals,04-01-2021 00:00,,,,,,
3794,hologic-to-acquire-somatex-leader-in-biopsy-site-markers-and-localization-technologies-for-64-million,05-01-2021 00:00,,,,,,
3795,us-fda-accepts-regulatory-submission-from-pfizer-and-opko-for-review-of-somatrogon-to-treat-pediatric-patients-with-growth-hormone-deficiency,05-01-2021 00:00,,,,,,
3796,genentech?s-novel-anti-tigit-tiragolumab-granted-fda-breakthrough-therapy-designation-in-combination-with-tecentriq-for-pd-l1-high-non-small-cell-lung-cancer,05-01-2021 00:00,,,,,,
3797,atyr-pharma-announces-positive-topline-results-from-phase-2-clinical-trial-of-atyr1923-in-covid-19-patients-with-severe-respiratory-complications,05-01-2021 00:00,,,,,,
3798,y-biologics-signed-license-agreement-with-3d-medicines-for-t-cell-bispecific-engager-in-greater-china-territory,05-01-2021 00:00,,,,,,
3799,vigeneron-signs-global-collaboration-agreement-for-ophthalmic-gene-therapy-development,05-01-2021 00:00,,,,,,
3800,stryker-acquires-orthosensor,06-01-2021 00:00,,,,,,
3801,evotec-achieves-milestone-in-its-neurodegeneration-collaboration-with-bristol-myers-squibb,06-01-2021 00:00,,,,,,
3802,regenxbio-announces-update-on-rgx-314-and-pivotal-program-for-the-treatment-of-wet-amd-and-new-gene-therapy-program-for-the-treatment-of-duchenne-muscular-dystrophy,06-01-2021 00:00,,,,,,
3803,risankizumab-skyrizi?-phase-3-results-demonstrate-improvements-in-disease-activity-across-joint-and-skin-symptoms-among-psoriatic-arthritis-patients,06-01-2021 00:00,,,,,,
3804,farxiga-granted-priority-review-in-the-us-for-the-treatment-of-patients-with-chronic-kidney-disease,06-01-2021 00:00,,,,,,
3805,nirmidas-biotech-receives-fda-emergency-use-authorization-for-its-covid-19-rapid-antibody-fingerstick-test,06-01-2021 00:00,,,,,,
3806,dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy,07-01-2021 00:00,,,,,,
3807,ribometrix-announces-collaboration-with-genentech-to-discover-and-develop-rna-targeted-small-molecule-therapeutics,07-01-2021 00:00,,,,,,
3808,fda-accepts-for-priority-review-the-new-drug-application-for-mirabegron-for-oral-suspension-and-supplemental-new-drug-application-for-myrbetriq?-mirabegron-tablets-in-pediatric-patients,07-01-2021 00:00,,,,,,
3809,merck-acquires-amptec-to-expand-mrna-capabilities-for-vaccines-treatments-and-diagnostics,07-01-2021 00:00,,,,,,
3810,imaginab-announces-license-and-supply-agreement-with-pfizer-for-cd8-immunopet-technology,07-01-2021 00:00,,,,,,
3811,hologic-to-acquire-biotheranostics-leader-in-molecular-tests-for-breast-and-metastatic-cancers-for-approximately-230-million,07-01-2021 00:00,,,,,,
3812,curevac-and-bayer-join-forces-on-covid-19-vaccine-candidate-cvncov,08-01-2021 00:00,,,,,,
3813,alnylam-reports-positive-topline-results-from-helios-a-phase-3-study-of-vutrisiran-in-patients-with-hattr-amyloidosis-with-polyneuropathy,08-01-2021 00:00,,,,,,
3814,pfizer-doses-first-participant-in-phase-3-study-for-duchenne-muscular-dystrophy-investigational-gene-therapy,08-01-2021 00:00,,,,,,
3815,perkinelmer-to-acquire-oxford-immunotec-global-plc,08-01-2021 00:00,,,,,,
3816,sarepta-therapeutics-announces-top-line-results-for-part-1-of-study-102-evaluating-srp-9001-its-investigational-gene-therapy-for-the-treatment-of-duchenne-muscular-dystrophy,08-01-2021 00:00,,,,,,
3817,almirall-and-tyris-therapeutics-enter-into-strategic-partnership-to-develop-next-generation-gene-therapies,08-01-2021 00:00,,,,,,
3818,risankizumab-skyrizi?-demonstrates-significant-improvements-in-clinical-remission-and-endoscopic-response-in-two-phase-3-induction-studies-in-patients-with-crohn?s-disease,11-01-2021 00:00,,,,,,
3819,roche?s-xofluza-approved-by-the-european-commission-for-the-treatment-of-influenza-the-first-new-influenza-antiviral-for-patients-in-almost-20-years,11-01-2021 00:00,,,,,,
3820,biomarin-announces-positive-phase-3-gene-therapy-trial-results-in-adults-with-severe-hemophilia-a-study-met-all-primary-and-secondary-efficacy-endpoints-in-one-year-data-set,11-01-2021 00:00,,,,,,
3821,sanofi-to-acquire-kymab-adding-ky1005-to-its-pipeline-a-human-monoclonal-antibody-targeting-key-immune-system-regulator-ox40l,11-01-2021 00:00,,,,,,
3822,chi-med-and-inmagene-announce-strategic-partnership-to-develop-and-commercialize-portfolio-of-drug-candidates-for-immunological-diseases,11-01-2021 00:00,,,,,,
3823,arsenalbio-announces-multi-program-discovery-collaboration-with-bristol-myers-squibb-to-advance-next-generation-t-cell-therapies-for-solid-tumors,11-01-2021 00:00,,,,,,
3824,biogen-to-launch-pioneering-study-to-develop-digital-biomarkers-of-cognitive-health-using-apple-watch-and-iphone,12-01-2021 00:00,,,,,,
3825,novartis-expands-oncology-pipeline-with-in-licensing-of-tislelizumab-from-beigene,12-01-2021 00:00,,,,,,
3826,bluebird-bio-to-separate-oncology-business-into-independent-company,12-01-2021 00:00,,,,,,
3827,adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics,12-01-2021 00:00,,,,,,
3828,roche-to-present-updated-data-confirming-tecentriq-in-combination-with-avastin-substantially-improves-overall-survival-in-people-with-the-most-common-form-of-liver-cancer,12-01-2021 00:00,,,,,,
3829,vir-biotechnology-and-gsk-announce-nhs-supported-agile-study-to-evaluate-vir-7832-in-the-early-treatment-of-covid-19,12-01-2021 00:00,,,,,,
3830,gilead-and-vir-biotechnology-establish-clinical-collaboration-to-explore-combination-strategies-for-functional-cure-for-chronic-hepatitis-b-virus,13-01-2021 00:00,,,,,,
3831,health-canada-approves-lundbeck?s-prvyepti?-eptinezumab?the-first-and-only-intravenous-preventive-treatment-for-migraine,13-01-2021 00:00,,,,,,
3832,bayer-announces-us-fda-accepts-new-drug-application-and-grants-priority-review-for-investigational-drug-finerenone-for-patients-with-chronic-kidney-disease-and-type-2-diabetes,13-01-2021 00:00,,,,,,
3833,ucb-announces-launch-of-nile-ai-inc-a-digital-health-company-set-to-transform-the-course-of-epilepsy,13-01-2021 00:00,,,,,,
3834,teladoc-health-and-dexcom-bring-cgm-technology-and-personalized-insights-to-people-with-type-2-diabetes-at-no-cost,13-01-2021 00:00,,,,,,
3835,roche-confirms-us-government-agreement-to-purchase-additional-doses-of-regeneron?s-casirivimab-and-imdevimab,13-01-2021 00:00,,,,,,
3836,kamada-enters-into-two-new-agreements-for-the-distribution-of-three-biosimilar-products-in-israel,14-01-2021 00:00,,,,,,
3837,evoq-therapeutics-announces-a-license-and-collaboration-agreement-with-amgen,14-01-2021 00:00,,,,,,
3838,viiv-healthcare-receives-eu-marketing-authorisation-for-the-first-ever-dispersible-tablet-formulation-of-dolutegravir-tivicay-a-treatment-for-children-living-with-hiv-in-europe,14-01-2021 00:00,,,,,,
3839,celltrion-group-announces-positive-top-line-efficacy-and-safety-data-from-global-phase-iiiii-clinical-trial-of-covid-19-treatment-candidate-ct-p59,14-01-2021 00:00,,,,,,
3840,biond-biologics-and-sanofi-enter-into-global-licensing-agreement-for-bnd-22-a-novel-immune-checkpoint-inhibitor-targeting-the-ilt2-receptor,14-01-2021 00:00,,,,,,
3841,china-national-medical-products-administration-approves-tislelizumab-in-combination-with-chemotherapy-in-first-line-advanced-squamous-non-small-cell-lung-cancer,14-01-2021 00:00,,,,,,
3842,ksq-therapeutics-and-takeda-enter-broad-strategic-collaboration-to-research-develop-and-commercialize-novel-immuno-oncology-therapies,15-01-2021 00:00,,,,,,
3843,pfizer?s-xalkori-crizotinib-receives-the-us-fda?s-approval-for-alk-positive-anaplastic-large-cell-lymphoma-in-children-and-young-adults,15-01-2021 00:00,,,,,,
3847,novartis-ligelizumab-qge031-receives-fda-breakthrough-therapy-designation-for-patients-with-chronic-spontaneous-urticaria-csu,15-01-2021 00:00,,,,,,
3848,gsk-presents-positive-efficacy-data-of-dostarlimab-in-mismatch-repair-deficient-dmmr-solid-cancers-at-asco-gastrointestinal-cancers-symposium,18-01-2021 00:00,,,,,,
3849,adding-multimedia-?-enhertu?-approved-in-the-us-for-the-treatment-of-patients-with-previously-treated-her2-positive-advanced-gastric-cancer,18-01-2021 00:00,,,,,,
3850,imfinzi-approved-in-the-eu-for-less-frequent-fixed-dose-use-in-unresectable-non-small-cell-lung-cancer,18-01-2021 00:00,,,,,,
3851,genmab-announces-that-janssen-has-been-granted-us-fda-approval-for-darzalex-faspro?-daratumumab-and-hyaluronidase-fihj-for-patients-with-newly-diagnosed-light-chain-al-amyloidosis,18-01-2021 00:00,,,,,,
3852,cardiff-oncology-presents-data-that-continues-to-demonstrate-the-clinical-benefit-of-onvansertib-in-kras-mutated-mcrc-and-initial-findings-from-its-expanded-access-program,18-01-2021 00:00,,,,,,
3853,nanobiotix-announces-positive-first-results-for-novel-nbtxr3-in-rectal-cancer-study-at-asco-gi-2021,18-01-2021 00:00,,,,,,
3854,cure-genetics-collaborates-with-boehringer-ingelheim-to-develop-novel-aav-vectors-enabling-the-next-generation-liver-targeted-gene-therapy,19-01-2021 00:00,,,,,,
3855,tessa-therapeutics-receives-prime-designation-from-european-medicines-agency-for-cd30-car-t-therapy,19-01-2021 00:00,,,,,,
3856,tennor-enters-research-collaboration-with-janssen-for-potential-new-treatments-for-nontuberculous-mycobacteria-diseases,19-01-2021 00:00,,,,,,
3857,grifols-begins-clinical-trial-of-a-new-treatment-that-would-provide-immediate-immunity-against-covid-19,19-01-2021 00:00,,,,,,
3858,innovent-announces-an-out-license-agreement-with-pt-etana-biotechnologies-indonesia-to-launch-byvasda?-bevacizumab-biosimilar-in-indonesia,19-01-2021 00:00,,,,,,
3859,philips-to-expand-its-leadership-in-patient-care-management-solutions-for-the-hospital-with-the-acquisition-of-capsule-technologies-inc,19-01-2021 00:00,,,,,,
3860,biocryst-announces-fda-approval-of-orladeyo?-berotralstat-first-oral-once-daily-therapy-to-prevent-attacks-in-hereditary-angioedema-patients,15-12-2020 00:00,,,,,,
3861,myovant-sciences-announces-fda-approval-of-orgovyx?-relugolix-the-first-and-only-oral-gonadotropin-releasing-hormone-gnrh-receptor-antagonist-for-advanced-prostate-cancer,15-12-2020 00:00,,,,,,
3862,lilly-and-merus-nv-announce-collaboration-to-discover-novel-t-cell-re-directing-bispecific-antibodies,20-01-2021 00:00,,,,,,
3863,thermo-fisher-scientific-to-acquire-point-of-care-molecular-diagnostics-provider-mesa-biotech,20-01-2021 00:00,,,,,,
3864,biologics-license-application-for-narsoplimab-in-hsct-tma-accepted-for-priority-review-by-us-fda,20-01-2021 00:00,,,,,,
3865,enhertu?-approved-in-the-eu-for-the-treatment-of-her2-positive-metastatic-breast-cancer,20-01-2021 00:00,,,,,,
3866,sorrento-to-present-data-demonstrating-sti-2020-preserves-binding-against-uk-b117-sars-cov-2-mutated-spike-protein,20-01-2021 00:00,,,,,,
3867,biohaven-provides-update-on-phase-23-trial-and-alzheimer?s-disease-program,20-01-2021 00:00,,,,,,
3868,macrogenics-announces-fda-approval-of-margenza?-for-patients-with-pretreated-metastatic-her2-positive-breast-cancer,15-12-2020 00:00,,,,,,
3869,ridgeback-biotherapeutics-lp-announces-the-approval-of-ebangatm-for-ebola,22-12-2020 00:00,,,,,,
3870,sumitovant-biopharma-announces-urovant-sciences-receives-us-fda-approval-of-gemtesa?-vibegron-75-mg-tablets-for-the-treatment-of-patients-with-overactive-bladder-oab,23-12-2020 00:00,,,,,,
3871,merck-announces-update-on-the-intrpid-clinical-program-including-lung-037-study,21-01-2021 00:00,,,,,,
3872,fda-approves-hetlioz?-tasimelteon-for-the-treatment-of-nighttime-sleep-disturbances-in-smith-magenis-syndrome,01-12-2020 00:00,,,,,,
3873,merck-announces-us-fda-approval-of-verquvo?-vericiguat,21-01-2021 00:00,,,,,,
3874,haemonetics-to-acquire-cardiva-medical-inc-to-expand-hospital-portfolio,21-01-2021 00:00,,,,,,
3875,qiagen-confirms-effectiveness-of-its-sars-cov-2-pcr-tests-in-the-face-of-mutations-of-the-coronavirus,21-01-2021 00:00,,,,,,
3876,fda-grants-priority-review-to-roche?s-esbriet-pirfenidone-for-unclassifiable-interstitial-lung-disease,21-01-2021 00:00,,,,,,
3877,novo-nordisk-files-for-regulatory-approval-in-the-us-of-once-weekly-semaglutide-20-mg-for-the-treatment-of-type-2-diabetes,21-01-2021 00:00,,,,,,
3878,fda-approves-first-psma-targeted-pet-imaging-drug-for-men-with-prostate-cancer,01-12-2020 00:00,,,,,,
3879,boston-scientific-announces-agreement-to-acquire-preventice-solutions-inc,22-01-2021 00:00,,,,,,
3880,servier-and-mina-therapeutics-enter-collaboration-in-neurological-diseases,22-01-2021 00:00,,,,,,
3881,lilly?s-neutralizing-antibody-bamlanivimab-ly-cov555-prevented-covid-19-at-nursing-homes-in-the-blaze-2-trial-reducing-risk-by-up-to-80-percent-for-residents,22-01-2021 00:00,,,,,,
3882,viiv-healthcare-announces-fda-approval-of-cabenuva-cabotegravir-rilpivirine-the-first-and-only-complete-long-acting-regimen-for-hiv-treatment,22-01-2021 00:00,,,,,,
3883,mitsubishi-tanabe-pharma-america-and-aquestive-therapeutics-announce-us-licensing-and-supply-deal-for-riluzole-oral-film-for-als-treatment,22-01-2021 00:00,,,,,,
3884,manufacturing-and-marketing-approval-received-in-japan-for-alunbrig?-in-the-treatment-of-alk-fusion-gene-positive-unresectable-advanced-or-recurrent-non-small-cell-lung-cancer,22-01-2021 00:00,,,,,,
3885,exelixis-announces-us-fda-approval-of-cabometyx?-cabozantinib-in-combination-with-opdivo?-nivolumab-as-a-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma,25-01-2021 00:00,,,,,,
3886,pg-partners-with-rhinostics-to-take-innovative-nasal-swab-to-market-to-improve-speed-of-covid-19-testing,25-01-2021 00:00,,,,,,
3887,fda-approves-aurinia-pharmaceuticals?-lupkynis?-voclosporin-for-adult-patients-with-active-lupus-nephritis,25-01-2021 00:00,,,,,,
3888,pfizer-and-biontech-reach-agreement-with-covax-for-advance-purchase-of-vaccine-to-help-combat-covid-19,25-01-2021 00:00,,,,,,
3889,incyte-announces-acceptance-and-priority-review-of-bla-for-retifanlimab-as-a-potential-treatment-for-patients-with-squamous-cell-carcinoma-of-the-anal-canal-scac,25-01-2021 00:00,,,,,,
3890,ervaxx-and-cardiff-university-enter-collaboration-to-develop-novel-t-cell-and-t-cell-receptor-based-immunotherapeutics-targeting-dark-antigens,25-01-2021 00:00,,,,,,
3891,european-commission-approves-keytruda?-pembrolizumab-as-first-line-treatment-in-adult-patients-with-metastatic-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer,27-01-2021 00:00,,,,,,
3892,abcellera-discovered-antibody-bamlanivimab-administered-with-etesevimab-reduced-risk-of-covid-19-hospitalizations-and-death-by-70,27-01-2021 00:00,,,,,,
3893,shionogi-and-bioage-conclude-a-license-agreement-aimed-at-treating-covid-19,27-01-2021 00:00,,,,,,
3894,regeneron-reports-positive-interim-data-with-regen-cov?-antibody-cocktail-used-as-passive-vaccine-to-prevent-covid-19,27-01-2021 00:00,,,,,,
3895,european-commission-approves-abbvie?s-rinvoq?-upadacitinib-for-the-treatment-of-psoriatic-arthritis-and-ankylosing-spondylitis,27-01-2021 00:00,,,,,,
3896,abbott?s-panbio-rapid-antigen-test-receives-ce-mark-for-asymptomatic-screening-and-self-administered-sample-collection-with-nasal-swab,27-01-2021 00:00,,,,,,
3897,lilly-vir-biotechnology-and-gsk-announce-first-patient-dosed-in-expanded-blaze-4-trial-evaluating-bamlanivimab-ly-cov555-with-vir-7831-gsk4182136-for-covid-19,28-01-2021 00:00,,,,,,
3898,innovent-announces-the-nmpa-granted-new-indication-approval-for-byvasda?-bevacizumab-biosimilar-for-the-treatment-of-adult-recurrent-glioblastoma,21-12-2020 00:00,,,,,,
3899,amcp-partnership-forum-develops-innovative-strategies-that-support-the-use-and-development-of-biosimilars-in-the-us-health-care-system,21-12-2020 00:00,,,,,,
3900,benevolentai-and-astrazeneca-achieve-collaboration-milestone-with-novel-ai-generated-chronic-kidney-disease-target,28-01-2021 00:00,,,,,,
3901,pfizer-shares-co-primary-endpoint-results-from-post-marketing-required-safety-study-of-xeljanz?-tofacitinib-in-subjects-with-rheumatoid-arthritis-ra,28-01-2021 00:00,,,,,,
3902,regen-cov?-antibody-cocktail-is-active-against-sars-cov-2-variants-first-identified-in-the-uk-and-south-africa,28-01-2021 00:00,,,,,,
3903,imaginab-and-neuvogen-announce-licensing-agreement-for-cd8-immunopet-technology,28-01-2021 00:00,,,,,,
3904,bioinvent-phase-iiia-data-suggest-bi-1206-restores-activity-of-rituximab-in-relapsed-non-hodgkin?s-lymphoma-patients,28-01-2021 00:00,,,,,,
3905,bio-thera-solutions-partners-with-biomm-to-market-bat1706-in-brazil,17-12-2020 00:00,,,,,,
3906,celltrion-gets-eu-chmp-positive-opinion-for-biosimilar-adalimumab-ct-p17,11-12-2020 00:00,,,,,,
3907,henlius-adalimumab-biosimilar-?-approved-by-nmpa,07-12-2020 00:00,,,,,,
3908,artiva-biotherapeutics-announces-exclusive-worldwide-collaboration-and-license-agreement-with-merck-to-develop-candidate-car-nk-cell-therapies,29-01-2021 00:00,,,,,,
3909,amgen?s-investigational-kras-g12c-inhibitor-sotorasib-demonstrated-rapid-deep-and-durable-responses-in-previously-treated-patients-with-advanced-non-small-cell-lung-cancer,29-01-2021 00:00,,,,,,
3910,bio-thera-solutions-announces-fda-accepts-biologics-license-application-for-bat1706-a-proposed-biosimilar-to-avastin,29-01-2021 00:00,,,,,,
3911,lilly-and-asahi-kasei-pharma-announce-license-agreement-for-chronic-pain-drug-candidate,29-01-2021 00:00,,,,,,
3912,new-amivantamab-data-from-chrysalis-study-show-robust-clinical-activity-and-durable-responses-in-patients-with-metastatic-or-unresectable-non-small-cell-lung-cancer-and-egfr-exon-20-insertion-mutations,29-01-2021 00:00,,,,,,
3913,cambridge-quantum-to-develop-quantum-algorithms-with-roche-for-drug-discovery-development,29-01-2021 00:00,,,,,,
3914,merck-presents-results-from-head-to-head-phase-3-keynote-598-trial-evaluating-keytruda?-pembrolizumab-in-combination-with-ipilimumab-versus-keytruda-monotherapy-in-certain-patients-with-metastatic-non-small-cell-lung-cancer,01-02-2021 00:00,,,,,,
3915,novo-nordisk-receives-positive-opinion-from-the-european-regulatory-authorities-for-once-weekly-sogroya?-somapacitan-for-the-treatment-of-adult-growth-hormone-deficiency,01-02-2021 00:00,,,,,,
3916,amgen-announces-breakthrough-therapy-designation-granted-for-sotorasib-in-china,01-02-2021 00:00,,,,,,
3917,johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial,01-02-2021 00:00,,,,,,
3918,phase-1-drug-candidate-glr2007-developed-by-gan-lee-has-been-granted-fast-track-designation-by-the-us-fda,01-02-2021 00:00,,,,,,
3919,incyte-announces-positive-chmp-opinion-for-pemigatinib-for-the-treatment-of-adults-with-previously-treated-unresectable-locally-advanced-or-metastatic-cholangiocarcinoma-with-a-fibroblast-growth-factor-receptor-2-fgfr2-fusion-or-rearrangement,01-02-2021 00:00,,,,,,
3920,horizon-therapeutics-plc-to-acquire-viela-bio-inc-to-significantly-expand-development-pipeline-and-grow-rare-disease-medicine-portfolio,02-02-2021 00:00,,,,,,
3921,gilead-sciences-and-gritstone-announce-collaboration-utilizing-gritstone?s-vaccine-platform-technology-for-hiv-cure,02-02-2021 00:00,,,,,,
3922,janssen-announces-car-t-therapy-ciltacabtagene-autoleucel-cilta-cel-accepted-for-accelerated-assessment-in-europe-for-the-treatment-of-patients-with-heavily-pretreated-multiple-myeloma,02-02-2021 00:00,,,,,,
3923,medtronic-receives-fda-approval-of-diamondtemp-ablation-system-for-the-treatment-of-patients-with-atrial-fibrillation,02-02-2021 00:00,,,,,,
3924,clover-and-dynavax-announce-planned-global-phase-23-efficacy-trial-of-adjuvanted-covid-19-vaccine-candidate,02-02-2021 00:00,,,,,,
3925,celltrion-healthcare-receives-health-canada-marketing-authorization-for-world?s-first-subcutaneous-formulation-of-infliximab-remsima?-sc-for-the-treatment-of-people-with-rheumatoid-arthritis,02-02-2021 00:00,,,,,,
3926,bristol-myers-squibb-announces-positive-topline-results-from-second-pivotal-phase-3-psoriasis-study-showing-superiority-of-deucravacitinib-compared-to-placebo-and-otezla?-apremilast,03-02-2021 00:00,,,,,,
3927,x-chem-enters-into-multitarget-oncology-discovery-research-collaboration-and-license-agreement-with-genentech,03-02-2021 00:00,,,,,,
3928,innovent-and-lilly-jointly-announce-the-approval-of-tyvyt?-sintilimab-injection-by-china-nmpa-in-combination-with-pemetrexed-and-platinum-chemotherapy-as-first-line-therapy-for-nonsquamous-non-small-cell-lung-cancer,03-02-2021 00:00,,,,,,
3929,gsk-and-curevac-to-develop-next-generation-mrna-covid-19-vaccines,03-02-2021 00:00,,,,,,
3930,russia?s-sputnik-v-vaccine-92-effective-in-fighting-covid-19,03-02-2021 00:00,,,,,,
3931,covaxx-announces-initiation-of-phase-2-clinical-trials-in-taiwan-of-ub-612-vaccine-candidate-against-covid-19,03-02-2021 00:00,,,,,,
3932,jazz-pharmaceuticals-to-acquire-gw-pharmaceuticals-plc-creating-an-innovative-high-growth-global-biopharma-leader,04-02-2021 00:00,,,,,,
3933,alymsys,28-01-2021 00:00,,,,,,
3934,innovent-announces-nmpa-acceptance-of-a-supplemental-new-drug-application-for-tyvyt?-sintilimab-injection-in-combination-with-byvasda?-bevacizumab-injection-as-first-line-therapy-in-hepatocellular-carcinoma-hcc,13-01-2021 00:00,,,,,,
3935,fda-approves-tepmetko?-as-the-first-and-only-once-daily-oral-met-inhibitor-for-patients-with-metastatic-nsclc-with-metex14-skipping-alterations,04-02-2021 00:00,,,,,,
3936,imcyse-enters-into-research-collaboration-and-license-agreement-for-its-imotopetm-technology-with-pfizer-in-rheumatoid-arthritis,04-02-2021 00:00,,,,,,
3937,henlius-bevacizumab-has-received-clinical-trial-approval-in-australia,29-01-2021 00:00,,,,,,
3938,thermo-fisher-scientific-and-jw-therapeutics-announce-car-t-partnership-in-china,04-02-2021 00:00,,,,,,
3939,herthena-lung01-phase-2-study-of-daiichi-sankyo?s-patritumab-deruxtecan-initiated-in-patients-with-egfr-mutated-nsclc,04-02-2021 00:00,,,,,,
3940,astellas?-xospata?-gilteritinib-receives-conditional-approval-by-china?s-national-medical-products-administration-for-relapsed-or-refractory-acute-myeloid-leukemia-with-a-flt3-mutation,04-02-2021 00:00,,,,,,
3941,forxiga-approved-in-china-for-heart-failure,05-02-2021 00:00,,,,,,
3942,biocon-biologics-to-offer-its-oncology-biosimilars-through-cancer-access-partnership-in-over-30-countries,05-02-2021 00:00,,,,,,
3943,23andme-to-merge-with-virgin-group?s-vg-acquisition-corp-to-become-publicly-traded-company-set-to-revolutionize-personalized-healthcare-and-therapeutic-development-through-human-genetics,05-02-2021 00:00,,,,,,
3944,johnson-johnson-announces-submission-of-application-to-the-us-fda-for-emergency-use-authorization-of-its-investigational-single-shot-janssen-covid-19-vaccine-candidate,05-02-2021 00:00,,,,,,
3945,enzene-biosciences-ltd-obtains-marketing-authorization-for-its-first-biosimilar-molecule-in-india,05-02-2021 00:00,,,,,,
3946,positive-phase-2-results-for-reistone?s-jak-inhibitor-demonstrate-significant-improvement-in-patients-with-moderate-to-severe-ulcerative-colitis,05-02-2021 00:00,,,,,,
3947,fda-approves-new-treatment-for-adults-with-relapsed-or-refractory-large-b-cell-lymphoma,08-02-2021 00:00,,,,,,
3948,daiichi-sankyo-enters-into-outsourcing-agreement-to-manufacture-astrazeneca-covid-19-vaccine-in-japan,08-02-2021 00:00,,,,,,
3949,fda-grants-breakthrough-device-designation-for-roche?s-elecsys-growth-differentiation-factor-15-gdf-15-assay-to-help-identify-patients-suitable-for-innovative-treatment-addressing-unintentional-weight-loss-in-cancer-patients,08-02-2021 00:00,,,,,,
3950,curevac-and-uk-government-to-collaborate-on-development-of-vaccines-against-sars-cov-2-variants,08-02-2021 00:00,,,,,,
3951,update-on-kestrel-phase-iii-trial-of-imfinzi-with-or-without-tremelimumab-in-the-1st-line-treatment-of-recurrent-or-metastatic-head-and-neck-cancer,08-02-2021 00:00,,,,,,
3952,celltrion?s-covid-19-treatment-candidate-receives-korean-mfds-conditional-marketing-authorisation,08-02-2021 00:00,,,,,,
3953,viiv-healthcare-receives-marketing-authorisation-for-rukobia-fostemsavir-a-first-in-class-attachment-inhibitor-in-combination-with-other-antiretrovirals-for-the-treatment-of-adults-with-multidrug-resistant-hiv,09-02-2021 00:00,,,,,,
3954,hologic-and-google-cloud-announce-collaboration-to-advance-next-generation-digital-diagnostic-capabilities,09-02-2021 00:00,,,,,,
3955,signifier-medical-ushers-in-new-era-of-treatment-for-sleep-apnea-and-snoring-with-fda-approval-of-exciteosa-device,09-02-2021 00:00,,,,,,
3956,bristol-myers-squibb-receives-european-commission-approval-for-inrebic?-fedratinib-for-adult-patients-with-newly-diagnosed-and-previously-treated-myelofibrosis,09-02-2021 00:00,,,,,,
3957,medidata-launches-sensor-cloud-ushering-in-next-generation-solution-for-connected-devices-and-wearable-sensors-in-clinical-trials,09-02-2021 00:00,,,,,,
3958,opdivo?-nivolumab-in-combination-with-cabometyx?-cabozantinib-shows-sustained-survival-and-response-rate-benefits-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-in-the-phase-3-checkmate-9er-trial,09-02-2021 00:00,,,,,,
3959,lee?s-pharmaceutical-announces-its-anti-pd-l1-antibody-socazolimab-licensed-from-sorrento-therapeutics-receives-breakthrough-therapy-designation-in-china-for-the-treatment-of-recurrent-or-metastatic-cervical-cancer,10-02-2021 00:00,,,,,,
3960,fda-approves-libtayo?-cemiplimab-rwlc-as-first-immunotherapy-indicated-for-patients-with-advanced-basal-cell-carcinoma,10-02-2021 00:00,,,,,,
3961,abcellera-discovered-antibody-bamlanivimab-administered-with-etesevimab-receives-fda-emergency-use-authorization-for-covid-19,10-02-2021 00:00,,,,,,
3962,lannett-expands-strategic-relationship-to-include-biosimilar-fast-acting-insulin,10-02-2021 00:00,,,,,,
3963,european-commission-grants-vico-therapeutics-orphan-drug-designation-for-vo659-an-investigational-therapy-for-spinocerebellar-ataxia,10-02-2021 00:00,,,,,,
3964,lonza-signs-agreement-to-divest-specialty-ingredients-business-to-bain-capital-and-cinven,10-02-2021 00:00,,,,,,
3965,kaia-health-unveils-complete-musculoskeletal-care-solution-with-kaia-gateway-and-premium-partners,11-02-2021 00:00,,,,,,
3966,galapagos-and-gilead-discontinue-isabela-phase-3-trials-in-ipf,11-02-2021 00:00,,,,,,
3967,abbvie-and-caribou-biosciences-announce-collaboration-and-license-agreement-for-car-t-cell-products,11-02-2021 00:00,,,,,,
3968,i2o-therapeutics-announces-research-collaboration-with-sanofi-to-enable-oral-delivery-of-nanobody-based-medicines,11-02-2021 00:00,,,,,,
3969,astrazeneca-and-idt-biologika-sign-letter-of-intent-to-increase-covid-19-vaccine-manufacturing-in-europe-and-secure-long-term-supply-capacity,11-02-2021 00:00,,,,,,
3970,evotec-and-related-sciences-enter-integrated-drug-discovery-and-development-partnership,11-02-2021 00:00,,,,,,
3971,molecular-templates-establishes-multi-target-collaboration-with-bristol-myers-squibb-for-the-discovery-and-development-of-next-generation-engineered-toxin-bodies-for-the-treatment-of-cancer,12-02-2021 00:00,,,,,,
3972,sandoz-announces-agreement-to-acquire-gsk?s-cephalosporin-antibiotics-business-reinforcing-its-leading-global-position-in-antibiotics,12-02-2021 00:00,,,,,,
3973,fda-approves-first-in-class-evkeeza?-evinacumab-dgnb-for-patients-with-ultra-rare-inherited-form-of-high-cholesterol,12-02-2021 00:00,,,,,,
3974,new-phase-iii-data-show-roche?s-faricimab-is-the-first-investigational-injectable-eye-medicine-to-extend-time-between-treatments-up-to-four-months-in-two-leading-causes-of-vision-loss-potentially-reducing-treatment-burden-for-patients,12-02-2021 00:00,,,,,,
3975,ensoma-launches-to-pioneer-next-generation-in-vivo-approach-to-deliver-first-?off-the-shelf?-genomic-medicines,12-02-2021 00:00,,,,,,
3976,visby-medical?s-covid-19-pcr-point-of-care-test-authorized-for-use-in-clia-waived-settings,12-02-2021 00:00,,,,,,
3977,fda-approves-g1-therapeutics?-cosela?-trilaciclib-the-first-and-only-myeloprotection-therapy-to-decrease-the-incidence-of-chemotherapy-induced-myelosuppression,15-02-2021 00:00,,,,,,
3978,takeda?s-maribavir-phase-3-clinical-trial-met-primary-endpoint-of-superiority-to-conventional-antiviral-therapy-in-transplant-recipients-with-refractory-with-or-without-resistance-cytomegalovirus-infectiondisease,15-02-2021 00:00,,,,,,
3979,us-fda-approves-panzyga?-for-the-treatment-of-adults-with-chronic-inflammatory-demyelinating-polyneuropathy-cidp,15-02-2021 00:00,,,,,,
3980,keytruda?-pembrolizumab-plus-lenvima?-lenvatinib-demonstrated-superior-progression-free-survival-pfs-and-overall-survival-os-versus-sunitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma,15-02-2021 00:00,,,,,,
3981,biocon-biologics-and-viatris-receive-european-commission-approval-for-kixelle-biosimilar-insulin-aspart,15-02-2021 00:00,,,,,,
3982,roche-receives-first-fda-clearance-for-urine-sample-type-for-bk-virus-quantitative-test-to-aid-in-the-improvement-of-care-for-transplant-patients,15-02-2021 00:00,,,,,,
3983,exelixis-highlights-positive-results-for-cabometyx?-cabozantinib-in-patients-with-metastatic-papillary-renal-cell-carcinoma-in-swog-s1500papmet-study-at-asco-gu,16-02-2021 00:00,,,,,,
3984,celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17,16-02-2021 00:00,,,,,,
3985,targovax-receives-fast-track-designation-for-oncos-102,16-02-2021 00:00,,,,,,
3986,astrazeneca-covid-19-vaccine-authorised-for-emergency-use-by-the-world-health-organization,16-02-2021 00:00,,,,,,
3987,aker-biomarine-enters-into-research-collaboration-for-alzheimer?s,16-02-2021 00:00,,,,,,
3988,onward-therapeutics-and-biomunex-pharmaceuticals-enter-into-a-worldwide-exclusive-license-and-co-development-agreement-to-a-bispecific-antibody-for-immuno-oncology,16-02-2021 00:00,,,,,,
3989,guardant-health-launches-guardant-reveal?-liquid-biopsy-test-for-residual-disease-and-recurrence-monitoring-in-patients-with-early-stage-colorectal-cancer,17-02-2021 00:00,,,,,,
3990,health-canada-approves-reblozyl?-luspatercept-new-class-of-treatment-for-adult-patients-living-with-myelodysplastic-syndromes,17-02-2021 00:00,,,,,,
3991,novartis-data-show-multiple-sclerosis-patients-and-nurses-prefer-kesimpta?-ofatumumab-sensoready?-autoinjector-pen,17-02-2021 00:00,,,,,,
3992,gsk-starts-phase-iii-rsv-candidate-vaccine-programme-for-older-adults,17-02-2021 00:00,,,,,,
3993,novartis-entresto?-granted-expanded-indication-in-chronic-heart-failure-by-fda,17-02-2021 00:00,,,,,,
3994,boehringer-ingelheim-animal-health-usa-establishes-pawru-inc,17-02-2021 00:00,,,,,,
3995,boehringer-ingelheim-animal-health-usa-establishes-pawru-inc,18-02-2021 00:00,,,,,,
3996,tirzepatide-significantly-reduced-a1c-and-body-weight-in-people-with-type-2-diabetes-in-two-phase-3-trials-from-lilly?s-surpass-program,18-02-2021 00:00,,,,,,
3997,novartis-and-the-bill-melinda-gates-foundation-collaborate-to-discover-and-develop-an-accessible-in-vivo-gene-therapy-for-sickle-cell-disease,18-02-2021 00:00,,,,,,
3998,gsk-and-vir-biotechnology-expand-coronavirus-collaboration-to-advance-new-therapeutics-for-influenza-and-other-respiratory-viruses,18-02-2021 00:00,,,,,,
3999,myovant-sciences-and-pfizer-announce-publication-in-the-new-england-journal-of-medicine-of-phase-3-liberty-studies-of-once-daily-relugolix-combination-therapy-in-women-with-uterine-fibroids,18-02-2021 00:00,,,,,,
4000,beigene-announces-us-fda-acceptance-of-supplemental-new-drug-application-for-brukinsa-zanubrutinib-in-waldenstr?m?s-macroglobulinemia,18-02-2021 00:00,,,,,,
4001,fda-approves-first-extended-release-injectable-drug-regimen-for-adults-living-with-hiv,22-01-2021 00:00,,,,,,
4002,lilly-and-rigel-enter-strategic-collaboration-to-develop-ripk1-inhibitors-for-the-potential-treatment-of-immunological-and-neurodegenerative-diseases,19-02-2021 00:00,,,,,,
4003,fresenius-kabi-canada-launches-idacio?-adalimumab-injection-a-biosimilar-to-humira?-adalimumab-for-the-treatment-of-multiple-chronic-inflammatory-conditions,19-02-2021 00:00,,,,,,
4004,positive-data-from-psoaring-3-support-long-term-use-of-tapinarof-cream-in-adults-with-plaque-psoriasis-with-durable-on-therapy-and-remittive-off-therapy-benefits,19-02-2021 00:00,,,,,,
4005,fda-approves-first-in-the-world-first-of-its-kind-implant-for-the-treatment-of-rare-bone-disease-as-a-humanitarian-use-device,19-02-2021 00:00,,,,,,
4006,astellas-and-seagen-announce-submission-of-two-supplemental-biologics-license-applications-to-the-us-fda-for-padcev?-enfortumab-vedotin-ejfv-in-locally-advanced-or-metastatic-urothelial-cancer,19-02-2021 00:00,,,,,,
4007,redhill-biopharma-strengthens-partnership-with-cosmo-pharmaceuticals-with-manufacturing-agreements-for-movantik-and-rhb-204,19-02-2021 00:00,,,,,,
4008,chugai-in-licenses-new-oral-drug-candidate-for-covid-19-from-roche,22-02-2021 00:00,,,,,,
4009,immunocore?s-tebentafusp-granted-breakthrough-therapy-designation-for-unresectable-or-metastatic-uveal-melanoma-from-fda,22-02-2021 00:00,,,,,,
4010,astellas-announces-positive-topline-results-from-two-phase-3-pivotal-global-trials-of-fezolinetant-for-the-nonhormonal-treatment-of-vasomotor-symptoms-in-postmenopausal-women,22-02-2021 00:00,,,,,,
4011,incyte-announces-acceptance-and-priority-review-of-nda-for-ruxolitinib-cream-for-atopic-dermatitis,22-02-2021 00:00,,,,,,
4012,voluntary-withdrawal-of-imfinzi-indication-in-advanced-bladder-cancer-in-the-us,22-02-2021 00:00,,,,,,
4013,sanofi-and-gsk-initiate-new-phase-2-study-of-their-adjuvanted-recombinant-protein-based-covid-19-vaccine-candidate,22-02-2021 00:00,,,,,,
4014,fda-approves-libtayo?-cemiplimab-rwlc-monotherapy-for-patients-with-first-line-advanced-non-small-cell-lung-cancer-with-pd-l1-expression-of-50,23-02-2021 00:00,,,,,,
4015,second-phase-3-induction-study-confirms-upadacitinib-rinvoq?-improved-clinical-endoscopic-and-histologic-outcomes-in-ulcerative-colitis-patients,23-02-2021 00:00,,,,,,
4016,incyte-announces-acceptance-and-priority-review-of-snda-for-jakafi?-ruxolitinib-as-a-treatment-for-patients-with-chronic-graft-versus-host-disease,23-02-2021 00:00,,,,,,
4017,compugen-expands-clinical-collaboration-agreement-with-bristol-myers-squibb-with-phase-1b-combination-study-of-com701-with-opdivo,23-02-2021 00:00,,,,,,
4018,amgen-submits-supplemental-new-drug-application-for-otezla?-apremilast-for-adults-with-mild-to-moderate-plaque-psoriasis,23-02-2021 00:00,,,,,,
4019,matrisys-announces-positive-results-from-a-phase-i-study-of-msb-0221-for-the-topical-treatment-of-atopic-dermatitis,23-02-2021 00:00,,,,,,
4020,graviton-enters-into-global-licensing-agreement-for-rock2-inhibitor-from-beijing-tide,24-02-2021 00:00,,,,,,
4021,health-canada-approves-dupixent?-dupilumab-injection-as-the-first-biologic-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-in-children-aged-6-to-11-years,24-02-2021 00:00,,,,,,
4022,day-one-expands-clinical-stage-oncology-pipeline-announces-global-license-agreement-with-merck-kgaa-darmstadt-germany-to-develop-and-commercialize-mek-inhibitor-pimasertib,24-02-2021 00:00,,,,,,
4023,us-fda-accepts-for-priority-review-pfizer?s-application-for-ticovac?-tick-borne-encephalitis-vaccine,24-02-2021 00:00,,,,,,
4024,takeda-provides-updates-on-phase-12-clinical-trials-of-novavax?-and-moderna?s-covid-19-vaccine-candidates-in-japan,24-02-2021 00:00,,,,,,
4025,bio-techne-and-luminary-therapeutics-sign-license-agreement-for-use-of-bio-techne?s-tcbuster?-for-the-development-of-luminary?s-car-t-cell-therapies,24-02-2021 00:00,,,,,,
4026,ucb-and-microsoft-expand-collaboration-to-accelerate-drug-discovery-and-development,25-02-2021 00:00,,,,,,
4027,sirion-biotech-announces-collaboration-with-sanofi-to-innovate-gene-therapy-treatments-with-improved-adeno-associated-virus-capsids,25-02-2021 00:00,,,,,,
4028,roche-announces-results-from-evrysdi-risdiplam-study-in-infants-with-type-1-spinal-muscular-atrophy-sma-published-in-new-england-journal-of-medicine,25-02-2021 00:00,,,,,,
4029,humira?-adalimumab-receives-fda-approval-to-treat-pediatric-patients-living-with-moderately-to-severely-active-ulcerative-colitis,25-02-2021 00:00,,,,,,
4030,inovio-and-qiagen-expand-collaboration-to-develop-next-generation-sequencing-ngs-companion-diagnostic-for-inovio?s-vgx-3100-for-advanced-cervical-dysplasia,25-02-2021 00:00,,,,,,
4031,intra-cellular-therapies-announces-expansion-of-its-pipeline-with-the-introduction-of-a-new-molecular-entity-iti-1284,25-02-2021 00:00,,,,,,
4032,merck-to-acquire-pandion-therapeutics,26-02-2021 00:00,,,,,,
4033,otsuka-and-click-therapeutics-initiate-first-of-its-kind-fully-remote-clinical-trial-using-digital-therapeutics-as-adjunctive-therapy-in-adults-with-major-depressive-disorder,26-02-2021 00:00,,,,,,
4034,gsk-announces-results-evaluating-its-investigational-monoclonal-antibody-otilimab-for-the-treatment-of-hospitalised-adult-patients-with-covid-19,26-02-2021 00:00,,,,,,
4035,welldoc-and-lilly-collaborate-to-integrate-bluestar?-app-capabilities-into-lilly?s-connected-insulin-solutions,26-02-2021 00:00,,,,,,
4036,daiichi-sankyo-and-lysa-lysarc-calym-enter-research-collaboration-for-valemetostat-in-patients-with-relapsedrefractory-b-cell-lymphoma,26-02-2021 00:00,,,,,,
4037,independent-data-monitoring-committee-finds-clear-efficacy-for-regen-cov?-casirivimab-with-imdevimab-in-phase-3-covid-19-outpatient-outcomes-trial,26-02-2021 00:00,,,,,,
4038,bridgebio-pharma-and-affiliate-origin-biosciences-announce-fda-approval-of-nulibry?-fosdenopterin-the-first-and-only-approved-therapy-to-reduce-the-risk-of-mortality-in-patients-with-mocd-type-a,01-03-2021 00:00,,,,,,
4039,roivant-grows-computational-drug-discovery-engine-with-acquisition-of-silicon-therapeutics,01-03-2021 00:00,,,,,,
4040,tezepelumab-is-the-first-biologic-to-significantly-reduce-exacerbations-in-broad-population-of-patients-with-severe-uncontrolled-asthma,01-03-2021 00:00,,,,,,
4041,johnson-johnson-covid-19-vaccine-authorized-by-us-fda-for-emergency-use,01-03-2021 00:00,,,,,,
4042,ema-issues-advice-on-regeneron?s-antibody-cocktail-casirivimab-with-imdevimab-for-certain-covid-19-patients,01-03-2021 00:00,,,,,,
4043,bristol-myers-squibb-receives-positive-chmp-opinion-for-opdivo?-nivolumab-in-combination-with-cabometyx?-cabozantinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma,01-03-2021 00:00,,,,,,
4044,merck-kgaa-darmstadt-germany-builds-on-leadership-in-head-and-neck-cancer-through-worldwide-licensing-agreement-with-debiopharm-for-pivotal-stage-xevinapant,02-03-2021 00:00,,,,,,
4045,us-fda-accepts-merck?s-gefapixant-new-drug-application-for-review,02-03-2021 00:00,,,,,,
4046,samsung-bioepis-initiates-phase-1-clinical-trial-for-sb17-proposed-biosimilar-to-stelara-ustekinumab,02-03-2021 00:00,,,,,,
4047,hologic-acquires-european-molecular-diagnostic-company-diagenode-for-approximately-159-million,02-03-2021 00:00,,,,,,
4048,regarding-the-nda-filing-for-ylb217-a-biosimilar-product-of-long-acting-erythropoiesis-stimulating-agent-nesp?,02-02-2021 00:00,,,,,,
4049,junshi-biosciences-and-astrazeneca-announce-strategic-collaboration-to-commercialize-toripalimab-in-china,02-03-2021 00:00,,,,,,
4050,veru-receives-fda-agreement-to-advance-veru-111-into-phase-3-study-in-hospitalized-covid-19-patients-at-high-risk-for-acute-respiratory-distress-syndrome-ards,02-03-2021 00:00,,,,,,
4051,fujifilm-kyowa-kirin-biologics-and-mylan-epd-announce-launch-of-?adalimumab-genetical-recombination-adalimumab-biosimilar-1?-in-japan,15-02-2021 00:00,,,,,,
4052,sandoz-canada-completes-its-5th-biosimilar-launch-with-new-biosimilar-hyrimoz?-adalimumab,16-02-2021 00:00,,,,,,
4053,mitokinin-inc-enters-into-purchase-right-agreement-with-abbvie,03-03-2021 00:00,,,,,,
4054,viatris-launches-hulio?-adalimumab-biosimilar-in-canada,18-02-2021 00:00,,,,,,
4055,biocon-biologics-and-viatris-inc-receive-chmp-nod-for-abevmy?-a-biosimilar-to-avastin?-bevacizumab,03-03-2021 00:00,,,,,,
4056,positive-top-line-efficacy-and-safety-data-from-global-phase-iii-clinical-trial-of-tanvex-trastuzumab-biosimilar-candidate-tx05,20-02-2021 00:00,,,,,,
4057,celltrion-kicks-off-global-phase-3-trial-of-eylea-biosimilar,08-02-2021 00:00,,,,,,
4058,g1-therapeutics-and-boehringer-ingelheim-announce-commercial-availability-of-cosela?-trilaciclib-the-only-fda-approved-multilineage-myeloprotection-therapy-to-decrease-the-incidence-of-chemotherapy-induced-myelosuppression,03-03-2021 00:00,,,,,,
4059,fusion-pharmaceuticals-to-expand-pipeline-with-acquisition-of-ipn-1087-a-small-molecule-targeting-ntsr1-from-ipsen,03-03-2021 00:00,,,,,,
4060,health-canada-approves-brukinsa?-zanubrutinib-for-the-treatment-of-waldenstr?m?s-macroglobulinemia,03-03-2021 00:00,,,,,,
4061,blincyto?-blinatumomab-demonstrated-significantly-prolonged-event-free-survival-compared-with-consolidation-chemotherapy-in-pediatric-patients-with-relapsed-acute-lymphoblastic-leukemia,03-03-2021 00:00,,,,,,
4062,boston-scientific-announces-agreement-to-acquire-lumenis-ltd-surgical-business-from-baring-private-equity-asia,04-03-2021 00:00,,,,,,
4063,takeda-secures-global-rights-from-ovid-therapeutics-to-develop-and-commercialize-soticlestat-for-the-treatment-of-children-and-adults-with-dravet-syndrome-and-lennox-gastaut-syndrome,04-03-2021 00:00,,,,,,
4064,us-fda-expands-approval-of-pfizer?s-lorbrena?-as-first-line-treatment-for-alk-positive-metastatic-lung-cancer,04-03-2021 00:00,,,,,,
4065,fda-accepts-dupixent?-dupilumab-for-review-in-children-with-moderate-to-severe-asthma,04-03-2021 00:00,,,,,,
4066,tempest-therapeutics-announces-clinical-collaboration-with-roche-to-advance-tpst-1120-into-a-randomized-combination-study-in-first-line-hepatocellular-carcinoma,04-03-2021 00:00,,,,,,
4067,vir-biotechnology-and-gsk-provide-update-on-nih-sponsored-activ-3-trial-evaluating-vir-7831-in-hospitalized-adults-with-covid-19,04-03-2021 00:00,,,,,,
4068,amgen-to-acquire-five-prime-therapeutics-for-19-billion-in-cash,05-03-2021 00:00,,,,,,
4069,tirzepatide-achieved-superior-a1c-and-body-weight-reductions-across-all-three-doses-compared-to-injectable-semaglutide-in-adults-with-type-2-diabetes,05-03-2021 00:00,,,,,,
4070,agilent-to-acquire-resolution-bioscience-strengthening-leadership-position-in-cancer-diagnostics,05-03-2021 00:00,,,,,,
4071,roche?s-actemraroactemra-becomes-the-first-biologic-therapy-approved-by-the-fda-for-slowing-the-rate-of-decline-in-pulmonary-function-in-adults-with-systemic-sclerosis-associated-interstitial-lung-disease-a-rare-debilitating-condition,05-03-2021 00:00,,,,,,
4072,moderna-announces-new-drug-application-submitted-to-import-and-distribute-moderna?s-covid-19-vaccine-candidate-in-japan,05-03-2021 00:00,,,,,,
4073,baricitinib-is-first-jak-inhibitor-to-demonstrate-hair-regrowth-in-phase-3-alopecia-areata-aa-trial,05-03-2021 00:00,,,,,,
4074,viiv-healthcare-presents-data-for-long-acting-cabotegravir-and-rilpivirine-for-the-treatment-of-hiv-showing-continued-virologic-suppression-to-96-weeks,08-03-2021 00:00,,,,,,
4075,lee?s-pharmaceutical-announces-its-anti-pd-l1-antibody-socazolimab-licensed-from-sorrento-therapeutics-receives-clearance-to-start-phase-3-trial-as-a-first-line-treatment-of-extensive-stage-small-cell-lung-cancer,08-03-2021 00:00,,,,,,
4076,roche-provides-update-on-tecentriq-us-indication-in-prior-platinum-treated-metastatic-bladder-cancer,08-03-2021 00:00,,,,,,
4077,biktarvy?-demonstrates-high-efficacy-and-durable-viral-suppression-in-treatment-na?ve-adults-in-four-year-data-presented-at-croi,08-03-2021 00:00,,,,,,
4078,us-fda-approves-yescarta?-for-relapsed-or-refractory-follicular-lymphoma-after-two-or-more-lines-of-systemic-therapy,08-03-2021 00:00,,,,,,
4079,atea-pharmaceuticals-presents-favorable-phase-1-results-for-at-527-at-28th-annual-conference-on-retroviruses-and-opportunistic-infections,08-03-2021 00:00,,,,,,
4080,alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients,09-03-2021 00:00,,,,,,
4081,lilly-and-biolojic-design-announce-research-collaboration-to-discover-and-develop-antibody-therapies-for-diabetes,09-03-2021 00:00,,,,,,
4082,trinamix-gmbh-and-viavi-solutions-join-forces-to-bring-near-infrared-spectroscopy-into-smartphones,09-03-2021 00:00,,,,,,
4083,abbott-introduces-neurosphere?-virtual-clinic-first-of-its-kind-remote-neuromodulation-patient-care-technology-in-the-us,09-03-2021 00:00,,,,,,
4084,axsome-therapeutics-receives-fda-breakthrough-therapy-designation-for-axs-05-for-the-treatment-of-alzheimer?s-disease-agitation,26-06-2020 00:00,,,,,,
4085,roche-receives-fda-approval-for-ventana-alk-d5f3-cdx-assay-to-identify-lung-cancer-patients-eligible-for-targeted-treatment-with-lorbrena-lorlatinib,09-03-2021 00:00,,,,,,
4086,junshi-biosciences-receives-fda-breakthrough-therapy-designation-for-toripalimab-for-the-treatment-of-nasopharyngeal-carcinoma,10-09-2020 00:00,,,,,,
4087,novartis-investigational-oral-therapy-iptacopan-lnp023-receives-fda-breakthrough-therapy-designation-for-pnh-and-rare-pediatric-disease-designation-for-c3g,16-12-2020 00:00,,,,,,
4088,exelixis-enters-into-exclusive-license-agreement-with-wuxi-biologics-to-support-further-expansion-of-its-growing-oncology-biologics-pipeline,09-03-2021 00:00,,,,,,
4089,remegen-announces-us-fda-has-granted-breakthrough-therapy-designation-for-disitamab-vedotin-rc48-in-urothelial-cancer,25-09-2020 00:00,,,,,,
4090,zymeworks-receives-fda-breakthrough-therapy-designation-for-her2-targeted-bispecific-antibody-zanidatamab-in-patients-with-biliary-tract-cancer,30-11-2020 00:00,,,,,,
4091,the-food-and-drug-administration-fda-grants-io-biotech-breakthrough-therapy-designation-for-io102-and-io103-in-combination-with-anti-pd-1-in-unresectable-metastatic-melanoma,15-12-2020 00:00,,,,,,
4092,polypid-granted-breakthrough-therapy-designation-from-fda-for-d-plex100-for-the-prevention-of-surgical-site-infections-in-colorectal-surgery,24-11-2020 00:00,,,,,,
4093,immunogen-announces-fda-breakthrough-therapy-designation-for-imgn632-in-relapsed-or-refractory-blastic-plasmacytoid-dendritic-cell-neoplasm,05-10-2020 00:00,,,,,,
4094,takeda-to-acquire-maverick-therapeutics-to-advance-t-cell-engager-therapies-for-solid-tumors-and-expand-novel-immuno-oncology-portfolio,10-03-2021 00:00,,,,,,
4095,novartis-provides-update-on-phase-iii-study-evaluating-canakinumab-acz885-as-second-or-third-line-treatment-in-combination-with-chemotherapy-in-non-small-cell-lung-cancer,10-03-2021 00:00,,,,,,
4096,viiv-healthcare-presents-positive-proof-of-concept-findings-for-gsk3640254-a-novel-investigational-maturation-inhibitor-for-the-treatment-of-hiv,10-03-2021 00:00,,,,,,
4097,avelas-receives-fda-breakthrough-therapy-designation-for-pegloprastide-avb-620-for-use-during-breast-cancer-surgery,14-12-2020 00:00,,,,,,
4098,f2g-receives-second-us-fda-breakthrough-therapy-designation-for-olorofim,22-10-2020 00:00,,,,,,
4099,telix-granted-fda-breakthrough-therapy-designation-for-renal-cancer-imaging-product,01-07-2020 00:00,,,,,,
4100,sorrento-and-mount-sinai-health-system-enter-into-exclusive-license-agreement-for-development-of-potent-antibody-combinations-aimed-at-neutralizing-sars-cov-2-and-the-emerging-united-kingdom-and-south-africa-variants-of-covid-19,10-03-2021 00:00,,,,,,
4101,resverlogix-receives-us-fda-breakthrough-therapy-designation-for-apabetalone,03-02-2020 00:00,,,,,,
4102,concert-pharmaceuticals-receives-fda-breakthrough-therapy-designation-for-ctp-543-for-the-treatment-of-alopecia-areata,08-07-2020 00:00,,,,,,
4103,spinal-muscular-atrophy-sma-foundation-and-ptc-therapeutics-expand-partnership-to-advance-drug-discovery-and-development-research-in-regenerative-medicine,10-03-2021 00:00,,,,,,
4104,insmed-receives-fda-breakthrough-therapy-designation-for-brensocatib-in-patients-with-non-cystic-fibrosis-bronchiectasis-ncfbe,08-06-2020 00:00,,,,,,
4105,gilead?s-investigational-lenacapavir-demonstrates-sustained-long-acting-efficacy-through-week-26-in-data-presented-at-croi,10-03-2021 00:00,,,,,,
4106,myokardia-announces-receipt-of-breakthrough-therapy-designation-from-fda-for-mavacamten-for-the-treatment-of-symptomatic-obstructive-hypertrophic-cardiomyopathy,23-07-2020 00:00,,,,,,
4107,fda-grants-breakthrough-therapy-designation-for-debiopharm?s-novel-chemo-radio-sensitizer-debio-1143-for-front-line-treatment-of-head-neck-cancer,27-02-2020 00:00,,,,,,
4108,kiniksa-announces-breakthrough-therapy-designation-granted-to-vixarelimab-for-the-treatment-of-pruritus-associated-with-prurigo-nodularis,16-11-2020 00:00,,,,,,
4109,turning-point-therapeutics-granted-fda-breakthrough-therapy-designation-for-repotrectinib-treatment-in-patients-with-ros1-positive-metastatic-non-small-cell-lung-cancer-who-have-not-been-treated-with-a-ros1-tyrosine-kinase-inhibitor,08-12-2020 00:00,,,,,,
4110,inventiva-receives-fda-breakthrough-therapy-designation-for-lead-drug-candidate-lanifibranor-in-nash,12-10-2020 00:00,,,,,,
4111,lilly?s-bamlanivimab-and-etesevimab-together-reduced-hospitalizations-and-death-in-phase-3-trial-for-early-covid-19,11-03-2021 00:00,,,,,,
4112,grifols-reinforces-its-innovation-strategy-after-completing-the-acquisition-of-gigagen-to-boost-a-novel-method-to-generate-a-wide-range-of-immunoglobulins,11-03-2021 00:00,,,,,,
4113,empatica-first-to-receive-european-ce-mark-for-detecting-early-symptoms-of-covid-19-using-wearables,11-03-2021 00:00,,,,,,
4114,fortress-biotech-announces-breakthrough-therapy-designation-for-cutx-101-copper-histidinate-for-the-treatment-of-menkes-disease,15-12-2020 00:00,,,,,,
4115,roche-provides-update-on-the-phase-iii-remdacta-trial-of-actemraroactemra-plus-veklury-in-patients-with-severe-covid-19-pneumonia,11-03-2021 00:00,,,,,,
4116,aprea-therapeutics-receives-fda-breakthrough-therapy-designation-for-apr-246-in-combination-with-azacitidine-for-the-treatment-of-myelodysplastic-syndromes-mds-with-a-tp53-mutation,30-01-2020 00:00,,,,,,
4117,contrafect-announces-us-fda-grants-breakthrough-therapy-designation-to-exebacase-for-the-treatment-of-methicillin-resistant-staphylococcus-aureus-mrsa-bacteremia-including-right-sided-endocarditis,24-02-2020 00:00,,,,,,
4118,beyondspring-receives-breakthrough-therapy-designations-from-both-us-fda-and-china-nmpa-for-plinabulin-in-chemotherapy-induced-neutropenia-indication,08-09-2020 00:00,,,,,,
4119,lannett-development-of-biosimilar-insulin-glargine-product-continues-to-advance,11-03-2021 00:00,,,,,,
4120,vertex-announces-fda-fast-track-designation-and-initiation-of-a-phase-12-clinical-trial-for-vx-880-a-novel-investigational-cell-therapy-for-the-treatment-of-type-1-diabetes,11-03-2021 00:00,,,,,,
4121,acceleron-receives-fda-breakthrough-therapy-designation-for-sotatercept-in-pulmonary-arterial-hypertension,08-04-2020 00:00,,,,,,
4122,vir-biotechnology-and-gsk-announce-vir-7831-reduces-hospitalization-and-risk-of-death-in-early-treatment-of-adults-with-covid-19,12-03-2021 00:00,,,,,,
4123,astellas-submits-new-drug-application-for-enfortumab-vedotin-in-japan,12-03-2021 00:00,,,,,,
4124,abbott-announces-its-pandemic-defense-coalition-a-global-network-of-expert-collaborators-designed-to-help-prevent-future-pandemics-currently-searching-for-covid-19-variants,12-03-2021 00:00,,,,,,
4125,sanofi-and-translate-bio-initiate-phase-12-clinical-trial-of-mrna-covid-19-vaccine-candidate,12-03-2021 00:00,,,,,,
4126,takeda-submits-new-drug-application-in-japan-for-lanadelumab-as-a-preventive-treatment-for-hereditary-angioedema-attacks,12-03-2021 00:00,,,,,,
4127,phasebio-pharmaceuticals-and-biovectra-enter-into-supply-agreement-to-support-development-and-commercialization-of-bentracimab,12-03-2021 00:00,,,,,,
4128,lilly?s-donanemab-slows-clinical-decline-of-alzheimer?s-disease-in-positive-phase-2-trial,15-03-2021 00:00,,,,,,
4129,phase-3-trial-of-libtayo?-cemiplimab-monotherapy-in-advanced-cervical-cancer-stopped-early-for-positive-result-on-overall-survival,15-03-2021 00:00,,,,,,
4130,roche-signs-definitive-merger-agreement-with-genmark-diagnostics-inc-to-access-novel-technology-to-test-for-broad-range-of-pathogens-with-one-patient-sample,15-03-2021 00:00,,,,,,
4131,aveo-oncology-announces-collaboration-with-bristol-myers-squibb-to-evaluate-fotivda?-tivozanib-in-combination-with-opdivo?-nivolumab-in-pivotal-phase-3-tinivo-2-trial-in-io-relapsed-renal-cell-carcinoma,15-03-2021 00:00,,,,,,
4132,cardinal-health-signs-definitive-agreement-to-sell-its-cordis-business-to-hellman-friedman,15-03-2021 00:00,,,,,,
4133,bioxcel-therapeutics-receives-fda-breakthrough-therapy-designation-for-bxcl501-for-the-acute-treatment-of-agitation-associated-with-dementia,15-03-2021 00:00,,,,,,
4134,genevant-sciences-announces-global-collaboration-and-license-agreement-with-takeda-to-develop-novel-nucleic-acid-therapeutics-for-liver-fibrosis,16-03-2021 00:00,,,,,,
4135,gilead-and-merck-announce-agreement-to-jointly-develop-and-commercialize-long-acting-investigational-treatment-combinations-of-lenacapavir-and-islatravir-in-hiv,16-03-2021 00:00,,,,,,
4136,molecular-partners-and-novartis-announce-inclusion-of-covid-19-antiviral-candidate-ensovibep-in-nih-sponsored-activ-3-trial,16-03-2021 00:00,,,,,,
4137,roche-launches-sars-cov-2-variant-test-to-help-monitor-emerging-coronavirus-mutations,16-03-2021 00:00,,,,,,
4138,new-2-year-data-show-genentech?s-evrysdi-risdiplam-continues-to-demonstrate-improvement-or-maintenance-of-motor-function-in-people-aged-2-25-with-type-2-or-type-3-spinal-muscular-atrophy-sma,16-03-2021 00:00,,,,,,
4139,merck-receives-priority-review-from-fda-for-new-drug-application-for-hif-2a-inhibitor-belzutifan-mk-6482,16-03-2021 00:00,,,,,,
4140,tg-therapeutics-announces-fda-accelerated-approval-of-ukoniq?-umbralisib,05-02-2021 00:00,,,,,,
4141,fda-approves-oncopeptides?-pepaxto?-melphalan-flufenamide-for-patients-with-triple-class-refractory-multiple-myeloma,01-03-2021 00:00,,,,,,
4142,medicago-and-gsk-start-phase-3-trial-of-adjuvanted-covid-19-vaccine-candidate,17-03-2021 00:00,,,,,,
4143,lilly?s-mirikizumab-helps-patients-achieve-clinical-remission-and-improves-symptoms-in-adults-with-ulcerative-colitis-in-12-week-phase-3-induction-study,17-03-2021 00:00,,,,,,
4144,gbt-expands-sickle-cell-disease-pipeline-with-exclusive-in-license-of-two-novel-small-molecule-programs-from-sanofi-sa,17-03-2021 00:00,,,,,,
4145,fibrogen-initiates-lelantos-2-?-second-phase-3-clinical-study-of-pamrevlumab-for-the-treatment-of-duchenne-muscular-dystrophy,17-03-2021 00:00,,,,,,
4146,new-phase-3-data-show-first-in-class-tremfya?-guselkumab-achieved-complete-skin-clearance-and-favorable-joint-efficacy-in-adult-patients-with-active-psoriatic-arthritis-psa-through-two-years,17-03-2021 00:00,,,,,,
4147,nccn-announces-new-biosimilars-research-projects-in-oncology-in-collaboration-with-pfizer,17-03-2021 00:00,,,,,,
4148,amathus-therapeutics-signs-strategic-collaboration-with-merck-to-develop-treatments-for-neurodegenerative-diseases,18-03-2021 00:00,,,,,,
4149,wuxi-biologics-to-acquire-biologics-ds-and-dp-manufacturing-facilities-from-pfizer-china,18-03-2021 00:00,,,,,,
4150,m2gen-announces-new-collaboration-with-merck-to-advance-cancer-therapies,18-03-2021 00:00,,,,,,
4151,fsd-pharma-enters-into-license-agreement-to-develop-fda-approved-veterinary-drugs-for-the-treatment-of-gastro-intestinal-diseases-in-dogs-and-cats,18-03-2021 00:00,,,,,,
4152,european-commission-approves-expanded-indication-for-merck?s-keytruda?-pembrolizumab-in-adult-and-pediatric-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-chl,18-03-2021 00:00,,,,,,
4153,durect-corporation-announces-us-fda-approval-of-posimir?-for-post-surgical-pain-reduction-for-up-to-72-hours-following-arthroscopic-subacromial-decompression,02-02-2021 00:00,,,,,,
4154,sarepta-therapeutics-announces-fda-approval-of-amondys-45?-casimersen-injection-for-the-treatment-of-duchenne-muscular-dystrophy-dmd-in-patients-amenable-to-skipping-exon-45,25-02-2021 00:00,,,,,,
4155,gsk-starts-the-first-phase-3-study-with-a-long-acting-anti-il-5-treatment-for-patients-with-severe-asthma,18-03-2021 00:00,,,,,,
4156,b-braun-receives-the-first-and-only-fda-approval-for-acetaminophen-injection-in-multiple-doses,25-02-2021 00:00,,,,,,
4157,gilead-and-novo-nordisk-expand-nash-clinical-collaboration,19-03-2021 00:00,,,,,,
4158,boston-pharmaceuticals-enters-into-unique-multi-year-out-license-and-option-agreement-with-gsk-for-the-advancement-of-multiple-pre-phase-2-programs,19-03-2021 00:00,,,,,,
4159,pyxis-oncology-announces-worldwide-licensing-agreement-with-pfizer-to-develop-and-commercialize-multiple-antibody-drug-conjugates,19-03-2021 00:00,,,,,,
4160,sarepta-therapeutics?-investigational-gene-therapy-srp-9003-for-the-treatment-of-limb-girdle-muscular-dystrophy-type-2e-shows-sustained-expression-and-functional-improvements-2-years-after-administration,19-03-2021 00:00,,,,,,
4161,kiniksa-announces-fda-approval-of-arcalyst-?-rilonacept-for-recurrent-pericarditis,19-03-2021 00:00,,,,,,
4162,anima-biotech-announces-strategic-collaboration-with-takeda-to-discover-and-develop-mrna-translation-modulators-for-neurological-diseases,19-03-2021 00:00,,,,,,
4163,us-food-and-drug-administration-fda-accepts-bristol-myers-squibb?s-application-for-mavacamten-in-symptomatic-obstructive-hypertrophic-cardiomyopathy-ohcm,22-03-2021 00:00,,,,,,
4164,keytruda?-pembrolizumab-plus-lenvima?-lenvatinib-significantly-improved-progression-free-survival-and-overall-survival-versus-chemotherapy-in-patients-with-advanced-endometrial-cancer-following-prior-platinum-based-chemotherapy-in-phase-3-study,22-03-2021 00:00,,,,,,
4165,janssen-announces-us-fda-approval-of-ponvory?-ponesimod-an-oral-treatment-for-adults-with-relapsing-multiple-sclerosis-proven-superior-to-aubagio?-teriflunomide-in-reducing-annual-relapses-and-brain-lesions,22-03-2021 00:00,,,,,,
4166,bridgebio-pharma-announces-proof-of-concept-data-of-encaleret-in-adh1-at-the-endocrine-society?s-2021-annual-meeting,22-03-2021 00:00,,,,,,
4167,biomarin-announces-oral-presentation-at-endo2021-the-endocrine-society?s-annual-meeting-with-data-demonstrating-2-years-of-treatment-benefit-in-children-with-achondroplasia-treated-with-vosoritide,22-03-2021 00:00,,,,,,
4168,azd1222-us-phase-iii-trial-met-primary-efficacy-endpoint-in-preventing-covid-19-at-interim-analysis,22-03-2021 00:00,,,,,,
4169,evotec-and-takeda-enter-strategic-rna-targeting-drug-discovery-and-development-alliance,23-03-2021 00:00,,,,,,
4170,pivotal-phase-iii-study-shows-roche?s-tecentriq-helped-people-with-early-lung-cancer-live-longer-without-their-disease-returning,23-03-2021 00:00,,,,,,
4171,roche-provides-update-on-tominersen-programme-in-manifest-huntington?s-disease,23-03-2021 00:00,,,,,,
4172,insulet?s-omnipod?-5-automated-insulin-delivery-system-improves-clinical-outcomes-in-type-1-diabetes,23-03-2021 00:00,,,,,,
4173,novo-nordisk-receives-refusal-to-file-letter-for-once-weekly-semaglutide-20-mg-for-the-treatment-of-type-2-diabetes,23-03-2021 00:00,,,,,,
4174,phase-3-trial-shows-regen-cov?-casirivimab-with-imdevimab-antibody-cocktail-reduced-hospitalization-or-death-by-70-in-non-hospitalized-covid-19-patients,23-03-2021 00:00,,,,,,
4175,roche-launches-new-high-throughput-configurations-for-cobas-pro-integrated-solutions-to-increase-testing-efficiency,24-03-2021 00:00,,,,,,
4176,zealand-pharma-announces-fda-approval-of-zegalogue?-dasiglucagon-injection-for-the-treatment-of-severe-hypoglycemia-in-people-with-diabetes,24-03-2021 00:00,,,,,,
4177,incyte-announces-approval-of-pemazyre?-pemigatinib-in-japan-for-the-treatment-of-patients-with-unresectable-biliary-tract-cancer-btc-with-a-fibroblast-growth-factor-receptor-2-fgfr2-fusion-gene-worsening-after-cancer-chemotherapy,24-03-2021 00:00,,,,,,
4178,davita-kidney-care-expands-use-of-nxstage-home-hemodialysis-machines-from-fresenius-medical-care,24-03-2021 00:00,,,,,,
4179,adults-with-obesity-treated-with-semaglutide-24-mg-achieved-and-maintained-a-significant-amount-of-weight-loss-in-a-68-week-trial,24-03-2021 00:00,,,,,,
4180,bayer-receives-approval-for-vitrakvi?-in-japan,24-03-2021 00:00,,,,,,
4181,azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy,25-03-2021 00:00,,,,,,
4182,chugai-obtains-approval-for-polivy-for-the-treatment-of-relapsed-or-refractory-diffuse-large-b-cell-lymphoma,25-03-2021 00:00,,,,,,
4183,johnson-johnson-vision-receives-approval-of-world?s-first-and-only-drug-releasing-combination-contact-lens-for-vision-correction-and-allergic-eye-itch-acuvue?-theravision?-with-ketotifen,25-03-2021 00:00,,,,,,
4184,"taipei-march-24-2021-prnewswire-?-in-a-press-conference-today-eirgenix-inc-6589tt-announced-that-the-phase-iii-clinical-trial-trial-no-egc002-nct03433313-of-its-breast-cancer-biosimilar-eg12014-proposed-trastuzumab-biosimilar-also-called-egi014-has-met-its-primary-endpoint-eg12014-has-shown-equivalent-efficacy-to-herceptin?-in-regards-to-its-clinical-response-pathologic-complete-response-pcr-in-addition-to-demonstrating-a-comparable-safety-profile-eirgenix-will-proceed-with-the-preparations-for-submissions-of-biologics-license-application-bla-to-the-us-fda-market-approval-application-maa-to-european-medicines-agency-ema-and-new-drug-application-to-tfda-exact-timings-remain-confidential
-
-this-phase-iii-clinical-trial-is-a-multi-national-multi-center-randomized-double-blinded-study-involving-female-with-early-her2-positive-breast-cancer-the-purpose-of-the-trial-was-to-demonstrate-the-therapeutic-equivalence-in-terms-of-efficacy-between-eg12014-to-herceptin?-and-to-compare-the-safety-immunogenicity-and-pk-between-the-two-trastuzumab-products-a-total-of-807-enrolled-patients-were-randomly-assigned-in-a-11-ratio-to-one-of-the-two-parallel-treatment-groups-and-received-anthracycline-based-chemotherapy-every-3-weeks-for-12-weeks-cycle-1-to-4-after-chemotherapy-patients-received-eg12014-or-herceptin?-in-combination-with-paclitaxel-every-3-weeks-for-12-weeks-cycle-5-to-8-all-patients-were-scheduled-for-tumor-removal-surgery-breast-and-axillary-lymph-nodes-3-to-6-weeks-after-completion-of-neoadjuvant-therapy-pre-operative-treatment-two-2-to-6-weeks-after-surgery-eligible-patients-continued-with-trastuzumab-therapy-in-the-adjuvant-study-to-complete-12-months-of-overall-trastuzumab-treatment-adjuvant-cycle-1-to-13-followed-by-a-20-week-long-term-safety-follow-up-after-final-dose-of-trastuzumab
-
-during-tumor-removal-surgery-samples-were-collected-for-assessment-of-a-pathologic-complete-response-pcr-by-an-independent-central-laboratory-the-primary-endpoint-of-pcr-is-defined-as-absence-of-invasive-cancer-in-the-breast-and-axillary-nodes-irrespective-of-ductal-carcinoma-in-situ-ypt0is-ypn0-demonstration-of-therapeutic-equivalence-in-regards-to-the-pcr-between-the-two-treatment-groups-eg12014-vs-herceptin?-in-the-pre-operative-treatment-setting-was-based-on-the-pre-specified-risk-ratio-0741-?-1349-and-probability-difference-013-?-013-the-topline-results-demonstrated-that-eg12014-met-equivalence-to-herceptin?-in-terms-of-clinical-response-in-both-analysis-populations-per-protocol-and-full-analysis-sets-additionally-the-safety-profiles-of-the-two-treatment-arms-were-shown-to-be-comparable-in-the-pre-operative-treatment-setting
-
-according-to-roche?s-annual-report-global-sales-of-herceptin?-totaled-373-billion-chf-in-2020-the-us-and-eu-market-are-136-billion-chf-and-067-billion-chf-respectively-herceptin?-sales-were-34-lower-than-in-2019-driven-by-biosimilar-competition-which-was-introduced-in-the-second-half-of-2019-in-the-us-and-mid-2018-in-japan-and-europe-upon-approval-sandoz-ag-a-global-leader-in-generics-and-biosimilars-will-sell-eg12014-globally-in-all-markets-except-for-taiwan-and-mainland-china-as-per-the-licensing-agreement-signed-with-eirgenix-in-april-2019-the-licensing-agreement-included-a-signing-fee-and-milestone-payments-and-a-profit-sharing-of-product-sales-in-the-authorized-markets-after-product-launch-the-revenue-from-the-milestone-payments-will-be-recognized-in-stages-in-accordance-to-standard-accounting-procedures-and-will-serve-to-benefit-the-company?s-current-operations-and-further-development-in-2019-taiwan?s-national-health-insurance-nhi-paid-approximately-1657-billion-new-taiwan-dollars-ntd-for-herceptin?
-
-current-demand-for-complex-biological-drugs-has-increased-and-will-continue-to-rise-in-the-future-with-the-drug-patents-of-major-biological-drugs-set-to-expire-in-the-near-future-the-development-of-biosimilars-has-been-greatly-encouraged-within-the-industry-the-demand-has-been-driven-by-the-need-for-more-cost-effective-drugs-in-countries-with-limited-medical-resources-eirgenix-is-currently-the-first-and-only-biopharmaceutical-company-in-taiwan-to-have-successfully-signed-a-licensing-agreement-with-a-global-pharmaceutical-company-for-a-biosimilar-eirgenix-is-also-one-of-only-a-handful-of-taiwanese-biopharmaceutical-companies-to-have-independently-developed-a-biosimilar-product-into-phase-iii-clinical-trials-and-successfully-demonstrating-its-equivalent-efficacy-with-such-developmental-achievements-eirgenix-is-rightfully-worthy-of-investors?-attention-and-expectations
-
-source-eirgenix-inc
-
-
-
-related-links
-httpwwweirgenixcom",25-03-2021 00:00,,,,,,
4185,proqr-announces-positive-results-from-clinical-trial-of-qr-421a-in-usher-syndrome-and-plans-to-start-pivotal-trials,25-03-2021 00:00,,,,,,
4186,myovant-sciences-and-pfizer-announce-positive-data-from-phase-3-liberty-randomized-withdrawal-study-of-once-daily-relugolix-combination-therapy-in-women-with-uterine-fibroids,25-03-2021 00:00,,,,,,
4187,bristol-myers-squibb-announces-relativity-047-a-trial-evaluating-anti-lag-3-antibody-relatlimab-and-opdivo-nivolumab-in-patients-with-previously-untreated-metastatic-or-unresectable-melanoma-meets-primary-endpoint-of-progression-free-survival,26-03-2021 00:00,,,,,,
4188,takeda-begins-regulatory-submissions-for-dengue-vaccine-candidate-in-eu-and-dengue-endemic-countries,26-03-2021 00:00,,,,,,
4189,european-medicines-agency-accepts-marketing-authorization-application-for-enfortumab-vedotin,26-03-2021 00:00,,,,,,
4190,immunai-acquires-dropprint-genomics-and-strengthens-leadership-team-with-experts-in-immunology-to-expand-target-discovery-capabilities,26-03-2021 00:00,,,,,,
4191,tetra-bio-pharma-initiates-additional-studies-on-leading-drug-candidate-ards-003,26-03-2021 00:00,,,,,,
4192,pfizer-biontech-launch-covid-19-vaccine-trial-in-kids-under-12,26-03-2021 00:00,,,,,,
4193,us-food-and-drug-administration-approves-bristol-myers-squibb?s-and-bluebird-bio?s-abecma-idecabtagene-vicleucel-the-first-anti-bcma-car-t-cell-therapy-for-relapsed-or-refractory-multiple-myeloma,29-03-2021 00:00,,,,,,
4194,gsk-receives-chmp-positive-opinion-recommending-approval-of-benlysta-for-adult-patients-with-active-lupus-nephritis,29-03-2021 00:00,,,,,,
4195,fda-authorizes-marketing-of-device-to-improve-gait-in-multiple-sclerosis-patients,29-03-2021 00:00,,,,,,
4196,gsk-and-vir-biotechnology-announce-submission-of-emergency-use-authorization-request-to-fda-for-vir-7831-for-the-early-treatment-of-covid-19,29-03-2021 00:00,,,,,,
4197,qiagen-receives-fda-emergency-use-authorization-for-neumodx-multiplex-test-expanding-covid-19-portfolio,29-03-2021 00:00,,,,,,
4198,roche-receives-positive-chmp-opinion-for-tecentriq-as-a-first-line-monotherapy-treatment-for-people-with-a-type-of-metastatic-non-small-cell-lung-cancer,29-03-2021 00:00,,,,,,
4199,samsung-bioepis-continues-global-market-expansion-with-launch-of-hadlima?-in-australia-and-canada-in-partnership-with-merck-co,30-03-2021 00:00,,,,,,
4200,roche?s-evrysdi-approved-by-european-commission-as-first-and-only-at-home-treatment-for-spinal-muscular-atrophy,30-03-2021 00:00,,,,,,
4201,medtronic-receives-fda-approval-for-?breakthrough?-transcatheter-pulmonary-valve-replacement-for-patients-with-congenital-heart-disease,30-03-2021 00:00,,,,,,
4202,lilly-vir-biotechnology-and-gsk-announce-positive-topline-data-from-the-phase-2-blaze-4-trial-evaluating-bamlanivimab-with-vir-7831-in-low-risk-adults-with-covid-19,30-03-2021 00:00,,,,,,
4203,cipla-gulf-and-alvotech-expand-partnership-for-commercialization-of-biosimilars-in-australia-and-new-zealand,02-03-2021 00:00,,,,,,
4204,cerecor-announces-new-worldwide-license-agreement-with-kyowa-kirin-for-anti-light-antibody-cerc-002,30-03-2021 00:00,,,,,,
4205,novartis-receives-eu-approval-for-kesimpta?-ofatumumab-the-first-and-only-self-administered-targeted-b-cell-therapy-for-adult-patients-with-relapsing-multiple-sclerosis,30-03-2021 00:00,,,,,,
4206,novartis-expands-targeted-radioligand-therapy-pipeline-with-in-license-for-compounds-targeting-fibroblast-activation-protein-fap,31-03-2021 00:00,,,,,,
4207,merck-announces-acquisition-of-alydia-health-on-behalf-of-its-planned-spinoff-of-organon,31-03-2021 00:00,,,,,,
4208,us-fda-accepts-abbvie?s-new-drug-application-for-atogepant-for-the-preventive-treatment-of-migraine,31-03-2021 00:00,,,,,,
4209,european-commission-approves-cabometyx?-in-combination-with-opdivo?-as-a-first-line-treatment-for-patients-living-with-advanced-renal-cell-carcinoma,31-03-2021 00:00,,,,,,
4210,amgen-to-acquire-rodeo-therapeutics-corporation,31-03-2021 00:00,,,,,,
4211,waters-peptide-multi-attribute-method-for-bioaccord-system-boosts-innovator-and-biosimilar-drug-development-and-commercialization,18-03-2021 00:00,,,,,,
4212,roche-launches-elecsys-epstein-barr-virus-ebv-immunoassay-panel-to-improve-ebv-infection-staging,31-03-2021 00:00,,,,,,
4213,first-patient-dosed-in-phase-iiiii-clinical-trial-of-henlius-anti-pd-1-mab-hlx10-combined-with-bevacizumab-for-the-first-line-treatment-of-mcrc,11-03-2021 00:00,,,,,,
4214,henlius-bevacizumab-has-received-ind-approval-from-us-fda-for-the-treatment-of-wamd,19-03-2021 00:00,,,,,,
4215,formycon-confirms-bla-submission-strategy-and-timeline-for-its-lucentisr-biosimilar-candidate-fyb201-following-consultation-with-the-fda,01-03-2021 00:00,,,,,,
4216,bridgebio-pharma?s-affiliate-qed-therapeutics-and-helsinn-group-announce-strategic-collaboration-to-co-develop-and-commercialize-infigratinib-in-oncology,01-04-2021 00:00,,,,,,
4217,bioxcel-therapeutics-announces-results-of-phase-1b2-study-of-bxcl501-for-the-treatment-of-opioid-withdrawal-symptoms,01-04-2021 00:00,,,,,,
4218,amryt-submits-a-new-drug-application-to-the-us-food-and-drug-administration-for-oleogel-s10-filsuvez?,01-04-2021 00:00,,,,,,
4219,bausch-health-agrees-to-sell-amoun-pharmaceuticals,01-04-2021 00:00,,,,,,
4220,fda-approves-sarclisa?-isatuximab-in-combination-with-carfilzomib-and-dexamethasone-for-patients-with-relapsed-or-refractory-multiple-myeloma,01-04-2021 00:00,,,,,,
4221,alnylam-announces-publication-of-illuminate-a-phase-3-study-results-for-lumasiran-in-the-new-england-journal-of-medicine,01-04-2021 00:00,,,,,,
4222,beyondspring-announces-submission-of-new-drug-application-to-us-fda-and-china-nmpa-for-plinabulin-and-g-csf-combination-for-the-prevention-of-chemotherapy-induced-neutropenia-cin,02-04-2021 00:00,,,,,,
4223,kite-submits-supplemental-biologics-license-application-to-us-food-and-drug-administration-for-tecartus?-in-adult-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukemia,02-04-2021 00:00,,,,,,
4224,springworks-therapeutics-announces-dosing-of-first-patient-in-phase-1b-combination-study-evaluating-nirogacestat-and-janssen?s-bcma-bispecific-antibody-teclistamab-in-patients-with-relapsed-or-refractory-multiple-myeloma,02-04-2021 00:00,,,,,,
4225,revance-to-showcase-phase-3-results-evaluating-daxibotulinumtoxina-for-injection-for-the-treatment-of-cervical-dystonia-at-the-american-academy-of-neurology-annual-2021-virtual-meeting,02-04-2021 00:00,,,,,,
4226,new-england-journal-of-medicine-publishes-results-of-the-pulsar-phase-2-trial-of-sotatercept-in-patients-with-pulmonary-arterial-hypertension,02-04-2021 00:00,,,,,,
4227,pfizer-and-biontech-confirm-high-efficacy-and-no-serious-safety-concerns-through-up-to-six-months-following-second-dose-in-updated-topline-analysis-of-landmark-covid-19-vaccine-study,02-04-2021 00:00,,,,,,
4228,f-star-therapeutics-announces-third-option-exercised-by-merck-kgaa-darmstadt-germany-in-immuno-oncology-collaboration,05-04-2021 00:00,,,,,,
4229,abcellera-and-gilead-sciences-announce-new-multi-year-multi-target-antibody-discovery-collaboration,05-04-2021 00:00,,,,,,
4230,fda-grants-breakthrough-therapy-designation-for-taiho-oncology?s-futibatinib-for-treatment-of-advanced-cholangiocarcinoma,05-04-2021 00:00,,,,,,
4231,taltz?-ixekizumab-approved-by-health-canada-for-the-treatment-of-pediatric-patients-six-to-less-than-18-years-of-age-with-moderate-to-severe-plaque-psoriasis,05-04-2021 00:00,,,,,,
4232,european-commission-approves-mabxience?s-bevacizumab-for-the-treatment-of-certain-types-of-cancer,05-04-2021 00:00,,,,,,
4233,uniqure-announces-completion-of-enrollment-in-first-cohort-of-phase-iii-clinical-trial-of-amt-130-for-the-treatment-of-huntington?s-disease,05-04-2021 00:00,,,,,,
4234,sorrento-enters-into-merger-agreement-to-acquire-late-stage-oncology-company-acea-therapeutics,06-04-2021 00:00,,,,,,
4235,welldoc-and-dexcom-expand-strategic-partnership-to-integrate-platforms-and-offer-integrated-type-2-diabetes-management-solution,06-04-2021 00:00,,,,,,
4236,n-lorem-foundation-partners-with-ultragenyx-to-bolster-development-of-personalized-medicines-for-patients-with-ultra-rare-diseases,06-04-2021 00:00,,,,,,
4237,exelixis-announces-us-fda-accepts-investigational-new-drug-application-for-xb002-in-patients-with-advanced-solid-tumors,06-04-2021 00:00,,,,,,
4238,new-uplizna?-inebilizumab-cdon-data-in-people-with-neuromyelitis-optica-spectrum-disorder-nmosd-to-be-presented-at-the-american-academy-of-neurology?s-73rd-annual-meeting,06-04-2021 00:00,,,,,,
4239,passage-bio-receives-european-commission-orphan-designation-for-pbkr03-for-treatment-of-krabbe-disease,06-04-2021 00:00,,,,,,
4240,lilly-and-incyte-communicate-review-extension-of-supplemental-new-drug-application-for-baricitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis,07-04-2021 00:00,,,,,,
4241,pear-therapeutics-expands-platform-with-digital-biomarkers-machine-learning-algorithms-and-sensor-based-technologies,07-04-2021 00:00,,,,,,
4242,progenity-and-ionis-pharmaceuticals-enter-into-agreement-to-evaluate-progenity?s-ingestible-oral-biotherapeutics-technology-for-delivery-of-antisense-therapies,07-04-2021 00:00,,,,,,
4243,astrazeneca-announces-collaboration-with-massachusetts-general-hospital-to-accelerate-digital-health-solutions,07-04-2021 00:00,,,,,,
4244,johnson-johnson-vision-announces-global-collaboration-with-menicon-to-bring-forward-contact-lenses-to-help-manage-the-progression-of-myopia-in-children,07-04-2021 00:00,,,,,,
4245,artios-pharma-announces-collaboration-with-novartis-to-create-next-generation-ddr-cancer-therapies,07-04-2021 00:00,,,,,,
4246,psioxus-therapeutics-updates-agreement-with-bristol-myers-squibb-to-advance-their-clinical-stage-immuno-oncology-collaboration,08-04-2021 00:00,,,,,,
4247,the-european-commission-grants-marketing-authorization-for-new-subcutaneous-administration-of-tysabri?-natalizumab-to-treat-relapsing-remitting-multiple-sclerosis,08-04-2021 00:00,,,,,,
4248,abbvie-submits-regulatory-applications-for-skyrizi?-risankizumab-in-psoriatic-arthritis-to-fda-and-ema,08-04-2021 00:00,,,,,,
4249,pra?s-remote-patient-monitoring-platform-selected-by-merck-kgaa-darmstadt-germany-to-work-in-combination-with-its-human-growth-hormone-treatment-system,08-04-2021 00:00,,,,,,
4250,phase-12-trial-initiated-for-daiichi-sankyo?s-menin-inhibitor-ds-1594-in-patients-with-acute-myeloid-leukemia-and-acute-lymphoblastic-leukemia,08-04-2021 00:00,,,,,,
4251,lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients,08-04-2021 00:00,,,,,,
4252,biogen-and-bio-thera-solutions-announce-commercialization-and-license-agreement-for-proposed-biosimilar-currently-in-phase-3-with-the-potential-to-treat-moderate-to-severe-rheumatoid-arthritis,09-04-2021 00:00,,,,,,
4253,hologic-to-acquire-mobidiag-innovator-in-near-patient-acute-care-diagnostic-testing-for-approximately-795-million,09-04-2021 00:00,,,,,,
4254,merck?s-keytruda?-pembrolizumab-demonstrated-superior-disease-free-survival-dfs-compared-with-placebo-as-adjuvant-therapy-in-patients-with-renal-cell-carcinoma-rcc-following-surgery,09-04-2021 00:00,,,,,,
4255,bristol-myers-squibb-announces-opdivo-nivolumab-plus-chemotherapy-and-opdivo-plus-yervoy-ipilimumab-demonstrate-superior-survival-benefit-compared-to-chemotherapy-in-unresectable-advanced-or-metastatic-esophageal-squamous-cell-carcinoma,09-04-2021 00:00,,,,,,
4256,plantform-signs-agreement-with-bio-manguinhosfiocruz-to-develop-a-biosimilar-pembrolizumab-cancer-drug,09-04-2021 00:00,,,,,,
4257,evotec-and-exscientia-announce-start-of-human-clinical-trials-of-novel-immuno-oncology-drug,09-04-2021 00:00,,,,,,
4258,sanofi-acquires-tidal-therapeutics-adding-innovative-mrna-based-research-platform-with-applications-in-oncology-immunology-and-other-disease-areas,12-04-2021 00:00,,,,,,
4259,phase-iii-prevention-trial-showed-subcutaneous-administration-of-investigational-antibody-cocktail-casirivimab-and-imdevimab-reduced-risk-of-symptomatic-covid-19-infections-by-81,12-04-2021 00:00,,,,,,
4260,update-on-the-dare-19-phase-iii-trial-for-farxiga-in-covid-19,12-04-2021 00:00,,,,,,
4261,daiichi-sankyo-initiates-phase-2-trial-to-evaluate-pexidartinib-in-japanese-patients-with-tgct,12-04-2021 00:00,,,,,,
4262,investigational-combination-of-aliqopa?-copanlisib-and-rituximab-significantly-increases-progression-free-survival-in-patients-with-relapsed-indolent-non-hodgkin?s-lymphoma,12-04-2021 00:00,,,,,,
4263,neoadjuvant-opdivo-nivolumab-plus-chemotherapy-significantly-improves-pathologic-complete-response-in-patients-with-resectable-non-small-cell-lung-cancer-in-phase-3-checkmate-816-trial,12-04-2021 00:00,,,,,,
4264,microsoft-accelerates-industry-cloud-strategy-for-healthcare-with-the-acquisition-of-nuance,13-04-2021 00:00,,,,,,
4265,novartis-receives-fda-approval-of-xolair?-omalizumab-self-injection-with-prefilled-syringe-across-all-indications-for-appropriate-patients,13-04-2021 00:00,,,,,,
4266,sage-therapeutics-and-biogen-announce-sage-324-phase-2-placebo-controlled-kinetic-study-in-essential-tremor-met-primary-endpoint,13-04-2021 00:00,,,,,,
4267,diasorin-to-acquire-luminex-corporation-for-usd-3700-per-share-or-approximately-usd-18-billion,13-04-2021 00:00,,,,,,
4268,up-to-?414-million-exclusive-worldwide-licensing-agreement-with-sanofi-for-c4xd-oral-il-17a-inhibitor-programme,13-04-2021 00:00,,,,,,
4269,avantor?-to-acquire-ritter-gmbh-and-its-affiliates-expands-proprietary-offering-for-diagnostic-and-drug-discovery-workflows,13-04-2021 00:00,,,,,,
4270,joint-cdc-and-fda-statement-on-johnson-johnson-covid-19-vaccine,14-04-2021 00:00,,,,,,
4271,biocorp-and-roche-diabetes-care-france-launch-mallya-an-innovative-medical-device-to-better-the-daily-life-of-patients-with-diabetes,14-04-2021 00:00,,,,,,
4272,tagrisso-approved-in-china-in-early-lung-cancer,14-04-2021 00:00,,,,,,
4273,senti-bio-enters-collaboration-with-spark-therapeutics-to-develop-next-generation-precision-gene-therapies,14-04-2021 00:00,,,,,,
4274,innovent-and-lilly-release-phase-3-results-of-tyvyt?-sintilimab-injection-as-a-second-line-treatment-for-squamous-non-small-cell-lung-cancer-at-aacr-annual-meeting-2021,14-04-2021 00:00,,,,,,
4275,nkmax-and-merck-kgaa-darmstadt-germany-expand-clinical-collaboration-to-include-phase-iiia-trial-investigating-the-combination-of-snk01-with-erbitux?-cetuximab-in-metastatic-nsclc,14-04-2021 00:00,,,,,,
4276,scineuro-pharmaceuticals-announces-exclusive-licensing-agreement-with-eli-lilly-company,15-04-2021 00:00,,,,,,
4277,genentech?s-evrysdi-continues-to-improve-motor-function-and-survival-in-babies-with-type-1-spinal-muscular-atrophy-sma,15-04-2021 00:00,,,,,,
4278,medtronic-announces-european-launch-of-world?s-first-infusion-set-with-wear-up-to-seven-days-to-help-reduce-burden-for-people-with-diabetes,15-04-2021 00:00,,,,,,
4279,bristol-myers-squibb-receives-european-commission-approval-for-opdivo?-nivolumab-in-combination-with-cabometyx?-cabozantinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma,15-04-2021 00:00,,,,,,
4280,melinta-therapeutics-announces-fda-approval-of-kimyrsa?-oritavancin-for-the-treatment-of-adult-patients-with-acute-bacterial-skin-and-skin-structure-infections-absssi,15-03-2021 00:00,,,,,,
4281,astellas-garners-new-indication-new-product-formulation-approvals-from-us-fda-for-children-with-neurogenic-detrusor-overactivity-ndo,26-03-2021 00:00,,,,,,
4282,aveo-oncology-announces-us-fda-approval-of-fotivda?-tivozanib-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-advanced-renal-cell-carcinoma,10-03-2021 00:00,,,,,,
4283,boehringer-ingelheim-and-md-anderson-expand-collaboration-to-accelerate-development-of-kras-and-trailr2-compounds-in-lung-cancer,15-04-2021 00:00,,,,,,
4284,us-food-and-drug-administration-approves-novel-once-daily-capsule-azstarys?-serdexmethylphenidate-and-dexmethylphenidate-first-and-only-product-containing-dexmethylphenidate-prodrug-for-adhd-in-patients-age-6-years-and-older,03-03-2021 00:00,,,,,,
4285,fda-approves-althera?s-roszet-rosuvastatin-and-ezetimibe-tablets-a-new-oral-therapy-for-powerful-cholesterol-reduction,31-03-2021 00:00,,,,,,
4286,prestige-biopharma-and-pharmapark-announce-license-and-supply-agreement-to-commercialize-prestige?s-bevacizumab-biosimilar-in-the-russian-federation,16-04-2021 00:00,,,,,,
4287,new-data-for-genentech?s-ocrevus-ocrelizumab-reinforce-significant-benefit-on-slowing-disease-progression-in-relapsing-and-primary-progressive-multiple-sclerosis,16-04-2021 00:00,,,,,,
4288,omada-health-launches-physician-guided-care-program-the-first-virtual-cardiometabolic-clinic,16-04-2021 00:00,,,,,,
4289,gsk-provides-update-on-feladilimab-an-investigational-inducible-t-cell-co-stimulatory-icos-agonist,16-04-2021 00:00,,,,,,
4290,health-canada-authorizes-evrysdi?-risdiplam-for-the-treatment-of-spinal-muscular-atrophy-sma-in-adults-and-children,16-04-2021 00:00,,,,,,
4291,thermo-fisher-scientific-to-acquire-ppd-inc-a-leading-clinical-research-organization,16-04-2021 00:00,,,,,,
4292,zogenix-presents-new-data-from-a-study-highlighting-the-impact-of-treatment-with-fintepla?-fenfluramine-oral-solution-on-dravet-syndrome-patients-caregivers-and-families-at-virtual-aan-2021,19-04-2021 00:00,,,,,,
4293,european-commission-approves-second-indication-of-sarclisa?-isatuximab-for-relapsed-multiple-myeloma,19-04-2021 00:00,,,,,,
4294,evotec-enters-partnership-with-kazia-therapeutics-for-clinical-development-of-evt801,19-04-2021 00:00,,,,,,
4295,janssen-showcases-phase-2-nipocalimab-m281-data-in-adults-with-generalized-myasthenia-gravis-gmg-at-the-2021-american-academy-of-neurology-virtual-meeting,19-04-2021 00:00,,,,,,
4296,kesimpta?-ofatumumab-data-at-aan-showed-reduction-in-disability-progression-independent-of-relapse-activity-in-newly-diagnosed-patients-with-rms,19-04-2021 00:00,,,,,,
4297,incyte-and-morphosys-announce-first-patient-dosed-in-phase-3-inmind-study-evaluating-the-addition-of-tafasitamab-to-lenalidomide-and-rituximab-in-relapsed-or-refractory-follicular-or-marginal-zone-lymphoma,20-04-2021 00:00,,,,,,
4298,astellas-and-seagen-announce-us-fda-acceptance-of-two-supplemental-biologics-license-applications-for-padcev?-enfortumab-vedotin-ejfv-in-locally-advanced-or-metastatic-urothelial-cancer,20-04-2021 00:00,,,,,,
4299,alnylam-presents-positive-results-from-helios-a-phase-3-study-of-investigational-vutrisiran,20-04-2021 00:00,,,,,,
4300,18-month-pre-specified-analysis-showing-consistent-reduction-in-clinical-outcome-measures-from-a-lecanemab-ban2401-phase-2b-clinical-trial-in-early-alzheimer?s-disease-published-in-peer-reviewed-journal-alzheimer?s-research-and-therapy,20-04-2021 00:00,,,,,,
4301,darzalex?-sc-becomes-the-first-and-only-health-canada-approved-treatment-for-patients-with-newly-diagnosed-light-chain-al-amyloidosis-a-rare-disease,20-04-2021 00:00,,,,,,
4302,lilly-and-incyte?s-baricitinib-improved-hair-regrowth-for-alopecia-areata-patients-in-second-phase-3-study,20-04-2021 00:00,,,,,,
4303,vertex-pharmaceuticals-and-crispr-therapeutics-amend-collaboration-for-development-manufacturing-and-commercialization-of-ctx001?-in-sickle-cell-disease-and-beta-thalassemia,21-04-2021 00:00,,,,,,
4304,jazz-pharmaceuticals-presents-phase-3-study-results-of-xywav?-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-in-adult-patients-with-idiopathic-hypersomnia-at-2021-american-academy-of-neurology-annual-meeting,21-04-2021 00:00,,,,,,
4305,sparingvision-expands-novel-ocular-disease-pipeline-with-acquisition-of-gamut-therapeutics,21-04-2021 00:00,,,,,,
4306,physiq-announces-strategic-collaboration-to-scale-digital-medicine,21-04-2021 00:00,,,,,,
4307,gw-pharmaceuticals-receives-european-commission-approval-for-epidyolex?-cannabidiol-for-the-treatment-of-seizures-associated-with-tuberous-sclerosis-complex,21-04-2021 00:00,,,,,,
4308,lexeo-therapeutics-announces-fda-fast-track-designation-granted-to-lx1001-for-the-treatment-of-apoe4-associated-alzheimer?s-disease,21-04-2021 00:00,,,,,,
4309,medtronic-receives-us-fda-approval-for-pipeline?-flex-embolization-device-with-shield-technology?,22-04-2021 00:00,,,,,,
4310,novo-nordisk-to-initiate-phase-3a-development-in-obesity-with-oral-semaglutide,22-04-2021 00:00,,,,,,
4311,tg-therapeutics-announces-launch-of-the-ultra-v-phase-3-trial-evaluating-the-triple-combination-of-ukoniq?-umbralisib-ublituximab-and-venetoclax,22-04-2021 00:00,,,,,,
4312,agenebio-announces-completion-of-patient-enrollment-in-phase-2b-clinical-trial-to-evaluate-agb101-to-treat-amnestic-mild-cognitive-impairment-due-to-alzheimer?s-disease,22-04-2021 00:00,,,,,,
4313,johnson-johnson-single-shot-covid-19-vaccine-phase-3-data-published-in-new-england-journal-of-medicine,22-04-2021 00:00,,,,,,
4314,claritas-announces-agreement-with-cmax-clinical-research-for-phase-1-clinical-study-of-r-107,22-04-2021 00:00,,,,,,
4315,vertex-and-obsidian-therapeutics-establish-collaboration-to-discover-novel-therapies-that-regulate-gene-editing,23-04-2021 00:00,,,,,,
4316,roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-endometrial-cancer-patients-eligible-for-immunotherapy,23-04-2021 00:00,,,,,,
4317,fda-approves-jemperli-dostarlimab-gxly-for-dmmr-endometrial-cancer,23-04-2021 00:00,,,,,,
4318,abbvie-receives-health-canada-approval-of-humira?-adalimumab-for-the-treatment-of-pediatric-patients-with-moderately-to-severely-active-ulcerative-colitis,23-04-2021 00:00,,,,,,
4319,gilead-sciences-submits-new-drug-application-in-japan-for-filgotinib-for-the-treatment-of-ulcerative-colitis-with-an-inadequate-response-to-conventional-therapies,23-04-2021 00:00,,,,,,
4320,bristol-myers-squibb-receives-positive-chmp-opinion-for-onureg?-azacitidine-tablets-cc-486-as-frontline-oral-maintenance-therapy-for-adults-with-acute-myeloid-leukemia-in-first-remission,23-04-2021 00:00,,,,,,
4321,bristol-myers-squibb-presents-positive-data-from-two-pivotal-phase-3-psoriasis-studies-demonstrating-superiority-of-deucravacitinib-compared-to-placebo-and-otezla?-apremilast,26-04-2021 00:00,,,,,,
4322,european-commission-approves-jemperli-dostarlimab-the-first-anti-pd-1-therapy-approved-for-recurrent-or-advanced-dmmrmsi-h-endometrial-cancer-in-europe,26-04-2021 00:00,,,,,,
4323,dermavant-to-showcase-pasi90-itch-and-quality-of-life-data-from-phase-3-pivotal-trials-for-tapinarof-at-aad-vmx-2021,26-04-2021 00:00,,,,,,
4324,nirsevimab-demonstrated-protection-against-respiratory-syncytial-virus-disease-in-healthy-infants-in-phase-3-trial,26-04-2021 00:00,,,,,,
4325,selumetinib-recommended-for-approval-in-the-eu-by-chmp-as-the-first-medicine-for-paediatric-patients-with-neurofibromatosis-type-1-and-plexiform-neurofibromas,26-04-2021 00:00,,,,,,
4326,tagrisso-recommended-for-approval-in-the-eu-by-chmp-for-the-adjuvant-treatment-of-patients-with-early-stage-egfr-mutated-lung-cancer,26-04-2021 00:00,,,,,,
4327,biocon-biologics-and-viatris-receive-european-commission-approval-for-biosimilar-bevacizumab,27-04-2021 00:00,,,,,,
4328,medtronic-partners-with-surgical-theater-to-provide-first-augmented-reality-platform-for-use-in-real-time-during-complex-cranial-procedures,27-04-2021 00:00,,,,,,
4329,i-mab-announces-positive-topline-phase-2-results-for-olamkicept-in-ulcerative-colitis,27-04-2021 00:00,,,,,,
4330,pieris-pharmaceuticals-and-boston-pharmaceuticals-enter-into-an-exclusive-worldwide-product-license-for-prs-342-a-4-1bbgpc3-immuno-oncology-bispecific,27-04-2021 00:00,,,,,,
4331,esperion-expands-partnership-with-daiichi-sankyo-group-to-additional-territories,27-04-2021 00:00,,,,,,
4332,glenmark?s-ryaltris?-nasal-spray-now-approved-in-europe-for-the-first-line-treatment-of-allergic-rhinitis-in-patients-over-12-years-of-age,27-04-2021 00:00,,,,,,
4333,takeda-announces-us-fda-grants-priority-review-for-new-drug-application-for-mobocertinib-tak-788-as-a-treatment-for-egfr-exon20-insertion-metastatic-non-small-cell-lung-cancer,28-04-2021 00:00,,,,,,
4334,abbott?s-new-coronary-imaging-platform-powered-by-artificial-intelligence-launches-in-europe,28-04-2021 00:00,,,,,,
4335,y-mabs-submits-omburtamab-marketing-authorization-application-to-the-european-medicines-agency,28-04-2021 00:00,,,,,,
4336,inveniai-and-shionogi-enter-ai-powered-multi-target-drug-discovery-collaboration,28-04-2021 00:00,,,,,,
4337,logicbio-therapeutics-announces-strategic-collaboration-and-option-agreement-with-canbridge-pharmaceuticals-leveraging-gene-editing-and-gene-delivery-platforms,28-04-2021 00:00,,,,,,
4338,voluntis-and-eisai-to-collaborate-on-digital-therapeutics-for-oncology-patients,28-04-2021 00:00,,,,,,
4339,pfizer-acquires-amplyx-pharmaceuticals,29-04-2021 00:00,,,,,,
4340,organicell-announces-positive-results-of-initial-covid-19-zofin?-patient-trial-in-india-and-trial-expansion,29-04-2021 00:00,,,,,,
4341,allen-institute-and-biomarin-team-up-to-develop-gene-therapies-for-rare-brain-diseases,29-04-2021 00:00,,,,,,
4342,brukinsa?-zanubrutinib-demonstrates-superior-objective-response-rate-by-investigator-assessment-and-reduced-rates-of-atrial-fibrillation-or-flutter-at-interim-analysis-in-head-to-head-trial-against-ibrutinib-in-chronic-lymphocytic-leukemia,29-04-2021 00:00,,,,,,
4343,alcon-to-acquire-us-commercialization-rights-to-ophthalmic-eye-drop-simbrinza,29-04-2021 00:00,,,,,,
4344,angion-and-vifor-pharma-announce-completion-of-enrollment-in-phase-2-study-of-ang-3777-for-cardiac-surgery-associated-acute-kidney-injury,29-04-2021 00:00,,,,,,
4345,alphamab-announced-pd-l1ctla-4-bispecific-antibody-kn046-will-enter-new-phase-ii-clinical-trial-in-combination-with-pfizer?s-inlyta?-axitinib,30-04-2021 00:00,,,,,,
4346,innovent-announces-first-patient-dosed-in-the-phase-2-clinical-trial-of-ibi302-a-first-in-class-ophthalmic-anti-vegf-and-anti-complement-bispecific-fusion-protein-for-neovascular-age-related-macular-degeneration,30-04-2021 00:00,,,,,,
4347,celltrion?s-anti-covid-19-monoclonal-antibody-treatment-regdanvimab-ct-p59-demonstrates-neutralising-effect-against-the-south-african-variant-b1351,30-04-2021 00:00,,,,,,
4348,repertoire-immune-medicines-enters-collaboration-on-novel-antigen-discovery-and-t-cell-receptor-research-in-multiple-sclerosis,30-04-2021 00:00,,,,,,
4349,janssen-submits-marketing-authorisation-application-to-the-european-medicines-agency-seeking-approval-of-bcma-car-t-therapy-ciltacabtagene-autoleucel-cilta-cel-for-the-treatment-of-relapsed-andor-refractory-multiple-myeloma,30-04-2021 00:00,,,,,,
4350,us-food-and-drug-administration-accepts-for-priority-review-bristol-myers-squibb?s-application-for-opdivo-nivolumab-as-adjuvant-treatment-for-patients-with-muscle-invasive-urothelial-carcinoma,30-04-2021 00:00,,,,,,
4351,farxiga-approved-in-the-us-for-the-treatment-of-chronic-kidney-disease-in-patients-at-risk-of-progression-with-and-without-type-2-diabetes,03-05-2021 00:00,,,,,,
4352,samsung-bioepis-announces-analytical-similarity-data-on-sb11-ranibizumab-at-the-arvo-annual-meeting-2021,03-05-2021 00:00,,,,,,
4353,novartis-phase-iii-beovu?-data-show-potential-for-fluid-resolution-in-more-diabetic-macular-edema-patients-with-fewer-injections-versus-aflibercept,03-05-2021 00:00,,,,,,
4354,british-columbia-adds-humira-adalimumab-to-biosimilar-switching-program,09-04-2021 00:00,,,,,,
4355,valeo-pharma-announces-commercial-launch-of-redesca?-and-redesca-hp?,15-04-2021 00:00,,,,,,
4356,xcenda?s-formularydecisions-launches-resource-hub-for-biosimilar-products,08-04-2021 00:00,,,,,,
4357,sobi-and-hellenic-institute-for-the-study-of-sepsis-anakinra-improved-overall-clinical-outcomes-by-64-in-hospitalised-patients-with-covid-19-pneumonia,03-05-2021 00:00,,,,,,
4358,study-shows-guardant-reveal?-blood-only-liquid-biopsy-test-predicts-risk-for-colorectal-cancer-recurrence-with-industry-leading-sensitivity,03-05-2021 00:00,,,,,,
4359,olumiant?-showed-significant-improvements-in-the-severity-and-extent-of-atopic-dermatitis-and-other-patient-reported-outcomes-in-phase-3-study-analyses,03-05-2021 00:00,,,,,,
4360,province-expands-the-use-of-biosimilars-to-improve-the-sustainability-of-public-drug-plans,21-04-2021 00:00,,,,,,
4361,voltaire-x-phase-iii-data-in-patients-with-moderate-to-severe-chronic-plaque-psoriasis-support-interchangeability-application,23-04-2021 00:00,,,,,,
4362,new-biosimilar-switch-policy-in-new-brunswick-improves-patient-access-to-safe-and-effective-medicines,21-04-2021 00:00,,,,,,
4363,roivant-sciences-and-montes-archimedes-acquisition-corp-maac-to-combine-and-create-publicly-traded-leader-in-biopharma-and-health-technology,04-05-2021 00:00,,,,,,
4364,labcorp-to-acquire-myriad-autoimmune?s-vectra-testing-business-from-myriad-genetics,04-05-2021 00:00,,,,,,
4365,sandoz-confirms-late-stage-clinical-development-plans-for-proposed-biosimilar-aflibercept-a-key-ophthalmology-medicine,04-05-2021 00:00,,,,,,
4366,novavax-initiates-pediatric-expansion-for-phase-3-clinical-trial-of-covid-19-vaccine,04-05-2021 00:00,,,,,,
4367,bristol-myers-squibb-presents-new-clinical-and-real-world-data-on-mavacamten-and-obstructive-hypertrophic-cardiomyopathy-at-upcoming-american-college-of-cardiology?s-70th-annual-scientific-session,04-05-2021 00:00,,,,,,
4368,new-data-from-vaxart-oral-covid-19-vaccine-phase-i-study-suggests-broad-cross-reactivity-against-other-coronaviruses,04-05-2021 00:00,,,,,,
4369,athenex-to-acquire-kuur-therapeutics-to-expand-cell-therapy-development-with-off-the-shelf-engineered-car-nkt-platform,05-05-2021 00:00,,,,,,
4370,roche?s-tecentriq-approved-by-european-commission-as-a-first-line-monotherapy-treatment-for-people-with-a-type-of-metastatic-non-small-cell-lung-cancer,05-05-2021 00:00,,,,,,
4371,amgevita?-a-biosimilar-to-humira?-adalimumab-is-now-available-in-canada-for-the-treatment-of-multiple-chronic-inflammatory-diseases,05-05-2021 00:00,,,,,,
4372,new-abcellera-discovered-antibody-that-neutralizes-viral-variants-of-covid-19-ly-cov1404-enters-clinical-trials,05-05-2021 00:00,,,,,,
4373,proqr-therapeutics-and-yarrow-biotechnology-an-rtw-investments-lp-incubated-company-announce-exclusive-worldwide-license-and-discovery-collaboration-for-undisclosed-target,05-05-2021 00:00,,,,,,
4374,exelixis-expands-its-biotherapeutics-portfolio-with-acquisition-of-gamamabs-pharma?s-first-in-class-humanized-antibody-program-against-a-novel-oncology-target,05-05-2021 00:00,,,,,,
4375,european-commission-approves-benlysta-for-adult-patients-with-active-lupus-nephritis,06-05-2021 00:00,,,,,,
4376,phenomix-sciences-signs-exclusive-technology-licensing-deal-with-mayo-clinic-for-obesity-phenotype-blood-test,06-05-2021 00:00,,,,,,
4377,medtronic-announces-careguidepro?-a-new-mobile-app-and-online-platform-for-patients-to-navigate-their-spinal-cord-stimulation-journey,06-05-2021 00:00,,,,,,
4378,sanofi-establishes-three-year-collaboration-with-stanford-medicine-to-accelerate-immunology-research,06-05-2021 00:00,,,,,,
4379,roche-receives-emergency-use-authorisation-in-india-for-its-investigational-antibody-cocktail-casirivimab-and-imdevimab-used-in-the-treatment-of-covid-19,06-05-2021 00:00,,,,,,
4380,fda-accepts-amgen?s-supplemental-new-drug-application-for-otezla?-apremilast-for-adults-with-mild-to-moderate-plaque-psoriasis,06-05-2021 00:00,,,,,,
4381,merck-and-eisai-receive-priority-review-from-fda-for-keytruda?-pembrolizumab-plus-lenvima?-lenvatinib-applications-for-advanced-renal-cell-carcinoma-and-for-advanced-endometrial-carcinoma,07-05-2021 00:00,,,,,,
4382,abcellera-partners-with-angios-to-develop-therapeutics-to-combat-blindness-caused-by-diabetic-retinopathy,07-05-2021 00:00,,,,,,
4383,beigene-and-asieris-enter-into-clinical-collaboration-for-apl-1202-tislelizumab-to-treat-muscle-invasive-bladder-cancer,07-05-2021 00:00,,,,,,
4384,darwinhealth-announces-a-research-collaboration-with-bristol-myers-squibb-for-a-novel-cancer-target-discovery-ncti-initiative,07-05-2021 00:00,,,,,,
4385,fusion-pharmaceuticals-announces-clinical-collaboration-with-merck-to-evaluate-fusion?s-targeted-alpha-therapy-tat-in-combination-with-merck?s-keytruda?-pembrolizumab-in-patients-with-solid-tumors-expressing-igf-1r,07-05-2021 00:00,,,,,,
4386,imfinzi-and-tremelimumab-with-chemotherapy-demonstrated-overall-survival-benefit-in-poseidon-trial-for-1st-line-stage-iv-non-small-cell-lung-cancer,07-05-2021 00:00,,,,,,
4387,gsk-and-vir-biotechnology-announce-the-start-of-the-ema-rolling-review-of-vir-7831-sotrovimab-for-the-early-treatment-of-covid-19,10-05-2021 00:00,,,,,,
4388,bd-announces-intent-to-spin-off-diabetes-care-business-to-enhance-focus-on-innovation-and-priority-growth-markets,10-05-2021 00:00,,,,,,
4389,lilly-collaborates-internationally-with-leading-diabetes-technology-companies-to-integrate-connected-insulin-pen-solutions-for-people-with-diabetes,10-05-2021 00:00,,,,,,
4390,walmart-health-to-acquire-telehealth-provider-memd,10-05-2021 00:00,,,,,,
4391,pfizer-and-biontech-initiate-rolling-submission-of-biologics-license-application-for-us-fda-approval-of-their-covid-19-vaccine,10-05-2021 00:00,,,,,,
4392,aurinia-announces-publication-of-aurora-1-phase-3-study-results-with-lupkynis?-voclosporin-in-the-lancet,10-05-2021 00:00,,,,,,
4393,bayer?s-finerenone-meets-primary-endpoint-in-phase-iii-figaro-dkd-cardiovascular-outcomes-study-in-patients-with-chronic-kidney-disease-and-type-2-diabetes,11-05-2021 00:00,,,,,,
4394,pfizer-and-biontech-initiate-rolling-submission-of-biologics-license-application-for-us-fda-approval-of-their-covid-19-vaccine,11-05-2021 00:00,,,,,,
4395,amgen-announces-tezepelumab-biologics-license-application-submitted-to-us-fda,11-05-2021 00:00,,,,,,
4396,allergan-aesthetics-to-acquire-soliton-expanding-body-contouring-portfolio,11-05-2021 00:00,,,,,,
4397,biogen-and-capsigen-announce-collaboration-to-discover-and-develop-novel-aav-capsids-for-targeted-cns-and-neuromuscular-disorders,11-05-2021 00:00,,,,,,
4398,lilly-and-mina-therapeutics-announce-sarna-research-collaboration,11-05-2021 00:00,,,,,,
4399,autobahn-therapeutics-acquires-clinical-stage-faah-inhibitor-from-astellas-strengthening-its-brain-targeting-chemistry-platform,12-05-2021 00:00,,,,,,
4400,cellectis-and-sanofi-partner-on-alemtuzumab-as-lymphodepletion-agent-for-allogeneic-car-t,12-05-2021 00:00,,,,,,
4401,incyte-and-morphosys-announce-first-patient-dosed-in-phase-3-frontmind-study-evaluating-tafasitamab-combination-as-a-first-line-treatment-for-diffuse-large-b-cell-lymphoma,12-05-2021 00:00,,,,,,
4402,nanobiotix-partners-with-lianbio-to-develop-and-commercialize-potential-first-in-class-radioenhancer-nbtxr3-across-tumor-types-and-therapeutic-combinations-in-china-and-other-asian-markets,12-05-2021 00:00,,,,,,
4403,medtronic-launches-new-pediatric-monitor-that-alerts-clinicians-to-potential-airway-obstructions-during-ventilation,12-05-2021 00:00,,,,,,
4404,adc-therapeutics-announces-fda-approval-of-zynlonta-loncastuximab-tesirine-lpyl-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma,23-04-2021 00:00,,,,,,
4405,05-2021-inflarx-announces-positive-topline-results-for-vilobelimab-from-the-us-phase-ii-anca-associated-vasculitis-ixplore-study,12-05-2021 00:00,,,,,,
4406,us-fda-approves-nextstellis-new-oral-contraceptive,16-04-2021 00:00,,,,,,
4407,biogen-announces-exercise-of-option-to-acquire-the-investigational-drug-tms-007-for-acute-ischemic-stroke-based-on-positive-phase-2a-data,13-05-2021 00:00,,,,,,
4408,supernus-announces-fda-approval-of-qelbree-spn-812-for-the-treatment-of-adhd,02-04-2021 00:00,,,,,,
4409,positive-phase-3-libtayo?-cemiplimab-results-in-advanced-cervical-cancer-presented-at-esmo-virtual-plenary,13-05-2021 00:00,,,,,,
4410,antengene-announces-ind-approval-in-china-for-a-global-phase-iii-trial-of-selinexor-in-advanced-or-recurrent-endometrial-cancer,13-05-2021 00:00,,,,,,
4411,new-tezepelumab-data-continue-to-strengthen-profile-for-a-broad-population-of-severe-asthma-patients,13-05-2021 00:00,,,,,,
4412,fulcrum-therapeutics-announces-us-food-and-drug-administration-grants-fast-track-designation-to-losmapimod-for-the-potential-treatment-of-facioscapulohumeral-muscular-dystrophy-fshd,13-05-2021 00:00,,,,,,
4413,pregene-and-dr-reddy?s-announce-license-agreement-for-anti-bcma-car-t-prg1801-in-india,13-05-2021 00:00,,,,,,
4414,hikma-announces-us-fda-approval-of-kloxxadotm-naloxone-hydrochloride-nasal-spray-8mg,30-04-2021 00:00,,,,,,
4415,biogen-and-envisagenics-announce-collaboration-to-advance-rna-splicing-research,14-05-2021 00:00,,,,,,
4416,semaglutide-in-people-with-obesity-boosts-wellbeing-and-ability-to-perform-daily-physical-activities,14-05-2021 00:00,,,,,,
4417,heron-therapeutics-announces-us-fda-approval-of-zynrelef?-htx-011-for-the-management-of-postoperative-pain-for-up-to-72-hours,14-05-2021 00:00,,,,,,
4418,reistone-announces-first-patient-dosed-in-phase-iii-global-study-in-atopic-dermatitis,14-05-2021 00:00,,,,,,
4419,goldfinch-bio-initiates-phase-1-clinical-trial-of-gfb-024-a-novel-precision-medicine-product-candidate-for-patients-with-severe-insulin-resistant-diabetic-nephropathy-dn,14-05-2021 00:00,,,,,,
4420,azurrx-biopharma-announces-positive-interim-data-in-phase-2-clinical-trial-of-ms1819-in-combination-with-pert-in-the-treatment-of-cystic-fibrosis-patients-with-severe-exocrine-pancreatic-insufficiency,14-05-2021 00:00,,,,,,
4421,biogen-announces-topline-results-from-phase-23-gene-therapy-study-for-xlrp,17-05-2021 00:00,,,,,,
4422,bristol-myers-squibb-presents-late-breaking-phase-3-data-demonstrating-health-status-benefits-of-mavacamten-in-patients-with-obstructive-hypertrophic-cardiomyopathy-at-american-college-of-cardiology?s-70th-annual-scientific-session,17-05-2021 00:00,,,,,,
4423,sanofi-and-gsk-covid-19-vaccine-candidate-demonstrates-strong-immune-responses-across-all-adult-age-groups-in-phase-2-trial,17-05-2021 00:00,,,,,,
4424,perkinelmer-to-acquire-in-vitro-diagnostics-company-immunodiagnostic-systems-holdings-plc,17-05-2021 00:00,,,,,,
4425,apellis-announces-us-food-and-drug-administration-fda-approval-of-empaveli?-pegcetacoplan-for-adults-with-paroxysmal-nocturnal-hemoglobinuria-pnh,17-05-2021 00:00,,,,,,
4426,charles-river-laboratories-to-acquire-vigene-biosciences-to-enhance-gene-therapy-capabilities,17-05-2021 00:00,,,,,,
4427,abbott-receives-ce-mark-for-navitor?-the-latest-generation-transcatheter-aortic-valve-implantation-tavi-system-to-treat-aortic-stenosis,18-05-2021 00:00,,,,,,
4428,pivotal-data-at-ats-2021-show-dupixent?-dupilumab-significantly-reduced-asthma-attacks-and-improved-lung-function-in-children,18-05-2021 00:00,,,,,,
4429,us-fda-accepts-regulatory-submission-for-sintilimab-in-combination-with-pemetrexed-and-platinum-chemotherapy-for-the-first-line-treatment-of-people-with-nonsquamous-non-small-cell-lung-cancer,18-05-2021 00:00,,,,,,
4430,roche-receives-fda-authorisation-for-testing-of-asymptomatic-people-with-the-cobas-sars-cov-2-test-to-help-control-the-spread-of-covid-19,18-05-2021 00:00,,,,,,
4431,medicago-and-gsk-announce-positive-interim-phase-2-results-for-adjuvanted-covid-19-vaccine-candidate,18-05-2021 00:00,,,,,,
4432,bluerock-therapeutics-fujifilm-cellular-dynamics-and-opsis-therapeutics-enter-into-a-strategic-rd-alliance-to-discover-and-develop-cell-therapies-for-eye-diseases,18-05-2021 00:00,,,,,,
4433,agenus-and-bristol-myers-squibb-announce-exclusive-global-license-for-agenus?-anti-tigit-bispecific-antibody-program,19-05-2021 00:00,,,,,,
4434,sarepta-therapeutics?-investigational-gene-therapy-for-the-treatment-of-duchenne-muscular-dystrophy-srp-9001-demonstrates-robust-expression-and-consistent-safety-profile-using-sarepta?s-commercial-process-material,19-05-2021 00:00,,,,,,
4435,glaukos-expands-its-preserflo?-microshunt-relationship-with-santen-via-new-license-agreement,19-05-2021 00:00,,,,,,
4436,mestag-therapeutics-announces-collaboration-with-janssen-focused-on-the-discovery-of-novel-fibroblast-targets-for-the-treatment-of-inflammatory-disease,19-05-2021 00:00,,,,,,
4437,exscientia-announces-multi-target-ai-driven-drug-discovery-collaboration-with-bristol-myers-squibb,19-05-2021 00:00,,,,,,
4438,bioxcel-therapeutics-announces-fda-acceptance-for-filing-of-nda-for-bxcl501-for-the-acute-treatment-of-agitation-associated-with-schizophrenia-and-bipolar-disorders-i-and-ii,19-05-2021 00:00,,,,,,
4439,pivotal-phase-iii-data-at-asco-show-genentech?s-tecentriq-helps-certain-people-with-early-lung-cancer-live-significantly-longer-without-their-disease-returning,20-05-2021 00:00,,,,,,
4440,takeda-presents-updated-results-for-mobocertinib-further-substantiating-the-clinical-benefit-in-patients-with-egfr-exon20-insertion-mnsclc,20-05-2021 00:00,,,,,,
4441,updated-amivantamab-and-lazertinib-combination-data-demonstrate-durable-responses-and-clinical-activity-for-osimertinib-relapsed-patients-with-egfr-mutated-non-small-cell-lung-cancer,20-05-2021 00:00,,,,,,
4442,allogene-therapeutics-cd19-forum-highlights-positive-results-from-phase-1-studies-of-allo-501-and-allo-501a-in-relapsedrefractory-non-hodgkin-lymphoma-and-plan-to-initiate-pivotal-study-in-2021,20-05-2021 00:00,,,,,,
4443,imbruvica?-ibrutinib-based-combination-regimen-as-a-fixed-duration-first-line-treatment-for-chronic-lymphocytic-leukemia-demonstrates-high-rates-of-disease-control,20-05-2021 00:00,,,,,,
4444,lilly?s-tirzepatide-achieves-all-primary-and-key-secondary-study-outcomes-against-insulin-glargine-in-adults-with-type-2-diabetes-and-increased-cardiovascular-risk-in-surpass-4-trial,20-05-2021 00:00,,,,,,
4445,takeda-announces-approval-of-moderna?s-covid-19-vaccine-in-japan,21-05-2021 00:00,,,,,,
4446,astrazeneca-covid-19-vaccine-vaxzevria-authorised-for-emergency-use-in-japan,21-05-2021 00:00,,,,,,
4447,us-food-drug-administration-grants-priority-review-of-maribavir-for-the-treatment-of-post-transplant-recipients-with-cytomegalovirus-infection-in-those-resistant-andor-refractory-to-prior-anti-cmv-treatment,21-05-2021 00:00,,,,,,
4448,astellas-and-seagen-announce-updated-results-from-two-trials-of-padcev?-enfortumab-vedotin-ejfv-in-patients-with-locally-advanced-or-metastatic-urothelial-cancer-not-eligible-for-cisplatin-chemotherapy,21-05-2021 00:00,,,,,,
4449,aurinia-to-present-supportive-aurora-2-continuation-study-interim-analysis-demonstrating-long-term-safety-efficacy-of-lupkynis?-voclosporin-in-subjects-with-lupus-nephritis,21-05-2021 00:00,,,,,,
4450,beigene-announces-positive-topline-results-from-phase-3-trial-of-tislelizumab-in-combination-with-chemotherapy-as-first-line-treatment-for-recurrent-or-metastatic-nasopharyngeal-cancer,21-05-2021 00:00,,,,,,
4451,bristol-myers-squibb-receives-positive-chmp-opinion-recommending-opdivo-nivolumab-plus-yervoy-ipilimumab-for-treatment-of-mismatch-repair-deficient-or-microsatellite-instability?high-metastatic-colorectal-cancer-after-prior-chemotherapy,24-05-2021 00:00,,,,,,
4452,rybrevant?-amivantamab-vmjw-receives-fda-approval-as-the-first-targeted-treatment-for-patients-with-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations,24-05-2021 00:00,,,,,,
4453,libtayo?-cemiplimab-receives-positive-chmp-opinion-for-the-treatment-in-europe-of-two-advanced-cancers,24-05-2021 00:00,,,,,,
4454,potential-impact-of-takeda?s-dengue-vaccine-candidate-reinforced-by-long-term-safety-and-efficacy-results,24-05-2021 00:00,,,,,,
4455,mirikizumab-improves-fatigue-in-patients-with-crohn?s-disease-in-phase-2-trial,24-05-2021 00:00,,,,,,
4456,pfizer-initiates-study-exploring-coadministration-of-its-20-valent-pneumococcal-conjugate-vaccine-candidate-along-with-a-third-dose-of-the-pfizer-biontech-covid-19-vaccine-in-older-adults,24-05-2021 00:00,,,,,,
4457,dicerna-announces-boehringer-ingelheim?s-acceptance-of-candidate-for-development-under-rnai-research-collaboration-and-license-agreement,25-05-2021 00:00,,,,,,
4458,janssen-presents-results-of-first-head-to-head-study-of-biologic-therapies-in-patients-with-moderate-to-severe-crohn?s-disease,25-05-2021 00:00,,,,,,
4459,abbvie-presents-new-late-breaking-data-analyses-showing-risankizumab-skyrizi?-achieves-clinical-remission-and-endoscopic-response-at-week-12-in-patients-with-moderate-to-severe-crohn?s-disease,25-05-2021 00:00,,,,,,
4460,precision-oncology-treatment-larotrectinib-submitted-for-marketing-authorization-in-china,25-05-2021 00:00,,,,,,
4461,boehringer-ingelheim?s-investigational-treatment-for-cognitive-impairment-associated-with-schizophrenia-receives-fda-breakthrough-therapy-designation,25-05-2021 00:00,,,,,,
4462,xilio-therapeutics-announces-clinical-trial-collaboration-with-merck-on-anti-ctla-4-monoclonal-antibody-program,25-05-2021 00:00,,,,,,
4463,xencor-and-bristol-myers-squibb-enter-license-agreement-for-use-of-xtend?-xmab?-technology-in-sars-cov-2-neutralizing-monoclonal-antibody-combination-for-the-treatment-of-covid-19,26-05-2021 00:00,,,,,,
4464,qiagen-partners-with-mirati-therapeutics-inc-to-develop-krasg12c-companion-diagnostic-for-non-small-cell-lung-cancer-nsclc,26-05-2021 00:00,,,,,,
4465,biofactura-announces-initiation-of-phase-i-study-of-bfi-751-a-stelara?-ustekinumab-biosimilar,26-05-2021 00:00,,,,,,
4466,abbvie-receives-european-commission-approval-of-venclyxto?-venetoclax-in-combination-with-a-hypomethylating-agent-for-patients-with-newly-diagnosed-acute-myeloid-leukemia-who-are-ineligible-for-intensive-chemotherapy,26-05-2021 00:00,,,,,,
4467,moderna-announces-teencove-study-of-its-covid-19-vaccine-in-adolescents-meets-primary-endpoint-and-plans-to-submit-data-to-regulators-in-early-june,26-05-2021 00:00,,,,,,
4468,tg-therapeutics-announces-fda-acceptance-of-biologics-license-application-for-ublituximab-in-combination-with-ukoniq?-umbralisib-as-a-treatment-for-patients-with-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma,26-05-2021 00:00,,,,,,
4469,gsk-and-vir-biotechnology-announce-sotrovimab-vir-7831-receives-emergency-use-authorization-from-the-us-fda-for-treatment-of-mild-to-moderate-covid-19-in-high-risk-adults-and-paediatric-patients,27-05-2021 00:00,,,,,,
4470,myovant-sciences-and-pfizer-receive-fda-approval-for-myfembree?-the-first-once-daily-treatment-for-heavy-menstrual-bleeding-associated-with-uterine-fibroids,27-05-2021 00:00,,,,,,
4471,sanofi-and-gsk-initiate-global-phase-3-clinical-efficacy-study-of-covid-19-vaccine-candidate,27-05-2021 00:00,,,,,,
4472,novartis-and-molecular-partners-announce-start-of-empathy-clinical-trial-for-ensovibep-for-the-treatment-of-covid-19,27-05-2021 00:00,,,,,,
4473,senti-bio-and-bluerock-therapeutics-enter-collaboration-to-develop-gene-circuit-engineered-cell-therapies-for-regenerative-medicine,27-05-2021 00:00,,,,,,
4474,dicerna-announces-fda-acceptance-of-lilly?s-investigational-new-drug-ind-application-for-ly3819469,27-05-2021 00:00,,,,,,
4475,opdivo-and-yervoy-combination-therapy-approved-in-japan-for-first-line-treatment-of-unresectable-advanced-or-recurrent-malignant-pleural-mesothelioma,28-05-2021 00:00,,,,,,
4476,us-food-and-drug-administration-approves-bristol-myers-squibb?s-zeposia?-ozanimod-an-oral-treatment-for-adults-with-moderately-to-severely-active-ulcerative-colitis,28-05-2021 00:00,,,,,,
4477,tagrisso-approved-in-the-eu-for-the-adjuvant-treatment-of-patients-with-early-stage-egfr-mutated-lung-cancer,28-05-2021 00:00,,,,,,
4478,uniqure-announces-positive-recommendation-to-advance-phase-iii-clinical-trial-of-amt-130-for-the-treatment-of-huntington?s-disease,28-05-2021 00:00,,,,,,
4479,fda-advisory-committee-votes-in-favor-of-the-benefits-of-teplizumab-outweighing-the-risks-in-support-of-approval-to-delay-clinical-type-1-diabetes-t1d,28-05-2021 00:00,,,,,,
4480,seelos-therapeutics-receives-european-orphan-drug-designation-for-sls-005-trehalose-in-amyotrophic-lateral-sclerosis-als,28-05-2021 00:00,,,,,,
4481,fda-approves-lumakras?-sotorasib-the-first-and-only-targeted-treatment-for-patients-with-kras-g12c-mutated-locally-advanced-or-metastatic-non-small-cell-lung-cancer,31-05-2021 00:00,,,,,,
4482,pfizer-and-biontech-receive-first-authorization-in-european-union-for-covid-19-vaccine-in-adolescents,31-05-2021 00:00,,,,,,
4483,novartis-reports-one-year-results-of-phase-iii-merlin-study-evaluating-beovu?-every-four-week-dosing-and-provides-update-on-beovu-clinical-program,31-05-2021 00:00,,,,,,
4484,bridgebio-pharma?s-affiliate-qed-therapeutics-and-partner-helsinn-group-announce-fda-approval-of-truseltiq?-infigratinib-for-patients-with-cholangiocarcinoma,31-05-2021 00:00,,,,,,
4485,novo-nordisk-resubmits-once-weekly-semaglutide-20-mg-for-the-treatment-of-type-2-diabetes-for-us-regulatory-approval,31-05-2021 00:00,,,,,,
4486,ipsen-confirms-us-fda-accepts-new-drug-application-for-palovarotene-as-the-first-potential-treatment-worldwide-for-fibrodysplasia-ossificans-progressiva-fop,31-05-2021 00:00,,,,,,
4487,health-canada-approves-abecma?-idecabtagene-vicleucel-the-first-and-only-anti-bcma-car-t-cell-therapy-for-relapsed-and-refractory-multiple-myeloma,01-06-2021 00:00,,,,,,
4488,sanofi-provides-update-on-venglustat-clinical-program,01-06-2021 00:00,,,,,,
4489,ab-science-announced-today-that-it-has-taken-the-decision-to-suspend-inclusions-and-treatment-initiation-in-its-clinical-studies-with-masitinib-worldwideab-science-announced-today-that-it-has-taken-the-decision-to-suspend-inclusions-and-treatment-initiation-in-its-clinical-studies-with-masitinib-worldwideab-science-announced-today-that-it-has-taken-the-decision-to-suspend-inclusions-and-treatment-initiation-in-its-clinical-studies-with-masitinib-worldwide,01-06-2021 00:00,,,,,,
4490,fda-approves-biohaven?s-nurtec?-odt-rimegepant-for-prevention-now-the-first-and-only-migraine-medication-for-both-acute-and-preventive-treatment,01-06-2021 00:00,,,,,,
4491,amgen-and-kyowa-kirin-to-jointly-develop-and-commercialize-khk4083-a-phase-3-ready-potential-first-in-class-treatment-for-atopic-dermatitis,01-06-2021 00:00,,,,,,
4492,santhera-and-reveragen-announce-positive-and-statistically-highly-significant-topline-results-with-vamorolone-in-pivotal-vision-dmd-study,01-06-2021 00:00,,,,,,
4493,novartis-cosentyx-receives-fda-approval-for-treatment-of-children-and-adolescents-with-moderate-to-severe-plaque-psoriasis,02-06-2021 00:00,,,,,,
4494,janssen-announces-us-fda-breakthrough-therapy-designation-granted-for-teclistamab-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma,02-06-2021 00:00,,,,,,
4495,alnylam-completes-enrollment-in-apollo-b-phase-3-study-of-patisiran-in-transthyretin-mediated-attr-amyloidosis-patients-with-cardiomyopathy,02-06-2021 00:00,,,,,,
4496,anifrolumab-showed-benefit-across-different-measures-of-skin-and-joint-disease-activity-in-patients-with-systemic-lupus-erythematosus,02-06-2021 00:00,,,,,,
4497,novartis-presents-positive-phase-iii-results-from-junipera-study-supporting-cosentyx?-as-a-potential-treatment-in-a-jia-population-at-eular-2021,02-06-2021 00:00,,,,,,
4498,new-long-term-efficacy-and-safety-analyses-evaluating-rinvoq?-upadacitinib-in-patients-with-rheumatoid-arthritis-to-be-presented-at-eular-2021-virtual-congress,02-06-2021 00:00,,,,,,
4499,morphosys-to-acquire-constellation-pharmaceuticals,03-06-2021 00:00,,,,,,
4500,prime-therapeutics-launches-meddrivetm-a-first-of-its-kind-medical-drug-management-program-uniquely-aligned-with-its-blue-plan-clients,26-05-2021 00:00,,,,,,
4501,bristol-myers-squibb-receives-european-commission-approval-for-opdivo-nivolumab-plus-yervoy-ipilimumab-as-first-line-treatment-for-unresectable-malignant-pleural-mesothelioma,03-06-2021 00:00,,,,,,
4502,xbrane-announces-ambition-to-generate-positive-operating-cash-flow-monthly-by-late-2023early-2024-and-to-initiate-one-new-biosimilar-development-program-per-annum,17-05-2021 00:00,,,,,,
4503,novartis-kymriah?-pivotal-trial-demonstrates-strong-response-rates-and-a-remarkable-safety-profile-in-relapsed-or-refractory-follicular-lymphoma,03-06-2021 00:00,,,,,,
4504,"quebec-announces-intention-to-implement-a-biosimilar-switching-policy
-quebec-announces-intention-to-implement-a-biosimilar-switching-policy",19-05-2021 00:00,,,,,,
4505,sandoz-canada-congratulates-the-quebec-government-on-implementing-a-shift-towards-biosimilars,18-05-2021 00:00,,,,,,
4506,sandoz-canada-launches-its-6th-biosimilar-with-inclunox?-and-inclunox?-hp-enoxaparin-sodium-solution-for-injection-100-mgml-and-150-mgml-high-potency,17-05-2021 00:00,,,,,,
4507,zydus-launches-ujvira-trastuzumab-emtansine-a-breakthrough-in-breast-cancer-treatment,24-05-2021 00:00,,,,,,
4508,celltrion-healthcare-presents-positive-one-year-data-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17-in-patients-with-rheumatoid-arthritis-at-eular-2021,03-06-2021 00:00,,,,,,
4509,correcting-and-replacing-meiji-seika-pharma-promising-results-of-phase-i-clinical-trial-of-dmb-3115-a-proposed-ustekinumab-biosimilar-and-initiation-of-phase-iii-clinical-trial-in-patients-with-plaque-psoriasis,21-05-2021 00:00,,,,,,
4510,lupin-announces-us-fda-acceptance-for-pegfilgrastim-biosimilar-application,03-06-2021 00:00,,,,,,
4511,biogen-and-bio-thera-announce-positive-results-from-phase-3-study-of-bat1806-a-proposed-biosimilar-referencing-actemra?-tocilizumab,03-06-2021 00:00,,,,,,
4512,us-supreme-court-denies-sandoz-petition-to-review-biosimilar-erelzi?-etanercept-szzs-case,17-05-2021 00:00,,,,,,
4513,viatris-expects-first-?interchangeable?-designation-in-july-2021-for-insulin-products,14-05-2021 00:00,,,,,,
4514,alvotech-seeks-to-end-abbvie?s-wrongful-monopoly-on-humira-and-bring-affordable-arthritis-treatment-to-us,11-05-2021 00:00,,,,,,
4515,innovent-and-lilly-jointly-announce-the-china-nmpa-approval-of-tyvyt?-sintilimab-injection-in-combination-with-gemcitabine-and-platinum-chemotherapy-as-first-line-therapy-for-people-with-squamous-non-small-cell-lung-cancer,04-06-2021 00:00,,,,,,
4516,merck?s-keytruda?-pembrolizumab-given-after-surgery-reduced-the-risk-of-disease-recurrence-or-death-by-32-versus-placebo-as-adjuvant-therapy-in-patients-with-renal-cell-carcinoma-rcc,04-06-2021 00:00,,,,,,
4517,united-therapeutics-announces-first-patient-enrolled-in-phase-3-teton-study-of-tyvaso-in-patients-with-idiopathic-pulmonary-fibrosis,04-06-2021 00:00,,,,,,
4518,bristol-myers-squibb-presents-data-from-checkmate-648-showing-opdivo-plus-chemotherapy-and-opdivo-plus-yervoy-significantly-improved-overall-survival-compared-to-chemotherapy-in-unresectable-advanced-or-metastatic-esophageal-squamous-cell-carcinoma,04-06-2021 00:00,,,,,,
4519,dermavant-submits-new-drug-application-nda-to-fda-for-tapinarof-cream-for-the-treatment-of-adults-with-plaque-psoriasis,04-06-2021 00:00,,,,,,
4520,tonix-pharmaceuticals-presents-positive-results-from-phase-3-relief-study-of-tnx-102-sl-for-the-management-of-fibromyalgia-at-the-2021-american-society-of-clinical-psychopharmacology-ascp-annual-meeting,04-06-2021 00:00,,,,,,
4521,novartis-announces-iptacopan-met-phase-ii-study-primary-endpoint-in-rare-kidney-disease-iga-nephropathy-igan,07-06-2021 00:00,,,,,,
4522,fda-approves-first-treatment-for-patients-with-plasminogen-deficiency-a-rare-genetic-disorder,07-06-2021 00:00,,,,,,
4523,wegovy?-semaglutide-24-mg-the-first-and-only-once-weekly-glp-1-therapy-for-weight-management-approved-in-the-us,07-06-2021 00:00,,,,,,
4524,calquence-demonstrated-fewer-incidences-of-atrial-fibrillation-versus-ibrutinib-in-previously-treated-patients-with-chronic-lymphocytic-leukaemia-and-sustained-patient-benefit-at-four-years-in-the-front-line-setting,07-06-2021 00:00,,,,,,
4525,imfinzi-demonstrated-unprecedented-survival-in-unresectable-stage-iii-lung-cancer-with-43-of-patients-surviving-five-years,07-06-2021 00:00,,,,,,
4526,springworks-therapeutics-announces-clinical-collaboration-with-seagen-to-evaluate-nirogacestat-in-combination-with-sea-bcma-in-patients-with-relapsed-or-refractory-multiple-myeloma,07-06-2021 00:00,,,,,,
4527,fda-grants-accelerated-approval-for-aduhelm?-as-the-first-and-only-alzheimer?s-disease-treatment-to-address-a-defining-pathology-of-the-disease,08-06-2021 00:00,,,,,,
4528,msd-animal-health-to-acquire-assets-of-lic-automation-ltd,08-06-2021 00:00,,,,,,
4529,argenx-to-regain-global-rights-to-cusatuzumab,08-06-2021 00:00,,,,,,
4530,roche-obtains-ce-mark-for-the-sars-cov-2-antigen-self-test-nasal-allowing-for-rapid-self-testing-of-covid-19-at-home,08-06-2021 00:00,,,,,,
4531,beigene-announces-acceptance-of-a-supplemental-biologics-license-application-in-china-for-tislelizumab-in-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-solid-tumors,08-06-2021 00:00,,,,,,
4532,health-canada-approves-abbvie?s-rinvoq?-upadacitinib-for-the-treatment-of-adults-with-active-psoriatic-arthritis,08-06-2021 00:00,,,,,,
4533,bayer-to-advance-two-first-of-its-kind-investigational-cell-and-gene-therapies-for-parkinson?s-disease,09-06-2021 00:00,,,,,,
4534,progentec-announces-research-collaboration-with-gsk-to-assess-proteomics-and-digital-health-tools-for-lupus-sle-care,09-06-2021 00:00,,,,,,
4535,us-fda-approves-prevnar-20?-pfizer?s-pneumococcal-20-valent-conjugate-vaccine-for-adults-ages-18-years-or-older,09-06-2021 00:00,,,,,,
4536,cardiff-oncology-announces-first-patient-dosed-in-a-phase-2-trial-of-onvansertib-in-combination-with-irinotecan-and-5-fu-in-pancreatic-cancer,09-06-2021 00:00,,,,,,
4537,bio-thera-solutions-initiates-phase-iii-clinical-trial-for-bat2506-a-proposed-biosimilar-of-simponi?-golimumab,09-06-2021 00:00,,,,,,
4538,caraway-therapeutics-establishes-collaboration-with-abbvie-to-develop-novel-small-molecule-therapeutics-for-parkinson?s-disease-and-other-related-disorders,09-06-2021 00:00,,,,,,
4539,merck-announces-supply-agreement-with-us-government-for-molnupiravir-an-investigational-oral-antiviral-candidate-for-treatment-of-mild-to-moderate-covid-19,10-06-2021 00:00,,,,,,
4540,inovio-expands-partnership-with-advaccine-to-conduct-global-phase-3-efficacy-trial-of-covid-19-dna-vaccine-candidate-ino-4800,10-06-2021 00:00,,,,,,
4541,hummingbird-bioscience-and-novogene-enter-into-strategic-partnership-to-expand-precision-medicine-testing-for-individuals-with-nrg1-fusion-driven-cancers-in-china,10-06-2021 00:00,,,,,,
4542,vertex-announces-us-fda-approval-for-trikafta?-elexacaftortezacaftorivacaftor-and-ivacaftor-in-children-with-cystic-fibrosis-ages-6-through-11-with-certain-mutations,10-06-2021 00:00,,,,,,
4543,shoreline-biosciences-and-beigene-announce-strategic-worldwide-collaboration-to-develop-and-commercialize-genetically-modified-natural-killer-nk-cell-therapies,10-06-2021 00:00,,,,,,
4544,codexis-and-takeda-expand-strategic-collaboration-and-license-agreement-to-discover-additional-gene-therapy-for-a-fourth-rare-genetic-disorder,10-06-2021 00:00,,,,,,
4545,us-food-and-drug-administration-approves-new-formulation-of-epclusa?-expanding-pediatric-indication-to-treat-children-ages-3-and-older-with-chronic-hepatitis-c,11-06-2021 00:00,,,,,,
4546,beyondspring-announces-final-positive-data-from-the-protective-1-phase-3-cin-program-of-plinabulin-as-a-single-agent-compared-to-pegfilgrastim-at-the-american-society-of-clinical-oncology-asco-annual-meeting,11-06-2021 00:00,,,,,,
4547,verona-pharma-and-nuance-pharma-announce-219-million-strategic-collaboration-to-develop-and-commercialize-ensifentrine-in-greater-china,11-06-2021 00:00,,,,,,
4548,new-roche-data-for-evrysdi-show-improved-motor-function-in-pre-symptomatic-babies-after-one-year-and-confirm-safety-profile-in-previously-treated-people-with-spinal-muscular-atrophy-sma,11-06-2021 00:00,,,,,,
4549,new-data-shows-abbvie?s-venclyxto?venclexta?-fixed-duration-combination-demonstrates-sustained-progression-free-survival-in-chronic-lymphocytic-leukemia-patients-after-three-years-off-treatment,11-06-2021 00:00,,,,,,
4550,vertex-and-crispr-therapeutics-present-new-data-in-22-patients-with-greater-than-3-months-follow-up-post-treatment-with-investigational-crisprcas9-gene-editing-therapy-ctx001?-at-european-hematology-association-annual-meeting,11-06-2021 00:00,,,,,,
4551,new-pivotal-data-at-eha-2021-reinforces-sutimlimab-as-a-first-in-class-investigational-c1s-inhibitor-with-the-potential-to-be-the-first-approved-treatment-for-hemolysis-in-people-with-cad-a-serious-and-chronic-autoimmune-hemolytic-anemia,14-06-2021 00:00,,,,,,
4552,celltrion-healthcare-presents-the-first-real-world-data-for-truxima?-biosimilar-rituximab-in-patients-with-diffuse-large-b-cell-lymphoma-at-the-eha-2021-virtual-congress,14-06-2021 00:00,,,,,,
4553,janssen-announces-results-from-phase-3-maia-study-showing-significant-overall-survival-benefits-for-treatment-with-darzalex?-daratumumab-in-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-ineligible,14-06-2021 00:00,,,,,,
4554,imbruvica?-ibrutinib-plus-venclexta?venclyxto?-venetoclax-combination-shows-superior-progression-free-survival-compared-to-chlorambucil-plus-obinutuzumab-in-first-line-chronic-lymphocytic-leukemia-cll-phase-3-glow-study,14-06-2021 00:00,,,,,,
4555,longer-term-data-for-kite?s-yescarta?-in-relapsed-or-refractory-follicular-lymphoma-demonstrate-substantial-survival-improvement-over-current-therapies-in-comparative-analysis,14-06-2021 00:00,,,,,,
4556,incyte-announces-us-fda-has-extended-the-new-drug-application-review-period-for-ruxolitinib-cream-for-the-treatment-of-atopic-dermatitis,14-06-2021 00:00,,,,,,
4557,biogen-announces-topline-results-from-phase-3-gene-therapy-study-in-choroideremia,15-06-2021 00:00,,,,,,
4558,novavax-covid-19-vaccine-demonstrates-90-overall-efficacy-and-100-protection-against-moderate-and-severe-disease-in-prevent-19-phase-3-trial,15-06-2021 00:00,,,,,,
4559,covid-19-vaccine-astrazeneca-effective-against-delta-?indian?-variant,15-06-2021 00:00,,,,,,
4560,the-us-fda-approved-ind-application-to-investigate-combination-of-asieris?-apl-1202-and-beigene?s-tislelizumab-as-neoadjuvant-therapy-for-mibc-patients,15-06-2021 00:00,,,,,,
4561,update-on-azd7442-storm-chaser-trial-in-post-exposure-prevention-of-symptomatic-covid-19,15-06-2021 00:00,,,,,,
4562,sage-therapeutics-and-biogen-announce-positive-pivotal-phase-3-results-for-zuranolone-an-investigational-two-week-once-daily-therapeutic-being-evaluated-for-major-depressive-disorder,15-06-2021 00:00,,,,,,
4563,innovent-announces-first-overweight-or-obese-subject-dosed-in-a-phase-2-clinical-trial-of-ibi362-a-glp-1-and-glucagon-receptor-dual-agonist-in-china,16-06-2021 00:00,,,,,,
4564,linnaeus-therapeutics-announces-expanded-clinical-collaboration-with-merck-to-include-multiple-additional-cohorts-to-evaluate-lns8801-in-combination-with-keytruda?-in-patients-with-advanced-cancer,16-06-2021 00:00,,,,,,
4565,jounce-therapeutics-achieves-first-milestone-in-exclusive-license-agreement-with-gilead-sciences-and-fda-clearance-of-investigational-new-drug-application-for-anti-ccr8-antibody,16-06-2021 00:00,,,,,,
4566,regen-cov?-casirivimab-and-imdevimab-phase-3-recovery-trial-meets-primary-outcome-improving-survival-in-hospitalized-covid-19-patients-lacking-an-immune-response-to-sars-cov-2,16-06-2021 00:00,,,,,,
4567,organicell-announces-positive-results-of-their-expanded-access-trial-for-the-treatment-of-mild-to-moderate-covid-19-using-zofintm,16-06-2021 00:00,,,,,,
4568,the-journal-of-the-american-medical-association-publishes-data-on-efficacy-and-safety-of-preventive-migraine-treatment-vyepti?-eptinezumab-jjmr-when-administered-during-an-active-migraine-attack,16-06-2021 00:00,,,,,,
4569,data-published-in-new-england-journal-of-medicine-shows-pfizer?s-tofacitinib-meets-primary-endpoint-in-brazilian-study-in-patients-hospitalized-with-covid-19-pneumonia,17-06-2021 00:00,,,,,,
4570,united-therapeutics-announces-fda-acceptance-of-tyvaso-dpi?-new-drug-application-for-priority-review,17-06-2021 00:00,,,,,,
4571,curevac-provides-update-on-phase-2b3-trial-of-first-generation-covid-19-vaccine-candidate-cvncov,17-06-2021 00:00,,,,,,
4572,fda-approves-blueprint-medicines?-ayvakit?-avapritinib-for-the-treatment-of-adults-with-advanced-systemic-mastocytosis,17-06-2021 00:00,,,,,,
4573,atea-pharmaceuticals-announces-achievement-of-at-527-development-milestone-under-license-agreement-with-roche,17-06-2021 00:00,,,,,,
4574,biogen-announces-topline-results-from-phase-2-study-of-gosuranemab-an-anti-tau-antibody-for-alzheimer?s-disease,17-06-2021 00:00,,,,,,
4575,lantheus-receives-us-fda-approval-of-pylarify?-piflufolastat-f-18-injection-the-first-and-only-commercially-available-psma-pet-imaging-agent-for-prostate-cancer,27-05-2021 00:00,,,,,,
4576,biogen-announces-first-patient-dosed-in-phase-3-systemic-lupus-erythematosus-study,18-06-2021 00:00,,,,,,
4577,kite-and-shoreline-biosciences-enter-into-strategic-partnership-to-develop-novel-allogeneic-cell-therapies,18-06-2021 00:00,,,,,,
4578,beigene-announces-first-patient-dosed-in-global-phase-3-trial-of-anti-tigit-antibody-ociperlimab-in-non-small-cell-lung-cancer,18-06-2021 00:00,,,,,,
4579,cytoreason-collaborates-with-sanofi-using-its-ai-technology-to-gain-better-understanding-of-disease-mechanisms,18-06-2021 00:00,,,,,,
4580,biontech-announces-first-patient-dosed-in-phase-2-clinical-trial-of-mrna-based-bnt111-in-patients-with-advanced-melanoma,18-06-2021 00:00,,,,,,
4581,lineage-announces-exclusive-option-agreement-with-amasa-therapeutics-for-supply-and-use-of-clinical-grade-hystem?,18-06-2021 00:00,,,,,,
4582,european-commission-approves-aubagio?-teriflunomide-as-the-first-oral-ms-therapy-for-first-line-treatment-of-children-and-adolescents-living-with-relapsing-remitting-multiple-sclerosis,21-06-2021 00:00,,,,,,
4583,bristol-myers-squibb-receives-european-commission-approval-for-onureg?-azacitidine-tablets-as-frontline-oral-maintenance-therapy-for-adults-with-acute-myeloid-leukemia,21-06-2021 00:00,,,,,,
4584,new-zolgensma-data-demonstrate-age-appropriate-development-when-used-presymptomatically-and-rapid-clinically-meaningful-efficacy-in-symptomatic-children-even-those-with-severe-sma-at-baseline,21-06-2021 00:00,,,,,,
4585,eisai-and-bristol-myers-squibb-enter-into-global-strategic-collaboration-for-eisai?s-morab-202-antibody-drug-conjugate,21-06-2021 00:00,,,,,,
4586,beigene-announces-china-nmpa-approval-of-brukinsa?-zanubrutinib-for-the-treatment-of-patients-with-relapsed-or-refractory-waldenstr?m?s-macroglobulinemia,21-06-2021 00:00,,,,,,
4587,fibrogen-and-hifibio-announce-transformative-partnership-to-advance-next-generation-therapies-for-patients-with-cancer-and-autoimmune-disease,21-06-2021 00:00,,,,,,
4588,bayer-submits-regulatory-applications-for-oncology-treatment-combination-of-copanlisib-and-rituximab-in-the-us-and-eu,22-06-2021 00:00,,,,,,
4589,arrowhead-pharmaceuticals-and-horizon-therapeutics-announce-collaboration-to-develop-rnai-therapeutic-for-uncontrolled-gout,22-06-2021 00:00,,,,,,
4590,study-results-of-sintilimab-in-combination-with-bevacizumab-biosimilar-ibi305-for-the-first-line-treatment-of-hepatocellular-carcinoma-published-in-the-lancet-oncology,22-06-2021 00:00,,,,,,
4591,koselugo-approved-in-the-eu-for-children-with-neurofibromatosis-type-1-and-plexiform-neurofibromas,22-06-2021 00:00,,,,,,
4592,viiv-healthcare-and-halozyme-enter-global-collaboration-and-license-agreement-for-enhanze?-drug-delivery-technology-to-enable-development-of-?ultra-long-acting?-medicines-for-hiv,22-06-2021 00:00,,,,,,
4593,gsk-and-vir-biotechnology-announce-continuing-progress-of-the-comet-clinical-development-programme-for-sotrovimab,22-06-2021 00:00,,,,,,
4594,macrogenics-and-zai-lab-enter-into-broad-strategic-collaboration-to-develop-and-commercialize-preclinical-bispecific-antibodies-in-oncology,16-06-2021 00:00,,,,,,
4595,study-results-of-sintilimab-in-combination-with-bevacizumab-biosimilar-ibi305-for-the-first-line-treatment-of-hepatocellular-carcinoma-published-in-the-lancet-oncology,23-06-2021 00:00,,,,,,
4596,kesimpta?-ofatumumab-data-show-long-term-preservation-of-iggigm-levels-and-no-increased-risk-of-serious-infections-in-people-living-with-multiple-sclerosis,23-06-2021 00:00,,,,,,
4597,uniqure-announces-positive-52-week-clinical-data-from-hope-b-pivotal-trial-of-etranacogene-dezaparvovec-gene-therapy-in-patients-with-hemophilia-b-and-provides-regulatory-update,23-06-2021 00:00,,,,,,
4598,uniqure-to-acquire-corlieve-therapeutics-and-advance-its-gene-therapy-program-to-treat-temporal-lobe-epilepsy-tle,23-06-2021 00:00,,,,,,
4599,pear-therapeutics-to-become-a-public-company-and-expand-its-leadership-position-in-prescription-digital-therapeutics,23-06-2021 00:00,,,,,,
4600,sorrento-enters-into-multi-year-cooperative-research-and-development-agreement-with-the-us-naval-medical-research-unit-?-no-3-namru-3-for-pandemic-preparedness-combating-covid-19,23-06-2021 00:00,,,,,,
4601,fda-accepts-application-for-roche?s-port-delivery-system-with-ranibizumab-pds-for-treatment-of-neovascular-or-?wet?-age-related-macular-degeneration-namd,24-06-2021 00:00,,,,,,
4602,eisai-and-biogen-inc-announce-us-fda-grants-breakthrough-therapy-designation-for-lecanemab-ban2401-an-anti-amyloid-beta-protofibril-antibody-for-the-treatment-of-alzheimer?s-disease,24-06-2021 00:00,,,,,,
4603,vericiguat-approved-in-japan-to-treat-patients-with-chronic-heart-failure,24-06-2021 00:00,,,,,,
4604,chugai-obtains-regulatory-approval-for-evrysdi-for-the-treatment-of-spinal-muscular-atrophy,24-06-2021 00:00,,,,,,
4605,janssen-submits-new-drug-application-to-us-fda-for-xarelto?-rivaroxaban-to-help-prevent-and-treat-blood-clots-in-pediatric-patients,24-06-2021 00:00,,,,,,
4606,tecan-expands-its-commercial-reach-its-capabilities-and-its-us-and-asia-presence-with-the-acquisition-of-paramit-corporation,24-06-2021 00:00,,,,,,
4607,abbvie-exercises-right-to-acquire-teneoone-and-lead-asset-tnb-383b-for-the-potential-treatment-of-relapsed-or-refractory-multiple-myeloma,25-06-2021 00:00,,,,,,
4608,lilly?s-donanemab-receives-us-fda?s-breakthrough-therapy-designation-for-treatment-of-alzheimer?s-disease,25-06-2021 00:00,,,,,,
4609,chmp-recommends-approval-of-rinvoq?-upadacitinib-for-the-treatment-of-atopic-dermatitis,25-06-2021 00:00,,,,,,
4610,roche?s-actemraroactemra-receives-us-fda-emergency-use-authorization-for-the-treatment-of-covid-19-in-hospitalised-adults-and-children,25-06-2021 00:00,,,,,,
4611,libtayo?-cemiplimab-approved-by-the-european-commission-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-with-50-pd-l1-expression,25-06-2021 00:00,,,,,,
4612,libtayo?-cemiplimab-approved-by-the-european-commission-as-the-first-immunotherapy-indicated-for-patients-with-advanced-basal-cell-carcinoma,25-06-2021 00:00,,,,,,
4613,first-covid-19-variant-vaccine-azd2816-phase-iiiii-trial-participants-vaccinated,28-06-2021 00:00,,,,,,
4614,mirati-therapeutics?-adagrasib-receives-breakthrough-therapy-designation-from-us-food-and-drug-administration-for-patients-with-advanced-non-small-cell-lung-cancer-harboring-the-krasg12c-mutation,28-06-2021 00:00,,,,,,
4615,lilly?s-surpass-1-results-published-in-the-lancet-show-tirzepatide?s-superior-a1c-and-body-weight-reductions-versus-placebo-in-adults-with-type-2-diabetes,28-06-2021 00:00,,,,,,
4616,roche?s-enspryng-approved-by-european-commission-as-first-and-only-at-home-subcutaneous-treatment-for-neuromyelitis-optica-spectrum-disorder-nmosd,28-06-2021 00:00,,,,,,
4617,forxiga-recommended-for-approval-in-the-eu-by-chmp-for-the-treatment-of-patients-with-chronic-kidney-disease,28-06-2021 00:00,,,,,,
4618,samsung-bioepis-and-biogen-receive-positive-chmp-opinion-for-ranibizumab-biosimilar-byooviz?,28-06-2021 00:00,,,,,,
4619,gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-lenacapavir-an-investigational-long-acting-capsid-inhibitor-for-the-treatment-of-hiv-1-in-people-with-limited-therapy-options,29-06-2021 00:00,,,,,,
4620,innovent-announces-the-china-nmpa-approval-of-tyvyt?-sintilimab-injection-in-combination-with-byvasda?-bevacizumab-biosimilar-injection-as-first-line-therapy-for-people-with-hepatocellular-carcinoma,29-06-2021 00:00,,,,,,
4621,teva-and-bioeq-announce-commercial-partnership-for-biosimilar,29-06-2021 00:00,,,,,,
4622,vaxzevria-induced-immunity-for-at-least-one-year-following-a-single-dose-and-strong-immune-responses-following-either-a-late-second-dose-or-a-third-dose,29-06-2021 00:00,,,,,,
4623,medtronic-inpen?-real-world-data-and-extended-infusion-set-pivotal-trial-results-demonstrate-strong-clinical-outcomes-and-positive-user-experience,29-06-2021 00:00,,,,,,
4624,new-soliqua?-data-shows-improved-blood-sugar-control-without-weight-gain-versus-premixed-insulin,29-06-2021 00:00,,,,,,
4625,medtronic-launches-app-based-study-to-better-understand-relationship-between-atrial-fibrillation-disease-burden-and-impact-on-patient-outcomes,30-06-2021 00:00,,,,,,
4626,bristol-myers-squibb-receives-european-commission-approval-for-opdivo-nivolumab-plus-yervoy-ipilimumab-for-the-treatment-of-mismatch-repair-deficient-or-microsatellite-instability?high-metastatic-colorectal-cancer-after-prior-chemotherapy,30-06-2021 00:00,,,,,,
4627,upadacitinib-rinvoq?-met-the-primary-and-all-secondary-endpoints-in-the-52-week-phase-3-maintenance-study-in-ulcerative-colitis-patients,30-06-2021 00:00,,,,,,
4628,amneal-announces-us-fda-filing-acceptance-of-biologics-license-application-bla-for-bevacizumab,17-06-2021 00:00,,,,,,
4629,theramex-uk-ltd-announces-a-license-and-supply-agreement-with-enzene-biosciences-limited-for-the-registration-and-commercialisation-of-denosumab-an-antiresorptive-treatment-for-osteoporosis-a-biosimilar-of-reference-medicine-prolia?-in-europe-the-uk-switzerland-and-australia,10-06-2021 00:00,,,,,,
4630,celltrion-healthcare-launches-remsima?-sc-the-world?s-first-subcutaneous-formulation-of-infliximab-in-canada-for-the-treatment-of-people-with-rheumatoid-arthritis,07-06-2021 00:00,,,,,,
4631,arbutus-biopharma-and-antios-therapeutics-announce-clinical-collaboration-agreement-to-evaluate-ab-729-in-combination-with-ati-2173-in-subjects-with-chronic-hepatitis-b-virus-infection,30-06-2021 00:00,,,,,,
4632,alvotech-reaches-primary-completion-date-in-its-switching-study-for-avt02-a-proposed-interchangeable-biosimilar-to-abbvie?s-humira?,15-06-2021 00:00,,,,,,
4633,vivoryon-therapeutics-and-simcere-announce-strategic-regional-licensing-partnership-to-develop-and-commercialize-n3pe-amyloid-targeting-medicines-to-treat-alzheimer?s-disease-in-greater-china,30-06-2021 00:00,,,,,,
4634,iksuda-therapeutics-closes-47-million-financing-round,07-06-2021 00:00,,,,,,
4635,formycon-and-bioeq-announce-submission-of-the-marketing-authorization-application-for-fyb201-a-biosimilar-candidate-to-lucentisr1-ranibizumab-to-the-european-medicines-agency-ema,30-06-2021 00:00,,,,,,
4636,apellis-and-beam-therapeutics-enter-exclusive-research-collaboration-to-apply-base-editing-to-discover-novel-therapies-for-complement-driven-diseases,01-07-2021 00:00,,,,,,
4637,stada-and-partner-xbrane-advance-biosimilar-ranibizumab-candidate,01-07-2021 00:00,,,,,,
4638,lexeo-therapeutics-receives-rare-pediatric-disease-designation-and-orphan-drug-designation-for-lx2006-for-the-treatment-of-friedreich?s-ataxia,01-07-2021 00:00,,,,,,
4639,abbott?s-xience-stent-receives-fda-approval-for-shortest-blood-thinner-course-for-high-bleeding-risk-patients,01-07-2021 00:00,,,,,,
4640,jazz-pharmaceuticals-announces-us-fda-approval-of-rylaze?-asparaginase-erwinia-chrysanthemi-recombinant-rywn-for-the-treatment-of-acute-lymphoblastic-leukemia-or-lymphoblastic-lymphoma,01-07-2021 00:00,,,,,,
4641,orchard-therapeutics-and-pharming-group-announce-collaboration-to-develop-and-commercialize-ex-vivo-autologous-hsc-gene-therapy-for-hereditary-angioedema,01-07-2021 00:00,,,,,,
4642,seres-therapeutics-nestl?-health-science-announce-ser-109-co-commercialization-license-agreement,02-07-2021 00:00,,,,,,
4643,foundationone-cdx-receives-fda-approval-as-a-companion-diagnostic-for-alunbrig?-brigatinib-to-identify-patients-with-alk-positive-metastatic-non-small-cell-lung-cancer,02-07-2021 00:00,,,,,,
4644,almirall-and-kaken-pharmaceutical-enter-into-a-license-and-distribution-agreement-for-european-rights-to-the-topical-formulation-of-efinaconazole,02-07-2021 00:00,,,,,,
4645,zydus-applies-to-the-dcgi-for-eua-to-launch-zycov-d-the-world?s-first-plasmid-dna-vaccine-for-covid-19,02-07-2021 00:00,,,,,,
4646,denovo-biopharma-in-licenses-late-stage-alzheimer?s-disease-asset-from-lundbeck,02-07-2021 00:00,,,,,,
4647,us-fda-accepts-filing-of-hutchmed?s-nda-for-surufatinib-for-the-treatment-of-advanced-neuroendocrine-tumors,02-07-2021 00:00,,,,,,
4648,gsk-and-alector-announce-global-collaboration-in-immuno-neurology-for-two-clinical-stage-first-in-class-monoclonal-antibodies-for-neurodegenerative-diseases,05-07-2021 00:00,,,,,,
4649,new-data-on-phase-1-proposed-biosimilar-gan-lee-insulins-aspart-gl-asp-lispro-gl-lis-and-glargine-gl-gla-presented-at-the-american-diabetes-association?s-81st-scientific-sessions,05-07-2021 00:00,,,,,,
4650,roche-to-present-new-data-at-the-isth-2021-congress-highlighting-long-standing-commitment-to-advancing-haemophilia-a-standard-of-care,05-07-2021 00:00,,,,,,
4651,ocugen?s-covid-19-vaccine-co-development-partner-bharat-biotech-shares-phase-3-results-demonstrating-778-protection-against-overall-disease,05-07-2021 00:00,,,,,,
4652,ngm-amends-collaboration-with-merck-to-focus-primarily-on-advancing-novel-medicines-for-retinal-and-cardiovascular-and-metabolic-cvm-diseases,05-07-2021 00:00,,,,,,
4653,lupin-announces-fda-approval-of-supplemental-new-drug-application-for-solosec?-secnidazole-for-the-treatment-of-trichomoniasis,05-07-2021 00:00,,,,,,
4654,everest-medicines-announces-that-spero-therapeutics-entered-into-licensing-agreement-with-pfizer-inc-for-spr206-in-ex-us-and-ex-asia-territories,06-07-2021 00:00,,,,,,
4655,immunic-inc-announces-fda-clearance-to-begin-imu-838-phase-3-ensure-studies-in-relapsing-remitting-multiple-sclerosis-and-phase-2-calliper-study-in-progressive-multiple-sclerosis,06-07-2021 00:00,,,,,,
4656,abbisko-and-sperogenix-announce-an-exclusive-agreement-to-develop-absk021-for-als-and-other-rare-neurological-diseases-in-greater-china,06-07-2021 00:00,,,,,,
4657,hutchmed-initiates-phase-i-trials-of-novel-erk-inhibitor-hmpl-295-in-patients-with-advanced-solid-tumors-in-china,06-07-2021 00:00,,,,,,
4658,mimetas-and-roche-enter-into-a-collaboration-to-develop-human-disease-models-for-drug-development,06-07-2021 00:00,,,,,,
4659,fda-approves-expanded-indication-for-merck?s-keytruda?-pembrolizumab-in-locally-advanced-cutaneous-squamous-cell-carcinoma-cscc,06-07-2021 00:00,,,,,,
4660,eureka-therapeutics-announces-new-gprc5d-license-agreement-with-sanofi-to-target-multiple-myeloma,07-07-2021 00:00,,,,,,
4661,alvotech-initiates-clinical-studies-for-avt04-a-proposed-biosimilar-to-stelara?-ustekinumab,07-07-2021 00:00,,,,,,
4662,fda-clears-sorrento-phase-2-trial-of-non-opioid-product-candidate-resiniferatoxin-rtx-for-treatment-of-the-knee-pain-in-osteoarthritis-oa-patients,07-07-2021 00:00,,,,,,
4663,oncosec-enters-into-a-collaboration-agreement-with-merck-for-a-pivotal-global-phase-3-study-keynote-c87-of-tavo?-combined-with-keytruda?-for-late-stage-metastatic-melanoma,07-07-2021 00:00,,,,,,
4664,y-mabs-announces-nmpa-submission-of-bla-for-danyelza?-naxitamab-gqgk-in-china,07-07-2021 00:00,,,,,,
4665,mallinckrodt-announces-publication-of-phase-3-strata2016-study-in-burns,07-07-2021 00:00,,,,,,
4666,polpharma-biologics-group-announces-that-its-joint-venture-company-bioeq-has-entered-into-a-commercialization-agreement-for-biosimilar-ranibizumab,08-07-2021 00:00,,,,,,
4667,chugai-files-for-additional-indication-of-tecentriq-for-the-adjuvant-treatment-of-non-small-cell-lung-cancer,08-07-2021 00:00,,,,,,
4668,treos-bio-enters-into-clinical-collaboration-to-evaluate-its-polypeptide-cancer-immunotherapy-polypepi1018-in-combination-with-roche?s-pd-l1-inhibitor,08-07-2021 00:00,,,,,,
4669,puretech-announces-clinical-trial-and-supply-agreement-with-beigene-to-evaluate-lyt-200-and-tislelizumab-in-patients-with-difficult-to-treat-solid-tumors,08-07-2021 00:00,,,,,,
4670,beigene-announces-acceptance-of-a-supplemental-biologics-license-application-in-china-for-tislelizumab-in-esophageal-squamous-cell-carcinoma-escc,08-07-2021 00:00,,,,,,
4671,tezepelumab-regulatory-submission-accepted-and-granted-fda-priority-review-in-the-us-for-the-treatment-of-patients-with-asthma,08-07-2021 00:00,,,,,,
4672,f-star-therapeutics-enters-into-exclusive-licensing-agreement-with-astrazeneca-for-novel-sting-inhibitors,09-07-2021 00:00,,,,,,
4673,beigene-announces-the-approval-in-china-of-kyprolis?-carfilzomib-for-injection-for-adult-patients-with-relapsed-or-refractory-multiple-myeloma,09-07-2021 00:00,,,,,,
4674,verge-genomics-announces-three-year-collaboration-with-lilly-to-discover-and-develop-novel-treatments-using-its-ai-driven-all-in-human-platform,09-07-2021 00:00,,,,,,
4675,vor-biopharma-announces-collaboration-with-janssen-to-develop-engineered-hematopoietic-stem-cell-transplants-combined-with-a-bi-specific-antibody-therapy-for-acute-myeloid-leukemia-aml,09-07-2021 00:00,,,,,,
4676,health-canada-approves-vyxeos?-the-first-chemotherapy-advance-in-over-40-years-for-adults-with-high-risk-acute-myeloid-leukemia-aml,09-07-2021 00:00,,,,,,
4677,lysogene-announces-fda-fast-track-designation-for-lys-gm101-gene-therapy-for-the-treatment-of-gm1-gangliosidosis,09-07-2021 00:00,,,,,,
4678,us-fda-approves-finerenone-for-the-treatment-of-patients-with-chronic-kidney-disease-associated-with-type-2-diabetes,12-07-2021 00:00,,,,,,
4679,new-data-from-the-phase-3-help-study?-open-label-extension-evaluating-safety-and-efficacy-of-takhzyro?-lanadelumab-for-hereditary-angioedema-patients-to-be-presented-at-european-academy-of-allergy-and-clinical-immunology-eaaci-hybrid-congress,12-07-2021 00:00,,,,,,
4680,us-fda-grants-regular-approval-and-expands-indication-for-padcev?-enfortumab-vedotin-ejfv-for-patients-with-locally-advanced-or-metastatic-urothelial-cancer,12-07-2021 00:00,,,,,,
4681,innovent-announces-the-first-patient-dosed-in-the-phase-1-study-of-ibi323-anti-lag-3pd-l1-bispecific-antibody-in-patients-with-advanced-malignant-tumors,12-07-2021 00:00,,,,,,
4682,galapagos-announces-new-data-supporting-rapid-symptom-improvement-and-sustained-steroid-free-remission-with-filgotinib-in-patients-with-ulcerative-colitis,12-07-2021 00:00,,,,,,
4683,stelara?-ustekinumab-demonstrated-sustained-symptomatic-and-corticosteroid-free-remission-rates-in-adults-with-moderately-to-severely-active-ulcerative-colitis-at-nearly-three-years-in-long-term-extension-of-phase-3-trial,12-07-2021 00:00,,,,,,
4684,scynexis-announces-fda-approval-of-brexafemme?-ibrexafungerp-tablets-as-the-first-and-only-oral-non-azole-treatment-for-vaginal-yeast-infections,02-06-2021 00:00,,,,,,
4685,chimerix-receives-us-food-and-drug-administration-approval-for-tembexa?-brincidofovir-for-the-treatment-of-smallpox,04-06-2021 00:00,,,,,,
4686,prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothena?s-attr-amyloidosis-programme,13-07-2021 00:00,,,,,,
4687,biogen-and-innocare-announce-license-and-collaboration-agreement-for-orelabrutinib-an-innovative-cns-penetrant-btk-inhibitor-for-the-potential-treatment-of-multiple-sclerosis,13-07-2021 00:00,,,,,,
4688,menagen-middleeast-announces-commercializing-agreement-with-ckd-for-biosimilar-darbepotein-alfa,13-07-2021 00:00,,,,,,
4689,hutchmed-announces-first-commercial-sale-of-orpathys?-in-china-triggering-a-us25-million-milestone-payment-from-astrazeneca,13-07-2021 00:00,,,,,,
4690,janssen-announces-us-fda-approval-of-darzalex-faspro?-daratumumab-and-hyaluronidase-fihj-in-combination-with-pomalidomide-and-dexamethasone-for-patients-with-multiple-myeloma-after-first-or-subsequent-relapse,13-07-2021 00:00,,,,,,
4691,affinivax-and-astellas-present-safety-and-immunogenicity-data-from-phase-2-study-of-asp3772-a-novel-24-valent-maps?-vaccine-for-streptococcus-pneumoniae,13-07-2021 00:00,,,,,,
4692,hepion-pharmaceuticals-announces-positive-topline-data-from-phase-2a-?ambition?-nash-trial-all-primary-endpoints-achieved,14-07-2021 00:00,,,,,,
4693,hologic-obtains-european-ce-mark-for-use-of-saliva-samples-with-covid-19-test,14-07-2021 00:00,,,,,,
4694,bicycle-therapeutics-enters-exclusive-license-and-collaboration-agreement-with-ionis-to-develop-targeted-oligonucleotide-therapeutics,14-07-2021 00:00,,,,,,
4695,excellthera-and-astellas-enter-into-a-license-for-the-use-of-molecule-um171-in-the-field-of-pluripotent-stem-cells,14-07-2021 00:00,,,,,,
4696,strongbridge-biopharma-plc-announces-publication-of-long-term-efficacy-and-safety-results-for-keveyis?-dichlorphenamide-for-the-treatment-of-primary-periodic-paralysis-in-muscle-nerve,14-07-2021 00:00,,,,,,
4697,caribou-biosciences-announces-dosing-of-first-patient-in-phase-1-clinical-trial-evaluating-cb-010-a-crispr-edited-allogeneic-anti-cd19-car-t-cell-therapy-in-patients-with-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma,14-07-2021 00:00,,,,,,
4698,lilly-announces-acquisition-of-protomer-technologies,15-07-2021 00:00,,,,,,
4699,galapagos-reports-positive-topline-results-with-selective-tyk2-inhibitor-glpg3667-in-phase-1b-psoriasis-study,15-07-2021 00:00,,,,,,
4700,novartis-announces-nejm-publication-of-positive-phase-iii-reach3-data-for-jakavi-in-chronic-gvhd,15-07-2021 00:00,,,,,,
4701,johnson-johnson-single-shot-covid-19-vaccine-demonstrated-a-durable-immune-response-and-elicited-dual-mechanisms-of-protection-against-delta-and-other-sars-cov-2-variants-of-concern-in-data-published-in-new-england-journal-of-medicine,15-07-2021 00:00,,,,,,
4702,heat-biologics-enters-into-research-license-agreement-for-probiogen?s-transposase-system-and-suspension-hek293-cell-line,15-07-2021 00:00,,,,,,
4703,aragen-announces-partnership-with-skyhawk-therapeutics-aimed-at-developing-novel-small-molecule-therapeutics-that-correct-rna-expression,15-07-2021 00:00,,,,,,
4704,eton-pharmaceuticals-announces-fda-approval-of-rezipres?-ephedrine-hydrochloride-injection,15-06-2021 00:00,,,,,,
4706,ipsen-and-irlab-enter-exclusive-worldwide-licensing-agreement-aimed-to-improve-the-lives-of-people-living-with-parkinson?s-disease,16-07-2021 00:00,,,,,,
4707,alexion-announces-positive-topline-results-from-phase-3-study-of-ultomiris?-ravulizumab-cwvz-in-adults-with-generalized-myasthenia-gravis-gmg,16-07-2021 00:00,,,,,,
4708,vir-biotechnology-initiates-phase-2-clinical-trial-evaluating-the-combination-of-vir-2218-and-vir-3434-as-a-functional-cure-regimen-for-chronic-hepatitis-b-virus-infection,16-07-2021 00:00,,,,,,
4709,bio-thera-solutions-announces-the-first-patient-dosed-in-phase-iii-clinical-trial-for-bat2206-a-proposed-biosimilar-of-stelara?-ustekinumab,16-07-2021 00:00,,,,,,
4710,acelrx-enters-into-licensing-agreement-for-dzuveo?-in-europe-and-in-licensing-agreement-for-two-products-in-the-us,16-07-2021 00:00,,,,,,
4711,lilly-and-banner-alzheimer?s-institute-collaborate-on-planned-phase-3-prevention-trial-of-donanemab,16-07-2021 00:00,,,,,,
4712,gsk-announces-positive-headline-results-from-five-phase-3-studies-of-daprodustat-for-patients-with-anaemia-due-to-chronic-kidney-disease,19-07-2021 00:00,,,,,,
4713,samsung-bioepis-and-yuhan-corporation-signed-a-domestic-sales-partnership-for-?humira?-biosimilar?-adalloce?,15-03-2021 00:00,,,,,,
4714,mabxience-expanding-biosimilar-and-cdmo-manufacturing-capacity-with-abec-4-000-liter-single-use-bioreactor,23-03-2021 00:00,,,,,,
4715,merck-announces-us-fda-approval-of-vaxneuvance?-pneumococcal-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-adults-18-years-and-older-caused-by-15-serotypes,19-07-2021 00:00,,,,,,
4716,us-fda-approves-fexinidazole-as-the-first-all-oral-treatment-for-sleeping-sickness,19-07-2021 00:00,,,,,,
4717,imfinzi-approved-in-china-for-the-treatment-of-extensive-stage-small-cell-lung-cancer,19-07-2021 00:00,,,,,,
4718,new-phase-3-data-support-the-sustained-long-acting-efficacy-of-lenacapavir-gilead?s-investigational-hiv-1-capsid-inhibitor,19-07-2021 00:00,,,,,,
4719,new-data-for-genentech?s-hemlibra-emicizumab-kxwh-reinforce-safety-profile-in-people-with-hemophilia-a,19-07-2021 00:00,,,,,,
4720,aridis-pharmaceuticals-announces-exclusive-license-of-suvratoxumab-a-phase-3-ready-monoclonal-antibody-from-astrazeneca,20-07-2021 00:00,,,,,,
4721,japan-becomes-first-country-to-approve-regeneron-antibody-cocktail-casirivimab-and-imdevimab-for-the-treatment-of-mild-to-moderate-covid-19,20-07-2021 00:00,,,,,,
4722,samsung-bioepis-initiates-phase-3-clinical-trial-for-sb17-proposed-biosimilar-to-stelara-ustekinumab,20-07-2021 00:00,,,,,,
4723,us-fda-grants-full-approval-of-rezurock-belumosudil-for-the-treatment-of-patients-with-chronic-graft-versus-host-disease-cgvhd,20-07-2021 00:00,,,,,,
4724,biontech-to-acquire-kite?s-neoantigen-tcr-cell-therapy-rd-platform-and-manufacturing-facility-in-gaithersburg-md,20-07-2021 00:00,,,,,,
4725,myovant-sciences-announces-european-commission-approval-for-ryeqo?-for-the-treatment-of-women-with-uterine-fibroids,20-07-2021 00:00,,,,,,
4726,merck-presents-new-data-from-ongoing-phase-2a-clinical-trial-evaluating-the-safety-tolerability-and-pharmacokinetics-of-investigational-once-monthly-oral-islatravir-for-hiv-1-prevention-at-ias-2021,21-07-2021 00:00,,,,,,
4727,relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc,21-07-2021 00:00,,,,,,
4728,albireo-announces-fda-approval-of-bylvay?-odevixibat-the-first-drug-treatment-for-patients-with-progressive-familial-intrahepatic-cholestasis-pfic,21-07-2021 00:00,,,,,,
4729,scilex-holding-company-a-sorrento-company-announces-complete-enrollment-on-non-opioid-injectable-sp-102-semdexa?-phase-3-pivotal-trial-clear-program-for-sciatica-pain-management,21-07-2021 00:00,,,,,,
4730,fda-grants-breakthrough-therapy-designation-for-venclexta-in-combination-with-azacitidine-for-the-treatment-of-patients-with-myelodysplastic-syndromes,21-07-2021 00:00,,,,,,
4731,calliditas-therapeutics-and-stada-partner-to-register-and-commercialize-specialty-therapy-for-iga-nephropathy-in-europe,21-07-2021 00:00,,,,,,
4732,lexeo-therapeutics-expands-cardiac-gene-therapy-pipeline-with-acquisition-of-stelios-therapeutics-and-its-gene-therapy-programs-for-rare-cardiovascular-diseases,22-07-2021 00:00,,,,,,
4733,verquvo?-vericiguat-approved-in-the-european-union,22-07-2021 00:00,,,,,,
4734,im-therapeutics-reports-positive-results-in-safety-tolerability-and-mechanism-of-action-of-phase-1b-trial-of-lead-drug-imt-002-in-type-1-diabetes,22-07-2021 00:00,,,,,,
4735,sorrento-announces-its-partner-mabpharm-has-received-marketing-approval-in-china-for-infliximab-biobetter,22-07-2021 00:00,,,,,,
4736,bluebird-bio-receives-ec-approval-for-skysona?-elivaldogene-autotemcel-lenti-d?-gene-therapy-for-patients-less-than-18-years-of-age-with-early-cerebral-adrenoleukodystrophy-cald-without-matched-sibling-donor,22-07-2021 00:00,,,,,,
4737,fda-approves-keytruda?-pembrolizumab-plus-lenvima?-lenvatinib-combination-for-patients-with-certain-types-of-advanced-endometrial-carcinoma,22-07-2021 00:00,,,,,,
4738,polpharma-biologics-group-announces-that-its-joint-venture-company-bioeq-has-entered-into-a-commercialization-agreement-for-biosimilar-ranibizumab,07-07-2021 00:00,,,,,,
4739,synaffix-announces-deal-with-profoundbio-worth-up-to-246-million-providing-access-to-multiple-novel-linker-payload-technologies,23-07-2021 00:00,,,,,,
4740,ngm-announces-completion-of-enrollment-in-phase-2-catalina-study-of-ngm621-in-patients-with-geographic-atrophy-secondary-to-age-related-macular-degeneration,23-07-2021 00:00,,,,,,
4741,inhalon-collaborates-with-celltrion-inc-to-develop-nebulized-form-of-regdanvimab-to-treat-covid-19-patients-at-home,23-07-2021 00:00,,,,,,
4742,meiji-and-dong-a-st-enter-into-an-exclusive-license-agreement-with-intas-to-commercialize-dmb-3115-a-proposed-biosimilar-to-ustekinumab,23-07-2021 00:00,,,,,,
4743,imaginab-announces-extension-of-long-standing-partnership-with-boehringer-ingelheim,23-07-2021 00:00,,,,,,
4744,bydureon-bcise-exenatide-extended-release-approved-in-the-us-for-the-treatment-of-type-2-diabetes-in-pediatric-patients-ages-10-years-and-older,23-07-2021 00:00,,,,,,
4745,vaxzevria-is-highly-effective-after-one-dose-against-severe-disease-or-hospitalisation-caused-by-beta-and-delta-variants-of-concern,26-07-2021 00:00,,,,,,
4746,vaxzevria-is-highly-effective-after-one-dose-against-severe-disease-or-hospitalisation-caused-by-beta-and-delta-variants-of-concern,26-07-2021 00:00,,,,,,
4747,new-data-presented-on-the-safety-and-efficacy-of-investigational-agn-190584-as-a-potential-novel-treatment-for-presbyopia-a-common-and-progressive-eye-condition,26-07-2021 00:00,,,,,,
4748,incyte-provides-regulatory-update-on-retifanlimab-for-the-treatment-of-certain-patients-with-squamous-cell-carcinoma-of-the-anal-canal-scac,26-07-2021 00:00,,,,,,
4749,denali-therapeutics-announces-positive-interim-data-from-phase-12-study-with-etvids-dnl310-in-patients-with-the-lysosomal-storage-disease-hunter-syndrome-mps-ii,26-07-2021 00:00,,,,,,
4750,perkinelmer-to-acquire-antibody-and-reagent-leader-biolegend,26-07-2021 00:00,,,,,,
4751,beigene-announces-approval-in-canada-of-brukinsa?-zanubrutinib-for-the-treatment-of-patients-with-mantle-cell-lymphoma,27-07-2021 00:00,,,,,,
4752,prothena-presents-new-data-from-robust-alzheimer?s-portfolio-at-the-alzheimer?s-association-international-conference-2021,27-07-2021 00:00,,,,,,
4753,shingrix-approved-in-the-us-for-prevention-of-shingles-in-immunocompromised-adults,27-07-2021 00:00,,,,,,
4754,adagio-therapeutics-partners-with-biocon-biologics-to-bring-potent-and-broadly-neutralizing-covid-19-antibody-treatment-to-patients-in-india-and-select-emerging-markets,27-07-2021 00:00,,,,,,
4755,biontech-provides-update-on-plans-to-develop-sustainable-solutions-to-address-infectious-diseases-on-the-african-continent,27-07-2021 00:00,,,,,,
4756,regeneron-and-astrazeneca-to-research-develop-and-commercialize-new-small-molecule-medicines-for-obesity,27-07-2021 00:00,,,,,,
4757,amgen-to-acquire-privately-held-teneobio-for-900-million-in-cash-with-future-contingent-milestone-payments,28-07-2021 00:00,,,,,,
4758,peptidream-and-takeda-expand-collaborative-research-and-license-agreement-to-develop-peptide-drug-conjugates-for-cns-diseases,28-07-2021 00:00,,,,,,
4759,abbvie-and-calico-announce-second-extension-of-collaboration-focused-on-aging-and-age-related-diseases,28-07-2021 00:00,,,,,,
4760,sanofi-provides-update-on-avalglucosidase-alfa-eu-submission-for-patients-with-pompe-disease,28-07-2021 00:00,,,,,,
4761,bridgebio-announces-clinical-collaboration-with-bristol-myers-squibb-to-study-bbp-398-a-potentially-best-in-class-shp2-inhibitor-in-combination-with-opdivo?-nivolumab-in-advanced-solid-tumors-with-kras-mutations,28-07-2021 00:00,,,,,,
4762,arena-pharmaceuticals-and-aristea-therapeutics-establish-collaboration-for-development-of-rist4721-for-treatment-of-serious-immune-mediated-inflammatory-diseases,28-07-2021 00:00,,,,,,
4763,bd-acquires-tepha-inc-to-drive-new-innovations-in-soft-tissue-repair-and-regeneration,29-07-2021 00:00,,,,,,
4764,fda-accepts-application-for-roche?s-faricimab-for-the-treatment-of-neovascular-age-related-macular-degeneration-namd-and-diabetic-macular-edema-dme,29-07-2021 00:00,,,,,,
4765,dupixent?-dupilumab-significantly-improved-itch-and-hives-in-patients-with-chronic-spontaneous-urticaria-a-step-forward-in-demonstrating-the-role-of-type-2-inflammation-in-these-patients,29-07-2021 00:00,,,,,,
4766,viatris-inc-and-biocon-biologics-receive-historic-approval-for-first-interchangeable-biosimilar-semglee?-insulin-glargine-yfgn-injection-for-the-treatment-of-diabetes,29-07-2021 00:00,,,,,,
4767,protagonist-therapeutics-announces-amendment-of-agreement-with-janssen-biotech-for-the-continued-development-and-commercialization-of-il-23-antagonists,29-07-2021 00:00,,,,,,
4768,us-food-and-drug-administration-grants-breakthrough-therapy-designation-to-takeda?s-investigational-compound-tak-994-an-oral-orexin-agonist-in-clinical-development-for-narcolepsy-type-1-nt1,29-07-2021 00:00,,,,,,
4769,first-patient-dosed-in-phase-1-clinical-trial-of-henlius-bevacizumab-hlx04-o,19-07-2021 00:00,,,,,,
4770,lilly-and-kumquat-biosciences-announce-collaboration-to-discover-and-develop-novel-small-molecules-that-stimulate-tumor-specific-immune-responses,30-07-2021 00:00,,,,,,
4771,gsk-announces-fda-approval-for-nucala-mepolizumab-for-use-in-adults-with-chronic-rhinosinusitis-with-nasal-polyps,30-07-2021 00:00,,,,,,
4772,junshi-biosciences-announces-acceptance-by-nmpa-of-supplemental-new-drug-application-for-toripalimab-plus-chemotherapy-as-first-line-treatment-for-advanced-or-metastatic-esophageal-squamous-cell-carcinoma,30-07-2021 00:00,,,,,,
4773,alnylam-and-peptidream-enter-into-collaboration-agreement-to-discover-and-develop-peptide-sirna-conjugates-for-targeted-delivery-of-rnai-therapeutics-to-a-broader-range-of-extrahepatic-tissues,30-07-2021 00:00,,,,,,
4774,beigene-announces-positive-topline-results-from-phase-3-sequoia-trial-comparing-brukinsa?-zanubrutinib-to-bendamustine-plus-rituximab-in-patients-with-treatment-na?ve-chronic-lymphocytic-leukemia,30-07-2021 00:00,,,,,,
4775,data-for-roche?s-evrysdi?-risdiplam-published-in-new-england-journal-of-medicine-shows-significant-improvement-in-survival-and-motor-milestones-in-babies-with-type-1-spinal-muscular-atrophy-sma,30-07-2021 00:00,,,,,,
4776,astellas-and-minovia-therapeutics-announce-strategic-collaboration-for-novel-mitochondrial-cell-therapy-programs,02-08-2021 00:00,,,,,,
4777,takeda-and-frazier-healthcare-partners-announce-collaboration-to-launch-hillevax-inc-to-develop-clinical-stage-norovirus-vaccine-candidate,02-08-2021 00:00,,,,,,
4778,saphnelo-anifrolumab-approved-in-the-us-for-moderate-to-severe-systemic-lupus-erythematosus,02-08-2021 00:00,,,,,,
4779,uptravi?-selexipag-receives-fda-approval-for-intravenous-use-in-adult-patients-with-pulmonary-arterial-hypertension-pah,02-08-2021 00:00,,,,,,
4780,ipsen-and-exicure-enter-into-exclusive-collaboration-targeting-rare-neurodegenerative-disorders,02-08-2021 00:00,,,,,,
4781,fda-expands-authorized-use-of-regen-cov?-casirivimab-and-imdevimab,02-08-2021 00:00,,,,,,
4782,biofactura-announces-initiation-of-phase-i-study-of-bfi-751-a-stelara?-ustekinumab-biosimilar,25-05-2021 00:00,,,,,,
4783,abzena-and-bioxpress-therapeutics-announce-partnership-to-support-the-development-and-manufacture-of-biosimilars-for-global-customers,27-07-2021 00:00,,,,,,
4784,abbott-introduces-jot-dx?-insertable-cardiac-monitor-designed-to-reduce-data-burden-and-improve-accurate-diagnosis-of-difficult-to-detect-abnormal-heart-rhythms,03-08-2021 00:00,,,,,,
4785,sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development,03-08-2021 00:00,,,,,,
4786,us-fda-grants-priority-review-to-roche?s-tecentriq-as-adjuvant-treatment-for-certain-people-with-early-non-small-cell-lung-cancer,03-08-2021 00:00,,,,,,
4787,novartis-announces-lift-of-partial-clinical-trial-hold-and-plans-to-initiate-a-new-pivotal-phase-3-study-of-intrathecal-oav-101-in-older-patients-with-sma,03-08-2021 00:00,,,,,,
4788,nice-approves-first-treatment-in-pilot-of-new-approach-to-cost-comparison-fast-track-appraisals,03-08-2021 00:00,,,,,,
4789,lilly-and-incyte?s-baricitinib-reduced-deaths-among-patients-with-covid-19-receiving-invasive-mechanical-ventilation,03-08-2021 00:00,,,,,,
4790,marinus-pharmaceuticals-announces-exclusive-collaboration-with-orion-corporation-for-european-commercialization-of-ganaxolone,04-08-2021 00:00,,,,,,
4791,bayer?s-investigational-p2x3-antagonist-meets-primary-efficacy-endpoint-and-shows-favorable-safety-and-tolerability-profile,04-08-2021 00:00,,,,,,
4792,tachyon-and-abcellera-collaborate-to-develop-novel-antibody-therapeutic-targeting-tgf-?-superfamily-member-for-the-treatment-of-cancer,04-08-2021 00:00,,,,,,
4793,celltrion-healthcare?s-anticancer-therapeutics-herzuma?-trastuzumab-and-truxima?-rituximab-win-brazilian-tender-for-two-consecutive-years,04-08-2021 00:00,,,,,,
4794,outlook-therapeutics-reports-positive-efficacy-and-safety-data-from-pivotal-phase-3-norse-two-trial-of-ons-5010-lytenava?-bevacizumab-vikg-for-the-treatment-of-wet-amd,04-08-2021 00:00,,,,,,
4796,f-star-therapeutics-announces-collaboration-with-msd-to-evaluate-fs120-in-combination-with-keytruda,05-08-2021 00:00,,,,,,
4797,schr?dinger-and-zai-lab-announce-a-global-rd-collaboration-in-oncology,05-08-2021 00:00,,,,,,
4798,pfizer-announces-positive-top-line-results-from-phase-2b3-trial-of-ritlecitinib-in-alopecia-areata,05-08-2021 00:00,,,,,,
4799,phase-3-trial-of-libtayo?-cemiplimab-combined-with-chemotherapy-stopped-early-due-to-significant-improvement-in-overall-survival-in-patients-with-first-line-advanced-non-small-cell-lung-cancer,05-08-2021 00:00,,,,,,
4800,phase-3-trial-of-libtayo?-cemiplimab-combined-with-chemotherapy-stopped-early-due-to-significant-improvement-in-overall-survival-in-patients-with-first-line-advanced-non-small-cell-lung-cancer,05-08-2021 00:00,,,,,,
4801,merck?s-keytruda?-pembrolizumab-significantly-prolonged-recurrence-free-survival-rfs-compared-to-placebo-as-adjuvant-therapy-for-patients-with-stage-ii-resected-high-risk-melanoma-in-phase-3-keynote-716-trial,05-08-2021 00:00,,,,,,
4802,bayer-strengthens-drug-discovery-platform-through-acquisition-of-vividion-therapeutics,06-08-2021 00:00,,,,,,
4803,sierra-oncology-signs-exclusive-global-in-licensing-agreement-with-astrazeneca-for-novel-bet-inhibitor-to-expand-myelofibrosis-pipeline,06-08-2021 00:00,,,,,,
4804,final-results-from-the-longest-hereditary-angioedema-study-of-active-treatment-duration-conducted-to-date-support-the-sustained-safety-and-efficacy-of-takhzyro?-lanadelumab-injection-for-long-term-prevention-of-hereditary-angioedema-attacks,06-08-2021 00:00,,,,,,
4805,polpharma-biologics-group-announces-that-its-joint-venture-bioeq-has-submitted-a-biologics-license-application-bla-for-biosimilar-ranibizumab-to-the-us-food-and-drug-administration-fda,06-08-2021 00:00,,,,,,
4806,kite-and-appia-bio-announce-collaboration-to-research-and-develop-allogeneic-cell-therapies-for-cancer,06-08-2021 00:00,,,,,,
4807,medtronic-to-acquire-intersect-ent,06-08-2021 00:00,,,,,,
4808,fda-approves-nexviazyme?-avalglucosidase-alfa-ngpt-an-important-new-treatment-option-for-late-onset-pompe-disease,09-08-2021 00:00,,,,,,
4809,phase-iii-study-shows-genentech?s-polivy-plus-r-chp-is-the-first-regimen-in-20-years-to-significantly-improve-outcomes-in-previously-untreated-aggressive-form-of-lymphoma-compared-to-standard-of-care,09-08-2021 00:00,,,,,,
4810,updated-overall-survival-data-and-biomarker-results-from-sintilimab-orient-11-study-in-first-line-nonsquamous-non-small-cell-lung-cancer-published-in-the-journal-of-thoracic-oncology,09-08-2021 00:00,,,,,,
4811,forxiga-approved-in-the-eu-for-the-treatment-of-chronic-kidney-disease-in-patients-with-and-without-type-2-diabetes,09-08-2021 00:00,,,,,,
4812,new-two-year-data-showed-bimekizumab-maintained-high-levels-of-skin-clearance-in-patients-with-moderate-to-severe-plaque-psoriasis,09-08-2021 00:00,,,,,,
4813,calliditas-receives-fda-fast-track-designation-for-setanaxib-in-pbc,09-08-2021 00:00,,,,,,
4814,molecular-partners-to-regain-global-rights-to-abicipar,10-08-2021 00:00,,,,,,
4815,harmony-biosciences-acquires-asset-with-novel-mechanism-of-action-for-the-potential-treatment-of-narcolepsy-and-other-rare-neurological-diseases,10-08-2021 00:00,,,,,,
4816,mission-and-abbvie-collaboration-in-alzheimer?s-and-parkinson?s-diseases-reaches-next-milestone,10-08-2021 00:00,,,,,,
4817,seagen-and-remegen-announce-exclusive-worldwide-license-and-co-development-agreement-for-disitamab-vedotin,10-08-2021 00:00,,,,,,
4818,alnylam-completes-enrollment-in-helios-b-phase-3-study-of-investigational-vutrisiran-in-patients-with-transthyretin-mediated-attr-amyloidosis-with-cardiomyopathy,10-08-2021 00:00,,,,,,
4819,fda-grants-priority-review-to-merck?s-supplemental-biologics-license-application-for-keytruda?-pembrolizumab-as-adjuvant-therapy-in-certain-patients-with-renal-cell-carcinoma-rcc-following-surgery,10-08-2021 00:00,,,,,,
4820,finch-therapeutics-announces-takeda-to-accelerate-leadership-role-in-fin-524-ulcerative-colitis-development-program,11-08-2021 00:00,,,,,,
4821,dermavant-announces-fda-acceptance-for-filing-of-new-drug-application-nda-for-tapinarof-cream-for-the-treatment-of-adults-with-plaque-psoriasis,11-08-2021 00:00,,,,,,
4822,gw-pharmaceuticals-receives-approval-for-epidyolex?-cannabidiol-from-the-mhra-for-the-treatment-of-seizures-associated-with-tuberous-sclerosis-complex,11-08-2021 00:00,,,,,,
4823,fda-accepts-application-for-merck?s-keytruda?-pembrolizumab-as-single-agent-for-certain-patients-with-msi-hdmmr-advanced-endometrial-carcinoma,11-08-2021 00:00,,,,,,
4824,boston-scientific-receives-fda-clearance-for-exalt?-model-b-single-use-bronchoscope,11-08-2021 00:00,,,,,,
4825,fibrogen-receives-complete-response-letter-from-the-fda-for-roxadustat-for-anemia-of-chronic-kidney-disease,11-08-2021 00:00,,,,,,
4826,sorrento-and-dyadic-announce-binding-term-sheet-to-license-dyadic?s-lead-covid-19-vaccine-candidate-?dyai-100?-and-c1-technology-for-protein-based-coronavirus-vaccines-and-therapeutics,12-08-2021 00:00,,,,,,
4827,fda-approves-keytruda?-pembrolizumab-plus-lenvima?-lenvatinib-combination-for-first-line-treatment-of-adult-patients-with-advanced-renal-cell-carcinoma-rcc,12-08-2021 00:00,,,,,,
4828,c4-therapeutics-announces-fda-orphan-drug-designation-for-cft7455-for-the-treatment-of-multiple-myeloma,12-08-2021 00:00,,,,,,
4829,innovent-announces-ibi306-anti-pcsk-9-antibody-meets-the-primary-endpoint-in-a-phase-3-clinical-study-for-chinese-heterozygous-familial-hypercholesterolemia,12-08-2021 00:00,,,,,,
4830,i-mab-reports-positive-interim-analysis-from-phase-23-study-of-its-gm-csf-antibody-plonmarlimab-tjm2-to-treat-patients-with-severe-covid-19,12-08-2021 00:00,,,,,,
4831,gc-pharma-announces-publication-of-results-from-phase-iii-clinical-trial-of-?gc5107?-immune-globulin-in-frontiers-in-immunology,12-08-2021 00:00,,,,,,
4832,jazz-pharmaceuticals-announces-us-fda-approval-of-xywav?-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-idiopathic-hypersomnia-in-adults,13-08-2021 00:00,,,,,,
4833,aprea-therapeutics-announces-clinical-hold-on-lymphoid-malignancy-program,13-08-2021 00:00,,,,,,
4834,wise-therapeutics-and-nyu-langone-health-publish-results-of-multiple-sclerosis-study-demonstrating-meaningful-anxiety-reduction-through-game-based-digital-therapeutic,13-08-2021 00:00,,,,,,
4835,ipsen-announces-withdrawal-of-palovarotene-nda-confirming-intention-to-re-submit-following-additional-data-analyses,13-08-2021 00:00,,,,,,
4836,brazilian-health-regulatory-agency-anvisa-grants-emergency-use-authorisation-eua-for-celltrion?s-regdanvimab-ct-p59,13-08-2021 00:00,,,,,,
4837,junshi-biosciences-and-coherus-announce-us-fda-breakthrough-therapy-designation-granted-for-toripalimab-for-1st-line-treatment-of-nasopharyngeal-carcinoma,13-08-2021 00:00,,,,,,
4838,fda-approves-merck?s-hypoxia-inducible-factor-2-alpha-hif-2a-inhibitor-welireg?-belzutifan-for-the-treatment-of-patients-with-certain-types-of-von-hippel-lindau-vhl-disease-associated-tumors,16-08-2021 00:00,,,,,,
4839,sesen-bio-receives-complete-response-letter-from-fda-for-vicineum?-oportuzumab-monatox-qqrs,16-08-2021 00:00,,,,,,
4840,lilly?s-lebrikizumab-significantly-improved-skin-clearance-and-itch-in-people-with-moderate-to-severe-atopic-dermatitis-in-two-phase-3-trials,16-08-2021 00:00,,,,,,
4841,us-fda-approves-ticovac?-pfizer?s-tick-borne-encephalitis-tbe-vaccine,16-08-2021 00:00,,,,,,
4842,merck-canada-initiates-rolling-submission-to-health-canada-for-molnupiravir-an-investigational-oral-therapeutic-agent-for-the-treatment-of-covid-19,16-08-2021 00:00,,,,,,
4843,rocket-pharmaceuticals-announces-fda-lifts-clinical-hold-on-danon-disease-trial-of-rp-a501,16-08-2021 00:00,,,,,,
4844,fda-approves-lyumjev?-insulin-lispro-aabc-injection-100-unitsml-for-use-in-insulin-pumps,17-08-2021 00:00,,,,,,
4845,incyte-and-innocare-announce-collaboration-and-license-agreement-for-tafasitamab-in-greater-china,17-08-2021 00:00,,,,,,
4846,exelixis-and-invenra-expand-collaboration-to-discover-and-develop-novel-biologics-in-oncology,17-08-2021 00:00,,,,,,
4847,abbott?s-amplatzer?-amulet?-device-approved-by-fda-to-treat-people-with-atrial-fibrillation-at-risk-of-stroke,17-08-2021 00:00,,,,,,
4848,novartis-secures-new-approval-in-china-for-cosentyx?-secukinumab-in-pediatric-psoriasis,17-08-2021 00:00,,,,,,
4849,ema-validates-bristol-myers-squibb?s-applications-for-opdivo-nivolumab-yervoy-ipilimumab-and-opdivo-chemotherapy-as-first-line-treatments-for-unresectable-advanced-recurrent-or-metastatic-esophageal-squamous-cell-carcinoma,17-08-2021 00:00,,,,,,
4850,sol-gel-technologies-announces-fda-approval-of-twyneo,27-07-2021 00:00,,,,,,
4851,gsk-receives-fda-accelerated-approval-for-jemperli-dostarlimab-gxly-for-adult-patients-with-mismatch-repair-deficient-dmmr-recurrent-or-advanced-solid-tumors,18-08-2021 00:00,,,,,,
4852,agios-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-mitapivat-for-treatment-of-adults-with-pyruvate-kinase-deficiency,18-08-2021 00:00,,,,,,
4853,verily-to-acquire-signalpath-expanding-company?s-clinical-research-capabilities,18-08-2021 00:00,,,,,,
4854,beigene-and-eusa-pharma-announce-china-nmpa-approval-of-qarziba?-dinutuximab-beta-for-patients-with-high-risk-neuroblastoma,18-08-2021 00:00,,,,,,
4855,novartis-announces-positive-results-from-phase-iii-trials-of-beovu?-in-diabetic-macular-edema-including-dosing-intervals-up-to-16-weeks,18-08-2021 00:00,,,,,,
4856,bristol-myers-squibb-exercises-option-to-develop-exscientia?s-ai-designed-immune-modulating-drug-candidate,18-08-2021 00:00,,,,,,
4857,new-england-journal-of-medicine-publishes-12-week-results-from-study-evaluating-atogepant-for-the-preventive-treatment-of-migraine,19-08-2021 00:00,,,,,,
4858,us-fda-approves-jardiance?-empagliflozin-to-treat-adults-living-with-heart-failure-with-reduced-ejection-fraction,19-08-2021 00:00,,,,,,
4859,coherus-and-junshi-biosciences-announce-positive-interim-results-of-choice-01-a-phase-3-clinical-trial-evaluating-toripalimab-in-combination-with-chemotherapy-as-first-line-treatment-for-non-small-cell-lung-cancer,19-08-2021 00:00,,,,,,
4860,werewolf-therapeutics-announces-clinical-trial-collaboration-with-merck-on-its-wtx-124-indukine?-program,19-08-2021 00:00,,,,,,
4861,alligator-bioscience-announces-immuno-oncology-research-collaboration-and-license-agreement-with-orion-corporation,19-08-2021 00:00,,,,,,
4862,adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda?-pembrolizumab,19-08-2021 00:00,,,,,,
4863,bristol-myers-squibb-receives-european-commission-approval-for-abecma-idecabtagene-vicleucel-the-first-anti-bcma-car-t-cell-therapy-for-relapsed-and-refractory-multiple-myeloma,20-08-2021 00:00,,,,,,
4864,european-medicines-agency-validates-gilead?s-marketing-authorization-application-for-lenacapavir-an-investigational-long-acting-capsid-inhibitor-for-the-treatment-of-hiv-1-in-people-with-limited-therapy-options,20-08-2021 00:00,,,,,,
4865,astellas-receives-european-commission-approval-for-first-in-class-evrenzotm-roxadustat-for-adult-patients-with-symptomatic-anemia-of-chronic-kidney-disease,20-08-2021 00:00,,,,,,
4866,janssen-presents-phase-1-results-for-rybrevant?-amivantamab-vmjw-in-the-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-with-met-exon-14-skipping-mutations,20-08-2021 00:00,,,,,,
4867,azd7442-provent-phase-iii-prophylaxis-trial-met-primary-endpoint-in-preventing-covid-19,20-08-2021 00:00,,,,,,
4868,roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-dmmr-solid-tumour-patients-eligible-for-anti-pd-1-immunotherapy,20-08-2021 00:00,,,,,,
4869,us-food-and-drug-administration-approves-opdivo?-nivolumab-for-the-adjuvant-treatment-of-patients-with-high-risk-urothelial-carcinoma,23-08-2021 00:00,,,,,,
4870,beigene-announces-acceptance-of-a-supplemental-biologics-license-application-in-china-for-tislelizumab-in-nasopharyngeal-cancer,23-08-2021 00:00,,,,,,
4871,xeljanz?-tofacitinib-citrate-receives-marketing-authorization-in-the-european-union-for-the-treatment-of-active-polyarticular-juvenile-idiopathic-arthritis-and-juvenile-psoriatic-arthritis,23-08-2021 00:00,,,,,,
4872,zydus-receives-eua-from-dcgi-for-zycov-d-the-only-needle-free-covid-vaccine-in-the-world,23-08-2021 00:00,,,,,,
4873,update-on-champion-als-phase-iii-trial-of-ultomiris-in-amyotrophic-lateral-sclerosis,23-08-2021 00:00,,,,,,
4874,pfizer-to-acquire-trillium-therapeutics-inc,23-08-2021 00:00,,,,,,
4875,pfizer-to-acquire-trillium-therapeutics-inc,24-08-2021 00:00,,,,,,
4876,genevant-sciences-announces-global-collaboration-and-license-agreement-with-takeda-to-develop-novel-nonviral-gene-therapies-for-up-to-two-rare-liver-diseases,24-08-2021 00:00,,,,,,
4877,theravance-biopharma-inc-announces-top-line-results-from-phase-2b-dose-finding-induction-study-of-izencitinib-in-patients-with-ulcerative-colitis,24-08-2021 00:00,,,,,,
4878,merck-statement-on-phase-ii-study-of-bintrafusp-alfa-in-first-line-treatment-of-biliary-tract-cancer,24-08-2021 00:00,,,,,,
4879,novartis-provides-update-on-belinda-study-investigating-kymriah?-as-second-line-treatment-in-aggressive-b-cell-non-hodgkin-lymphoma,24-08-2021 00:00,,,,,,
4880,ucb-announces-european-commission-approval-of-bimzelx?-bimekizumab-for-the-treatment-of-adults-with-moderate-to-severe-plaque-psoriasis,24-08-2021 00:00,,,,,,
4881,shape-therapeutics-enters-into-a-strategic-research-collaboration-with-roche-to-advance-breakthrough-aav-based-rna-editing-technology-for-neuroscience-and-rare-disease-indications,25-08-2021 00:00,,,,,,
4882,european-commission-approves-rinvoq?-upadacitinib-as-first-jak-inhibitor-in-the-european-union-for-the-treatment-of-both-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis,25-08-2021 00:00,,,,,,
4883,vertex-and-arbor-biotechnologies-establish-new-partnership-to-develop-novel-ex-vivo-engineered-cell-therapies,25-08-2021 00:00,,,,,,
4884,ono-and-takeda-receive-an-approval-for-opdivo?-nivolumab-and-cabometyx?-cabozantinib-combination-therapy-in-japan-for-treatment-of-unresectable-or-metastatic-renal-cell-carcinoma,25-08-2021 00:00,,,,,,
4885,argenx-announces-validation-of-european-marketing-authorization-application-for-efgartigimod-in-generalized-myasthenia-gravis,25-08-2021 00:00,,,,,,
4886,argenx-announces-validation-of-european-marketing-authorization-application-for-efgartigimod-in-generalized-myasthenia-gravis,25-08-2021 00:00,,,,,,
4887,lilly-and-lycia-therapeutics-enter-into-strategic-collaboration-to-discover-and-develop-novel-lysosomal-targeting-chimera-lytac-degraders,26-08-2021 00:00,,,,,,
4888,fda-approves-ngs-based-companion-diagnostic-for-previously-treated-idh1-mutated-cholangiocarcinoma,26-08-2021 00:00,,,,,,
4889,merck-announces-vaxneuvance?-pneumococcal-15-valent-conjugate-vaccine-met-key-immunogenicity-and-safety-endpoints-in-phase-3-pivotal-trial-evaluating-use-in-infants-pneu-ped-v114-029,26-08-2021 00:00,,,,,,
4890,forxiga-approved-in-japan-for-the-treatment-of-chronic-kidney-disease-in-patients-with-and-without-type-2-diabetes,26-08-2021 00:00,,,,,,
4891,forxiga-approved-in-japan-for-the-treatment-of-chronic-kidney-disease-in-patients-with-and-without-type-2-diabetes,26-08-2021 00:00,,,,,,
4892,alxn1840-focus-phase-iii-trial-in-wilson-disease-met-primary-endpoint-demonstrating-improvement-in-copper-mobilisation-from-tissues,26-08-2021 00:00,,,,,,
4893,novarock-biotherapeutics-announces-exclusive-license-agreement-and-strategic-partnership-with-flame-biosciences,27-08-2021 00:00,,,,,,
4894,incyte-and-morphosys-announce-the-european-commission-approval-of-minjuvi?-tafasitamab-in-combination-with-lenalidomide-for-the-treatment-of-adults-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma,27-08-2021 00:00,,,,,,
4895,beyondspring-announces-exclusive-commercialization-and-co-development-agreement-with-jiangsu-hengrui-pharmaceuticals-for-plinabulin-in-greater-china,27-08-2021 00:00,,,,,,
4896,innovent-and-bolt-biotherapeutics-announce-collaboration-to-develop-three-new-oncology-boltbody?-isac-programs,27-08-2021 00:00,,,,,,
4897,new-data-at-esc-congress-2021-shows-repatha?-evolocumab-improves-features-of-plaque-stability-in-patients-with-acute-coronary-syndrome-acs,27-08-2021 00:00,,,,,,
4898,ascendis-pharma-as-announces-us-food-and-drug-administration-approval-of-skytrofa?-lonapegsomatropin-tcgd-the-first-once-weekly-treatment-for-pediatric-growth-hormone-deficiency,27-08-2021 00:00,,,,,,
4899,immixbio-announces-clinical-trial-and-supply-agreement-with-beigene-to-evaluate-combination-of-imx-110-and-tislelizumab-in-solid-tumors,30-08-2021 00:00,,,,,,
4900,fda-approves-first-of-its-kind-stroke-rehabilitation-system,30-08-2021 00:00,,,,,,
4901,bio-thera-solutions-and-hikma-pharmaceuticals-announce-exclusive-commercialization-and-license-agreement-for-bat2206-in-the-us-a-proposed-biosimilar-referencing-stelara?-ustekinumab,30-08-2021 00:00,,,,,,
4902,dupixent?-dupilumab-pivotal-trial-meets-all-primary-and-secondary-endpoints-becoming-first-biologic-medicine-to-significantly-reduce-signs-and-symptoms-of-moderate-to-severe-atopic-dermatitis-in-children-as-young-as-6-months,30-08-2021 00:00,,,,,,
4903,springworks-therapeutics-enters-into-research-collaboration-with-leading-cancer-institute-to-further-evaluate-nirogacestat-as-a-bcma-potentiator-in-multiple-myeloma,30-08-2021 00:00,,,,,,
4904,positive-top-line-results-from-pfizer?s-phase-3-jade-dare-trial-comparing-the-efficacy-of-abrocitinib-and-dupilumab-for-moderate-to-severe-atopic-dermatitis,30-08-2021 00:00,,,,,,
4905,late-breaking-data-shows-abbott?s-amplatzer?-amulet?-occluder-offers-superior-left-atrial-appendage-closure-compared-to-watchman?-device-for-people-with-atrial-fibrillation-at-risk-of-stroke,31-08-2021 00:00,,,,,,
4906,sk-bioscience-and-gsk-start-phase-3-trial-of-adjuvanted-covid-19-vaccine-candidate,31-08-2021 00:00,,,,,,
4907,bone-therapeutics-announces-topline-results-from-phase-iii-knee-osteoarthritis-study-with-its-enhanced-viscosupplement-jta-004,31-08-2021 00:00,,,,,,
4908,baxter-in-advanced-talks-to-acquire-hill-rom-for-10-billion-source,31-08-2021 00:00,,,,,,
4909,new-data-demonstrate-the-benefits-of-early-use-of-uptravi?-selexipag-in-delaying-disease-progression-in-a-broad-population-of-patients-with-pulmonary-arterial-hypertension-pah,31-08-2021 00:00,,,,,,
4910,landmark-trial-demonstrates-empagliflozin-is-the-first-therapy-to-show-statistically-significant-improvement-in-heart-failure-outcomes-in-adults-with-preserved-ejection-fraction,31-08-2021 00:00,,,,,,
4911,centus-bevacizumab-candidate-demonstrates-equivalence-in-phase-3-study,19-08-2021 00:00,,,,,,
4912,cipla-and-kemwell-biopharma-announce-execution-of-a-joint-venture-agreement-for-developing-manufacturing-and-commercialising-biosimilars,25-08-2021 00:00,,,,,,
4913,formycon-and-bioeq-announce-submission-of-the-biologics-license-application-bla-for-fyb201-a-biosimilar-candidate-to-lucentisr1-ranibizumab-to-the-us-food-and-drug-administration-fda,05-08-2021 00:00,,,,,,
4914,samsung-bioepis-gets-nod-for-sale-of-ophthalmology-biosimilar-drug-in-europeposted-2021-08-23-1612updated-2021-08-23-1612,23-08-2021 00:00,,,,,,
4915,world-first-agreement-between-novartis-and-the-nhs-enables-broad-and-rapid-access-to-first-in-class-cholesterol-lowering-medicine-leqvio?-inclisiran,01-09-2021 00:00,,,,,,
4916,ac-immune-announces-first-positive-cognitive-results-for-a-tau-targeting-monoclonal-antibody-in-alzheimer?s-disease,01-09-2021 00:00,,,,,,
4917,bayer-starts-phase-iii-clinical-development-program-oasis-with-investigational-product-elinzanetant,01-09-2021 00:00,,,,,,
4918,johnson-johnson-and-global-partners-announce-results-from-phase-2b-imbokodo-hiv-vaccine-clinical-trial-in-young-women-in-sub-saharan-africa,01-09-2021 00:00,,,,,,
4919,fda-approves-updated-indication-for-merck?s-keytruda?-pembrolizumab-for-treatment-of-certain-patients-with-urothelial-carcinoma-bladder-cancer,01-09-2021 00:00,,,,,,
4920,merck-and-ridgeback-biotherapeutics-announce-initiation-of-pivotal-phase-3-move-ahead-study-evaluating-molnupiravir-for-post-exposure-prophylaxis-of-covid-19-infection,01-09-2021 00:00,,,,,,
4921,celltrion?s-herzuma-outsells-original-breast-gastric-cancer-treatments-in-japan,11-08-2021 00:00,,,,,,
4922,enzene-biosciences-ltd-obtains-marketing-authorization-for-its-romiplostim-biosimilar-drug-in-india,20-08-2021 00:00,,,,,,
4923,nora-pharma-entering-into-an-agreement-to-launch-a-biosimilar-for-canada,24-08-2021 00:00,,,,,,
4924,thermo-fisher-scientific-and-astrazeneca-to-co-develop-ngs-based-companion-diagnostics,02-09-2021 00:00,,,,,,
4925,cvs-?-cvs-drops-sanofi?s-diabetes-drugs-for-biosimilars,13-08-2021 00:00,,,,,,
4926,takeda-provides-update-on-phase-3-panther-pevonedistat-3001-trial,02-09-2021 00:00,,,,,,
4927,evotec-announces-bristol-myers-squibb-opt-in-of-evt8683-as-the-first-programme-from-ipsc-based-neurodegeneration-collaboration,02-09-2021 00:00,,,,,,
4928,us-fda-grants-brukinsa?-zanubrutinib-approval-in-waldenstr?m?s-macroglobulinemia,02-09-2021 00:00,,,,,,
4929,astellas-provides-update-on-aspiro-clinical-trial-of-at132-in-patients-with-x-linked-myotubular-myopathy,02-09-2021 00:00,,,,,,
4930,janssen-announces-us-fda-approval-of-invega-hafyera?-6-month-paliperidone-palmitate-first-and-only-twice-yearly-treatment-for-adults-with-schizophrenia,02-09-2021 00:00,,,,,,
4931,study-biosimilar-rhgh-well-tolerated-and-effective-in-turner-syndrome,23-08-2021 00:00,,,,,,
4932,baxter-to-acquire-hillrom-expanding-connected-care-and-medical-innovation-globally,03-09-2021 00:00,,,,,,
4933,abbott-expands-peripheral-vascular-offerings-with-acquisition-of-walk-vascular-llc,03-09-2021 00:00,,,,,,
4934,ultomiris-approved-in-the-eu-for-children-and-adolescents-with-paroxysmal-nocturnal-haemoglobinuria,03-09-2021 00:00,,,,,,
4935,ultomiris-approved-in-the-eu-for-children-and-adolescents-with-paroxysmal-nocturnal-haemoglobinuria,03-09-2021 00:00,,,,,,
4936,nice-recommends-novartis-cosentyx?-secukinumab-for-children-and-young-people-with-moderate-to-severe-psoriasis,03-09-2021 00:00,,,,,,
4937,clinical-trial-of-fb-401-for-the-treatment-of-atopic-dermatitis-fails-to-meet-statistical-significance,03-09-2021 00:00,,,,,,
4938,novartis-announces-discontinuation-of-cirrus-1-study-of-cfz533-iscalimab-in-kidney-transplant-patients,06-09-2021 00:00,,,,,,
4939,dr-reddy?s-laboratories-enters-into-definitive-agreement-with-citius-pharmaceuticals-inc-to-sell-its-rights-to-anti-cancer-agent-e7777-denileukin-diftitox,06-09-2021 00:00,,,,,,
4940,us-fda-placed-a-clinical-hold-on-bmn-307-phearless-phase-12-gene-therapy-study-in-adults-with-pku-based-on-interim-pre-clinical-study-findings,06-09-2021 00:00,,,,,,
4941,new-tezepelumab-data-show-86-reduction-in-exacerbations-in-patients-with-severe-asthma-and-comorbid-nasal-polyps,06-09-2021 00:00,,,,,,
4942,bayer?s-eliapixant-significantly-decreased-cough-frequency-in-phase-iib-trial-in-patients-with-refractory-chronic-cough,06-09-2021 00:00,,,,,,
4943,tga-provisional-approval-of-moderna-covid-19-vaccine-to-include-12-17-years-age-group,06-09-2021 00:00,,,,,,
4944,jw-therapeutics-announces-nmpa-approval-of-relmacabtagene-autoleucel-injection-in-china,07-09-2021 00:00,,,,,,
4945,neuexcell-therapeutics-and-spark-therapeutics-announce-research-collaboration-agreement-to-develop-a-novel-gene-therapy-for-huntington?s-disease,07-09-2021 00:00,,,,,,
4946,statement-by-the-board-of-directors-of-swedish-orphan-biovitrum-ab-in-relation-to-the-public-cash-offer-by-advent-and-gic,07-09-2021 00:00,,,,,,
4947,impel-neuropharma-announces-us-fda-approval-of-trudhesa?-dihydroergotamine-mesylate-nasal-spray-for-the-acute-treatment-of-migraine,07-09-2021 00:00,,,,,,
4948,sorrento-announces-enrollment-of-first-subject-in-brazil-phase-2-study-of-covi-msc-for-treatment-of-covid-19-associated-acute-respiratory-distress-in-icu-patients,07-09-2021 00:00,,,,,,
4949,hetero?s-biosimilar-version-of-tocilizumab-tocira-receives-emergency-use-authorization-eua-from-dcgi-for-the-treatment-of-covid-19-in-hospitalized-adults,07-09-2021 00:00,,,,,,
4950,adaptimmune-enters-into-a-strategic-collaboration-with-genentech-to-research-develop-and-commercialize-cancer-targeted-allogeneic-t-cell-therapies,08-09-2021 00:00,,,,,,
4951,sanofi-to-acquire-kadmon-to-further-strengthen-growth-of-transplant-business,08-09-2021 00:00,,,,,,
4952,mayo-google-research-develop-new-ai-algorithm-to-improve-brain-stimulation-devices-to-treat-disease,08-09-2021 00:00,,,,,,
4953,am-pharma-and-kyowa-kirin-sign-exclusive-license-agreement-for-commercialization-of-ilofotase-alfa-in-japan,08-09-2021 00:00,,,,,,
4954,united-therapeutics-presents-tyvaso-dpi?-breeze-clinical-data-at-the-european-respiratory-society-international-congress-2021,08-09-2021 00:00,,,,,,
4955,new-fasenra-data-from-the-ponente-trial-show-sustained-robust-oral-corticosteroid-reductions-in-largest-ever-steroid-sparing-trial-in-severe-asthma,08-09-2021 00:00,,,,,,
4956,bio-thera-solutions-announces-commercialization-and-license-agreement-for-bat1706-a-proposed-biosimilar-referencing-avastin?-bevacizumab,09-09-2021 00:00,,,,,,
4957,hutchmed-and-astrazeneca-initiate-sanovo-phase-iii-trial-of-orpathys?-and-tagrisso?-combination-as-a-first-line-therapy-for-certain-lung-cancer-patients-in-china,09-09-2021 00:00,,,,,,
4958,sanofi-provides-update-on-phase-3-study-evaluating-rilzabrutinib-for-the-treatment-of-pemphigus,09-09-2021 00:00,,,,,,
4959,fixed-dose-combination-of-albuterol-and-budesonide-pt027-demonstrated-significant-benefits-for-asthma-patients-in-mandala-and-denali-phase-iii-trials,09-09-2021 00:00,,,,,,
4960,cardiff-oncology-announces-new-data-from-phase-1b2-trial-in-kras-mutated-metastatic-colorectal-cancer-showing-robust-objective-response-rate-and-progression-free-survival,09-09-2021 00:00,,,,,,
4961,icu-medical-inc-to-acquire-smiths-medical-division-from-smiths-group-plc-for-235-billion-in-cash-and-stock-plus-the-assumption-of-certain-liabilities-and-a-stock-price-performance-based-earn-out,09-09-2021 00:00,,,,,,
4962,proqr-announces-axiomer?-rna-editing-licensing-and-research-collaboration-with-lilly,10-09-2021 00:00,,,,,,
4963,roche-signs-definitive-share-purchase-agreement-with-long-term-partner-tib-molbiol-to-expand-pcr-test-portfolio-in-the-fight-against-new-infectious-diseases,10-09-2021 00:00,,,,,,
4964,dermavant-announces-first-patient-dosed-in-adoring-its-pivotal-phase-3-clinical-program-for-tapinarof-for-the-topical-treatment-of-atopic-dermatitis,10-09-2021 00:00,,,,,,
4965,fda-grants-jardiance?-breakthrough-therapy-designation-for-heart-failure-with-preserved-ejection-fraction,10-09-2021 00:00,,,,,,
4966,a-post-hoc-analysis-of-phase-3-study-demonstrates-baseline-factors-associated-with-visual-acuity-and-anatomical-outcomes-of-samsung-bioepis?-byooviz?-ranibizumab-in-namd-at-the-euretina-2021,10-09-2021 00:00,,,,,,
4967,boehringer-ingelheim-and-twist-bioscience-enter-therapeutic-antibody-discovery-collaboration,10-09-2021 00:00,,,,,,
4968,novartis-announces-first-fda-filing-acceptance-for-anti-pd-1-antibody-tislelizumab-for-people-with-esophageal-cancer,13-09-2021 00:00,,,,,,
4969,imfinzi-and-tremelimumab-with-chemotherapy-improved-progression-free-survival-by-28-and-overall-survival-by-23-in-1st-line-stage-iv-non-small-cell-lung-cancer-vs-chemotherapy,13-09-2021 00:00,,,,,,
4970,zoll-medical-corporation-signs-definitive-agreement-to-acquire-itamar-medical,13-09-2021 00:00,,,,,,
4971,hutchmed-receives-breakthrough-therapy-designation-in-china-for-amdizalisib-hmpl-689-for-treatment-of-relapsed-or-refractory-follicular-lymphoma,13-09-2021 00:00,,,,,,
4972,abbvie-and-regenxbio-announce-eye-care-collaboration,13-09-2021 00:00,,,,,,
4973,opdivo-nivolumab-plus-yervoy-ipilimumab-demonstrates-durable-overall-survival-at-three-yearscompared-to-chemotherapy-in-first-line-unresectable-malignant-pleural-mesothelioma-in-phase-3-checkmate-743-trial,13-09-2021 00:00,,,,,,
4974,worldwide-licensing-agreement-with-oxilio-for-nxp001,14-09-2021 00:00,,,,,,
4975,azurrx-biopharma-announces-acquisition-of-first-wave-bio-and-its-proprietary-niclosamide-formulations-targeting-multi-billion-dollar-inflammatory-bowel-disease-indications,14-09-2021 00:00,,,,,,
4976,positive-interim-results-of-choice-01-study-evaluating-coherus?-and-junshi-biosciences?-toripalimab-for-first-line-treatment-of-non-small-cell-lung-cancer-presented-at-world-conference-on-lung-cancer,14-09-2021 00:00,,,,,,
4977,positive-interim-results-of-choice-01-study-evaluating-coherus?-and-junshi-biosciences?-toripalimab-for-first-line-treatment-of-non-small-cell-lung-cancer-presented-at-world-conference-on-lung-cancer,14-09-2021 00:00,,,,,,
4978,applications-submitted-for-combination-therapy-of-opdivo-yervoy-and-opdivo-chemotherapy-for-first-line-treatment-of-unresectable-advanced-or-recurrent-esophageal-cancer-in-japan,14-09-2021 00:00,,,,,,
4979,health-canada-approves-lumakras?-sotorasib-the-first-and-only-targeted-treatment-for-patients-with-kras-g12c-mutated-locally-advanced-or-metastatic-non-small-cell-lung-cancer,14-09-2021 00:00,,,,,,
4980,ginkgo-bioworks-to-go-public-with-over-16-billion-in-proceed,15-09-2021 00:00,,,,,,
4981,redhill-biopharma-reports-top-line-data-from-opaganib-phase-23-study-in-severe-covid-19-patients,15-09-2021 00:00,,,,,,
4982,temedica-develops-new-digital-companion-brisa-for-people-with-multiple-sclerosis-in-cooperation-with-roche,15-09-2021 00:00,,,,,,
4983,abcellera-acquires-tetragenetics-enhancing-capabilities-to-generate-antibodies-against-high-value-targets,15-09-2021 00:00,,,,,,
4984,io-biotech-announces-clinical-collaboration-with-msd-to-evaluate-io102-io103-with-keytruda?-pembrolizumab-as-first-line-treatment-in-metastatic-melanoma-patients-in-a-phase-3-trial,15-09-2021 00:00,,,,,,
4985,us-fda-grants-brukinsa?-zanubrutinib-accelerated-approval-in-relapsed-or-refractory-marginal-zone-lymphoma,15-09-2021 00:00,,,,,,
4986,takeda?s-exkivity?-mobocertinib-approved-by-us-fda-as-the-first-oral-therapy-specifically-designed-for-patients-with-egfr-exon20-insertion-nsclc,16-09-2021 00:00,,,,,,
4987,biogen-plans-to-initiate-phase-3b-study-evaluating-potential-benefit-of-a-higher-dose-of-nusinersen-in-patients-previously-treated-with-evrysdi?-risdiplam,16-09-2021 00:00,,,,,,
4988,hookipa-announces-clinical-collaboration-with-merck-co-inc-kenilworth-nj-usa-to-evaluate-hb-200-in-combination-with-keytruda?-pembrolizumab-in-patients-with-advanced-head-and-neck-cancers,16-09-2021 00:00,,,,,,
4989,nice-recommends-biocryst?s-orladeyo?-berotralstat-the-first-oral-once-daily-therapy-to-prevent-attacks-in-hae-patients-in-the-u,16-09-2021 00:00,,,,,,
4990,lumakras?-sotorasib-combined-with-vectibix?-panitumumab-showed-encouraging-efficacy-and-safety-in-patients-with-kras-g12c-mutated-colorectal-cancer,16-09-2021 00:00,,,,,,
4991,five-year-data-from-checkmate-214-show-opdivo-nivolumab-plus-yervoy-ipilimumab-demonstrates-longest-median-overall-survival-currently-reported-in-phase-3-trial-of-patients-with-previously-untreated-advanced-or-metastatic-renal-cell-carcinoma,16-09-2021 00:00,,,,,,
4992,boehringer-ingelheim-enters-clinical-collaboration-with-amgen-to-study-bi-1701963-a-sos1pan-kras-inhibitor-in-combination-with-lumakras?-sotorasib-a-krasg12c-inhibitor,17-09-2021 00:00,,,,,,
4993,clarus-therapeutics-and-mcgill-university-announce-exclusive-worldwide-licensing-agreement-to-develop-and-commercialize-technology-to-treat-rare-conditions-associated-with-coenzyme-q10-ubiquinone-deficiencies,17-09-2021 00:00,,,,,,
4994,biogen-announces-positive-topline-results-from-phase-2-convey-study-in-small-fiber-neuropathy,17-09-2021 00:00,,,,,,
4995,abbvie-submits-regulatory-applications-to-fda-and-ema-for-upadacitinib-rinvoq?-for-the-treatment-of-adults-with-moderately-to-severely-active-ulcerative-colitis,17-09-2021 00:00,,,,,,
4996,coherus-and-junshi-biosciences-to-present-positive-progression-free-survival-and-overall-survival-results-from-jupiter-06-a-phase-3-clinical-trial-evaluating-toripalimab-in-combination-with-chemotherapy-as-first-line-treatment-for-advanced-esophageal-squamous-cell-carcinoma,17-09-2021 00:00,,,,,,
4997,coave-therapeutics-and-th?a-open-innovation-sign-exclusive-licensing-co-development-and-commercialization-agreement-for-europe-for-ctx-pde6b-a-novel-gene-therapy-candidate-in-retinitis-pigmentosa,17-09-2021 00:00,,,,,,
4998,everest-medicines-sinovent-and-sinomab-announce-licensing-agreement-for-global-development-manufacturing-and-commercialization-of-novel-btk-inhibitor-in-renal-diseases,20-09-2021 00:00,,,,,,
4999,mirati-therapeutics-presents-positive-clinical-data-with-investigational-adagrasib-as-monotherapy-and-in-combination-with-cetuximab-in-patients-with-kras-g12c-mutated-colorectal-cancer,20-09-2021 00:00,,,,,,
5000,esmo-late-breaking-data-show-libtayo?-cemiplimab-and-chemotherapy-first-line-treatment-combination-significantly-improved-overall-survival-in-patients-with-advanced-nsclc,20-09-2021 00:00,,,,,,
5001,merck?s-keytruda?-pembrolizumab-plus-chemotherapy-with-or-without-bevacizumab-reduced-risk-of-death-by-one-third-versus-chemotherapy-with-or-without-bevacizumab-as-first-line-treatment-for-persistent-recurrent-or-metastatic-cervical-cancer,20-09-2021 00:00,,,,,,
5002,exelixis-announces-us-fda-approval-of-cabometyx?-cabozantinib-for-patients-with-previously-treated-radioactive-iodine-refractory-differentiated-thyroid-cancer,20-09-2021 00:00,,,,,,
5003,imfinzi-plus-chemotherapy-tripled-patient-survival-at-three-years-in-the-caspian-phase-iii-trial-in-extensive-stage-small-cell-lung-cancer,20-09-2021 00:00,,,,,,
5004,fda-approves-samsung-bioepis-and-biogen?s-byooviz?-sb11-lucentis?-biosimilar-ranibizumab-nuna,21-09-2021 00:00,,,,,,
5005,abbott-receives-fda-approval-for-minimally-invasive-portico?-with-flexnav?-tavr-system-to-treat-patients-with-aortic-valve-disease,21-09-2021 00:00,,,,,,
5006,gubra-aps-and-bayer-ag-collaborate-to-develop-next-generation-cardiorenal-treatments,21-09-2021 00:00,,,,,,
5007,novartis-acquires-arctos-medical-expanding-optogenetics-portfolio-to-bring-gene-therapies-to-patients-with-severe-vision-loss,21-09-2021 00:00,,,,,,
5008,verastem-oncology-and-amgen-partner-to-evaluate-vs-6766-in-combination-with-lumakrastm-sotorasib-in-patients-with-kras-g12c-mutant-non-small-cell-lung-cancer,21-09-2021 00:00,,,,,,
5009,boston-scientific-announces-agreement-to-acquire-devoro-medical-inc,21-09-2021 00:00,,,,,,
5010,incyte-announces-us-fda-approval-of-opzelura?-ruxolitinib-cream-a-topical-jak-inhibitor-for-the-treatment-of-atopic-dermatitis-ad,22-09-2021 00:00,,,,,,
5011,boehringer-ingelheim-acquires-abexxa-biologics-to-further-expand-its-research-efforts-in-cancer-immunology-and-novel-immunotherapeutic-approaches,22-09-2021 00:00,,,,,,
5012,seagen-and-genmab-announce-fda-accelerated-approval-for-tivdak?-tisotumab-vedotin-tftv-in-previously-treated-recurrent-or-metastatic-cervical-cancer,22-09-2021 00:00,,,,,,
5013,exelixis-announces-final-results-from-phase-3-cosmic-311-pivotal-trial-of-cabometyx?-in-patients-with-previously-treated-radioactive-iodine-refractory-differentiated-thyroid-cancer-presented-at-esmo-2021,22-09-2021 00:00,,,,,,
5014,mirum-pharmaceuticals-and-takeda-enter-into-exclusive-licensing-agreement-to-develop-and-commercialize-maralixibat-for-rare-pediatric-liver-diseases-in-japan,22-09-2021 00:00,,,,,,
5015,vigeo-therapeutics-provides-clinical-update-for-lead-asset-vt1021-and-welcomes-new-chief-executive-officer,22-09-2021 00:00,,,,,,
5016,abcellera-and-everest-medicines-announce-multi-target-collaboration-to-advance-new-antibody-therapies,23-09-2021 00:00,,,,,,
5017,innovent-announces-nmpa-acceptance-of-a-supplemental-new-drug-application-for-sintilimab-in-combination-with-chemotherapy-as-first-line-therapy-for-esophageal-squamous-cell-carcinoma-escc,23-09-2021 00:00,,,,,,
5018,fda-approves-abbott?s-epic?-plus-tissue-valves-for-people-in-need-of-mitral-or-aortic-valve-replacement,23-09-2021 00:00,,,,,,
5019,incyte-announces-fda-approval-of-jakafi?-ruxolitinib-for-treatment-of-chronic-graft-versus-host-disease-gvhd,23-09-2021 00:00,,,,,,
5020,veklury?-remdesivir-significantly-reduced-risk-of-hospitalization-in-high-risk-patients-with-covid-19,23-09-2021 00:00,,,,,,
5021,vigeo-therapeutics-provides-clinical-update-for-lead-asset-vt1021-and-welcomes-new-chief-executive-officer,23-09-2021 00:00,,,,,,
5022,roche-presents-new-data-at-world-muscle-society-wms-2021-highlighting-new-advances-for-people-living-with-rare-neuromuscular-disorders,24-09-2021 00:00,,,,,,
5023,astrazeneca-to-discover-and-develop-self-amplifying-rna-therapeutics-in-new-collaboration-with-vaxequity,24-09-2021 00:00,,,,,,
5024,innovent-announces-first-patient-dosed-in-a-phase-2-clinical-trial-of-ibi112-il-23-monoclonal-antibody-in-patients-with-moderate-to-severe-plaque-psoriasis,24-09-2021 00:00,,,,,,
5025,pfizer-and-biontech-receive-first-us-fda-emergency-use-authorization-of-a-covid-19-vaccine-booster,24-09-2021 00:00,,,,,,
5026,ge-healthcare-to-acquire-bk-medical-expanding-ultrasound-portfolio-into-surgical-visualization,24-09-2021 00:00,,,,,,
5027,everest-medicines-announces-approval-of-investigational-new-drug-application-by-china-nmpa-for-spr206,24-09-2021 00:00,,,,,,
5028,fda-approves-repatha?-evolocumab-in-pediatric-patients-age-10-and-older-with-heterozygous-familial-hypercholesterolemia,27-09-2021 00:00,,,,,,
5029,innovent-and-anheart-announce-interim-data-from-phase-2-trial-of-taletrectinib-in-ros1-positive-nsclc-at-the-csco-2021-annual-meeting,27-09-2021 00:00,,,,,,
5030,jw-therapeutics-announces-updated-1-year-follow-up-result-of-relmacabtagene-autoleucel-injection-at-the-24th-annual-meeting-of-the-chinese-society-of-clinical-oncology-csco,27-09-2021 00:00,,,,,,
5031,boehringer-ingelheim-receives-positive-opinion-for-the-combined-use-of-ingelvac-circoflex?-and-ingelvac-prrsflex-eu?-in-the-eu,15-09-2021 00:00,,,,,,
5032,japan?s-mhlw-approves-padcev?-enfortumab-vedotin-for-advanced-urothelial-cancer,27-09-2021 00:00,,,,,,
5033,takeda-receives-approval-to-manufacture-and-market-alofisel?-darvadstrocel-in-japan-for-treatment-of-complex-perianal-fistulas-in-patients-with-non-active-or-mildly-active-luminal-crohn?s-disease,27-09-2021 00:00,,,,,,
5034,syndax-pharmaceuticals-and-incyte-announce-global-collaboration-to-develop-and-commercialize-axatilimab-for-chronic-graft-versus-host-disease-and-other-fibrotic-diseases,27-09-2021 00:00,,,,,,
5035,bio-thera-solutions-and-intract-pharma-enter-global-collaboration-and-license-agreement-for-soteria?-and-phloral?-drug-delivery-technologies-to-enable-development-of-oral-antibody-medicines,28-09-2021 00:00,,,,,,
5036,innovent-and-union-therapeutics-enter-into-strategic-collaboration-and-license-agreement-for-orismilast-a-next-generation-pde4-inhibitor-for-inflammatory-dermatology-conditions,28-09-2021 00:00,,,,,,
5037,saphnelo-approved-in-japan-for-systemic-lupus-erythematosus,28-09-2021 00:00,,,,,,
5038,eisai-initiates-rolling-submission-for-the-us-fda-biologics-license-application-of-lecanemab-for-early-alzheimer?s-disease-under-the-accelerated-approval-pathway,28-09-2021 00:00,,,,,,
5039,viiv-healthcare-announces-exclusive-license-agreement-with-shionogi-to-develop-third-generation-hiv-integrase-inhibitor-with-potential-for-ultra-long-acting-dosing-intervals,28-09-2021 00:00,,,,,,
5040,boehringer-ingelheim-and-invetx-announce-strategic-collaboration-to-advance-monoclonal-antibody-biotherapeutics-in-animal-health,28-09-2021 00:00,,,,,,
5041,fda-expands-lilly?s-erbitux?-cetuximab-label-with-combination-of-braftovi?-encorafenib-for-the-treatment-of-braf-v600e-mutation-positive-metastatic-colorectal-cancer-crc-after-prior-therapy,29-09-2021 00:00,,,,,,
5042,fda-approves-qulipta?-atogepant-the-first-and-only-oral-cgrp-receptor-antagonist-specifically-developed-for-the-preventive-treatment-of-migraine,29-09-2021 00:00,,,,,,
5043,astrazeneca-to-fully-acquire-caelum-biosciences,29-09-2021 00:00,,,,,,
5044,viiv-healthcare-presents-three-year-switch-data-for-dovato-dolutegravirlamivudine-confirming-long-term-non-inferior-efficacy-with-no-virologic-failure-versus-continuation-of-taf-based-regimens-of-at-least-three-drugs,29-09-2021 00:00,,,,,,
5045,novartis-data-show-achieving-complete-control-of-chronic-spontaneous-urticaria-csu-improves-overall-quality-of-life-as-reported-by-patients,29-09-2021 00:00,,,,,,
5046,medtronic-receives-ce-mark-approval-for-radial-artery-access-portfolio,29-09-2021 00:00,,,,,,
5047,new-england-journal-of-medicine-publishes-positive-phase-3-trial-results-for-regen-cov?-casirivimab-and-imdevimab-to-treat-covid-19,30-09-2021 00:00,,,,,,
5048,janssen-announces-start-of-phase-3-trial-for-investigational-respiratory-syncytial-virus-rsv-vaccine-in-older-adults,30-09-2021 00:00,,,,,,
5049,transmedics-receives-fda-approval-for-its-ocs-liver-system-for-preservation-and-assessment-of-donor-livers-for-transplantation,30-09-2021 00:00,,,,,,
5050,takeda-to-commercialize-next-generation-hunter-syndrome-therapy-through-collaboration-with-jcr-pharmaceuticals,30-09-2021 00:00,,,,,,
5051,lilly?s-tirzepatide-led-to-greater-improvements-in-liver-fat-content-compared-to-insulin-degludec-in-adults-with-type-2-diabetes-in-surpass-3-mri-sub-study,30-09-2021 00:00,,,,,,
5052,merck-to-acquire-acceleron-pharma-inc,30-09-2021 00:00,,,,,,
5053,sumitomo-dainippon-pharma-and-otsuka-announce-a-worldwide-collaboration-and-license-agreement-for-four-psychiatry-and-neurology-compounds,01-10-2021 00:00,,,,,,
5054,novartis-data-show-rapid-and-effective-disease-activity-control-with-remibrutinib-lou064-in-patients-with-chronic-spontaneous-urticaria,01-10-2021 00:00,,,,,,
5055,dermavant-showcases-new-long-term-data-from-phase-3-psoaring-3-trial-of-tapinarof-in-patients-with-plaque-psoriasis-at-the-30th-eadv-virtual-congress,01-10-2021 00:00,,,,,,
5056,new-late-breaking-data-at-eadv-highlights-emerging-clinical-profile-of-amlitelimab-formerly-ky1005-in-adults-with-inadequately-controlled-moderate-to-severe-atopic-dermatitis,01-10-2021 00:00,,,,,,
5057,merck-and-ridgeback?s-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderate-covid-19-in-positive-interim-analysis-of-phase-3-study,01-10-2021 00:00,,,,,,
5058,european-medicines-agency-validates-bristol-myers-squibb?s-application-for-lag-3-blocking-antibody-relatlimab-and-nivolumab-fixed-dose-combination-as-first-line-treatment-for-patients-with-unresectable-or-metastatic-melanoma,01-10-2021 00:00,,,,,,
5059,us-fda-approves-kite?s-tecartus-as-the-first-and-only-car-t-for-adults-with-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukemia,04-10-2021 00:00,,,,,,
5060,merck-announces-mutual-decision-to-end-bintrafusp-alfa-agreement-with-gsk,04-10-2021 00:00,,,,,,
5061,selecta-biosciences-announces-strategic-licensing-agreement-with-takeda-to-develop-next-generation-gene-therapies-for-patients-with-lysosomal-storage-disorders,05-10-2021 00:00,,,,,,
5062,polpharma-biologics-group-announces-that-the-biologics-license-application-bla-submitted-by-its-joint-venture-bioeq-for-its-biosimilar-ranibizumab-has-been-accepted-for-review-by-the-us-food-and-drug-administration-fda,05-10-2021 00:00,,,,,,
5063,azd7442-request-for-emergency-use-authorization-for-covid-19-prophylaxis-filed-in-us,05-10-2021 00:00,,,,,,
5064,positive-results-of-clinical-trial-comparing-coherus?-ranibizumab-biosimilar-candidate-chs-201-to-reference-product-lucentis-ranibizumab-in-the-treatment-of-neovascular-wet-age-related-macular-degeneration-namd-presented-at-retina-society-annual-scientific-meeting,05-10-2021 00:00,,,,,,
5065,xenon-pharmaceuticals-announces-positive-topline-results-from-phase-2b-?x-tole?-clinical-trial-of-xen1101-for-the-treatment-of-focal-epilepsy,05-10-2021 00:00,,,,,,
5066,guardant-health-initiates-oracle-study-to-evaluate-performance-of-guardant-reveal-blood-test-to-predict-recurrence-across-early-stage-cancers,05-10-2021 00:00,,,,,,
5067,johnson-johnson-announces-submission-of-emergency-use-authorization-amendment-to-the-us-fda-to-support-booster-of-its-single-shot-covid-19-vaccine,06-10-2021 00:00,,,,,,
5068,inotiv-inc-announces-expansion-of-in-vivo-pharmacology-offering-with-acquisition-of-plato-biopharma-inc,06-10-2021 00:00,,,,,,
5069,sage-therapeutics-and-biogen-announce-consistent-clinically-meaningful-data-for-zuranolone-across-the-landscape-and-nest-clinical-development-programs-presented-at-the-european-college-of-neuropsychopharmacology-ecnp-congress,06-10-2021 00:00,,,,,,
5070,nice-recommends-first-treatment-in-two-decades-for-sickle-cell-disease,06-10-2021 00:00,,,,,,
5071,kaleido-biosciences-announces-new-clinical-and-preclinical-data-supporting-advancement-of-kb295-to-a-phase-2-clinical-study-in-mild-to-moderate-ulcerative-colitis,06-10-2021 00:00,,,,,,
5072,boston-scientific-announces-agreement-to-acquire-baylis-medical-company-inc,06-10-2021 00:00,,,,,,
5073,tanvex-presents-positive-findings-for-trastuzumab-candidate-at-esmo,17-09-2021 00:00,,,,,,
5074,fresenius-kabi?s-tocilizumab-biosimilar-candidate-msb11456-shows-positive-results-in-two-clinical-trials,07-09-2021 00:00,,,,,,
5075,tanvex-presents-positive-findings-for-trastuzumab-candidate-at-esmo,20-09-2021 00:00,,,,,,
5076,alvotech-welcomes-positive-chmp-opinion-for-avt02-a-proposed-biosimilar-to-humira,17-09-2021 00:00,,,,,,
5077,samsung-bioepis-announces-five-year-follow-up-results-for-ontruzant?-trastuzumab-in-early-or-locally-advanced-her2-positive-breast-cancer-at-the-european-society-for-medical-oncology-esmo-virtual-congress-2021,12-09-2021 00:00,,,,,,
5078,voyager-therapeutics-announces-license-option-agreement-with-pfizer-for-next-generation-tracer-aav-capsids-to-enable-neurologic-and-cardiovascular-gene-therapy-programs,07-10-2021 00:00,,,,,,
5079,positive-results-from-the-first-study-of-high-dose-influenza-vaccine-with-a-covid-19-mrna-booster-support-co-administration-recommendations,07-10-2021 00:00,,,,,,
5080,pharmather-initiates-phase-2-clinical-trial-of-ketamine-for-the-treatment-of-parkinson?s-disease,07-10-2021 00:00,,,,,,
5081,denali-therapeutics-announces-positive-clinical-results-and-regulatory-progress-for-development-programs-in-amyotrophic-lateral-sclerosis-als,07-10-2021 00:00,,,,,,
5082,bristol-myers-squibb-provides-update-on-phase-2-study-of-deucravacitinib-in-patients-with-moderate-to-severe-ulcerative-colitis,07-10-2021 00:00,,,,,,
5083,amgen-and-neumora-therapeutics-announce-strategic-rd-collaboration-to-accelerate-novel-precision-therapies-for-brain-diseases,07-10-2021 00:00,,,,,,
5084,canadian-cancer-patients-have-new-affordable-treatment-option,27-09-2021 00:00,,,,,,
5085,alvotech-announces-positive-top-line-results-for-switching-study-between-proposed-biosimilar-avt02-and-humira,10-09-2021 00:00,,,,,,
5086,abbvie?s-upadacitinib-rinvoq?-met-primary-and-most-ranked-secondary-endpoints-in-phase-3-study-for-non-radiographic-axial-spondyloarthritis,08-10-2021 00:00,,,,,,
5087,md-anderson-and-schr?dinger-announce-strategic-research-collaboration-to-accelerate-development-of-wee1-program,08-10-2021 00:00,,,,,,
5088,mirati-therapeutics-to-collaborate-with-sanofi-on-phase-12-study-evaluating-combination-of-adagrasib-with-a-shp2-inhibitor-in-kras-g12c-mutated-lung-cancer,08-10-2021 00:00,,,,,,
5089,allogene-therapeutics-reports-fda-clinical-hold-of-allocar-t-trials-based-on-a-single-patient-case-in-alpha2-trial,08-10-2021 00:00,,,,,,
5090,fda-advisory-committee-recommends-use-of-investigational-drug-maribavir-tak-620-to-treat-post-transplant-recipients-with-cytomegalovirus-cmv-infection-and-disease-refractory-to-treatment-with-or-without-resistance,08-10-2021 00:00,,,,,,
5091,health-canada-approves-the-use-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis,08-10-2021 00:00,,,,,,
5092,janssen-submits-application-seeking-us-fda-approval-of-stelara-ustekinumab-for-the-treatment-of-pediatric-patients-with-juvenile-psoriatic-arthritis,11-10-2021 00:00,,,,,,
5093,genentech?s-anti-amyloid-beta-antibody-gantenerumab-granted-fda-breakthrough-therapy-designation-in-alzheimer?s-disease,11-10-2021 00:00,,,,,,
5094,turning-point-therapeutics-presents-trident-1-study-clinical-data-for-repotrectinib-in-ntrk-advanced-solid-tumors-in-plenary-session-at-2021-aacr-nci-eortc-conference,11-10-2021 00:00,,,,,,
5095,regenxbio-presents-positive-initial-data-from-phase-ii-altitude?-trial-of-rgx-314-for-the-treatment-of-diabetic-retinopathy-using-suprachoroidal-delivery-at-american-society-of-retina-specialists-annual-meeting,11-10-2021 00:00,,,,,,
5096,merck-and-ridgeback-announce-submission-of-emergency-use-authorization-application-to-the-us-fda-for-molnupiravir-an-investigational-oral-antiviral-medicine-for-the-treatment-of-mild-to-moderate-covid-19-in-at-risk-adults,11-10-2021 00:00,,,,,,
5097,supernus-pharmaceuticals-to-acquire-adamas-pharmaceuticals-strengthening-its-cns-product-portfolio,11-10-2021 00:00,,,,,,
5098,azd7442-reduced-risk-of-developing-severe-covid-19-or-death-in-tackle-phase-iii-outpatient-treatment-trial,12-10-2021 00:00,,,,,,
5099,pacira-biosciences-to-acquire-flexion-therapeutics-further-expanding-leadership-position-in-non-opioid-pain-management,12-10-2021 00:00,,,,,,
5100,sarepta-therapeutics?-srp-9001-shows-sustained-functional-improvements-in-multiple-studies-of-patients-with-duchenne,12-10-2021 00:00,,,,,,
5101,salipro-biotech-enters-into-a-collaboration-and-license-agreement-with-abcellera-for-access-to-the-salipro?-platform-for-antibody-discovery-against-gpcrs-ion-channels-and-transporters,12-10-2021 00:00,,,,,,
5102,sutro-biopharma-and-bionova-pharmaceuticals-enter-into-collaboration-for-stro-001-in-greater-china,12-10-2021 00:00,,,,,,
5103,protagonist-therapeutics-announces-removal-of-fda-clinical-hold-on-the-rusfertide-clinical-development-program,12-10-2021 00:00,,,,,,
5104,poseida-therapeutics-announces-research-collaboration-with-takeda-for-novel-non-viral-in-vivo-gene-therapies,13-10-2021 00:00,,,,,,
5105,spark-therapeutics-and-combigene-enter-into-exclusive-global-licensing-agreement-for-gene-therapy-candidate-cg01,13-10-2021 00:00,,,,,,
5106,ultimovacs-announces-positive-24-month-follow-up-data-from-phase-i-uv1-cancer-vaccine-pembrolizumab-combination-study-in-metastatic-melanoma,13-10-2021 00:00,,,,,,
5107,new-long-term-data-reinforcing-promising-safety-and-efficacy-profile-of-brain-penetrant-tolebrutinib-presented-at-ectrims-2021,13-10-2021 00:00,,,,,,
5108,fda-approves-verzenio-abemaciclib-as-the-first-and-only-cdk46-inhibitor-for-certain-people-with-hr-her2-high-risk-early-breast-cancer,13-10-2021 00:00,,,,,,
5109,new-sarclisa-isatuximab-for-injection-combination-now-approved-by-health-canada-for-adults-with-relapsed-andor-refractory-multiple-myeloma,13-10-2021 00:00,,,,,,
5110,pharmather-granted-fda-orphan-drug-designation-for-ketamine-to-treat-complex-regional-pain-syndrome,14-10-2021 00:00,,,,,,
5111,turning-point-therapeutics-and-eqrx-announce-clinical-collaboration-to-evaluate-elzovantinib-in-combination-with-aumolertinib-in-patients-with-egfr-mutant-met-amplified-advanced-non-small-cell-lung-cancer,14-10-2021 00:00,,,,,,
5112,fda-approves-merck?s-keytruda?-pembrolizumab-plus-chemotherapy-with-or-without-bevacizumab-as-treatment-for-patients-with-persistent-recurrent-or-metastatic-cervical-cancer-whose-tumors-express-pd-l1-cps-1,14-10-2021 00:00,,,,,,
5113,novartis-announces-fda-and-ema-filing-acceptances-of-beovu-for-patients-with-diabetic-macular-edema,14-10-2021 00:00,,,,,,
5114,fda-accepts-regen-cov-casirivimab-and-imdevimab-for-priority-review-for-treatment-and-prophylaxis-of-covid-19,14-10-2021 00:00,,,,,,
5115,the-cde-approved-ind-application-to-investigate-combination-of-asieris?-apl-1202-and-beigene?s-tislelizumab-as-neoadjuvant-therapy-for-mibc-patients,14-10-2021 00:00,,,,,,
5116,lilly-announces-updated-verzenio-abemaciclib-phase-3-monarche-trial-data-presented-at-esmo-virtual-plenary-and-simultaneously-published-in-the-annals-of-oncology,15-10-2021 00:00,,,,,,
5117,imfinzi-plus-tremelimumab-significantly-improved-overall-survival-in-himalaya-phase-iii-trial-in-1st-line-unresectable-liver-cancer,15-10-2021 00:00,,,,,,
5118,hologic-to-acquire-bolder-surgical-for-160-million-expanding-its-surgical-franchise,15-10-2021 00:00,,,,,,
5119,exelixis-in-licenses-second-anti-cancer-compound-from-aurigene-following-fda-acceptance-of-investigational-new-drug-application-for-phase-1-clinical-trial-in-non-hodgkin?s-lymphoma,15-10-2021 00:00,,,,,,
5120,gan-lee-pharmaceuticals-concludes-phase-3-studies-of-gan-lee-insulin-glargine-gl-gla,15-10-2021 00:00,,,,,,
5121,bristol-myers-squibb-receives-positive-chmp-opinion-for-zeposia-ozanimod-as-a-treatment-for-adult-patients-with-moderately-to-severely-active-ulcerative-colitis,15-10-2021 00:00,,,,,,
5122,fda-approves-genentech?s-tecentriq-as-adjuvant-treatment-for-certain-people-with-early-non-small-cell-lung-cancer,18-10-2021 00:00,,,,,,
5123,abbvie-receives-chmp-positive-opinion-for-risankizumab-skyrizi-for-the-treatment-of-adults-with-active-psoriatic-arthritis-in-the-european-union-eu,18-10-2021 00:00,,,,,,
5124,us-fda-approves-cyltezo-adalimumab-adbm-as-first-interchangeable-biosimilar-with-humira,18-10-2021 00:00,,,,,,
5125,bio-thera-solutions-expands-partnership-with-pharmapark-in-russia-and-other-cis-countries-with-addition-of-bat2206-a-stelara-biosimilar,18-10-2021 00:00,,,,,,
5126,innovent-announces-orient-31-a-phase-3-study-of-sintilimab-in-patients-with-egfr-mutated-nonsquamous-non-small-cell-lung-cancer-with-prior-egfr-tki-treatment-has-met-primary-endpoint,18-10-2021 00:00,,,,,,
5127,ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3,18-10-2021 00:00,,,,,,
5128,wave-life-sciences-and-takeda-amend-cns-collaboration,19-10-2021 00:00,,,,,,
5129,lipocine-and-antares-pharma-enter-into-us-licensing-agreement-to-commercialize-tlando,19-10-2021 00:00,,,,,,
5130,us-food-and-drug-administration-approves-expanded-indication-of-gilead?s-biktarvy-for-treatment-of-hiv-1-in-pediatric-populations,19-10-2021 00:00,,,,,,
5131,calithera-expands-oncology-pipeline-with-acquisition-of-two-clinical-stage-assets-from-takeda-pharmaceuticals,19-10-2021 00:00,,,,,,
5132,tirzepatide-results-published-in-the-lancet-show-superior-a1c-and-body-weight-reductions-compared-to-insulin-glargine-in-adults-with-type-2-diabetes-with-increased-cardiovascular-risk,19-10-2021 00:00,,,,,,
5133,nice-recommends-dupixent-dupilumab-for-the-treatment-of-severe-asthma1,19-10-2021 00:00,,,,,,
5134,sana-biotechnology-obtains-a-non-exclusive-license-to-crispr-cas12b-gene-editing-technology-from-beam-therapeutics-to-enable-engineered-cell-programs,20-10-2021 00:00,,,,,,
5135,antios-therapeutics-and-assembly-biosciences-announce-clinical-collaboration-agreement-to-evaluate-the-combination-of-ati-2173-and-vebicorvir-in-patients-with-chronic-hepatitis-b-virus-infection,20-10-2021 00:00,,,,,,
5136,oxford-biomedica-announces-that-boehringer-ingelheim-has-exercised-option-relating-to-a-novel-gene-therapy-treatment-for-cystic-fibrosis,20-10-2021 00:00,,,,,,
5137,atea-pharmaceuticals-provides-update-and-topline-results-for-phase-2-moonsong-trial-evaluating-at-527-in-the-outpatient-setting,20-10-2021 00:00,,,,,,
5138,dicerna-announces-results-for-phyox?4-single-dose-study-of-nedosiran-in-primary-hyperoxaluria-type-3-ph3,20-10-2021 00:00,,,,,,
5139,springworks-therapeutics-to-collaborate-with-leading-academic-institutions-to-advance-portfolio-of-next-generation-mutation-selective-egfr-inhibitors,20-10-2021 00:00,,,,,,
5140,f-star-therapeutics-announces-license-agreement-with-janssen-to-develop-and-commercialize-multiple-next-generation-bispecific-antibody-therapeutics,21-10-2021 00:00,,,,,,
5141,sumitomo-dainippon-pharma-and-behavr-announce-landmark-deal-for-multiple-virtual-reality-digital-therapeutics,21-10-2021 00:00,,,,,,
5142,fda-expands-approval-of-dupixent?-dupilumab-to-include-children-aged-6-to-11-years-with-moderate-to-severe-asthma,21-10-2021 00:00,,,,,,
5143,pfizer-and-biontech-announce-phase-3-trial-data-showing-high-efficacy-of-a-booster-dose-of-their-covid-19-vaccine,21-10-2021 00:00,,,,,,
5144,advisory-committee-on-immunization-practices-votes-to-recommend-routine-use-of-pfizer?s-prevnar-20?-pneumococcal-20-valent-conjugate-vaccine-in-adults,21-10-2021 00:00,,,,,,
5145,antengene-enters-into-a-research-collaboration-license-option-agreement-with-legochem-biosciences-for-new-antibody-drug-conjugate-candidates,21-10-2021 00:00,,,,,,
5146,us-fda-approves-livmarli-maralixibat-as-the-first-and-only-approved-medication-for-the-treatment-of-cholestatic-pruritus-in-patients-with-alagille-syndrome-one-year-of-age-and-older,29-09-2021 00:00,,,,,,
5147,selecta-biosciences-and-genovis-enter-exclusive-license-agreement-to-advance-next-generation-igg-protease-in-gene-therapy-and-autoimmune-disease,22-10-2021 00:00,,,,,,
5148,specialised-therapeutics-enters-into-a-new-supply-and-distribution-agreement-with-incyte-to-launch-two-new-cancer-therapies-tafasitamab-and-pemigatinib-in-australia-new-zealand-and-singapore,22-10-2021 00:00,,,,,,
5149,scynexis-pivotal-phase-3-vanish-303-trial-results-published-in-clinical-infectious-diseases-demonstrate-significant-superiority-of-ibrexafungerp-over-placebo-for-treatment-of-vaginal-yeast-infection,22-10-2021 00:00,,,,,,
5150,dupixent?-dupilumab-is-the-first-biologic-to-significantly-reduce-itch-and-skin-lesions-in-phase-3-trial-for-prurigo-nodularis-demonstrating-the-role-of-type-2-inflammation-in-this-disease,22-10-2021 00:00,,,,,,
5151,tralokinumab-achieves-primary-and-secondary-endpoints-in-phase-3-trial-of-adolescents-with-moderate-to-severe-atopic-dermatitis,22-10-2021 00:00,,,,,,
5152,first-marinosolv?-platform-deal-marinomed-biotech-ag-and-luoxin-pharmaceutical-group-stock-co-ltd-sign-agreement-on-budesolv-to-treat-allergic-rhinitis-in-greater-china,22-10-2021 00:00,,,,,,
5153,agenus-provides-update-on-balstilimab-development,25-10-2021 00:00,,,,,,
5154,fda-approves-genentech?s-susvimo-a-first-of-its-kind-therapeutic-approach-for-wet-age-related-macular-degeneration-amd,25-10-2021 00:00,,,,,,
5155,second-dupixentdupilumab-phase-3-eosinophilic-esophagitis-trial-to-demonstrate-significant-disease-improvements-underscoring-role-of-type-2-inflammation-in-this-complex-disease,25-10-2021 00:00,,,,,,
5156,merck-announces-positive-top-line-results-from-pivotal-phase-3-trials-evaluating-investigational-once-daily-oral-fixed-dose-combination-of-doravirineislatravir-for-the-treatment-of-people-with-hiv-1-infection,25-10-2021 00:00,,,,,,
5157,merck-and-ridgeback-announce-initiation-of-a-rolling-review-by-the-european-medicines-agency-for-molnupiravir-an-investigational-oral-antiviral-medicine-for-the-treatment-of-covid-19-in-adults,25-10-2021 00:00,,,,,,
5158,novartis-top-line-results-for-canopy-1-phase-iii-study-support-further-evaluation-of-canakinumab-in-lung-cancer,25-10-2021 00:00,,,,,,
5159,second-clinical-trial-collaboration-initiated-to-evaluate-datopotamab-deruxtecan-in-combination-with-keytruda-pembrolizumab-in-patients-with-metastatic-non-small-cell-lung-cancer,26-10-2021 00:00,,,,,,
5160,evaxion-biotech-announces-clinical-collaboration-to-evaluate-lead-product-candidate-with-keytruda-pembrolizumab-in-patients-with-melanoma,26-10-2021 00:00,,,,,,
5161,imfinzi-plus-chemotherapy-significantly-improved-overall-survival-in-1st-line-advanced-biliary-tract-cancer-in-topaz-1-phase-iii-trial-at-interim-analysis,26-10-2021 00:00,,,,,,
5162,moderna-announces-positive-top-line-data-from-phase-23-study-of-covid-19-vaccine-in-children-6-to-11-years-of-age,26-10-2021 00:00,,,,,,
5163,glenmark-becomes-the-first-company-to-launch-remogliflozin-vildagliptin-metformin-fixed-dose-combination-at-an-affordable-price-for-adults-with-type-2-diabetes-in-india,26-10-2021 00:00,,,,,,
5164,data-presented-at-acg-shows-guardant-health?s-blood-based-test-accurately-detects-early-stage-colorectal-cancer,26-10-2021 00:00,,,,,,
5165,fda-advisory-committee-votes-in-favor-of-granting-emergency-use-authorization-for-the-pfizer-biontech-covid-19-vaccine-in-children-5-to-12-years,27-10-2021 00:00,,,,,,
5166,selecta-biosciences-and-ginkgo-bioworks-announce-partnership-to-advance-treatments-for-orphan-and-rare-diseases,27-10-2021 00:00,,,,,,
5167,vertex-and-mammoth-biosciences-announce-collaboration-to-develop-in-vivo-gene-editing-therapies-for-serious-diseases,27-10-2021 00:00,,,,,,
5168,angion-and-vifor-pharma-report-topline-results-from-phase-3-trial-of-ang-3777-in-kidney-transplant-patients-at-risk-for-delayed-graft-function,27-10-2021 00:00,,,,,,
6208,bridgebio-pharma-and-helsinn-group-announce-strategic-collaboration-to-co-develop-and-co-commercialize-bridgebio?s-novel-gpx4-inhibitor-in-multiple-cancer-tumor-types,22-11-2021 00:00,,,,,,
6209,innovent-releases-the-orient-31-phase-3-study-first-interim-analysis-results-of-sintilimab-plus-byvasda-bevacizumab-biosimilar-injection-and-chemotherapy-in-patients-with-egfr-mutated-nonsquamous-non-small-cell-lung-cancer-who-progressed-after-egfr-tki-therapy-at-esmo-virtual-plenary-2021,22-11-2021 00:00,,,,,,
6210,"cstone-pharmaceuticals-and-jiangsu-hengrui-pharmaceuticals-announce-strategic-partnership-and-exclusive-licensing-agreement-on-anti-ctla-4-monoclonal-antibody-cs1002-in-greater-china
",22-11-2021 00:00,,,,,,
6212,"gilead-submits-biologics-license-application-to-us-food-and-drug-administration-for-bulevirtide-an-investigational-treatment-for-people-living-with-chronic-hepatitis-delta
",22-11-2021 00:00,,,,,,
6215,zenas-biopharma-acquires-exclusive-worldwide-rights-to-obexelimab-from-xencor,22-11-2021 00:00,,,,,,
6216,positive-top-line-results-from-bimekizumab-phase-3-psoriatic-arthritis-study-demonstrated-significant-improvements-in-joint-and-skin-symptoms,22-11-2021 00:00,,,,,,
6218,neurocrine-biosciences-anticipates-initiating-a-phase-2-study-with-the-selective-m4-agonist-htl-0016878-in-schizophrenia-in-2022-and-phase-1-studies-for-a-dual-m1m4-and-selective-m1-agonist-in-2023,23-11-2021 00:00,,,,,,
6219,arrowhead-entered-into-an-exclusive-license-agreement-with-gsk-to-develop-and-commercialize-aro-hsd-for-nonalcoholic-steatohepatitis,23-11-2021 00:00,,,,,,
6220,south-san-francisco-calif-business-wire-twist-bioscience-corporation-nasdaq-twst,23-11-2021 00:00,,,,,,
6221,NULL,23-11-2021 18:14,,,,,,
6223,NULL,23-11-2021 18:37,,,,,,
6224,NULL,23-11-2021 18:43,,,,,,
6225,NULL,24-11-2021 12:08,,,,,,
6226,NULL,24-11-2021 13:20,,,,,,
6227,NULL,24-11-2021 13:44,,,,,,
6229,NULL,23-11-2021 15:26,,,,,,
6230,NULL,27-10-2021 00:00,,,,,,
6231,NULL,27-10-2021 00:00,,,,,,
6232,NULL,28-10-2021 00:00,,,,,,
6233,NULL,28-10-2021 00:00,,,,,,
6234,NULL,28-10-2021 00:00,,,,,,
6235,NULL,28-10-2021 00:00,,,,,,
6236,NULL,28-10-2021 00:00,,,,,,
6237,NULL,28-10-2021 00:00,,,,,,
6238,NULL,29-10-2021 00:00,,,,,,
6239,NULL,29-10-2021 00:00,,,,,,
6240,NULL,29-10-2021 00:00,,,,,,
6241,NULL,29-10-2021 00:00,,,,,,
6242,NULL,29-10-2021 00:00,,,,,,
6243,NULL,29-10-2021 00:00,,,,,,
6244,NULL,01-11-2021 00:00,,,,,,
6245,NULL,01-11-2021 00:00,,,,,,
6246,NULL,01-11-2021 00:00,,,,,,
6247,NULL,01-11-2021 00:00,,,,,,
6248,NULL,01-11-2021 00:00,,,,,,
6249,NULL,01-11-2021 00:00,,,,,,
6250,new-phase-3-first-in-class-tremfya-guselkumab-data-show-durability-of-joint-efficacy-including-low-rates-of-structural-damage-progression-and-a-demonstrated-safety-profile-in-adults-with-act,02-11-2021 00:00,,,,,,
6251,NULL,02-11-2021 00:00,,,,,,
6252,NULL,02-11-2021 00:00,,,,,,
6253,NULL,02-11-2021 00:00,,,,,,
6254,NULL,02-11-2021 00:00,,,,,,
6255,NULL,02-11-2021 00:00,,,,,,
6256,NULL,03-11-2021 00:00,,,,,,
6257,NULL,03-11-2021 00:00,,,,,,
6258,NULL,03-11-2021 00:00,,,,,,
6259,NULL,03-11-2021 00:00,,,,,,
6260,NULL,03-11-2021 00:00,,,,,,
6261,NULL,03-11-2021 00:00,,,,,,
6262,NULL,01-10-2021 00:00,,,,,,
6263,NULL,27-10-2021 00:00,,,,,,
6264,NULL,20-10-2021 00:00,,,,,,
6265,NULL,08-11-2021 00:00,,,,,,
6266,NULL,08-11-2021 00:00,,,,,,
6267,NULL,08-11-2021 00:00,,,,,,
6268,NULL,08-11-2021 00:00,,,,,,
6269,NULL,08-11-2021 00:00,,,,,,
6270,NULL,08-11-2021 00:00,,,,,,
6271,NULL,09-11-2021 00:00,,,,,,
6272,NULL,09-11-2021 00:00,,,,,,
6273,NULL,09-11-2021 00:00,,,,,,
6274,NULL,09-11-2021 00:00,,,,,,
6275,NULL,09-11-2021 00:00,,,,,,
6276,NULL,09-11-2021 00:00,,,,,,
6277,NULL,10-11-2021 00:00,,,,,,
6278,NULL,10-11-2021 00:00,,,,,,
6279,NULL,10-11-2021 00:00,,,,,,
6280,NULL,10-11-2021 00:00,,,,,,
6281,NULL,10-11-2021 00:00,,,,,,
6282,NULL,10-11-2021 00:00,,,,,,
6283,NULL,11-11-2021 00:00,,,,,,
6284,NULL,11-11-2021 00:00,,,,,,
6285,NULL,11-11-2021 00:00,,,,,,
6286,NULL,11-11-2021 00:00,,,,,,
6287,NULL,11-11-2021 00:00,,,,,,
6288,NULL,11-11-2021 00:00,,,,,,
6289,NULL,12-11-2021 00:00,,,,,,
6290,NULL,12-11-2021 00:00,,,,,,
6291,NULL,12-11-2021 00:00,,,,,,
6292,NULL,12-11-2021 00:00,,,,,,
6293,NULL,12-11-2021 00:00,,,,,,
6294,NULL,12-11-2021 00:00,,,,,,
6295,NULL,15-11-2021 00:00,,,,,,
6296,NULL,15-11-2021 00:00,,,,,,
6297,NULL,15-11-2021 00:00,,,,,,
6298,NULL,15-11-2021 00:00,,,,,,
6299,NULL,15-11-2021 00:00,,,,,,
6300,NULL,15-11-2021 00:00,,,,,,
6301,NULL,16-11-2021 00:00,,,,,,
6302,NULL,16-11-2021 00:00,,,,,,
6303,NULL,16-11-2021 00:00,,,,,,
6304,NULL,16-11-2021 00:00,,,,,,
6305,NULL,16-11-2021 00:00,,,,,,
6306,NULL,16-11-2021 00:00,,,,,,
6307,NULL,17-11-2021 00:00,,,,,,
6308,NULL,17-11-2021 00:00,,,,,,
6309,NULL,17-11-2021 00:00,,,,,,
6310,NULL,17-11-2021 00:00,,,,,,
6311,NULL,17-11-2021 00:00,,,,,,
6312,NULL,17-11-2021 00:00,,,,,,
6313,NULL,18-11-2021 00:00,,,,,,
6314,NULL,18-11-2021 00:00,,,,,,
6315,NULL,18-11-2021 00:00,,,,,,
6316,NULL,29-10-2021 00:00,,,,,,
6317,NULL,08-10-2021 00:00,,,,,,
6318,NULL,18-11-2021 00:00,,,,,,
6319,NULL,18-11-2021 00:00,,,,,,
6320,NULL,25-10-2021 00:00,,,,,,
6321,NULL,18-11-2021 00:00,,,,,,
6322,NULL,19-11-2021 00:00,,,,,,
6323,NULL,19-11-2021 00:00,,,,,,
6324,NULL,19-11-2021 00:00,,,,,,
6325,NULL,19-11-2021 00:00,,,,,,
6326,NULL,19-11-2021 00:00,,,,,,
6327,NULL,19-11-2021 00:00,,,,,,
6328,NULL,23-11-2021 16:37,,,,,,
6329,NULL,22-11-2021 17:38,,,,,,
6330,NULL,23-11-2021 10:49,,,,,,
6331,NULL,24-11-2021 11:23,,,,,,
6332,NULL,24-11-2021 13:08,,,,,,
6333,NULL,24-11-2021 15:28,,,,,,
6336,NULL,23-11-2021 16:47,,,,,,
6338,NULL,22-11-2021 17:41,,,,,,
6344,NULL,25-11-2021 11:19,,,,,,
6346,NULL,25-11-2021 11:52,,,,,,
6349,NULL,24-11-2021 12:59,,,,,,
6350,NULL,23-11-2021 15:40,,,,,,
6351,NULL,26-11-2021 17:22,,,,,,
6352,NULL,26-11-2021 18:09,,,,,,
6353,NULL,29-11-2021 13:23,,,,,,
6354,NULL,29-11-2021 15:57,,,,,,
6355,NULL,29-11-2021 16:21,,,,,,
6356,NULL,29-11-2021 16:46,,,,,,
6357,NULL,29-11-2021 17:01,,,,,,
6358,NULL,29-11-2021 18:37,,,,,,
6359,NULL,30-11-2021 11:05,,,,,,
6360,NULL,30-11-2021 11:57,,,,,,
6361,NULL,29-11-2021 13:42,,,,,,
6362,NULL,30-11-2021 15:37,,,,,,
6363,NULL,29-11-2021 16:59,,,,,,
6364,NULL,30-11-2021 17:54,,,,,,
6365,NULL,30-11-2021 11:36,,,,,,
6366,NULL,30-11-2021 12:15,,,,,,
6367,NULL,30-11-2021 13:22,,,,,,
6368,NULL,30-11-2021 15:22,,,,,,
6369,NULL,03-11-2021 15:29,,,,,,
6370,NULL,30-11-2021 16:41,,,,,,
6371,NULL,01-12-2021 17:46,,,,,,
6372,NULL,08-11-2021 17:57,,,,,,
6373,NULL,02-12-2021 10:50,,,,,,
6374,NULL,02-11-2021 11:54,,,,,,
6375,NULL,04-11-2021 12:02,,,,,,
6376,NULL,08-11-2021 12:05,,,,,,
6377,NULL,01-12-2021 12:40,,,,,,
6378,NULL,01-12-2021 12:50,,,,,,
6379,NULL,02-12-2021 15:21,,,,,,
6380,NULL,01-12-2021 16:25,,,,,,
6381,NULL,11-11-2021 15:55,,,,,,
6382,NULL,02-12-2021 17:38,,,,,,
6383,NULL,02-12-2021 12:12,,,,,,
6384,NULL,02-12-2021 13:14,,,,,,
6385,NULL,02-12-2021 13:46,,,,,,
6386,NULL,03-12-2021 15:43,,,,,,
6387,NULL,02-12-2021 16:56,,,,,,
6388,NULL,03-12-2021 17:49,,,,,,
6389,NULL,03-12-2021 11:17,,,,,,
6390,NULL,04-12-2021 12:23,,,,,,
6391,NULL,05-12-2021 14:05,,,,,,
6392,NULL,05-12-2021 15:17,,,,,,
6393,NULL,06-12-2021 16:38,,,,,,
6394,NULL,06-12-2021 17:52,,,,,,
6395,NULL,06-12-2021 11:22,,,,,,
6396,NULL,06-12-2021 11:36,,,,,,
6397,NULL,06-12-2021 13:32,,,,,,
6398,NULL,07-12-2021 15:47,,,,,,
6399,NULL,07-12-2021 16:39,,,,,,
6400,NULL,06-12-2021 17:47,,,,,,
6401,NULL,07-12-2021 11:26,,,,,,
6402,NULL,07-12-2021 11:34,,,,,,
6403,NULL,07-12-2021 13:28,,,,,,
6404,NULL,07-12-2021 15:30,,,,,,
6405,NULL,07-12-2021 16:28,,,,,,
6406,NULL,08-12-2021 17:45,,,,,,
6407,NULL,08-12-2021 11:42,,,,,,
6408,NULL,08-12-2021 12:13,,,,,,
6409,NULL,09-12-2021 13:30,,,,,,
6410,NULL,08-12-2021 15:19,,,,,,
6411,NULL,08-12-2021 16:38,,,,,,
6412,NULL,08-12-2021 17:35,,,,,,
6413,NULL,10-12-2021 11:06,,,,,,
6414,NULL,10-12-2021 13:09,,,,,,
6415,NULL,10-12-2021 13:34,,,,,,
6416,NULL,09-12-2021 15:48,,,,,,
6417,NULL,10-12-2021 16:44,,,,,,
6418,NULL,09-12-2021 17:33,,,,,,
6419,NULL,10-12-2021 11:09,,,,,,
6420,NULL,10-12-2021 12:22,,,,,,
6421,NULL,13-12-2021 13:05,,,,,,
6422,NULL,12-12-2021 15:13,,,,,,
6423,NULL,13-12-2021 16:25,,,,,,
6424,NULL,12-12-2021 17:20,,,,,,
6425,NULL,13-12-2021 11:00,,,,,,
6426,NULL,13-12-2021 12:44,,,,,,
6427,NULL,13-12-2021 13:25,,,,,,
6428,NULL,13-12-2021 15:21,,,,,,
6429,NULL,14-12-2021 16:45,,,,,,
6430,NULL,13-12-2021 17:48,,,,,,
6431,NULL,14-12-2021 10:59,,,,,,
6432,NULL,14-12-2021 12:01,,,,,,
6433,NULL,14-12-2021 12:14,,,,,,
6434,NULL,19-11-2021 13:21,,,,,,
6435,NULL,18-11-2021 13:26,,,,,,
6436,NULL,14-12-2021 15:37,,,,,,
6437,NULL,14-12-2021 16:50,,,,,,
6438,NULL,14-12-2021 17:24,,,,,,
6439,NULL,15-12-2021 11:14,,,,,,
6440,NULL,29-11-2021 11:23,,,,,,
6441,NULL,08-11-2021 11:26,,,,,,
6442,NULL,05-11-2021 11:28,,,,,,
6443,NULL,08-11-2021 11:31,,,,,,
6444,NULL,15-12-2021 12:23,,,,,,
6445,NULL,15-12-2021 13:17,,,,,,
6446,NULL,15-12-2021 15:08,,,,,,
6447,NULL,15-12-2021 16:01,,,,,,
6448,NULL,15-12-2021 17:29,,,,,,
6449,NULL,16-12-2021 11:01,,,,,,
6450,NULL,16-12-2021 11:25,,,,,,
6451,NULL,16-12-2021 13:28,,,,,,
6452,NULL,16-12-2021 15:14,,,,,,
6453,NULL,16-12-2021 16:26,,,,,,
6454,NULL,17-12-2021 17:26,,,,,,
6455,NULL,17-12-2021 11:03,,,,,,
6456,NULL,17-12-2021 12:19,,,,,,
6457,NULL,17-12-2021 13:14,,,,,,
6458,NULL,17-12-2021 15:30,,,,,,
6459,NULL,20-12-2021 16:29,,,,,,
6460,NULL,20-12-2021 17:24,,,,,,
6461,NULL,20-12-2021 11:25,,,,,,
6462,NULL,20-12-2021 12:07,,,,,,
6463,NULL,20-12-2021 13:19,,,,,,
6464,NULL,21-12-2021 15:16,,,,,,
6465,NULL,21-12-2021 16:13,,,,,,
6466,NULL,21-12-2021 17:20,,,,,,
6467,NULL,17-11-2021 17:29,,,,,,
6468,NULL,17-11-2021 17:36,,,,,,
6469,NULL,18-11-2021 17:40,,,,,,
6470,NULL,21-12-2021 11:22,,,,,,
6471,NULL,21-12-2021 12:05,,,,,,
6472,NULL,21-12-2021 12:58,,,,,,
6473,NULL,22-12-2021 15:39,,,,,,
6474,NULL,21-12-2021 16:04,,,,,,
6475,NULL,20-12-2021 16:34,,,,,,
6476,NULL,23-12-2021 12:53,,,,,,
6477,NULL,23-12-2021 13:12,,,,,,
6478,NULL,22-12-2021 14:00,,,,,,
6479,NULL,22-12-2021 15:26,,,,,,
6480,NULL,22-12-2021 16:11,,,,,,
6481,NULL,23-12-2021 17:28,,,,,,
6482,NULL,23-12-2021 10:52,,,,,,
6483,NULL,23-12-2021 11:47,,,,,,
6484,NULL,24-12-2021 13:03,,,,,,
6485,NULL,24-12-2021 14:49,,,,,,
6486,NULL,23-12-2021 16:26,,,,,,
6487,NULL,23-12-2021 16:41,,,,,,
6488,NULL,27-12-2021 11:26,,,,,,
6489,NULL,27-12-2021 12:42,,,,,,
6490,NULL,27-12-2021 13:11,,,,,,
6491,NULL,27-12-2021 16:01,,,,,,
6492,NULL,27-12-2021 16:49,,,,,,
6493,NULL,28-12-2021 17:32,,,,,,
6494,NULL,28-12-2021 11:11,,,,,,
6495,NULL,28-12-2021 11:58,,,,,,
6496,NULL,28-12-2021 13:16,,,,,,
6497,NULL,27-12-2021 15:55,,,,,,
6498,NULL,29-12-2021 16:44,,,,,,
6499,NULL,27-12-2021 17:42,,,,,,
6500,NULL,29-12-2021 11:25,,,,,,
6501,NULL,29-12-2021 11:45,,,,,,
6502,NULL,20-12-2021 11:53,,,,,,
6503,NULL,11-12-2021 11:56,,,,,,
6504,NULL,29-12-2021 13:15,,,,,,
6505,NULL,08-12-2021 13:29,,,,,,
6506,NULL,29-12-2021 15:31,,,,,,
6507,NULL,01-12-2021 16:03,,,,,,
6508,NULL,03-12-2021 16:07,,,,,,
6509,NULL,29-12-2021 16:48,,,,,,
6510,NULL,29-12-2021 17:47,,,,,,
6511,NULL,30-12-2021 10:50,,,,,,
6512,NULL,30-12-2021 11:22,,,,,,
6513,NULL,30-12-2021 11:48,,,,,,
6514,NULL,14-12-2021 13:42,,,,,,
6515,NULL,23-12-2021 14:58,,,,,,
6516,NULL,30-12-2021 15:06,,,,,,
6517,NULL,14-12-2021 15:13,,,,,,
6518,NULL,03-12-2021 15:19,,,,,,
6519,NULL,15-12-2021 15:23,,,,,,
6520,NULL,30-12-2021 15:29,,,,,,
6521,NULL,30-12-2021 16:08,,,,,,
6522,NULL,20-12-2021 17:33,,,,,,
6523,NULL,13-12-2021 19:07,,,,,,
6524,NULL,02-01-2022 11:21,,,,,,
6525,NULL,31-12-2021 13:39,,,,,,
6526,NULL,03-01-2022 15:16,,,,,,
6527,NULL,03-01-2022 17:23,,,,,,
6528,NULL,03-01-2022 17:42,,,,,,
6529,NULL,03-01-2022 11:29,,,,,,
6530,NULL,03-01-2022 12:08,,,,,,
6531,NULL,04-01-2022 13:43,,,,,,
6532,NULL,04-01-2022 15:43,,,,,,
6533,NULL,03-01-2022 16:34,,,,,,
6534,NULL,03-01-2022 17:29,,,,,,
6535,NULL,04-01-2022 11:16,,,,,,
6536,NULL,04-01-2022 12:24,,,,,,
6537,NULL,04-01-2022 13:03,,,,,,
6538,NULL,04-01-2022 15:11,,,,,,
6539,NULL,04-01-2022 16:11,,,,,,
6540,NULL,04-01-2022 17:36,,,,,,
6541,NULL,05-01-2022 10:51,,,,,,
6542,NULL,05-01-2022 12:18,,,,,,
6543,NULL,05-01-2022 13:03,,,,,,
6544,NULL,06-01-2022 15:08,,,,,,
6545,NULL,05-01-2022 16:09,,,,,,
6546,NULL,05-01-2022 16:52,,,,,,
6547,NULL,08-12-2021 17:57,,,,,,
6548,NULL,20-12-2021 18:28,,,,,,
6549,NULL,09-12-2021 18:35,,,,,,
6550,NULL,06-01-2022 11:17,,,,,,
6551,NULL,06-01-2022 12:26,,,,,,
6552,NULL,06-01-2022 13:11,,,,,,
6553,NULL,07-01-2022 15:39,,,,,,
6554,NULL,07-01-2022 16:19,,,,,,
6555,NULL,06-01-2022 17:53,,,,,,
6556,NULL,07-01-2022 11:08,,,,,,
6557,NULL,07-01-2022 11:55,,,,,,
6558,NULL,10-01-2022 12:55,,,,,,
6559,NULL,10-01-2022 13:45,,,,,,
6560,NULL,10-01-2022 15:26,,,,,,
6561,NULL,10-01-2022 17:20,,,,,,
6562,NULL,10-01-2022 11:24,,,,,,
6563,NULL,10-01-2022 13:34,,,,,,
6564,NULL,10-01-2022 13:47,,,,,,
6565,NULL,10-01-2022 15:37,,,,,,
6566,NULL,10-01-2022 16:12,,,,,,
6567,NULL,10-01-2022 17:42,,,,,,
6568,NULL,11-01-2022 10:33,,,,,,
6569,NULL,11-01-2022 12:35,,,,,,
6570,NULL,10-01-2022 13:40,,,,,,
6571,NULL,11-01-2022 15:17,,,,,,
6572,NULL,11-01-2022 16:13,,,,,,
6573,NULL,11-01-2022 17:35,,,,,,
6574,NULL,12-01-2022 11:32,,,,,,
6575,NULL,12-01-2022 11:55,,,,,,
6576,NULL,12-01-2022 12:37,,,,,,
6577,NULL,12-01-2022 15:31,,,,,,
6578,NULL,13-01-2022 16:01,,,,,,
6579,NULL,12-01-2022 17:10,,,,,,
6580,NULL,13-01-2022 12:27,,,,,,
6581,NULL,13-01-2022 13:24,,,,,,
6582,NULL,13-01-2022 13:59,,,,,,
6583,NULL,13-01-2022 16:14,,,,,,
6584,NULL,13-01-2022 17:09,,,,,,
6585,NULL,13-01-2022 17:20,,,,,,
6586,NULL,14-01-2022 11:29,,,,,,
6587,NULL,15-01-2022 12:11,,,,,,
6588,NULL,13-01-2022 13:23,,,,,,
6589,NULL,14-01-2022 15:31,,,,,,
6590,NULL,14-01-2022 16:22,,,,,,
6591,NULL,17-01-2022 17:39,,,,,,
6592,NULL,17-01-2022 11:15,,,,,,
6593,NULL,17-01-2022 12:02,,,,,,
6594,NULL,17-01-2022 12:59,,,,,,
6595,NULL,17-01-2022 13:42,,,,,,
6596,NULL,18-01-2022 16:29,,,,,,
6597,NULL,18-01-2022 17:25,,,,,,
6598,NULL,18-01-2022 11:06,,,,,,
6599,NULL,18-01-2022 11:32,,,,,,
6600,NULL,18-01-2022 13:31,,,,,,
6601,NULL,18-01-2022 13:56,,,,,,
6602,NULL,19-01-2022 16:25,,,,,,
6603,NULL,19-01-2022 17:33,,,,,,
6604,NULL,18-01-2022 11:20,,,,,,
6605,NULL,19-01-2022 11:37,,,,,,
6606,NULL,19-01-2022 12:39,,,,,,
6607,NULL,18-01-2022 15:23,,,,,,
6608,NULL,20-01-2022 17:10,,,,,,
6609,NULL,18-01-2022 17:17,,,,,,
6610,NULL,20-01-2022 11:40,,,,,,
6611,NULL,20-01-2022 11:50,,,,,,
6612,NULL,20-01-2022 13:05,,,,,,
6613,NULL,20-01-2022 15:52,,,,,,
6614,NULL,20-01-2022 16:52,,,,,,
6615,NULL,20-01-2022 16:57,,,,,,
6616,NULL,21-01-2022 11:15,,,,,,
6617,NULL,21-01-2022 12:10,,,,,,
6618,NULL,21-01-2022 13:00,,,,,,
6619,NULL,21-01-2022 15:21,,,,,,
6620,NULL,24-01-2022 16:34,,,,,,
6621,NULL,23-01-2022 17:28,,,,,,
6622,NULL,24-01-2022 11:49,,,,,,
6623,NULL,24-01-2022 12:39,,,,,,
6624,NULL,24-01-2022 13:15,,,,,,
6625,NULL,25-01-2022 15:52,,,,,,
6626,NULL,24-01-2022 16:44,,,,,,
6627,NULL,24-01-2022 17:48,,,,,,
6628,NULL,22-12-2021 11:11,,,,,,
6629,NULL,17-12-2021 11:15,,,,,,
6630,NULL,13-12-2021 11:20,,,,,,
6631,NULL,15-12-2021 11:25,,,,,,
6632,NULL,07-12-2021 11:30,,,,,,
6633,NULL,20-12-2021 11:34,,,,,,
6634,NULL,25-01-2022 11:38,,,,,,
6635,NULL,25-01-2022 12:21,,,,,,
6636,NULL,25-01-2022 12:56,,,,,,
6637,NULL,26-01-2022 15:29,,,,,,
6638,NULL,25-01-2022 16:20,,,,,,
6639,NULL,27-01-2022 17:57,,,,,,
6640,NULL,27-01-2022 11:45,,,,,,
6641,NULL,27-01-2022 12:27,,,,,,
6642,NULL,27-01-2022 12:47,,,,,,
6643,NULL,27-01-2022 15:32,,,,,,
6644,NULL,28-01-2022 15:34,,,,,,
6645,NULL,28-01-2022 17:27,,,,,,
6646,NULL,27-01-2022 11:30,,,,,,
6647,NULL,28-01-2022 12:10,,,,,,
6648,NULL,28-01-2022 12:38,,,,,,
6649,NULL,30-01-2022 13:02,,,,,,
6650,NULL,31-01-2022 16:30,,,,,,
6651,NULL,28-01-2022 17:11,,,,,,
6652,NULL,31-01-2022 11:30,,,,,,
6653,NULL,31-01-2022 11:34,,,,,,
6654,NULL,31-01-2022 12:36,,,,,,
6655,NULL,31-01-2022 14:47,,,,,,
6656,NULL,01-02-2022 16:24,,,,,,
6657,NULL,01-02-2022 17:34,,,,,,
6658,NULL,01-02-2022 11:29,,,,,,
6659,NULL,01-02-2022 12:21,,,,,,
6660,NULL,01-02-2022 12:40,,,,,,
6661,NULL,01-02-2022 15:39,,,,,,
6662,NULL,01-02-2022 16:31,,,,,,
6663,NULL,01-02-2022 17:32,,,,,,
6664,NULL,10-01-2022 10:56,,,,,,
6665,NULL,21-01-2022 11:00,,,,,,
6666,NULL,19-01-2022 11:14,,,,,,
6667,NULL,03-01-2022 11:17,,,,,,
6668,NULL,05-01-2022 11:22,,,,,,
6669,NULL,02-02-2022 11:45,,,,,,
6670,NULL,02-02-2022 12:38,,,,,,
6671,NULL,02-02-2022 12:59,,,,,,
6672,NULL,17-01-2022 15:36,,,,,,
6673,NULL,26-01-2022 15:40,,,,,,
6674,NULL,02-02-2022 15:54,,,,,,
6675,NULL,02-02-2022 16:44,,,,,,
6676,NULL,05-01-2022 17:09,,,,,,
6677,NULL,11-01-2022 17:57,,,,,,
6678,NULL,03-02-2022 18:05,,,,,,
6679,NULL,03-02-2022 11:13,,,,,,
6680,NULL,03-02-2022 11:30,,,,,,
6681,NULL,03-02-2022 12:05,,,,,,
6682,NULL,03-02-2022 13:02,,,,,,
6683,NULL,03-02-2022 15:55,,,,,,
6684,NULL,03-02-2022 17:17,,,,,,
6685,NULL,04-02-2022 11:22,,,,,,
6686,NULL,04-02-2022 11:31,,,,,,
6687,NULL,04-02-2022 12:28,,,,,,
6688,NULL,07-02-2022 15:46,,,,,,
6689,NULL,07-02-2022 15:55,,,,,,
6690,NULL,07-02-2022 17:34,,,,,,
6691,NULL,07-02-2022 11:41,,,,,,
6692,NULL,07-02-2022 11:54,,,,,,
6693,NULL,07-02-2022 12:37,,,,,,
6694,NULL,07-02-2022 15:31,,,,,,
6695,NULL,07-02-2022 16:41,,,,,,
6696,NULL,07-02-2022 17:37,,,,,,
6697,NULL,08-02-2022 11:01,,,,,,
6698,NULL,08-02-2022 12:31,,,,,,
6699,NULL,08-02-2022 13:04,,,,,,
6700,NULL,08-02-2022 14:57,,,,,,
6701,NULL,09-02-2022 16:49,,,,,,
6702,NULL,09-02-2022 17:32,,,,,,
6703,NULL,09-02-2022 11:41,,,,,,
6704,NULL,09-02-2022 12:00,,,,,,
6705,NULL,08-02-2022 12:42,,,,,,
6706,NULL,09-02-2022 14:47,,,,,,
6707,NULL,10-02-2022 15:26,,,,,,
6708,NULL,09-02-2022 17:56,,,,,,
6709,NULL,11-02-2022 11:40,,,,,,
6710,NULL,11-02-2022 11:41,,,,,,
6711,NULL,11-02-2022 13:41,,,,,,
6712,NULL,11-02-2022 15:37,,,,,,
6713,NULL,11-02-2022 17:01,,,,,,
6714,NULL,11-02-2022 17:37,,,,,,
6715,NULL,11-02-2022 11:18,,,,,,
6716,NULL,11-02-2022 12:47,,,,,,
6717,NULL,11-02-2022 13:34,,,,,,
6718,NULL,13-02-2022 14:53,,,,,,
6719,NULL,14-02-2022 16:17,,,,,,
6720,NULL,14-02-2022 17:09,,,,,,
6721,NULL,14-02-2022 11:46,,,,,,
6722,NULL,14-02-2022 12:34,,,,,,
6723,NULL,15-02-2022 13:21,,,,,,
6724,NULL,15-02-2022 16:47,,,,,,
6725,NULL,15-02-2022 17:12,,,,,,
6726,NULL,14-02-2022 18:05,,,,,,
6727,NULL,15-02-2022 10:48,,,,,,
6728,NULL,15-02-2022 12:40,,,,,,
6729,NULL,14-02-2022 13:37,,,,,,
6730,NULL,15-02-2022 14:32,,,,,,
6731,NULL,15-02-2022 16:47,,,,,,
6732,NULL,16-02-2022 17:36,,,,,,
6733,NULL,10-01-2022 11:07,,,,,,
6734,NULL,14-01-2022 11:18,,,,,,
6735,NULL,16-02-2022 11:24,,,,,,
6736,NULL,16-02-2022 12:14,,,,,,
6737,NULL,16-02-2022 12:58,,,,,,
6738,NULL,03-09-2021 13:07,,,,,,
6739,NULL,15-02-2022 13:33,,,,,,
6740,NULL,17-02-2022 16:42,,,,,,
6741,NULL,16-02-2022 17:30,,,,,,
6742,NULL,17-02-2022 11:05,,,,,,
6743,NULL,17-02-2022 11:24,,,,,,
6744,NULL,17-02-2022 12:42,,,,,,
6745,NULL,17-02-2022 13:27,,,,,,
6746,NULL,18-02-2022 16:41,,,,,,
6747,NULL,17-02-2022 17:40,,,,,,
6748,NULL,18-02-2022 10:58,,,,,,
6749,NULL,18-02-2022 11:50,,,,,,
6750,NULL,18-02-2022 13:18,,,,,,
6751,NULL,17-02-2022 15:41,,,,,,
6752,NULL,06-05-2021 16:31,,,,,,
6753,NULL,18-02-2022 16:39,,,,,,
6754,NULL,24-05-2021 16:36,,,,,,
6755,NULL,18-02-2022 17:56,,,,,,
6756,NULL,21-02-2022 11:08,,,,,,
6757,NULL,21-02-2022 11:41,,,,,,
6758,NULL,21-02-2022 12:29,,,,,,
6759,NULL,18-02-2022 15:17,,,,,,
6760,NULL,22-02-2022 16:10,,,,,,
6761,NULL,22-02-2022 17:13,,,,,,
6762,NULL,22-02-2022 10:40,,,,,,
6763,NULL,22-02-2022 11:24,,,,,,
6764,NULL,22-02-2022 13:16,,,,,,
6765,NULL,22-02-2022 15:11,,,,,,
6766,NULL,22-02-2022 16:24,,,,,,
6767,NULL,23-02-2022 17:36,,,,,,
6768,NULL,23-02-2022 11:25,,,,,,
6769,NULL,23-02-2022 11:31,,,,,,
6770,NULL,23-02-2022 11:49,,,,,,
6771,NULL,23-02-2022 14:57,,,,,,
6772,NULL,23-02-2022 16:24,,,,,,
6773,NULL,23-02-2022 17:42,,,,,,
6774,NULL,24-02-2022 11:55,,,,,,
6775,NULL,24-02-2022 12:36,,,,,,
6776,NULL,24-02-2022 13:04,,,,,,
6777,NULL,24-02-2022 14:59,,,,,,
6778,NULL,25-02-2022 16:03,,,,,,
6779,NULL,24-02-2022 17:39,,,,,,
6780,NULL,25-02-2022 12:16,,,,,,
6781,NULL,25-02-2022 13:28,,,,,,
6782,NULL,25-02-2022 13:59,,,,,,
6783,NULL,25-02-2022 15:20,,,,,,
6784,NULL,26-02-2022 16:02,,,,,,
6785,NULL,26-02-2022 17:23,,,,,,
6786,NULL,28-02-2022 11:08,,,,,,
6787,NULL,28-02-2022 11:26,,,,,,
6788,NULL,28-02-2022 12:34,,,,,,
6789,NULL,07-02-2022 15:23,,,,,,
6790,NULL,09-02-2022 15:33,,,,,,
6791,NULL,01-02-2022 15:45,,,,,,
6792,NULL,28-02-2022 16:01,,,,,,
6793,NULL,21-02-2022 16:12,,,,,,
6794,NULL,28-02-2022 16:32,,,,,,
6795,NULL,28-02-2022 17:20,,,,,,
